



PROGRESS IN NUCLEIC ACID RESEARCH AND MOLECULAR BIOLOGY

Volume 76

Kivie Moldave

PROGRESS IN
Nucleic Acid Research
and Molecular Biology

Volume 76

Cumulative Index

Volumes 40–72

This Page Intentionally Left Blank

PROGRESS IN

Nucleic Acid Research and Molecular Biology

edited by

KIVIE MOLDAVE

*Department of Molecular Biology and Biochemistry
University of California, Irvine
Irvine, California*

Volume 76

Cumulative Index

Volumes 40–72



ELSEVIER
ACADEMIC
PRESS

AMSTERDAM • BOSTON • HEIDELBERG • LONDON

NEW YORK • OXFORD • PARIS • SAN DIEGO

SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO

Academic Press is an imprint of Elsevier

This book is printed on acid-free paper. ∞

Copyright © 2003, Elsevier Inc.

All Rights Reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the Publisher.

The appearance of the code at the bottom of the first page of a chapter in this book indicates the Publisher's consent that copies of the chapter may be made for personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee through the Copyright Clearance Center, Inc. (222 Rosewood Drive, Danvers, Massachusetts 01923), for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Copy fees for pre-2003 chapters are as shown on the title pages. If no fee code appears on the title page, the copy fee is the same as for current chapters. 0079-6603/2003 \$35.00

Permissions may be sought directly from Elsevier's Science & Technology Rights Department in Oxford, UK: phone: (+44) 1865 843830, fax: (+44) 1865 853333, e-mail: permissions@elsevier.com.uk. You may also complete your request on-line via the Elsevier homepage (<http://elsevier.com>), by selecting "Customer Support" and then "Obtaining Permissions."

Academic Press

An Elsevier Imprint.

525 B Street, Suite 1900, San Diego, California 92101-4495, USA
<http://www.academicpress.com>

Academic Press

84 Theobald's Road, London WC1X 8RR, UK
<http://www.academicpress.com>

International Standard Book Number: 0-12-540076-4

PRINTED IN THE UNITED STATES OF AMERICA

03 04 05 06 07 08 9 8 7 6 5 4 3 2 1

Cumulative Subject Index	1
Contributor Index	233

Contents of Volumes 40–72

VOLUME 40

1. msDNA of Bacteria	
Bert C. Lampson, Sumiko Inouye, and Masayori Inouye	1
2. Vertebrate Protamine Genes and the Histone-to-Protamine Replacement Reaction	
Rafael Oliva and Gordon H. Dixon	25
3. Aminoacyl-tRNA Synthetase Family from Prokaryotes and Eukaryotes: Structural Domains, and Their Implications	
Marc Mirande	97
4. Nucleosome Positioning: Occurrence, Mechanisms, and Functional Consequences	
Robert T. Simpson	143
5. Specific Interaction between RNA Phage Coat Proteins and RNA	
Gary W. Witherell, Jonatha M. Gott, and Olke C. Uhlenbeck	185
6. Superoxide Dismutases	
Wayne Beyer, James Imlay, and Irwin Fridovich	221
7. Genetics of Human Alcohol-Metabolizing Enzymes	
Akira Yoshida, Lily C. Hsu, and Michio Yasunami	255
8. DNA Helicases of <i>Escherichia coli</i>	
Steven W. Matson	291

VOLUME 41

- 1. Molecular Structure and Transcriptional Regulation of the Salivary Gland Proline-Rich Protein Multigene Families**
Don M. Carlson, Jie Zhou, and Paul S. Wright 1
- 2. Recognition of tRNAs by Aminoacyl-tRNA Synthetases**
LaDonne H. Schulman 23
- 3. Ribosome Biogenesis in Yeast**
H. A. Raué and R. J. Planta 89
- 4. Structural Elements in RNA**
Michael Chastain and Ignacio Tinoco, Jr. 131
- 5. Nuclear RNA-binding Proteins**
Jack D. Keene and Charles C. Query 179
- 6. Amplification of DNA Sequences in Mammalian Cells**
Joyce L. Hamlin, Tzeng-Horng Leu, James P. Vaughn, Chi Ma,
and Pieter A. Dijkwel 203
- 7. Molecular-Biology Approaches to Genetic Defects
of the Mammalian Nervous System**
J. Gregor Sutcliffe and Gabriel H. Travis 241
- 8. Lens Proteins and Their Genes**
Hans Bloemendal and Wilfried W. de Jong 259

VOLUME 42

- 1. The Trp Repressor, A Ligand-Activated Regulatory Protein**
Ronald Somerville 1

- 2. Immunochemical Analyses of Nucleic Acids**
B. David Stollar 39
- 3. Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression**
Mridul K. Ghosh and Jack S. Cohen 79
- 4. 5,6-Dihydropyrimidine Adducts in the Reactions and Interactions of Pyrimidines with Proteins**
Kathryn M. Ivanetich and Daniel V. Santi 129
- 5. RNA Replication of Plant Viruses Containing an RNA Genome**
Chantal David, Radhia Gargouri-Bouzid, and Anne-Lise Haenni 157
- 6. Intron Splicing and Intron-Mediated Enhanced Expression in Monocots**
Ralph M. Sinibaldi and Irvin J. Mettler 229
- 7. *De Novo* Purine Nucleotide Biosynthesis**
Howard Zalkin and Jack E. Dixon 261

VOLUME 43

- 1. Regulation of Gene Expression by Steroid Hormones**
Andrew C. B. Cato, Helmut Ponta, and Peter Herrlich 3
- 2. Developmental Regulation of Nuclear Gene Expression in *Trypanosoma brucei***
Christine Clayton 37
- 3. The Role of Protein Domains in the Assembly Process of Intermediate Filaments**
J. M. H. Raats and H. Bloemendal 67

4. Modeling DNA Structures	
Eberhard von Kitzing	89
5. Two Prokaryotic Transcriptional Enhancer Systems	
E. Peter Geiduschek	111
6. Latent Viruses and Mutated Oncogenes: No Evidence for Pathogenicity	
Peter H. Duesberg and Jody R. Schwartz	137
7. Structure, Function, Evolution of Transcription Factor IIIA	
Jay S. Hanas, Chris J. Gaskins, James F. Smith, and Martha K. Ogilvie	205

VOLUME 44

1. Structure and Action of Mammalian Ribonuclease (Angiogenin) Inhibitor	
Frank S. Lee and Bert L. Vallee	1
2. Bacterial Adenylyl Cyclases	
Alan Peterkofsky, Aiala Reizer, Jonathan Reizer, Natan Gollop, Peng-Peng Zhu, and Niranjana Amin	31
3. Initiation of Transcription by RNA Polymerase II: A Multi-step Process	
Leigh Zawel and Danny Reinberg	67
4. Regulation of Repair of Alkylation Damage in Mammalian Genomes	
Sankar Mitra and Bernd Kaina	109

- 5. Cell Delivery and Mechanisms of Action of Antisense Oligonucleotides**
Jean Paul Leonetti, Geneviève Degols, Jean Pierre Clarenc,
Nadir Mechti, and Bernard Lebleu 143
- 6. Enzyme Organization in DNA Precursor Biosynthesis**
Christopher K. Mathews 167
- 7. Identification and Characterization of Novel Substrates for Protein Tyrosine Kinases**
Michael D. Schaller, Amy H. Bouton, Daniel C. Flynn,
and J. Thomas Parsons 207

VOLUME 45

- 1. Analysis of Rice Genes in Transgenic Plants**
Ray Wu, Xiaolan Duan, and Deping Xu 1
- 2. Immunoglobulin Gene Diversification by Gene Conversion**
Wayne T. McCormack, Larry W. Tjoelker, and Craig B. Thompson 29
- 3. ADP-ribosylation Factors: Protein Activators of Cholera Toxin**
Joel Moss and Martha Vaughan 49
- 4. Molecular Biology in the Eicosanoid Field**
Colin D. Funk 69
- 5. Mammalian 6-Phosphofructo-2-kinase/fructose-2, 6-bisphosphatase: A Bifunctional Enzyme That Controls Glycolysis**
Guy G. Rousseau and Louis Hue 99

- 6. tRNA Structure and Aminoacylation Efficiency**
Richard Giegé, Joseph D. Puglisi, and Catherine Florentz 131
- 7. Evolution of Ca²⁺-dependent Animal Lectins**
Kurt Drickamer 207

VOLUME 46

- 1. Adenoviral DNA Integration and Changes in DNA Methylation Patterns: A Different View of Insertional Mutagenesis**
Walter Doerfler 1
- 2. Posttranscriptional Control of the Lysogenic Pathway in Bacteriophage Lambda**
Amos B. Oppenheim, Daniel Kornitzer, Shoshy Altuvia, and Donald L. Court 37
- 3. Global Regulation of Mitochondrial Biogenesis in *Saccharomyces cerevisiae***
J. H. de Winde and L. A. Grivell 53
- 4. DNA Polymerase II, the Epsilon Polymerase of *Saccharomyces cerevisiae***
Alan Morrison and Akio Sugino 93
- 5. Regulation of *Bacillus subtilis* Gene Expression during the Transition from Exponential Growth to Stationary Phase**
Mark A. Strauch 123
- 6. Genomic Organization of T and W, a New Family of Double-Stranded RNAs from *Saccharomyces cerevisiae***
Rosa Esteban, Nieves Rodriguez-Cousiño, and Luis M. Esteban 155

7. Mechanism of Action and Regulation of Protein Synthesis Initiation Factor 4E: Effects on mRNA Discrimination, Cellular Growth Rate, and Oncogenesis
Robert E. Rhoads, Swati Joshi-Barve, and Carrie Rinker-Schaeffer 183
8. Enzymology of Homologous Recombination in *Saccharomyces cerevisiae*
W.-D. Heyer and R. D. Kolodner 221

VOLUME 47

Progress in Nucleic Acid Research and Molecular Biology

Waldo Cohn and Kivie Moldave

1. Prestalk Cell-Differentiation and Movement during the Morphogenesis of *Dictyostelium discoideum*
Jeffrey Williams and Alastair Morrison 3
2. Collagen Genes: Mutations Affecting Collagen Structure and Expression
William G. Cole 29
3. Signal-Transducing G Proteins: Basic and Clinical Implications
C. W. Emala, W. F. Schwindinger, G. S. Wand, and M. A. Levine 81
4. The *tis* Genes, Primary Response Genes Induced by Growth Factors and Tumor Promoters in 3T3 Cells
Harvey R. Herschman, Dean A. Kujubu, Bradley S. Fletcher, Qiufu Ma, Brian C. Varnum, Rebecca S. Gilbert, and Srinivasa T. Reddy 115
5. Nuclear Pre-mRNA Processing in Higher Plants
Kenneth R. Luehrsen, Sharif Taha, and Virginia Walbot 149

- 6. New Concepts in Protein–DNA Recognition:
Sequence-Directed DNA Bending and Flexibility**
Rodney E. Harrington and Ilga Winicov 195
- 7. Nonsense-mediated mRNA Decay in Yeast**
Stuart W. Peltz, Feng He, Ellen Welch, and Allan Jacobson 271
- 8. Molecular Biology and Regulatory Aspects of Glycogen
Biosynthesis in Bacteria**
Jack Preiss and Tony Romeo 301
- 9. Diverse Mechanisms for Regulating Ribosomal Protein
Synthesis in *Escherichia coli***
Janice M. Zengel and Lasse Lindahl 331
- 10. Enzymologic Mechanism of Replicative DNA Polymerases
in Higher Eukaryotes**
Paul A. Fisher 371

VOLUME 48

Progress in Nucleic Acid Research and Molecular Biology

Waldo Cohn and Kivie Moldave

- 1. START Control in Cycling *Saccharomyces cerevisiae* Cells**
Hans Küntzel, Hans-Werner Rottjakob, Angelika Schwed,
and Werner Zwerschke 1
- 2. Adeno-associated Virus Type 2: A Latent Life Cycle**
C. J. Leonard and Kenneth I. Berns 29
- 3. DNA Methylation from Embryo to Adult**
Aharon Razin and Tal Kafri 55

- 4. Aminoacyl-tRNA Synthetases from Higher Eukaryotes**
Lev L. Kisselev and Alexey D. Wolfson 85

- 5. The Role of Multisite Phosphorylation in the Regulation of RNA Polymerase II Activity**
Michael E. Dahmus 145

- 6. The Role of the 5' Untranslated Region of Eukaryotic Messenger RNAs in Translation and Its Investigation Using Antisense Technologies**
Kostas Pantopoulos, Hans E. Johansson, and Matthias W. Hentze 181

- 7. Regulation of Replication of an Iteron-Containing DNA Molecule**
Marcin Filutowicz, Stephanie Dellis, Igor Levchenko, Marjeta Urh, Frank Wu, and Dona York 241

- 8. The Balbiani Ring Multigene Family: Coding Repetitive Sequences and Evolution of a Tissue-Specific Cell Function**
Lars Wieslander 277

- 9. Uracil-Excision DNA Repair**
Dale W. Mosbaugh and Samuel E. Bennett 315

VOLUME 49

Progress in Nucleic Acid Research and Molecular Biology

Waldo Cohn and Kivie Moldave

- 1. The Prosomes (Multicatalytic Proteinases; Proteasomes) and Their Relationship to the Untranslated Messenger Ribonucleoproteins, the Cytoskeleton, and Cell Differentiation**
Klaus Scherrer and Fayçal Bey 1

- 2. Biological Implications of the Mechanism of Action of Human DNA (Cytosine-5)methyltransferase**
Steven S. Smith 65
- 3. Molecular Properties and Regulation of G-Protein-Coupled Receptors**
Claire M. Fraser, Norman H. Lee, Susan M. Pellegrino,
and Anthony R. Kerlavage 113
- 4. The Human Immunodeficiency Virus Type-1 Long Terminal Repeat and Its Role in Gene Expression**
Joseph A. Garcia and Richard B. Gaynor 157
- 5. Processing of Eukaryotic Ribosomal RNA**
Duane C. Eichler and Nessly Craig 197
- 6. Adenylyl Cyclases: A Heterogeneous Class of ATP-Utilizing Enzymes**
Octavian Bărză and Antoine Danchin 241
- 7. Mutational Spectrometry: Means and Ends**
K. Khrapko, P. André, R. Cha, G. Hu, and W. G. Thilly 285
- 8. Polynucleotide Recognition and Degradation by Bleomycin**
Stefanie A. Kane and Sidney M. Hecht 313
- 9. Interaction of Epidermal Growth Factor with Its Receptor**
Stephen R. Campion and Salil K. Niyogi 353

VOLUME 50**Progress in Nucleic Acid Research and
Molecular Biology**

Waldo Cohn and Kivie Moldave

- 1. Ribosome-Catalyzed Peptide-Bond Formation**
Kathy R. Lieberman and Albert E. Dahlberg 1
- 2. Promotion and Regulation of Ribosomal Transcription
in Eukaryotes by RNA Polymerase I**
Tom Moss and Victor Y. Stefanovsky 25
- 3. Targeting and Regulation of Immunoglobulin Gene Somatic
Hypermutation and Isotype Switch Recombination**
Markus Hengstschläger, Nancy Maizels, and Helios Leung 67
- 4. Capping Enzyme in Eukaryotic mRNA Synthesis**
Stewart Shuman 101
- 5. Rearrangement of snRNA Structure during Assembly
and Function of the Spliceosome**
Manuel Ares, Jr. and Bryn Weiser 131
- 6. Transcriptional Control of the Human Apolipoprotein B Gene
in Cell Culture and in Transgenic Animals**
Beatriz Levy-Wilson 161
- 7. Early Growth Response Protein 1 (Egr-1): Prototype of a
Zinc-Finger Family of Transcription Factors**
Andrea Gashler and Vikas P. Sukhatme 191
- 8. Two New Collagen Subgroups: Membrane-Associated
Collagens and Types XV and XVIII**
Taina Pihlajaniemi and Marko Rehn 225

- 9. Genetic Dissection of Synthesis and Function of Modified Nucleosides in Bacterial Transfer RNA**
Glenn R. Björk 263

VOLUME 51

Progress in Nucleic Acid Research and Molecular Biology

Waldo Cohn and Kivie Moldave

- 1. Molecular Regulation of Heme Biosynthesis in Higher Vertebrates**
Brian K. May, Satish C. Dogra, Tim J. Sadlon, C. Ramana Bhasker, Timothy C. Cox, and Sylvia S. Bottomley 1
- 2. The Flp Recombinase of the 2- μ m Plasmid of *Saccharomyces cerevisiae***
Paul D. Sadowski 53
- 3. Reconstitution of Mammalian DNA Replication**
Robert A. Bambara and Lin Huang 93
- 4. Transcription of the Herpes Simplex Virus Genome during Productive and Latent Infection**
Edward K. Wagner, John F. Guzowski, and Jasbir Singh 123
- 5. Structure, Function, and Inhibition of O⁶-Alkylguanine-DNA Alkyltransferase**
Anthony E. Pegg, M. Eileen Dolan, and Robert C. Moschel 167
- 6. Replicable RNA Vectors: Prospects for Cell-Free Gene Amplification, Expression, and Cloning**
Alexander B. Chetverin and Alexander S. Spirin 225

7. Examination of Mitotic Recombination by Means of Hyper-recombination Mutants in *Saccharomyces cerevisiae*
Hannah L. Klein 271
8. Gene Structure at the Human *UGT1* Locus Creates Diversity in Isozyme Structure, Substrate Specificity, and Regulation
Ida S. Owen and Joseph K. Ritter 305
9. Growth Control of Translation in Mammalian Cells
David R. Morris 339

VOLUME 52

Progress in Nucleic Acid Research and Molecular Biology

E. Cohn and Kivie Moldave

1. Structure, Reactivity, and Biology of Double-Stranded RNA
Allen W. Nicholson 1
2. Evolution, Expression, and Possible Function of a Master Gene for Amplification of an Interspersed Repeated DNA Family in Rodents
Prescott L. Deininger, Henri Tiedge, Joomyeong Kim, and Jürgen Brosius 67
3. Nutritional and Hormonal Regulation of Expression of the Gene for Malic Enzyme
Alan G. Goodridge, Stephen A. Klautky, Dominic A. Fantozzi, Rebecca A. Baillie, Dean W. Hodnett, Weizu Chen, Debbie C. Thurmond, Gang Xu, and Cesar Roncero 89

- 4. Oxidative Chemical Nucleases**
David M. Perrin, Abhijit Mazumder, and David S. Sigman 123
- 5. The Decay of Bacterial Messenger RNA**
Donald P. Nierlich and George J. Murakawa 153
- 6. The Linker Histones and Chromatin Structure: New Twists**
Jordanka Zlatanova and Kensal van Holde 217
- 7. Development of Antisense and Antigene Oligonucleotide Analogs**
Paul S. Miller 261
- 8. Hidden Infidelities of the Translational Stop Signal**
Warren P. Tate, Elizabeth S. Poole, and Sally A. Mannering 293
- 9. Structure of Replicating Chromatin**
Claudia Gruss and Rolf Knippers 337

VOLUME 53

Progress in Nucleic Acid Research and Molecular Biology

Waldo Cohn and Kivie Moldave

- 1. Uracil Metabolism—UMP Synthesis from Orotic Acid or Uridine and Conversion of Uracil to β -Alanine: Enzymes and cDNAs**
Thomas W. Traut and Mary Ellen Jones 1
- 2. The Importance of Being Modified: Roles of Modified Nucleosides and Mg^{2+} in RNA Structure and Function**
Paul F. Agris 79

- 3. Chemical and Computer Probing of RNA Structure**
N. A. Kolchanov, I. I. Titov, I. E. Vlassova, and V. V. Vlassov 131
- 4. Transcriptional Activation of Thymidine Kinase, a Marker for Cell Cycle Control**
Qing-Ping Dou and Arthur B. Pardee 197
- 5. Eukaryotic Gene Expression: Metabolite Control by Amino Acids**
Roney O. Laine, Richard G. Hutson, and Michael S. Kilberg 219
- 6. Molecular Recognition in the Assembly of the Segmented Reovirus Genome**
Wolfgang K. Joklik and Michael R. Roner 249
- 7. Alu: Structure, Origin, Evolution, Significance, and Function of One-Tenth of Human DNA**
Carl W. Schmid 283
- 8. Recent Advances in the Molecular Biology of Vitamin D Action**
Hisham M. Darwish and Hector F. DeLuca 321
- 9. Regulation of Synthesis of Ribonucleotide Reductase and Relationship to DNA Replication in Various Systems**
G. Robert Greenberg and John M. Hilfinger 345

VOLUME 54

Progress in Nucleic Acid Research and Molecular Biology

Waldo Cohn and Kivie Moldave

- 1. Structure and Function of the Human Immunodeficiency Virus Leader RNA**
Benjamin Berkhout 1

- 2.** High-Mobility-Group Chromosomal Proteins:
Architectural Components That Facilitate Chromatin Function
Michael Bustin and Raymond Reeves 35
- 3.** Homologous Genetic Recombination in *Xenopus*: Mechanism
and Implications for Gene Manipulation
Dana Carroll 101
- 4.** Hormonal and Cell-specific Regulation of the Human Growth
Hormone and Chorionic Somatomammotropin Genes
Norman L. Eberhardt, Shi-Wen Jiang, Allan R. Shepard,
Andrew M. Arnold, and Miguel A. Trujillo 127
- 5.** Role of Translation Initiation Factor eIF-2B in the Regulation
of Protein Synthesis in Mammalian Cells
Scot R. Kimball, Harry Mellor, Kevin M. Flowers,
and Leonard S. Jefferson 165
- 6.** Enzymology of DNA Transfer by Conjugative Mechanisms
Werner Pansegrau and Erich Lanka 197
- 7.** *recA*-independent DNA Recombination between Repetitive
Sequences: Mechanisms and Implications
Xin Bi and Leroy F. Liu 253
- 8.** The Elongation Phase of Protein Synthesis
John Czworkowski and Peter B. Moore 293
- 9.** Signals in Eukaryotic DNA Promote and Influence Formation
of Nucleosome Arrays
Arnold Stein 333

VOLUME 55**Progress in Nucleic Acid Research and
Molecular Biology**

Waldo Cohn and Kivie Moldave

- 1. Experimental Analysis of Global Gene Regulation in
*Escherichia coli***
Robert M. Blumenthal, Deborah W. Borst, and Rowena G. Matthews 1
- 2. Eukaryotic Nuclear RNase P: Structures and Functions**
Joel R. Chamberlain, Anthony J. Tranguch, Eileen Pagán-Ramos,
and David R. Engelke 87
- 3. Effects of the Ferritin Open Reading Frame on Translational
Induction by Iron**
David P. Mascotti, Lisa S. Goessling, Diane Rup, and Robert E. Thach 121
- 4. Depletion of Nuclear Poly(ADP-ribose) Polymerase by
Antisense RNA Expression: Influence on Genomic Stability,
Chromatin Organization, DNA Repair, and DNA Replication**
Cynthia M. G. Simbulan-Rosenthal, Dean S. Rosenthal,
Ruchuang Ding, Joany Jackman, and Mark E. Smulson 135
- 5. The Large Ribosomal Subunit Stalk as a Regulatory Element
of the Eukaryotic Translational Machinery**
Juan P. G. Ballesta and Miguel Remacha 157
- 6. Regulation and Function of Adenosine Deaminase in Mice**
Michael R. Blackburn and Rodney E. Kellems 195
- 7. S1-Nuclease-sensitive DNA Structures Contribute to
Transcriptional Regulation of the Human PDGF A-chain**
Zhao-Yi Wang and Thomas F. Deuel 227

- 8. Minute Virus of Mice *cis*-Acting Sequences Required for Genome Replication and the Role of the *trans*-Acting Viral Protein, NS-1**
Caroline R. Astell, Qingquan Liu, Colin E. Harris, John Brunstein,
Hitesh K. Jindal, and Pat Tam 245

VOLUME 56

Progress in Nucleic Acid Research and Molecular Biology

E. Cohn and Kivie Moldave

- 1. Developmental Genome Reorganization in Ciliated Protozoa:
The Transposon Link**
Lawrence A. Klobutcher and Glenn Herrick 1
- 2. DNA Excision Repair Assays**
David Mu and Aziz Sancar 63
- 3. The Mitochondrial Uncoupling Protein: Structural
and Genetic Studies**
Daniel Ricquier and Frédéric Bouillaud 83
- 4. Molecular Regulation of Cytokine Gene Expression:
Interferon- γ as a Model System**
Howard A. Young and Paritosh Ghosh 109
- 5. RecA Protein: Structure, Function, and Role in Recombinational
DNA Repair**
Alberto I. Roca and Michael M. Cox 129
- 6. Molecular Biology of Axon–Glia Interactions in the Peripheral
Nervous System**
Verdon Taylor and Ueli Suter 225

- 7. Regulation of Eukaryotic Messenger RNA Turnover**
Lakshman E. Rajagopalan and James S. Malter 257
- 8. New and Atypical Families of Type I Interferons in Mammals: Comparative Functions, Structures, and Evolutionary Relationships**
R. Michael Roberts, Limin Liu, and Andrei Alexenko 287
- 9. General Transcription Factors for RNA Polymerase II**
Ronald C. Conaway and Joan Weliky Conaway 327
- 10. Biochemistry and Molecular Genetics of Cobalamin Biosynthesis**
Michelle R. Rondon, Jodi R. Trzebiatowski,
and Jorge C. Escalante-Semerena 347

VOLUME 57

Progress in Nucleic Acid Research and Molecular Biology

Kivie Moldave

- 1. Mismatch Base Pairs in RNA**
Stefan Limmer 1
- 2. The Mechanism of 3' Cleavage and Polyadenylation of Eukaryotic Pre-mRNA**
Elmar Wahle and Uwe Kühn 41
- 3. Stimulation of Kinase Cascades by Growth Hormone: A Paradigm for Cytokine Signaling**
Timothy J. J. Wood, Lars-Arne Haldosén, Daniel Sliva,
Michael Sundström, and Gunnar Norstedt 73

- 4. Oligonucleotides and Polynucleotides as Biologically Active Compounds**
V. V. Vlassov, I. E. Vlassova, and L. V. Pautova 95
- 5. Replication Control of Plasmid P1 and Its Host Chromosome: The Common Ground**
Dhruba K. Chattoraj and Thomas D. Schneider 145
- 6. Changes in Gene Structure and Regulation of E-Cadherin during Epithelial Development, Differentiation, and Disease**
Janusz A. Jankowski, Fiona K. Bedford, and Young S. Kim 187
- 7. The Formation of DNA Methylation Patterns and the Silencing of Genes**
Jean-Pierre Jost and Alain Bruhat 217
- 8. The Role of mRNA Stability in the Control of Globin Gene Expression**
J. Eric Russell, Julia Morales, and Stephen A. Liebhaber 249
- 9. Self-Glucosylating Initiator Proteins and Their Role in Glycogen Biosynthesis**
Peter J. Roach and Alexander V. Skurat 289
- 10. Molecular Genetics of Yeast TCA Cycle Isozymes**
Lee McAlister-Henn and W. Curtis Small 317

VOLUME 58**Progress in Nucleic Acid Research and
Molecular Biology**

Kivie Moldave

- 1. The Hairpin Ribozyme: Discovery, Two-Dimensional Model,
and Development for Gene Therapy**
Arnold Hampel 1
- 2. Serum and Polypeptide Growth Factor-Inducible Gene
Expression in Mouse Fibroblasts**
Jeffrey A. Winkles 41
- 3. Regulation of Translational Initiation during Cellular Responses
to Stress**
Charles O. Brostrom and Margaret A. Brostrom 79
- 4. Lactose Repressor Protein: Functional Properties and Structure**
Kathleen Shive Matthews and Jeffrey C. Nichols 127
- 5. Copper-Regulatory Domain Involved in Gene Expression**
Dennis R. Winge 165
- 6. Molecular Biology of Trehalose and the Trehalases in the Yeast
*Saccharomyces cerevisiae***
Solomon Nwaka and Helmut Holzer 197
- 7. Molecular and Structural Features of the Proton-Coupled
Oligopeptide Transporter Superfamily**
You-Jun Fei, Vadivel Ganapathy, and Frederick H. Leibach 239
- 8. Double-Strand Break-Induced Recombination in Eukaryotes**
Fekret Osman and Suresh Subramani 263

9. Impaired Folding and Subunit Assembly as Disease Mechanism: The Example of Medium-Chain acyl-CoA Dehydrogenase Deficiency
Peter Bross, Brage S. Andresen, and Niels Gregersen 301
10. Interaction of Retroviral Reverse Transcriptase with Template–Primer Duplexes during Replication
Eric J. Arts and Stuart F. J. Le Grice 339

VOLUME 59

Progress in Nucleic Acid Research and Molecular Biology

Kivie Moldave

1. Rhodopsin: A Prototypical G Protein-Coupled Receptor
Thomas P. Sakmar 1
2. Cell Membrane and Chromosome Replication in *Bacillus subtilis*
Noboru Sueoka 35
3. Stability and Structure of Model DNA Triplexes and Quadruplexes and Their Interactions with Small Ligands
Richard H. Shafer 55
4. On the Physiological Role of Casein Kinase II in *Saccharomyces cerevisiae*
Claiborne V.C. Glover III 95
5. The Heparan Sulfate–Fibroblast Growth Factor Family: Diversity of Structure and Function
Wallace L. McKeehan, Fen Wang, and Mikio Kan 135

- 6.** The Ribosomal Elongation Cycle and the Movement of tRNAs across the Ribosome
 Knud H. Nierhaus, Heinrich B. Stuhmann, and Dmitri Svergun 177
- 7.** Life on the Salvage Path: The Deoxynucleoside Kinases of *Lactobacillus acidophilus* R-26
 David H. Ives and Seiichiro Ikeda 205
- 8.** Molecular Analyses of Metallothionein Gene Regulation
 Susan L.-A. Samson and Lashitew Gedamu 257
- 9.** Transcriptional Regulation of the Steroid Receptor Genes
 M. Vijay Kumar and Donald J. Tindall 289
- 10.** Molecular Evolution of Snake Toxins: Is the Functional Diversity of Snake Toxins Associated with a Mechanism of Accelerated Evolution?
 M. Ohno, R. Ménez, T. Ogawa, J. M. Danse, Y. Shimohigashi, C. Fromen, F. Ducancel, S. Zinn-Justin, M. H. Le Du, J.-C. Boulain, T. Tamiya, and A. Ménez 307

VOLUME 60

Progress in Nucleic Acid Research and Molecular Biology

Kivie Moldave

- 1.** *Bacillus thuringiensis* Insecticidal Proteins: Molecular Mode of Action
 Francis Rajamohan, Mi Kyong Lee, and Donald H. Dean 1
- 2.** Transcription Activation and Repression by Interaction of a Regulator with the α Subunit of RNA Polymerase: The Model of Phage ϕ 29 Protein p4
 Fernando Rojo, Mario Mencía, María Monsalve, and Margarita Salas 29

3.	Eukaryotic Translation Elongation Factor 1 α: Structure, Expression, Functions, and Possible Role in Aminoacyl-tRNA Channeling	
	B. S. Negrutskii and A. V. El'skaya	47
4.	Type X Collagen and Other Up-Regulated Components of the Avian Hypertrophic Cartilage Program	
	Thomas F. Linsenmayer, Fanxin Long, Maria Nurminskaya, Qian Chen, and Thomas M. Schmid	79
5.	Domains of Human Topoisomerase I and Associated Functions	
	James J. Champoux	111
6.	Autoregulation of Eukaryotic Transcription Factors	
	Erik Bateman	133
7.	Development of More Efficacious Antibodies for Medical Therapy and Diagnosis	
	Ameurfina D. Santos and Eduardo A. Padlan	169
8.	Molecular Regulation of Insulin-like Growth Factor-I and Its Principal Binding Protein, IGFBP-3	
	Lawrence S. Phillips, Ching-I Pao, and Betty C. Villafuerte	195
9.	Molecular Genetics of Succinate: Quinone Oxidoreductase in Eukaryotes	
	Immo E. Scheffler	267
10.	Regulation of Fat Synthesis and Adipose Differentiation	
	Hei Sook Sul, Cynthia M. Smas, Dong Wang, and Li Chen	317

VOLUME 61**Progress in Nucleic Acid Research and
Molecular Biology**

Kivie Moldave

- 1. Neurofilaments in Health and Disease**
Jean-Pierre Julien and Walter E. Mushynski 1
- 2. Regulation of Cytochrome P450 Gene Transcription
by Phenobarbital**
Byron Kemper 25
- 3. RNA and Protein Interactions Modulated by Protein
Arginine Methylation**
Jonathan D. Gary and Steven Clarke 65
- 4. Genetic Regulation of Phospholipid Metabolism: Yeast
as a Model Eukaryote**
Susan A. Henry and Jana L. Patton-Vogt 133
- 5. Inosine-5'-Monophosphate Dehydrogenase: Regulation
of Expression and Role in Cellular Proliferation and
T Lymphocyte Activation**
Albert G. Zimmermann, Jing-Jin Gu, Josée Laliberté,
and Beverly S. Mitchell 181
- 6. Structure and Function Analysis of *Pseudomonas* Plant Cell Wall
Hydrolases**
Geoffrey P. Hazlewood and Harry J. Gilbert 211
- 7. Regulation of the Spatiotemporal Pattern of Expression of the
Glutamine Synthetase Gene**
Heleen Lie-Venema, Theodorus B. M. Hakvoort, Formijn J. van Hemert,
Antoon F. M. Moorman, and Wouter H. Lamers 243

- 8.** Structural Organization and Transcription Regulation of Nuclear Genes Encoding the Mammalian Cytochrome c Oxidase Complex
Nibedita Lenka, C. Vijayasathy, Jayati Mullick,
and Narayan G. Avadhani 309
- 9.** Control of Meiotic Recombination in *Schizosaccharomyces pombe*
Mary E. Fox and Gerald R. Smith 345
- 10.** The Nucleosome: A Powerful Regulator of Transcription
Alan P. Wolffe and Hitoshi Kurumizaka 379

VOLUME 62

Progress in Nucleic Acid Research and Molecular Biology

Kivie Moldave

- 1.** Structural and Functional Characteristics of Dyk, a Novel Subfamily of Protein Kinases with Dual Specificity
Walter Becker and Hans-Georg Joost 1
- 2.** Transcriptional and Posttranscriptional Regulation of Proteoglycan Gene Expression
Renato V. Iozzo and Keith G. Danielson 19
- 3.** Degradation of mRNA in *Escherichia coli*: An Old Problem with Some New Twists
Glen A. Coburn and George A. Mackie 55
- 4.** Regulation of Mammalian Ribosomal Gene Transcription by RNA Polymerase I
Ingrid Grummt 109

- 5.** The Initiation of DNA Base Excision Repair of Dipyrimidine Photoproducts
R. Stephen Lloyd 155
- 6.** Domain Organization, Genomic Structure, Evolution, and Regulation of Expression of the Aggrecan Gene Family
Nancy B. Schwartz, Edward W. Pirok III, James R. Mensch, Jr., and Miriam S. Domowicz 177
- 7.** Modulation of DNA Damage and DNA Repair in Chromatin
Michael J. Smerdon and Antonio Conconi 227
- 8.** The Search for Trans-Acting Factors Controlling Messenger RNA Decay
Gerald M. Wilson and Gary Brewer 257
- 9.** Regulation of RNA Polymerase I Transcription in Yeast and Vertebrates
Ronald H. Reeder 293
- 10.** Regulation of the *Bacillus subtilis* Pyrimidine Biosynthetic Operon by Transcriptional Attenuation: Control of Gene Expression by an mRNA-Binding Protein
Robert L. Switzer, Robert J. Turner, and Yang Lu 329
- 11.** DNA Damage and Replication Checkpoints in the Fission Yeast, *Schizosaccharomyces pombe*
Joel A. Huberman 369

VOLUME 63**Progress in Nucleic Acid Research and
Molecular Biology**

Kivie Moldave

- 1. The Molecular Biology of Cyclic Nucleotide Phosphodiesterases**
Marco Conti and S.-L. Catherine Jin 1
- 2. PriA: At the Crossroads of DNA Replication and Recombination**
Kenneth J. Marians 39
- 3. The Cell Biology of the Prohormone Convertases PC1 and PC2**
L. Muller and I. Lindberg 69
- 4. Transcriptional Regulation of Syndecan-1 Expression by Growth Factors**
Panu Jaakkola and Markku Jalkanen 109
- 5. Retinoic Acid: Its Biosynthesis and Metabolism**
Joseph L. Napoli 139
- 6. Genetic Disorders Associated with Cancer Predisposition and Genomic Instability**
Carina J. Vessey, Christopher J. Norbury, and Ian D. Hickson 189
- 7. The Role of POU Domain Proteins in the Regulation of Mammalian Pituitary and Nervous System Development**
Robert J. McEvilly and Michael G. Rosenfeld 223
- 8. DNA Repair and Chromatin Structure in Genetic Diseases**
Muriel W. Lambert and W. Clark Lambert 257

- 9.** Recombinational DNA Repair in Bacteria and the RecA Protein
Michael M. Cox 311
- 10.** A Survey of the Sequence-Specific Interaction of Damaging Agents with DNA: Emphasis on Antitumor Agents
Vincent Murray 367

VOLUME 64

Progress in Nucleic Acid Research and Molecular Biology

Kivie Moldave

- 1.** ATP-Dependent Restriction Enzymes
Desirazu N. Rao, Swati Saha, and Vinita Krishnamurthy 1
- 2.** DNA Polymerase of the T4-Related Bacteriophages
Jim D. Karam and William H. Konigsberg 65
- 3.** The Peripheral Myelin Protein 22 and Epithelial Membrane Protein Family
Anton M. Jetten and Ueli Suter 97
- 4.** Translational Frameshifting: Implications for the Mechanism of Translational Frame Maintenance
Philip J. Farabaugh 131
- 5.** Syndromes Associated with *Homo sapiens* Pol II Regulatory Genes
Minou Bina, Sarah Demmon, and Elsie I. Pares-Matos 171
- 6.** Topoisomerase II as a Target for Anticancer Drugs: When Enzymes Stop Being Nice
John M. Fortune and Neil Osheroff 221

- 7. The Biological Properties and Evolutionary Dynamics of Mammalian LINE-1 Retrotransposons**
Anthony V. Furano 255
- 8. Regulation of the Mammalian Alcohol Dehydrogenase Genes**
Howard J. Edenberg 295
- 9. Transcriptional Regulation by Cyclic AMP-Responsive Factors**
Dario De Cesare and Paolo Sassone-Corsi 343

VOLUME 65

Progress in Nucleic Acid Research and Molecular Biology

Kivie Moldave

- 1. Cyclic Nucleotide Phosphodiesterases: Relating Structure and Function**
Sharron H. Francis, Illarion V. Turko, and Jackie D. Corbin 1
- 2. Thyroid Hormone Regulation of Apoptotic Tissue Remodeling: Implications from Molecular Analysis of Amphibian Metamorphosis**
Yun-Bo Shi and Atsuko Ishizuya-Oka 53
- 3. Role of S6 Phosphorylation and S6 Kinase in Cell Growth**
Siniša Volarević and George Thomas 101
- 4. Molecular Characterization of Monoamine Oxidases A and B**
Creed W. Abell and Sau-Wah Kwan 129
- 5. Squalene Synthase: Structure and Regulation**
Terese R. Tansey and Ishaiahu Shechter 157

- 6. Yeast Chromatin Structure and Regulation of *GAL* Gene Expression**
R. Bash and D. Lohr 197
- 7. A Coordinated Interplay: Proteins with Multiple Functions in DNA Replication, DNA Repair, Cell Cycle/Checkpoint Control, and Transcription**
Manuel Stucki, Igor Stagljär, Zophonias O. Jónsson, and Ulrich Hübscher 261
- 8. Signal Transduction Pathways and the Modification of Chromatin Structure**
James R. Davie and Virginia A. Spencer 299
- 9. RGS Proteins: Lessons from the RGS9 Subfamily**
Christopher W. Cowan, Wei He, and Theodore G. Wensel 341
- 10. Regulation of Mammalian Cell Membrane Biosynthesis**
Athanasios Lykidis and Suzanne Jackowski 361

VOLUME 66

Progress in Nucleic Acid Research and Molecular Biology

Kivie Moldave

- 1. Structure, Mechanism, and Evolution of the mRNA Capping Apparatus**
Stewart Shuman 1
- 2. Folding of a Nascent Peptide on the Ribosome**
Boyd Hardesty and Gisela Kramer 41
- 3. Exoribonucleases and Their Multiple Roles in RNA Metabolism**
Murray P. Deutscher and Zhongwei Li 67

- 4. Protein Traffic in Bacteria: Multiple Routes From the Ribosome To and Across the Membrane**
 Matthias Müller, Hans-Georg Koch, Konstanze Beck, and Ute Schäfer 107
- 5. The Intrinsically Unstable Life of DNA Triplet Repeats Associated with Human Hereditary Disorders**
 Richard P. Bowater and Robert D. Wells 159
- 6. Molecular and Cell Biology of Acid β -Glucosidase and Prosaposin**
 Xiaoyang Qi and Gregory A. Grabowski 203
- 7. Regulation and Function of the Cyclic Nucleotide Phosphodiesterase (PDE3) Gene Family**
 Yasmin Shakur, Lena Stenson Holst, Tova Rahn Landstrom, Matthew Movsesian, Eva Degerman, and Vincent Manganiello 241
- 8. Understanding Nuclear Receptor Function: From DNA to Chromatin to the Interphase Nucleus**
 Gordon L. Hager 279
- 9. A Unique Combination of Transcription Factors Controls Differentiation of Thyroid Cells**
 Giuseppe Damante, Gianluca Tell, and Roberto Di Lauro 307
- 10. Regulation of Metallothionein Gene Expression**
 Kalpana Ghoshal and Samson T. Jacob 357

VOLUME 67

Progress in Nucleic Acid Research and Molecular Biology

Kivie Moldave

- 1. The Molecular Biology of the Group VIA Ca^{2+} -Independent Phospholipase A^2**
 Zhongmin Ma and John Turk 1

- 2. CooA: A Heme-Containing Regulatory Protein That Serves as a Specific Sensor of Both Carbon Monoxide and Redox State**
Gary P. Roberts, Marc V. Thorsteinsson, Robert L. Kerby,
William N. Lanzilotta, and Thomas Poulos 35
- 3. The msDNAs of Bacteria**
Bert Lampson, Masayori Inouye, and Sumiko Inouye 65
- 4. Cisplatin: From DNA Damage to Cancer Chemotherapy**
Seth M. Cohen and Stephen J. Lippard 93
- 5. Molecular and Cellular Biology of the Human Reduced Folate Carrier**
Larry H. Matherly 131
- 6. Gene Targeting via Triple-Helix Formation**
Brian P. Casey and Peter M. Glazer 163
- 7. Searching New Targets for Anticancer Drug Design: The Families of Ras and Rho GTPases and Their Effectors**
Salvador Aznar and Juan Carlos Lacal 193
- 8. Major Histocompatibility Class I Folding, Assembly, and Degradation: A Paradigm for Two-Stage Quality Control in the Endoplasmic Reticulum**
Mark R. Farmery and Neil J. Bulleid 235

VOLUME 68**Progress in Nucleic Acid Research and
Molecular Biology**

Kivie Moldave, Sankar Mitra, Amanda McCullough,
R. Lloyd, and Samuel Wilson

**Session I Multiple Pathways for DNA Base
Excision Repair**

- 1. The Mechanism of Switching among Multiple BER Pathways**
Eugenia Dogliotti, Paola Fortini, Barbara Pascucci,
and Eleonora Parlanti 3
- 2. Yeast Base Excision Repair: Interconnections and Networks**
Paul W. Doetsch, Natalie J. Morey, Rebecca L. Swanson,
and Sue Jinks-Robertson 29
- 3. BER, MGMT, and MMR in Defense against Alkylation-Induced
Genotoxicity and Apoptosis**
Bernd Kaina, Kirsten Ochs, Sabine Grösch, Gerhard Fritz, Jochen Lips,
Maja Tomicic, Torsten Dunkern, and Markus Christmann 41
- 4. Session 2 Gene Targeting in the Mouse for Elucidating the Role
of BER**
Samuel H. Wilson 55
- 5. Mammalian DNA β -Polymerase in Base Excision Repair of
Alkylation Damage**
Robert W. Sobol and Samuel H. Wilson 57
- 6. Regulation of Intracellular Localization of Human MTH1,
OGG1, and MYH Proteins for Repair of Oxidative DNA
Damage**
Yusaku Nakabeppu 75

- 7. Repair of 8-Oxoguanine and Ogg 1-Incised Apurinic Sites in a CHO Cell Line**
Serge Boiteux and Florence Le Page 95
- 8. Mammalian *Ogg1/Mmh* Gene Plays a Major Role in Repair of the 8-Hydroxyguanine Lesion in DNA**
Susumu Nishimura 107
- 9. Session 3 Complexities of BER**
Michael Weinfeld 125
- 10. Molecular Mechanism of PCNA-Dependent Base Excision Repair**
Yoshihiro Matsumoto 129
- 11. Factors Influencing the Removal of Thymine Glycol from DNA in γ -Irradiated Human Cells**
Michael Weinfeld, James Z. Xing, Jane Lee, Steven A. Leadon, Priscilla K. Cooper, and X. Chris Le 139
- 12. Completion of Base Excision Repair by Mammalian DNA Ligases**
Alan E. Tomkinson, Ling Chen, Zhiwan Dong, John B. Leppard, David S. Levin, Zachary B. Mackey, and Teresa A. Motycka 151
- 13. Uracil-Initiated Base Excision DNA Repair Synthesis Fidelity in Human Colon Adenocarcinoma LoVo and *Escherichia coli* Cell Extracts**
Russell J. Sanderson, Samuel E. Bennett, Jung-Suk Sung, and Dale W. Mosbaugh 165
- 14. Session 4 DNA Glycosylases: Specificity and Mechanisms**
Sankar Mitra 189
- 15. Multiple DNA Glycosylases for Repair of 8-Oxoguanine and Their Potential *in Vivo* Functions**
Tapas K. Hazra, Jeff W. Hill, Tadahide Izumi, and Sankar Mitra 193

- 16.** DNA Substrates Containing Defined Oxidative Base Lesions and Their Application to Study Substrate Specificities of Base Excision Repair Enzymes
Hiroshi Ide 207
- 17.** Mechanism of Action of *Escherichia coli* Formamidopyrimidine *N*-Glycosylase: Role of K155 in Substrate Binding and Product Release
Lois Rabow, Radhika Venkataraman, and Yoke W. Kow 223
- 18.** Thymine DNA Glycosylase
Ulrike Hardeland, Marc Bentele, Teresa Lettieri, Roland Steinacher, Josef Jiricny, and Primo Schär 235
- 19.** Session 5 Mitochondrial DNA Repair
Vilhelm A. Bohr 255
- 20.** Enzymology of Mitochondrial Base Excision Repair
Daniel F. Bogenhagen, Kevin G. Pinz, and Romina M. Perez-Jannotti 257
- 21.** Base Excision Repair of Mitochondrial DNA Damage in Mammalian Cells
S. P. LeDoux and G. L. Wilson 273
- 22.** Base Excision Repair in Nuclear and Mitochondrial DNA
Grigory L. Dianov, Nadja Souza-Pinto, Simon G. Nyaga, Tanja Thybo, Tinna Stevnsner, and Vilhelm A. Bohr 285
- 23.** Session 6 Structural Implications of BER Enzymes: Dragons Dancing—The Structural Biology of DNA Base Excision Repair
John A. Tainer 299
- 24.** Crystallizing Thoughts about DNA Base Excision Repair
Thomas Hollis, Albert Lau, and Tom Ellenberger 305

- 25. DNA Damage Recognition and Repair Pathway Coordination Revealed by the Structural Biochemistry of DNA Repair Enzymes**
David J. Hosfield, Douglas S. Daniels, Clifford D. Mol,
Christopher D. Putnam, Sudip S. Parikh, and John A. Tainer 315
- 26. Potential Double-Flipping Mechanism by *E. coli* MutY**
Paul G. House, David E. Volk, Varatharasa Thiviyanathan,
Raymond C. Manuel, Bruce A. Luxon, David G. Gorenstein,
and R. Stephen Llyod 349
- 27. Properties and Functions of Human Uracil-DNA Glycosylase from the *UNG* Gene**
Hans E. Krokan, Marit Otterlei, Hilde Nilsen, Bodil Kavli,
Frank Skorpen, Sonja Andersen, Camilla Skjelbred,
Mansour Akbari, Per Arne Aas, and Geir Slupphaug 365

VOLUME 69

Progress in Nucleic Acid Research and Molecular Biology

Kivie Moldave

- 1. Modulation of RNA Function by Oligonucleotides Recognizing RNA Structure**
J. J. Toulmé, C. Di Primo, and S. Moreau 1
- 2. Regulation of the DNA Methylation Machinery and Its Role in Cellular Transformation**
Moshe Szyf and Nancy Detich 47
- 3. Lysosomal Multienzyme Complex: Biochemistry, Genetics, and Molecular Pathophysiology**
Alexey V. Pshzhetsky and Mila Ashmarina 81

- 4.** Phosphoribosylpyrophosphate Synthetase and the Regulation of Phosphoribosylpyrophosphate Production in Human Cells
Michael A. Becker 115
- 5.** Ethanol Catabolism in *Aspergillus nidulans*: A Model System for Studying Gene Regulation
Béatrice Felenbok, Michel Flipphi, and Igor Nikolaev 149
- 6.** The ROR Nuclear Orphan Receptor Subfamily: Critical Regulators of Multiple Biological Processes
Anton M. Jetten, Shogo Kurebayashi, and Eiichiro Ueda 205
- 7.** PDE4 cAMP-Specific Phosphodiesterases
Miles D. Houslay 249
- 8.** Domain–Domain Communication in Aminoacyl-tRNA Synthetases
Rebecca W. Alexander and Paul Schimmel 317

VOLUME 70

Progress in Nucleic Acid Research and Molecular Biology

Kivie Moldave

- 1.** Lysyl Oxidases: A Novel Multifunctional Amine Oxidase Family
Katalin Csiszar 1
- 2.** Distinct Regulatory Properties of Pyruvate Dehydrogenase Kinase and Phosphatase Isoforms
Thomas E. Roche, Jason C. Baker, Xiaohua Yan, Yasuaki Hiromasa, Xiaoming Gong, Tao Peng, Jianchun Dong, Ali Turkan, and Shane A. Kastan 33

- 3. A Tale of Two HSV-1 Helicases: Roles of Phage and Animal Virus Helicases in DNA Replication and Recombination**
Boriana Marintcheva and Sandra K. Weller 77
- 4. The RNA World of Plant Mitochondria**
Michaela Hoffmann, Josef Kuhn, Klaus Däschner, and Stefan Binder 119
- 5. Multiple Controlling Mechanisms of FGF1 Gene Expression through Multiple Tissue-Specific Promoters**
Ing-Ming Chiu, Kathy Touhalisky, and Chris Baran 155
- 6. Structure and Function of Branched Chain Aminotransferases**
Susan Hutson 175
- 7. Functional Significance and Mechanism of eIF5-Promoted GTP Hydrolysis in Eukaryotic Translation Initiation**
Supratik Das and Umadas Maitra 207
- 8. Nonribosomal Biosynthesis of Microbial Chromopeptides**
Ulrich Keller and Florian Schauwecker 233
- 9. Manipulation of tRNA Properties by Structure-Based and Combinatorial *in Vitro* Approaches**
Stefan Vörtler, Joern Pütz, and Richard Giegé 291

VOLUME 71

Progress in Nucleic Acid Research and Molecular Biology

Kivie Moldave

- 1. DNA Modifications by Antitumor Platinum and Ruthenium Compounds: Their Recognition and Repair**
Viktor Brabec 1

- 2. AMP- and Stress-Activated Protein Kinases: Key Regulators of Glucose-Dependent Gene Transcription in Mammalian Cells?**
Isabelle Leclerc, Gabriela da Silva Xavier, and Guy A. Rutter 69
- 3. Molecular Basis of Fidelity of DNA Synthesis and Nucleotide Specificity of Retroviral Reverse Transcriptases**
Luis Menéndez-Arias 91
- 4. Muc4/Sialomucin Complex, the Intramembrane ErbB2 Ligand, in Cancer and Epithelia: To Protect and To Survive**
Kermit L. Carraway, Aymee Perez, Nebila Idris, Scott Jepson, Maria Arango, Masanobu Komatsu, Bushra Haq, Shari A. Price-Schiavi, Jin Zhang, and Coralie A. Carothers Carraway 149
- 5. Functions of Alphavirus Nonstructural Proteins in RNA Replication**
Leevi Kääriäinen and Tero Ahola 187
- 6. The Unique Biochemistry of Methanogenesis**
Uwe Deppenmeier 223
- 7. A History of Poly A Sequences: From Formation to Factors to Function**
Mary Edmonds 285
- 8. A Growing Family of Guanine Nucleotide Exchange Factors Is Responsible for Activation of Ras-Family GTPases**
Lawrence A. Quilliam, John F. Rebhun, and Ariel F. Castro 391
- 9. Practical Approaches to Long Oligonucleotide-Based DNA Microarray: Lessons from Herpesviruses**
Edward K. Wagner, J. J. Garcia Ramirez, S. W. Stingley, S. A. Aguilar, L. Buehler, G. B. Devi-Rao, and Peter Ghazal 445
- 10. Sphingosine Kinases: A Novel Family of Lipid Kinases**
Hong Liu, Debyani Chakravarty, Michael Maceyka, Sheldon Milstien, and Sarah Spiegel 493

SUBJECT INDEX

Boldface numerals indicate volume number.

A

ATH1, *see* Trehalase

A protein, regulation of messenger RNA
polyadenylation, **57**, 62–63

A-Raf, **67**, 211

A+U rich elements, messenger RNA

AUF1 binding

α -globin messenger RNA stability
complex binding, **62**, 279–280

β -adrenergic receptor messenger RNA
turnover role, **62**, 263–264, 282–283

affinity of binding, **62**, 280–281

cloning, **62**, 273

destabilizing mechanism, **62**,
277–278, 287

dimerization, **62**, 278–279

discovery, **62**, 269–271

granulocyte-macrophage
colony-stimulating factor messenger
RNA turnover role, **62**, 283–284

Gro α messenger RNA turnover role,
62, 284

hexamer binding to *c-fos* messenger
RNA, **62**, 279

interleukin-1 β messenger RNA turnover
role, **62**, 284

isoforms from alternative RNA splicing, **62**,
275–277

protein-protein interactions, **62**, 278
purification, **62**, 271, 273
RNA recognition motifs, **62**, 273–275
subcellular localization, **62**, 276

AUH binding, **62**, 287

c-fos messenger RNA

half-life, **62**, 258, 268

mechanisms of ARE-mediated turnover,
62, 261–262, 269–271, 279

coexistence with multiple turnover
determinants, **62**, 262

deadenylation of messenger RNA, **62**,
261–262, 277

destabilizing activity, **62**, 259, 261

elav-like protein binding, **62**, 285

glyceraldehyde-3-phosphate binding, **62**,
285, 287

identification and characterization, **62**, 260

inducible turnover with trans-acting

factors, **62**, 263–264

site-directed mutagenesis studies, **62**, 260

trans-acting factor identification

affinity purification, **62**, 267

gel mobility-shift assay, **62**, 264–265, 280

Northwestern blot analysis, **62**, 263–264

reconstitution of decay reactions, **62**,
267–268

ultraviolet cross-linking, **62**,
265–266, 280

translation coupling with turnover, **62**,
262–263

A23187

double-stranded RNA-activated protein
kinase activation, **58**, 106–107

effect on protein translation, **58**, 94–95

A3:U70 substitution, in AlaRS, **69**, 326–327

A375 cells, Muc4/SMC, **71**, 174

A549 cells

DNA

electropherogram, **68**, 144

AA, **67**, 12

AA8 CHO cells

8-oxoG, **68**, 101

kinetics, **68**, 102

AAG, **68**, 306

D-AAT, *see* D-Amino acid aminotransferase

AAG-DNA complex

human, **68**, 307

AAG proteins

cisplatin, **67**, 114–115

AARS, *see* Aminoacyl-tRNA synthetases

- D-AAT, *see* D-Amino acid aminotransferase
- AAUAAA signal
 hybridization, **71**, 302–303
 poly A site UV crosslinking, **71**, 308
 polyadenylation, **71**, 291–292
- AB-GP205
 ankyrin-repeat domains, **67**, 12
- ABA, wound response, **72**, 190
- Abasic (AP) site. *See* AP site
- ABC transporter, *see* ATP-binding cassette transporter
- Abd1p, *see* RNA (guanine-7) methyltransferase
- ABF1
 autonomously replicating sequence binding, **65**, 288
 functions, overview, **65**, 264
- ABF1, autoregulation of promoter, **60**, 141–142
- ABF1, mitochondrial biogenesis in *Saccharomyces cerevisiae* and, **46**, 76–80
- ABP140, programmed +1 frameshifting, **64**, 157
- AbrB protein, *Bacillus subtilis* gene expression and, **46**, 124–132
- Acceptor stem, recognition of tRNA and, **41**, 44–58
- Accessory proteins, reverse transcription fidelity, **71**, 110–112
- Ace1
 A-T hook motif, **58**, 181–182
 copper binding stoichiometry, **58**, 178
 DNA binding, **58**, 174–175
 extended X-ray absorption fine structure analysis, **58**, 178–180
 mediation of copper activation of genes, **58**, 174, 186–188
 polycopper-thiolate cluster, **58**, 177–180
 structure, **58**, 174–176
 tetracopper domain, structure and function, **58**, 182–185
 transactivation domain, **58**, 182
 zinc binding, **58**, 180–181
- Acetaldehyde
 induction and intoxicification of *alc* gene system, **69**, 172–173
 intracellular levels, **69**, 191–192
- Acetate, methanogens
 conversion to CO₂ and methane, **71**, 238
 proton translocation, **71**, 256–258
- bis*-Acetatoaminedichloro(cyclohexylamine) platinum (IV)–DNA interactions, **71**, 33–34
- N-Acetoxyacetylaminofluorene, DNA sequence specificity, **63**, 381, 393–394
- Acetyl-coenzyme A, **70**, 55, 58
- N-2-Acetylaminofluorene, immunochemical analyses of nucleic acids and, **42**, 69–70
- Acetylation, histone, protamines and, **40**, 71–74
- N-Acetylglactosamine-6-sulfate-sulfatase, *see* GALNS
- Acetylhydrolase
 PAF, **67**, 4
 group VIA PLA₂, **67**, 21–22
 group VIIIA, **67**, 7
- Achondrogenesis type-II, collagen type-II gene mutations, **47**, 48–51
- Acid β -glucosidase
 acid phospholipid interactions and properties in activation, **66**, 226–227
 catalytic mechanism, **66**, 233–234
 control of expression, **66**, 210
 deficiency in Gaucher disease, **66**, 203
 dimerization on lipid binding, **66**, 227
 gene
 mutations in Gaucher disease, **66**, 206, 234
 structure of locus and surrounding region, **66**, 204
 glycosylation, **66**, 207
 lysosomal targeting, **66**, 207–209
 prospects for study, **66**, 234–235
 purification and reconstitution, **66**, 226
 saposin C activation
 acid phospholipid interaction, **66**, 225–226
 fusogenic activity, **66**, 229–233
 mechanism, **66**, 228–229
 structural analysis of activating segments, **66**, 223–225
 site-directed mutagenesis, **66**, 233–234
 tissue expression patterns, **66**, 206–207
 translational control, **66**, 209–210
- ACK 1/2, **67**, 201
 biological functions, **67**, 197
 drug design, **67**, 222
- Aclarubicin, inhibition of topoisomerase II, **64**, 242–243
- ACOI, *see* Aconitase, yeast
- Aconitase, yeast
 gene, **57**, 333

- mutant phenotypes, **57**, 333–334
- regulation of expression, **57**, 334
- signal sequence, **57**, 334
- structure, **57**, 333
- ACP domain, *see* Acyl carrier domain
- Acrocephalo-syndactyly type III, *TWIST*
 - mutation, **64**, 191–192
- ACT, role in cyclic AMP-responsive element
 - modulator activation in spermatogenesis, **64**, 361–363
- Actin-1 gene, rice, **45**, 16–17
- Actin filament binding protein, protein tyrosine kinase substrates and, **44**, 221
- Actin genes, *see* cl-15; pME₁ Aft1, mediation of iron repression of genes, **58**, 190
- Actin genes, rice, **45**, 3–5
- Actinomycin D, DNA sequence specificity, **63**, 382, 398
- Actinomycin D, effect on mRNA decay, **56**, 265–266
- Actinomycin synthetases, **70**, 253–255
- Actinomycin, biosynthesis
 - actinomycin synthetases, **70**, 253–255
 - enzymes, **70**, 252–253
 - phenoxazinone chromophore formation, **70**, 255–257
- Activating regions (AR), **67**, 57
- Activating transcription factor-1, **69**, 223
- Activating transcription factor 1 (ATF-1)
 - basic domain/leucine zipper, **64**, 346
 - dimerization, **64**, 346–347
- Activation
 - recombination by transcription factors, **50**, 92–93
 - ribosomal, growth-regulated, **50**, 54–55
- Activator protein 1, effect on HIV gene expression, **49**, 164
- Activators
 - PRPP synthetase reaction, **69**, 132–133
 - RORs as, ligand role, **69**, 217–218
- Activators, bacterial adenyl cyclases and, **44**, 41–43
- Acute lymphoblastic leukemia (ALL), **67**, 135
- Acute myeloid leukemia, *ELL* translocation, **56**, 340–341
- Acyl carrier domain, **70**, 242–243
- AD-1, conserved residues and motifs with Dyrk-related kinases, **62**, 4–7
- ADCL, *see* 4-Amino-4-deoxychorismate lyase
- Adenine, **68**, 209
- 8-oxoguanine
 - hMYH, **68**, 85–88
- Adeno-associated virus, **48**, 29–49
 - anti-oncogenesis, **48**, 41
 - as potential gene-therapy vector, **48**, 48–49
 - DNA in
 - integration, **48**, 35–40
 - integrated genome and flanking sequences in, **48**, 39–40
 - pre-integration site and, **48**, 38–39
 - site-specific, **48**, 36–38
 - replication of
 - auto-inhibition, **48**, 34–35
 - rep* proteins and, **48**, 43, 48
 - gene expression, negative regulation, **48**, 34
 - genetic map, **48**, 31–33
 - latency of
 - consequences, **48**, 40–41
 - establishment, **48**, 33–35
 - permissive state, **48**, 41–43
 - rescue and replication, **48**, 43–48
 - structure, **48**, 30
 - type 2, genome of, **48**, 31
- Adenocarcinoma
 - pol beta, **68**, 21
- Adenocarcinoma cells, Muc4/SMC, **71**, 173
- Adenosine 3',5'-cyclic monophosphate, *see* Cyclic AMP
- Adenosine deaminase, murine
 - biological roles, **55**, 196–197
 - gastrointestinal tract, **55**, 220–221
 - immune system
 - lymphopenia prevention, **55**, 217–218
 - metabolic disturbances and immuno-deficiency, **55**, 216, 218–219
 - secondary deciduum
 - postimplantation development, **55**, 219
 - reproductive status, **55**, 219–220
- deficient mice
 - generation by homologous recombination, **55**, 208–209
 - knockout in specific tissues, **55**, 216
 - metabolic disturbances, **55**, 209, 211–213
- expression
 - placenta regulation, **55**, 204–206
 - postnatal expression, **55**, 200–201, 203
 - prenatal development, **55**, 198, 200
 - thymus regulation, **55**, 206–207, 222
 - tissue-specific activity, **55**, 197–198, 200, 221–222

- Adenosine deaminase, murine (*cont.*)
 gene
 model for expression, **55**, 207–208
 promoter, **55**, 203–204
 structure, **55**, 203–204
 reaction catalyzed, **55**, 195
 reconstitution in placenta
 effect on survival, **55**, 214, 222–223
 minigene, **55**, 213
 prevention of metabolic disturbances, **55**,
 214–216
 sequence analysis, **55**, 195–196
 structure, **55**, 196
- Adenosine–uridine binding factor (AUBF)
 discovery, **56**, 276
 mRNA stabilization, **56**, 280
 regulation, **56**, 277–280
 sequence recognition, **56**, 276–277
- Adenosine, RNA phage coat proteins and, **40**,
 204–206
- S-Adenosylmethionine
 methyl donor
 DNA (cytosine-5)methyltransferase, **49**,
 66–68, 72
 rRNA methylation, **49**, 232
 nonenzymatic methylation of DNA, **49**, 104
- Adenoviral DNA integration, **46**, 1–5
 gene expression, **46**, 30–32
 insertional mutagenesis, **46**, 32–33
 mechanism, **46**, 21–23
 cell-free system, **46**, 11–18
 recombination, **46**, 18–21
 methylation, **46**, 23–26
 host defense mechanism, **46**, 26–27
 insertion in sequences, **46**, 30
 origin, **46**, 28–29
 viral replication cycles, **46**, 27–28
 survey of findings, **46**, 5–8
 uptake by mammalian cells, **46**, 8, 10–11
 DNA–protamine complexes, **46**, 8–10
- Adenovirus, polyadenylation sites in late
 transcription unit messenger RNA, **57**, 59
- Adenovirus, primary transcript processing,
71, 290
- Adenovirus, shunt, **72**, 17–19
- Adenylate cyclase, Ras-response, in *Saccharo-
 myces cerevisiae* growth control, **48**, 4–5
- Adenylation domains, **70**, 236–237
- Adenylosuccinate lyase, purine nucleotide
 biosynthesis and, **42**, 278–279
- Adenylosuccinate synthetase, purine
 nucleotide biosynthesis and, **42**, 280–282
- Adenylyl cyclase, AC3, colocalization with
 PDE1C2, **69**, 258–259
- Adenylyl cyclases
 abundance in cells, **49**, 241–243, 261–262
Bacillus anthracis enzyme
 active site residues, **49**, 260
 calmodulin
 binding domain, **49**, 260–261
 enzyme activation, **49**, 251, 260
 evolution, **49**, 272, 275
 gene cloning, **49**, 259
 metal requirement, **49**, 260
 purification, **49**, 259
 secondary structure, **49**, 260–261
- Bordetella pertussis* enzyme
 calmodulin
 binding site, **49**, 254–256
 enzyme activation, **49**, 251, 254, 257
 domains
 catalytic, **49**, 253–257
 hemolysin, **49**, 257–259
 evolution, **49**, 272, 275
 gene cloning, **49**, 252–253
 heterogeneity of preparations, **49**, 251–252
 inhibitors, **49**, 256–257
 purification, **49**, 252
 site-directed mutagenesis, **49**, 276
 size, **49**, 252–253
- calcium modulation, **49**, 271
- class III enzymes
 domains, **49**, 263
 gene cloning, **49**, 262–266
 heterodimerization, **49**, 267
 modulation of activity
 calmodulin, **49**, 263–265
 forskolin, **49**, 262
 G proteins, **49**, 262–263
 phylogenic relationship, **49**, 273–275
 purification, **49**, 262, 264
 recombinant enzyme expression,
 49, 264–265
 sequence homology, **49**, 262–263,
 265–266, 268–269
 types, **49**, 265–266, 273
- classes, **49**, 242
- Gram-negative facultative anaerobe enzyme
 domains, **49**, 246
 gene cloning, **49**, 243–246

- modulation of activity
 - cAMP, **49**, 246
 - glucose, **49**, 249
 - G proteins, **49**, 250–251
 - phosphorylation, **49**, 250
- oxidation, **49**, 244
- phylogenetic relationships, **49**, 271–272
- purification, **49**, 242–243
- secondary structure, **49**, 244
- sequence homology, **49**, 244–249
- storage, **49**, 243
- pulsation of cAMP production, **49**, 275–276
- similarity to guanylyl cyclases, **49**, 267, 270–271, 273–274
- Adenylyl cyclases, bacterial, *see* Bacterial adenylyl cyclases
- ADH, *see* Alcohol dehydrogenase
- Adipocyte differentiation
 - growth factor effects, **60**, 329
 - insulin effects, **60**, 328–329
 - models *in vitro*, **60**, 328
 - peroxisome proliferator activator receptor role, **60**, 328
- preadipocyte factor-1
 - adipocyte differentiation role, **60**, 340–342
 - embryogenesis role, **60**, 342–343
 - epidermal growth factor repeat motif, **60**, 329–330
 - gene structure, **60**, 332–334
 - glycosylation, **60**, 335–336
 - levels during differentiation, **60**, 330–332, 342
 - phosphorylation, **60**, 338–339
 - proteolytic processing, **60**, 336–337
 - signal sequence, **60**, 339–340
 - soluble forms, **60**, 337–340
 - spliced products, **60**, 334–335, 341–342
- AdoMet, *nrdG* protein, **72**, 119
- AdoMet, *see* S-Adenosylmethionine
- Adozelesin, DNA sequence specificity, **63**, 379, 387–388
- ADP-ribosylation factors, **45**, 47–49
 - biochemistry, **45**, 49–55
 - function in animal cells, **45**, 60–63
 - structure, **45**, 55–60
- ADP, inhibitor of PRPP synthetase, **69**, 130–132
- ADP glucose pyrophosphorylase, bacterial
 - allosteric properties
 - alternation via cloning, **47**, 324–326
 - regulation via, **47**, 315–319
 - effector sites, **47**, 319–326
 - chemical modification studies, **47**, 319
 - site-directed mutagenesis
 - lysine residue, **47**, 39, 195, 319–324
 - tyrosine residue, **47**, 114, 322–323
- β -Adrenergic kinase
 - inhibition, **49**, 139
 - role in receptor desensitization, **49**, 138–139
 - substrate phosphorylation sites, **49**, 138, 142
- β_2 -Adrenergic receptors
 - agonist
 - binding site, **49**, 121–124
 - structure, **49**, 121–123
 - desensitization, **49**, 137–140
 - down-regulation, **49**, 143
 - effects of domain deletions, **49**, 121
 - G protein binding site, **49**, 131–133
 - messenger RNA stability, **49**, 143–144
 - phosphorylation, **49**, 138–139, 143
 - regulation by steroid hormones, **49**, 144
 - sequestration, **49**, 140–141
- Adriamycin, DNA sequence specificity, **63**, 380, 391
- β -Adrenergic receptor messenger RNA, turnover role of AUF1, **62**, 263–264, 282–283
- ADRP, *see* Autosomal dominant retinitis pigmentosa
- AF-2 region, ROR, **69**, 211–212
- Affinity chromatography, *see specific deoxynucleotide kinases*
- Affinity chromatography, enzymes in DNA precursor biosynthesis and, **44**, 183–185
- Affinity selection, and somatic hypermutation, **50**, 70–71
- Affinity, *vs.* specificity, antisense oligomer, **69**, 16–18
- Aflatoxin, DNA sequence specificity, **63**, 381, 394
- AFM, *see* Atomic force microscopy
- African green monkey kidney cells, **68**, 236
- Agarose gel electrophoresis
 - M13mp2op14 DNA, **68**, 173
- Aggrecan
 - developmental expression, **62**, 182–184, 204
 - domains
 - C-terminal domain, **62**, 193–194
 - chondroitin sulfate-rich region, **62**, 195–197
 - keratin sulfate domain, **62**, 194–195

- Aggrecan (*cont.*)
 N-terminal hyaluronate-binding region, **62**, 191–193
 sequence alignment, **62**, 188, 191
 gene
 evolution
 exon shuffling, **62**, 209–210
 link protein comparison, **62**, 210–211
 phylogenetic analysis, **62**, 211, 215–216
 exons
 chondroitin sulfate-rich region, **62**, 201
 comparison between species, **62**, 197
 C-terminal G3 domain, **62**, 201–202
 interglobular domain, **62**, 198
 keratin sulfate domain, **62**, 198, 201
 N-terminal domain, **62**, 198
 mapping, **62**, 217–220
 promoter homology between species, **62**, 36–37
 size, **62**, 216–217
 mutations in disease, **62**, 218–220
 structure, **62**, 35–36, 179–192
 synthesis and secretion, **62**, 184
 transcriptional regulation
c-fos, **62**, 40
 cytokines, **62**, 39–40
 growth factors, **62**, 39
 link protein comparison, **62**, 208–209
 NF- κ B, **62**, 205–206
 promoter, **62**, 36–37, 204–207
 prostaglandins, **62**, 37
 silencers, **62**, 205
 vitamin D, **62**, 37
 AGGTCA core motif
 mutation, **69**, 240
 ROREs, **69**, 214–215
 Aging, **68**, 274
 mtDNA, **68**, 295–296
 ROS, **68**, 96
Agrobacterium tumefaciens, *OccR*
 transcriptional activator, **47**, 245
Agrobacterium, rice genes and, **45**, 16
 AGT, **68**, 316–319
 O⁶-MeG, **68**, 43–44
 pol beta-deficient cells, **68**, 52
 regulation, **68**, 47–49
 AICAR transformylase, purine nucleotide biosynthesis and, **42**, 279–280
 AICAR, *see* 5-Aminoimidazole-4-carboxamide riboside
 AIDS, latent viruses and mutated oncogenes and, **43**, 140–152
 AIR carboxylase, purine nucleotide biosynthesis and, **42**, 276–278
 AIR synthetase, purine nucleotide biosynthesis and, **42**, 274–276
 Airborne molecules, in synthesis of RQ RNAs, **51**, 240–241
 Airway, mucociliary transport, Muc4/SMC, **71**, 163–164
 D-Alanine aminotransferase, **70**, 189–190
 β -Alanine synthase
 5-fluorouracil degradation, **53**, 51–52
 allosteric regulation by oligomer dissociation, **53**, 13–15, 52–57
 complementary DNA from rat liver, **53**, 57–59
 importance, **53**, 49–51
 sequence homology with other enzymes, **53**, 57–59
 Alanine synthetases, recognition of tRNA and, **41**, 44–51
 Alanyl-tRNA synthetase
 fragment 461N, **69**, 321–322
 G3:U70 base pair, **69**, 320–321, 326–327
 ALAS-1 *see* 5-Aminolevulinate synthase, housekeeping
 ALAS-2, *see* 5-Aminolevulinate synthase, erythroid
 ALAS, *see* 5-Aminolevulinate synthase
 Albright hereditary osteodystrophy
 characterization, **47**, 95–97
 G α expression, **47**, 97–100
 Albumin, mRNA, stability regulation, **72**, 142–143
alc gene system
 induction, **69**, 167–174
 role in research, **69**, 192–195
alc genes
 cluster, **69**, 188–190
 regulation: mechanism, **69**, 180–192
alcA
 promoter, *AlcR* targets in, **69**, 183–186
 transcriptional repression, **69**, 186
alcA/ADH I, *A. nidulans*, **69**, 154
 Alcohol dehydrogenase, **40**, 255–256
 biochemistry
 distribution of isozymes, **40**, 256
 expression, **40**, 260
 regulation, **40**, 260

- structure, **40**, 257–260
- substrates, **40**, 256–257
- isozymes, genetics of
 - evolution, **40**, 268–269
 - genomic structure, **40**, 260–265
 - polymorphism, **40**, 267–268
 - RFLP, **40**, 265–267
- Alcohol dehydrogenase (ADH)
 - cellular retinol-binding protein, activity against bound ligands, **63**, 149
 - classes in retinol dehydration, **63**, 178–180
 - classification, **63**, 177
 - classification
 - history of classification, **64**, 297
 - overview, **64**, 297–298
 - prospects, **64**, 298
 - fetal alcohol syndrome, retinol dehydrogenation inhibition in pathogenesis, **63**, 180–182
 - gene regulation, *see* Class I alcohol dehydrogenase gene; Class II alcohol dehydrogenase gene; Class III alcohol dehydrogenase gene; Class IV alcohol dehydrogenase gene; Class V alcohol dehydrogenase gene; Class VI alcohol dehydrogenase gene
 - gene structure and localization, **64**, 300–301
 - kinetic parameters, **64**, 299
 - ligand binding of various types, **63**, 177–178
 - physiological functions, **64**, 296
 - promoters
 - CCAAT/enhancer-binding protein sites, **64**, 333
 - cis-acting elements, **64**, 333
 - Sp1 sites, **64**, 333
 - types, **64**, 303
 - retinoic acid
 - biosynthesis role, **63**, 179–180
 - responsive elements in genes, **63**, 179
 - retinol metabolism in deer mouse, **63**, 178
 - tissue-specific expression
 - expressed sequence tag studies in tissue libraries, **64**, 302–303
 - overview, **64**, 301–302
 - upstream AUG codons in messenger RNA, **64**, 334
- Alcohol dehydrogenase, three forms, **69**, 154–155
- Alcohol-metabolizing enzymes, *see* Human alcohol-metabolizing enzymes
- AlcR
 - alcA* promoter
 - binding sites, **69**, 195
 - targets in, **69**, 183–186
 - consensus repeated sites, **69**, 180–181
 - control of *aldA* promoter, **69**, 187
 - dimer *vs.* monomer, **69**, 159–160
 - in *alc* gene expression, **69**, 189
 - overexpression, **69**, 174
 - specificity of DNA binding, **69**, 160–164, 196
 - subcellular localization, **69**, 165–166
 - zinc binuclear cluster protein, **69**, 156–159
- alcR-alcA*, expression system, **69**, 193–195
- AlcR(1:60)–DNA complex, NMR structure, **69**, 164–165
- alcR*
 - characteristics, **69**, 156
 - gene expression, control of, **69**, 181–183
 - promoter, **69**, 180–181
- aldA*
 - absence of direct repression, **69**, 197–198
 - loss-of-function mutants, **69**, 170–172
 - promoters, **69**, 191
 - regulation, **69**, 187–188
- aldA*/ALDH, *A. nidulans*, **69**, 155–156
- Aldehyde
 - structure, **68**, 8
- Aldehyde dehydrogenase, **40**, 269–270
 - aldA* encoded by, **69**, 167
 - biochemistry, **40**, 270–276
 - characteristics, **69**, 155–156
 - genetics, **40**, 277
 - genomic structure, **40**, 277–279
 - polymorphisms, **40**, 279–282
 - isozymes, **40**, 274–276
 - developmental expression, **40**, 276
 - structure, **40**, 272–274
 - role in multiple catabolic pathways, **69**, 170–172
 - substrates: inducers of *alc* gene system, **69**, 173–174
- Aldehyde-reactive probe-slot-blot method
 - AP site, **68**, 62
- ALDH, *see* Aldehyde dehydrogenase
- Alfalfa mosaic virus RNA, replication of, **42**, 186–193
- Aliphatic amines, DNA–transplatin analogs, **71**, 42
- Alka
 - Escherichia coli*, **68**, 308–310

- Alkali-labile sites
 comet assay, **68**, 62
- Alkaline single-cell electrophoresis (SCGE), **68**, 18
- Alkoxyamine-adducted site, **68**, 12
- Alkyladenine DNA glycosylase
 human
 structure, **68**, 307–308
- Alkyladenine glycosylase (AAG), **68**, 306
- O*⁶-Alkylguanine, alkylation damage repair in
 genomes and, **44**, 112–114
- N*-Alkylpurines, alkylation damage repair in
 genomes and, **44**, 114–116
- Alkylated bases
 recognition, **68**, 311–312
- Alkylating agents, **68**, 30, 42
 chromatin-bound PCNA complex, **68**, 23
- Alkylation damage repair in genomes
 cloning, **44**, 118–120
 DNA methylation, **44**, 128–129
 drug resistance
 DNA repair, **44**, 132–135
 gene amplification, **44**, 135–136
 history, **44**, 109–112
 inducibility, **44**, 129–132
N-alkylpurines, **44**, 114–116
N-methylpurine-DNA glycosylase
 (MPG), **44**, 120–128
*O*⁶-alkylguanine, **44**, 112–114
*O*⁶-methylguanine-DNA methyltransferases
 (MGMT)
 properties, **44**, 116–118
 regulation, **44**, 120–128
 outlook, **44**, 136–137
- O*⁶-Alkylguanine-DNA alkyltransferase,
see Alkyltransferase
- O*⁶-Alkylguanines, in chemotherapy, **51**,
 210–214
- Alkylnitrosoureas, cytotoxic effects,
 resistance, **51**, 201
- Alkylphosphocholines (APCs), **67**, 217
- O*⁴-Alkylthymine, repair, **51**, 191–192
- Alkyltransferase
 gene structure and promoter activity, **51**,
 196–198
 inactivation, in enhancement of
 chemotherapy, **51**, 209–214
 induction and tissue-specific levels, **51**,
 198–200
 mechanism of inhibition, **51**, 187–189
 occurrence and purification, **51**, 170–174
 small inactivators, **51**, 182–187
 structure and reaction mechanism, **51**,
 174–178
 substrate specificity and metabolism, **51**,
 191–196
 transgenic expression, **51**, 208–209
- ALL, **67**, 135
- Allene oxide cyclase, **72**, 175–176
- Allene oxide synthase, **72**, 173–175
- Allosteric mechanism, ribonucleotide
 reductases, **72**, 108–114
- Allosteric regulation
 conformational change stabilized by
 ligand, **53**, 16–17
 enzyme oligomer dissociation, **53**, 13–15
 ligand binding between subunits, **53**, 17–18
- Allosteric three-site model, *see* Elongation,
 protein
- Alpha-hOgg1, **68**, 96
- Alpha operon, **47**, 348–351
- α proteins, HSV-1, *trans*-activation by, **51**,
 134–137
- α - ϵ model, *see* Elongation, protein
- $\alpha_2\beta_2$ complex, *nrdG* protein, **72**, 115–116
- α_2 -Adrenergic receptors,
 desensitization, **49**, 141
- Alphavirus-like superfamily, **71**, 190–191
- Alphaviruses
 characteristics, **71**, 187–188
 nonstructural polyprotein P1234, **71**, 197
- nsP1
 guanylyltransferase activity, **71**, 198–201
 membrane association, **71**, 201–203
 methyltransferase activity, **71**, 198–201
 minus-strand RNA synthesis, **71**, 203–204
- nsP2
 neuropathogenicity, **71**, 206–208
 NTPase activity, **71**, 204–205
 nuclear transport, **71**, 206–208
 protease activity, **71**, 206
 RNA helicase activity, **71**, 204–205
 RNA triphosphatase activity, **71**, 205–206
- nsP3
 features, **71**, 210
 phosphorylation, **71**, 209–210
 sequence conservation, **71**, 208–209
- nsP4, **71**, 210–211
- replication complex, **71**, 211–214
- replication cycle, **71**, 188–190

- RNA replication
 - genome complement, **71**, 192–194
 - plus-strand RNA synthesis, **71**, 194–196
 - 26S mRNA, **71**, 196–197
- Alport's syndrome, *COLA/A5* mutations, **47**, 64
- ALS, **68**, 278
- ALS, *see* Amyotrophic lateral sclerosis
- Alternative splicing
 - iPLA₂ β , **67**, 17–19
- Altromycins, DNA sequence specificity, **63**, 378, 387
- Alu
 - arrangement in genome, **53**, 304
 - cheap-gene hypothesis, **53**, 284–285, 302–303
 - EPL Alu, **53**, 299–300
 - evolution, **53**, 296, 298–301
 - genetic effects, **53**, 284, 301–302
 - internal promoter, **53**, 291–292
 - methylation and imprinting role, **53**, 305–307, 313–314
 - prevalence in human genome, **53**, 291
- RNA
 - cell stress response, **53**, 311–313
 - expression *in vivo*, **53**, 307–308
 - promoter strength, **53**, 308–309
 - regulation of expression, **53**, 309–310
 - species, **53**, 310
- SINE inactivation, **53**, 300–301
- subfamilies, **53**, 298–299
- Alzheimer's disease, **68**, 278
- Alzheimer's disease, neurofilament disorders, **61**, 2, 10
- AMD574, DNA sequence specificity, **63**, 386
- AmidoPRTase, in purine synthesis, **69**, 122–123
- Amiloride-sensitive sodium channel
 - ankyrin-repeat domains, **67**, 12
- trans*-Amine(cyclohexylamine)
 - dichlorodihydroxoplatinum(IV), **71**, 42
- Amine ligand, DNA-transplatin analogs, **71**, 38–40
- 4-Amino-4-deoxychorismate lyase
 - branched chain aminotransferase, **70**, 193–194
 - distribution, **70**, 190
- Amino-acid-acceptor specificity, recognition of tRNA and, **41**, 25–29
- D-Amino acid aminotransferase
 - branched chain aminotransferase, 193–194
 - structure, 190–193
- Amino acid residues, HIV-1 RT
 - dNTP-binding site, **71**, 114–121
 - mutational analysis overview, **71**, 112–113
 - other residues, **71**, 127–128
 - primer strand, **71**, 123–126
 - template strand, **71**, 121–123
- D-Amino acid aminotransferase
 - branched chain aminotransferase, 193–194
 - structure, 190–193
- Amino acid sequence, alkyltransferase, **51**, 171
- Amino-acid sequences, proline-rich protein
 - multigene families and, **41**, 9–11
- Amino acid sequences, protamines and, **40**, 30–33
 - avian, **40**, 37–38
 - bony fish, **40**, 33–37
 - dogfish, **40**, 38–39
 - mammalian P1, **40**, 37–38
 - mammalian P2, **40**, 38
- Amino acid substitution, PRS1 cDNAs, **69**, 136–137
- Amino acid, control of gene expression
 - asparagine synthetase, **53**, 232–237
 - bacteria, **53**, 219–220
 - plasma membrane transport, adaptive regulation, **53**, 226–232
 - ribosomal proteins, **53**, 238–239, 241–245
 - yeast, **53**, 220–221, 223–228
- Amino acids
 - CAD, TAF interaction, **72**, 281
 - RNA contacts, **72**, 229–230
- Amino acids, aromatic, biosynthesis, **50**, 322–323
- Amino acids, misactivated, editing of, **69**, 340
- Amino acids, tRNA mimic affinity, **70**, 327–332
- Amino acids, trp repressor and, **42**, 16–18
- Amino oxidase activity
 - LOXL, **70**, 16–18
 - lysyl oxidase, **70**, 16–18
- 9-Aminoacridine carboxamide platinum
 - complexes, DNA sequence specificity, **63**, 378, 386
- Aminoacyl-tRNA
 - binding by eukaryotic translation elongation factor 1 α , **60**, 57–58
 - channeling by eukaryotic translation elongation factor 1 α , **60**, 62–64, 72
- Aminoacyl-tRNA synthetase, transcriptional attenuation role, **62**, 364

- Aminoacyl-tRNA synthetases, **40**, 95–97,
 134–135; **45**, 147–149
 arginine-accepting tRNAs, **70**, 319–321
 as autoantigens, **48**, 122–124
 aspartate-accepting tRNAs, **70**, 319–321
 binding domain
 evidence for, **40**, 107–110
 in vivo, **40**, 115–116
 structure, **40**, 110–115
 biosynthesis in eukaryotic cells, **40**,
 128–134
 catalytic domains, **69**, 318
 cell biology and, **48**, 133–134
 complexes, **45**, 159–166
 complexes
 spatial structure, **48**, 102–103
 with mRNA, **48**, 121–122
 complexes in higher eukaryotes
 composition, **40**, 116–122
 function, **40**, 126–128
 hydrophobic interactions, **40**, 122–126
 conformational changes, **69**, 333
 example, **48**, 107–114
 features, **40**, 97–99
 eukaryotic, **40**, 107
 free cytoplasmic, tryptophanyl-tRNA
 synthetase as
 glutamyl-tRNA synthetase, **70**, 315–316
 higher eukaryotic, **48**, 83–134
 classification, **48**, 86–87, 87–89, 90
 identity, **45**, 166–169
 antideterminants, **45**, 189–190
 conformational features, **45**, 186–188
 evolution, **45**, 190–192
 nucleotides, **45**, 169–180
 RNA substrates, **45**, 180–186
 in dinucleoside oligophosphate synthesis, **48**,
 125–126
 in glycosyl bond cleavage, **48**, 126–127
 in splicing mitochondrial group-I introns, **48**,
 119–121
 isoleucyl-tRNA synthetase, **70**, 317
 leucine-accepting tRNAs, **70**, 319–321
 mammalian
 compartmentalization, **48**, 105–106
 genes encoding
 chromosomal location, **48**, 117
 genomic organization, **48**, 117
 transcriptional regulation, **48**, 117–118
 intracellular localization, **48**, 106–107
 structural features of N-terminal
 extensions, **48**, 94–95, 96–97, 98, 99
 multiplicity, **48**, 115–117
 phenylalanine-accepting tRNAs, **70**,
 318–319
 phenylalanine-tRNA synthetase, **70**,
 316–317
 purinenucleoside triphosphatase activity
 and, **48**, 127–128
 ribozyme-catalyzed tRNA
 aminoacylation, **70**, 326–327
 self-aminoacylatable RNA, **70**, 324–325
 serine-accepting tRNAs, **70**, 319–321
 structure
 oligomeric, **40**, 99–101
 primary, **40**, 101–107
 tRNA identity elements recognized by, **69**,
 345
 tRNA mimic selection, **70**, 314
 tRNA pair, **70**, 300–301
 unusual reactions catalyzed by, **48**, 125–128
 valine-accepting tRNA-like molecules, **70**,
 321–323
 Aminoacyl-tRNA synthetases, recognition of
 tRNA by, *see* tRNA, recognition of
 Aminoacylation
 communication in, **69**, 335–337
 efficiency, domain–domain communication
 and, **69**, 325–329
 ribozyme-catalyzed tRNA
 aminoacylation, **70**, 326–327
 systems, noncovalent assembly, **69**, 323–325
 transplanted tRNAs, **70**, 299–300
 tRNA, **69**, 322–324
 Aminoacylation, tRNA structure and, *see*
 tRNA structure, aminoacylation and
 2'-Aminoethoxy substitution, and triplex
 stabilization, **69**, 22
 Aminoglycosides, RNA ligands, **69**, 4
 5-Aminoimidazole-4-carboxamide riboside,
 AMPK activation, **71**, 72–73
 5-Aminolevulinate synthase
 erythroid, synthesis, **51**, 33
 hepatic, heme effects, **51**, 13–15
 housekeeping and erythroid
 gene structure, **51**, 9–11
 isozymes, **51**, 6–9
 housekeeping, molecular regulation, **51**,
 11–17
 role in heme biosynthesis, **51**, 3–6

- transcription, drug-induced, **51**, 17–20
- Aminopeptidase N, δ -endotoxin binding, **60**, 15–16
- Aminophosphine platinum(II) compounds–DNA interactions, **71**, 31–32
- Ammonia, glutamine synthetase role in homeostasis, **61**, 244, 251–252, 257
- Ammonia, role in *Dictyostelium discoideum* stalk cell differentiation, **47**, 21
- AMP-activated protein kinase
- characteristics and function, **71**, 70
 - gene transcription downstream targets, **71**, 77–78
 - liver gene expression, **71**, 71–73
 - muscle tissue gene expression, **71**, 77
 - pancreatic β -cell gene expression, **71**, 74–77
- Amphibian metamorphosis, thyroid hormone regulation
- comparison with mammalian models, **65**, 91–92
 - interconversion of hormone forms, **65**, 58–59
 - intestine development, *see* Intestinal remodeling, *Xenopus* studies of thyroid hormone
 - levels in development, **65**, 56
 - overview, **65**, 54–55
 - precocious metamorphosis induction, **65**, 56–57
 - prospects for study, **65**, 93
 - thyroid inhibition effects, **65**, 57–58
- AMPK, *see* AMP-activated protein kinase
- Amplification, of DNA sequences, *see* DNA sequence amplification in mammalian cells
- Ampligen, **52**, 55
- Amt1
- A-T hook motif, **58**, 181–182
 - copper binding stoichiometry, **58**, 178
 - extended X-ray absorption fine structure analysis, **58**, 178–180
 - mediation of copper activation of genes, **58**, 175
 - polycopper-thiolate cluster, **58**, 177–180
 - structure, **58**, 175–176
 - tetracopper domain, structure and function, **58**, 182–185
 - transactivation domain, **58**, 182
 - zinc binding, **58**, 180–181
- AMT1, autoregulation of promoter, **60**, 156
- AMV, *see* Avian myeloblastosis virus
- Amyloid precursor protein, mRNA stability, **56**, 271–272
- Amyloid precursor protein, polyadenylation sites in messenger RNA, **57**, 58
- Amyotrophic lateral sclerosis
- neurofilament disorders, **61**, 2, 10, 13–16
 - superoxide dismutase mutation
 - incidence in disease, **61**, 16–17
 - role in neurofilament accumulation, **61**, 18
 - toxicity, **61**, 17–18
- Amyotrophic lateral sclerosis (ALS), **68**, 278
- Anaerobic CO-oxidizing microbes, **67**, 37
- Anaerobic ribonucleotide reductases
- gene organization and regulation, **72**, 120
 - multicomponent system definition, **72**, 99
- nrdD* protein
- allosteric regulation, **72**, 108–114
 - glycyl radical enzyme definition, **72**, 99–101
 - site-directed mutagenesis studies, **72**, 101–103
 - substrate reduction, **72**, 106–108
 - 3D structure, **72**, 103–106
- nrdG* protein
- activation reaction, **72**, 116–119
 - $\alpha_2\beta_2$ complex, **72**, 115–116
 - iron–sulfur protein definition, **72**, 114–115
 - iron–sulfur protein prototype, **72**, 119
 - overview, **72**, 96–98
 - RNA–DNA link, **72**, 120–124
- Anaphase-promoting complex, proteolysis in mitosis, **72**, 52
- Androgen receptor (AR)
- gene structure
 - DNA binding domain, **59**, 290–291
 - overview, **59**, 290
 - steroid binding domain, **59**, 291 - posttranscriptional regulation of gene, **59**, 296–298
 - transcription
 - autoregulation, **59**, 293, 303–304
 - characterization of 5' flanking region, **59**, 294–296
 - cyclic-AMP response element, **59**, 295
 - enhancers, **59**, 291, 298
 - negative regulation, **59**, 295–296

- Androgen receptor (AR) (*cont.*)
 second messengers in regulation, **59**, 293–294
 suppressors/repressors, **59**, 292–293, 298
 trans-acting factors, **59**, 291–292
- Androgen receptor, *see* Steroid receptor
- Androgen receptor, mutation in human disease, **64**, 199, 201
- Anemia
 sickle cell, **67**, 179
- Anemia, hereditary sideroblastic, **51**, 41–46
- Angiogenin, *see* Mammalian ribonuclease inhibitor
- Animal lectins, calcium-dependent, *see* Calcium-dependent animal lectins
- Animal viruses, shunt
 adenovirus, **72**, 17–19
 internal initiation combinations, **72**, 21
 papillomaviruses, **72**, 20–21
 Sendai virus, **72**, 19–20
- Aniridia type II, *PAX6* mutation, **64**, 194, 196
- Ankyrin
 brain, **67**, 12
 epithelial, **67**, 12
 erythroid, **67**, 12
 iPLA₂, **67**, 13
 lymphocyte, **67**, 12
- Ankyrin-binding glycoprotein 205 (AB-GP205)
 ankyrin-repeat domains, **67**, 12
- Ankyrin proteins
 ankyrin repeats, **67**, 11
- Ankyrin-repeat domains
 integral membrane proteins, **67**, 12
 iPLA₂ β , **67**, 10–14
 alignment, **67**, 10
 proteins, **67**, 11
- Annealing, nucleic acid chaperone proteins, **72**, 235–237, 245
- ANPG, **68**, 14
- Anterior-like cells, *Dictyostelium discoideum*
 characterization, **47**, 10–13
 movement at culmination, **47**, 17–18
- Anterior pituitary, Pit-1 expression in development, **63**, 226, 248
- Anthramycin, DNA sequence specificity, **63**, 380, 392
- Anti-idiotypic antibodies, enzymes in DNA precursor biosynthesis and, **44**, 185–186
- Antiadhesion agent, Muc4/SMC, **71**, 155
- Antibiotic resistance, EF-Tu target, **71**, 534–535
- Antibiotic, inhibition of protein translation, **54**, 311–313
- Antibiotics
 mikamycin B-streptogramin, **70**, 259–261
 quinoxaline, biosynthesis, **70**, 257–259
- Antibiotics, complexes with aptamers, **69**, 38
- Antibiotics, EF-Tu target
 binding sites, **71**, 535–537
 kirromycin and EF-1 α , **71**, 537–538
 mode of action, **71**, 532–533
 overview, **71**, 531–532
 resistance, **71**, 534–535
- Antibodies
 antisense oligonucleotides and, **44**, 158–160
 enzymes in DNA precursor biosynthesis and, **44**, 185–186
 protein tyrosine kinase substrates and, **44**, 216–222
- Antibodies, ASGP-1 and ASGP-2, **71**, 154–155
- Antibodies, immunochemical analyses of
 nucleic acids and, **42**, 40–44
 alkylated nucleic acids, **42**, 66–70
 B-DNA, **42**, 44–48
 cruciform DNA, **42**, 63–65
 DNA, **42**, 48–50, 62–63
 RNA, **42**, 62–63
 Z-DNA, **42**, 50–60
- Antibodies, to alkyltransferase, **51**, 173–174
- Antibody
 complementarity-determining regions, **60**, 170, 172
 humanization
 complementarity-determining region grafting, **60**, 172–173
 goals, **60**, 172
 nonantibody proteins, **60**, 192
 specificity-determining residues, identification and transfer, **60**, 173, 176–177, 182–183
 isotypes, **60**, 170
 multivalent/multispecific antibody generation
 applications, **60**, 171, 190
 bispecific molecule construction, **60**, 188–190
 electrostatic complementarity, **60**, 183, 186, 188, 192

- immunoglobulin class considerations,
 60, 186–188
- tetraspecific molecule construction,
 60, 190
- structure, **60**, 170, 172
- Antibody precipitation, nuclear RNA-binding
 proteins and, **41**, 185
- Anticancer drug development
 - Ras signaling pathway, **67**, 215–216
 - Rho signaling pathway, **67**, 215–216
- Anticodon-binding domain
 - absent in TyrRS, **69**, 328
 - hinge movement, **69**, 341
 - MetRS, **69**, 323–324
 - reorientation, **69**, 342
- Anticodon, recognition of tRNA and, **41**, 29–44
- Antigen presentation, **49**, 3, 30–32
- Antigene oligonucleotide
 - base triad formation, **52**, 276–278
 - 8-oxoadenine, targeting of G–C base
 pairs, **52**, 278–281
 - homopurine tract, targeting of
 interruptions, **52**, 282–285
 - mechanism of action, **52**, 262, 276
 - triplex formation by oligonucleoside
 methylphosphonates, **52**, 285–287
- Antigens, large T, SV40, **70**, 100
- Antiinflammatory agents, PDE4-selective
 inhibitors, **69**, 261–262
- Antiprogestins, steroid hormones
 and, **43**, 29–30
- Antirecognition agent, Muc4/SMC, **71**, 155
- Antisense DNA
 - msDNAs, **67**, 86–87
- Antisense inhibitors, oligodeoxynucleotides as,
 see Oligodeoxynucleotides
- Antisense oligodeoxynucleotide, **67**, 219
- Antisense oligonucleotide
 - analogs, **57**, 97–102
 - brain targeting, **57**, 112, 114–115
 - cellular uptake, **57**, 105–110
 - circular oligonucleotides, **57**, 102–103
 - clinical applications, **57**, 117–122
 - D-loop formation, **57**, 103–104
 - degradation, **57**, 114–116
 - delivery strategies
 - adenovirus release from vesicles, **57**, 110
 - erythrocyte ghosts, **57**, 114
 - hydrophobic modification, **57**,
 111–112, 121
 - liposomes, **57**, 110–113
 - mannose 6-phosphate receptors, **57**, 112
 - polylysine conjugates, **57**, 112, 121
 - pore-forming agents, **57**, 110
 - reconstituted viral envelopes, **57**, 113–114
 - transferrin receptor, **57**, 112
 - effectors, **57**, 102
 - herpes simplex virus, effect on
 replication, **52**, 273–276
 - length optimization, **57**, 101
 - mechanism of action, **52**, 261–262
 - mechanism of action, **57**, 116–117
 - methylphosphonate analogs
 - cell uptake, **52**, 270–272
 - hybridization stability, **52**, 265–267
 - nuclease resistance, **52**, 262–263
 - psoralen conjugation, **52**, 267–270
 - structure, **52**, 263
 - synthesis, **52**, 264–265
 - proof of efficacy, **57**, 116
 - ras* inhibition, **52**, 275
 - ribonuclease activation in therapy, **57**, 100,
 119–120
 - RNA hairpin targeting, **57**, 102
- Systematic Evolution of Ligands by
 Exponential enrichment, sequence
 optimization, **57**, 101
- target folding and binding, **57**, 100
- tissue distribution, **57**, 114–115
- toxicity, **57**, 116
- triple-stranded complexes, **57**, 102–103,
 120–121
- vesicle entrapment, **57**, 110
- Antisense oligonucleotides, **44**, 163–164
 - affinity or specificity, **69**, 16–18
 - history, **44**, 143–144
 - internalization, **44**, 153–154
 - cell targeting, **44**, 158–160
 - poly(L-lysine), **44**, 155, 157–158
 - polyanions, **44**, 157–158
 - intracellular distribution, **44**, 160–161
 - invader, chemically modified, **69**, 14–16
 - mini-exon sequence target for, **69**, 8–9
 - principles and limitations, **69**, 5–8
 - reactive, **69**, 18–19
 - RNA structures invaded by, **69**, 9–13
- SNAIGE concept, **44**, 145–146
 - compartmentalization, **44**, 151–152
 - limitations, **44**, 148–149
 - metabolic stability, **44**, 149, 151

- Antisense oligonucleotides (*cont.*)
 sense oligonucleotides, **44**, 148
 side effects, **44**, 153
 synthetic ribozymes, **44**, 147–148
 target choice, **44**, 149–150
 target hybrids, **44**, 152–153
 triple helix, **44**, 145, 147
 VSV model, **44**, 156, 161–163
- Antisense oligonucleotides, *see*
 Oligonucleotides, antisense
- Antisense oligonucleotides, HIV therapy, **49**,
 182–183
- Antisense RNA
 ColE1 plasmid replication control, **52**, 28–29
 design strategies, **52**, 32–33, 56
 FtsZ protein, regulation of expression,
 52, 32
 in R6K regulation, **48**, 262
 in replication control, **48**, 251–253
 IS10 transposable expression control, **52**, 31
 lysogeny regulation in bacteriophage λ ,
 52, 31
 OmpF, regulation of expression, **52**, 32
 plasmid killer gene expression,
 regulation, **52**, 30–31
 R1 plasmid replication control, **52**, 29–30
 ribozyme function, **52**, 33–34
- Antisense RNA, nuclear poly(ADP-ribose)
 polymerase
 effects
 apoptosis, **55**, 151–154
 cell differentiation, **55**, 148
 cell survival after DNA damage,
 55, 147–148
 chromatin organization, **55**, 144–145
 DNA repair, **55**, 147–148
 DNA replication, **55**, 148, 150–151
 DNA strand-break rejoining, **55**, 146–147
 endogenous mRNA transcripts, **55**, 142
 genomic stability, **55**, 146
 nuclear activity depletion, **55**, 138–139,
 143–144
 protein expression, **55**, 142–143
 expression in transfected cells, **55**, 139,
 141–142
 vectors, **55**, 139
- Antisense technologies, *see also*
 Oligonucleotides
 eukaryotic mRNA translation and, **48**,
 205–219
- Antitumor activity, cisplatin–DNA
 adducts, **71**, 24–25
- Antitumor ruthenium compounds–DNA
 interactions
 chloropolypyridyl ruthenium compounds,
 71, 53
 dimethyl sulfoxide complexes, **71**, 49–52
 heterocyclic complexes, **71**, 52
 heterodinuclear (Ru,Pt) compounds, **71**,
 53–54
- Antiviral strategies, models, **72**, 458–459
- Antp homeodomain peptide, NMR
 structure, **47**, 222–223
- AOC, *see* Allene oxide cyclase
- AOS, *see* Allene oxide synthase
- AP endonucleases
 eukaryotic, **68**, 264
- AP lyase
 AP endonuclease, **68**, 262
 HhH, **68**, 342
 Mmh mutant
 liver extracts, **68**, 113
 mouse liver crude extracts, **68**, 116
 mtDNA
 BER, **68**, 261
 mtDNA ligase, **68**, 268–269
 OGG1, **68**, 204
 reactions
 postulated intermediates, **68**, 225
 substrate specificity, **68**, 117
- AP site, **68**, 1, 4, 30, 36, 107, 165, 209, 287
 aldehyde-reactive probe-slot-blot
 method, **68**, 62
 chemical structure, **68**, 8
 detection
 endo IV, **68**, 337
 DNA structure, **68**, 20
 methoxyamine-modified, **68**, 11
 structure, **68**, 8
 oxidized, **68**, 12–13
 structure, **68**, 14
 plasmid substrate, **68**, 125
 repair
 PCNA-dependent, **68**, 130–132
 pol beta, **68**, 22
 reduced, **68**, 13
- AP2, autoregulation of promoter, **60**, 161
- Apaf-1, interaction with Bcl-X_L, **69**, 234
- APC–TCF pathway, link with *Dnmt1*, **69**,
 58–59

- APC, *see* Anaphase-promoting complex
 APCs, **67**, 217
 APE, **68**, 42, 90, 129, 131, 287, 328–338
 adaptive response, **68**, 50
 AP lyase, **68**, 262
 BER, **68**, 46–47
 CKII, **68**, 49
 dRP lyase, **68**, 262
 mtDNA
 BER, **68**, 263–265
 posttranscriptional regulation, **68**, 49
 promoter
 CRE binding site, **68**, 50
 Xenopus, **68**, 264
 APE1, **68**, 203, 329–335
 flipped-out AP-DNA, **68**, 330–331
 human, **68**, 191
 penetrating loop mutants, **68**, 332–333
 APEX. *See* APE1
 Aphidicolin, **68**, 10, 11, 19
 uracil-DNA BER, **68**, 177–180
 API, *see* Activator protein, I
 Apn1p, **68**, 31
 Apoptosis
 cisplatin, **67**, 116–117
 DNA alkylation damage, **68**, 42–43
 intestinal development role of matrix metal-
 loproteinases in amphibians
 cell fate determination mechanisms,
 65, 91
 collagenase, **65**, 87
 differential expression analysis, **65**, 87
 extracellular matrix remodeling, **65**, 85
 Gela, **65**, 87
 stromelysin-3
 apoptosis association, **65**, 86–87, 89
 developmental expression pattern,
 65, 86
 substrates, **65**, 89–90
 thyroid hormone regulation, **65**, 84–85
 iPLA₂ β , **67**, 24–25
 mtDNA, **68**, 274
 O⁶-MeG, **68**, 43–44
 PDE4A5 role, **69**, 283
 phosphatidylcholine biosynthesis inhibition
 and apoptosis induction, **65**, 382–386
 ROR γ effect on, **69**, 236–238
 ROR γ role in, **69**, 231–236
 tumor necrosis factor, **68**, 274
 Apoptosis, E-cadherin role, **57**, 203–204
 Apoptosis, nuclear poly(ADP-ribose)
 polymerase role, **55**, 151–154
 Apoptosis, repression by Muc4/SMC, **71**,
 161–163
 Aptamers
 complex with
 antibiotics, **69**, 38
 hairpins, **69**, 27–28
 identified by SELEX, **69**, 26–27
 to TAR RNA of HIV-1, **69**, 28–31
 Apurinic (AP) site. *See* AP site
 Apurinic/aprimidinic (AP) site. *See* AP site
 AR, **67**, 57
 AR, *see* Androgen receptor
Arabidopsis thaliana, SPHK and S1P, **71**, 497
 Arabinan, structure and degradation, **61**,
 215, 217
 Arabinanase, *Pseudomonas fluorescens*
 sub-sp. *cellulosa*
 cellulose-binding domain, **61**, 227
 overview, **61**, 221–222
 Arabis mosaic virus hairpin ribozyme, *see*
 Hairpin ribozyme
 Arachidonate
 glucose-stimulated, **67**, 22
 Arachidonic acid (AA), **67**, 12
 Archaea
 characteristics, **71**, 224–225
 methanogenesis, cofactors, **71**, 232
Archaeoglobus fulgidus, F₄₂₀H₂
 dehydrogenase, **71**, 249–253
 ARE-binding proteins, unstable mRNAs, **72**,
 134–135
 AREs, *see* A+U rich elements,
 messenger RNA
 Arginine-accepting tRNAs, **70**, 319–321
 Arginine methylation, *see* Protein arginine
 methylation
 Arginine, HIV-1 RT
 Arg-72, **71**, 120–122
 Arg-78, **71**, 122–123
 Arginine, in eIF5 function, **70**, 223–225
 ArgRS, anticodon loop, **69**, 342–343
 Arsenite ion
 double-stranded RNA-activated protein
 kinase activation, **58**, 107
 inhibition of translation, **58**, 97–98, 101–102
 Arthro-ophthalmopathy, collagen type-II gene
 mutations, **47**, 53–54
 Arylpeptide-siderophores, **70**, 246–248

- Ascites sialoglycoprotein 1
 antibody production, **71**, 154–155
 cloning, **71**, 153–154
 isolation, **71**, 153
- Ascites sialoglycoprotein 2
 antibody production, **71**, 154–155
 isolation, **71**, 153
 Muc4/SMC, **71**, 175–176
 soluble Muc4/SMC production, **71**, 156–157
- 5-Aminolevulinate synthase, erythroid,
 transcripts encoding, translational
 regulation, **48**, 198–199
- ASGP-1, *see* Ascites sialoglycoprotein 1
- ASGP-2, *see* Ascites sialoglycoprotein 2
- asp-box motifs, in sialidases, **69**, 93
- Asp 256, **68**, 65
- Asparagine-linked glycosylation, **67**, 237–238
- Asparagine synthetase, amino acid control of
 gene expression, **53**, 232–237
- Aspartate-accepting tRNAs, **70**, 319–321
- Aspartic acid residue 76, HIV-1 RT, **71**,
 122–123
- Aspergillus nidulans*
alc gene regulon, **69**, 168–169
alc genes and products, **69**, 152–156
 CreA repressor, **69**, 174–180
 ethanol regulon, transcriptional
 activation, **69**, 156–167
 ethanol utilization pathway, **69**, 151
 mammalian protein production in, **69**,
 193–194
- AspRS, complex with tRNA^{Asp}, **69**, 332
- Assays
 CAD in pol II, **72**, 289–291
 GEF, **71**, 404–405
 nucleic acid chaperone proteins,
72, 237–239
 oxidative DNA damage, **68**, 140–143
 pRNA, phi29, **72**, 420–421
 retroviral RT fidelity, **71**, 99–108
- Asthma, PDE3 inhibitor therapy, **66**, 266
- Asymmetric aliphatic amines,
 DNA-transplatin analogs, **71**, 42
- Ataxia telangiectasia, **68**, 236
 clinical features, **63**, 191–192
 genomic instability
ATM
 protein structure and functions,
63, 195–199
 structure, **63**, 195
 cancer risk, **63**, 192–193
 chromosomal translocations, **63**, 193–194
 tumor suppressor gene mutations, **63**,
 194–195
 incidence, **63**, 191
- Ataxia telangiectasia and Rad-3-related, **72**, 77
- Ataxia telangiectasia-mutated, **72**, 77, 79–80
- 18A2, identification as late response gene,
58, 50
- ATF-1, *see* Activating transcription factor 1
- ATF, autoregulation of promoter, **60**, 155, 163
- Atherosclerosis, ROR α role, **69**, 228
- ATM, *see* Ataxia telangiectasia-mutated
- ATM, *see* Ataxia telangiectasia
- Atomic force microscopy (AFM),
 internucleosomal DNA length
 measurement, **65**, 206–207
- ATP-binding cassette (ABC) transporter
 energetics, **58**, 241, 243
 physiological roles of peptide transport,
58, 240
 structure, **58**, 241
 substrate specificity, **58**, 241, 243
- ATP-binding domains
 iPLA₂ β , **67**, 8–10
- ATP-binding protein, **70**, 50–51
- ATP-binding site
 kinase motifs, **53**, 60
 types, **53**, 60–63, 71
- ATP-binding sites, bacterial adenyl cyclases
 and, **44**, 56–61
- ATP synthases, *Methanosarcina*, **71**, 265–270
- ATP, allosteric regulation of RNRs, **72**,
 108–114
- ATP, methanogenic archaea, **71**, 240–242
- ATP, substrate for PRPP synthetase
 reaction, **69**, 128–129
- ATR, *see* Ataxia telangiectasia and
 Rad-3-related
- AU-rich elements, unstable mRNAs, **72**,
 134–135
- AUBF, *see* Adenosine–uridine binding factor
- AUF1, A+U rich element binding
 affinity of binding, **62**, 280–281
 α -globin messenger RNA stability complex
 binding, **62**, 279–280
 β -adrenergic receptor messenger RNA
 turnover role, **62**, 263–264, 282–283
 cloning, **62**, 273
 destabilizing mechanism, **62**, 277–278, 287

- dimerization, **62**, 278–279
 - discovery, **62**, 269–271
 - granulocyte-macrophage colony-stimulating factor messenger RNA turnover role, **62**, 283–284
 - Gro α messenger RNA turnover role, **62**, 284
 - hexamer binding to *c-fos* messenger RNA, **62**, 279
 - interleukin-1 β messenger RNA turnover role, **62**, 284
 - isoforms from alternative RNA splicing, **62**, 275–277
 - protein-protein interactions, **62**, 278
 - purification, **62**, 271, 273
 - RNA recognition motifs, **62**, 273–275
 - subcellular localization, **62**, 276
 - AUG codon
 - cap-dependent scanning, **72**, 4–5
 - internal translation initiation, **72**, 6
 - leaky scanning, **72**, 5
 - MuLV genomic mRNA, **72**, 380–382
 - Sendai virus shunt, **72**, 19–20
 - AUGs, upstream, in 5' UTR of eukaryotic mRNA, **48**, 185
 - Autoantibody, oligonucleotides, **57**, 128–129
 - Autoantigens, aminoacyl-tRNA synthetases as, **48**, 122–124
 - Autosomal dominant retinitis pigmentosa (ADRP), rhodopsin mutation, **59**, 28–29
 - AUU codon, shunting ribosome initiation, **72**, 15
 - Avian myeloblastosis virus, misinsertion fidelity assay, **71**, 102–103
 - Avian protamines, **40**, 37–38
 - genes, **40**, 44–45
 - Axon
 - regeneration regulation, **56**, 247
 - Schwann cell interactions
 - bilateral communication, **56**, 235, 248
 - myelination role, **56**, 235–243
 - neural crest development, **56**, 227–229
 - transcriptional regulation, **56**, 243–246
 - Axon, *see* Neurofilament
 - 5-Azacytidine, alkylation damage repair in transgenes and, **44**, 129
 - 5-Azacytidine, effect on chromosome structure, **49**, 98–99
 - 5-Azadeoxycytidine
 - DNA (cytosine-5)methyltransferase inhibition, **49**, 66–67
 - effect on DNA methylation pattern, **49**, 98–99
 - Azidothymidine (AZT), DNA hypermethylation and drug resistance, **57**, 233
 - AZT, *see* Azidothymidine
- B**
- Bacillus thuringiensis* insecticide proteins, *see* δ -Endotoxins
 - B-catenin
 - quality control, **67**, 251
 - B cells, immunoglobulin gene diversification and, **45**, 31–32
 - B cell, stimulation by CpG oligonucleotides, **57**, 130–131
 - B-globulin, **67**, 179, 186
 - B-hairpin motifs, **67**, 13
 - B-Raf, **67**, 211
 - B23 protein, role in RNA processing, **49**, 221
 - B72.3, humanization, **60**, 182–183
 - Bacilliform Caulimoviridae, **72**, 22–23
 - Bacillus anthracis*, bacterial adenyl cyclases and, **44**, 44–49
 - Bacillus cereus*, **68**, 336
 - Bacillus subtilis* transition-state gene expression, **46**, 121–125, 148–149
 - modulators, **46**, 138
 - ComA protein, **46**, 142–143
 - ComP protein, **46**, 142–143
 - Deg proteins, **46**, 138–141
 - SenS protein, **46**, 141–142
 - TenA protein, **46**, 142
 - TenI protein, **46**, 142
 - redundant control, **46**, 146–148
 - regulators, **46**, 124
 - AbrB protein, **46**, 124–132
 - Hpr protein, **46**, 132–134
 - Pai protein, **46**, 136–138
 - Sin protein, **46**, 134–136
 - sporulation, **46**, 143, 145–146
 - signal transduction, **46**, 143–145
 - spoO* genes, **46**, 143–145
 - Bacillus subtilis*, membrane-chromosome replication
 - advantages of *Bacillus subtilis* in study, **59**, 36

- Bacillus subtilis*, membrane–chromosome replication (*cont.*)
- chromosomal membrane attachment sites, **59**, 44–45, 49, 51
 - chromosome initiation mutants, **59**, 39
 - chromosome replication initiation *in vitro*, **59**, 46–47
 - comparison to *Escherichia coli*, **59**, 36–38, 47, 49
 - configurations of chromosome binding to membrane, **59**, 47–48
- dnab*
- encoded protein properties, **59**, 41, 44
 - locus, **59**, 41
 - open reading frames, **59**, 41, 44
 - role in origin–membrane binding, **59**, 40–41, 43–44, 46, 48–49
- history of study and early evidence for membrane–chromosome association, **59**, 36–38
- membrane attachment to terminus, **59**, 47
- membrane sliding models of chromosome separation, **59**, 49–50
- origin–membrane complex preparation, **59**, 39–40
- terminus–membrane complex preparation, **59**, 39–40
- Bacillus subtilis*, PRPP synthetase, **69**, 125–126
- Bacillus subtilis*, purine nucleotide biosynthesis and, **42**, 264–269
- Bacteria
- arylpeptide–siderophores, **70**, 246–248
 - branched chain aminotransferases, **70**, 180–181
 - DNA replication, helicase role, **70**, 84
 - enterobactin biosynthesis, **70**, 264–265
 - mycobactin biosynthesis, **70**, 269–270
 - purple nonsulfur
 - CO metabolism, **67**, 37
 - pyochelin biosynthesis, **70**, 268–269
 - pyoverdine biosynthesis, **70**, 270–274
 - yersiniabactin biosynthesis, **70**, 265–268
- Bacteria, *see Escherichia coli*
- Bacteria, defective in tRNA modification, **50**, 267–268
- Bacteria, msDNA of, *see* msDNA of bacteria
- Bacteria*
- characteristics, **71**, 224–225
 - methanogenesis, cofactors, **71**, 232
- Bacterial adenyl cyclases, **44**, 31–32, 61–62
- activators, **44**, 41–43
 - ATP-binding sites, **44**, 56–61
- Bacillus anthracis*, **44**, 44–49
- Bordetella pertussis*, **44**, 44–49
- cya* gene, **44**, 35–36
- cyclic AMP
- regulation of levels, **44**, 34–35
 - transcription regulation, **44**, 32–34
- inhibitors, **44**, 43–44
- Mycoplasma*, **44**, 44
- Rhizobium*, **44**, 49–53
- sequences, **44**, 53–56
- sugar transport, **44**, 36–41
- Bacterial cells, enzymes in DNA precursor biosynthesis and, **44**, 186–187
- Bacterial reverse transcriptase, 80D81
- Bacteriophage λ , *see* Lysogenic pathway in bacteriophage λ
- Bacteriophage λ , lysogeny regulation, **52**, 31
- Bacteriophage ϕ X174
- life cycle, **63**, 40
 - primer synthesis proteins, **63**, 41
 - reconstitution of ss(c)→RF DNA replication, **63**, 40–41
- Bacteriophage PB32, **48**, 353–354
- uracil-DNA glycosylase inhibitor, **48**, 353–356
- mechanism of action, **48**, 355
 - phenotype, **48**, 356
 - properties, **48**, 354–355
- Bacteriophage RB69, *see* DNA polymerase, RB69
- Bacteriophage T4
- chromosome features, **64**, 69–71
 - deoxyribonucleotide synthetase extended complex, **53**, 387–390
 - developmental stages, **64**, 69
- DNA replication
- comparison with other phages, **64**, 70–71
 - cytosine modification role, **64**, 71–72
 - host components, **64**, 89–90
 - initiation modes, **64**, 69–70
 - overview, **64**, 66–67
 - polymerase, *see* DNA polymerase, T4
 - primase, **64**, 70
 - protein requirements, **64**, 68
 - replisome
 - assembly, **64**, 77

- components and functions, **64**, 77–81
 - helicase–primase complex coordination
 - with replicase, **64**, 82–83
 - kinetic studies of clamp loader, **64**, 81–82, 90
- expression of ribonucleotide reductase, **53**, 351–356
- gp32, RNA binding and translational repression, **64**, 76
- inhibitory activity in host, **64**, 67–68
- initiation of replication, **53**, 349–351, 383–384
- RegA, translational repression, **64**, 76
- similarity with other T-even phages, **64**, 66
- synthesis of deoxyribonucleotides and ratio of bases, **53**, 384–386
- template damage and deoxyribonucleotide synthesis, **53**, 386
- translational hopping in gene, **64**, 60, 160–162
- Bacteriophage T4, **70**, 87–89
- Bacteriophage T4, coupling of replication and recombination, **63**, 330–331
- Bacteriophage T5, uracil-DNA glycosylase inhibitor, **48**, 356
- Bacteriophage T7, **70**, 89–91
- Bacteriorhodopsin, structural homology to other opsins, **59**, 25
- Baculovirus DNA, integration, and methylation patterns, **46**, 18–21
- Balbani ring multigene family, **48**, 275–309, *see also Chironomus tentans*
- evolution, **48**, 297–309
 - building gene family members from functionally different gene elements, **48**, 297–299
 - dynamic behavior of coding tandem repeats in, **48**, 301–307
 - sequence homogenization mechanisms in, **48**, 307–309
 - subfamilies in, **48**, 299–301
- expression, **48**, 280–281
 - of members, **48**, 294–297
- genes, **48**, 285–297
 - BR3, **48**, 287, 289, 290
 - chromosomal locations, **48**, 293–294
 - prepupal, **48**, 295
 - sp-115, **48**, 140, 289, 290–291
 - sp-12, **48**, 289, 292
 - sp-17, **48**, 289, 291–292
 - sp-195, **48**, 287, 288
 - sp-240/420, **48**, 289, 292–293
 - sp-38–40 A and B, **48**, 289, 291
 - sp-38–40 subfamily in evolution, **48**, 301
 - spI subfamily, **48**, 286–287, 288
 - in evolution, **48**, 300–301
 - salivary glands, **48**, 278–281
 - secretory proteins encoded, **48**, 281–285
- Bap31
 - quality control, **67**, 251
- Barbie box
 - binding proteins in phenobarbital induction of cytochromes P450, **61**, 32–34, 58
 - mammalian homologs, **61**, 34–35
- Barbiturate, *see* Phenobarbital
- Bare lymphocyte syndrome, mutation in transcription factor genes, **64**, 198
- Base excision repair (BER)
 - enzyme
 - mitochondria, **68**, 292–293
 - oxidative purine lesions, **68**, 212
 - oxidative thymine lesions, **68**, 211–212
 - structural implications, **68**, 299–304
 - three-dimensional structures, **68**, 301
 - factors
 - gene expression, **68**, 21–23
 - intermediates pathways
 - pol beta-deficient cells, **68**, 51
 - mutant strains
 - menadione, **68**, 34
 - replication-coupled
 - DNA glycosylases, **68**, 134–137
 - short-patch. *See* Short-patch base excision repair
 - uracil, **68**, 166–187
 - dUTPase, **68**, 320
 - yeast, **68**, 29–38
- Base excision repair (BER) pathway, **68**, 1, 33, 188, 208
 - 8-OH-G, **68**, 194
 - 8-oxoguanine, **68**, 194
 - APE, **68**, 46–47
 - cell cycle, **68**, 23–24
 - cell-free extracts, **68**, 11–20
 - complexities, **68**, 125–126
 - coordination, **68**, 291
 - damage type, **68**, 9–10
 - defect strain
 - hyper-rec phenotype, **68**, 36
 - deficient cells

- Base excision repair (BER) pathway (*cont.*)
 hypermutable, **68**, **71**
 DNA glycosylase-AP lyase, **68**, **16**
 DNA ligase I, **68**, **161**
 DNA ligase III, **68**, **161**
 DNA structure, **68**, **20–21**
 DNA substrates
 containing BER lesions, **68**, **12–16**
 with AP site analogs, **68**, **11–12**
 higher eukaryotes, **68**, **125**
 mammalian cells, **68**, **5–7**, **58**
 mammalian DNA beta-polymerase, **68**,
 57–72
 functional scheme, **68**, **70**
 mammalian DNA ligases, **68**, **151–162**
 mitochondrial
 vs. nuclear, **68**, **259–260**
 monofunctional DNA glycosylase, **68**, **15**
 MPG, **68**, **46**
 mtDNA, **68**, **255–256**
 enzymology, **68**, **259–270**
 further study, **68**, **270**
 mammalian, **68**, **275–276**
 multiple
 switch mechanism, **68**, **3–25**
 oxidative base lesions, **68**, **287–288**
 PARP nuclear protein, **68**, **161–162**
 PCNA
 molecular mechanism, **68**, **129–137**
 permeabilized cell systems, **68**, **9–11**
 pol beta, **68**, **47**
 mutant cell lines, **68**, **16–20**
 process, **68**, **4**
 redundancy, **68**, **24**
 regulation, **68**, **47–49**
 steps, **68**, **146**
 versatility, **68**, **24**
 viability, **68**, **42**
 yeast, **68**, **33–36**
 Base excision repair (BER), *see* DNA repair
 Base excision repair, dipyrimidine
 photoproducts
 nontarget DNA scanning by repair enzymes
 assay, *in vivo*, **62**, **162–163**
 biological relevance, **62**, **163–164**
 overview of repair enzymes
 Chlorella virus PBCV-1 pyrimidine dimer
 glycosylase, **62**, **157**
 hydrolytic UV endonucleases,
 62, **158–159**
 Micrococcus luteus UV endonuclease, **62**,
 156–157
 microorganism glycosylase survey, **62**, **158**
 yeast pyrimidine dimer endonuclease, **62**,
 157–158
 T4 endonuclease V
 activities, **62**, **156**
 base flipping in catalysis, **62**, **170–171**
 discovery, **62**, **156**
 glutamate-23 role, **62**, **167**, **169**
 N-terminus role, **62**, **164**, **166–167**
 processive nicking activity, **62**, **159–162**
 sodium borohydride trapping of
 intermediates, **62**, **164**, **166–167**, **172**
 transition-state analogs, **62**, **169–170**
 target location by repair enzymes, **62**,
 159–161
 Base-pairing, RNA, **50**, **16–19**
 Base pairs, G3:U70, in AlaRS, **69**, **320–321**,
 326–327
 Base triples, in dimerization initiation site, **69**,
 34
 Base, branchpoint and last intron, **50**, **154**
 Basement membranes, LOXL2 association, **70**,
 23–24
 Basic fibroblast growth factor, *see* Fibroblast
 growth factor 2
 Basic fibroblast growth factor, arginine
 methylation, **61**, **92–93**
 Basic helix–loop–helix (bHLH), DNA-binding
 domain, **64**, **174–175**
 BBR3464–DNA interactions
 overview, **71**, **42–44**
 trinuclear compounds, **71**, **47–49**
 BBR3535–DNA interactions, **71**, **47**
 BBR3537–DNA interactions, **71**, **47**
 BBR3571–DNA interactions, **71**, **47**
 BC1 RNA
 3' end amplification role, **52**, **78**
 biological functions, **52**, **85–86**
 rodent specificity, **52**, **69**
 subcellular localization, **52**, **79**, **81**
 tissue distribution, **52**, **79–81**
 transcription, **52**, **68**
 BC1 RNA gene
 conservation between rodent species, **52**,
 72–73
 duplication in guinea pig, **52**, **71–72**
 evolutionary origin, **52**, **69–71**
 identifier-element, **52**, **75–77**

- master gene controlling ID family
 - amplification, **52**, 74–75
 - times of amplification, **52**, 76
 - transcriptional regulation, **52**, 81–84
- BCAAs, *see* Branched chain amino acids
- BCAR3, *see* Breast cancer
 - anti-estrogen-resistance gene 3
- BCATs, *see* Branched chain aminotransferases
- Bcl-2, **68**, 51
- Bcl-X_L
 - effect on cytochrome c release, **69**, 233
 - interaction with Apaf-1, **69**, 234
 - mRNA expression, **69**, 235–236
- BCNU, *see* Carmustine
- BEL, **67**, 27
 - suicide substrate
 - iPLA₂ β , **67**, 6, 22
- Benzo(a)pyrene diol epoxide (BPDE)
 - pol beta-defective cells, **68**, 17
- Benzo[a]pyrene, DNA sequence specificity, **63**, 381, 393
- O⁶-Benzylguanine, as alkyltransferase
 - substrate, **51**, 189–191
- BER, *see* Base excision repair
- Beta-hOGG1, **68**, 96
- Beta-lyase 8-oxoG-DNA glycosylase
 - (OGG1), **68**, 14
- Beta-pol null cells, **68**, 57
- bFGF, *see* Basic fibroblast growth factor
- bgIGFB* operon, transcriptional
 - attenuation, **62**, 363–364
- bgf* operon, transcriptional attenuation, **62**, 363–364
- bHLH, *see* Basic helix–loop–helix
- Biglycan
 - genes, **62**, 45, 46
 - structure, **62**, 42–43
 - transcriptional regulation
 - AP1, **62**, 47–48
 - cytokines, **62**, 47
 - promoter, **62**, 45, 47
 - retinoic acid, **62**, 47
- Bilirubin transferase, microregion
 - definition, **51**, 324–326
- Bilirubin, chemistry and biochemistry, **51**, 307–314
- Binding domain, aminoacyl-tRNA
 - synthetases and
 - evidence for, **40**, 107–110
 - in vivo*, **40**, 115–116
 - structure, **40**, 110–115
- Binding proteins, RNA phage coat proteins
 - and, **40**, 212–215
- Binding sites, RNA phage coat proteins and, **40**, 192–196
- Binomial distribution, pRNA stoichiometry, **72**, 423–424
- Biochemical mechanisms for demethylation
 - process, **48**, 59–60
- Biogenesis, mitochondrial, in *Saccharomyces cerevisiae*, *see* Mitochondrial biogenesis in *Saccharomyces cerevisiae*
- Biostistic method, rice genes and, **45**, 11–13
- Biological assays, GEF, **71**, 404–405
- Biological function, RNA–RNA kissing
 - complexes, **69**, 31–32
- Biomass, plant contribution, **61**, 212
- Biosynthetic enzymes, heme, gene
 - expression, **51**, 25–27
- Biotechnology, *alc* system as tool, **69**, 192–195
- Biotin, nuclear RNA-binding proteins and, **41**, 185–186
- BiP, *see* GRP78
 - calcium content, **58**, 85
 - protein processing and chaperones, **58**, 85–86
- Bipartite antimutagenic processing
 - 8-OH-G, **68**, 197–198
- Bipartite nuclei localization signal
 - iPLA₂ β , **67**, 14–15
- Bipyrimidine adducts, **68**, 30
- Bisulfite, deamination of DNA, **49**, 103
- Bisulfite, probing of RNA structure, **53**, 143, 146
- Bizelesin, DNA sequence specificity, **63**, 379, 388
- bla*, mRNA decay mechanisms, **52**, 175–176
- Blastocyst implantation, Muc4/SMC, **71**, 164–167
- Blenoxane, *see* Bleomycin
- Bleomycin
 - bithiazole derivatives, **49**, 330–331, 336–338
 - Blenoxane composition, **49**, 314–315
 - cancer chemotherapy, **49**, 314
 - DNA-bleomycin interactions
 - binding constants, **49**, 329
 - bithiazole, **49**, 329–330, 333–338
 - carboxy terminus, **49**, 329, 334
 - hydrophobic interactions, **49**, 329–330

- Bleomycin (*cont.*)
 ionic interactions, **49**, 329
 mannose carbamoyl group, **49**, 330–332
 metal-binding domain, **49**, 336
 minor groove, **49**, 332–333, 348
DNA cleavage
 bithiazole derivative specificity, **49**, 333–337
 catalytic cycle, **49**, 320–322
 cisplatin binding effect on cleavage site, **49**, 345
 deglycobleomycin specificity, **49**, 333–334
 deuterium isotope effects, **49**, 324
 effect of DNA methylation, **49**, 345–346
 mechanism of catalysis by iron-bound complex, **49**, 320–327
 oxygen requirement, **49**, 326–327
 products of reaction, **49**, 322–323
 recognition of conformation, **49**, 344–348
 RNA hybrid strains, **49**, 343–344
 site specificity, **49**, 314, 330–332, 348
 solvent oxygen exchange, **49**, 327
 stereochemistry, **49**, 323–324
 triple helix, **49**, 346–348
DNA unwinding activity, **49**, 329–330
domains, role in DNA cleavage site specificity, **49**, 314, 333, 336
metal ion complexes
 Co(III), **49**, 327
 coordination geometries, **49**, 315–316, 332
 Cu(I), **49**, 328
 Cu(II), **49**, 328
 Fe(II) activation, **49**, 316–317
 Mn(II), **49**, 327–328
olefin oxidation, **49**, 317–320
oxidation substrates, **49**, 317–318
RNA cleavage
 DNA hybrid strands, **49**, 343–344
 mechanism, **49**, 341–343
 reaction products, **49**, 342–343
 recognition of conformation, **49**, 339, 341, 344
 specificity for RNA type, **49**, 339, 343–344
 substrate accessibility, **49**, 338–339
 structure, **49**, 315
Bleomycin, **68**, 11, 13
Bleomycin, biosynthesis, **70**, 277–279
Bleomycin, DNA sequence
 specificity, **63**, 381, 395
BLM, *see* Bloom's syndrome
Bloom's syndrome, **68**, 236
Bloom's syndrome (BS)
 BLM
 mapping, **63**, 202
 mutations in disease, **63**, 202–203
 protein structure and functions, **63**, 203–206
 clinical features, **63**, 202
BMI
BM3
 barbie box binding proteins, **61**, 32–34, 58
 BM3RI repression, **61**, 30, 33
 phenobarbital induction by repressor
 binding inhibition, **61**, 32–34
BMP-1, *see* Bone morphogenetic protein-1
BMV, *see* Brome mosaic virus
Bone metabolism, ROR α role, **69**, 228
Bone morphogenetic protein-1, **70**, 13–14
Bony-fish protamines, **40**, 33–37
Bordetella pertussis, bacterial adenyl cyclases
 and, **44**, 44–49
Borg family
 biological functions, **67**, 197
Boston-type craniostynosis, *MSX2*
 mutation, **64**, 192
BPAG1, cross-linking neurofilament to
 actin, **61**, 9, 16, 20
BPDE
 pol beta-defective cells, **68**, 17
Brain
 LOXL3 expression, **70**, 24–25
 mouse, FGF-1.B, **70**, 160–161
 pyruvate dehydrogenase kinase, **70**, 51–52
 rat
 iPLA $_2\beta$, **67**, 21
Brain ankyrin, **67**, 12
Branched chain amino acids
 nitrogen transfer, **70**, 199
 transamination, **70**, 177–178
Branched chain aminotransferases
 active site, **70**, 193–195
 cloning and structure, **70**, 188–189
 enzyme substrate specificity, **70**, 181–183
 fold type IV proteins
 crystal structures, **70**, 190–193
 distribution, **70**, 189–190
 function, **70**, 176

- gabapentin specificity, **70**, 199–201
- hypoglycin effect, **70**, 197–198
- identification, **70**, 177–178
- in bacteria, **70**, 180–181
- in insects, **70**, 180–181
- in lower eukaryotes, **70**, 180–181
- in plants, **70**, 180–181
- inhibitor structures, **70**, 195–197
- mammalian isozymes, **70**, 178–180
- Michaelis constants, **70**, 183–185
- oxfenicine effect, **70**, 198
- physical properties, **70**, 185–186
- spectral properties, **70**, 186–187
- sulphydryl reagent effects, **70**, 183
- BRCA1**
 - functions, overview, **65**, 264
 - histone deacetylase recruitment, **65**, 316–317
 - transcriptional activation, **65**, 289
- BRCT family**, DNA replication, **72**, 74–77
- BrdU**, **68**, 141
- Breast cancer**
 - MCF-7**
 - cisplatin, **67**, 124
- Breast cancer anti-estrogen-resistance gene 3**, **71**, 422–423
- Breast cancer**, **Muc4/SMC**, **71**, 170–175
- Brevican**
 - developmental expression, **62**, 187
 - domains
 - C-terminal domain, **62**, 193–194
 - chondroitin sulfate-rich region, **62**, 195–197
 - keratin sulfate domain, **62**, 194–195
 - N-terminal hyaluronate-binding region, **62**, 191–193
 - sequence alignment, **62**, 188, 191
 - gene structure, **62**, 204, 216–217
 - phylogenetic analysis, **62**, 211, 215–216
 - structure, **62**, 187
- Brn-2**
 - homology with other class III POU domain proteins, **63**, 229
 - hypothalamic development role, **63**, 230–235
 - transgenic mice
 - development of homozygous knockout mice, **63**, 232–234
 - expression in gene-disrupted mice, **63**, 230
- Brn-3.0**
 - expression profile, **63**, 239
 - transgenic mouse, homozygous knockout
 - Brn-3.1** expression, **63**, 241
 - Brn-3.2** expression, **63**, 240
 - peripheral nervous system
 - development, **63**, 240–242
 - phenotype, **63**, 239–240, 249–250
 - tyrosine kinase receptor regulation, **63**, 249–250
- Brn-3.1**
 - expression in development, **63**, 242
 - human gene mutations, **63**, 243–244
 - transgenic mouse, homozygous knockout effects, **63**, 242–243
- Brn-3.2**
 - expression in development, **63**, 244
 - transgenic mouse, homozygous knockout
 - embryogenesis defects, **63**, 244–245
 - retinal ganglion cell effects, **63**, 245–247
- Brn-4**
 - homology with other class III POU domain proteins, **63**, 229
 - human gene mutations, **63**, 235–236
 - hypothalamic development role, **63**, 230–232
 - targeted disruption in mice and developmental effects, **63**, 236
- Brome mosaic virus RNA**, replication of, **42**, 163–175
- Brome mosaic virus***
 - nsP1, **71**, 199–201
 - nsP2, **71**, 205
- Bromoacetaldehyde**, DNA sequence
 - specificity of damage, **63**, 383, 401
- Bromodeoxyuridine (BrdU)**, **68**, 141
- 5-Bromodeoxyuridine**, effect on DNA
 - methylation pattern, **49**, 99
- Bromodeoxyuridine**, immunochemical
 - analyses of nucleic acids and, **42**, 65–67
- Bromoenoil lactone (BEL)**, **67**, 27
 - suicide substrate
 - iPLA₂ β , **67**, 6, 22
- Brown adipose tissue**
 - functions, **56**, 84
 - innervation, **56**, 84
 - morphology, **56**, 83
 - uncoupling pathway of mitochondria, **56**, 85–86
 - uncoupling protein, *see* Uncoupling protein

- BS, *see* Bloom's syndrome
- Budding yeast, **68**, 130
- Budding yeast
 Cdc6/Cdc18 protein, **72**, 55–56
 cyclin-dependent kinases, **72**, 43–44
 proteolysis at G1–S transition, **72**, 51–52
 SBF and MBF, **72**, 48–49
- Bulged adenosine, RNA phage coat proteins
 and, **40**, 204–206
- Burkitt's lymphoma, latent viruses and mutated
 oncogenes and, **43**, 166–170
- Busulfan, DNA sequence specificity, **63**, 378,
 386–387
- Butyrate, histone acetylation effects on DNA
 repair, **62**, 248–249
- Butyric acid, binding to HIV LTR, **49**, 167
- Bypass replication
 model, **67**, 188
- C**
- c-Fos*
 cell cycle control in mice, **58**, 65
 identification as immediate-early response
 gene, **58**, 52
- c-Jun*, cell cycle control in mice, **58**, 65
- c-Myc*, cell cycle control in mice, **58**, 65–66
- C-myc*, mRNA
 overview, **72**, 396–397
 P0 leader, **72**, 397–398
 P2, IRES identification, **72**, 397
- c-myc* mRNA, translation, **48**, 201–202
- C-1027, DNA sequence specificity, **63**,
 381, 396
- C domains, *see* Condensation domains
- c-fos* messenger RNA
 half-life, **62**, 258, 268
 mechanisms of ARE-mediated turnover, **62**,
 261–262, 269–271, 279
- c-fos*, unstable mRNAs, **72**, 135
- c-Ha-ras*, cell cycle control in mice, **58**, 67–68
- c-Jun*
 docking site for JNK, **69**, 287
 in cooperation with Rb, **69**, 58
- c-Jun*, transcriptional regulation in Schwann
 cells, **56**, 246
- C-terminal domain
 glycosylation, **48**, 173–174
 in RNA polymerase II
 discovery, **48**, 145–147, 148
 phosphorylation of RNA polymerase
 subunit IIa in, **48**, 147–148
 phosphorylation
 in transition from complex assembly to
 elongation, **48**, 163–165
 protein kinases in, **48**, 165–172
 unphosphorylated, interaction with
 preinitiation complex components, **48**,
 160–162
- C-terminal domain kinases
 associated with transcription factors, **48**,
 166–168
 binding DNA, **48**, 169
 phosphorylating serine and treonine, **48**,
 169–171
 phosphorylating tyrosine, **48**, 171–172
- C-terminal domain phosphatase
 dephosphorylation and transcript
 termination, **72**, 354
 discovery, **72**, 335–337
 early elongation complexes, **72**, 349–350
 elongation complex RNAP II, **72**, 355–357
 mRNA processing regulation, **72**, 353–354
 recombinant, cloning and expression, **72**,
 342–346
 RNAP II mobilization, **72**, 347–348
 TFIIF and TFIIB regulation, **72**, 341–342
 transcript elongation link, **72**, 350–351
 transcript elongation turnover, **72**,
 351–352
 transcription cycle, **72**, 346–347
 yeast and mammalian, **72**, 337–341
- CAD, *see* Constitutive activation domain
- Cadherin, *see also* E-cadherin
 cell-specific recognition, **57**, 199
 classification, **57**, 188
 functional domains, **57**, 193
 genes, **57**, 190–191, 193
 processing, **57**, 193
 sequence homology between species, **57**,
 188, 190, 207
 structure, **57**, 188, 190
 tissue distribution, **57**, 198
 types, **57**, 188
- c/EBP α* , autoregulation of promoter, **60**, 161
- C3G, *see* Crk SH3 domain-binding guanine
 nucleotide exchange factor
- Cadmium, inhibition of translation, **58**, 98
- Caenorhabditis elegans*, **67**, 10

- Calcitonin/CGRP, pre-mRNA, poly A sites, **71**, 337–341
- Calcitonin gene-related peptide (CGRP), splicing of polyadenylation site in gene, **57**, 62
- Calcium
- depletion and double-stranded RNA-activated protein kinase activation, **58**, 106–107
 - endoplasmic reticulum stress response signaling, **58**, 80–81, 84–86, 92–95, 112–113
 - sensing in cells, **58**, 167
 - translation initiation role, **58**, 92–95
- Calcium-dependent animal lectins, **45**, 207–208
- carbohydrate-recognition domains, **45**, 208–215
- history, **45**, 229–230
- C-type genes
- exons, **45**, 218–220
 - introns, **45**, 216–218
- saccharide-binding specificity
- convergent evolution, **45**, 225–227
 - oligosaccharides, **45**, 227–229
 - sequences, **45**, 222–225
 - sugar binding, **45**, 220–222
- Calcium ion, pRNA effect, **72**, 449
- Calcium signaling
- pyruvate dehydrogenase complex effect, **70**, 46
 - pyruvate dehydrogenase phosphatase 1 control, **70**, 64–65
- Calicheamicin, DNA sequence specificity, **63**, 381, 396
- Calmegin
- C-terminal cytosolic domains, **67**, 242
- Calmodulin
- iPLA₂ β , **67**, 16–17
- Calmodulin, binding and stimulation of PDE1, **63**, 19–21
- Calmodulin-dependent cyclic nucleotide phosphodiesterase, calcium depletion effects on stability, **58**, 80–81
- Calnexin, binding of prohormone convertase 2 proenzyme, **63**, 83
- Calnexin/calreticulin cycle, **67**, 240
- Calnexin (CNX), **67**, 237–238
- C-terminal cytosolic domains, **67**, 242
 - glycoprotein folding
- ER, **67**, 241–243
 - major histocompatibility class I, **67**, 255–258
- Calreticulin/calnexin cycle, **67**, 24–25240
- Calreticulin (CRT), **67**, 237–238
- major histocompatibility class I, **67**, 258
- CaMKIV
- link with ROR activation, **69**, 241
 - regulation of ROR-dependent transactivation, **69**, 223–224
- CAMP, **67**, 41
- cAMP
- anti* conformation binding, **69**, 269–270
 - compartmentalized signaling, **69**, 252–253, 299
 - degradation, **69**, 250
 - hydrolysis, PDE3 isoenzymes with affinity for, **69**, 255–256
- cAMP response element-binding protein, ROR cofactor, **69**, 219–222
- cAMP, *see* Cyclic AMP, **56**, **63**, **64**
- Campomelic dysplasia, SOX9 mutation, **64**, 186
- Camptothecin, DNA sequence specificity, **63**, 398
- Camptothecin, topoisomerase I inhibition
- linker region role, **60**, 125–126
 - mechanism, **60**, 113
 - resistant mutants, **60**, 127
- CaMV, *see* Cauliflower mosaic virus
- Cancer, **68**, 274
- ROS, **68**, 96
 - TDG, **68**, 250–251
- Cancer cells
- cell cycle control of DNMT1 in, deregulation, **69**, 66–67
 - DNMT1 overexpression, **69**, 65
 - lung, DNA replication inhibition, **69**, 63–64
 - tumor suppressors hypermethylated in, **69**, 67
- Cancer, FGF-1 role, **70**, 157
- Cancer, latent viruses and mutated oncogenes and, **43**, 181–184
- clonal cancer, **43**, 157–167
 - int* genes, **43**, 178–181
 - proto-*abl* genes, **43**, 167–170
 - proto-*myc* genes, **43**, 167–170
 - proto-*ras* genes, **43**, 173–178
- Candidate mRNA, genetic defects of mammalian nervous system and, **41**, 243

- Candidate protein, genetic defects of
mammalian nervous system and,
41, 243
- Cap-dependent scanning, eukaryote
translation initiation, **72**, 4–5
- Capillary electrophoresis laser-induced
fluorescence detection (CE-LIF), **68**,
141–143
- thymine glycol, **68**, 143–145
- Capillary electrophoresis, *see* Constant
denaturant capillary electrophoresis
- Capping enzyme
and mRNA identity, **50**, 122–124
from *Schizosaccharomyces pombe*, **50**,
117–118
genetic link with pre-mRNA splicing, **50**,
124–125
role in vaccinia virus transcription, **50**,
112–114
Saccharomyces cerevisiae mRNA, **50**,
114–117
sequence conservation, **50**, 119–122
vaccinia virus, domain structure, **50**,
103–109
- Capsid proteins
pRNA association, **72**, 450
pRNA binding, **72**, 445–447
pRNA departure, **72**, 450
- Carbohydrate-recognition domains,
calcium-dependent animal lectins and,
45, 208–215, 229–230
- Carbon catabolite, repression, **69**, 181–183,
190–191, 197
- Carbon compounds, methylated
methanogenesis, **71**, 235–238
proton translocation, **71**, 256
- Carbon dioxide
acetate conversion, **71**, 238
methanogens, $H_2 + CO_2$
methanogenesis, **71**, 232–234
proton translocation, **71**, 256
- Carbon monoxide (CO)
binding
CooA, **67**, 41
CooA, **67**, 40–42
HIS-77, **67**, 48–49
model, **67**, 50–52
Cys-75, **67**, 48
metabolism
purple nonsulfur bacteria, **67**, 37
oxidation
Rhodospirillum rubrum, **67**, 36–38
- PRO-2
heme, **67**, 49–50
sensor
CooA, **67**, 53–54
source
aquatic environments, **67**, 37
- Carbon monoxide dehydrogenase
(CODH), **67**, 37
- Carbon, mitochondrial biogenesis in
Saccharomyces cerevisiae and, **46**, 64–70
- Carboplatin, **67**, 117
chemical structure, **67**, 118
structure, **67**, 94
- Carboplatin–DNA interactions, **71**, 25–26
- Carboplatin, DNA sequence specificity, **63**,
378, 385
- Carboxydotherrnus hydrogenoformans*, **67**, 37
- Carboxylesterase
quality control, **67**, 251
- Carboxyl-terminal extension, RORs, **69**,
214–215
- Carcinogenicity, from alkylating agents,
protection, **51**, 207–208
- Carmethizoles, DNA sequence specificity, **63**,
381, 394
- Carmustine (BCNU), DNA sequence
specificity, **63**, 380, 390
- Cartilage hypertrophy, *see also* Type X collagen
matrix components
alterations, **60**, 80
diffusion, **60**, 98–102
up-regulated genes
galectin, **60**, 105–106
identification, **60**, 103, 105
transglutaminase, **60**, 106
- β -Casein, cell shape and structure in gene
regulation, **65**, 330
- Casein kinase (CKII)
APE, **68**, 49
- Casein kinase II (CKII)
regulation, **59**, 97–98
Saccharomyces cerevisiae, *see* Casein
kinase II, *Saccharomyces cerevisiae*
Schizosaccharomyces pombe enzyme,
59, 99
substrates, **59**, 96, 98
subunits, **59**, 96–97
tissue distribution in mammals, **59**, 98

- transgenic mice, **59**, 98–99
- Casein kinase II, *Saccharomyces cerevisiae*
 - catalytic subunit structure, **59**, 101
 - Cdc37 activation, **59**, 112–113
 - conditional allele analysis, **59**, 102, 104
 - functions
 - cell cycle progression, **59**, 111–113, 116, 127–128
 - cell polarity, **59**, 113–117
 - flocculation, **59**, 109–110
 - gene expression and chromatin structure, **59**, 110–111, 128–129
 - ion homeostasis, **59**, 117–118, 128
 - signal transduction, **59**, 127–128
 - heat shock protein, **59**, 90
 - association, **59**, 113
 - multicopy suppression screens
 - alleles in screens, **59**, 104
 - CDC37*, **59**, 105–106, 112
 - controls, **59**, 105
 - SUN2*, **59**, 107–109
 - ZDS1*, **59**, 106–107, 116
 - ZDS2*, **59**, 106–107, 116
 - null allele analysis, **59**, 102–104
 - regulation, **59**, 129
 - regulatory subunit structure, **59**, 101
 - substrates
 - criteria for identification, **59**, 119–120
 - eIF-2 α , **59**, 120
 - Nopp140, **59**, 121
 - prediction by recognition site, **59**, 121–127
 - Srp40, **59**, 121
 - topoisomerase II, **59**, 120–121
 - subunits and genes, **59**, 100
- Casein kinases I and II, in C-terminal domain
 - phosphorylation, **48**, 166
- Caspase-3
 - cleavage of PDE4A5, **69**, 282–283
 - PDE4A4/5 activation, **69**, 306
- Caspase-3 cleavage site
 - iPLA $_2\beta$, **67**, 15
- CAT, *see* Chloramphenicol acetyl transferase
- Catabolite responsive protein (CRP), **67**, 36, 40–41
 - consensus target sequences, **67**, 58
 - effector binding sites, **67**, 46
 - effector-bound
 - F helices, **67**, 46
 - hinge region residues
 - differential contacts, **67**, 45
 - monomer, **67**, 43
 - structure
 - vs.* CooA, **67**, 42–46
 - three-dimensional structures, **67**, 57–58
- Catalytic domains
 - protein kinase family, **67**, 8
- Catalytic overactivity, PRPP synthetase, **69**, 138–139, 145
- Catalytic unit
 - PDE4 isoenzymes, **69**, 266–279
 - UCR2 connected to, **69**, 264
- α -Catenin
 - E-cadherin binding, **57**, 194, 196–197, 201–202
 - gene, **57**, 196
 - loss in cancer, **57**, 206
 - modulation of adhesion, **57**, 198
- β -Catenin, APC binding to, **69**, 58–59
- Cathepsin A
 - activity and structure, **69**, 85–86
 - complex with
 - EBP and sialidase, **69**, 98–99
 - GAL, **69**, 97–98
 - mutations in, **69**, 102–103
 - precursor, sialidase association with, **69**, 94
 - protective role, **69**, 84–85
 - quality control, **67**, 251
 - synthesis and function, **69**, 86–87
- Cauliflower mosaic virus
 - RNA translation–packaging interplay, **72**, 9
- sORF-dependent shunt
 - adenovirus comparison, **72**, 17–19
 - other initiation events, **72**, 17
 - overview, **72**, 12
 - shunting as reinitiation, **72**, 16
 - shunting ribosomes, **72**, 15–16
 - take-off and landing sites, **72**, 14–15
- Caulimoviridae, sORF-dependent shunt
 - other initiation events, **72**, 17
 - overview, **72**, 12–14
 - shunting as reinitiation, **72**, 16
 - shunting ribosome initiation, **72**, 15–16
 - take-off and landing sites, **72**, 14–15
- CBFA1*, mutation in cleidocranial dysplasia, **64**, 187–188
- CBP, *see* cAMP response element-binding protein
- CBP, *see* CREB-binding protein

- Ccm1p, *see* RNA (guanine-7) methyltransferase
- CCNU, *see* Lomustine
- CCT, *see* CTP:phosphocholine cytidyl-transferase
- CD, *see* Circular dichroism
- CD4, inhibition by oligonucleotide binding, **57**, 123–124
- Cdc, *see* Cell division cycle proteins
- CDC1*, mutation effects on double-strand break-induced recombination, **58**, 294
- cdc2*, G₂-M checkpoint regulation, **62**, 380–382
- Cdc25 protein
 feedback inhibition, **48**, 8
 in *Saccharomyces cerevisiae* growth control, **48**, 5–8
 membrane association, **48**, 7–8
 nutrient response, **48**, 6–7
- CDC25^{Mm}, *see* Guanine nucleotide releasing factor 1
- CDC25p
 early identification, **71**, 393–395
 homology domains, **71**, 396–401
- CDC37*, multicopy suppression of casein kinase yeast mutants, **59**, 105–106, 112
- Cdc42
 E-cadherin, **67**, 199–200
 effectors, **67**, 197, 199–200
 lung cancer, **67**, 201
- Cdc46 protein, in transcriptional control of
 G1/S genes in *Saccharomyces cerevisiae*, **48**, 16–19
- Cdc6 protein, in transcriptional control of
 G1/S genes in *Saccharomyces cerevisiae*, **48**, 16–19
- CDC9* gene
 Saccharomyces cerevisiae, **68**, 151–152
- CDG
 UNG expressing
 active-site mutants, **68**, 377–378
- CDK inhibitors, **67**, 13
- Cdk, *see* Cyclin-dependent kinases
- cdk2*, activation in ROR $\gamma^{-/-}$ DP thymocytes, **69**, 235–236
- CDNA
 hRFC
 characterization, **67**, 139–147
 cloning, **67**, 140–146
 heterogeneous 5' UTRs, **67**, 142
- KS6, **67**, 144
- KS32, **67**, 144
- synthesis
 in vivo, **67**, 87
 msDNAs, **67**, 77
 polymerization, **67**, 77–80
 termination, **67**, 77–80
- cDNA, *see* Complementary DNA
- CDP-choline:1,2-diacylglycerol phospho-transferase (CPT)
 inhibition and apoptosis induction, **65**, 385–386
 regulation, **65**, 374
 structure, **65**, 373
 subcellular localization, **65**, 374
- CDP-diacylglycerol synthase (CDS),
 features, **65**, 377–378
- CDS, *see* CDP-diacylglycerol synthase
- cds1*
 intra-S-phase checkpoint role, **62**, 391–392
 S-M checkpoint regulation, **62**, 385–388
- Cdt1p, chromatin binding, **72**, 56–57
- CE-LIF, **68**, 141–143
 thymine glycol, **68**, 143–145
- Ceg1p, *see* RNA guanylyltransferase
- Cell adhesion/signaling molecules
 ankyrin-repeat domains, **67**, 12
- Cell-cell junctions
 structural changes during tumorigenesis, **57**, 204–207
 types, **57**, 188, 198–199
- Cell culture, UL9, **70**, 98
- Cell cultures
 expression of transgenic constructs, **50**, 173–175
 models, **50**, 163–172
- Cell cycle
 BER pathways, **68**, 23–24
 cancer, **53**, 198, 214
 control by checkpoints
 coiled-coil proteins, **72**, 77
 effector kinases, **72**, 78
 overview, **72**, 73–74
 phosphoinositol-3-kinase-like complexes, **72**, 77
 protein network, **72**, 78–80
 sensors, **72**, 74–77
 control of DNMT1, deregulation in cancer cells, **69**, 66–67
 eukaryotic, *see* Eukaryotic cell cycle

- regulation of demethylase expression, **69**, 59–61
- ribonucleotide reductase expression, **53**, 361–367
- signal transduction and G0 to S transition, **53**, 198–201
- thymidine kinase, transcriptional regulation, **53**, 202–214
- Cell cycle checkpoint, *see* DNA damage/replication checkpoints, *Schizosaccharomyces pombe*
- Cell cycle, control in mouse fibroblasts, **58**, 44, 61, 65–70
- Cell death
 - cisplatin, **67**, 116–117
 - iPLA₂ β , **67**, 24–25
- Cell division cycle proteins
 - Cdc6 and Cdc18, chromosomal DNA replication, **72**, 55–56
 - Cdc45, G1–S phase transition, **72**, 61–63
- Cell-free extracts
 - BER pathways, **68**, 11–20
- Cell growth, role of *CEG1* capping activity, **50**, 116–117
- Cell lines
 - human
 - hMMH type 1a protein, **68**, 112
 - human OGG1/MMH type 1a protein, **68**, 110
- Cell membrane, *see* Membrane, cell
- Cell membranes, macromolecular translocation, **72**, 461
- Cell motility, sphingosine-1-phosphate receptor, **71**, 494–495
- Cell separation, in G1 phase of yeast cell cycle, **48**, 2–3
- Cell stress, RNA destruction, **72**, 136–138
- Cell transformation
 - FGF-2 isoforms, **72**, 390–391
 - IRES activity, **72**, 398–399
 - Rho proteins, **67**, 195
- Cell wall, plants
 - composition and structure
 - arabinan, **61**, 215
 - arabinogalactan, **61**, 215
 - cellulose, **61**, 213–214
 - galactan, **61**, 215
 - hemicellulose, **61**, 214–215
 - overview, **61**, 213
 - hydrolases
 - arabinan-degrading enzymes, **61**, 217
 - catalytic mechanisms, **61**, 231, 233
 - cellulases, **61**, 216
 - diversity, **61**, 215–216
 - galactan-degrading enzymes, **61**, 217
 - mannan-degrading enzymes, **61**, 217
 - xylan-degrading enzymes, **61**, 216–217
- Cellodextrinase, cellulose-binding domain in *Pseudomonas fluorescens* subsp. *cellulosa*, **61**, 219
- Cellular differentiation, *Dictyostelium discoideum*
 - DIF-induced prestalk-specific mRNAs, **47**, 8–10
 - markers
 - identification, **47**, 3–6
 - prestalk-enriched, **47**, 7–8
- prestalk cells
 - ammonia effects, **47**, 21
 - DIF-inducible genes, **47**, 6–7
 - extracellular cAMP effects, **47**, 21–22
 - heterogeneity, **47**, 10–13
- stalk cells
 - ammonia effects, **47**, 21
 - extracellular cAMP effects, **47**, 21–22
- Cellular messenger RNA, IRESs, **72**, 374–376
- Cellular proteins, DNA adduct recognition
 - cisplatin-damaged DNA-binding proteins, **71**, 23
 - DNA photolyase, **71**, 20–21
 - DNA-repair proteins, **71**, 19
 - histone H1, **71**, 18–19
 - HMG-domain proteins, **71**, 15–18
 - overview, **71**, 14–15
 - p53 protein, **71**, 21
 - T4 endonuclease VII, **71**, 21
 - TATA-binding protein, **71**, 18
 - Y-box binding protein, **71**, 1, 18
- Cellular resistance, cisplatin-DNA adducts
 - mechanisms, **71**, 11
 - mismatch repair, **71**, 14
 - nucleotide excision repair, **71**, 13
- Cellular retinoic acid-binding protein (CRABP)
 - binding specificity, **63**, 141–142, 145
 - levels of expression, **63**, 142, 145
 - retinoic acid metabolite binding, **63**, 156–158
 - sequence homology between species, **63**, 142, 144

- Cellular retinoic acid-binding protein (CRABP) (*cont.*)
 subcellular localization, **63**, 158
 tissue distribution
 adults, **63**, 142, 144
 embryos, **63**, 142–143
 transgenic mouse studies, **63**, 158
- Cellular retinol-binding protein (CRBP)
 binding specificity, **63**, 141–142, 145
 cellular retinol uptake, effects, **63**, 152
 enzyme access to bound retinoids
 alcohol dehydrogenase activities, **63**, 149
 lecithin:retinol acetyltransferase versus
 ARAT activity, **63**, 146–148, 153
 retinal metabolism, **63**, 147–149, 171–173
 retinol dehydrogenase activities, **63**,
 149–151, 154, 160–161
 retinol protection in liver, **63**, 145–146
 levels of expression, **63**, 142, 145
 purification, **63**, 144–145
 retinyl ester hydrolase stimulation, **63**, 160
 sequence homology between species, **63**,
 142, 144
 tissue distribution
 adults, **63**, 142, 144
 embryos, **63**, 142–143
- Cellular signaling
 compartmentalized, **69**, 252–253
 sialidase role, **69**, 94–95
- Cellular transformation, *Dnmt1* expression
 role, **69**, 56–58
- Cellulase, *see* Cellodextrinase; Endoglucanase;
 β -Glucan glucohydrolase
- Cellulose-binding domain
 classification, **61**, 223, 225
 function in cellulases, **61**, 219, 225, 227–229
 sequence alignment, **61**, 224, 226
 structures, **61**, 223–225
- Cellulose, structure and degradation, **61**,
 213–214, 216–217
- CEM-NK^R, **67**, 255–256
- Centromeres, nucleosome positioning and, **40**,
 167–168
- Ceramide, phosphatidylcholine metabolism
 relationship in apoptosis induction,
65, 386
- Cervical cancer, latent viruses and mutated
 oncogenes and, **43**, 160–164
- Cervix, Muc4/SMC, **71**, 177
- Cet1p, *see* RNA triphosphatase
- CF1 complex, **71**, 354
- CF1_m cleavage factors, **71**, 331–333
- CF11 complex, **71**, 355–356
- CF11_m cleavage factors, **71**, 331–333
- CFI_m, *see* Cleavage factor I_m
- cGMP
 cross-talk with cAMP, **69**, 255
 PDE5 and PDE6 specific for, **69**, 256–257
- cGMP, *see* Cyclic GMP
- CGRP, *see* Calcitonin gene-related peptide
- Channeling
 aminoacyl-tRNA, **60**, 62–64, 72
 theory, **60**, 62
- Chaperone, *see also specific chaperones*
 nascent peptide folding, *see* Nascent peptide
 periplasmic chaperones of *Escherichia coli*
 biogenesis of outer membrane proteins,
 66, 140–141
 general chaperones, **66**, 139–140
- Chaperones, EF-Ts in EF-Tu folding, **71**,
 529–531
- Charcot-Marie-Tooth disease type 1A
 (CMT1A), peripheral myelin protein 22
 mutations, **64**, 114–116
- Charcot-Marie-Tooth disease (CMT),
 genetics, **56**, 242–243
- Chemical modification interference, pRNA,
72, 436
- Chemical modification, pRNA, **72**, 435–436
- Chemical probing, procapsid-bound pRNA,
72, 447
- Chemotherapy, enhancement, **51**, 209–214
- Chemotherapy, *see* DNA-damaging agents,
 sequence specificity of damage
- χ -structure, *see also* Strand exchange, Holliday
 intermediate
 synthetic, resolution by Flp, **51**, 81–83
- Chickory yellow mottle virus type 1 hairpin
 ribozyme, *see* Hairpin ribozyme
- Chimeras, antisense, **69**, 17
- Chinese hamster ovary (CHO) cell line
 8-oxoguanine, **68**, 85–103
 AA8
 8-oxoG, **68**, 101, 102
- CHIP assay, *see* Chromatin
 immunoprecipitation assay
- Chips, HSV-1 DNA microarray
 data evaluation, **71**, 465–468
 experimental data, **71**, 470–472
 fabrication, **71**, 464–465

- Chironomus tentans*, *see also* Balbiani ring
 multigene family
 biology, **48**, 277–281
 extracorporeal protein tubes, **48**, 277–278
 salivary glands, **48**, 278–281
- chk1
 G₂-M checkpoint regulation, **62**, 379–382
 S-M checkpoint regulation, **62**, 386–388
- Chk1, cell cycle control, **72**, 78
- Chk2, cell cycle control, **72**, 78
- CHL1
 gene cloning, **58**, 246
 hydrophobicity analysis, **58**, 257–258
 sequence homology with other
 transporters, **58**, 248, 250–256
 structure, **58**, 248–249
- Chloroacetaldehyde, DNA sequence specificity
 of damage, **63**, 383, 401
- Chlorambucil, DNA sequence specificity, **63**,
 379, 388–389
- Chloramphenicol acetyl transferase
 FGF-2 mRNA expression, **72**, 392–393
 FGF-2 translational silencing, **72**, 401
- Chlorethylation, carcinogenic, prevention,
51, 207
- Chlorodiethylenetriamineplatinum(II)
 chloride–DNA interactions, **71**, 7–8
- Chloromycin, DNA sequence specificity of
 damage, **63**, 383, 402
- Chloroplast
 degradosome complex, **66**, 92
 poly(A) polymerase complex, **66**, 93
 spontaneous insertion of proteins in
 membranes, **66**, 135–136
- Chloropolypyridyl ruthenium compounds–D-
 NA interactions, **71**, 53
- CHO cell line
 8-oxoguanine, **68**, 85–103
 AAS
 8-oxoG, **68**, 101, 102
- ChoK
 inhibitors
 antitumor activity, **67**, 217–219
- Cholera toxin, ADP-ribosylation factors and,
see ADP-ribosylation factors
- Cholesterol
 antisense oligonucleotide delivery, **57**,
 111–112, 121
 protein inhibition by modified
 nucleotides, **57**, 125
- Cholesterol synthesis, *see* Squalene synthase
- Choline kinase (ChoK)
 inhibitors
 antitumor activity, **67**, 217–219
- Choline kinase (CK)
 activation in mitogenesis, **65**, 364–365
 genes and isoforms, **65**, 364
- Chorionic somatomammotropin gene
 cyclic AMP, control of expression, **54**, 137
 evolution, **54**, 128–131
 placenta
 CSEF-1 control of CSEn function, **54**,
 152–154
 CSEn enhancer, **54**, 149–150, 152
 hormonal control of gene expression, **54**,
 156–157
 InrE initiator element, **54**, 154–155
 negative control by pituitary, **54**,
 155–156
 physiological actions, **54**, 131–134
 receptors, **54**, 130–131
 similarity to growth hormone gene, **54**, 128
 splicing, **54**, 128–130
 triiodothyronine, control of expression, **54**,
 138–140, 142
- Chromatid exchange, DNA sequence
 amplification in mammalian cells and,
41, 219–220
- Chromatin
 assembly, reconstitution systems, **52**,
 345–346
 benzo[a]pyrene diol epoxide adduct
 distribution, **62**, 232, 237
 binding by Cdt1p, geminin, and
 Mcm10p, **72**, 56–57
 DNA repair heterogeneity
 nucleosomes, **62**, 238–241
 transcribed chromatin, **62**, 241–244
 electron microscopy, **52**, 344–345
 eukaryotic, usage, **72**, 2
 fiber condensation, role of linker
 histones, **52**, 218–220, 236–237, 243,
 245, 254
 histone H1 and folding of replicating
 chromatin, **52**, 357–359
 histone modification and replication, **52**,
 358–359
 histone proteins in nucleosome structure,
62, 228
 limited digestion, **52**, 344

Chromatin (*cont.*)

- nucleosome assembly during complementary strand synthesis, **52**, 348
- nucleosome-free origins, **52**, 350–351
- nucleosome positioning and, **40**, 144–147
 - in vivo*, **40**, 174–175
 - function, **40**, 175–180
- protamines and, **40**, 68–70
- pyrimidine dimer photoproduct
 - distribution, **62**, 228–229, 231–232
- replication-initiation factors organization
 - activation of origins, **72**, 71
 - elongation reaction, **72**, 72–73
 - leading and lagging strands, **72**, 72
 - overview, **72**, 69–70
 - prereplicative complex assembly, **72**, 70–71
- structure
 - chromatin transcription implications, **52**, 245–246
 - core particles, **52**, 339–340
 - diameter, **52**, 247
 - dynamics, **52**, 340–341
 - effect of linker histone removal, **52**, 243, 245
 - high mobility group proteins, **52**, 341–342
 - histones, **52**, 338–339
 - linker DNA, **52**, 248–250
 - low ionic strength, **52**, 242–243
 - mass per unit length, **52**, 247
 - newly replicated chromatin, **52**, 347–348
 - nucleosome orientation, **52**, 247–248, 341
 - replicated DNA strands, **52**, 352–357
- structure modulation by DNA damage
 - higher order chromatin structure, **62**, 236–237
 - nucleosome structure, **62**, 235–236
 - sequence-specific DNA-protein interactions, **62**, 237
- structure modulation of DNA damage
 - distribution
 - nucleosomes formed on random DNA sequences, **62**, 228–229, 231–232
 - nucleosomes formed on single sequence, **62**, 232–233
 - sequence-specific DNA-protein complexes, **62**, 233, 235
- supercoiling assay, **52**, 342–344
- viral minichromosome model, **52**, 348–349

- structure modulation during DNA repair
 - histone modifications, **62**, 248–250
 - maturation of newly repaired regions of chromatin, **62**, 250–251
 - nucleosome structure, **62**, 244–248

Chromatin barrier

- TFO, **67**, 174–177

Chromatin, DNA sequence amplification in

- mammalian cells and, **41**, 211–213

Chromatin, immunoglobulin gene

- diversification and, **45**, 38–39

Chromatin immunoprecipitation (CHIP) assay,

- acetylated histones
- caveats in studies, **65**, 320–321
- cell cycle studies, **65**, 319
- fine-mapping, **65**, 319–320
- transcription studies, **65**, 318–319

Chromatin, organization of human apo-B

- gene, **50**, 162–163

Chromatin remodeling

- metallothionein expression, **66**, 372–373
- steroid receptors
 - bimodal model for receptor function, **66**, 284–286
 - differential expression from transient and replicated templates, **66**, 286–288
- dynamics of glucocorticoid receptor interactions, **66**, 296
- glucocorticoid receptor-dependent
 - transition, molecular characterization
 - higher-order structure transitions, **66**, 295–296
- model systems, **66**, 288–290
- multiple nucleosome frames, **66**, 292–294
- nucleosome mapping, **66**, 290–292
- transition regions defined by hormone response elements, **66**, 294–295
- histone acetyl transferases and deacetylases as receptor coactivators and repressors, **66**, 285–286
- kinase cascades, **66**, 288
- nuclear factor 1 binding, **66**, 282–285, 298, 300
- protein–protein interaction model, **66**, 281–282
- template-dependent signaling cross-talk, **66**, 288
- triplet repeat sequence methylation, **66**, 185–186

- Chromatin, *see also* High-mobility-group chromosomal protein; Nucleosome assembly systems, *in vitro*
 crude extracts, **54**, 344–345
 purified components
 polyglutamate-mediated reactions, **54**, 346–347, 350–351, 353–356
 salt concentrations for assembly, **54**, 346
 synthetic polynucleotides, **54**, 347–350
 DNA accessibility, **54**, 35–36
 genomic signals influencing assembly
 β -globin DNA, chicken, **54**, 363–366
 growth hormone gene introns,
 rat, **54**, 366–367, 369–373
 mechanisms, **54**, 358–359
 ovalbumin gene introns, chicken, **54**, 359–363
 plasmids in transfected cells, **54**, 374–375
 packaging, **54**, 35
 Chromatin, *see also* Histone; Karyoskeleton
 DNA winding on nucleosome core, **65**, 208–209
 imaging in living cells, **65**, 301–302
 mechanical signaling pathways and nuclear
 DNA organization, **65**, 329–331
 proliferating cell nuclear antigen role in
 assembly, **65**, 285
 remodeling in thyroid hormone-responsive
 gene regulation
 chromatin disruption assays, **65**, 66, 68
 histone acetylation regulation, **65**, 65–66
 Xenopus oocyte system advantages,
 65, 63, 65, 93
 structure
 overview, **65**, 300–301
 transcriptionally active chromatin, **65**, 303–304
 transcription factors in replication, **65**, 291
 yeast chromatin properties
 GAL gene-specific chromatin structure,
 see GAL
 discrete length linkers, **65**, 199, 202–203
 DNA unpeeling from core ends, linker
 length effects, **65**, 206–208
 higher-order structure, **65**, 212–214
 histone contributions to unique
 features, **65**, 211–212
 metazoan core nucleosome similarity, **65**, 198–199, 210–211, 213
 nucleosome conformational changes
 in situ, **65**, 203, 205–206
 nucleosome core with short linkers,
 65, 198–199
 terminal core nucleosome DNA liability
 and consequences, **65**, 209–211
 Chromatin, *see* Nucleosome
 Chromatin structural, accessibility of
 demethylase to DNA gated by, **69**, 69–70
 Chromatin, structure, methylation and,
 48, 48, 64
 Chromatography, enzymes in DNA precursor
 biosynthesis and, **44**, 183–185
 Chromogranins, genetic defects of mammalian
 nervous system and, **41**, 251
 Chromopeptide, biosynthesis
 actinomycin
 actinomycin synthetases, **70**, 253–255
 enzymes, **70**, 252–253
 phenoxazinone chromophore formation,
 70, 255–257
 ergopeptides, **70**, 261–264
 future research, **70**, 282–283
 D-lysergic acid amides, **70**, 261–264
 mikamycin B–streptogramin antibiotics, **70**, 259–261
 nonribosomal, *see* Nonribosomal
 chromopeptides
 quinoxaline antibiotics, **70**, 257–259
 starter activation, **70**, 249–251
 Chromapeptide–siderophores, biosynthesis
 enterobactin, **70**, 264–265
 mycobactin, **70**, 269–270
 pyochelin, **70**, 268–269
 pyoverdines, **70**, 270–274
 yersiniabactin, **70**, 265–268
 Chromopolyketides, **70**, 249
 Chromosomal localization,
 ROR γ , **69**, 224–226
 Chromosome 2p13, **70**, 7
 Chromosome 5q23, **70**, 6–7
 Chromosome 15q24, **70**, 7
 Chromosome 22q13.1, **67**, 19
 Chromosome 8p21, **70**, 6–7
 Chromosome partitioning, recombinatorial
 DNA repair effects at cell division, **63**, 325
 Chromosome replication, *see* *Bacillus subtilis*,
 membrane–chromosome replication
 Chromosomes
 aberrations, resistance to, **51**, 202–203

Chromosomes (*cont.*)

- DNA sequence amplification in mammalian cells and, **41**, 208–211
 - engineering, F1p as reagent, **51**, 86–87
 - genetic defects of mammalian nervous system and, **41**, 242, 253, 255
 - in Balbiani ring multigene family, locations of genes, **48**, 293–294
 - localization
 - iPLA₂ β , **67**, 17–19
 - location of mammalian aminoacyl-tRNA synthetase genes, **48**, 117
 - mutations
 - TFOs, **67**, 176
 - X, modification and inactivation of,
 - methylation and, **48**, 69
 - Chromosomes, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and, **45**, 118–119
 - Chromosomes, latent viruses and mutated oncogenes and, **43**, 190–194
 - Chromosomes, purine nucleotide biosynthesis and, **42**, 270–271
 - Chronic myelogenous leukemia (CML),
 - antisense oligonucleotide therapy, **57**, 118
 - Chronic obstructive pulmonary disease (COPD), PDE3 inhibitor therapy, **66**, 266–268
 - Chronic progressive external
 - ophthalmoplegia, **68**, 274
 - Chs7p
 - quality control, **67**, 250
 - cII* translation, lysogenic pathway in bacteriophage λ and, **46**, 45
 - CIITA*, mutation in bare lymphocyte syndrome, **64**, 198
 - Ciliary neurotrophic factor (CNTF),
 - release in nerve injury, **56**, 247–248
 - Ciliates
 - conjugation, **56**, 5–6
 - DNA rearrangement
 - chromosomal fragmentation, **56**, 6–7, 41–43
 - gene scrambling, **56**, 8, 43–44
 - interstitial DNA deletion, **56**, 7–8
 - evolution, **56**, 3
 - internal eliminated sequences
 - cis*-acting sequence requirements, **56**, 30–35
 - evolution
 - abdication and fading, **56**, 52–54
 - bloom, **56**, 48–52
 - germ-line soma system,
 - role in ciliates, **56**, 49–51
 - overview, **56**, 46, 58
 - Tetrahymena*, **56**, 54–56
 - transposon function maintenance, **56**, 51–52
 - transposon invasion, **56**, 47–48
 - transposon multiplication limits, **56**, 48–49
 - excision products
 - macronuclear junctions, **56**, 20–21, 26
 - M-region, **56**, 26–31
 - polymerase chain reaction analysis, **56**, 27–28
 - R-region, **56**, 26–27, 29
 - Tec transposon circles, **56**, 21–23, 32–34
 - telomere-bearing element transposon circles, **56**, 24–25
 - functions, **56**, 44–45
 - Oxytricha*, **56**, 34–35
 - Paramecium*, **56**, 18–19
 - phylogenetic distribution, **56**, 56–58
 - rearrangement mechanism, **56**, 7–8
 - short sequences, **56**, 8–9
 - Tetrahymena*, **56**, 15–18, 26–30
 - trans*-acting factors
 - conjugation-specific proteins, **56**, 35–37
 - old macronucleus influence on
 - excision, **56**, 38–41
 - transposon-encoded proteins, **56**, 37–38
 - transposon sequences, **56**, 9, 11–15
 - life cycle, **56**, 3, 5
 - macronuclear development, **56**, 6
 - nuclear dimorphism, **56**, 3, 5
- Ciprofloxacin, *see* Topoisomerase II poisons
- Circadian rhythm
 - cyclic AMP-responsive element binding
 - protein role, **64**, 365
 - inducible cyclic AMP early repressor
 - role, **64**, 364–365
- Circular dichroism (CD)
 - guanine quadruplex, **59**, 82, 84–85
 - pyr*pur·pyr triplex, **59**, 65
 - three-fingered fold snake toxins, **59**, 339
- Circular permutation analysis, GAL DNA
 - bends, **65**, 242–243

- Circularly permuted pRNA, **72**, 421–423
- cis*-acting element, multipartite structure, **48**, 243–246
- cis*-acting elements
- in κ locus regulating hypermutation, **50**, 74–79
 - in targeting of recombination, **50**, 93–94
- Cis*-acting elements,
- FGF-2 translation, **72**, 387
- cis*-acting elements, mitochondrial biogenesis
- in *Saccharomyces cerevisiae* and, **46**, 54–55
- cis*-acting sequence, **70**, 164–167
- Cisplatin, **67**, **68**, 93–125, 275–276
- AAG proteins, **67**, 114–115
 - apoptosis, **67**, 116–117
 - cancer chemotherapy, **49**, 345
 - dinucleotide crosslink, **67**, 105
 - DNA binding effect on bleomycin cleavage specificity, **49**, 345
 - H1, **67**, 114–115
 - HeLa cells, **67**, 113
 - MCF-7 breast cancer
 - cytotoxicity assay plots, **67**, 124 - pol beta-defective cells, **68**, 17
 - repair shielding, **67**, 97
 - screening, **67**, 122
 - structure, **67**, 94
 - TBP, **67**, 114–115
 - telomere shortening, **67**, 112–114
 - ubiquitination, **67**, 116–117
- Cisplatin adducts
- HMG-domain protein binding
 - kinetics, **67**, 100–104
 - thermodynamics, **67**, 99–100 - HMG-domain proteins
 - sequence selectivity, **67**, 101
- Cisplatin-DNA, **67**, 95–96
- damage, **67**, 97
 - HMG 1 domain
 - platinum coordination center, **67**, 109
 - protein-DNA interactions, **67**, 108
 - structure, **67**, 107–110
 - x-ray crystal, **67**, 107 - intrastrand crosslink structure
 - determinations
 - geometric parameters, **67**, 106
- Cisplatin-DNA adducts
- protein binding, **67**, 98–104
- Cisplatin, DNA adducts
- adducts *in vitro*, **71**, 3–5
 - adducts *in vivo*, **71**, 6–7
 - adduct stability, **71**, 5–6
 - antitumor activity, **71**, 24–25
 - cellular resistance
 - mismatch repair, **71**, 14
 - nucleotide excision repair, **71**, 13
 - resistance mechanisms, **71**, 11 - crosslinks, **71**, 8
 - damaged DNA-binding proteins
 - recognition, **71**, 23 - monodentate platinum(II) compounds, **71**, 34–38
 - monofunctional adducts, **71**, 7–8
 - replication effects, **71**, 10
 - targeted analogs, **71**, 29–32
 - tetravalent analogs, **71**, 32–34
 - transcription effects, **71**, 11
- Cisplatin, DNA sequence specificity, **63**, 378, 384–385
- Cisplatin-DNA ternary complex
- HMG-domain
 - structure, **67**, 104–112
- Cisplatin, immunochemical analyses of
- nucleic acids and, **42**, 66, 68–69
- Cisplatin-modified DNA duplex
- NMR solution structure
 - diagram, **67**, 106 - x-ray solid-state structure
 - diagram, **67**, 106
- Citrate synthase, yeast
- genes, **57**, 331
 - mutant phenotypes, **57**, 331–333, 336
 - regulation of expression, **57**, 332–333
 - structures, **57**, 332
- Citron, **67**, 196
- biological functions, **67**, 197
- Citron kinase
- biological functions, **67**, 197
- Citron Rho-interacting kinase/citron kinase (CRIK), **67**, 196
- CIT*, *see* Citrate synthase, yeast
- CK, *see* Choline kinase
- CKII
- APE, **68**, 49
- CKII, *see* Casein kinase II
- cl-15, identification as immediate-early
- response gene, **58**, 52, 58
- Class I alcohol dehydrogenase gene
- expression patterns

- Class I alcohol dehydrogenase gene (*cont.*)
 baboons, **64**, 305
 humans
 blood vessels, **64**, 305
 gastrointestinal tract, **64**, 305
 liver, **64**, 303–305
 mice, **64**, 305, 307–308
 hormonal regulation, **64**, 308
 polymorphisms in humans
 alcoholism relevance, **64**, 300
 effects on kinetic parameters, **64**, 299
 promoters
 CACGTG sequence, **64**, 314–315
 CCAAT/enhancer-binding protein sites, **64**, 312–314
 CCAAT transcription factor-related sequences, **64**, 317–318
 distant sequences, **64**, 322
 G-string, **64**, 320
 G3T sequence, **64**, 315–317
 glucocorticoid response element, **64**, 319, 322
 hepatocyte nuclear factor-1 sequence, **64**, 318–319
 negative elements
 NRE1, **64**, 321
 NRE2, **64**, 321
 palindrome sequence, **64**, 320
 repeated sequence in intron 1, **64**, 321–322
 retinoic acid response elements, **64**, 320–322
 sequence alignment of genes, **64**, 306–307, 309–310
 site at–150bp, **64**, 318
 TATA box, **64**, 312
 transcriptional start site, **64**, 311–312
 transient transfection assays, **64**, 310–311
 structure, **64**, 300–301
Class II alcohol dehydrogenase gene
 expression patterns in tissue, **64**, 323
 promoter
 polymorphisms, **64**, 325
 site-directed mutagenesis, **64**, 324
 TATA box, **64**, 323
 transcription factor binding sites, **64**, 323–325
Class III alcohol dehydrogenase gene
 expression patterns in tissue, **64**, 325
 promoter structure and features, **64**, 326–327
 upstream AUG codons, **64**, 327–328
Class IV alcohol dehydrogenase gene
 expression patterns in tissue, **64**, 328–329
 promoter structure and function, **64**, 329–331
 upstream AUG codons, **64**, 331
Class V alcohol dehydrogenase gene
 expression patterns in tissue, **64**, 331
 promoter, **64**, 332
Class VI alcohol dehydrogenase gene
 expression patterns in tissue, **64**, 332
 promoter, **64**, 332
 upstream AUG codons, **64**, 332
Clb5 protein, in transcriptional control of G1/S genes in *Saccharomyces cerevisiae*, **48**, 16
Clb6 protein, in transcriptional control of G1/S genes in *Saccharomyces cerevisiae*, **48**, 16
Cleavage and polyadenylation specificity factor
 cDNA clones, **71**, 328
 mRNA 3' end processing, **71**, 347–349
 poly A-binding protein, **71**, 317–318
 RNA binding, **71**, 315–316
 SnRNP, **71**, 314–315
 subunit interactions, **71**, 314
Cleavage and polyadenylation specificity factor (CPSF)
 cytoplasmic protein, **57**, 55–56
 RNA binding, **57**, 49–50, 53, 55
 structure, **57**, 49
Cleavage factor I_m (CFI_m)
 RNA binding, **57**, 50, 53
 structure, **57**, 49
Cleavage/polyadenylation
 cleavage stimulation factor, **71**, 312–313
 CPSF, **71**, 313–316
 CPSF–RNA binding, **71**, 315–316
 CPSF subunit interactions, **71**, 314
 mechanism, **71**, 299–301
 poly A-binding protein, **71**, 317–318
 poly A polymerase, **71**, 316–317
 SnRNP in CPSF, **71**, 314–315
Cleavage/polyadenylation proteins
 complex assembly, **71**, 309–311
 component separation, **71**, 304–305
 nuclear extract fractionation, **71**, 305–308
 poly A sites, crosslinking to proteins, **71**, 309
 UV crosslinking, **71**, 308

- Cleavage stimulation factor
 50-kDa subunit, **71**, 326–327
 64-kDa subunit, **71**, 326, 343–347
 77-kDa subunit, **71**, 327–328
 cDNA clones, **71**, 325–326
 characterization, **71**, 312–313
- Cleavage stimulation factor (CstF)
 RNA binding, **57**, 49, 53, 62
 structure, **57**, 49
- Cleidocranial dysplasia, *CHFAI* mutation, **64**, 187–188
- Clonal cancer, latent viruses and mutated oncogenes and, **43**, 157–167
- Cloned Ca^{2+} iPLA₂
 characteristics, **67**, 7
- Clones, genetic defects of mammalian nervous system and, **41**, 244, 250–251
- Cloning
 branched chain aminotransferases, **70**, 188–189
 DNA–protein interaction, **70**, 162–164
 eIF5 cDNA, **70**, 215–216
 FGF-1 gene, **70**, 159
 mammalian sphingosine kinases, **71**, 500–503
 poly A polymerase cDNA, **71**, 320–322
 purine nucleotide biosynthesis and, **42**, 271–272
 trp repressor and, **42**, 5–7
- Cloning, cell-free, prospects, **51**, 225–270
- Closed circular plasmids
 8-oxoG, **68**, 97–98
- Clp proteins, protein folding role, **58**, 307, 331
- Clr, repression of meiotic recombination, **61**, 372–373
- CLs, *see* Cross-links
- CML, *see* Chronic myelogenous leukemia
- cmo³U, *see* Uridine-5-oxyacetic acid
- CMS, *see* Cytoplasmic male sterility
- CMT, *see* Charcot–Marie–Tooth disease
- CMT1A, *see* Charcot–Marie–Tooth disease type 1A
- CMV, *see* Cytomegaloviruses
- CNTF, *see* Ciliary neurotrophic factor
- CNX, **67**, 237–238
 C-terminal cytosolic domains, **67**, 242
 glycoprotein folding
 ER, **67**, 241–243
 major histocompatibility class I, **67**, 255–258
- CO. *See* Carbon monoxide
- Coat complex II (COPII), **67**, 248
- Coat proteins, yeast double-stranded RNAs and, **46**, 177–178
- COB, RNA folding, **72**, 231–232
- Cobalamin
 adenosylcobalamin–dependent enzymes, **56**, 352–353
 biosynthesis
 adenosylcobalamin, **56**, 365–369
 adenosylcobyrinic acid, **56**, 365
 cobinamide phosphate, **56**, 365–366
 cobyrinic acid *a,c*-diamide, **56**, 364–365
 cyanocobalamin, **56**, 368
 5,6-dimethylbenzimidazole
 ribonucleotide, **56**, 366
 genes
cob gene organization and homology, **56**, 373, 376
Escherichia coli, **56**, 371–372
hem genes in uroporphyrinogen III synthesis, **56**, 369–370
Pseudomonas denitrificans, **56**, 371
Salmonella typhimurium, **56**, 370–371
Synechocystis, **56**, 372
 uro'gen III methyltransferase, **56**, 373, 375–376
 hydrogenobyrinic acid, **56**, 364
 lower ligands, **56**, 367–368, 379
 methylcobalamin, **56**, 369
 pathways, **56**, 378–379
 precorrins, **56**, 356–359, 362–364
 regulation of synthesis
Escherichia coli, **56**, 378
 metabolic flux, **56**, 379
Salmonella typhimurium, **56**, 376–379
 uroporphyrinogen III, **56**, 354, 356
 discovery, **56**, 349
 methylcobalamin–dependent
 enzymes, **56**, 353–354
 structure, **56**, 347–348
- Cobra venom ribonuclease, *see* Ribonuclease V₁
- Cockayne syndrome B (CSB), **68**, 147
- Cockayne's syndrome (CS), genetic defects, **63**, 210–211
- CODH, **67**, 37
- Coding exons, poly A sites
 calcitonin/CGRP pre-mRNA, **71**, 337–341

- Coding exons, poly A sites (*cont.*)
immunoglobulin heavy-chain pre-mRNA, **71**, 341–347
- Codon–anticodon interactions, function of
m¹G37 in, **50**, 313–314
- Codon usage, msDNA of bacteria and, **40**, 19–20
- Coenzyme B, methanogenesis, **71**, 231
- Coenzyme F₄₂₀, methanogenesis, **71**, 231, 273
- Coenzyme M, methanogenesis, **71**, 231
- Coiled-coil proteins, cell cycle, **72**, 77
- Collagen
fibrillar and nonfibrillar, **50**, 228–230
membrane-associated, **50**, 230–248
types XV and XVIII, **50**, 248–257
sequence homologies, **50**, 250–252
types XVII and XIII, **50**, 235–246
- Collagen genes
chromosomal locations, **47**, 32
procollagen domain structures, **47**, 33
tabulation, **47**, 31
- Collagen type-I genes
mutations
Ehlers–Danlos syndrome, **47**, 43–44
osteogenesis imperfecta
biochemical classification, **47**, 36
carboxy-propeptide, **47**, 41–42
carboxy-telopeptide, **47**, 41–42
COL1A1 insertional and site-directed
mutagenesis, **47**, 44–46
gonadal mosaicism, **47**, 43
helical deletions/insertions, **47**, 40–41
helical glycine substitutions, **47**, 36–38
helical splicing, **47**, 39–40
null allelic, **47**, 42–43
somatic mosaicism, **47**, 43
normal, **47**, 30–35
- Collagen type-II gene
mutations
achondrogenesis type-II, **47**, 48–51
genotype–phenotype relationships, **47**, 54–55
hypochondrogenesis, **47**, 48–51
Kniest syndrome, **47**, 53
spondyloepiphyseal dysplasia congenita, **47**, 51–53
Stickler syndrome, **47**, 53–54
normal, **47**, 47–48
site-directed mutagenesis, **47**, 55–57
- Collagen type-III gene
mutations
dominant-negative, in Ehlers–Danlos syndrome, **47**, 58–59
genotype–phenotype relationships, **47**, 61
helical deletions, **47**, 60
helical glycine substitutions, **47**, 61
helical splicing, **47**, 60–61
null allelic, **47**, 61
normal, **47**, 57–58
- Collagen type-IV genes
mutations, **47**, 63–64
normal, **47**, 62–63
- Collagen type-VII gene
mutations, **47**, 65–66
normal, **47**, 65
- Collagen type-IX genes
normal, **47**, 66
site-directed mutagenesis, **47**, 68
- Collagen type-X gene
mutations, **47**, 69
normal, **47**, 68–69
site-directed mutagenesis, **47**, 69–70
- Collagen, type X, *see* Type X collagen
- Colon adenocarcinoma
LoVo cell extracts
uracil-initiated BER, **68**, 171–175
- Colon tumors
TDG, **68**, 250–251
- ComA protein, *Bacillus subtilis* gene
expression and, **46**, 142–143
- Combinatorial selection, tRNA mimics
amino acid affinities, **70**, 327–328
aminoacylated tRNAs, **70**, 315
aminoacyl-tRNA synthetases, **70**, 314
arginine-accepting tRNAs, **70**, 319–321
aspartate-accepting tRNAs, **70**, 319–321
elongation factor-recognizing variants, **70**, 323–324
elongation factors, **70**, 314
glutamyl-tRNA synthetase affinity, **70**, 315–316
in vitro selection, **70**, 309–311
isoleucyl-tRNA synthetase aptamer, **70**, 317
leucine-accepting tRNAs, **70**, 319–321
library choice, **70**, 311–313
phenylalanine-accepting tRNAs, **70**, 318–319
phenylalanine-tRNA synthetase
aptamers, **70**, 316–317

- ribozyme-catalyzed tRNA
 - aminoacylation, **70**, 326–327
- self-aminoacylatable RNA, **70**, 324–325
- serine-accepting tRNAs, **70**, 319–321
- valine-accepting tRNA-like molecules, **70**, 321–323
- Comet assay, **68**, 140
 - DNA damage, **68**, 62
 - MMS, **68**, 62
- Complement, subcomplement C1q, **50**, 234–235
- Complementary DNA
 - CPSF, cloning, **71**, 328
 - CstF, cloning, **71**, 325–326
 - genetic defects of mammalian nervous system and, **41**, 250–251
 - lenticular, **41**, 269–272
 - poly A polymerases, **71**, 320–322
 - proline-rich protein multigene families and, **41**, 9–11
- Complementary DNA, self-primed synthesis, **72**, 241–242
- Complex II, *see* Succinate:quinone oxidoreductase
- α -Complex proteins
 - discovery, **57**, 271
 - incorporation into α -complex, **57**, 273–274
 - messenger RNA stabilization, **57**, 271, 273–275, 278, 283
 - types, **57**, 271, 273
- α CP-1, *see* α -Complex proteins
- α CP-2, *see* α -Complex proteins
- ComP protein, *Bacillus subtilis* gene expression and, **46**, 142–143
- Condensation domains, **70**, 239–240
- Cone cell
 - chloride ion and pigment binding, **59**, 12–13
 - heredity of color vision defects, **59**, 11–12
 - iodopsin, **59**, 4–5
 - spectral properties of recombinant cone pigments, **59**, 11–13
- Cone-rod retinal dystrophy type 2, *CRX* mutation, **64**, 196–197
- Conformational change, pRNA
 - dimer-hexamer transition, **72**, 444–445
 - monomer-dimer transition, **72**, 443–444
 - motion task, **72**, 445
 - overview, **72**, 443
- Conformational changes
 - AARS, **69**, 333
 - in tRNA, communication by, **69**, 334–335
 - PDE4 catalytic unit, **69**, 271–279
- Congenital hypothyroidism
 - clinical presentation, **66**, 339–340
 - gene mutations
 - dysgenesis mutations, **66**, 339–340
 - hormone synthesis, **66**, 339
 - thyroid-specific transcription factors, **66**, 340–341
 - incidence, **66**, 309, 339
- Congenital nephrogenic diabetes insipidus
 - mutations in vasopressin receptor, **49**, 134
 - symptoms, **49**, 134
- Conjugation, bacteria
 - antibiotic resistance, **54**, 198
 - DNA primase role, **54**, 232–234
 - DNA relaxase
 - domain structure, **54**, 223–226
 - initiation of replication role, **54**, 218, 220
 - termination of replication role, **54**, 220–223
- F-factor, **54**, 198
- gram-positive versus gram-negative bacterial plasmids, **54**, 235–240
- IncP plasmid
 - clustering of transfer functions, **54**, 200–201, 203
 - physical properties of transfer-related products, **54**, 215–216
 - regulation of transfer gene expression, **54**, 203–206
 - relaxosome assembly at transfer origin, **54**, 217–218, 245
- mating aggregate formation
 - conjugative DNA transport, **54**, 210–211
 - donor-specific phage propagation, **54**, 210
 - IncP entry exclusion function, **54**, 212–214
 - Mpf role, **54**, 214, 217, 245–246
 - pilus assembly, **54**, 210
 - Tra core system, **54**, 207–208, 210
- model systems, **54**, 199
- phylogenetic analysis, **54**, 234–245
- relaxosome characterization, **54**, 229–231
- species specificity, **54**, 198
- steps in process, **54**, 199–200
- T-DNA transfer in *Agrobacterium tumefaciens*, **54**, 240–243

- Conjugation, bacteria (*cont.*)
 toxin secretion in *Bordetella pertussis*, **54**,
 243–244
 Tra protein roles
 TraG, **54**, 211–212
 TraH, **54**, 228–229
 TraJ, **54**, 226–227
 TraK, **54**, 227–228
- Conjunctiva, Muc4/SMC, **71**, 177–179
- Connector
 domain for pRNA binding, **72**, 447–448
 pRNA binding, **72**, 445–447
- Consensus structure, RNA phage coat
 proteins and, **40**, 201–204
- Conservative transposition, DNA sequence
 amplification in mammalian cells and, **41**,
 226–228
- Constant denaturant capillary electrophoresis
 experimental set-up, **49**, 304
 separation efficiency, **49**, 305–308
 separations in mutational spectrometry, **49**,
 288, 304–310
- Constant denaturant gel electrophoresis
 experimental set-up, **49**, 304
 separation efficiency, **49**, 305–308
 separations in mutational spectrometry, **49**,
 302, 304–308
- Constitutive activation domain, CREB
 definition, **72**, 274–279
 transcription
 CAD:TAF interaction, **72**, 291–292
 overview, **72**, 284–287
 polymerase complex assay, **72**, 289–291
 transcription factor interactions, **72**,
 279–284
- CooA, **67**, 35–60
 binding, **67**, 56
 C helices
 effector-binding domain, **67**, 45
- CO, **67**, 40–42
 binding, **67**, 41
 model, **67**, 50–52
 sensor, **67**, 53–54
 consensus target sequences, **67**, 58
 cyanide binding, **67**, 55
 DNA recognition properties, **67**, 58–59
 effector binding sites, **67**, 46
 effector-free
 C helix, **67**, 44–45
 F helices, **67**, 46
 future direction, **67**, 59–60
 heme region, **67**, 47–50
 hinge region residues
 differential contacts, **67**, 45
 HIS-77
 CO, **67**, 48–49
 ligand binding, **67**, 54–56
 monomer, **67**, 43
 redox sensor, **67**, 52–53
 redox state, **67**, 40–42
 structure, **67**, 42–52
 vs. CRP, **67**, 42–46
 three-dimensional structures, **67**, 57–58
 transcriptional activation, **67**, 56–58
 transcriptional activator, **67**, 40–42
- CooA gene, **67**, 39
 CooH, **67**, 39, 40
 Coo genes
 regulation, **67**, 38–40
 Coo regulon
Rhodospirillum rubrum
 transcriptional organization, **67**, 38
 Cool/PIX/p85SPR, **67**, 202
 CooMKLXUH
 operon, **67**, 38
- Cooperative binding, RNA phage coat proteins
 and, **40**, 212
- Cooperative interactions, EF-Tu, **71**, 539
- CooS, **67**, 39, 40
- CopA, stem-loop structure, **69**, 32
- COPD, *see* Chronic obstructive pulmonary
 disease
- COPII, **67**, 248
- Copper, binding site in lysyl oxidase, **70**, 15
- Copper ion sensing
Chlamydomonas reinhardtii, **58**, 168–169
Enterococcus hirae, **58**, 168
Escherichia coli, **58**, 168
 importance to organism, **58**, 166–167
 mammalian cells, **58**, 169–170, 191
Pseudomonas, **58**, 168
 yeast
 copper-induced genes, **58**, 170–174
 copper-requiring enzymes, **58**, 170
 human disease correlation, **58**, 169–170
 Mac1 sensing, **58**, 171, 188–189
 mediation of copper activation of genes
 Acl1, **58**, 174–176, 186–188, 191
 Amt1, **58**, 175–176, 191
 Crf1, **58**, 177

- functional domains of *trans*-acting factors, **58**, 180–185
- Lpz8, **58**, 177
- mechanism, **58**, 185–188
- polycopper-thiolate cluster in
 - trans*-acting factors, **58**, 177–180, 182–185
 - transporters, **58**, 170
- Copper, superoxide dismutases and, **40**, 225
- Copy number of protamine genes, **40**, 42–45
- Coralyne, **67**, 171
- Core homology, role in resolution reaction, **51**, 83
- Core promoter binding factor, ribosomal gene transcription regulation, **62**, 122, 300
- Corepressors
 - recruited by Mbds, **69**, 51–53
 - ROR interactions with, **69**, 218–223
- Cornea, Muc4/SMC, **71**, 177–179
- Corrective factor, missing in GS cells, **69**, 83–84
- Corrinoids, *see also* Cobalamin
 - diversity of ligands, **56**, 350–351
 - nomenclature, **56**, 349–350
 - prokaryotic production, **56**, 352
- Covalent bonds, RNA phage coat proteins and, **40**, 206–209
- Cowpea chlorotic mottle virus RNA, replication of, **42**, 175–178
- Cowpea mosaic virus RNA, replication of, **42**, 207–212
- Cox genes, **67**, 37
- COX, *see* Cytochrome *c* oxidase
- CP-115,953, *see* Topoisomerase II poisons
- CPBF, *see* Core promoter binding factor
- CPF1, mitochondrial biogenesis in *Saccharomyces cerevisiae* and, **46**, 77–78
- CpG island methylation
 - definition of island, **66**, 374
 - metallothionein expression regulation
 - cancer role, **66**, 377
 - hypermethylation, **66**, 376–377
 - Ku overexpression studies of repression, **66**, 377–379
 - repression mechanisms, **66**, 375–376
 - tumor cell studies, **66**, 374–375, 377
 - overview, **66**, 373–374
- CpG islands
 - free of methylation during replication, **69**, 72
 - multiple, methylation, **69**, 68–69
- CpG islands, demethylation, **48**, 57
- CpG sequence
 - DNA methylation and, **69**, 50–52
 - methyated, **69**, 54, 65
- CPLA_{2γ}
 - characteristics, **67**, 7
- cp-pRNA, *see* Circularly permuted pRNA
- CPSF, *see* Cleavage and polyadenylation specificity factor
- CPT, *see* CDP-choline:1,2-diacylglycerol phosphotransferase
- CPVs, *see* Cytoplasmic vacuoles
- CRABP, *see* Cellular retinoic acid-binding protein
- Craniofacial deafness–hand syndrome, *PAX3* mutation, **64**, 194
- crb2, *see* rhp9/crb2
- CRBP, *see* Cellular retinol-binding protein
- CreA
 - A. nidulans*, **69**, 174–175
 - DNA-binding domains, **69**, 175
 - functional targets, **69**, 175–177
 - homologs in filamentous fungi, **69**, 179–180
 - role in
 - alc* gene expression, **69**, 189
 - carbon catabolite repression, **69**, 181–183, 197–198
 - structure–function relationships, **69**, 177–178
 - target disruption, **69**, 186
- CREB-1, **67**, 151–152
- CREB/ATF transcription factor-binding site, **68**, 48
- CREB, autoregulation of promoter, **60**, 154
- CREB-binding protein (CBP)
 - activation of cyclic AMP-responsive element binding protein, **64**, 352–354
 - mutation in Rubinstein–Taybi syndrome, **64**, 185–186
- CREB binding site
 - APE promoter, **68**, 50
- CREB, *see* Cyclic AMP response element-binding protein
- CREB, *see* Cyclic AMP-responsive element binding protein
- CREM, *see* Cyclic AMP-responsive element modulator

- CREM, autoregulation of promoter, **60**, 154–155
- Crfl, mediation of copper activation of genes, **58**, 177
- CRIK, **67**, 196
- Crithidia fasciculata*, **68**, 265
- Crk SH3 domain-binding guanine nucleotide exchange factor, **71**, 412–414
- Cro protein–O₃ complex, DNA bending evidence, **47**, 206–209
site-specific flexibility, **47**, 209–213
- Crosslinking
photoaffinity, pRNA, **72**, 431–433
pRNA, phenphi, **72**, 435
pRNA, psoralen, **72**, 433–435
- Cross-linking, RNA in spliceosome, **50**, 138–139
- Crosslinking, structural elements in RNA and, **41**, 165
- Cross-links
cisplatin–DNA adducts
adducts *in vitro*, **71**, 3–5
adducts *in vivo*, **71**, 6–7
adduct stability, **71**, 5–6
monofunctional adducts, **71**, 7–8
nucleotide excision repair, **71**, 13
DNA–BBR3464, **71**, 48
DNA–dinuclear platinum compounds, **71**, 45–47
HMG-domain protein DNA adduct recognition, **71**, 15–18
oxaliplatin–DNA interactions, **71**, 26–29
[PtCl(dien)]Cl–DNA, **71**, 7–8
transplatin–DNA, **71**, 4, 8–9
UV, proteins to poly A sites, **71**, 308
- Crossover, meiotic recombination in yeast, **61**, 347
- CRP. *See* Catabolite responsive protein
- CRS5, induction by copper, **58**, 171–174, 186
- CRT, **67**, 237–238
glycoprotein folding
ER, **67**, 241–243
major histocompatibility class I, **67**, 258
- CRX, mutation in cone-rod retinal dystrophy type 2, **64**, 196–197
- Cryo-AFM, *see* Cryo-atomic force microscopy
- Cryo-atomic force microscopy, pRNA
dimer images, **72**, 440
monomer images, **72**, 440
- Cryo-electron microscopy, pRNA, **72**, 428–429
- Cryo-EM, *see* Cryo-electron microscopy
 α -crystallin, lens protein and, **41**, 261–263
Cry toxins, *see* δ -Endotoxins
- Crystallization, tRNA structure and, **45**, 163–164
- Crystallography
DNA bending, **47**, 204–206
engrailed homeodomain in *Drosophila melanogaster*, **47**, 224–227
MAT α 2 homeodomain in yeast, **47**, 224–227
- Crystal structure
nrdD protein, **72**, 103–106
pRNA, **72**, 442
- CSB, **68**, 147
- CS, *see* Cockayne's syndrome
- CstF, *see* Cleavage stimulation factor, **57**, 71
- CTD, *see* C-terminal domain phosphatase
- C-terminal domain phosphatases, **48**, 172–173
- Cth1p, *see* RNA triphosphatase
- CTLs, **67**, 251
- CTP:phosphocholine cytidyltransferase (CCT)
cell cycle regulation of expression and activity, **65**, 371–373, 388
domains, **65**, 365–366
genes and isoforms, **65**, 365, 367, 387
inhibition and apoptosis induction, **65**, 382–386
knockout mouse, **65**, 387
lipid regulation, **65**, 369–371, 384–385
membrane contact and regulation, **65**, 384–385
nuclear signaling, **65**, 387
overexpression effects, **65**, 380
phosphorylation, **65**, 366–367, 370, 373
subcellular localization of isoforms, **65**, 368–369
tissue distribution, **65**, 367–368
- CTRI, repression by copper, **58**, 188–189
- Cucumber mosaic virus RNA, replication of, **42**, 178–186
- CUG codon
FGF-2 mRNA, **72**, 383–385
GCSA synthesis, **72**, 378–379
L-VEGF identification, **72**, 394–396
MuLV genomic mRNA, **72**, 380–382
survival factor-like FGF-2 isoform, **72**, 386–387
- Culmination, *Dictyostelium discoideum*
anterior-like cell movement, **47**, 17–18

- ecmB* promoter role, **47**, 18–19
- intracellular cAMP role, **47**, 19–20
- stalk tube formation, **47**, 16–17
- Cup1
 - gene induction by copper, **58**, 171–174, 186–188
 - polycopper-thiolate cluster, **58**, 180
- cut5*, *see* *rad4/cut5*
- cya* gene, bacterial adenylyl cyclases and, **44**, 35–36
- Cyanide binding
 - CooA, **67**, 55
- Cyanomorpholinoadriamycin, DNA sequence specificity, **63**, 380, 391
- Cyclic AMP
 - ancestral functions, **49**, 274
 - discovery, **49**, 241
 - growth condition effect on bacterial level, **49**, 242–243
 - pulses, **49**, 276
 - receptor, **49**, 250
 - second messenger activity, **49**, 241, 267
 - synthesis, **49**, 241
- Cyclic AMP, bacterial adenylyl cyclases and regulation of levels, **44**, 34–35
- transcription regulation, **44**, 32–34
- Cyclic AMP (cAMP), regulation of cyclic nucleotide phosphodiesterases, **63**, 15–18
- Cyclic AMP (cAMP), regulation of intracellular levels, **64**, 345
- Cyclic AMP (cAMP), Schwann cell regulation, **56**, 229–230
- Cyclic AMP, control of growth hormone expression
 - cascade mechanism, **54**, 134
 - GHF-1 role, **54**, 135–137
 - response elements on gene promoter, **54**, 135–137
 - transcription factors, **54**, 134–135
- Cyclic AMP-dependent protein kinase
 - regulation of *Dictyostelium* stalk cell differentiation, **47**, 19–20
 - role in *Dictyostelium* morphogenesis, **47**, 19–20
- Cyclic AMP-dependent protein kinase (PKA), compartmentalization, **63**, 3
- Cyclic AMP, periodic fluctuation in *Saccharomyces cerevisiae*, **48**, 20–21
- Cyclic AMP response element-binding protein
 - activation domain
 - CAD and KID definitions, **72**, 274–279
 - CAD–transcription factor interactions, **72**, 279–284
 - constitutive and kinase-inducible activities, **72**, 273–274
 - experimental model, **72**, 272–273
 - basic function, **72**, 270
 - CAD and P-KID, transcription
 - CAD:TAF interaction, **72**, 291–292
 - KID phosphorylation, **72**, 293–296
 - overview, **72**, 284–287
 - polymerase complex assay, **72**, 289–291
 - phosphorylated, transcription model, **72**, 296–298
- Cyclic AMP-responsive element binding protein (CREB)
 - activation domains
 - glutamine-rich activation domains, **64**, 352
 - kinase-inducible domain, **64**, 351
 - overview, **64**, 347
 - activation role of CREB-binding protein/p300, **64**, 352–354
 - basic domain/leucine zipper, **64**, 346
 - circadian rhythm role, **64**, 365
 - dimerization, **64**, 346–347
 - DNA binding, **64**, 347–348
 - memory role, **64**, 365–366
 - phosphorylation
 - calcium/calmodulin-dependent kinase type IV, **64**, 349–350
 - protein kinase A, **64**, 344, 349, 351
 - signaling pathways, **64**, 350–351
 - site, **64**, 349
 - pituitary gland regulation, **64**, 363–364
- Cyclic AMP-responsive element modulator (CREM)
 - activation domains
 - glutamine-rich activation domains, **64**, 352
 - kinase-inducible domain, **64**, 351
 - overview, **64**, 347
 - activation role of CREB-binding protein/p300, **64**, 352–354
 - alternative promoter protein product, *see* Inducible cyclic AMP early repressor
 - basic domain/leucine zipper, **64**, 346
 - dimerization, **64**, 346–347
 - DNA binding, **64**, 347–348
 - phosphorylation
 - protein kinase A, **64**, 344, 349, 351
 - signaling pathways, **64**, 350–351

- Cyclic AMP-responsive element modulator (CREM) (*cont.*)
 site, **64**, 349
- RNA processing
 alternative polyadenylation, **64**, 356
 alternative splicing, **64**, 355–356
 alternative translation initiation, **64**, 356
 overview, **64**, 354–355
- spermatogenesis regulation
 ACT protein, role in CREM activation, **64**, 361–363
 germ cell expression levels, **64**, 358, 360
 haploid gene expression regulation, **64**, 360–361
- Cyclic AMP-signaling, *Dictyostelium*
discoideum
 extracellular
 developmental roles, **47**, 3
 in stalk cell differentiation, **47**, 21–22
 prestalk cell apical sorting response, **47**, 15
 transduction system, **47**, 3
 intracellular, **47**, 19–20
- Cyclic GMP
 ancestral functions, **49**, 274
 role in phototransduction, **49**, 267, 271
 second messenger activity, **49**, 267
 synthesis, **49**, 267
- Cyclic GMP (cGMP), regulation of cyclic nucleotide phosphodiesterases, **63**, 21–22, 29–30
- Cyclic nucleotide phosphodiesterase (PDE)
 calmodulin binding and stimulation of PDE1, **63**, 19–21
 catalytic mechanism
 chemistry, **65**, 9
 conserved residues, **65**, 12–14
 metal requirements, **65**, 14–16
 structural determinants, **65**, 11
 classes, **65**, 3, 5
 classification and nomenclature, **63**, 2–4
 compartmentalization, **63**, 3, 31
 cyclic GMP binding and regulation, **63**, 21–22, 29–30
 discovery, **63**, 2
 domain organization, **63**, 4–5, 7–8
 domains
 alignment in class I superfamily, **65**, 3–5, 7
 catalytic domain, **65**, 7–8
 regulatory domains, **65**, 8
 expression regulation
 cyclic AMP regulation, **63**, 15–18
 differentiation in *Dictyostelium*, **63**, 14–15, 32
 mammalian development, **63**, 15
 rationale for system complexity, **63**, 32
 spermatogenesis, **63**, 15
 tissue-specific expression in *Drosophila*, **63**, 14
 families, *see* PDE1–PDE11
 functional overview, **63**, 2–3
 functions, **65**, 2–3
 gene structure
dunce, **63**, 9
 mammalian *PDE* genes, **63**, 9, 11–12
 mapping, **63**, 12–13
psdA, **63**, 9
regA, **63**, 9
 inhibitors, **65**, 16–18
 messenger RNA stability regulation, **63**, 18–19
 mutation in disease
 PDE4 mutations, **63**, 13
 retinal generation and PDE6, **63**, 12–13
 phosphorylation, **63**, 7–8, 28–30
 photoaffinity labeling, **65**, 7–8
 phototransduction, **65**, 343, 353–354
 phylogeny of class I superfamily, **65**, 5–6
 regulation
 extracellular signaling pathways, **65**, 19
 long-term regulation, **65**, 20
 overview, **65**, 2, 18
 short-term feedback, **65**, 19–20
 regulatory domains, **63**, 8, 27–28
 sequence conservation between species, **63**, 4–7
 splicing variants
 PDE1, **63**, 19–21
 PDE2, **63**, 21–23
 PDE3, **63**, 23–24
 PDE4, **63**, 24–25, 27–29
 PDE5, **63**, 29–30
 PDE6, **63**, 30–31
 PDE7, **63**, 31
 substrate features for catalysis, **65**, 8–9
 substrate specificity
 amino acid residues in binding, **65**, 10
 cyclic AMP versus cyclic GMP, **65**, 9–11
 hydropathy analysis of catalytic domains, **65**, 10
 syn versus anti configuration, **65**, 9–10

- therapeutic targeting, **63**, 3
- Cyclic nucleotide phosphodiesterase (PDE),
 - see also* PDE3
 - classification and substrate specificities, **66**, 242–243
 - compartmentalization of signaling, **66**, 246
 - inhibitor specificity, **66**, 246–247, 268–269
 - regulatory protein binding sites, **66**, 244
 - signal transduction role, **66**, 242
 - structural organization, **66**, 244–245
- Cyclic nucleotide phosphodiesterase, *see*
 - Calmodulin-dependent cyclic nucleotide phosphodiesterase
- Cyclic-nucleotide phosphodiesterase, *see* PDE
- Cyclin A-dependent kinase, cell cycle regulation, **53**, 200–201
- Cyclin D-dependent kinase, cell cycle regulation, **53**, 199–200
- Cyclin D1, cell cycle control in mice, **58**, 68
- Cyclin-dependent kinase (CDK) inhibitors, **67**, 13
- Cyclin-dependent kinases, eukaryotic cell cycle, **72**, 43–45
- Cyclin E-dependent kinase, cell cycle regulation, **53**, 200
- cyclin, in transcriptional control of G1/S genes in
 - Cyclin proteins, in transcriptional control of G1/S genes in *Saccharomyces cerevisiae*, **48**, 11, 13
- Cyclization domains, **70**, 241
- Cycloheximide, effect on mRNA decay, **56**, 265
- 1-Cyclohexyl-3-(2-morpholinoethyl)
 - carbodiimide metho-*p*-toluene sulfate, probing of RNA structure, **53**, 143, 149
- Cyclohexylamine ligands, DNA–transplatin analogs, **71**, 42
- Cyclols, **70**, 244–246
- Cyclooxygenase, **45**, 83–86
- Cyclophosphamide, DNA sequence specificity, **63**, 379, 389
- Cy domains, *see* cyclization domains
- CYP102, *see* BM3
- CYP106, *see* BM1
- CYP1A1, proximal promoter element in phenobarbital induction, **61**, 40
- CYP26, retinoic acid metabolism, **63**, 176
- CYP2B1/2
 - distal phenobarbital-responsive enhancer in phenobarbital induction, **61**, 43–44
 - proximal promoter element in phenobarbital induction, **61**, 35–36, 38, 58
- CYP2B1, distal phenobarbital-responsive enhancer, **61**, 48, 57
- Cyp2b10, phenobarbital induction
 - distal phenobarbital-responsive enhancer assay by *in situ* transient transfection, **61**, 51–53
 - assay by transfection in primary hepatocytes, **61**, 53–55
 - proximal promoter element, **61**, 40–41
- CYP2B2, phenobarbital induction
 - distal phenobarbital-responsive enhancer assay by *in situ* transient transfection, **61**, 45–47
 - localization by transfection in primary hepatocytes, **61**, 44–45
 - transgenic analysis, **61**, 42–43
 - proximal promoter element, **61**, 38–41
- Cyp2b9, distal phenobarbital-responsive enhancer
 - assay by *in situ* transient transfection, **61**, 51–53
 - assay by transfection in primary hepatocytes, **61**, 53–55
- CYP2C1, distal phenobarbital-responsive enhancer, **61**, 44, 47, 50–51
- CYP2H1, distal phenobarbital-responsive enhancer, **61**, 41, 43
- Cyr61, identification as immediate-early response gene, **58**, 51
- Cys-75
 - CO, **67**, 48
- Cysteine, protamines and, **40**, 29–30
- Cysteine residues, AlcR, **69**, 158–159
- Cystine-DNA glycosylase (CDG)
 - UNG expressing
 - active-site mutants, **68**, 377–378
- CYT-18, RNA folding, **72**, 232–233
- Cytidine deaminase, 5,6-dihydropyrimidine adducts and, **42**, 149–150
- Cytidine nucleotide, sources in *Escherichia coli*, **53**, 359–361
- Cytochrome C, **68**, 281–282
- Cytochrome c, antiapoptotic proteins and, **69**, 233–234
- Cytochrome c oxidase
 - coordinate regulation of genes
 - coordinate regulation of nuclear genes, **61**, 335–337

- Cytochrome *c* oxidase (*cont.*)
- intergenic regulation of mitochondrial and nuclear gene expression, **61**, 333–335, 338
 - overview of mechanisms, **61**, 332–333
 - deficiency in disease, **61**, 313
 - developmental regulation of transcription, **61**, 312
 - functions, **61**, 311
 - gene structure of nuclear-encoded subunits
 - CpG islands, **61**, 321
 - exon/intron sizes, **61**, 321–323
 - muscle-specific regulatory motifs, **61**, 330–332
 - negative enhancers, **61**, 330
 - transcription initiation sites, **61**, 321, 323, 325–329
 - upstream transcription activators, **61**, 329
 - isoforms in heart and liver, **61**, 311–312
 - sequence properties of nuclear-encoded subunits
 - COX IV, **61**, 313–314
 - COX Va, **61**, 314–315
 - COX Vb, **61**, 315
 - COX VIa, **61**, 315–316
 - COX VIb, **61**, 316, 318
 - COX VIc, **61**, 318
 - COX VIIa, **61**, 318–319
 - COX VIIb, **61**, 319
 - COX VIIc, **61**, 319–320
 - COX VIII, **61**, 320
 - subunit composition, **61**, 311
- Cytochrome P450
- abundance of types, **61**, 27
 - biological functions, **61**, 26–27
 - induction mechanism, **61**, 28
 - phenobarbital induction
 - Bacillus megaterium*, *see* BM1; BM3
 - barbie box role, **61**, 32–35, 58
 - distal phenobarbital-responsive enhancer
 - CYP2B1*, **61**, 48, 57
 - CYP2B1/2*, DNase I hypersensitivity, **61**, 43–44, 58
 - Cyp2b10*, **61**, 51–56
 - CYP2B2*, **61**, 42–51, 55–57
 - Cyp2b9*, **61**, 51–57
 - CYP2C1*, **61**, 44, 47, 50–51
 - CYP2H1*, **61**, 41, 43
 - NF-1 binding to phenobarbital-responsive unit, **61**, 49–51, 53–55, 59–61
 - models, **61**, 60–61
 - overview, **61**, 27–30
 - proximal promoter elements and binding proteins
 - CYP1A1*, **61**, 40
 - CYP2B1/2*, **61**, 35–36, 38
 - cyp2b10*, **61**, 40–41
 - CYP2B2*, **61**, 38–41
 - reactions in detoxification, **61**, 27
- Cytochrome P450, hepatic, drug-induced, **51**, 17–20
- Cytokine receptor-like domain, **70**, 18–19
- Cytokine, *see also specific cytokines*
- general features, **57**, 74
 - receptors, **57**, 77
 - signal transduction, *see* Growth hormone receptor
- Cytomegaloviruses, infection and latency, **71**, 450–451
- Cytoplasm, protein tyrosine kinase substrates and, **44**, 214–215
- Cytoplasmic male sterility, **70**, 147–149
- Cytoplasmic vacuoles
- alphavirus plus-strand RNA, **71**, 195–196
 - alphavirus replication complex, **71**, 212, 214
- Cytosine **68**, 209
- 8-oxyguanine
 - hOGG1, **68**, 83–85
 - deamination
 - chemical-induced, U·G mispairs and, **48**, 334
 - spontaneous
 - or hydrolytic, **48**, 322–323, 324
 - U·G mispairs and, **48**, 333–334
 - uracil introduced into DNA by, **48**, 322–330
 - UV-induced, **48**, 325–330
 - U·G mispairs and, **48**, 334–336
 - residues, chemical modification, **48**, 323
- Cytosine methylation, *see* DNA (cytosine-5) methyltransferase
- Cytoskeleton, protein tyrosine kinase substrates and, **44**, 214–215, 220–221
- Cytoskeleton, *see also* Intermediate filaments
- filaments, **49**, 36–37
 - networks, **49**, 36
- Cytotoxic T lymphocytes (CTLs), **67**, 251

D

- de novo* purine nucleotide biosynthesis, *see*
Purine nucleotide biosynthesis, *de novo*
- D loop
binding by PriA, **63**, 59–61
formation dependence on recombination
proteins, **63**, 63–64
replication fork assembly, **63**, 61, 63–64
- D04 aptamer, binding to TAR RNA, **69**, 29
- Dacarbazine, DNA sequence specificity, **63**,
381, 392
- DACH, *see* Oxaliplatin
- DAG θ kinase
biological functions, **67**, 197
- DAGKc, *see* Diacylglycerol kinase
catalytic domain
- Dam
DNA replication role, **57**, 174–175
synchrony regulation, **57**, 176
- Daughter nuclei, reorganization, in G1 phase of
yeast cell cycle, **48**, 2
- Daunomycin, DNA sequence specificity, **63**,
380, 391
- Daunorubicin, **67**, 152–153
- DAXI, mutation in human disease, **64**,
199, 201
- Dbf4-dependent kinase, DNA replication,
72, 45
- Dbf4p–Cdc7p kinase, DNA replication
origins, **72**, 45
- DCA, *see* Dichloroacetate
- DDK, *see* Dbf4-dependent kinase
- DdTTP, **68**, 10, 19
- DEAD box proteins
characteristics, **72**, 308
eIF4A, *see* eIF4A
research overview, **72**, 328–329
- DEAD box sequences, eIF4A, **72**, 323–324
- Deadenylation
mRNA decay, **72**, 131–133
mRNA degradation coordinate
regulation, **72**, 138–139
- Dealkylation, O-alkylated purine and
pyrimidine, **51**, 178–181
- Decorin
development role, **62**, 43
genes, **62**, 43
structure, **62**, 42–43
transcriptional regulation
cytokines, **62**, 44–45
promoter, **62**, 43–44
retinoic acid, **62**, 45
- Defective-interfering RNAs, alphavirus, **71**,
192–194
- Deg proteins, *Bacillus subtilis* gene expression
and, **46**, 138–141
- DegP, expression regulation and function,
66, 139
- Degradosome, poly A sequence, **71**, 372
- Dehalogenation, 5,6-dihydropyrimidine
adducts and, **42**, 132–133
- Delayed-early response genes, *see also*
specific genes
differential hybridization screening in
identification, **58**, 49–57
transcriptional regulation, **58**, 47–48
- Deletion, DNA sequence amplification in
mammalian cells and, **41**, 224–226
- Deletion, pRNA genetic analysis, **72**, 438–439
- Demethylase
accessibility to
DNA, **69**, 69–70
methylated CpG sites, **69**, 69
expression, regulated by cell cycle, **69**,
59–61
repair or replication mechanisms, **69**, 54–55
- Demyelinating polyneuropathy, **68**, 274
- Denaturant gradient gel electrophoresis
experimental set-up, **49**, 304
separation efficiency, **49**, 305–308
separations in mutational spectrometry, **49**,
286–289, 304–308
- Denaturing polyacrylamide gel
autoradiography, **68**, 13
- Dendroaspis, functional site elucidation,
59, 353
- Deoxyadenosine kinase, *Lactobacillus*
acidophilus R-26
affinity labeling, **59**, 244–247
amino acid composition, **59**, 244, 246
assay, **59**, 212, 214
conformational probing with limited
proteolysis, **59**, 243–244
gene cloning
colony screening by polymerase chain
reaction, **59**, 234–235
hybridization probes, **59**, 232, 234
heterotropic activation, **59**, 226, 228,
249–250, 252

- Deoxyadenosine kinase, *Lactobacillus acidophilus* R-26 (*cont.*)
inhibition by dNTP end products, **59**, 228–230
kinetic mechanism, **59**, 224–226
pH dependence, **59**, 224
purification
 Blue Sepharose pseudoaffinity chromatography, **59**, 214–217
 deoxynucleoside derivatives for affinity chromatography
 base modifications, **59**, 218–219
 bisubstrate analogs, **59**, 219–220
 deoxyribose modification, **59**, 217–218
 dNTP-Sepharose chromatography, **59**, 220–223
 recombinant kinases, **59**, 223–224
 UDP-Sepharose, **59**, 217
regulation, **59**, 251–252
sequencing
 gene, **59**, 235–237
 homology with other nucleoside kinases, **59**, 235, 238
 protein, **59**, 230, 232
site-directed mutagenesis
 deoxynucleoside-binding site, **59**, 248–249
 heterodimer interface, **59**, 249–250
 thermostability, **59**, 214
- Deoxycytidine kinase, *Lactobacillus acidophilus* R-26
affinity labeling, **59**, 244–247
amino acid composition, **59**, 244, 246
assay, **59**, 212, 214
conformational probing with limited proteolysis, **59**, 243–244
gene
 cloning
 colony screening by polymerase chain reaction, **59**, 234–235
 hybridization probes, **59**, 232, 234
 identification as deoxyguanosine kinase
 gene
 mass determination, **59**, 240
 protein sequencing, **59**, 238–240, 251
 recombinant protein engineering
 evidence, **59**, 241–243
 inhibition by dNTP end products, **59**, 228–230
 kinetic mechanism, **59**, 224–226
 pH dependence, **59**, 224
 purification
 Blue Sepharose pseudoaffinity chromatography, **59**, 214–217
 deoxynucleoside derivatives for affinity chromatography
 base modifications, **59**, 218–219
 bisubstrate analogs, **59**, 219–220
 deoxyribose modification, **59**, 217–218
 dNTP-Sepharose chromatography, **59**, 220–223
 recombinant kinases, **59**, 223–224
 UDP-Sepharose, **59**, 217
 regulation, **59**, 251–252
 sequencing
 gene, **59**, 235–237
 homology with other nucleoside kinases, **59**, 235, 238
 protein, **59**, 230, 232, 239
 site-directed mutagenesis
 deoxynucleoside-binding site, **59**, 248–249
 heterodimer interface, **59**, 249–250
- Deoxyguanosine kinase, *Lactobacillus acidophilus* R-26
affinity labeling, **59**, 244–247
amino acid composition, **59**, 244, 246
assay, **59**, 212, 214
conformational probing with limited proteolysis, **59**, 243–244
gene cloning
 colony screening by polymerase chain reaction, **59**, 234–235
 hybridization probes, **59**, 232, 234
 inhibition by dNTP end products, **59**, 228–230
 kinetic mechanism, **59**, 224–226
 pH dependence, **59**, 224
 purification
 Blue Sepharose pseudoaffinity chromatography, **59**, 214–217
 deoxynucleoside derivatives for affinity chromatography
 base modifications, **59**, 218–219
 bisubstrate analogs, **59**, 219–220
 deoxyribose modification, **59**, 217–218
 dNTP-Sepharose chromatography, **59**, 220–223
 recombinant kinases, **59**, 223–224
 UDP-Sepharose, **59**, 217
 regulation, **59**, 251–252
 sequencing
 gene, **59**, 235–237
 homology with other nucleoside kinases, **59**, 235, 238
 protein, **59**, 230, 232, 239
 site-directed mutagenesis
 deoxynucleoside-binding site, **59**, 248–249
 heterodimer interface, **59**, 249–250

- regulation, **59**, 251–252
 - sequencing
 - gene, **59**, 235–237
 - homology with other nucleoside kinases, **59**, 235, 238
 - protein, **59**, 230, 232
 - site-directed mutagenesis
 - deoxynucleoside-binding site, **59**, 248–249
 - heterodimer interface, **59**, 249–250
 - thermostability, **59**, 214
 - Deoxynucleoside triphosphate, RT fidelity
 - misinsertion fidelity assays, **71**, 100–102
 - mutational analysis
 - Arg-72, **71**, 120–121
 - Gln-151, **71**, 119–120
 - Lys-65, **71**, 120–121
 - Met-184, **71**, 117–119
 - overview, **71**, 112–113
 - Tyr-115, **71**, 114–117
 - pre-steady-state kinetic assays, **71**, 105
 - reverse transcription initiation, **71**, 108–109
 - Deoxyribonucleic acid
 - adeno-associated virus
 - integration, **48**, 35–40
 - integrated genome and flanking sequences, **48**, 39–40
 - pre-integration site, **48**, 38–39
 - site-specific, **48**, 36–38
 - replication
 - auto-inhibition, **48**, 34–35
 - rep* proteins, **48**, 43, 48
 - C-terminal domain kinases binding, **48**, 169
 - demethylation, **48**, 56–60
 - biochemical mechanisms, **48**, 59–60
 - by active mechanism, **48**, 57–59
 - CpG-island, **48**, 57
 - genome-wide, in morula, **48**, 66–67
 - iteron-containing, **48**, 239–267, *see also*
 - Replicons, iteron containing
 - looping, in R6K regulation, **48**, 263–264
 - methylation
 - de novo*, in pregastrula, **48**, 67–68
 - chromatin structure, **48**, 64
 - during embryogenesis, **48**, 64–70
 - effects on gene expression, **48**, 60–64
 - from embryo to adult, **48**, 53–78
 - in gametogenesis, **48**, 68–69
 - in parental imprinted genes, **48**, 71–77
 - in postimplantation embryo, **48**, 69–70
 - methylcytosine-binding protein mediated transcription and, **48**, 62–63
 - patterns
 - gene-specific, **48**, 55–56
 - housekeeping genes, **48**, 55–56
 - tissue-specific genes, **48**, 56
 - sites not serving as imprinting signal, **48**, 75–76
 - X chromosome modification and inactivation, **48**, 69
- repair, uracil-excision, **48**, 315–363
- replication
 - alternative modes, **48**, 264–267
 - control, **48**, 251–264
 - antisense RNA, **48**, 251–253
 - Rep-iteron complexes, **48**, 253–255
 - repressor protein, **48**, 252, 253
 - copy-up mutations, **48**, 266–267
 - enhancer, **48**, 265–266
 - R6K, control
 - antisense RNA, **48**, 262
 - autoregulation of *pit* gene, **48**, 255–256
 - DNA looping, **48**, 263–264
 - π protein, **48**, 256–260
 - regulatory circuits, **48**, 255–262
 - synthesis, dUMP incorporation during, **48**, 316–321
- uracil introduced into, by cytosine deamination, **48**, 322–330
- uracil residues, **48**, 316–330
- Deoxyribonucleoside triphosphates, allosteric regulation of RNRs, **72**, 108–114
- Deoxyribonucleotides, enzymes in DNA precursor biosynthesis and, **44**, 188–189, 195–196
- 2'-deoxyribose 5'-phosphatase (dRPase)
 - pol-beta, **68**, 65, 67, 68
- Deoxyribose phosphate (dRP), **68**, 1, 191
 - MMS-induced cytotoxicity, **68**, 63–69
- Deoxyribose phosphate (dRP) lyase, **68**, 266
 - AP endonuclease, **68**, 262
- Deoxyuridine
 - HMG-domain proteins
 - kinetics, **67**, 104
- Deoxyuridine 5'-triphosphate
 - nucleotidohydrolase, in dUTP and dTTP metabolism, **48**, 318–320
- Deoxyuridine triphosphatase
 - pyrophosphatase
 - See* Deoxyuridine triphosphate

- Deoxyuridine triphosphate pyrophosphatase (dUTPase), **68**, 319–323
- Dephosphorylation, CTD, transcript termination, **72**, 354
- Deprenyl, monoamine oxidase inhibition, **65**, 151–152
- Dermatoparaxis, **47**, 44
- Development, *Egr-1* induction during, **50**, 195–197
- Developmental proteins
 ankyrin repeats, **67**, 11
- DGK, *see* Diacylglycerol kinase
- Dgt1p
 quality control, **67**, 250
- DHFR, **67**, 134–135
- DHT, **68**, 214
 repair activity, **68**, 215
- DHU, **68**, 198–199
- DI-RNAs, *see* Defective-interfering RNAs
- Diabetes, **68**, 274
- Diabetes mellitus, insulin-like growth factor-I regulation
 downstream regions in exon 1, mechanisms of response, **60**, 225–226, 230, 254
 in vivo effects, **60**, 219–221
 hepatocyte culture response, **60**, 221, 224–225
- Diabetes, PDE3 inhibitor therapy, **66**, 262, 269
- Diabetes, pyruvate dehydrogenase kinase effects, **70**, 53
- Diacylglycerol kinase (DGK), features, **65**, 377
- Diacylglycerol kinase catalytic domain, SPHK domains, **71**, 504–508
- Diagnostics, in cell-free molecular cloning, **51**, 263–264
- 1,2-Diaminocyclohexane, *see* Oxaliplatin
- Dichloroacetate, pyruvate dehydrogenase kinase effects, **70**, 52–53
- Dictyostelium discoideum*
 cellular differentiation, markers
 identification, **47**, 3–6
 prestalk-enriched, **47**, 7–8
 culmination
 anterior-like cell movement, **47**, 17–18
 ecmB promoter structure, **47**, 18–19
 stalk-tube formation, **47**, 17–18
- DIF-induced prestalk-specific mRNAs, **47**, 8–10
- extracellular cAMP-signaling
 characterization, **47**, 3
- prestalk cell apical sorting response, **47**, 15
- prestalk cell heterogeneity, **47**, 10–13
- slug formation
 apical sorting of prestalk cells, **47**, 15
- pstB cell migration, **47**, 15
- tip formation, **47**, 13–15
- stalk cell differentiation
 ammonia effects, **47**, 21
- cAMP-dependent protein kinase role, **47**, 19–20
- extracellular cAMP effects, **47**, 21–22
- 5,10-dideaza-5,6,7,8-tetrahydrofolate
 structure, **67**, 136
- DideoxyTTP (ddTTP), **68**, 10, 19
- Diethyl pyrocarbonate, DNA sequence specificity of damage, **63**, 383, 401
- Diethyloxadicarbocyanine (DODC), binding to guanine quadruplex, **59**, 90–91
- Diethylpyrocarbonate, probing of RNA structure, **53**, 143, 149, 154
- Diethylsulfate, DNA sequence specificity, **63**, 381, 393
- DIF genes, *see* Differentiation-inducing factor genes
- Differential scanning calorimetry (DSC), analysis of DNA triple helices, **59**, 71–73, 75
- Differential screening, for *Egr-1* cDNA, **50**, 192–193
- Differentiation
 cellular, and gene regulation, **50**, 217–219
 Egr-1 induction during, **50**, 195–197
- Differentiation-inducing factor-inducible genes
 alternative types, **47**, 7–8
 markers of prestalk differentiation, **47**, 6–7
 prestalk-specific mRNA analyses, **47**, 8–10
- Differentiation, *Trypanosoma brucei* and, **43**, 57–61
- Dihydrofolate reductase (DHFR), **67**, 134–135
- Dihydrofolate reductase mRNA,
 translation, **48**, 204
- Dihydrofolate reductase, poly A site, **71**, 336
- 5,6-Dihydropyrimidine adducts
 detection, **42**, 131–133
- enzyme systems, formation by, **42**, 134
- cytidine deaminase, **42**, 149–150
- hydroxymethylases, **42**, 144–145
- methyltransferases, **42**, 145–149
- protein-nucleic acid interactions, **42**, 152–154

- thymidylate synthase, **42**, 134–144
 tRNA-pseudouridine synthase, **42**, 150–151
- Dihydrotestosterone
 metabolism by retinol dehydrogenase, **63**, 167–169
 retinoid effects on androgen activity, **63**, 169
- Dihydrothymine (DHT), **68**, 214
 repair activity, **68**, 215
- Dihydrouracil (DHU), **68**, 198–199
- Dihydrouridine, conformation and dynamics, **53**, 116–117
- 2,3-Dimercaptopropanol, HIV therapy, **49**, 184
- Dimerization initiation site
 HIV-1 isolates, 3-D structures, **69**, 33–34
 stem-loop structure, **69**, 32
- Dimerization, half-FRT sites, **51**, 70–72
- Dimers, AlcR as, **69**, 159–160
- Dimethyl methanesulfonate
 O^6 -MeG, **68**, 45–46
- Dimethyl sulfate (DMS), DNA sequence specificity, **63**, 381, 392–393, 403–404
- Dimethyl sulfate, probing of RNA structure, **53**, 142
- Dimethyl sulfoxide complexes–DNA interactions, **71**, 49–52
- Dinuclear platinum compounds–DNA interactions, **71**, 44–47
- Dinucleoside oligophosphate, synthesis, aminoacyl-tRNA syntheses in, **48**, 125–126
- Dinucleotide repeats, DNA repair, **66**, 190
- 2,3-Diphosphoglycerate, inhibitor of PRPP synthetase, **69**, 130–132
- Dipyrimidine photoproducts, *see* Base excision repair, dipyrimidine photoproducts; Chromatin
- Direct defense, plant–insect interactions, **72**, 190–192
- DI-RNAs, *see* Defective-interfering RNAs
- Discriminator base at position 73, recognition of tRNA and, **41**, 44–58
- Disease, GEF relationship, **71**, 425–426
- Dissociating enzyme, allosteric regulation, **53**, 13–15
- Dissociation model, adenovirus shunt, **72**, 19
- Distamycin A, DNA sequence specificity, **63**, 382, 398–399
- Distamycin–DNA interactions, **71**, 31
- Distinct bands, protamines and, **40**, 53–58
- Dithiothreitol, *nrdD* protein, **72**, 100
- Dithiothreitol, effect on protein translation, **58**, 95, 98
- Divalent cations, pRNA effect, **72**, 448–449
- DLX3*, mutation in tricho-dento-osseous syndrome, **64**, 193–194
- DM, *see* Myotonic dystrophy
- DMS, **68**, 275–276
- DMS, *see* Dimethyl sulfate
- DNA
 aberrations, preventive role of alkyltransferase, **51**, 202–207
 alkylation damage
 apoptotic cell death, **68**, 42–43
 anaerobic ribonucleotide reductases, **72**, 120–124
 bacterial, replication, helicase role, **70**, 84
 baculoviral, *see* Baculovirus DNA bases
 nucleotide flipping, **68**, 333–334
 bending, mutant Flp proteins, defect, **51**, 66–68
 binding, Flp to FRT site, **51**, 64–66
 BER
 glycosylases, **68**, 323–328
 multiple pathways, **68**, 1–25
 binding activity of Egr-1, **50**, 205–210
 binding, Flp to FRT site, **51**, 64–66
 bulge, **49**, 346
 cleavage by metal complexes, **49**, 313
 complementary, *Egr-1*, identification, **50**, 192–193
 damage
Saccharomyces cerevisiae, **68**, 37
 comet assay, **68**, 62
 Fenton-type reactions, **68**, 208
 ionizing irradiation, **68**, 208
 oxidative, **68**, 140–143, 286–291, 293
 radiation-induced, **68**, 140–141
 reversal and avoidance, **68**, 316–323
 sequence context effects, **68**, 216–218
 sources, **68**, 140
 damage tolerance pathways, **68**, 31
 disruption
 oxidizing agent sensitization, **68**, 33
 damaging agents
 pol beta-deficient mouse cells, **68**, 17
 defined oxidative base lesions, **68**, 208–210
 eIF5, cloning, **70**, 215–216

DNA (*cont.*)

- electrophoresis of mutants, **49**, 303–304
 - constant denaturant capillary
 - electrophoresis, **49**, 288, 304–310
 - constant denaturant gel
 - electrophoresis, **49**, 302, 304–308
 - denaturant gradient gel electrophoresis, **49**, 286–289, 304–308
 - experimental set-up, **49**, 304–305, 308
 - separation efficiency, **49**, 305
- endonuclease
 - eukaryotic, **68**, 268
- glycosylase deficient
 - knockout mice, **68**, 381–382
- homologous recombination in
 - Saccharomyces cerevisiae*, **46**, 232–244
- HSV-1, replication
 - circular DNA intermediates, **70**, 95
 - greater-than-unit-length, **70**, 95–97
 - helicase–primase
 - DNA-binding activities, **70**, 104
 - gene structure, **70**, 102–103
 - UL5 mutations, **70**, 104–106
 - UL52 role, **70**, 106–107
 - model, **70**, 107–111
 - overview, **70**, 93–94
 - proteins, **70**, 97–98
 - UL9
 - biochemical properties, **70**, 98–100
 - in cell culture, **70**, 98
 - domain structure, **70**, 98–100
 - SV40 comparison, **70**, 100
 - unwinding activity, **70**, 101–102
- immunochemical analyses of, *see* Nucleic acids, immunochemical analyses of
- immunoglobulin gene diversification and, **45**, 43
- integration, adenoviral, *see* Adenoviral DNA integration
- lens, **41**, 269–276
- ligase-associated proteins, **68**, 155–158
- ligase-deficient cell lines
 - phenotype, **68**, 158–160
- lysyl oxidase family, **70**, 3–5
- melting
 - cooperativity, **49**, 302
 - domains, **49**, 302–303
 - factors affecting melting temperature, **49**, 303

- metabolism, genes, **51**, 274–277
- methylation, *see* DNA (cytosine-5) methyltransferase
- minor groove, HIV-1 RT, **71**, 126
- mitochondrial. *See* Mitochondrial DNA
- mutational spectrum, *see* Mutational spectrometry
- nuclear
 - oxidative DNA damage, **68**, 286–291
- nucleosome positioning and, **40**, 154–158
- plasmid
 - AAS cells, **68**, 97–98
- plasmids, PAP1 regulation, **71**, 366–367
- prokaryotic transcriptional enhancers and, **43**, 128–130
- protamines and, **40**, 86
- rice genes and, *Agrobacterium*, **45**, 9–15
- RR, **68**, 31
- self-primed synthesis, **72**, 241–242
- steroid hormones and, **43**, 3–6
- structural elements in RNA and, **41**, 170–171
- structure
 - AP sites, **68**, 20
 - BER pathways, **68**, 20–21
- substrates
 - containing BER lesions, **68**, 12–16
 - oxidative base lesions, **68**, 209
 - with AP site analogs, **68**, 11–12
- synthesis, **68**, 57
- templates, fidelity assay, **71**, 103
- triple-helix conformation, **49**, 346–347
- trp repressor and, **42**, 5–8, 29–32
- uracil, **68**, 290
- viral composition, **72**, 416–417

DnaA

- ADP inhibition, **57**, 167–168
 - aggregation, **57**, 156, 170
 - ATP-dependence of initiation, **57**, 158
 - binding sites in *oriC*, **57**, 157
 - concentration autoregulation, **57**, 169
 - DnaB interactions, **57**, 157, 172
 - initiator titration, **57**, 164
 - plasmid replication role, **57**, 172–174
 - primase loading, **57**, 172
 - strand opening, **57**, 158–159
 - synchrony regulation, **57**, 176–177
- DNA adducts
- [PtCl(dien)]Cl, **71**, 7–8

- cellular protein recognition
 - cisplatin-damaged DNA-binding
 - proteins, **71**, 23
 - DNA photolyase, **71**, 20–21
 - DNA-repair proteins, **71**, 19
 - histone H1, **71**, 18–19
 - HMG-domain proteins, **71**, 15–18
 - overview, **71**, 14–15
 - p53 protein, **71**, 21
 - T4 endonuclease VII, **71**, 21
 - TATA-binding protein, **71**, 18
 - Y-box binding protein, **71**, 1, 18
- cisplatin
 - adduct stability, **71**, 5–6
 - adducts *in vitro*, **71**, 3–5
 - adducts *in vivo*, **71**, 6–7
 - antitumor activity, proposed
 - mechanism, **71**, 24–25
 - cellular resistance, **71**, 11, 13–14
 - crosslinks, **71**, 8
 - monofunctional adducts, **71**, 7–8
 - replication effects, **71**, 10
 - transcription effects, **71**, 10–11
 - telomerase effects, **71**, 23
 - topoisomerase effects, **71**, 23–24
 - transplatin, crosslinks, **71**, 8–9
- DnaB protein, **40**, 301–305
- DNaB, primosome assembly role, **63**, 45, 47–48, 60, 63, 323–324
- dnab*
 - chromosome initiation mutants, **59**, 39, 41
 - encoded protein properties, **59**, 41, 44
 - locus, **59**, 41
 - open reading frames, **59**, 41, 44
 - role in origin–membrane binding, **59**, 40–41, 43–44, 46, 48–49
- DNA bending
 - anisotropic flexibility, **47**, 200, 211
 - characterization, **47**, 199–200
 - Cro–O₃ nucleoprotein complex, **47**, 206–209
 - crystallographic evidence, **47**, 204–206
 - gel migration evidence, **47**, 202–204
 - models, **47**, 199–200
- DNA-bending proteins
 - C_n class, **47**, 227–233
 - C₂H₂ class, **47**, 227–233
 - catabolic gene activator protein, **47**, 208–209
 - Cro protein
 - from phage, **47**, 434, 214–215
 - from phage λ , **47**, 215–218
 - engrailed homeodomain in *Drosophila melanogaster*, **47**, 224–227
 - eukaryotic, **47**, 221–227
 - Fos transcription factor, **47**, 236–237
 - GAL4 transcriptional factor, **47**, 233–234
 - GCN4 transcription factor, **47**, 239–240
 - initiation complex for phage ϕ DNA
 - replication, **47**, 247
 - Jun transcription factor, **47**, 236–237
 - leucine zippers, **47**, 236–240
 - MAT α 2 homeodomain in yeast, **47**, 224–227
 - minor-groove-binding, **47**, 240–243
 - Myc proteins, **47**, 237–239
 - NF κ B protein, **47**, 243–245
 - nuclear receptor proteins, **47**, 234–236
 - OccR transcriptional activator, **47**, 245
 - p6 complex, **47**, 247
 - plant
 - AT-rich binding sites, **47**, 251–252
 - DNA-binding motifs, **47**, 252–253
 - G-box motif, **47**, 249–250
 - leucine zippers, **47**, 249–250
 - triple helix-turn-helix motif, **47**, 252
 - zinc-binding, **47**, 250–251
 - prokaryotic, **47**, 214–221
 - repressor protein
 - from phage, **47**, 434, 214–215
 - from phage λ , **47**, 215–218
 - sequence-directed structure–function
 - relationships
 - phytochrome *phA3* promoter in oats, **47**, 256–259
 - proximal β^{maj} globin promoter in mouse, **47**, 254–256
 - TATA promoter element, **47**, 242–243
 - TFIID transcription factor complex, **47**, 240–243
 - TFIIIA, **47**, 227–233
 - trp* repressor protein, **47**, 219–221
 - Zif268, **47**, 232–233
 - zinc-binding, **47**, 227–233
 - zinc fingers, **47**, 227–233
- DNaC, primosome assembly role, **63**, 48, 63, 324
- DNA-cytosine methyltransferase, 5,6-dihydro-purimidine adducts and, **42**, 146–149
- DNA (cytosine-5)methyltransferase
 - S-adenosylmethionine
 - binding site, **49**, 72
 - methyl donor, **49**, 66–67

- DNA (cytosine-5)methyltransferase (*cont.*)
- asymmetric binding site
 - enzyme-DNA interactions
 - cytosine methyl acceptor, **49**, 81–83
 - cytosine methyl director, **49**, 83
 - guanine, **49**, 84
 - experimental evidence, **49**, 79–80
 - structure, **49**, 78–79
 - catalytic cysteine residue, **49**, 67, 80
 - covalent bonding with, 5-fluorodeoxycytidine oligodeoxynucleotides, **49**, 67
 - demethylation of DNA, **49**, 98
 - DNA binding protein effect on activity, **49**, 93
 - DNA conformation effect on reaction
 - rate, **49**, 70–71, 75–78, 93–96, 105–106
 - gene locus, **49**, 80
 - hydrolytic deamination of DNA
 - S-adenosylmethionine effects, **49**, 102
 - mechanism, **49**, 71, 101–103
 - nonenzymatic, **49**, 103–104
 - role in genetic drift away from G–C pairs, **49**, 100–101, 104
 - role of DNA conformation, **49**, 104
 - thymine production, **49**, 72, 101
 - uracil production, **49**, 71–72, 101
 - inhibitors
 - 2-pyrimidinone 1- β -D-2'-deoxyribofuranoside, **49**, 66–67
 - 5-azadeoxycytidine, **49**, 66–67, 99
 - methylation modes
 - de novo* methylation, **49**, 73–74
 - methyl-directed methylation, **49**, 74–76
 - modulation factors, **49**, 91–96, 106
 - passive continuous *de novo* methylation, **49**, 96–98
 - structurally induced methylation, **49**, 76–78
 - patterns of DNA methylation
 - biological role, **49**, 84, 86–87
 - concerted modification, **49**, 87–90
 - effect of gene copy number, **49**, 90–91
 - effect of mutagens, **49**, 99–100
 - effect on bleomycin cleavage
 - specificity, **49**, 345–346
 - interspersed repeated sequences, **49**, 87–90
 - p53, **49**, 103–104
 - restriction fragment-length
 - polymorphisms, **49**, 89–91
 - tissue specificity, **49**, 87
 - transient expression of modulators, **49**, 91–96
 - phosphorylation, **49**, 92–93
 - proton exchange at C-5, **49**, 66–67, 69–70
 - reaction mechanism
 - 5,6 dihydrocytosine carbanion
 - intermediate, **49**, 66
 - nucleophilic attack at C-6, **49**, 66–67
 - sp²sp³ energetics, **49**, 68–70
 - stereochemistry, **49**, 68–70
 - S-adenosylmethionine
 - binding site, **49**, 72
 - methyl donor, **49**, 66–67
 - sequence homology between species, **49**, 72
 - substrate specificity, **49**, 73–79, 85, 97
 - DNA-binding domain
 - AlcR, **69**, 157–159
 - CreA repressor, **69**, 175
 - Gal4p, **69**, 166–167
 - ROR proteins, **69**, 212–214
 - ROR α , **69**, 208–209
 - DNA-binding domain, steroid hormones
 - and, **43**, 11–12
 - DNA-binding domains
 - basic helix–loop–helix domain, **64**, 174–175
 - forkhead domain, **64**, 175
 - high-mobility group domain, **64**, 174–176
 - homeodomain, **64**, 177
 - LIM domain, **64**, 178
 - paired domain, **64**, 178
 - Runt domain, **64**, 176–177
 - zinc fingers, **64**, 177
 - DNA-binding proteins, cisplatin-damaged, **71**, 23
 - DNA-binding proteins, replication
 - protein A, **72**, 63–65
 - DNA-cellulose assay, steroid hormones
 - and, **43**, 7
 - DNA-cytosine methyltransferase,
 - 5,6-dihydropyrimidine adducts
 - and, **42**, 146–147
 - DNA damage/replication checkpoints,
 - Schizosaccharomyces pombe*
 - cut mitoses, **62**, 383
 - definition and overview of pathways, **62**, 373
 - DNA damage tolerance, **62**, 382–383
 - functional overview, **62**, 370
 - G₁-M checkpoint, **62**, 390
 - G₂-M checkpoint

- signal generators
 - hus1, **62**, 379
 - rad1, **62**, 376–377
 - rad3, **62**, 377–378
 - rad4/cut5, **62**, 375
 - rad9, **62**, 378
 - rad17, **62**, 378–379
 - rad26, **62**, 379
 - rhp9/crb2, **62**, 376
 - signal transmitters
 - cdc2, **62**, 380–382
 - chk1, **62**, 379–382
 - rad4/cut5, **62**, 380
 - rhp9/crb2, **62**, 380
 - intra-S-phase checkpoint
 - discovery, **62**, 390–391
 - roles
 - cds1, **62**, 391–392
 - rad4/cut5, **62**, 391–392
 - rad26, **62**, 391–392
 - nomenclature of genes and proteins, **62**, 371
 - S-M checkpoint pathways
 - mutant phenotypes, **62**, 383
 - signal generators
 - rad26, **62**, 385
 - replication/initiation polymerase complex, **62**, 384–385
 - signal transmitters
 - cds1, **62**, 385–388
 - chk1, **62**, 386–388
 - rhp9/crb2, **62**, 387
 - types of pathways, **62**, 383–384
 - S-phase recovery
 - definition, **62**, 388
 - mutant phenotypes, **62**, 383
 - rad11 role, **62**, 389–390
 - rql1 role, **62**, 388–389
 - signal generators and transmitters, overview, **62**, 371
 - DNA damage, superoxide dismutases and, **40**, 238–239
 - enzymatic repair, **40**, 240–242
 - prevalence, **40**, 242
 - products, **40**, 239–240
 - DNA-damaging agents, sequence specificity of damage
 - alkylating agents, **63**, 386–395
 - antitumor mechanisms in chemotherapy, **63**, 404–405
 - applications of agents, **63**, 368, 406
 - bias, **63**, 375
 - chromatin structure
 - effects on structure, **63**, 375
 - probes, **63**, 403–404
 - components of specificity, **63**, 374–375
 - coordination complexes, **63**, 384–386
 - definition of specificity, **63**, 375
 - determinants, **63**, 405–406
 - determination of sequence specificity
 - concentration of agent, **63**, 375
 - end-labeled fragment, **63**, 371–372, 376
 - footprinting, **63**, 373
 - history of techniques, **63**, 369–370
 - ligation-mediated polymerase chain reaction, **63**, 372–374, 376
 - linear amplification, **63**, 372, 374, 376
 - overview of techniques, **63**, 370–371
 - problems in published reports, **63**, 377
 - sensitivity of techniques, **63**, 376
 - single-strand ligation polymerase chain reaction, **63**, 373–374, 376
 - spectroscopy and spectrometry, **63**, 374
 - dial-up sequence specificity, **63**, 402–403
 - DNA targeting hypothesis, **63**, 405
 - enzymes, **63**, 400
 - free radicals, **63**, 395–396
 - minor groove binders, **63**, 398–400
 - miscellaneous compounds, **63**, 402
 - radiation, **63**, 400–401
 - simple chemicals, **63**, 401
 - survey of agents, overview, **63**, 377–384
 - topoisomerase inhibitors, **63**, 396–398
- DNA-DNA hybridization, protamines and, **40**, 51–53
- distinct bands, **40**, 53–58
- smear signal, **40**, 53
- DNA endonuclease complex, *see* Endonuclease
- DNA endonuclease, function of 5'-to-3'
 - exonuclease, **51**, 112–113
- DNA-filled capsids, pRNA, **72**, 450
- DNA footprinting, *see* GAL
- DNaG, primosome assembly role, **63**, 45, 324
- DNA glycosylase, **68**, 4, 14, 24, 350
 - classes, **68**, 189–190
 - DNA long-term maintenance, **68**, 382–384
 - duplex DNA, **68**, 189
 - features, **68**, 189–190
 - mammalian genome
 - evolution, **68**, 381–382

- DNA glycosylase (*cont.*)
- molecular mass, **68**, 190
 - monofunctional
 - BER, **68**, 15
 - mtDNA, **68**, 261–263
 - multiple enzymes, **68**, 191
 - reaction mechanisms, **68**, 352–353
 - replication-coupled BER, **68**, 134–137
 - substrate bases, **68**, 190
 - substrates, **68**, 13–16
 - uracil
 - conserved gene family, **68**, 368–369
- DNA-glycosylase 3-methyladenine DNA glycosylase (ANPG), **68**, 14
- DNA helicases of *Escherichia coli*, **40**, 289–291, 320–321
- helicase I, **40**, 313–315
 - helicase III, **40**, 315–316
 - helicase IV, **40**, 316–318
 - RecBCD enzyme, **40**, 310–312
- repair helicases
- helicase II, **40**, 305–309
 - UvrAB complex, **40**, 309–310
- replicative helicases
- DnaB protein, **40**, 301–305
 - PriA protein, **40**, 299–301, 305
 - rep protein, **40**, 296–299
 - Rho protein, **40**, 318–320
- unwinding reaction
- helicase assays, **40**, 292–294
 - mechanisms, **40**, 294–296
- DNA helicases, homologous recombination in *Saccharomyces cerevisiae* and, **46**, 256–258
- DNA–histone interactions, *see* Nucleosome
- DNA interactions
- carboplatin, **71**, 25–26
 - chloropolypyridyl Ru compounds, **71**, 53
 - dimethyl sulfoxide complexes, **71**, 49–52
 - heterodinuclear (Ru,Pt) compounds, **71**, 53–54
 - monodentate Pt(II) compounds, **71**, 34–38
 - oxaliplatin, **71**, 26–29
 - polynuclear platinum antitumor drugs
 - dinuclear compounds, **71**, 44–47
 - overview, **71**, 42–44
 - trinuclear compounds, **71**, 47–49
 - ruthenium heterocyclic complexes, **71**, 52
 - targeted cisplatin analogs, **71**, 29–32
 - tetravalent cisplatin analogs, **71**, 32–34
 - transplatin analogs
 - asymmetric aliphatic amines, **71**, 42
 - cyclohexylamine ligands, **71**, 42
 - imino ether groups, **71**, 40–41
 - planar amine ligand, **71**, 38–40
- DnaJ, rhodanese folding studies, **66**, 58–59, 61
- DnaK
- rhodanese folding studies, **66**, 58–59, 61
 - trigger factor complementarity, **66**, 60–61
- DNA ligase, **68**, 129
- mammalian
 - BER, **68**, 151–162
 - encoding, **68**, 152
- DNA ligase I, **68**, 131, 155–157, 250, 267–268
- BER, **68**, 161
 - deficient cell lines, **68**, 158–159
 - DNA replication, **68**, 153–154
 - one-nucleotide gap, **68**, 157
 - PCNA, **68**, 132, 156
- DNA ligase III, **68**, 90, 154, 157–158, 250, 267–268
- BER, **68**, 161
 - deficient cell lines, **68**, 159
- DNA ligase IV, **68**, 155, 158, 267–268
- deficient cell lines, **68**, 159–160
 - Saccharomyces cerevisiae*, **68**, 150
- DNA ligase, homologous recombination in *Saccharomyces cerevisiae* and, **46**, 259–260
- DNA methylation
- assay, **56**, 114, 116
 - coordinated with DNA replication, **69**, 55–63
 - ectopic, suppression of gene expression, **69**, 50–51
 - as epigenetic modification of DNA, **69**, 49–50
 - interference with transcription factor binding, **69**, 51
 - interferon- γ gene regulation, **56**, 114, 116–119
- DNA methylation, *see also* DNA methyltransferase
- binding proteins to methylated DNA, *see* MeCp1; MeCp2; Methylated DNA binding protein 2 H1
 - de novo* methylation, **57**, 220–222, 231–232
 - demethylation, *see also* m⁵Cytosine-DNA glycosylase

- active mechanism, **57**, 222, 224
- enzymes, **57**, 226–227
- genome-wide demethylation, **57**, 224–225
- nonhistone protein 1 role, **57**, 227
- passive mechanism, **57**, 222
- site-specific demethylation, **57**, 224
- determination factors, **57**, 228
- gene silencing mechanisms
 - DNA structure alteration, **57**, 234
 - repressor protein binding, **57**, 235–241, 243
 - transcription factor binding inhibition, **57**, 234–235
- hypermethylation, **57**, 233–234
- methyl-directed maintenance methylation, **57**, 219–220
- p53 gene, **57**, 218
- structure-induced methylation, **57**, 222, 232–233
- tumorigenesis effects, **57**, 218–219
- DNA methylation, proliferating cell nuclear antigen role, **65**, 284–285
- DNA methyltransferase
 - de novo* methylation, **57**, 220–222, 231–232
 - lesion effects on methylation, **57**, 222
 - models for formation of specific methylation patterns, **57**, 229, 231–232
 - modulators, **57**, 232
 - mutation effects in mice, **57**, 217–218, 243
 - regulation of expression, **57**, 220
 - replication foci association, **57**, 220
 - sequence specificity, **57**, 219
- DNA methyltransferases, candidate, **69**, 53
- DNA microarrays, herpesvirus
 - design, **71**, 454–455
 - development rationale, **71**, 446–447
 - glass slide-based, HSV-1
 - chip data, **71**, 465–468
 - chip fabrication and scanning, **71**, 464–465
 - experimental data, **71**, 470–472
 - hybridization, **71**, 455
 - receiver operating characteristic, **71**, 465
 - scanning protocols, **71**, 456–459
 - specific oligonucleotides, **71**, 461–464
 - transcript labeling, **71**, 455–456
- oligonucleotide-based approach, **71**, 453–454
- PCR fragment-based approach, **71**, 453
- transcription, **71**, 452–453
- DNA mismatch repair
 - uracil-initiated BER
 - LoVo cells, **68**, 182–183
- DNA-N-glycosylases
 - human, **68**, 134
- DNA oligonucleotides
 - annealing assay, **72**, 235–237
 - strand exchange assay, **72**, 237–239
- DNA packaging
 - inactive pRNA, **72**, 430
 - phi29, pRNA role, **72**, 417–419
 - pRNA domain, **72**, 449–450
 - pRNA minimal sequence, **72**, 453
 - viral, model, **72**, 458–459
- DNA photolyase, DNA adduct recognition, **71**, 20–21
- DNA-PK, ribosomal gene transcription regulation, **62**, 133
- DNA polymerase
 - inhibitors
 - permeable mammalian cell systems, **68**, 10
- DNA polymerase α
 - catalytic core
 - dNTP recognition and binding, **47**, 378–379
 - Mg²⁺ role, **47**, 376–378
 - primer recognition and binding, **47**, 375–376
 - substrate recognition and binding, mechanism, **47**, 372–373, 379–380
 - template recognition and binding, **47**, 372–375
 - human, holoenzyme
 - and catalytic core protomer, comparison, **47**, 380–382
 - and holoenzyme purified from *Drosophila* embryos, comparison, **47**, 382–385
 - incorporation mechanism, **47**, 389–390
 - interactions with template–primers containing chemically damaged nucleotides, **47**, 386–389
- DNA polymerase α (Pol α)
 - cell cycle checkpoint role, **65**, 269–270
 - cell cycle control of DNA replication, role, **65**, 268–269
- DNA repair role, **65**, 270
- functions, overview, **65**, 264
- mechanism, **65**, 263, 265
- protein interaction
 - cell cycle control, **65**, 269

- DNA polymerase α (Pol α) (*cont.*)
 coordinated and error-free lagging-strand replication, **65**, 267–268
 stable of interacting proteins, **65**, 266
 subunits, **65**, 265
 viral DNA replication, **65**, 265, 267
- DNA polymerase β (Pol β), base excision repair role, **65**, 275, 277
- DNA polymerase δ
 PAGE-detectable complex with PCNA and synthetic oligonucleotide
 template–primers, **47**, 393–394
 stimulation by proliferating cell nuclear antigen, **47**, 391–392
 substrate recognition and binding, **47**, 390–391
- DNA polymerase δ (Pol δ)
 functions
 base excision repair, **65**, 277
 double-strand break repair, **65**, 279
 mismatch repair, **65**, 278
 nucleotide excision repair, **65**, 278
 overview, **65**, 264, 271
 postreplicative bypass of
 UV-damaged DNA, **65**, 279
 gap-filling synthesis, **65**, 273
 holoenzyme assembly, **65**, 272–274
 protein interactions, **65**, 271–272
 subunits, **65**, 271
 viral DNA replication, **65**, 274
- DNA polymerase ϵ (Pol ϵ)
 functions
 base excision repair, **65**, 277
 double-strand break repair, **65**, 279
 gap-filling synthesis, **65**, 273
 nucleotide excision repair, **65**, 278
 overview, **65**, 264
 S phase checkpoint control, **65**, 275
 holoenzyme assembly, **65**, 272–274
 subunits, **65**, 272
 viral DNA replication, **65**, 274
- DNA polymerase α –primase
 characteristics and function, **72**, 65–68
 replication initiation, **72**, 72
- DNA polymerase accessory proteins,
 prokaryotic transcriptional enhancers
 and, **43**, 125–127
- DNA polymerase beta (pol beta), **68**,
 4, 24, 42, 58, 125, 129
 adenocarcinoma, **68**, 21
- AP site repair, **68**, 22
- BER, **68**, 47
- deficient cells
 alternative repair pathway, **68**, 50–51
 BER intermediates pathways, **68**, 51
 MGMT, **68**, 52
- deficient mouse cells
 DNA-damaging agents, **68**, 17
- deleted mouse cell extracts
 AP site repair
 pol beta, **68**, 22
- dependent pathway, **68**, 11
- dRPlase, **68**, 65, 67, 68
- inhibition, **68**, 10
- long-patch BER, **68**, 289–291
- mammalian
 BER, **68**, 57–72
 mutagenesis, **68**, 69–71
 POL3 mutants, **68**, 21
- MMS, **68**, 58–59
- mtDNA
 BER, **68**, 256–266
- mutant cell lines
 BER pathways, **68**, 16–20
- mutant mouse cell lines, **68**, 16–20
- null cells
 MMS, **68**, 61
- null genotype
 mammalian cells, **68**, 59–62
- null mouse fibroblasts
 POL3 mutants, **68**, 21
- polymerase active site, **68**, 63
- quiescent cells, **68**, 23
- recombinant, **68**, 60
- short-patch BER, **68**, 289–291
- yeast, **68**, 21
- DNA polymerase delta (pol delta),
68, 129, 165
- DNA polymerase epsilon (pol epsilon),
68, 165
- DNA polymerase gamma (pol gamma),
68, 90, 265–266
- DNA polymerase II, **46**, 93–94, 116–117
 catalytic subunit
 POL2 homologs, **46**, 109–110
 C-terminal half, **46**, 105
 exonuclease active site, **46**, 105–109
 polymerase domain, **46**, 104–105
 categorization, **46**, 94–96
 cell cycle regulation, **46**, 103–104

- DNA repair, **46**, 112–114
- DNA replication, **46**, 114–115
 - genetics of exonuclease
 - epistatic relationships, **46**, 111–112
 - spontaneous mutator phenotype, **46**, 110–111
- structure
 - mammalian DNA polymerase ϵ , **46**, 102–103
 - purification, **46**, 96–99
 - stimulatory factors, **46**, 101–102
 - subunits, **46**, 97–101
- DNA polymerase, RB69
 - accessory proteins, **64**, 91
 - homology with T4 DNA polymerase, **64**, 83–84
- RNA binding and translational repression, **64**, 75–76
- structure
 - crystallization, **64**, 83
 - DNA–protein interactions, **64**, 85–86
 - domains, **64**, 84–86, 88
 - sequence alignment of B family polymerases, **64**, 87–89
- DNA polymerase, T4
 - fidelity functions
 - accessory protein roles, **64**, 74–75
 - catalytic activities, **64**, 72–73
 - mutant analysis, **64**, 73–74
 - genetic analysis, overview, **64**, 72
 - replisome
 - assembly, **64**, 77
 - components and functions, **64**, 77–81
 - helicase–primase complex coordination with replicase, **64**, 82–83
 - kinetic studies of clamp loader, **64**, 81–82
- RNA binding and translational repression
 - comparison with bacteriophage RB69, **64**, 75–76
 - extension to other systems, **64**, 76–77
 - sequence recognition and affinity, **64**, 75
- structure
 - comparison with bacteriophage RB69, **64**, 83–88
 - sequence alignment of B family polymerases, **64**, 87–89
- DNA polymerase, triplet repeat sequence replication and instability, **66**, 170–171, 190
- DNA polymerases in DNA synthesis, **48**, 321
- DNA polymerases, homologous recombination in *Saccharomyces cerevisiae* and, **46**, 259–260
- DNA polymerases, in reconstitution of SV40 DNA replication, **51**, 100–101
- DNA precursor biosynthesis, enzymes in, *see* Enzymes in DNA precursor biosynthesis
- DNA primase, in conjugative DNA transfer, **54**, 232–234
- DNA–protamine complexes, adenoviral DNA integration and, **46**, 8–10
- DNA–protein interaction cloning, **70**, 162–164
- DNA quadruplex, *see* Guanine quadruplex
- DNA recombination, *recA*-independent
 - recombination between direct repeats
 - D-7 sequence, effects from a distance, **54**, 270–271
 - deletion and addition, **54**, 254–255
 - effect of distance between repeats, **54**, 259–260
 - models
 - misalignment exchange, **54**, 265–266, 268–269
 - replication slippage, **54**, 263
 - rolling-circle replication, **54**, 263
 - single-strand annealing, **54**, 263
 - sister-strand exchange, **54**, 264–265
 - plasmid substrate studies in *E. coli*, **54**, 256–257
 - products of recombination, **54**, 260–263
 - short repeats and genome instability, **54**, 271–272
 - sister chromatid exchange mediation, **54**, 272
 - tandem direct repeats, **54**, 257–259
- recombination between inverted repeats
 - chromosome inversion in bacteria and phage, **54**, 275
 - gene amplification, **54**, 283, 285–287, 289
 - genome rearrangement, **54**, 283, 285–287, 289
 - outcomes, **54**, 273
 - plasmid recombination, **54**, 275–277
 - product, head-to-head dimer in plasmids, **54**, 277–279
 - reciprocal-strand-switching model, **54**, 280, 282–283, 285–287, 289
- types, **54**, 254

- DNA relaxase
 assays, **54**, 229–231
 domain structure, **54**, 223–226
 initiation of replication role, **54**, 218, 220
 termination of replication role, **54**, 220–223
- DNA repair
 alkyltransferase sequence specificity in, **51**, 191–194
 DNA polymerase α role, **65**, 270
 DNA polymerase β , base excision repair role, **65**, 275, 277
 DNA polymerase δ roles
 base excision repair, **65**, 277
 double-strand break repair, **65**, 279
 mismatch repair, **65**, 278
 nucleotide excision repair, **65**, 278
 postreplicative bypass of UV-damaged DNA, **65**, 279
 DNA polymerase ϵ roles
 base excision repair, **65**, 277
 double-strand break repair, **65**, 279
 nucleotide excision repair, **65**, 278
 overview of mechanisms, **65**, 263, 275
 proliferating cell nuclear antigen role, **65**, 282–284
 role of polymerase β , **51**, 113
- DNA-repair proteins, DNA adduct recognition, **71**, 19
- DNA repair, *see* Base excision repair; dipyrimidine photoproducts; Chromatin; Nucleotide excision repair
- DNA repair, *see* Homologous genetic recombination; Nucleotide excision repair assay
- DNA repair, *see* Nucleotide excision repair; Recombinatorial DNA repair
- DNA repair, alkylation damage repair in genomes and, **44**, 132–135
- DNA replication
 BRCT family, **72**, 74–77
 coordinated with DNA methylation, **69**, 55–63
 Dbf4p–Cdc7p kinase, **72**, 45
 eukaryotic, *see* Eukaryotic DNA replication
 events at replisome, **65**, 262–263
 inhibition by DNMT1 inhibition, **69**, 63–64
 initiation by priming reactions, **51**, 96–97
 initiation, leading and lagging strands, **72**, 72
 leading-strand, **51**, 101–103
 origins, initiation at, **51**, 93–96
 polymerases, *see* DNA polymerase α ; DNA polymerase δ ; DNA polymerase ϵ
 reactions, regulation, **51**, 113–115
 SV40, **51**, 98–101, 108–109
 transcription factor roles, **65**, 289–291
- DNase-I footprinting assay, steroid hormones and, **43**, 8
- DNase I, hypersensitivity of actively transcribed genes, **55**, 227–228, 230–232
- DNase-I, hypersensitivity of integrated transgenes, **50**, 180–184, 187–188
- DNA sequence amplification in mammalian cells, **41**, 203–204, 232
 abnormally banding chromosome regions, **41**, 208–211
 cell lines, **41**, 228–232
 cytological characteristics of DNA, **41**, 207–213
 double-minute chromatin bodies, **41**, 211–213
 historical development of amplification field, **41**, 205–206
 mechanisms, **41**, 218–219
 conservative transposition, **41**, 226–228
 deletion, **41**, 224–226
 episome formation, **41**, 224–226
 re-replication, **41**, 220–224
 unequal sister-chromatid exchange, **41**, 219–220
 occurrence, **41**, 206–207
 structure of amplified DNA sequences, **41**, 213–218
- DNA single-strand breaks
 factories, **68**, 25
 induction, **68**, 18
- DNA strand exchange, *see* RecA
- DNA structures, modeling of, **43**, 87–89, 104–105
 empirical force fields, **43**, 89
 atomic fields, **43**, 89–91
 electrostatic interaction, **43**, 91–92
 force fields, use of, **43**, 92–93
 molecular dynamics, **43**, 101–102
 Monte Carlo method, **43**, 100–101
 optimization, **43**, 95–100
 torsion potential, **43**, 93–95
 model building, **43**, 102–103
 theoretical data, **43**, 103–104

DNA synthesis

- lagging-strand, completion, **51**, 104–113

- leading- and lagging-strand, **51**, 98–104

- proviral DNA, **71**, 97

- reverse transcriptase

 - amino acid role, **71**, 127–128

 - Arg-72, **71**, 120–121

 - Gln-151, **71**, 119–120

 - Lys-65, **71**, 120–121

 - Met-184, **71**, 117–119

 - minor groove binding track residues, **71**, 126

 - overview, **71**, 112–113

 - primer grip residues, **71**, 124–126

 - template strand residues, **71**, 121–123

 - Tyr-115, **71**, 114–117

 - Tyr-183, **71**, 123–124

- DNaT, primosome assembly role, **63**, 45

- DNA targeting, phi29 pRNA, **72**, 458

- DNA topoisomerase I, **72**, 68–69

- DNA topoisomerases, homologous recombination in *Saccharomyces cerevisiae* and, **46**, 258–259

- DNA translocation

 - nucleic acid sliding/riding processes, **72**, 459–461

 - phi29 pRNA role, **72**, 453–457

- DNA triplet repeat, *see* Triplet repeat sequence

- DNA triplex

 - discovery, **59**, 56–57

 - hydrogen bonding, **59**, 58–59, 63–64

 - ionic strength dependence, **59**, 58

 - ligand interactions

 - intercalators, **59**, 77–79

 - minor groove binding agents, **59**, 77

 - molecularly, **59**, 60

 - pH dependence, **59**, 65

 - pur*pur•pyr triplex

 - melting transition, **59**, 67–68

 - metal ion dependence, **59**, 67

 - nuclear magnetic resonance, **59**, 77

 - sequence dependence, **59**, 68

 - ultraviolet spectroscopy mixing curves, **59**, 67

 - pur/pyr*pur•pyr triplex properties, **59**, 68–69

 - pyr*pur•pyr triplex

 - circular dichroism, **59**, 65

 - Fourier transform infrared spectroscopy, **59**, 76

 - nuclear magnetic resonance, **59**, 61, 63, 65, 76–77

 - polyacrylamide gel electrophoresis, **59**, 61–63, 66

 - sequence dependence, **59**, 67

 - ultraviolet spectroscopy mixing curves, **59**, 61–63

 - sequence dependence, **59**, 57–58, 65, 67–68

 - strand orientation, **59**, 59–60

 - thermodynamic analysis

 - differential scanning calorimetry, **59**, 71–73, 75

 - ultraviolet spectroscopy melting

 - curves, **59**, 63–64, 67, 69–71

 - types, overview, **59**, 57

- DNA, *see* Deoxyribonucleic acid

- DNA. *See also* Cisplatin-DNA

 - antisense

 - msDNAs, **67**, 86–87

 - crosslinks

 - platinum drugs, **67**, 96

 - 3-methyladenine, **67**, 98

 - ms. *See* MsDNAs

 - recognition properties

 - CooA, **67**, 58–59

 - TFO

 - repair systems, **67**, 186–189

 - sequence change, **67**, 185–186

- DNases, DNA sequence specificity, **63**, 383, 400

- DNA gene

 - Saccharomyces cerevisiae*, **68**, 151–152

- DNMT1

 - de novo, **69**, 68–69

 - inhibition, and DNA replication

 - inhibition, **69**, 63–64

 - methylation pattern inheritance, **69**, 59–61

 - oncogenesis and, **69**, 64–71

 - role in growth suppressor gene

 - expression, **69**, 62–63

 - targeted to replication fork, **69**, 61–62

- Dnmt1*

 - expression, role in cellular

 - transformation, **69**, 56–58

 - posttranscriptional regulation, **69**, 59

 - regulatory regions, **69**, 56

- dNTP, enzymes in DNA precursor

 - biosynthesis and

 - compartmentation, **44**, 188–196

 - multienzyme aggregates, **44**, 196–198

 - organization, **44**, 171–177

- dNTP, enzymes in DNA precursor
 biosynthesis and (*cont.*)
 replication, **44**, 198–200
 synthesis in eukaryotic cells, **44**, 187
- dNTP synthetase, T4, DNA precursor
 biosynthesis and, **44**, 177–181
- dNTPs, *see* Deoxynucleoside triphosphate
- DOCK, guanine quadruplex ligand design
 principle, **59**, 89–90
 screening of compounds, **59**, 90–91
- DODC, *see* Diethyloxadecarboxyanine
- Dogfish protamines, **40**, 38–39
- Domain communication, in editing, **69**,
 337–341
- Domain-dependent repair
 nucleotide excision repair, **68**, 216
- Domain–domain communication
 and aminoacylation efficiency, **69**, 325–329
 by conformational changes in tRNA, **69**,
 334–335
 role of induced fit, **69**, 341–345
 via noncovalent assembly of aminoacylation
 systems, **69**, 323–325
- Domain functions, AARS, separable, **69**,
 320–323
- Domain V residues, in peptide-bond
 formation, **50**, 13–17
- Domains
 ankyrin-repeat
 integral membrane proteins, **67**, 12
 iPLA₂ β , **67**, 10–14
 alignment, **67**, 10
 proteins, **67**, 11
 ATP-binding
 iPLA₂, **67**, 8–10
 catalytic
 protein kinase family, **67**, 8
 structural
 retron reverse transcriptase, **67**, 81
- Dominant inhibitory Ras proteins, GEF
 targeting, **71**, 402–404
- Dose–response curves, pRNA
 stoichiometry, **72**, 424–425
- Dot-matrix sequence analysis of protamine
 genes, **40**, 46–50
- Double-minute chromatin bodies, DNA
 sequence amplification in mammalian
 cells and, **41**, 211–213
- Double pathway defect mutants
 spontaneous mutator phenotypes, **68**, 33–36
- Double-positive thymocytes, **69**, 231–233, 237
- Double-strand break-induced recombination
 DNA damaging techniques, **58**,
 264–265, 278
 experimental approaches in study, **58**,
 265–266, 278
 meiotic recombination
 biological functions, **58**, 288
 hot spots, **58**, 289–290
 mechanisms, **58**, 288–290
 mitotic recombination
 biological functions, **58**, 277, 287–288
 events, *in vitro* studies
Saccharomyces cerevisiae, **58**, 278–279
Saccharomyces pombe, **58**, 279–280
Ustilago maydis, **58**, 280
Xenopus, **58**, 280
 events, *in vivo* studies
Saccharomyces cerevisiae, **58**, 281–284
Saccharomyces pombe, **58**, 284–285
Xenopus, **58**, 285–287
 genetic control
Saccharomyces cerevisiae, **58**, 291–294
Saccharomyces pombe, **58**, 294–295
 P-element transposition in *Drosophila*,
58, 288
 V(D)J recombination, **58**, 277, 288
- models
 double-strand break–gap repair model, **58**,
 269, 285, 291
 one-sided invasion model, **58**, 269, 271
 postmeiotic segregation, **58**, 266–267
 Radding's model, **58**, 267
 Resnick's model, **58**, 267, 271
 single-strand annealing model, **58**,
 276–277, 282–283, 291
 stages, **58**, 277
 synthesis-dependent strand-annealing
 model, **58**, 271, 276
 recombination types, **58**, 264
- Double-strand breaks, initiation of
 recombination, **61**, 357
- Double-stranded RNA-activated protein
 kinase (PKR)
 activation, **58**, 104, 106–108
 calcium depletion and activation, **58**,
 106–107
 cloning, **54**, 177–178
 DNA sequence, rat, **54**, 176–177
 domains, **58**, 104

- eIF-2 α phosphorylation, **58**, 103–108
- growth control and tumor suppression, **58**, 105–106
- induction by interferons, **58**, 103
- phosphorylation of eIF-2 α , **54**, 169
- viral evasion, **58**, 105
- Double-stranded RNA adenine deaminase
 - biological role, **52**, 43–44
 - physical properties, **52**, 43
 - substrate recognition, **52**, 42–44
- Double-stranded RNA, *see also* Antisense RNA; Heterogeneous nuclear RNA
 - atomic structure, **52**, 6, 8, 10–11
 - biological origins, **52**, 2–3
 - cell proliferation moderation, **52**, 53–54
 - chemical stability, **52**, 17–18
 - enzymatic cleavage, **52**, 18–25
 - experimental identification, **52**, 3–4
 - molecular properties, **52**, 11–13
 - protein recognition, **52**, 13, 15–17, 56
 - purification, **52**, 3
 - receptor, **52**, 51
 - secondary structure, **52**, 5–6
 - signal transduction in mammalian cells, **52**, 51–53
 - therapeutic applications, **52**, 54–55, 57
 - viral infection role, **52**, 53
- Double-stranded RNA-dependent kinase
 - effect on HIV translation, **49**, 176
- Double-stranded RNAs, yeast, *see* Yeast double-stranded RNAs
- Doxorubicin, *see* Topoisomerase II poisons
- DP1, autoregulation of promoter, **60**, 144, 146, 162
- drifter*, development role, **63**, 249
- Drosophila melanogaster*, **67**, 10
- Drosophila melanogaster*, **68**, 248–249, 368–369
 - TDG homologs, **68**, 237
- Drosophila melanogaster*, DNA polymerase- α holoenzyme
 - comparison with human DNA polymerase- α holoenzyme, **47**, 382–385
 - interaction with abasic site-containing template–primers, **47**, 386–388
- Drosophila melanogaster*, ROR homologs, **69**, 211–212
- DRP, **68**, 1, 191
 - MMS-induced cytotoxicity, **68**, 63–69
- DRP lyase, **68**, 266
 - AP endonuclease, **68**, 262
- DRPase
 - pol-beta, **68**, 65, 67, 68
- Drug–AIDS hypothesis, latent viruses and mutated oncogenes and, **43**, 145–147
- Drug induction
 - hepatic ALAS, **51**, 13–14
 - hepatic cytochrome P450 and ALAS transcription, **51**, 17–20
- Drug resistance, alkylation damage repair in genomes and DNA repair, **44**, 132–135
- gene amplification, **44**, 135–136
- Drug-resistant viruses, enhanced polymerase fidelity, **71**, 129
- Drug-versus virus–AIDS hypothesis, latent viruses and mutated oncogenes and, **43**, 147–152
- Drugs
 - anticancer
 - development, **67**, 215–216
 - design
 - ACK 1/2, **67**, 222
 - WASP, **67**, 221
 - peptide-based
 - combinatorial/parallel synthesis approaches, **67**, 120–122
 - platinum
 - DNA crosslinks, **67**, 96
- Drugs, RT mutation rates, **71**, 130–131
- DSB-120, DNA sequence specificity, **63**, 382, 398–399
- Dsb proteins, thiol–disulfide exchange, **66**, 139
- DSC, *see* Differential scanning calorimetry
- DtpT
 - gene cloning, **58**, 246–247
 - hydrophobicity analysis, **58**, 257–258
 - sequence homology with other transporters, **58**, 248, 250–256
 - structure, **58**, 248, 250
- DTT, *see* Dithiothreitol
- DTT, effect on branched chain aminotransferases, **70**, 183
- dTTP (thymidine 5'-triphosphate)
 - biosynthesis, **48**, 316–318
 - inhibitors, **48**, 320–321
 - metabolism, deoxyuridine 5'-triphosphate nucleotidohydrolase in, **48**, 318–320
- Dual human reduced folate carrier
 - promoters
 - identification, **67**, 151–152

- dUMP (deoxyuridine 5'-monophosphate),
incorporation
during DNA synthesis, **48**, 316–321
- DUTP
recognition, **68**, 322
- dUTP (deoxyuridine 5'-triphosphate)
biosynthesis, **48**, 316–318
metabolism, deoxyuridine 5'-triphosphate
nucleotidohydrolase in, **48**, 318–320
- DUTP nucleotidohydrolase. *See* Deoxyuridine
triphosphate pyrophosphatase
- DUTPase, **68**, 319–323
beta hairpin, **68**, 321
biological function, **68**, 319
biological trimer, **68**, 322
uracil BER, **68**, 320
- Dyrk1A
activation by tyrosine phosphorylation, **62**, 14
comparison of N and C termini, **62**, 8
conserved residues and motifs with
Dyrk-related kinases, **62**, 4–7
DH-box, **62**, 9–10
discovery, **62**, 3
Down syndrome role, **62**, 3–4, 15
Drosophila homolog, *see* *minibrain*
dual-specificity protein kinase activity, **62**,
13–14
family classification, **62**, 2
functions, **62**, 15
genomic localization, **62**, 13
kinase activity, **62**, 3
mRNA splicing and polyadenylation, **62**, 12
PEST sequence, **62**, 10
phylogenetic analysis with other kinases, **62**,
10–12
tissue distribution, **62**, 12
YxY motif in activation loop, **62**, 7–8
- Dyrk2
comparison of N and C termini, **62**, 8
conserved residues and motifs with
Dyrk-related kinases, **62**, 4–7
DH-box, **62**, 9–10
genomic localization, **62**, 13
mRNA splicing and polyadenylation,
62, 13
phylogenetic analysis with other kinases, **62**,
10–12
YxY motif in activation loop, **62**, 7–8
- Dyrk3
comparison of N and C termini, **62**, 8
conserved residues and motifs with
Dyrk-related kinases, **62**, 4–7
DH-box, **62**, 9–10
dual-specificity protein kinase activity, **62**, 14
genomic localization, **62**, 13
phylogenetic analysis with other kinases, **62**,
10–12
YxY motif in activation loop, **62**, 7–8
- Dyrk4
comparison of N and C termini, **62**, 8
conserved residues and motifs with
Dyrk-related kinases, **62**, 4–7
DH-box, **62**, 9–10
phylogenetic analysis with other kinases, **62**,
10–12
YxY motif in activation loop, **62**, 7–8
- E**
- E-box, role in HIV gene expression, **49**,
169–170
- E-cadherin
apoptosis role, **57**, 203–204
catenin binding, **57**, 194, 196–197, 201–202
cDNA structure, **57**, 191, 193
cell-specific recognition, **57**, 199
cellular polarization effects, **57**, 201–202
colonic disease, spatial changes *in vivo*,
57, 204
embryogenesis role, **57**, 199–201
epithelial cell adhesion, **57**, 190, 203
functional domains, **57**, 193
gene
promoter, **57**, 191
structure, **57**, 190–191
interaction with other adhesion
molecules, **57**, 194
metastasis role, **57**, 202–203, 207, 209
phosphorylation in signal transduction,
57, 196–197
processing, **57**, 193
regulation of expression, **57**, 191
sequence homology between species, **57**,
188, 190
signal transduction via cytoskeleton, **57**, 194,
196–198
tissue differentiation role, **57**, 201
tumorigenesis changes
loss of heterozygosity, **57**, 204–205

- point mutations, **57**, 205
- posttranscriptional processing, **57**, 205
- posttranslational processing, **57**, 206
- transcriptional regulation, **57**, 205
- E domains, *see* Epimerization domains
- E2
 - pyruvate dehydrogenase kinase
 - activation, **70**, 59–64
 - pyruvate dehydrogenase kinase isoform
 - regulation, **70**, 65–69
 - pyruvate dehydrogenase phosphatase
 - 1 activation, **70**, 64–65
- E2-2 bHLH protein, isolation, **70**, 162–164
- E2F, cell cycle regulation, **53**, 201, 204–208
- E2F, pRB cooperation, **72**, 46–48
- E2F1, autoregulation of promoter, **60**, 144–145, 162
- E2F2, autoregulation of promoter, **60**, 144–146
- Early promoters, HSV, **51**, 144–147
- EBP, *see* Elastin-binding protein
- Ec107
 - characteristics, **67**, 69
- Ec48
 - characteristics, **67**, 69
- Ec67
 - characteristics, **67**, 69
- Ec73
 - characteristics, **67**, 69
- Ec78
 - characteristics, **67**, 69
- Ec83
 - characteristics, **67**, 69
- Ec86
 - characteristics, **67**, 69
- E-cadherin
 - IQGAP1, **67**, 199–200
 - Rho, **67**, 199–200
- Ech hydrogenase, methanogens, **71**, 248–249
- Echinomycin, DNA sequence specificity of damage, **63**, 383, 402
- ecmA* gene
 - extracellular cAMP stimulation, **47**, 21–22
 - mRNA
 - functional analysis, **47**, 8–10
 - induction kinetics, **47**, 6–7
 - promoters, **47**, 10–13
- ecmB* gene
 - extracellular cAMP stimulation, **47**, 21–22
 - mRNA
 - functional analysis, **47**, 8–10
 - induction kinetics, **47**, 6–7
 - promoter, **47**, 10–13, 18–19
 - regulation, **47**, 17–18
- EcoP151*
 - ATP hydrolysis, **64**, 40–41
 - discovery, **64**, 40
 - methylation of DNA, **64**, 43–46
 - mutant analysis, **64**, 45–46
 - recognition sequence, **64**, 40
 - tracking–collision model of cleavage, **64**, 41, 43
- EcoPI*
 - AdoMet requirement and functions, **64**, 32–33
 - ATP hydrolysis, **64**, 37–39
 - helicase requirement, **64**, 38–39
 - host specificity role, **64**, 32
 - methylation of DNA, **64**, 35–37
 - mutant analysis, **64**, 36–37, 39
 - recognition sequence, **64**, 35
 - subunits, **64**, 35
 - transcription of gene, **64**, 33–35
 - translation, **64**, 33–34
- EcoR124I*, mechanism of DNA cleavage, **64**, 23–24
- EcoR124II*, mechanism of DNA cleavage, **64**, 24
- Edatrexate, **67**, 135
 - structure, **67**, 136
- Editing, domain communication in, **69**, 337–341
- EDTA
 - bleomycin analog, **49**, 337–338
 - DNA cleavage by iron complex, **49**, 313, 337
- EDTA-Fe
 - TFO, **67**, 173
- eEF-2, phosphorylation, **58**, 109–110
- EF-1 α , *see* Eukaryotic translation elongation factor 1 α
- EF-1A, frameshift suppression, **64**, 148
- EF-1H, *see* Elongation factor 1H
- EF-Tu, *see* Elongation factor Tu
- Effector kinases, cell cycle control, **72**, 78
- Effector-bound CRP
 - F helices
 - CNA, **67**, 46
- Effector-free CoaA
 - C helix
 - extension/fusion, **67**, 44–45

- Effector-free CoaA (*cont.*)
 F helices
 CNA, **67**, 46
- Efficiency
 aminoacylation, **69**, 325–329
 antisense oligonucleotides, **69**, 6–8
- Egasy
 quality control, **67**, 251
- EGF, *see* Epidermal growth factor
- Egr genes
 cell cycle control in mice, **58**, 66
 identification as immediate-early response genes, **58**, 52
- EGTA, effect on protein translation, **58**, 92–96
- Ehlers–Danlos syndrome
 collagen type-III gene mutations, **47**, 58–59
 mutations of collagen type-I genes, **47**, 43–44
- Eicosanoid
 synthesis, **67**, 27
- Eicosanoids, **45**, 67–69, 93
 cyclooxygenase, **45**, 83–86
 leukotriene A₄ hydrolase, **45**, 81–83
 lipoxygenases, **45**, 69
 5-lipoxygenase, **45**, 69–74
 12-lipoxygenase, **45**, 75–78
 15-lipoxygenase, **45**, 78–81
 prostaglandin-D synthase, **45**, 87–89
 prostaglandin-F synthase, **45**, 89
 prostaglandin G/H synthase, **45**, 83–86
 receptors, **45**, 89–93
 thromboxane-A synthase, **45**, 86–87
- eIF-2 α , phosphorylation
 kinases
 double-stranded RNA-activated protein kinase, **58**, 103–108
 GCN2, **58**, 102
 HRI, **58**, 102–103
 stressor response, **58**, 91–92, 95–97, 101–102
- eIF-2B
 cloning
 α -subunit, **54**, 178–182
 β -subunit, **54**, 182–184
 δ -subunit, **54**, 185–186
 ϵ -subunit, **54**, 188, 190–193
 γ -subunit, **54**, 184–185
 discovery, **54**, 167–168
 regulation
 ϵ -subunit phosphorylation, **54**, 170–172,
 193
 eIF-2 α phosphorylation
 activity effects, **54**, 166
 kinases, activity and cloning, **54**,
 168–169, 172–173, 175, 177–178
 pyridine dinucleotides, **54**, 170, 194
 subunits, yeast, **54**, 171–172
- eIF4A
 biology, **72**, 312–313
 DEAD box sequences role, **72**, 323–324
 helicase activity, **72**, 324–325
 mRNA binding, **72**, 314–315
 original purification, **72**, 308
 other protein effects, **72**, 319–321
 research data inconsistencies, **72**, 321–323
 research overview, **72**, 328–329
 substrate specificity, **72**, 316
 unwinding assay, **72**, 316–321
- eIF5, *see* Eukaryotic translation initiation factor 5
- Elastin-binding protein, complex with sialidase and cathepsin A, **69**, 98–99
- Elav-like proteins, A+U rich element binding, **62**, 285
- Electron microscopy, steroid hormones and, **43**, 9–10
- Electron transport
 complex II, *see* Succinate:quinone oxidoreductase
 methanogenesis, **71**, 231–232
Methanosarcina mazei, **71**, 255
 mitochondria and bacteria, **60**, 268–269
- Electrophoretic mobility shift assay (EMSA)
 TDG, **68**, 242
- Elicitors, jasmonate levels, **72**, 166–167
- ELL, gene translocation in acute myeloid leukemia, **56**, 340–341
- Ellipticine, *see* Topoisomerase II poisons
- Elongation complexes
 early, CTD role, **72**, 349–350
 RNAP II, CTD phosphatase, **72**, 355–357
- Elongation factor 1 α , kirromycin, **71**, 537–538
- Elongation factor 1H
 phosphorylation, **60**, 67–68
 physiological roles
 cell cycle regulation, **60**, 67–68
 compartmentalization of translation machinery, **60**, 68
 storage of elongation factor, **60**, 66

- translation, **60**, 66–67
- subunits
 - functions, **60**, 65–66
 - stoichiometry, **60**, 64
 - structure, **60**, 65–66
- Elongation factor EF-1, aminoacyl-tRNA synthetases and, **40**, 122
- Elongation factor Ts
 - EF-Tu · EF-Ts, **71**, 521
 - EF-Tu folding, **71**, 529–531
- Elongation factor Tu
 - 3D structure, **71**, 517
 - antibiotic target
 - binding sites, **71**, 535–537
 - kirromycin and EF-1 α , **71**, 537–538
 - mode of action, **71**, 532–533
 - overview, **71**, 531–532
 - resistance, **71**, 534–535
 - catalytic domain 1, **71**, 524
 - cooperative interactions, **71**, 539
 - EF-Tu · EF-Ts, **71**, 521
 - folding, EF-Ts role, **71**, 529–531
 - functional overview, **60**, 48, 50–51
 - GTPase, **60**, 56–58
 - GTP/GDP binding, **60**, 51–53
 - hydrophobic gate, **71**, 540–542
 - identification and isolation, **71**, 514
 - magnesium coordination network, **71**, 527–529
 - nucleotide-binding pocket, **71**, 525–527
 - overview, **71**, 517
 - polypeptide elongation, **71**, 514–515
 - posttranslational modification, **60**, 49
 - primary structure, **60**, 49
 - properties and functions, **71**, 515–516
 - regulatory domains 2 and 3, **71**, 525
 - ribosome, **71**, 521–524
 - spatial structure, **60**, 50
 - stoichiometry, **71**, 538–539
 - ternary complex, **71**, 520–521
 - ternary complex formation, **60**, 53–55
- Elongation factors
 - tRNA mimic selection, **70**, 314
 - tRNA variants recognizing, **70**, 323–324
- Elongation factors, modulation of chaperone-like activity of ribosomes, **66**, 57
- Elongation reaction
 - eukaryotic DNA replication, **72**, 72–73
 - transcript, CTD phosphate turnover, **72**, 351–352
 - transcript, CTD phosphorylation link, **72**, 350–351
- Elongation, protein models
 - α - ϵ model, **59**, 184–188, 200–202
 - allosteric three-site model, **59**, 180–182
 - hybrid-site model, **59**, 182–184
 - ribosome shape, determination by scattering
 - angular envelope function, **59**, 191–193, 198
 - coherent scattering, **59**, 190–191
 - comparison with electron microscopy, **59**, 197–199
 - contrast, **59**, 188
 - direct shape restoration, **59**, 192–193
 - hybrid ribosome studies, **59**, 193–194
 - model fitting and nonlinear refinement, **59**, 188–189, 195–197
 - parameter determination, **59**, 189
 - scattering length, **59**, 189–190
 - small-angle scattering intensities from four-phase systems, **59**, 194–195
- steps
 - decoding, **59**, 178–179
 - peptide bond formation, **59**, 178–179
 - translocation, **59**, 178–179
- transfer RNA localization on ribosomes with spin-dependent scattering, **59**, 199–201
- Elongation, translation
 - antibiotic inhibition, **54**, 311–313
 - EF-G cycle, **54**, 308–311
 - EF-Tu cycle, **54**, 306–308
 - elongation factor interactions
 - 1060 region, **54**, 313
 - 30-S subunit, **54**, 315–316
 - sarcin/ricin loop, **54**, 314–315
 - factor-free, **54**, 303–304
 - fidelity, **54**, 300–303
 - kinetics, **54**, 301, 304–305
 - models
 - allosteric three-site, **54**, 297, 300
 - hybrid-sites, **54**, 297–298, 300
 - translocation, **54**, 322–326
 - two-site, **54**, 294–295
 - ribosomal site placement, **54**, 320–322
 - thermodynamics, **54**, 304–305
 - three-dimensional structures of complexes, **54**, 293–294, 316–317, 319–320
- tRNA
 - binding sites, **54**, 294–298

- Elongation, translation (*cont.*)
 orientation on ribosome, **54**, 322–323
- Elongin (SIH)
 regulation by von Hippel–Landau tumor suppressor, **56**, 338, 340
 subunits, **56**, 338
- Embryo
 postimplantation, methylation in, **48**, 69–70
 preimplantation, methylation status of single-copy genes in, **48**, 65–66
- Embryogenesis, DNA methylation during, **48**, 64–70
- EMP-1, *see* Epithelial membrane protein-1
- EMP-2, *see* Epithelial membrane protein-2
- EMP-3, *see* Epithelial membrane protein-3
- EMS
 pol beta-defective cells, **68**, 17
- EMSA
 TDG, **68**, 242
- EMX2, mutation in schizencephaly type II, **64**, 192
- Encapsidation, RNA phage coat proteins and, **40**, 210–211
- End-labeled fragment, determination of sequence specificity of DNA-damaging agents, **63**, 371–372, 376
- Endo G
 mitochondrial, **68**, 295–296
- Endoglucanase, *Pseudomonas fluorescens* subsp. *cellulosa*
 cellulose-binding domain, **61**, 219
 genes, **61**, 218
 structure, **61**, 219
- Endonuclease, **68**, 12
 AP
 eukaryotic, **68**, 264
 DNA
 eukaryotic, **68**, 268
- Endonuclease cleavage, mRNA
 coordinate regulation, **72**, 138–139
 other systems, **72**, 139–142
 site regulation, **72**, 138
- Endonuclease G (Endo G)
 mitochondrial, **68**, 295–296
- Endonuclease III, **68**, 190, 214, 223
 alpha complex, **68**, 232
 beta complex, **68**, 232
 HhH enzyme family, **68**, 323–324
 homologs
 substrate specificity, **68**, 210–215
 protein, **68**, 292–293
 substrate bases, **68**, 190
 Tg, **68**, 216–218
 urea, **68**, 216–218
- Endonuclease IV, **68**, 214, 335–338
 AP site detection, **68**, 337
 crystal structure, **68**, 336
 structure, **68**, 334
- Endonuclease V, T4
 activities, **62**, 156
 base flipping in catalysis, **62**, 170–171
 discovery, **62**, 156
 glutamate-23 role in catalysis, **62**, 167, 169
 N-terminus role in catalysis, **62**, 164, 166–167
 processive nicking activity, **62**, 159–162
 sodium borohydride trapping of intermediates, **62**, 164, 166–167, 172
 transition-state analogs, **62**, 169–170
- Endonuclease VIII, **68**, 190
E. coli, **68**, 198–199
 repair activity, **68**, 215
 substrate specificity, **68**, 199
- Endonuclease, *see also* Fanconi anemia;
 Xeroderma pigmentosum
 electroporation of normal endonuclease complexes into XPA cells, **63**, 290–291, 301
- FA-A and FA-D endonucleolytic incision activity
 correction of repair defects at cellular and molecular levels, **63**, 276–277
 incision of DNA containing psoralen interstrand cross-links and monoadducts, **63**, 274–276, 302
 incision of DNA containing psoralen interstrand cross-links and monoadducts assays, **63**, 264
 characterization of complexes, **63**, 264
 mutagenic agents, **63**, 263
 sites of incision, **63**, 265–267, 269, 271
 incision of DNA irradiated with ultraviolet C light, **63**, 271
 isolation of human DNA endonuclease complexes, **63**, 260, 300–301
 nucleosomal DNA, activity of endonuclease complexes
 correction of XPA defects by normal endonuclease complexes, **63**, 291
 FA-A and FA-D cell endonuclease complex activity, **63**, 289

- mutagens and DNA damage, **63**, 282
- normal endonuclease activity, **63**, 284–287
- reconstituted assay system and mutagenesis, **63**, 282–284
- structure of nucleosomes, **63**, 281–282
- XPA cell endonuclease complex activity, **63**, 287–289
- nucleotide excision repair complexes, **63**, 262–263, 301
- repair defect modeling in XPA cells, **63**, 299–300
- target site localization for repair
 - distributive versus processive mechanisms, **63**, 291, 293, 297–299
 - FA-A endonucleases, **63**, 299, 301
 - normal and XPA endonucleases
 - naked DNA, **63**, 293–294, 296
 - nucleosomal DNA, **63**, 296
 - processive mechanism restoration to XPA endonucleases, **63**, 298–299
 - potassium chloride concentration effects on mechanism, **63**, 296–298
- XPA endonucleolytic incision activity, **63**, 272–273, 302
- Endonucleases, mRNA cleavage, cell stress, **72**, 136–138
- Endoplasmic reticulum (ER)
 - functions, **58**, 84
 - protein folding
 - future perspectives, **67**, 263–264
 - quality control, **67**, 237, 249–252
 - structure, **58**, 83–84
- Endoplasmic reticulum (ER), prohormone processing, **63**, 70
- Endoplasmic reticulum stress response
 - calcium signaling, **58**, 80–81, 84–86, 92–95, 112–113
 - glucose regulated proteins, *see also* GRP78 gene structure, **58**, 86–87
 - types, **58**, 86
 - relationship with heat shock response, **58**, 114–116
- translational accommodation
 - depletion of calcium stores, **58**, 110–111
 - GRP78 role, **58**, 111–112
 - herpes simplex virus 1 infection
 - and translational tolerance, **58**, 115
 - physiological relevance, **58**, 115–116
 - signaling, **58**, 112–113
 - unfolded protein response in yeast, **58**, 88–89
- Endoplasmic reticulum-associated degradation (ERAD), **67**, 243–246
- major histocompatibility class I
 - biogenesis, **67**, 258–259
- regulation, **67**, 245
- Endoplasmic reticulum-Golgi intermediate compartment (ERGIC), **67**, 248
- quality control, **67**, 250
- Endothelin-1, hydrolysis, cathepsin A role, **69**, 87
- Energy conservation, methanogens
 - ATP synthases, **71**, 265–270
- Ech hydrogenase, **71**, 248–249
- F₄₂₀H₂ dehydrogenase, **71**, 249–253
- F₄₂₀-nonreducing hydrogenase, **71**, 246–248
- F₄₂₀-reducing hydrogenase, **71**, 245–246
- formyl-methanofuran dehydrogenase
 - system, **71**, 261–265
- growth, proton translocation, **71**, 256–258
- heterodisulfide reductase, **71**, 253–255
- membrane-bound electron transport systems, **71**, 255
- membrane-bound methyltransferases, **71**, 259–261
- obligate hydrogenotrophic methanogens, **71**, 270–274
- proton-translocating pyrophosphatases, **71**, 258–259
- redox-driven proton dislocation, **71**, 242–245
- sodium ion pump, **71**, 260
- Engrailed homeodomain, in *Drosophila melanogaster*, cocrystal structure, **47**, 224–227
- Enhancement
 - single-copy enhancers and terminators, **50**, 52–54
 - spacer promoters and repetitive enhancers, **50**, 49–51
- Enhancer, replication and, **48**, 265–266
- Enhancers
 - repetitive, **50**, 49–51, 56–57
 - second and third intron, **50**, 166–170
 - second intron, requirement for expression, **50**, 175–179
- Enhancers, prokaryotic, *see* Prokaryotic transcriptional enhancers

- Enhancesome, structure and role in promotion, **50**, 45–49
- Enterobactin, biosynthesis, **70**, 264–265
- Enterotoxins, ADP-ribosylation factors and, **45**, 54–55
- Enzymatic method
 vs. phosphoramidite method, **68**, 210
- Enzyme activation therapy, **69**, 106
- Enzyme evolution
 ATP-binding sites, kinase motifs, types, **53**, 60–63, 71
 gene fusion and multifunctional proteins, **53**, 66–70
 nucleoside monophosphate-binding sites, **53**, 63–66
- Enzyme I, tissue distribution, **70**, 178
- Enzymes
 alcohol-metabolizing, *see* Human alcohol-metabolizing enzymes
 D-lysergyl peptide assembly, **70**, 262–264
 5,6-Dihydropyrimidine adducts and, *see* 5,6-Dihydropyrimidine adducts
 capping, *see* Capping enzyme
 in actinomycin biosynthesis, **70**, 252–253
 purine nucleotide biosynthesis and, **42**, 267–269
 repair of DNA damage and, **40**, 240–242
 switch recombination, cell-type specificity, **50**, 94–95
 triotin assembly, **70**, 257–259
- Enzymes in DNA precursor biosynthesis, **44**, 200
- bacterial cells, **44**, 186–187
- dNTP organization, **44**, 171–177
- dNTP synthesis in eukaryotic cells, **44**, 187
- compartmentation, **44**, 188–196
- DNA replication, **44**, 199–200
- multienzyme aggregates, **44**, 196–198
- replication sites, **44**, 198–199
- organization, **44**, 167–168
- DNA metabolism, **44**, 170–171
- patterns, **44**, 168–170
- replication, **44**, 181–182
- affinity chromatography, **44**, 183–185
- antibodies, **44**, 185–186
- genetic evidence, **44**, 182–183
- T4 dNTP synthetase, **44**, 177
- genetic specificity, **44**, 178–179
- kinetic coupling, **44**, 177–178
- properties, **44**, 179–181
- Enzymes, glycolysis and, *see* 6-Phospho-fructo-2-kinase/fructose-2,6-bisphosphatase
- Enzymes, lens protein and, **41**, 263–265
- Enzymes, protein tyrosine kinase substrates and, **44**, 208, 210
- Enzymology, of homologous recombination, *see* Homologous recombination in *Saccharomyces cerevisiae*
- Epac/cyclic AMP-guanine nucleotide exchange factors, **71**, 414–416
- Eph, Schwann cell regulation, **56**, 233
- Epidermal growth factor
 assays
 HPLC determination of gross structure changes, **49**, 364
 mitogenic potential, **49**, 365
 receptor affinity, **49**, 363
 tyrosine kinase stimulation, **49**, 363–364
 effect on tyrosine kinase domain on receptor, **49**, 354
 gene
 cloning, **49**, 360
 expression in *E. coli*, **49**, 361–362
 site-directed mutagenesis, **49**, 360–361, 365–379
 mutation effects on receptor affinity, **49**, 367–370
 acidic residues, **49**, 366, 371
 aromatic residues, **49**, 373–376
 basic residues, **49**, 370–371
 double-site mutations, **49**, 377–379
 hydrophobic residues, **49**, 372–373, 379
 polar residues, **49**, 376–377, 379
 structural residues, **49**, 377
 purification of recombinant proteins, **49**, 362–363
 sequence conservation between species, **49**, 355–356
 size, **49**, 353
 three-dimensional structure, **49**, 356–358
- Epidermal growth factor (EGF)
 inducible genes in mouse fibroblasts, **58**, 58
 receptor, **58**, 58
- Epidermal growth factor receptor
 assays
 HPLC determination of gross structure changes, **49**, 364
 ligand affinity, **49**, 363
 tyrosine kinase stimulation, **49**, 363–364
 dimerization, **49**, 354

- homology with insulin receptor, **49**, 358
- ligand-binding pocket, **49**, 358–359
- ligand effects on receptor affinity, **49**, 367–370
 - acidic residues, **49**, 366, 371
 - aromatic residues, **49**, 373–376
 - basic residues, **49**, 370–371
 - double-site mutations, **49**, 377–379
 - hydrophobic residues, **49**, 372–373, 379
 - polar residues, **49**, 376–377, 379
 - structural residues, **49**, 377
- sequence conservation between species, **49**, 358
- size, **49**, 353
- tyrosine kinase domain, **49**, 353–354
- Epidermolysis bulbosa, collagen type-VII
 - gene mutation, **47**, 65–66
- Epigenome
 - DNA methylation as component of, **69**, 50
 - reversibility, **69**, 49
- Epimerization domains, **70**, 240–241
- Episomal chromatin, nucleosome positioning and, **40**, 174–175
- Episome formation, DNA sequence
 - amplification in mammalian cells and, **41**, 224–226
- Epithelial ankyrin, **67**, 12
- Epithelial membrane protein-1 (EMP-1)
 - expression levels, **64**, 101–102
 - four transmembrane domain structure, **64**, 98
- functions
 - differentiation, **64**, 112–113
 - growth control, **64**, 112
- gene
 - cloning, **64**, 100–101
 - locus, **64**, 108
 - structure, **64**, 107–108
- glycosylation, **64**, 105
- sequence homology analysis, **64**, 103, 105
- Epithelial membrane protein-2 (EMP-2)
 - expression levels, **64**, 102–103
 - four transmembrane domain structure, **64**, 98
- gene locus, **64**, 108
- sequence homology analysis, **64**, 103, 105
- Epithelial membrane protein-3 (EMP-3)
 - expression levels, **64**, 102–103
 - four transmembrane domain structure, **64**, 98
- gene
 - locus, **64**, 108
 - structure, **64**, 107–108
- sequence homology analysis, **64**, 103, 105
- Epithelium, Muc4/SMC
 - cornea and conjunctiva, **71**, 177–179
 - mucociliary transport, **71**, 163–164
 - oviduct, **71**, 167–170
 - uterus, **71**, 164–167
 - vagina and cervix, **71**, 177
- Epitopes, immunochemical analyses of nucleic acids and, **42**, 45–47, 49–50, 63–64
- Epothilone, biosynthesis, **70**, 279–281
- Epstein–Barr virus, latent viruses and mutated oncogenes and, **43**, 166–167
- ER, **67**, 236–237
 - protein folding
 - future perspectives, **67**, 263–264
 - quality control, **67**, 237, 249–252
- ER, *see* Endoplasmic reticulum
- ER, *see* Estrogen receptor
- Erabutoxin a, functional site elucidation, **59**, 350–351
- ERAD, **67**, 243–246
 - major histocompatibility class I biogenesis, **67**, 258–259
 - regulation, **67**, 245
- ErbB2/HER2/Neu, Muc4/SMC
 - ligand quality, **71**, 157–160
 - tumor progression, **71**, 162
- ErbB2, Muc4/SMC
 - lacrimal gland, **71**, 176
 - localized forms, **71**, 167–170
 - mammary acinar cells, **71**, 170–171
 - ocular protection, **71**, 178–179
 - vagina and cervix, **71**, 177
- ERGIC, **67**, 248
 - quality control, **67**, 250
- Ergopeptides, **70**, 261–264
- ERK
 - docking, PDE4 species, **69**, 286–288
 - MAP kinases, phosphorylation of PDE4 enzymes, **69**, 290–297
- ERKs, *see* Extracellular regulated kinases
- Erp57
 - ER
 - primary quality control, **67**, 246–247
 - major histocompatibility class I, **67**, 258

- Error catastrophe, mutator RT, **71**, 129–130
- Erv14p
 quality control, **67**, 250
- Erythrocyte ghost, antisense oligonucleotide delivery, **57**, 114
- Erythroid ankyrin, **67**, 12
- Erythroid cell
 destabilization of nonglobin messenger RNA, **57**, 256–257
 differentiation, **57**, 250, 253–255
 globin messenger RNA accumulation, **57**, 255–256
 terminally differentiating cells
- Erythropoiesis, and heme synthesis, **51**, 22–34
- Escherichia coli*
 AlkA, **68**, 308–310
 bacterial adenyl cyclases and, **44**, 32–36, 38–44
 cell free extracts
 uracil-initiated BER, **68**, 183
 DNA helicases of, *see* DNA helicases of *Escherichia coli*
 DNA repair, **68**, 9
 EF-Tu isolation, **71**, 514
 EF-Tu properties and functions, **71**, 515
 enzymes in DNA precursor biosynthesis and, **44**, 171–177
 fpg, **68**, 223–233
 cleavage activity, **68**, 228
 enzymes, **68**, 228
 oligonucleotides, **68**, 226–227
 pre-steady-state burst kinetics, **68**, 231
 results, **68**, 228–231
 substrates, **68**, 226–227
 glycogen biosynthesis
 ADPglucose pyrophosphorylase
 allosteric regulation, **47**, 315–319
 catalytic and effector sites, **47**, 319–322
 cloning from mutants, **47**, 324–326
 csrA mapping and characterization, **47**, 311–312
 enzyme induction in stationary phase, **47**, 301
 glgCAP(Y) operon control, **47**, 304–306
 glgC dependence on sigma factors, **47**, 312–314
 integrated model of genetic regulation, **47**, 314–315
 negative genetic control, **47**, 306–307
 transposon mutants, **47**, 307–309
 TR1-5 mutation effects in
 csr/A::kanR, **47**, 309–311
 positive control by genes outside *glg* gene cluster, **47**, 314
 structural genes, localization, **47**, 301–304
 hyper-recombinant mutants, **51**, 278
 lagging-strand DNA synthesis, **51**, 104–105
 msDNA of bacteria and, **40**, 18–19
- MuT
 C-terminal region, **68**, 87
 secondary structure, **68**, 82
- mutator mutants, **68**, 76
- MutM
 8-OH-G, **68**, 107
- MutY
 double-flipping, **68**, 361–362
- nei, **68**, 198–199
- OGG2, **68**, 198–199
- poly A sequences
 degradosome, **71**, 372
 mRNA decay, **71**, 370
 mRNA-degrading RNases, **71**, 370
 overview, **71**, 363–366
 PAP1, **71**, 366–367
 PAP1-stimulated mRNA
 decay, **71**, 370–372
 poly A polymerase gene, **71**, 366
 second gene search, **71**, 372–374
 target RNA decay, **71**, 367–369
- polyadenylation overview, **71**, 362–363
- purine nucleotide biosynthesis and, **42**, 262–264, 267–269
- retrotron
 insertion site, **67**, 72–74
- ribosomal protein synthesis
 alpha operon, **47**, 348–351
 autogenous control, **47**, 336–338
 gene organization, **47**, 332–336
 L10 operon, **47**, 358–359
 L11 operon, **47**, 356–358
 L20 operon, **47**, 361–362
 mRNA elongation, **47**, 340
 mRNA stability, **47**, 340
 rif region, **47**, 355–357
 spc operon, **47**, 353–355
 str operon, **47**, 362–363
 regulatory r-protein-mRNA
 interaction, **47**, 338–339
 S10 operon, L4-mediated regulation, **47**,

- 343–345
 - transcription, **47**, 345–346
 - translation, **47**, 346–348
- S15 operon, **47**, 351–353
 - translation inhibition, **47**, 339–340
- RNA phage coat proteins and, **40**, 185–189
- Tag, **68**, 191
- trp repressor and, **42**, 11–14
- Escherichia coli*, ADP-ribosylation factors and, **45**, 54–55
- Escherichia coli*, mutants, isolation, **50**, 296–298
- Escherichia coli* synthetases, recognition of
 - tRNA and, **41**, 55–57
 - arginine, **41**, 58–60
 - glutamine, **41**, 53–55
 - isoleucine, **41**, 64–65
 - phenylalanine, **41**, 62–63
 - serine, **41**, 51–53
- Escherichia coli*, recognition of tRNA and anticodon, **41**, 30–43
 - complex of glutamine tRNA and glutamine synthetase, **41**, 66–71
- Escherichia coli*, uracil-DNA glycosylase in, **48**, 336–339, 340
- EST3, programmed +1 frameshifting, **64**, 157
- Esterase activity, cathepsin A, **69**, 85
- Estrogen
 - inducible vitellogenin mRNA, **72**, 145–154
 - vitellogenin mRNA stabilization, **72**, 155–156
- Estrogen receptor
 - gene structure
 - DNA binding domain, **59**, 290–291
 - overview, **59**, 290
 - steroid binding domain, **59**, 291
 - transcription
 - autoregulation, **59**, 303–304
 - characterization of 5' flanking region, **59**, 301–303
 - enhancers, **59**, 291
 - promoter types, **59**, 302–303
 - suppressors/repressors, **59**, 292–293
 - trans-acting factors, **59**, 291–292
- Estrogen receptor (ER), karyoskeleton association, **65**, 328–329
- Estrogen receptor, *see* Steroid receptor
- Estrogen receptor, nucleosomal DNA
 - transcription analysis, **61**, 409, 411–412
- Ethanol
 - catabolism, in *A. nidulans*, **69**, 152–156
 - induction of *alc* gene system in presence of, **69**, 172
 - regulon, AlcR role, **69**, 156–167
 - utilization pathway, characteristics, **69**, 151–152
- Ethanol, effects on G protein expression, **47**, 102–105
- Ethanol, retinol dehydrogenation inhibition in fetal alcohol syndrome
 - pathogenesis, **63**, 180–182
- Ethanolamine cytidyltransferase, features, **65**, 375–376
- Ethanolamine kinase, features, **65**, 375
- Ethanolamine phosphotransferase,
 - features, **65**, 376
- Ethenoadenine
 - mitochondrial extracts, **68**, 293–294
- Ethenocytosine, **68**, 244, 249–250
- Ethidium, DNA triplex binding, **59**, 77–79
- Ethyl methanesulfonate (EMS)
 - pol beta-defective cells, **68**, 17
- Ethyl nitrosourea, probing of RNA
 - structure, **53**, 142
- Ethylation, carcinogenic, prevention, **51**, 205–207
- Ethylene, wound response, **72**, 189
- Ethyl nitrosourea, DNA sequence
 - specificity, **63**, 380, 390
- Etoposide, DNA sequence specificity, **63**, 382, 397
- Ets-1, autoregulation of promoter, **60**, 159–160
- Eukarya*
 - characteristics, **71**, 224–225
 - methanogenesis, **71**, 232
- Eukaryotes
 - higher, aminoacyl-tRNA synthetases of, **48**, 83–134
 - lower, branched chain aminotransferases, **70**, 180–181
 - mRNA synthesis, capping enzyme in, **50**, 101–129
 - replication, helicase role, **70**, 85
 - ribosomal transcription in, **50**, 25–66
 - translation initiation in, **48**, 181–228
- Eukaryotes, aminoacyl-tRNA synthetases
 - and, **40**, 97–107
 - biosynthesis, **40**, 128–134
 - composition, **40**, 116–122

- Eukaryotes, aminoacyl-tRNA synthetases and
(*cont.*)
function, **40**, 126–128
hydrophobic interactions, **40**, 122–126
- Eukaryotic AP endonucleases, **68**, 264
- Eukaryotic cell cycle
cyclin-dependent kinases, **72**, 43–45
Dbf4p–Cdc7p kinase, **72**, 45
E2F–pRM cooperation, **72**, 46–48
overview, **72**, 42–43
protein phosphatase 2A, **72**, 45–46
proteolysis at G0–G1 transition, **72**, 49–51
proteolysis at G1–S transition, **72**, 51–52
proteolysis in mitosis, **72**, 52
SBF and MBF, **72**, 48–49
- Eukaryotic cells, enzymes in DNA precursor
biosynthesis and, **44**, 187–200
- Eukaryotic DNA endonucleases, **68**, 268
- Eukaryotic DNA replication
elongation reaction, **72**, 72–73
initiation
Cdc6/Cdc18 protein, **72**, 55–56
Cdt1p, geminin, and Mcm10p, **72**, 56–57
DNA polymerase α -primase, **72**, 65–68
DNA topoisomerase I, **72**, 68–69
G1–S phase transition, **72**, 61–63
Mcm2p–7p complex, **72**, 57–61
origin recognition complex, **72**, 54–55
replication protein A, **72**, 63–65
origins, **72**, 53–54
- Eukaryotic initiation factor 4E, **46**, 183–184,
213–215
activities, **46**, 191
binding to caps, **46**, 191–193
binding to eIF-4A, **46**, 197
binding to 40-S ribosome, **46**,
193–198, 200
alteration of intracellular levels, **46**, 200–201
overexpression, **46**, 201–207
underexpression, **46**, 207–213
mRNA binding to ribosomes, **46**, 186–187
phosphorylation, **46**, 197, 199, 201
regulation of initiation, **46**, 184–185
structure, **46**, 188–191
- Eukaryotic translation elongation factor 1 α
ATPase, **60**, 59–60
channelling of aminoacyl-tRNA, **60**,
62–64, 72
EF-1 α $\beta\gamma\delta$ complex, *see* Elongation factor 1H
functions
cytoskeletal reorganization, **60**, 70–71
transcription, **60**, 71
translation, **60**, 48, 50–51
ubiquitin-dependent proteolysis, **60**, 72
gene expression and regulation, **60**, 68–69
- GTPase
aminoacyl-tRNA binding, effect on
activity, **60**, 57–58
monovalent ions, effect on activity,
60, 58
ribosome binding effects, **60**, 57–60
posttranslational modification, **60**, 49
primary structure, **60**, 49
spatial structure, **60**, 50
ternary complex formation, **60**, 54–56
- Eukaryotic translation initiation
alternative translations, **72**, 377–378
cap-dependent scanning, **72**, 4–5
internal initiation, **72**, 6
IRESs in cellular mRNAs, **72**, 374–376
IRESs in viral mRNAs, **72**, 372–374
leaky scanning, **72**, 5
reinitiation, **72**, 6
ribosome shunt, **72**, 376–377
scanning model, **72**, 371–372
shunting, **72**, 6
viral vs. cellular IRESs, **72**, 376
- Eukaryotic translation initiation factor 2
 β subunit, **70**, 219–223, 228
 ϵ subunit, **70**, 228
 γ subunit, **70**, 225–227
- Eukaryotic translation initiation factor 5
as 50-kDa monomeric protein, **70**, 210–212
as GTPase protein, **70**, 218–219
as translation initiation factor, **70**, 216–217
cDNA cloning, **70**, 215–216
GTP hydrolysis, **70**, 229–230
GTPase-activating protein function
eIF2 β subunit binding, **70**, 219–223
eIF2 γ subunit, **70**, 225–227
N-terminal region role, **70**, 223–225
in 80S ribosomal initiation complex
function, **70**, 212–215
protein–protein interactions, **70**, 228
yeast substitution, **70**, 217
- Evolution
alcohol dehydrogenase and, **40**, 268–269
binding properties of aminoacyl-tRNA
synthetases and, **40**, 107–116
lysyl oxidase genes, **70**, 7–8

- mitochondrial biogenesis in *Saccharomyces cerevisiae* and, **46**, 81–82
 - msDNA of bacteria and, **40**, 20–21
 - of protamine genes, **40**, 45–46
 - detailed alignments, **40**, 46
 - dot-matrix sequence analysis, **40**, 46–50
 - protamines and, **40**, 85
 - pyruvate dehydrogenase phosphatase
 - isoforms, **70**, 54–55
 - superoxide dismutases and, **40**, 230–233, 235
 - hybridization, **40**, 233
 - iron, **40**, 233–234
 - manganese, **40**, 233–234
 - yeast double-stranded RNAs and, **46**, 179
 - Evolution, ribosomal genes, **50**, 28–33
 - EXFAS, *see* Extended X-ray absorption fine structure
 - Exons, calcium-dependent animal lectins and, **45**, 218–220
 - Exons I, determination of transferase structural diversity, **51**, 319–324
 - Exon skipping model, calcitonin/CGRP pre-mRNA, **71**, 338–339
 - Exons, *PDE4* genes, **69**, 263–266
 - Exons, poly A sites
 - 3' noncoding exons, **71**, 336–337
 - calcitonin/CGRP pre-mRNA, **71**, 337–341
 - immunoglobulin heavy-chain pre-mRNA, **71**, 341–347
 - 5'-to-3' Exonuclease
 - in reconstitution, **51**, 105–107
 - role in Okazaki fragment processing, **51**, 110–112
 - substrate specificity, **51**, 107–108
 - Exonuclease, DNA polymerase II and catalytic subunit, **46**, 105–109
 - genetics, **46**, 110–112
 - Exoribonuclease
 - chloroplast degradosome complex, **66**, 92
 - chloroplast poly(A) polymerase complex, **66**, 93
 - classification, **66**, 71
 - degradosome from *Escherichia coli*, **66**, 91–92
 - differences between prokaryotes and eukaryotes, **66**, 95
 - Escherichia coli* enzymes and genes, **66**, 68–70
 - exosome, **66**, 93–94
 - functional redundancy, **66**, 70, 94
 - mtEXO complex, **66**, 94
 - novel ribonucleases awaiting classification, **66**, 89–91
 - organisms for study, **66**, 68
 - ExPaSy, **67**, 14
 - Expert Protein Analysis System (ExPaSy), **67**, 14
 - Expressed sequence tags, identification of
 - G protein receptors, **49**, 147
 - Expression patterns
 - ROR α mRNA, **69**, 208–209
 - ROR β mRNA, **69**, 209–210
 - ROR γ mRNA, **69**, 210–211
 - Expression profiles, Mbds, **69**, 52
 - Expression tool, heterologous, *alc* system as, **69**, 192–195
 - Extended X-ray absorption fine structure (EXFAS)
 - Ace1, **58**, 178–180
 - Amt1, **58**, 178–180
 - Cup1, **58**, 180
 - Extracellular matrix, role in peripheral nervous system development, **56**, 233–235
 - Extracellular regulated kinases, ERK2, **71**, 79
- F**
- FLP* recognition target, *see* FRT site
 - F₄₂₀-nonreducing hydrogenase
 - methanogens, **71**, 246–248
 - Methanothermobacter* strains, **71**, 271–273
 - F₄₂₀-reducing hydrogenase, methanogens, **71**, 245–246
 - F₄₂₀H₂ dehydrogenase, methanogens, **71**, 249–253
 - F₄₂₀H₂:heterodisulfide oxidoreductase
 - Methanosarcina mazei*, **71**, 242–243
 - proton translocation, **71**, 256
 - FA, *see* Fanconi anemia
 - Facilitates chromatin transcription (FACT), **67**, 97
 - FACT, **67**, 97
 - Family-A DNA polymerase, **68**, 266
 - Fanconi anemia (FA)
 - clinical features, **63**, 211, 259
 - complementation groups, **63**, 259
 - damage-recognition proteins in FA-A cells, **63**, 280–281

- Fanconi anemia (FA) (*cont.*)
 diagnosis, **63**, 211–212
 DNA repair defects compared to xeroderma pigmentosum, **63**, 259–260
 FA-A and FA-D endonucleases
 incision activity
 correction of repair defects at cellular and molecular levels, **63**, 276–277
 incision of DNA containing psoralen interstrand cross-links and monoadducts, **63**, 274–276, 302
 nucleosomal DNA activity, **63**, 289
 target site localization for repair, FA-A endonucleases, **63**, 299, 301
 gene defects, **63**, 212–213, 259
 prevalence, **63**, 211
- Farnesyl transferase (FT), **67**, 220
- FAS, *see* Fatty acid synthase
- Fasciculin, functional site elucidation, **59**, 351
- FasL, gene expression, **69**, 238
- Fat synthesis, *see also* Fatty acid synthase;
 Glycerol-3-phosphate acyltransferase
 enzymes, **60**, 318
 gene regulation by nutrients and hormones, overview, **60**, 318–319
- Fatty acid
 chick model and synthesis, **52**, 90–91
 malic enzyme gene regulation, **52**, 92, 104–108, 119–120
 nutritional state and synthesis, **52**, 90
- Fatty acid synthase
 active sites and activities, **60**, 319
 gene cloning, **60**, 319
 gene regulation by insulin
 insulin response sequence
 identification and characteristics, **60**, 322–325
 USF binding, **60**, 326–328
 quantitative response, **60**, 320
 transgenic mouse model, **60**, 320–321
 suppression by polyunsaturated fatty acids, **60**, 321–322
- Fatty acid, β -oxidation
 enzymes, *see* Medium-chain acyl-CoA dehydrogenase
 mitochondria pathway, **58**, 310
- Fatty acids
 pyruvate dehydrogenase complex role, **70**, 43
 pyruvate dehydrogenase kinase effect, **70**, 54
- Feedback effect, steroid hormones and, **43**, 20–21
- FEN1. *See* Flap endonuclease 1
- Fenton-type reactions
 DNA damage, **68**, 208
- Ferredoxin–NADP⁺ reductase (FNR),
 flavin-binding site, **65**, 141, 143
- Ferritin
 cytokine-responsive RNA in 5'-untranslated region, **55**, 126–127
 iron-responsive element
 augmentation by iron-responsive mRNA open reading frame sequences, **55**, 127–129, 131
 role in iron induction, **55**, 122–124, 131
 iron-responsive proteins
 hydrogen peroxide effects, **55**, 125–126
 iron response, **55**, 124
 nitric oxide effects, **55**, 125
 phosphorylation of IRP-1, **55**, 126
 role in iron induction, **55**, 122–123
 role in disease, **55**, 121
- Ferritin, transcripts encoding, translational regulation, **48**, 198–199
- Fetal alcohol syndrome, retinol
 dehydrogenation inhibition in pathogenesis, **63**, 180–182
- FGAM synthetase, purine nucleotide biosynthesis and, **42**, 282
- FGF-1, *see* Fibroblast growth factor-1
- FGF-2, *see* Fibroblast growth factor-2
- FGF, *see* Fibroblast growth factor
- FGFRHS, *see* Fibroblast growth factor receptor heparan sulfate
- FGFR TK, *see* Fibroblast growth factor receptor tyrosine kinase
- Fibrillar, arginine methylation, **61**, 89, 91, 105–106
- Fibrillar, role in RNA processing, **49**, 218–219, 223
- Fibroblast growth factor, **70**, 156–157
- Fibroblast growth factor (FGF)
 extraction from receptor complexes, **59**, 152
 heparin-binding domain, **59**, 151–152
 hepatocytes
 abnormalities in hepatoma cells, **59**, 164–166
 normal cell properties, **59**, 166–167
 resting cell properties, **59**, 167–168

- homologous factors and sequences, **59**, 136, 140
- nomenclature of peptides, **59**, 136–137
- prostate
 - proliferation role
 - normal cells, **59**, 168–173
 - PAP tumors, **59**, 170–171
 - receptor isoforms in malignant tumors, **59**, 172–173
 - tumor progression model, **59**, 173
- receptor dimer–ligand ternary complex
 - conformational models, **59**, 159–163
 - fibroblast growth factor receptor tyrosine kinase ectodomain and growth factor binding, **59**, 157–158, 164
 - modeling of structure, **59**, 155–157
 - mutation studies, **59**, 159–164
 - phosphorylation role, **59**, 158–161
- sequences, **59**, 136, 138–139, 142
- signal sequences, **59**, 142
- three-dimensional structures of FGF-1 and FGF-2, **59**, 142–143
- Fibroblast growth factor (FGF), Schwann cell regulation, **56**, 229
- Fibroblast growth factor-1
 - expression in human gliomas, **70**, 161–162
 - gene cloning, **70**, 159
 - in cancer, **70**, 157
 - in infarction, **70**, 157–158
 - in neural development, **70**, 158
 - promoters
 - differential responses, **70**, 167
 - GTPase effect, **70**, 167–168
 - serum response element, **70**, 167–168
 - tissue-specific expression, **70**, 158–159
- Fibroblast growth factor-1 (FGF-1)
 - inducible genes in mouse fibroblasts, **58**, 59–60
 - receptor and signal transduction, **58**, 42, 59
- Fibroblast growth factor-1.B
 - adult neural stem cell genesis, **70**, 171
 - gene expression mechanisms, **70**, 171–172
 - mRNA, *in situ* hybridization, **70**, 160–161
 - promoters
 - cis*-regulatory elements, **70**, 162
 - transgenic mouse tumors, **70**, 170–171
- Fibroblast growth factor 2
 - IRES-binding *trans*-acting factors, **72**, 391
 - isoform localization, **72**, 385
 - isoform modes of action, **72**, 385–386
 - isoforms in transformed and stressed cells, **72**, 390–391
 - mRNA CUG start codons, **72**, 383–385
 - mRNA expression control, **72**, 392–393
 - mRNA IRES identification, **72**, 387–390
 - survival factor-like isoform, **72**, 386–387
 - translation regulation, **72**, 387
 - translational silencing by p53, **72**, 400–403
- Fibroblast growth factor-2 (FGF-2), action
 - modification by syndecan-1, **63**, 112–113, 133–134
- Fibroblast growth factor-inducible response element (FiRE), syndecan-1 gene autoregulatory loop between fibroblast growth factors and syndecan-1, **63**, 133–134
- cell specificity of regulation, **63**, 123–124
- cross-linking with binding proteins, **63**, 121
- developmental regulation, **63**, 130–131
- discovery, **63**, 118–120
- DNase I footprinting studies, **63**, 120–121
- keratinocyte activation in wound healing
 - delay in activation, **63**, 131
 - growth factor receptor inhibitor studies, **63**, 126–127
 - signal transduction of growth factor receptors, **63**, 127, 130–132
 - transgenic mouse models, **63**, 124–126
- mutagenesis of protein-binding sites, **63**, 124
- specificity for fibroblast growth factors and mechanisms, **63**, 121–122, 128–130
- transcription factor antibodies in gel-retardation assays, **63**, 121
- fibroblast growth factor receptor
 - complex
 - fibroblast growth factor receptor heparan sulfate binding, **59**, 154–155
 - genes, **59**, 136, 143
 - hepatocytes
 - normal cell properties, **59**, 166–167
 - receptor abnormalities in hepatoma cells, **59**, 164–166
 - resting cell properties, **59**, 167–168
 - isoforms and structures, **59**, 136, 141, 143–151
 - juxtamembrane domains, **59**, 149
 - kinase domain, **59**, 149–151
 - mutations in disease, **59**, 159, 161, 163
 - prostate

- fibroblast growth factor receptor
 complex (*cont.*)
 isoforms in malignant tumors, **59**,
 172–173
 proliferation role
 normal cells, **59**, 168–173
 PAP tumors, **59**, 170–171
 tumor progression model, **59**, 173
 receptor dimer–ligand ternary complex
 conformational models, **59**, 159–163
 fibroblast growth factor receptor tyrosine
 kinase ectodomain and growth factor
 binding, **59**, 157–158, 164
 modeling of structure, **59**, 155–157
 mutation studies, **59**, 159–164
 phosphorylation role, **59**, 158–161
 signal transduction overview, **59**, 136–137,
 141–142, 150
 transmembrane domain, **59**, 149
- Fibroblast growth factor receptor heparan
 sulfate (FGFRHS)
 assembly of fibroblast growth factor receptor
 dimeric complex, **59**, 155–156
 fibroblast growth factor binding, **59**, 154
 fibroblast growth factor receptor tyrosine
 kinase binding and divalent cation
 requirement, **59**, 154–155
 receptor dimer–ligand ternary complex
 conformational models, **59**, 159–163
 fibroblast growth factor receptor tyrosine
 kinase ectodomain and growth factor
 binding, **59**, 157–158, 164
 modeling of structure, **59**, 155–157
 mutation studies, **59**, 159–164
 phosphorylation role, **59**, 158–161
 signal transduction overview, **59**, 136–137,
 141–142
- Fibroblast growth factor receptor tyrosine
 kinase (FGFR TK)
 assembly of fibroblast growth factor receptor
 dimeric complex, **59**, 155–156
 autophosphorylation sites, **59**, 149–150
 carboxy-terminal tail, **59**, 151
 extracellular domain
 amino-terminal loop I and FGFR_p
 isoform, **59**, 144–145
 interloop I/II acidic box, **59**, 145–146
 interloop II/III and loop II as secondary
 FGF binding sites, **59**, 146–149
 invariant loop II as binding site, **59**, 146
 fibroblast growth factor binding, **59**,
 146–149, 152–154
 Fibroblasts, PRS isoform levels, **69**, 142–143
- Fidelity, retroviral transcriptase
 accessory proteins, **71**, 110–112
 amino acid role, **71**, 127–128
 Arg-72, **71**, 120–121
 assays *in vitro*, **71**, 99–100
 enhanced fidelity, **71**, 129
 genetic assays, **71**, 105–108
 Gln-151, **71**, 119–120
 Lys-65, **71**, 120–121
 Met-184, **71**, 117–119
 minor groove binding track residues,
 71, 126
 misinsertion fidelity assay, **71**, 100–103
 mispair extension fidelity assay, **71**,
 103–104
 mutation rate variations, **71**, 130–131
 mutational analysis overview, **71**, 112–113
 mutator, error catastrophe, **71**, 129–130
 pre–steady-state kinetic assays, **71**, 104–105
 primer grip residues, **71**, 124–126
 strand transfer, **71**, 109–110
 template strand residues, **71**, 121–123
 transcription initiation, **71**, 108–109
 Tyr-115, **71**, 114–117
 Tyr-183, **71**, 123–124
- Filter binding, nuclear RNA-binding proteins
 and, **41**, 182–184
- FIP1 gene, yeast mRNA 3' end-processing
 factor, **71**, 360–361
- Fisp-12/connective tissue growth factor,
 identification as immediate-early response
 gene, **58**, 51
- Fission yeast, cyclin-dependent kinases, **72**,
 43–44
- Fit-1, identification as immediate-early
 response gene, **58**, 55
- FixL, **67**, 41
- FKHL7, mutation in iridogoniodysgenesis type
 1, **64**, 197
- FkpA, function, **66**, 139
- Flap endonuclease 1 (FEN1), **68**, 125, 129,
 131, 146–147, 287
 long-patch BER, **68**, 338–342
 PCNA, **68**, 132
 structure, **68**, 340
- Flower development, jasmonates and
 octadecanoids, **72**, 198–200

- Flp
 as reagent for chromosome engineering, **51**, 86–87
 as site-specific recombinase, **51**, 57–62
 function, **51**, 55
 mechanism of action, **51**, 62–86
 mediated recombination, **51**, 59–62
 resolution of synthetic χ -structures, **51**, 81–83
 structure and function, **51**, 84–86
- Fluorescein dyes
 structure, **67**, 102
- Fluorescein-modified nucleoside
 chemical structure, **67**, 103
- Fluorescence energy transfer, structural elements in RNA and, **41**, 165
- Fluorescence quenching, nuclear RNA-binding proteins and, **41**, 184
- Fluorescence resonance energy transfer (FRET), oligonucleotide hybridization analysis, **57**, 108
- 5-Fluorodeoxycytidine, effect on DNA methylation pattern, **49**, 98–99
- 5-Fluorouracil (5-FU)
 recombinant human TDG, **68**, 245
- 5-Fluorouracil, degradation, **53**, 51–52
- FMRP, ribonucleoparticle association, **72**, 257
- FNR, *see* Ferredoxin–NADP⁺ reductase
- Focal adhesion, protein tyrosine kinase substrates and, **44**, 217–220
- Folate
 antagonists, **67**, 133–138
 cancer therapy, **67**, 135–138
 metabolism, **67**, 133–138
 natural
 metabolic roles, **67**, 133–135
- Folic acid
 structure, **67**, 136
- Fomivirsen, FDA-approved
 oligonucleotide, **69**, 8
- Footprinting, procapsid-bound pRNA, **72**, 447
- Force fields, modeling DNA structures and empirical fields, **43**, 89–92
 use, **43**, 92–102
- Forkhead, DNA-binding domain, **64**, 175
- Formamidopyrimidine N-glycosylase (fpg), **68**, 77, 232
 beta-elimination products, **68**, 228–230, 233
Escherichia coli, **68**, 223–233
 homologs, **68**, 215–216
- K155A mutant
 oligonucleotides, **68**, 231
 transient kinetics assay, **68**, 231
- K57A mutant
 oligonucleotides, **68**, 231
 oxidative pyrimidine products, **68**, 223
 protein, **68**, 77
- Formate, methanogenesis, **71**, 234–235
- 5-Formyl tetrahydrofolate
 structure, **67**, 136
- Formyl-methanofuran dehydrogenase system, *Methanosarcina*, **71**, 261–265
- N-Formyl-peptide receptor, ligand binding site, **49**, 129
- 5-Formyl tetrahydrofolate structure, **67**, 136
- 5-Formyluracil, **68**, 208
- Forskolin, activation of adenylyl cyclases, **49**, 262
- Fos transcription factor, structure and recognition sequence, **47**, 236–237
- Fos, autoregulation of promoter, **60**, 153
- Fos-B*, cell cycle control in mice, **58**, 65
- fos*, serum-positive promoter assays for mRNA decay, **56**, 259–260
- Fourier transform infrared spectroscopy (FTIR)
 pyr*pur•pyr triplex, **59**, 76
 rhodopsin, light-induced conformational change, **59**, 14–15, 19, 23–24, 29
- Fpg. *See* Formamidopyrimidine N-glycosylase
- FR-1, identification as delayed-early response gene, **58**, 60
- Fractionation, cleavage/polyadenylation protein nuclear extract, **71**, 305–308
- Fragile X syndrome, trinucleotide repeat expansion, **66**, 163, 167
- Fragile XE mental retardation, trinucleotide repeat expansion, **66**, 163, 167
- Fragment 461N, AlaRS, **69**, 321–322
- Frameshifting
 amino acid limitation, induction of spontaneous frameshifting, **64**, 152–153
 class 1 frameshifts
 definition, **64**, 150
 functions, **64**, 151
 class 2 frameshifts
 definition, **64**, 150
 functions, **64**, 151–152
 class 3 frameshifts
 definition, **64**, 150–151

- Frameshifting (*cont.*)
- functions, **64**, 152
 - efficiency of programmed events, **64**, 150
 - HIV-1 *gag-pol* signal, **69**, 19
 - hopping, **64**, 160–162, 164
 - HTLV-I *gag-pro* hairpin, **69**, 21
 - overview, **64**, 149–150
 - programmed –1 frameshifting
 - peptidyltransferase site role, **64**, 160
 - RNA secondary structure, **64**, 159–160
 - Rous sarcoma virus, **64**, 158–159
 - programmed +1 frameshifting
 - examples, **64**, 153
 - ornithine decarboxylase antienzyme system, **64**, 157–158
 - prfB* mechanism, **64**, 154–155
 - Saccharomyces cerevisiae* mechanisms
 - ABP140*, **64**, 157
 - EST3*, **64**, 157
 - Ty1, **64**, 155–156, 163
 - Ty3, **64**, 156–157
 - retroviral, **69**, 3
 - suppression by proteins
 - EF-1A, **64**, 148
 - L7/L12, **64**, 147–148
 - overview, **64**, 146–147
 - S12, **64**, 147
 - suppression by ribosomal RNAs, **64**, 148–149
 - suppression by transfer RNAs
 - examples, **64**, 138–139
 - methylation patterns, **64**, 143–144
 - missing suppressors in modeling, **64**, 142, 164
 - overview, **64**, 135–136
 - peptidyl-transfer RNA slippage, **64**, 144–145, 163–164
 - quadruplet translocation model, **64**, 136–137, 140–141, 165
 - structures, **64**, 142–143
 - SUF5*, **64**, 165
 - sufA6*, **64**, 137, 140
 - sufB2* mutants, **64**, 144–146, 163
 - sufD42*, **64**, 136–137
 - suff128*, **64**, 140
 - sufT621*, **64**, 140
 - synthesis of alternative decoding events, **64**, 162–166
- FRE1*, repression by copper, **58**, 188–189
- FRET, *see* Fluorescence resonance energy transfer
- Friedreich's ataxia, trinucleotide repeat expansion, **66**, 163, 168, 185
- FRT site
 - asymmetry in, **51**, 60–61
 - half-, *see* Half-FRT site
- Fructose-2,6-bisphosphatase, *see* 6-Phospho-fructo-2-kinase/fructose-2,6-bisphosphatase
- FT, **67**, 220
- FTIR, *see* Fourier transform infrared spectroscopy
- ftz, autoregulation of promoter, **60**, 160, 162
- 5-FU
 - recombinant human TDG, **68**, 245
- FUM1*, *see* Fumarase, yeast
- Fumarase, yeast
 - cellular compartmentation and signal sequence, **57**, 334–335
 - gene, **57**, 334
 - structure, **57**, 334
- Functional domains, **70**, 2–3
- Fungi
 - filamentous, CreA homologs in, **69**, 179–180
 - metabolic pathways and gene clustering, **69**, 190
- Fungi, chromopeptide lactones, **70**, 244–246
- Furin
 - domain structure, **63**, 71–72
 - proteolytic processing, **63**, 74, 80
- FV3 ribonuclease, properties, **52**, 40
- G**
- G-box motif, plant regulatory proteins, **47**, 249–250
- G protein
 - binding sites in receptors, **49**, 130–136
 - GTP binding, **49**, 114–115
 - organization in plasma membrane, **49**, 115
 - receptors, *see* G protein receptors
 - second messenger amplification, **49**, 115
 - signal transduction, **49**, 114–115
 - subunits, **49**, 130
- G protein-coupled receptor, *see* Rhodopsin
- G protein receptors
 - α_2 -adrenergic receptors, **49**, 141
 - β -adrenergic receptors, **49**, 121–124, 131–133, 137–141

- binding sites
 - agonists, **49**, 121–129
 - G protein, **49**, 130–136
- constitutive activation, **49**, 135–136
- defects in disease, **49**, 134–135
- desensitization, **49**, 136–143
- down-regulation, **49**, 140–143
- G protein
 - induction of conformational change, **49**, 135–136
 - specificity, **49**, 130–131
- gene
 - cloning, **49**, 147
 - number in humans, **49**, 147
- identification using expressed sequence tags, **49**, 147–149
- interleukin-8 receptor, **49**, 129
- muscarinic acetylcholine receptors, **49**, 124–125, 133–134, 141–143
- N-formyl-peptide receptor, **49**, 129
- organization in plasma membrane, **49**, 115, 118, 121
- phylogenetic analysis, **49**, 148–149
- sequence homology, **49**, 116–117, 119, 130
- serotonin receptors, **49**, 125–126
- structure, **49**, 116–118, 120–121
- subfamilies, **49**, 118, 120
- subunits, **49**, 114–115
- tachykinin receptors, **49**, 127, 129
- thyrotropin-releasing hormone receptor, **49**, 129
- types, **49**, 115–117
- G proteins
 - α subunit
 - functions, **47**, 86–88
 - structure, **47**, 82–86
 - altered expression, **47**, 101–105
 - altered function, clinical implications, **47**, 93–94
 - β subunit, structure, **47**, 88–90
 - β_3 subunit, tissue distribution, **47**, 92–93
 - $\beta\gamma$ dimers, function, **47**, 90–92
 - mutations
 - Albright hereditary osteodystrophy, **47**, 95–97
 - analytical methods, **47**, 94–95
 - $G_s\alpha$ protein
 - expression in Albright hereditary osteodystrophy, **47**, 97–100
 - genetic studies, **47**, 94
 - McCune–Albright syndrome, **47**, 100–101
 - sporadic endocrine neoplasia, **47**, 100
- G-T mismatch correction
 - TDC, **68**, 247–248
- G.A, *see* Guanosine–adenosine base pair
- G.U, *see* Guanosine–uridine base pair
- G_{M1} -ganglioside β -galactosidase, *see* β -Galactosidase
- G_{M1} -gangliosidosis, **69**, 83
 - spectra of storage products, **69**, 100
- G0–G1 transition, proteolysis, **72**, 49–51
- G1–S transition
 - Cdc45 protein, **72**, 61–63
 - proteolysis, **72**, 51–52
- G3:U70, base pair in AlaRS, **69**, 320–321, 326–327
- Gabapentin, branched chain aminotransferase specificity, **70**, 199–201
- GAF domains, PDE isoenzymes, **69**, 255–258
- Gag–Pol translation, retroelement, **72**, 10–12
- Gag–Pol, retroviral RT, **71**, 94
- GAL, *see* β -Galactosidase
- GAL
 - chromatin structure in induced state
 - coding regions
 - DNase I digestion, **65**, 240–241
 - micrococcal nuclease digestion, **65**, 239, 241
 - nucleosome conformational changes and rearrangement, **65**, 239–242
 - digestion profiles versus patterns, **65**, 223–224
 - disruption mutants, **65**, 223
 - promoter regions
 - Gal4p-dependent disruption, **65**, 233–234
 - GAL80 nucleosome disruption, **65**, 237–239
 - Gal80p-dependent nucleosome deposition, **65**, 234, 236, 280–281
 - metabolic competence and nucleosome disruption/deposition, **65**, 236–237
 - chromatin structure in uninduced state of
 - promoter region
 - digestion profiles versus patterns, **65**, 223–224
 - disruption mutants, **65**, 223
 - hypersensitive region
 - constitutive UAS_G accessibility, **65**, 231–232

GAL (*cont.*)

- DNase I cleavage, **65**, 224–228
- factors keeping region free of nucleosomes, **65**, 228–230
- regulatory GAL genes, **65**, 224
- intracore ladder patterns, **65**, 228
- nucleosome covering of coding regions, **65**, 228
- nucleosome positioning, footprinting analysis, **65**, 230–231
- upstream region nucleosomes and basal repression, **65**, 232–233
- chromosomal architecture of promoter regions in induced state
- circular permutation analysis, **65**, 242–243
- higher-order structure, **65**, 245–246
- intrinsic DNA structure, **65**, 242–245
- Gal4
 - functions, overview, **65**, 264
 - transcriptional activation, **65**, 289
- Gal4p in transcriptional activation
 - coactivator utilization, **65**, 247
 - cooperating factors and processes, **65**, 253–254
 - nucleosome disruption, **65**, 233–234
 - nucleosome removal from TATA site, **65**, 249–250
 - protein interactions, **65**, 246–247
 - protein mutagenesis studies, **65**, 247–248
 - RNA polymerase II recruitment, **65**, 247
 - TATA-binding protein interaction, **65**, 246
- histone role in gene regulation, **65**, 248–249, 252–253
- history of study, **65**, 214
- nucleosome binding dynamics in gene regulation, **65**, 250–254
- regulatory genes
 - regulation of expression
 - comparison with structural gene induction, **65**, 222–223
 - GAL3 as galactose signal transducer, **65**, 222
 - GAL4 promoter, **65**, 220–221
 - GAL80 dual promoters, **65**, 221–222
 - types, **65**, 215
- structural genes
 - regulation
 - activation steps, **65**, 219–220
 - comparison with regulatory gene induction, **65**, 222–223
 - galactose induction, **65**, 216–217
 - glucose repression, **65**, 218–219
 - glycerol/lactate and poisoning for expression, **65**, 217–218
 - types, **65**, 215
- GAL4 transcriptional factor, structure and recognition sequence, **47**, 233–234
- GAL4, autoregulation of promoter, **60**, 156
- Gal4p, DNA-binding domain, **69**, 166–167
- Galactan, structure and degradation, **61**, 215, 217
- Galactanase A, *Pseudomonas fluorescens* subsp. *cellulosa*
 - catalytic mechanism, **61**, 238–239
 - overview, **61**, 222
- Galactosialidosis, **69**, 83
 - storage products, **69**, 102
- β -Galactosidase
 - activity and structure, **69**, 88–90
 - complex with cathepsin A, **69**, 97–98
 - features, **69**, 87–88
 - precursor, **69**, 103
 - synthesis and function, **69**, 90
- β -Galactosidosis, GM1-gangliosidosis, **69**, 100
- Galectin, expression in cartilage hypertrophy, **60**, 105–106
- galK operon, mRNA decay mechanisms, **52**, 175
- GALNS
 - features and specificity, **69**, 95–96
 - structure and function, **69**, 96
- Gametogenesis, methylation changes during, **48**, 68–69
- Gamma-irradiated human cells
 - thymine glycol, **68**, 139–148
- Gamma-LIZ shuttle vector, **68**, 69
- Gamma ray, DNA sequence specificity of damage, **63**, 383, 400
- γ -Globin, messenger RNA destabilization, **57**, 260–261
- Γ -globulin
 - upregulation, **67**, 179
- Gangliosides, sialylated, hydrolysis, **69**, 91–92
- Gap-filling synthesis, **68**, 156
- GAP, *see* GTPase-activating proteins
- GAPs, **67**, 194
- GAPs, *see* GTPase-accelerating proteins
- GAR synthetase, purine nucleotide biosynthesis and, **42**, 274–276

- GAR transformylase, purine nucleotide biosynthesis and, **42**, 274–276
- GARP, *see* Glutamic acid-rich proteins
- Gas chromatography/mass spectrometry (GC-MS), **68**, 140
- GAS6, Schwann cell regulation, **56**, 232
- GATA-1, autoregulation of promoter, **60**, 158–159, 162
- Gaucher disease, *see* Acid β -glucosidase
- Gaussian network model, **69**, 334
- GC-MS, **68**, 140
- GCGG motif, interacting, **69**, 161, 163
- GCN2, eIF-2 α phosphorylation, **58**, 102
- GCN2, phosphorylation of eIF-2 α , **54**, 169
- GCN4 transcriptional factor, yeast, structure and recognition sequence, **47**, 239–240
- GCN4, amino acid control of gene expression, **53**, 221, 223–226
- GCN4, in translational regulation, **48**, 194–197
- GCSA, *see* Gross cell surface antigen
- GDI, **67**, 194
- GE2270 A
EF-Tu, **71**, 532–533
EF-Tu binding sites, **71**, 535–536
EF-Tu resistance, **71**, 535
- GEF, *see* Guanine nucleotide exchange factors
- GEFs, **67**, 194
- Gel electrophoresis
detection of DNA bending in Cro protein-O₃ complex, **47**, 206–209
mobility shift assay for pol δ -PCNA-template-primer complex, **47**, 393–394
- Gel mobility-shift assay
A+U rich elements, trans-acting factor identification, **62**, 264–265, 280
pyr messenger RNA binding by PyrR, **62**, 353, 355
- Geminin, chromatin binding, **72**, 56–57
- Gene conversion, immunoglobulin gene diversification by, *see* Immunoglobulin gene diversification
- Gene economy, reverse-transcribing elements, **72**, 2–4
- Gene expression
adenoviral DNA integration and, **46**, 30–32
alc, **69**, 153–154, 189
alcR, control of, **69**, 181–183
BER factors, **68**, 21–23
cell-free, prospects, **51**, 225–270
FasL, **69**, 238
growth suppressor, DNMT1 regulation of, **69**, 62–63
immediate-early, early, and late, HSV, **51**, 129–132
in *Trypanosoma brucei*, *see* *Trypanosoma brucei*, nuclear gene expression in prokaryotic transcriptional enhancers and, **43**, 118–119
proline-rich protein multigene families and, **41**, 16–18
pseudo-constitutive, *aldA* mutants, **69**, 171–172
ribosome biogenesis in yeast and post-transcriptional regulation, **41**, 109–111
structure, **41**, 103–104
transcriptional regulation, **41**, 104–109
steroid hormones and, *see* Steroid hormones, gene expression and
suppression by DNA methylation, **69**, 50–51
transcription factor IIIA and, **43**, 229–232
transition-state, *see* *Bacillus subtilis* transition-state gene expression
- Gene expression in spermatogenesis, protamines and, **40**, 58–60
intercellular bridges, **40**, 61
post-transcriptional mechanisms, **40**, 61–64
timing, **40**, 60–61
transcription, **40**, 64–68
- Gene expression, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and, **45**, 119–123
- Gene expression, oligodeoxynucleotides as antisense inhibitors of, *see* Oligodeoxynucleotides
- Gene mapping, *csrA*, **47**, 311–312
- Gene organization, *PDE4*, **69**, 262–266
- Gene organization, anaerobic ribonucleotide reductases, **72**, 120
- Gene protein 4, T7 phage, helicase-primase, **70**, 91
- Gene protein 41, bacteriophage T4, **70**, 87–89
- Gene silencing, *see* DNA methylation; Methylated DNA binding protein 2 H1
- Gene targeting
triple-helix formation, **67**, 163–189

- Gene therapy
 oligonucleotide based
 problems, **67**, 164
- Gene therapy, *see* Hairpin ribozyme; Human immunodeficiency virus type 1
- Gene therapy, adeno-associated virus as potential vector for, **48**, 48–49
- Gene transcription
 AMPK regulation
 downstream targets, **71**, 77–78
 liver, **71**, 71–73
 muscle tissue gene expression, **71**, 77
 pancreatic β -cell, **71**, 74–77
 MAPK and SAPK regulation, **71**, 81–82
- General transcription factors
 CREB CAD and P-KID roles, **72**, 284–287, 289–290
 CREB CAD interactions, **72**, 279–284
- Genes
 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase and
 characterization, **45**, 116–119
 chromosomal localization, **45**, 118–119
 ALAS-1 and ALAS-2, **51**, 9–13
 alkyltransferase, **51**, 196–198
 apo-B, human, **50**, 161–190
 BCAR3, **71**, 422–423
 bone morphogenetic protein-1, **70**, 13–14
 calcium-dependent animal lectins and, **45**, 216–220
 CEG1, capping activity, **50**, 116–117
 Egr-1
 cDNA identification, **50**, 192–193
 distal events, **50**, 201–219
 expression, **50**, 193–199
 in family with *WT1* gene, **50**, 219–220
 proximal events, **50**, 199–201
 eIF5, **70**, 215–216
 encoding type XIII collagen, **50**, 238–239
 encoding types XV and XVIII collagen, **50**, 252
 FGF-1, **70**, 159
 FGF-1.B, **70**, 171–172
 FLP, **51**, 55–57
 globin, **50**, 184
 heme biosynthetic enzymes, **51**, 25–27
 HPRI, **51**, 285–291
 HtrA2 serine protease at 2p13, **70**, 7
 immediate-early, **50**, 191–192
 in DNA metabolism, **51**, 274–277
 jasmonate-induced regulation
 down-regulation, **72**, 181
 responsive promoters, **72**, 184–185
 up-regulation, **72**, 181–184
 LOXL3, overlap with HtrA2 serine protease gene at 2p13, **70**, 7
 lysyl oxidase
 as transcriptional regulator, **70**, 12
 evolutionary relationships, **70**, 7–8
 expression regulation, **70**, 8–10
 posttranscriptional regulation, **70**, 11–12
 transcriptional regulation, **70**, 10–11
 lysyl oxidase-like protein
 expression regulation, **70**, 8–10
 low-copy repeat sequences at 15q24, **70**, 7
 transcriptional regulation, **70**, 11
 mitochondrial, tissue-specific expression, **70**, 134–135
 poly A polymerase, **71**, 372–374
 rat steroid transferase, **51**, 326–327
 regulation, **50**, 216–219
 reporter, **50**, 82–83
 ribosomal, **50**, 27–33
 rice, *see* Rice genes
 specific, translational control, **51**, 341–343
 SRS2/HPR5, **51**, 291–299
 UGT1, **51**, 311–336
 vitellogenin, **72**, 143–144
 yeast mRNA 3' end-processing factor
 conditional mutants, **71**, 358–359
 FIP1, **71**, 360–361
 genetic approaches, **71**, 359
 mammalian homologs, **71**, 361–362
 PCF11, **71**, 361
 synergistic lethality, **71**, 359
 two-hybrid system, **71**, 360–361
- Genes, *see also specific genes*
 aminoacyl-tRNA synthetases, higher eukaryotic, **48**, 115–118
 expression
 in vivo inhibition, **48**, 224–226
 methylation and, **48**, 60–64
 housekeeping, methylation patterns, **48**, 55–56
 human uracil-DNA glycosylase, **48**, 347–351
 in Balbiani ring multigene family, **48**, 285–297
 parental imprinted, methylation, **48**, 71–77
 differential, **48**, 72–73

- single-copy, methylation status, in preimplantation embryo, **48**, 65–66
- tissue-specific, methylation patterns, **48**, 56
- Genes, lenticular, **41**, 272–276
- Genetic analysis, pRNA, **72**, 438–439
- Genetic assays, retroviral RT, **71**, 105–108
- Genetic defects of mammalian nervous system, **41**, 241–242, 254–256
 - making mutants, **41**, 254
 - neural mutants, **41**, 242–243
 - rds* gene, **41**, 243–250
 - secretogranin III, **41**, 250–254
- Genetic instability phenotype, **68**, 37
- Genetic recombination, *see* DNA recombination; Homologous genetic recombination
- Genetics, and modified nucleosides in bacterial tRNA, **50**, 263–338
- Genistein, *see* Topoisomerase II poisons
- Genome, HSV, transcription during infection, **51**, 123–165
- Genomes
 - alphavirus, complementary RNA, **71**, 192–194
 - cloning, poly A polymerase cDNA, **71**, 322
 - higher plant mitochondria
 - promoter primary structure, **70**, 127–129
 - tissue-specific gene expression, **70**, 134–135
 - transcription initiation sites, **70**, 126–127
 - transcription protein components, **70**, 130–131
 - transcription regulation, **70**, 131–134
 - transcriptional units, **70**, 124–126
 - mitochondria origin, **70**, 121–122
 - RecQ helicase role in stability, **70**, 86
 - yeast mRNA 3' end-processing factor genes, **71**, 361–362
- Genomes, alkylation damage repair in, *see* Alkylation damage repair in genomes
- Genomic imprinting, Alu role, **53**, 305–307, 313–314
- Genomic instability
 - cancer
 - ataxia telangiectasia, **63**, 191–199
 - Bloom's syndrome, **63**, 202–206
 - Fanconi anemia, **63**, 211–213
 - hereditary nonpolyposis colorectal cancer, **63**, 206–208
 - Lynch syndrome, **63**, 208
 - Muir–Torre syndrome, **63**, 208–209
 - Nijmegen breakage syndrome, **63**, 200–201
 - overview, **63**, 190–191
 - target gene functions, **63**, 191
 - universality in early tumorigenesis, **63**, 213–214
 - xeroderma pigmentosum, **63**, 209–211
 - definition, **63**, 190
- Genomic structure
 - of alcohol dehydrogenase, **40**, 260–265
 - of aldehyde dehydrogenase, **40**, 277–279
- Genomic structure, ROR γ , **69**, 224–226
- Genotype profiling
 - cell-specific temporal viral gene expression, **71**, 474, 478–479, 483, 486
 - HCMV, **71**, 472–474
- Germinal centers, somatic hypermutation in, **50**, 70–71
- Germination, plant, jasmonates and octadecanoids, **72**, 196–197
- GFR, **71**, 416
- GHRH receptor, *see* Growth-hormone–releasing hormone receptor
- GK, *see* Glucokinase
- Glandular secretory epithelia, Muc4/SMC
 - lacrimal gland, **71**, 176
 - mammary acinar cells, **71**, 170–175
 - salivary glands, **71**, 175
- Glass slides, HSV-1 DNA microarray
 - chip data, **71**, 465–468
 - chip fabrication and scanning, **71**, 464–465
 - experimental data, **71**, 470–472
 - hybridization, **71**, 455
 - receiver operating characteristic, **71**, 465
 - scanning protocols, **71**, 456–459
 - specific oligonucleotides, **71**, 461–464
 - transcript labeling, **71**, 455–456
- glg* operon
 - negative control via *csrA*, **47**, 306–311
 - positive control by alternative sigma factor, **47**, 314
- Glg1p
 - domains, **57**, 305–307, 309
 - gene, homology between species, **57**, 302, 304–307, 309
 - glucosylation substrates, **57**, 300
 - primary structure, **57**, 294
 - role, *in vivo*, **57**, 310
 - self glucosylation, **57**, 290, 299–300
- Glg2p
 - domains, **57**, 305–307, 309

- Glg2p (*cont.*)
 gene, homology between species, **57**, 302, 304–307, 309
 glucosylation substrates, **57**, 300
 overexpressing mutants and glycogen synthesis, **57**, 311
 primary structure, **57**, 294
 role, *in vivo*, **57**, 310
 self glucosylation, **57**, 290, 299–300
- GLI*, mutation in human syndromes
 Greig cephalopolysyndactyly, **64**, 186–187
 Pallister–Hall syndrome, **64**, 187
 postaxial polydactyly, **64**, 186–187
- Glial cells, **68**, 280
- Gliomas, human, FGF-1 expression, **70**, 161–162
- GlnRS, complex with tRNA^{Gln}, **69**, 330, 339
- Global regulator, *see* Regulon
- Globin formation, coupled to heme production, **51**, 33–34
- Globin, mRNA stabilization, **56**, 273
- α -Globin
 gene cluster, **57**, 257
 gene switching, **57**, 250
 messenger RNA
 α -complex proteins, **57**, 271, 273–275
 3' untranslated region, **57**, 259, 265–267, 269, 276, 282
 Constant Spring mutation and thalassemia, **57**, 252, 262–263, 265–266
 deadenylation, **57**, 274
 erythroid cell accumulation, **57**, 255–256
 experimental determination, **57**, 263, 265
 half life, **57**, 256
 identification, **57**, 271
 ribonucleoprotein complex formation and stability, **57**, 269, 274
 sequence of stability element, **57**, 267, 269, 276
 structural determinants of stability
 conservation between species, **57**, 276, 278
 trans-acting stability factors
- β -Globin
 gene cluster, **57**, 257
 gene switching, **57**, 250
 messenger RNA
 erythroid cell accumulation, **57**, 255–256
 half life, **57**, 256, 280
 stability elements in 3' untranslated region, **57**, 280, 282
- α -Globin messenger RNA, stability complex binding by AUFL, **62**, 279–280
- β -Globin, DNA and chromatin assembly, **54**, 363–366
- δ -Globin, messenger RNA stability, **57**, 260
- ζ -Globin, messenger RNA stability, **57**, 259–260
- Glucagon, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and, **45**, 121–123
- Glucagon, malic enzyme gene regulation, **52**, 91–92, 112
- β -Glucan glucohydrolase, *Pseudomonas fluorescens* subsp. *cellulosa*, **61**, 218
- Glucocorticoid receptor
 gene structure
 DNA binding domain, **59**, 290–291
 overview, **59**, 290
 steroid binding domain, **59**, 291
 transcription
 autoregulation, **59**, 303–304
 characterization of 5' flanking region, **59**, 299
 down-regulation, **59**, 300
 enhancers, **59**, 291, 299
 suppressors/repressors, **59**, 292–293
 trans-acting factors, **59**, 291–292, 298
- Glucocorticoid receptor, *see* Steroid receptor
- Glucocorticoid receptor, binding to HIV promoter, **49**, 173
- Glucocorticoid receptor, mutation in human disease, **64**, 199, 203
- Glucocorticoid receptor, nucleosomal DNA transcription analysis, **61**, 412, 414–415
- Glucocorticoid receptors, autoregulation, **60**, 161
- Glucocorticoids, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and, **45**, 119–120
- Glucocorticoids, effects on G protein expression, **47**, 102
- Glucokinase, glucose in gene expression, **71**, 72
- Glucose
 liver gene expression, **71**, 71–73
 preproinsulin gene expression, **71**, 81–82
 pyruvate dehydrogenase complex effects, **70**, 35
 pyruvate dehydrogenase complex role, **70**, 42

- pyruvate dehydrogenase kinase effects, **70**, **52**
- Glucose repression, mitochondrial biogenesis in *Saccharomyces cerevisiae* and, **46**, **65–67**
- Glucose repression, yeast SNF1, **71**, **71**
- Glucose, *A. nidulans* cultivation on, **69**, **194**
- Glucose-stimulated arachidonate, **67**, **22**
- β -Glucosidase, *see* Acid β -glucosidase
- Glucuronidation, bilirubin and phenols, **51**, **311–314**
- Glutamate receptor-interacting protein, **71**, **412**
- Glutamate receptor-interacting protein-associated protein, **71**, **412**
- Glutamic acid-89, HIV-1 RT, **71**, **123**
- Glutamic acid-rich proteins, role in PDE6 binding, **69**, **260–261**
- Glutamine PRPP amidotransferase, purine nucleotide biosynthesis and, **42**, **272–274**
- Glutamine synthetase
 - adipose tissue expression
 - functions, **61**, **261**
 - regulation of expression, **61**, **260–261**
 - topography, **61**, **260**
 - ammonia homeostasis role, **61**, **244**, **251–252**, **257**
 - developmental expression
 - chicken, **61**, **289–290**
 - patterns, **61**, **263–265**
 - topographical changes, **61**, **265–266**
 - translation efficiency, **61**, **268–269**
 - gastrointestinal tract expression
 - functions, **61**, **259**
 - regulation of expression, **61**, **259**
 - topography, **61**, **259**
 - gene
 - avian gene
 - cell specificity of expression, elements in determination, **61**, **292**
 - developmental regulation, **61**, **289–290**
 - hormonal inducibility, development, **61**, **290–293**
 - structure, **61**, **275**
 - evolution, **61**, **273**
 - mammalian gene
 - downstream regulatory regions, **61**, **285**, **288**
 - first intron regulatory regions, **61**, **284–285**, **287–288**
 - structure, **61**, **275–276**
 - upstream regulatory regions and functional delineation, **61**, **276**, **278–281**, **283–284**, **287**
- glutamine homeostasis role, **61**, **244–245**, **251–252**, **293–295**
- isoforms, **61**, **273**
- kidney expression
 - functions, **61**, **256–257**
 - regulation of expression, **61**, **256**
 - topography, **61**, **256**
- kinetic properties, **61**, **274**
- liver expression
 - functions, **61**, **251–253**
 - regulation of expression, **61**, **250–251**
 - topography, **61**, **246**
- lung expression
 - functions, **61**, **260**
 - regulation of expression, **61**, **260**
 - topography, **61**, **259–260**
- lymphoid tissue expression
 - functions, **61**, **262**
 - regulation of expression, **61**, **262**
 - topography, **61**, **262**
- muscle expression
 - functions, **61**, **258**
 - regulation of expression, **61**, **257–254**
 - topography, **61**, **257**
- nervous system expression
 - functions, **61**, **254–255**
 - regulation of expression, **61**, **253–254**
 - topography, **61**, **253**
- posttranslational regulation
 - acetaminophen inactivation, **61**, **268**
 - half-lives, *in vitro* versus *in vivo*, **61**, **266–267**
 - oxidation and degradation, **61**, **267–268**
- reproductive organ expression and functions
 - epididymus, **61**, **261**
 - ovary, **61**, **261**
 - testis, **61**, **261**
- subcellular localization, **61**, **273–274**
- tissue distribution in rats and mice, **61**, **246–249**
- transcriptional regulation
 - messenger RNA stability, **61**, **271–272**
 - rate of transcription, **61**, **272**
 - signal transduction pathways, **61**, **272–273**
- types, **61**, **273**

- Glutamine synthetase, *see* Leucine/Lrp regulon; Nitrogen regulon
- Glutamine synthetase, recognition of tRNA and, **41**, 66–67
- Glutamine, residue 151, HIV-1 RT, **71**, 119–120, 122
- Glutamyl-tRNA synthetase, **70**, 315–316
- Glutamyl-prolyl-tRNA synthetase, **48**, 95, 97–98, 100–101
- Glutelin gene, rice, **45**, 18–19
- Glyceraldehyde-3-phosphate, A+U rich element binding, **62**, 285, 287
- Glycerol-3-phosphate acyltransferase
- fat synthesis, **60**, 319
 - gene cloning, **60**, 319
 - regulation by insulin, **60**, 320, 326
- Glycerol-3-phosphate acyltransferase, mutants in yeast, **61**, 152–153
- Glycerophosphocholine, **67**, 27
- Glycine substitutions
- collagen type-I genes, **47**, 36–39
 - collagen type-III gene, **47**, 61
- Glycogen
- biosynthesis, *see also* Glg1p; Glg2p; Glycogenin
 - elongation, **57**, 291–293, 295–298, 301
 - initiation, **57**, 290–291, 311
 - rate determining step, **57**, 311
 - proglycogen, **57**, 291–293
 - structure, **57**, 289
- Glycogen, biosynthesis in *Escherichia coli*
- csrA* mapping and characterization, **47**, 311–312
 - enzyme induction in stationary phase, **47**, 301
 - glgC* dependence on sigma factors, **47**, 312–314
 - glgCAP*(Y) operon control, **47**, 304–306
 - integrated model of genetic regulation, **47**, 314–315
 - negative genetic control, **47**, 306–307
 - transposon mutants, **47**, 307–309
 - TR1-5 mutation effects in *csrA::kanR*, **47**, 309–311
 - positive control by genes outside *glg* gene cluster, **47**, 314
 - structural genes, localization, **47**, 301–304
- Glycogenin
- diabetes candidate gene, **57**, 313–314
 - discovery, **57**, 291
 - domains, **57**, 305–307, 309
 - gene homology between species, **57**, 302, 304–307, 309
 - glucose effects on activity, **57**, 312–313
 - glucosylation substrates, **57**, 300
 - glycogen synthase interactions
 - effects on activity, **57**, 312
 - elongation, **57**, 295–298, 301 - messenger RNA, tissue distribution, **57**, 302, 304
 - phosphorylation, **57**, 311–312
 - plants, **57**, 304–305
 - primary structure, **57**, 293–294
 - regulation, **57**, 311–313
 - roles, *in vivo*, **57**, 309–310, 313
 - self glucosylation, **57**, 290–291, 298–299
 - subunit structure, **57**, 294–295
- Glycolysis, control of, *see* 6-Phosphofructo-kinase/fructose-2,6-bisphosphatase
- Glycoprotein folding
- ER
 - nascent polypeptides, **67**, 239–241
 - primary quality control, **67**, 239–247
 - protein-specific quality control, **67**, 247–249
 - secondary quality control, **67**, 247–249
- Glycoprotein misfolding
- ER
 - primary quality control, **67**, 243–246
- Glycosyl bond cleavage, aminoacyl-tRNA synthetase in, **48**, 126–127
- Glycosylase
- DNA. *See* DNA glycosylase
- Glycosylase gene, alkylation damage repair in genomes and, **44**, 134
- Glycosylase step
- assay, **68**, 147
- Glycosylase/AP lyases
- reaction mechanisms, **68**, 352–353
- Glycosylation, C-terminal domain, **48**, 173–174
- Glycosylic bond cleavage
- catalysis, **68**, 312–313
- Glycyl radical
- nrdD* protein, **72**, 99–101
 - protein α , **72**, 116–119
- GM-CSF, *see* Granulocyte macrophage-colony stimulating factor
- GMP synthetase, purine nucleotide biosynthesis and, **42**, 282

- GMP, nsP1, **71**, 198, 201
- GMPS/aryl azide, *see* Guanine-monophosphorothioate/aryl azide
- GO system, **68**, 194–195
- Gonadal mosaicism, in osteogenesis imperfecta, **47**, 43
- gp33, prokaryotic transcriptional enhancers and, **43**, 127–128
- gp55 regulatory protein, prokaryotic transcriptional enhancers and, **43**, 118–119
- GPAT, *see* Glycerol-3-phosphate acyltransferase
- Gpt/Mmh*^{-/-} (O) mouse liver cells
mutation frequency, **68**, 119
- Gpt/Mmh*^{+/+} (W) mouse liver cells
mutation frequency, **68**, 119
- Granulocyte macrophage-colony stimulating factor (GM-CSF)
mRNA stabilization for gene therapy, **56**, 281–282
particle-mediated transfection and decay of mRNAs, **56**, 261, 263, 266–267
- Granulocyte-macrophage colony-stimulating factor messenger RNA, turnover role of AUF1, **62**, 283–284
- GRASP-1, Glutamate receptor-interacting protein-associated protein
- Greig cephalopolysyndactyly, *GLI* mutation, **64**, 186–187
- GRIP, *see* Glutamate receptor-interacting protein
- Gro-EL, similarity to prosomes, **49**, 2–3, 18, 52
- Groα messenger RNA turnover role of AUF1, **62**, 284
- GroEL, protein folding role, **58**, 306–308, 314, 316, 331
- GroES, protein folding role, **58**, 306–308, 314, 316
- Gross cell surface antigen
CUG initiation codon, **72**, 378–379
MuLV dissemination and pathogenicity, **72**, 380
- Group IVC PLA₂ (cPLA_{2γ})
characteristics, **67**, 7
- Group VIA Ca²⁺
iPLA_{2β}
molecular biology, **67**, 1–29
- Group VIA PLA₂
enzymology, **67**, 20–22
- lysophospholipase, **67**, 21–22
- PAF acetylhydrolase, **67**, 21–22
- phospholipids, **67**, 20–21
- transacylase, **67**, 21–22
- Growth
methanogens, **71**, 256–258
primary tumor, Muc4/SMC, **71**, 161–163
regulated repressors of ribosomal genes, **50**, 55–56
regulated ribosomal transcription, **50**, 54–55
- Growth control-related, **48**, 201–203
- Growth control, proteins related to, **48**, 201–203
- Growth control, translation in mammalian cells, **51**, 339–363
- Growth factors, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and, **45**, 123
- Growth hormone
categorization of effects, **57**, 75–76
IGFBP-3 regulation, **60**, 245–246
insulin-like growth factor regulation, **60**, 198–199, 217–218
receptor, *see* Growth hormone receptor
regulation
messenger RNA polyadenylation, **57**, 63
secretion, **57**, 74–75
transcription of other genes, **57**, 76
structure, **57**, 74
- Growth hormone gene
cAMP control of expression
cascade mechanism, **54**, 134
gene promoter response elements, **54**, 135–137
GHF-1 role, **54**, 135–137
transcription factors, **54**, 134–135
evolution, **54**, 128–131
introns and chromatin assembly, **54**, 366–367, 369–373
placenta
CSEF-1 control of CSEn function, **54**, 152–154
CSEn enhancer, **54**, 149–150, 152
hormonal control of gene expression, **54**, 156–157
InrE initiator element, **54**, 154–155
physiological actions, **54**, 131–134
pituitary negative control of, **54**, 155–156
receptors, **54**, 130–131

- Growth hormone gene (*cont.*)
 similarity to chorionic
 somatomammotropin gene, **54**, 128
 splicing, **54**, 128–130
 transcription, negative regulation
 mechanisms
 elongation, **54**, 147–148
 initiation, **54**, 145–147
 termination, **54**, 148
 triiodothyronine control of expression, **54**,
 138–140, 142–145
- Growth hormone receptor
 binding sites, **57**, 79
 crystal structure, **57**, 78–79
 dimerization, **57**, 79–80
 intracellular domain, **57**, 80
 signal transduction
 cellular phosphorylation
 kinase, **57**, 2, 81, 85–86
 mitogen-activated protein kinase,
57, 86–87
 serine protease inhibitor 2.1,
57, 85, 87–89
 signal transducer and activator of
 transcription, **57**, 81–83,
 85–86, 89–90
 stoichiometry of binding, **57**, 79
- Growth-hormone-releasing hormone receptor
 defects, **49**, 134–135
 gene locus in mice, **49**, 134
- Growth regulatory circuits, coordination with
 DNMT1 levels, **69**, 63–64
- Growth suppressor genes, DNMT1 regulatory
 role, **69**, 62–63
- GRP/CalDAG-GEF family
 characteristics, **71**, 409–410
 expression, **71**, 411–412
 founding member isolation, **71**, 410
 Ras activation, **71**, 410–411
 Ras and Rap specificity, **71**, 411
- GRP78
 ADP ribosylation, **58**, 90, 119
 calcium effects on expression, **58**, 81, 87
 gene structure, **58**, 86–87
 induction signaling, **58**, 88–89, 112–113
 messenger RNA structure, **58**, 87
 oligomerization, **58**, 89, 119
 partner proteins, **58**, 89
 phosphorylation, **58**, 90
 translation initiation role, **58**, 117–119
 translational accommodation in stress
 response, **58**, 111–112
- GrpE, rhodanese folding studies, **66**,
 58–59, 61
- GS, *see* Galactosialidosis
- GS, *see* Glutamine synthetase
- Gsf2p
 quality control, **67**, 250
- GTFs, *see* General transcription factors
- GTP
 cellular compartmentalization, **60**, 53, 67
 elongation factor binding and hydrolysis, **60**,
 51–53, 56–60, 66–67
- GTP binding protein, EF-Tu, *see* Elongation
 factor Tu
- GTP, allosteric regulation of RNRs, **72**,
 108–114
- GTP, hydrolysis
 eIF2 and 40S ribosome roles, **70**, 225–227
 eIF5 regulation, **70**, 229–230
- GTP, nsP1, **71**, 198–201
- GTPase-accelerating proteins (GAPs), *see also*
 Regulator of G protein signaling
 phototransduction, **65**, 343
 types, **65**, 342
- GTPase-activating protein, eIF5 functions
 eIF2 β subunit binding, **70**, 219–223
 eIF2 γ subunit, **70**, 225–227
 N-terminal region role, **70**, 223–225
- GTPase-activating protein, protein tyrosine
 kinase substrates and, **44**, 215
- GTPase-activating proteins, Ras-GTP *in vivo*
 regulation, **71**, 393
- GTPase, EF-Tu, *see* Elongation factor Tu
- GTPases
 eIF5 as, **70**, 218–219
 families, **67**, 194
 in FGF-1 promoter 1.D, **70**, 167–168
- Guanine
 alkylation in DNA, **49**, 99–100
 interactions at active site of DNA
 (cytosine-5) methyltransferase, **49**, 84
 regulatory binding proteins, *see* G proteins
- Guanine, **68**, 209
- Guanine-monophosphorothioate/aryl azide, **72**,
 431–433
- Guanine nucleotide binding proteins,
see G proteins
- Guanine-nucleotide-dependent complex,
 ADP-ribosylation factors and, **45**, 52

- Guanine nucleotide dissociation inhibitors (GDIs), **67**, 194
- Guanine nucleotide exchange factors
- BCAR3, **71**, 422–423
 - biological assays, **71**, 404–405
 - C3G, **71**, 412–414
 - disease relationship, **71**, 425–426
 - dominant inhibitory Ras protein targeting, **71**, 402–404
 - Epac/cyclic AMP-GEFs, **71**, 414–416
 - GRASP-1, **71**, 412–414
 - GRF1 and 2, **71**, 407–409
 - GRP/CalDAG-GEF family, **71**, 409–412
 - MR-GEF, **71**, 416
 - nuclear exchange reaction, **71**, 396, 401
 - PDZ-GEFs, **71**, 416–418
 - phospholipase C_ε, **71**, 418–420
 - RalGDS family, **71**, 420–421
 - RalGPS, **71**, 421–422
 - Rap1 GEFs, **71**, 420
 - Ras-family, early identification, **71**, 393–396
 - SmgGDS, **71**, 423–425
 - Sos1 and 2, **71**, 405–407
 - structure, **71**, 396, 401
- Guanine nucleotide releasing factor 1, **71**, 407–409
- Guanine nucleotide releasing factor 2, **71**, 407–409
- Guanine quadruplex
- biological roles, **59**, 80–81
 - cation dependence, **59**, 81–82, 84–85
 - circular dichroism, **59**, 82, 84–85
 - equilibrium ultracentrifugation and concentration profile, **59**, 83–84
 - guanine quartet structure, **59**, 79–80
 - kinetics of formation, **59**, 82
 - ligand interactions
 - diethyloxadicarbocyanine, **59**, 90–91
 - DOCK method in design principle, **59**, 89–90
 - screening of compounds, **59**, 90–91
 - types of ligands, **59**, 89
 - nuclear magnetic resonance, structure determination, **59**, 83–84, 86–88
 - strand configurations, **59**, 80, 88–89
 - thermodynamic analysis, **59**, 85–86
 - X-ray crystallography, **59**, 86, 88
- Guanine, sequences, role in switch recombination, **50**, 84–85
- Guanine-exchange factors (GEFs), **67**, 194
- Guanosine–adenosine base pair (G-A)
- DNA conformation, pH dependence, **57**, 15
 - flanking bases and stability, **57**, 19
 - hammerhead ribozyme, **57**, 17–18
 - nuclear magnetic resonance, structural studies of RNA
 - helical twist, **57**, 20
 - imino signal, **57**, 19
 - pairing mechanism elucidation, **57**, 19–20
 - tetraloops, **57**, 20–21
 - pairing arrangements, **57**, 15–16, 18–19
 - sequence content and stability, **57**, 22–23
 - stacking and stability, **57**, 17, 20
- X-ray structures
- DNA, **57**, 15–17
 - RNA, **57**, 15, 17–18
- Guanosine–uridine base pair (G.U)
- distribution in RNA, **57**, 2–3
 - function in tRNA^{Ala}, **57**, 34
 - glycosyl bond angles, **57**, 3
 - nuclear magnetic resonance, structural studies of RNA
 - hydrogen bond determination, **57**, 6
 - imino signal, **57**, 6–7, 11
 - manganese binding, **57**, 13–14
 - proton exchange and stability, **57**, 7–8, 11–13
 - stacking and chemical shifts, **57**, 7–10
 - orientation and stability, **57**, 12–13
 - stacking effects and sequence context, **57**, 3–5, 7–11, 13
 - water stabilization, **57**, 5, 8–9
 - X-ray structures of RNA duplexes, **57**, 4–5
- Guanylyl cyclases
- calcium modulation, **49**, 271
 - domains, **49**, 270–271
 - forms
 - cytoplasmic, **49**, 270
 - plasma membrane, **49**, 270–271
 - similarity to adenylyl cyclases, **49**, 267, 270–271, 273–274
- Guanylyltransferase
- vaccinia virus RNA, **50**, 104–106
 - yeast
 - active site, **50**, 114–115
 - structure probing, **50**, 115–116
- Guanylyltransferase, nsP1 activity, **71**, 198–201
- GW1843U89
- structure, **67**, 136

H

- H_2O_2 , superoxide dismutases and, **40**, 237–238
 H_4MPT , *see* Tetrahyromethanopterin
 H3TH , **68**, 339–340
 Hairpin binding proteins, RNA and, **40**, 212–215
 Hairpin ribozyme
 arabis mosaic virus, **58**, 2, 4, 33–35
 chickory yellow mottle virus type, **58**, 1, 2, 4, 33–37
 gene therapy
 catalytic optimization, **58**, 17–18, 35–36
 delivery systems
 autolytic hairpin cassette, **58**, 18–19
 promoters, **58**, 19, 22–24, 31–33
 helix 1 length optimization, **58**, 16–17, 36
 human immunodeficiency virus type 1,
 see Human immunodeficiency
 virus type 1
 target site selection, **58**, 16–17
 targeting rules, **58**, 15–16
 minimum catalytic center, **58**, 3, 5
 structure
 secondary structure, **58**, 3, 10, 13, 36
 three-dimensional modeling, **58**, 14
 tobacco ringspot virus
 catalytic center, **58**, 5
 criteria for catalytic reaction, **58**, 7
 discovery, **58**, 2, 5
 kinetic properties, **58**, 7
 metal dependence, **58**, 7
 mutation effects on activity, **58**, 10–11, 13
 pH effects, **58**, 7, 10
 substrate specificity, **58**, 3–7, 14, 34
 temperature optimum, **58**, 7
 Hairpins
 antisense RNA-binding, **69**, 10–11
 ArgRS, **69**, 343
 complex with aptamers, **69**, 27–28
 DNA, high-affinity, **69**, 35
 double, **69**, 24–25
 duplexes with Pu and Py moieties, **69**, 20–21
 Hairpins, structural elements in RNA and, **41**, 136–140
 β_{12} – β_{13} Hairpin, HIV-1 RT, **71**, 124–126
 Hairpins, tRNA, **70**, 304–306
 Half-FRT site
 complementation assay, **51**, 80–81
 dimerization, **51**, 70–72
 Hammerhead ribozyme cleavage, **72**, 239–241
 Hammerhead ribozymes, **69**, 12
 Hamster cells
 transport-impaired
 hRFC cDNA cloning, **67**, 140–146
 Hand–foot–uterus syndrome, *HOXA13*
 mutation, **64**, 189
 Handcuffing
 in interon-mediated replication
 inhibition, **48**, 255
 plasmid copy-number control by, **48**, 260–261
 Handoff model base excision repair, **68**, 203–204
 HAP1, **68**, 24, 243 *See also* APE1
 HAP1, mitochondrial biogenesis and, **46**, 59–62
 HAP2, mitochondrial biogenesis and, **46**, 62, 67–68
 HAP3, mitochondrial biogenesis and, **46**, 62, 67–68
 HAP4, mitochondrial biogenesis and, **46**, 62, 67–68
 HAP1, **68**, 191
 HB[*trans*-Ru(III)B₂Cl₄]-DNA
 interactions, **71**, 52
 HBV, *see* Hepatitis B virus
 HC-3, **67**, 218
 Hcelp
 bifunctional activities, **66**, 3
 triphosphatases generated from alternative
 splicing, **66**, 26
 Hcm1p, *see* RNA (guanine-7)
 methyltransferase
 HCMV, *see* Human cytomegalovirus
 HCP1/IR1B4, *see* Protein arginine
 methyl-transferase type I
 HCV NS3, *see* Hepatitis C virus NS3 proteins
 HD, *see* Huntington's disease
 H-DNA, *see* DNA triplex
 Heart failure, PDE3 inhibitor therapy, **66**, 266–268
 Heart, LOXL3 expression, **70**, 24–25
 Heat shock protein 70, arginine
 methylation, **61**, 97–98, 103, 123
 Heat shock protein 47 (HSP47), procollagen
 maturation role, **63**, 100
 Heat-shock proteins, lens protein and, **41**, 261–263

- Heat-shock regulon
 identification of members
 genes, **55**, 50
 proteins, **55**, 50–51
 polypeptide induction by heat shock
 identification, **55**, 47, 49
 kinetics, **55**, 47–49
 sigma factor control
 σ 32, **55**, 44–47, 51, 53
 σ 54, **55**, 53–54
 temperature-sensitive mutant, **55**, 44
- Heat shock response
 heat shock proteins, *see also* HSC70;
 HSP60; HSP70
 induction, **58**, 87
 messenger RNA structure, **58**, 83
 types, **58**, 83
 inducers, **58**, 82–83
 relationship with endoplasmic reticulum
 stress response, **58**, 114–116
 translational accommodation
 overview, **58**, 113–114
 physiological relevance, **58**, 115–116
 trehalase role, **58**, 219, 222–223, 226–228
 trehalose accumulation in yeast, **58**, 204–205
- Heat shock, *Trypanosoma brucei* and, **43**, 44
- Heat stress, effects on intron splicing, **47**,
 186–188
- HeCNU
 pol beta-defective cells, **68**, 17
- Hedamycin, DNA sequence specificity, **63**,
 378, 387
- HeLa cells
 cisplatin, **67**, 113
- HeLa S3 cells
 hMMH type 1a protein
 depletion, **68**, 110–112
 depletion analysis, **68**, 112
 detection, **68**, 111
- Helical clamp, **68**, 341
- Helicase I, **40**, 313–315
- Helicase II, **40**, 305–309
- Helicase III, **40**, 315–316
- Helicase IV, **40**, 316–318
- Helicase–primase
 DNA-binding activities, **70**, 104
 gene structure, **70**, 102–103
 T7 phage gene 4, **70**, 91
 UL5 mutations, **70**, 104–106
 UL52 role, **70**, 106–107
- Helicase, eIF4A, **72**, 324–325
- Helicases
 conserved motifs, **70**, 79
 in biological processes, **70**, 78–79
 in phage lambda recombination, **70**,
 91–92
 in recombination
 generalizations, **70**, 93
 higher organisms, **70**, 85
 overview, **70**, 83–84
 replication restart, **70**, 84–85
 T4 gp41 role, **70**, 89
 T7 phage, **70**, 89–91
 in replication
 bacterial DNA, **70**, 84
 eukaryotic origins, **70**, 85
 generalizations, **70**, 93
 overview, **70**, 83–84
 T4 gp41 role, **70**, 87–89
 T7 phage, **70**, 89–91
- RecQ, in genomic stability, **70**, 86
- superfamily 1, **70**, 80–82
- superfamily 2, **70**, 80–82
- superfamily 3, **70**, 82–83
- superfamily 4, **70**, 82–83
- UL9
 biochemical properties, **70**, 98–100
 domain structure, **70**, 98–100
 in cell culture, **70**, 98
 SV40 comparison, **70**, 100
 unwinding activity, **70**, 101–102
- Helicases, in translation, **48**, 218–219
- Helix 12, LBD of nuclear receptors, **69**,
 207–208, 221–222
- Helix-3turn-helix (H3TH), **68**, 339–340
- Helix-hairpin-helix (HhH), **68**, 353–354
 AP lyases, **68**, 342
 glycosylases, **68**, 342
- Helix interactions, structural elements in RNA
 and, **41**, 153–157
- Helix-loop-helix (HLH), **68**, 376–377
- Helix, destabilizing activity of chaperones, **72**,
 242–245
- Heme
 biosynthesis, **51**, 3–6
 CO
 PRO-2, **67**, 49–50
 degradation, **51**, 21–22
 effects on hepatic ALAS, **51**, 13–15
 synthesis, and erythropoiesis, **51**, 22–34

- Heme-controlled repressor (HCR)
 cloning, **54**, 173, 175, 177
 DNA sequence, rat, **54**, 174–175
 phosphorylation of eIF-2 α , **54**, 169
- Heme oxygenase, heme degradation, **51**, 21–22
- Heme region
 CooA, **67**, 47–50
- Heme, mitochondrial biogenesis and, **46**, 59–62
- Hemiacetal
 structure, **68**, 8
- Hemicellulose, structure and degradation, **61**, 214–215, 217
- Hemicholinium-3 (HC-3), **67**, 218
- Hemoglobin, *see* α -Globin; β -Globin
- Hepadnaviruses
 Gag–Pol translation, **72**, 11
 gene economy, **72**, 2
- Heparan, *see* Fibroblast growth factor receptor
 heparan sulfate
- Heparin antagonist, protamines as, **40**, 86
- Hepatitis B virus, **72**, 7–9
- Hepatitis B virus, latent viruses and mutated
 oncogenes and, **43**, 164–165
- Hepatitis, latent viruses and mutated
 oncogenes and, **43**, 153–154
- Hepatitis C virus NS3 proteins, **72**, 311–312
- Hepatocyte, fibroblast growth factor receptor
 complex
 abnormalities in hepatoma cells, **59**, 164–166
 normal cell properties, **59**, 166–167
 resting cell properties, **59**, 167–168
- Hereditary nephritis, *COLA/A5* gene
 mutations, **47**, 64
- Hereditary neuropathy with liability to
 pressure palsies (HNPP), genetics, **56**, 243
- Hereditary neuropathy with liability to
 pressure palsies (HNPP), peripheral
 myelin protein 22 mutations, **64**, 115–116
- Hereditary nonpolyposis colon cancer
 (HNPCC)
 TDG, **68**, 251
- Hereditary nonpolyposis colorectal cancer
 (HNPCC)
 clinical features, **63**, 206
 incidence, **63**, 206
- microsatellite instability, **63**, 206–207
 mismatch repair defects, **63**, 207–208
- Herpes simplex virus
 infection, transcriptional switches, **51**, 133–140
 mRNA expression, early/late switch, **51**, 153–154
 promoters, **51**, 140–155
 type 1, physical description, **51**, 125–129
- Herpes simplex virus-1
 DNA replication
 circular DNA intermediates, **70**, 95
 greater-than-unit-length, **70**, 95–97
 model, **70**, 107–111
 overview, **70**, 93–94
 helicase–primase
 DNA-binding activities, **70**, 104
 gene structure, **70**, 102–103
 UL5 mutations, **70**, 104–106
 UL52 role, **70**, 106–107
 replication proteins, **70**, 97–98
- Herpes simplex virus 1 (HSV-1), infection
 and translational tolerance to stress, **58**, 115
- Herpes simplex virus protein 16
 (HSV VP16), **67**, 179–180
- Herpes simplex virus, inhibition by
 oligonucleotides, **57**, 124
- Herpes virus
 ribonucleotide reductase, control of
 expression, **53**, 380–382
 subfamilies, **53**, 379
 transcriptional control, **53**, 380
- Herpes virus, latent viruses and mutated
 oncogenes and, **43**, 160–164
- Herpesviruses, DNA microarrays
 design, **71**, 454–455
 development rationale, **71**, 446–447
 oligonucleotide-based approach, **71**, 453–454
 PCR fragment-based approach, **71**, 453
 transcription, **71**, 452–453
- Heterodinuclear (Ru,Pt) compounds–DNA
 interactions, **71**, 53–54
- Heterodisulfide reductase
 methanogens, **71**, 253–255
Methanothermobacter strains, **71**, 271–273
- Heterogeneous nuclear ribonuclear protein
 A1, arginine methylation, **61**, 76–77, 89,
 91–92, 100, 106

- Heterogeneous nuclear RNA
 double-stranded RNA component, **52**, 34–35
 experimental identification, **52**, 34
- Heterologous templates, RNA
 amplification, **51**, 252–254
 copying, **51**, 230–231
- Heteroduplex DNA repair, immunoglobulin
 gene diversification and, **45**, 43
- Hexamethylmelamine, DNA sequence
 specificity, **63**, 379, 388
- Hexosaminidase A, association with
 LMC, **69**, 106
- HhH, **68**, 353–354
 AP lyases, **68**, 342
 glycosylases, **68**, 342
- H1, **67**, 98
 cisplatin, **67**, 114–115
- High-efficiency restriction-enzyme digestion
 assay, **49**, 288, 295
 DNA
 amplification, **49**, 299
 digestion, **49**, 296–298
 high-efficiency restriction digestion, **49**,
 298–299
 isolation, **49**, 296
 elimination of PCR-generated mutants, **49**,
 299–300
 mitochondrial mutational assay, **49**, 300–302
 mutant analysis, **49**, 300
 sensitivity, **49**, 296
- High-mobility group (HMG) domain, **64**,
 174–176
- High-mobility group chromosomal protein
 (HMG)
 DNA binding specificity, **54**, 42
 families, **54**, 36
- HMG-1 box
 DNA binding, sequence specificity,
 54, 40–42
 structure, **54**, 38–40
- HMG-14/17 family
 chromatin stabilization, **54**, 82
 conserved domains, **54**, 73–75, 77
 distribution, **54**, 72
 down-regulation during cellular
 differentiation, **54**, 86–87
 effects
 nucleosomal repeat, **54**, 82–84
 transcriptional potential of chromatin
 templates, **54**, 87–91
 enrichment in active genes, **54**, 84–86
 nucleosomal binding domain, **54**, 80
 nucleosome cores, cooperative
 interactions, **54**, 77–79
 organization in nucleosome cores,
 54, 80–81
 structure, **54**, 72–75, 77
 transcription factor activity, **54**, 87
- HMG-1/2 family
 abundance, **54**, 37, 92
 chromatin interactions, **54**, 47–48
 DNA binding, **54**, 40–45
 functions, **54**, 37, 45–46, 48–51, 91
 HMG-I(Y) similarities, **54**, 62–63
 structure, **54**, 38
- HMG-I(Y) family
 cancer role, **54**, 68–70
 chromatin interactions, **54**, 60–61
 DNA binding, **54**, 57–60
 gene, **54**, 51
 growth factor induction, **54**, 51–52, 54
 histone H1 competition, **54**, 70–72
 HMG-1/2 similarities, **54**, 62–63
 nucleosome binding, **54**, 61–62
 structure, **54**, 51, 54–56
 transcription factor activity, **54**,
 63–65, 67–68
 physical properties, **54**, 36, 91
- High mobility group protein
 linker histone interactions, **52**, 235–236
 structure, **52**, 341–342
- High mobility group protein 1 (HMG1), **67**, 98
 bandshift assay, **67**, 99
 cisplatin, **67**, 122–123
 adducts, **67**, 99–100
 EMSA, **67**, 99
 MCF-7 breast cancer
 estrogen, **67**, 122–124
- High mobility group protein 1
 domA-cisplatin-DNA
 platinum coordination center, **67**, 109
 protein-DNA interactions, **67**, 108
 structure, **67**, 107–110
 x-ray crystal, **67**, 107
- High mobility group protein 2 (HMG2),
 67, 98
- High mobility group protein-domain protein
 binding
 cisplatin adducts
 kinetics, **67**, 100–104

- High mobility group protein-domain protein binding (*cont.*)
thermodynamics, **67**, 99–100
- High mobility group protein-domain proteins
cisplatin adducts
sequence selectivity, **67**, 101
deoxyuridine
kinetics, **67**, 104
sequence alignments, **67**, 100
structure, **67**, 100
- High mobility group protein-domain-cisplatin-DNA ternary complex
structure, **67**, 104–112
- High-mobility group proteins, arginine
methylation, **61**, 97–98, 103
- High-molecular-weight complexes
composition and properties, **48**, 90–92
functions, possible, **48**, 103–105
in vivo, **48**, 101–102
multi-aminoacyl-tRNA synthetases, **48**, 90–92
occurrence, **48**, 93
stability, factors influencing, **48**, 93–94
ValRS-eEF1H, **48**, 92
- High-affinity folate receptors, **67**, 132–133
- Higher alkylation, carcinogenic, prevention, **51**, 205–207
- Higher eukaryotes
BER pathways, **68**, 125
- Highly glycosylated human reduced
folate carrier
protein
transport-upregulated K562 human
erythroleukemia cells, **67**, 139–141
- Hinf*III
AdoMet requirement and functions, **64**, 47–48
discovery, **64**, 46
purification, **64**, 46
recognition sites, **64**, 46–47
- his* operon, messenger RNA processing, **62**, 101–102
- His-77, **67**, 54
CooA
CO, **67**, 48–49
- HISAT, photodamage distribution, **62**, 232, 236
- Histidine, residue 84, EF-Tu, **71**, 540–542
- Histone deacetylases
and tumor suppressor gene
hypermethylation, **69**, 70–71
recruited by Mbds, **69**, 51–53
- Histone H1, DNA adduct recognition, **71**, 18–19
- Histone linker protein (H1), **67**, 98
cisplatin, **67**, 114–115
- Histone, *see also* Chromatin; GAL;
Karyoskeleton
acetylation
acetyltransferases
types and substrates, **65**, 308–310
Gcn5, **65**, 308–310
SAGA, **65**, 310
PCAF, **65**, 310–311
transcription factor recruitment, **65**, 311–313, 320
transcriptional activation, **65**, 313–314
Esal, **65**, 311
CBP/p300, **65**, 309
substrate specificity, **65**, 310
structure, **65**, 309–310
cancer role, **65**, 317
chromatin immunoprecipitation assay in
localization
caveats in studies, **65**, 320–321
cell cycle studies, **65**, 319
fine-mapping, **65**, 319–320
transcription studies, **65**, 318–319
chromatin structure effects, **65**, 308
deacetylases
gene repression, **65**, 314, 317
structure, **65**, 314
substrate specificity, **65**, 315
transcription factor recruitment,
65, 316–317, 320
types, **65**, 314–315
distribution in core histones, **65**, 307
susceptibility of histone types,
65, 307–308
thyroid hormone-responsive gene
regulation, **65**, 65–66
- core histones
modifications
overview, **65**, 306
signal transduction, **65**, 332
N-terminal tails and protein
interactions, **65**, 302–303
structures, **65**, 300
variants, **65**, 305
linker H1 histones
overview, **65**, 300

- subtypes, **65**, 305–306
- methylation, **65**, 321–322
- phosphorylation
 - cell cycle dependence, **65**, 322
 - early response gene transcription
 - correlation, **65**, 325
 - kinases and phosphatases, **65**, 325–326
 - sites, **65**, 322
 - transcription role, **65**, 322–325
- types, **65**, 300
- ubiquitination, **65**, 306–307
- Histone, *see* Chromatin
- Histone, *see* Nucleosome
- Histone, protamines and
 - acetylation, **40**, 71–74
 - ubiquitization, **40**, 75–76
- Histone, structure, **64**, 173
- Histones, *see* Chromatin; Linker histones
- HIV-1, *see* Human immunodeficiency virus type 1
- HIV, *see* Human immunodeficiency virus
- HIV, inhibition of, **42**, 89–93
- HLH, **68**, 376–377
- HLH462, identification as immediate-early response gene, **58**, 51
- HMG-domain proteins
 - DNA adduct recognition, **71**, 15–18
 - DNA interactions, **71**, 45–46
- HMG proteins, *see* High-mobility group proteins
- HMG, *see* High-mobility-group chromosomal protein
- HMG1, *See* High mobility group protein 1
- HMG2, **67**, 98
- HMGB1, DNA adduct recognition, **71**, 15–18
- HMGB2, DNA adduct recognition, **71**, 15, 18
- HMMH type 1a protein, **68**, 107
 - depletion
 - whole HeLa S3 cell extract, **68**, 110–112
 - detection
 - HeLa S3 cell, **68**, 111
 - HeLa S3 cells
 - depletion analysis, **68**, 112
 - human cell lines, **68**, 112
- HMTH1
 - 2-OH-dATP, **68**, 91
 - 8-oxoG, **68**, 91
 - amino acid residues, **68**, 80
 - C-terminal region
 - sequence alignment, **68**, 87
 - mRNA
 - SNP, **68**, 79–80
 - protein
 - hypothetical representation, **68**, 90
 - purine nucleoside triphosphates, **68**, 75
 - secondary structure, **68**, 82
- HMTH1 gene, **68**, 77–82
 - mRNA, **68**, 77–79
- HMYH, **68**, 88–90
 - 2-hydroxyadenine, **68**, 85–88
 - 8-oxoguanine
 - adenine, **68**, 85–88
 - C-terminal region
 - sequence alignment, **68**, 87
 - immunological detection, **68**, 87
- HMYH gene
 - genome structure
 - schematic representation, **68**, 89
 - RT-PCR, **68**, 86–87
- HMYH protein
 - substrate specificity, **68**, 86
- HNF4A*, mutation in maturity-onset diabetes of the young, **64**, 199, 203
- HNPCC
 - TDG, **68**, 251
- HNPCC, *see* Hereditary nonpolyposis colorectal cancer
- HNPP, *see* Hereditary neuropathy with liability to pressure palsies
- hnRNP A1, *see* Heterogeneous nuclear ribonuclear protein A1
- hnRNP C, effect on mRNA stability, **56**, 280–281
- HO endonuclease, double-strand
 - break-induced recombination role, **58**, 281–284, 287
- Hoechst 33258, DNA sequence specificity, **63**, 382, 399–400
- HOGG1
 - 8-oxoG, **68**, 91
 - 8-oxyguanine
 - cytosine, **68**, 83–85
 - MMH type 1a protein
 - 8-OH-G, **68**, 110–112
 - human cell lines, **68**, 110
 - multiple mRNA species, **68**, 196
 - polypeptides
 - MTS, **68**, 83
- HOGG1-2a, **68**, 88–90
 - C-terminal region, **68**, 83–85

- HOGG1 gene, **68**, 96
 exons, **68**, 83
 genome structure, **68**, 84
- Holt–Oram syndrome, *TBX5* mutation, **64**, 188
- Homeodomain, DNA-binding domain, **64**, 177
- Homocysteine thiolactone, formation catalyzed by MetRS, **48**, 128
- Homologous genetic recombination
 exogenous DNA in *Xenopus* oocyte
 developmental recombination, **54**, 116–119
 exonuclease resection, **54**, 106–108, 123
 gene-targeting implications, **54**, 121–123
 GV extracts, **54**, 113–114, 118
 kinetics, **54**, 112–113
 marker recovery, **54**, 114–116
 mismatch repair, **54**, 114–116
 single-strand annealing mechanism, **54**, 101–102, 108–111, 119–121, 123
 substrate selection, **54**, 103–106
 functions, **54**, 101
- Homologous genetic recombination, *see also* RecA
 functions in bacteria
 DNA repair, **56**, 132–133, 135
 importance of elucidation, **56**, 130–132
 initiation by DNA damage, **56**, 136–138
 mechanism, **56**, 131
- Homologous recombination in
Saccharomyces cerevisiae, **46**, 221–222, 264–266
 enzymology, **46**, 228–232
 DNA helicases, **46**, 256–258
 DNA ligase, **46**, 259–260
 DNA polymerases, **46**, 259–260
 DNA topoisomerases, **46**, 258–259
 nucleases, **46**, 244–253
 proteins in hybrid DNA formation, **46**, 232–244
 single-stranded DNA-binding
 proteins, **46**, 254–256
 models, **46**, 222–227
 physical analysis, **46**, 228
 reconstitution of *in vitro* system, **46**, 261–264
- Homologous recombination, immunoglobulin
 immunoglobulin gene diversification
 and, **45**, 33–34, 42–43
- Homologs
 CreA, in filamentous fungi, **69**, 179–180
- ROR, insect, **69**, 211–212
- Hormone-binding domain, steroid hormones
 and, **43**, 12–14
- Hormone-response element, gene expression
 and, **43**, 4–6
- Hormones
 ADP-ribosylation factors and, **45**, 54
 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase and, **45**, 119–123
- Hormones, *see also* Steroid hormones
- Hormones, pyruvate dehydrogenase complex
 effect, **70**, 47
- Host cell
 msDNAs, **67**, 84–86
- Housekeeping genes in *Trypanosoma brucei*, **43**, 41–46
- HOXA13*, mutation in human syndromes
 hand–foot–uterus syndrome, **64**, 189
 synpolydactyly, **64**, 189
- HOXD13*, mutation in syndactyly type II, **64**, 188–189
- HPLC-electrochemical detection, **68**, 140
- Hpr protein, *Bacillus subtilis* gene expression
 and, **46**, 132–134
- HRFC. *See* Human reduced folate carrier
- HRI
 eIF-2 α phosphorylation, **58**, 102–103
 heat shock protein association, **58**, 103
 heme regulation, **58**, 102
- HSC70
 oligomerization, **58**, 89
 partner proteins, **58**, 89
 translational accommodation,
58, 113–114
- HsCdc25p phosphatases, **72**, 44–45
- hsd* genes, *see* Type I restriction–modification
 enzymes
- HSP47
 quality control, **67**, 251
- HSP47, *see* Heat shock protein, 47
- Hsp60, protein folding role, **58**, 305–306, 308, 318–319, 331
- Hsp70
 oligomerization, **58**, 89
 partner proteins, **58**, 89
 protein folding role, **58**, 305–308, 318, 327, 331
- HSP70, *see* Heat shock protein 70
- HSPDE4A7 isoform, **69**, 266
- HSV-1, *see* Herpes simplex virus 1

- HSV-1, *see* Human herpesvirus type 1
- HSV VP16, **67**, 179–180
- HSV, *see* Herpes simplex virus
- HSV, *see* Human herpesvirus
- 5-HT receptors, *see* Serotonin receptors
- HTLV-I, *see* Human T-cell leukemia virus I
- HUBF, **67**, 98
- Human
- FGF-1 gene cloning, **70**, 159
 - FGF-1 promoter 1.D, **70**, 167–168
 - FGF-1.B promoter, **70**, 162
 - genomic stability, **70**, 86
 - gliomas, FGF-1 expression, **70**, 161–162
- Human AAG-DNA complex, **68**, 307
- Human alcohol-metabolizing enzymes, **40**, 255, 282–283
- alcohol dehydrogenase, **40**, 255–256
 - biochemistry, **40**, 256–260
 - genetics of isozymes, **40**, 260–269
 - aldehyde dehydrogenase, **40**, 269–270
 - biochemistry, **40**, 270–276
 - genetics of isozymes, **40**, 277–282
- Human alkyladenine DNA glycosylase structure, **68**, 307–308
- Human APE 1(hAPE1), **68**, 191
- Human cell lines
- hMMH type 1a protein, **68**, 112
 - human OGG1/MMH type 1a protein, **68**, 110
- Human cells
- transport-impaired
 - hRFC cDNA cloning, **67**, 140–146
- Human cells, HSV-1 transcript abundance, **71**, 474, 478–479, 483, 486
- Human colon adenocarcinoma
- LoVo cell extracts
 - uracil-initiated BER, **68**, 171–175
- Human cytomegalovirus
- genotype profiling, **71**, 472–474
 - infection and latency, **71**, 450–451
 - microarray analysis, **71**, 452–453
- Human development
- overview, **64**, 172
 - syndromes associated with transcriptional regulators, *see specific regulators and syndromes*
- Human DNA-N-glycosylases, **68**, 134
- Human herpesvirus
- ease of study, **71**, 447–448
 - genome maintenance, **71**, 449
 - productive infection, **71**, 448–449
 - reactivation, **71**, 449–450
 - replication and pathogenesis, **71**, 448
- Human herpesvirus type 1
- glass slide-based DNA microarrays
 - chip data, **71**, 465–468
 - chip fabrication and scanning, **71**, 464–465
 - experimental data, **71**, 470–472
 - hybridization, **71**, 455
 - receiver operating characteristic, **71**, 465
 - scanning protocols, **71**, 456–459
 - specific oligonucleotides, **71**, 461–464
 - transcript labeling, **71**, 455–456
 - transcript abundance changes, **71**, 474, 478–479, 483, 486
- 5-HT receptors, *see* Serotonia receptors
- Human immunodeficiency virus
- activation signals
 - cytokines, **49**, 160–161, 166, 182
 - heat shock, **49**, 162
 - heterologous viruses, **49**, 161–162
 - mitogens, **49**, 162
 - ultraviolet radiation, **49**, 162
 - gene
 - expression during infection, **49**, 157
 - expression studies
 - cell transfection, **49**, 159–160
 - in vitro* transcription, **49**, 158
 - viral replication analysis, **49**, 160
 - promoter strength, **49**, 158
 - long-terminal-repeat elements
 - core transcription control element, **49**, 162–163
 - modulators
 - downstream region, **49**, 173
 - enhancer region, **49**, 167
 - G–C-rich region, **49**, 167–168
 - TATA region, **49**, 168–170
 - upstream region, **49**, 164–167
 - modulatory transcription control element, **49**, 162–163
 - sequence, **49**, 163
 - steroid response element, **49**, 165
 - trans*-activation-response region, **49**, 162–164
 - RNA structure, **49**, 178–179
 - tatprotein binding, **49**, 171–173, 178–181
 - translational control, **49**, 175–177

- Human immunodeficiency virus (*cont.*)
- transcriptional initiation site, **49**, 157
 - messenger RNA
 - cellular factors in processing, **49**, 174
 - polyadenylation, **49**, 173–174
 - translational control, **49**, 174–176
 - therapy
 - antisense oligonucleotides, **49**, 182–183
 - antisense RNA, **49**, 183
 - ribozymes, **49**, 183
 - TAR RNA decoys, **49**, 183–184
 - tat inhibitors, **49**, 184
 - trans*-dominant inhibitors, **49**, 184–185
- Human immunodeficiency virus (HIV)
- gene therapy in AIDS treatment, **54**, 29
 - inhibition by oligonucleotides, **57**, 123–124
 - leader RNA
 - base composition, **54**, 25–29
 - dimer linkage structure, **54**, 18–19, 21
 - packaging signal, **54**, 21–23
 - poly(A) hairpin, **54**, 10–12, 14–15
 - primer-binding site, **54**, 15–18
 - secondary structure models, **54**, 2–3, 6, 29
 - splicing function, **54**, 23–24
 - trans-acting responsive hairpin, **54**, 6–7, 9–10
 - translational regulation role, **54**, 24–25
 - phylogenetic analysis, **54**, 1–2
 - Rev response element structure, **57**, 21–22, 30
- Human immunodeficiency virus reverse transcriptase
- α -helix H mutagenesis studies, **58**, 368
 - biogenesis, **58**, 344
 - deoxynucleotide binding and inhibition, **58**, 368–369
 - DNA footprinting, **58**, 364–366, 371, 373
 - drug targeting, **58**, 340–341, 361
 - fidelity and mutation effects, **58**, 369
 - polypurine tract primer and second-strand synthesis
 - central polypurine tract and central termination sequences of lentiviruses, **58**, 384, 386
 - reverse transcriptase mutations affecting selection and extension, **58**, 383–384
 - selection and initiation, **58**, 383
 - primer grip motif and mutagenesis effects, **58**, 361–363, 366–368
 - replication cycle of virus, **58**, 341, 343–344
 - retrovirus replication role, **58**, 340–341, 343–344
- ribonuclease H domain
- footprinting analysis, **58**, 371, 373
 - polymerization-dependent activity, **58**, 374, 376
 - polymerization-independent activity and strand transfer, **58**, 374, 376–377, 379–380
 - replication role, **58**, 376–377
 - ribonuclease H* activity, **58**, 373–374
 - structure, **58**, 370–371
- structural homology with other reverse transcriptases, **58**, 341
- template grip motif, **58**, 361–363
- three-dimensional structure, **58**, 344, 346
- tRNA^{Lys,3}
- genomic interactions, **58**, 347–349
 - initiation of (–) strand DNA synthesis, **58**, 353–355
 - p66–p51 mediation of primed events, **58**, 355–356, 359
 - packaging into viral particles, **58**, 346–349
 - PBS duplex recognition by heterologous reverse transcriptases, **58**, 360–361, 386
 - viral interactions outside the PBS, **58**, 349–350, 352–353
- Human immunodeficiency virus type 1
- double-stranded RNA therapy, **52**, 55
 - ribonuclease D properties, **52**, 41–42
- Human immunodeficiency virus type 1 (HIV-1),
- gene therapy with hairpin ribozymes
 - 5' leader target
 - catalytic efficiency, **58**, 22
 - inhibition of virus expression by ribozymes
 - diverse strain inhibition, **58**, 27
 - stable transfectants, **58**, 22–23, 26–27
 - T lymphocytes, **58**, 26–27
 - transient transfectants, **58**, 24–26
 - promoters
 - Moloney murine leukemia virus, **58**, 25–26
 - mouse mammary tumor virus, **58**, 22–24
 - polymerase II β -actin, **58**, 24–26
 - sequence, **58**, 21
 - stability of target site, **58**, 22–24
 - criteria for antiviral activity, **58**, 20–21

- delivery systems
 - autolytic hairpin cassette, **58**, 18–19
 - promoters, **58**, 19, 22–23, 31–33
- human clinical trials, **58**, 31, 37
- nef region target, **58**, 35
- protease region of pol gene as target
 - catalytic efficiency, **58**, 28–29
 - inhibition of virus expression, *in vivo*, **58**, 29–31
 - sequence, **58**, 29
 - stability of target site, **58**, 29
- simultaneous delivery of two ribozymes and virus inhibition, **58**, 29–31
- specificity of cleavage, **58**, 4
- target site selection, **58**, 16–17
- Human immunodeficiency virus type 1, RT
 - accessory proteins, **71**, 110–112
 - amino acid role, **71**, 127–128
 - Arg-72, **71**, 120–121
 - enhanced fidelity, **71**, 129
 - genetic assays, **71**, 106–108
 - Gln-151, **71**, 119–120
 - Lys-65, **71**, 120–121
 - Met-184, **71**, 117–119
 - minor groove binding track residues, **71**, 126
 - misinsertion fidelity assay, **71**, 102–103
 - mispair extension fidelity assay, **71**, 103–104
 - mutation rate variations, **71**, 130–131
 - mutational analysis overview, **71**, 112–113
 - mutator, error catastrophe, **71**, 129–130
 - pre-steady-state kinetic assays, **71**, 105
 - primer grip residues, **71**, 124–126
 - strand transfer fidelity, **71**, 109–110
 - structure, **71**, 94–95
 - template strand residues, **71**, 121–123
 - Tyr-115, **71**, 114–117
 - Tyr-183, **71**, 123–124
- Human immunodeficiency virus, latent
 - viruses and mutated oncogenes, **43**, 154–155
- AIDS, **43**, 140–152
- Human long iPLA₂ β isoform (LH-iPLA₂ β)
 - alignment, **67**, 16
 - proline-rich region, **67**, 15–16
- Human lymphoblastoid cell lines
 - mitochondrial extracts
 - 8-oxoG lesion, **68**, 294
 - oxidative DNA damage repair
 - mitochondria, **68**, 293
- Human proteins
 - PCNA-binding motif, **68**, 133
- Human reduced folate carrier (hRFC), **67**, 131–159
 - amino acid homologies, **67**, 143
 - exons, **67**, 148
 - expression
 - regulation, **67**, 147–153
 - gene
 - upstream organization, **67**, 148–150
 - promoters
 - dual, **67**, 151–152
 - protein
 - posttranslational modifications, **67**, 146–147
 - properties, **67**, 139–147
 - topology structure, **67**, 144
 - transcript heterogeneity, **67**, 147–150
 - transport-impaired K562, **67**, 146–147
 - Western blot, **67**, 145–146
 - wild-type p53, **67**, 152–153
- Human reduced folate carrier cDNA
 - characterization, **67**, 139–147
 - cloning, **67**, 140–146
 - heterogeneous 5' UTRs, **67**, 142
- Human reduced folate carrier-A promoter, **67**, 151–152
- Human reduced folate carrier-B promoter, **67**, 151
- Human short iPLA₂ β isoform (SH-iPLA₂ β), **67**, 19
- Human sphingosine kinases, **71**, 500–502
- Human T-cell leukemia virus I, mutation rates, **71**, 98–99
- Human U251
 - uracil-initiated BER, **68**, 174
 - mutation frequency, **68**, 182
- Human UNG2
 - dUMP residues, **68**, 379–380
- Human uracil-DNA glycosylase (UDG), **68**, 4
 - UNG gene, **68**, 365–384
- Humanization of antibodies
 - complementarity-determining region
 - grafting, **60**, 172–173
 - goals, **60**, 172
 - nonantibody proteins, **60**, 192
 - specificity-determining residues,
 - identification and transfer, **60**, 173, 176–177, 182–183
- HUNG gene, **68**, 370–371

- Huntington's disease (HD), trinucleotide repeat expansion, **66**, 163–164, 166, 187
- hus1, G₂-M checkpoint regulation, **62**, 379
- HVXXHPLLΦXLL consensus, in ROR transactivation, **69**, 224
- HX, **68**, 14
- HXTH2, **68**, 264
- Hyalectans, *see* Aggrecan; Versican
- Hybrid DNA, homologous recombination in *Saccharomyces cerevisiae* and, **46**, 232–244
- Hybrid-site model, *see* Elongation, protein
- Hybridization
- AAUAAA sequence, **71**, 302–303
 - HSV-1 microarrays, **71**, 455
 - msDNA of bacteria and, **40**, 6
 - protamines and, **40**, 51–53
 - distinct bands, **40**, 53–58
 - smear signal, **40**, 53
 - superoxide dismutases and, **40**, 233
- Hybridization, antisense compounds, **69**, 11
- Hybridomas, T cell, **69**, 238
- Hybrids
- alkylation damage repair in genomes and, **44**, 124–127
 - antisense oligonucleotides and, **44**, 152–153
- Hydrazine, DNA sequence specificity of damage, **63**, 383, 401
- Hydrogen
- methanogens, H₂ + CO₂, **71**, 232–234, 256
 - Methanosarcina mazei*, **71**, 242–243
- Hydrogen isotope, 5,6-dihydropyrimidine adducts and, **42**, 131–132
- Hydrogen peroxide, **68**, 18, 33–34, 76
- chromatin-bound PCNA complex, **68**, 23
 - DNA single-strand breaks, **68**, 19
 - endonucleases, **68**, 214
 - pol beta-defective cells, **68**, 48
 - yeast, **68**, 31
- Hydrogenases, methanogens, **71**, 245–249
- Hydrolysis, GTP
- eIF2 and 40S ribosome roles, **70**, 225–227
 - eIF5 regulation, **70**, 229–230
- Hydrophobic gate, EF-Tu, **71**, 540–542
- Hydrophobic interactions, aminoacyl-tRNA synthetases and, **40**, 122–126
- 2-hydroxy (OH)-dATP, **68**, 88, 90
- hMTH1, **68**, 75, 91
- 2-hydroxyadenine
- hMYH, **68**, 85–88
- 5-hydroxycytosine, **68**, 210
- Hydroxyl free radicals, DNA sequence specificity, **63**, 381, 396
- Hydroxyl radicals, **68**, 76
- Hydroxylamine, DNA sequence specificity of damage, **63**, 383, 401
- Hydroxylation, JA metabolism, **72**, 178
- Hydroxyethyl-N-chloroethylnitrosourea (HeCNU)
- pol beta-defective cells, **68**, 17
- Hydroxymethylases, 5,6-dihydropyrimidine adducts and, **42**, 144–145
- 5-Hydroxyuracil, **68**, 210
- Hydroxyurea inhibitors, enzymes in DNA precursor biosynthesis and, **44**, 194–195
- Hyper-recombination, and hypo-rec, mutant isolation, **51**, 274–299
- Hypermethylation
- DNA, **69**, 52
 - regional, and global hypomethylation, **69**, 64
 - tumor suppressor genes, **69**, 65, 67–68
 - histone deacetylases and, **69**, 70–71
- Hypermethylator phenotype, **69**, 68
- Hypermutation, somatic, **50**, 69–83
- Hyperrecombination phenotypes
- BER pathway defect strain, **68**, 36
 - single and double pathway defect mutants, **68**, 33–36
- Hypertrophic program, *see* Cartilage hypertrophy
- Hypochondrogenesis, collagen type-II gene mutations, **47**, 48–51
- Hypoglycemic agents, **70**, 197–201
- Hypoglycin, **70**, 197–198
- Hypomethylation, global, **69**, 54–55
- and regional hypermethylation, **69**, 64
- Hypoparathyroidism, G protein mutations, **47**, 95–97
- Hypothalamus
- class III POU domain protein protein expression in development, **63**, 231–234
 - overview of development, **63**, 230–231
- Hypoxanthine (HX), **68**, 14
- mitochondrial extracts, **68**, 293–294

I

- IDH*, *see* Isocitrate dehydrogenase, yeast
- IDP*, *see* Isocitrate dehydrogenase, yeast
- I-Sce-I, double-strand break-induced recombination role, **58**, 281, 285–286
- I κ B, autoregulation of promoter, **60**, 149–150
- ICER, *see* Inducible cyclic AMP early repressor
- Icosahedral Caulimoviridae, polycistronic translation
- TAV control, **72**, 23–24
- TAV–host interactions, **72**, 24–26
- ICP27, arginine methylation, **61**, 96–97
- ICRF-193, inhibition of topoisomerase II, **64**, 242–243
- Id2 gene, and ROR γ , **69**, 230–231
- IES, *see* Internal eliminated sequence
- IGF-I, *see* Insulin-like growth factor-I
- IGF-I, *see* Insulin-like growth factor-I
- IGF-II, *see* Insulin-like growth factor-II
- IGFBPs, *see* Insulin-like growth factor-binding proteins
- IGS, *see* Intergenic spacer
- IHF protein, binding to site 1 modulating replication inhibitor activity of π protein, **48**, 261–262
- Ii, *see* Invariant chain
- IL-1, *see* Interleukin-1
- IL-1 β , **67**, 24
- Imidazole, probing of RNA structure, **53**, 147
- Imino ether groups, DNA–transplatin analogs, **71**, 40–41
- Immediate-early response genes, *see also specific genes*
- classification, **58**, 44
- differential hybridization screening in identification, **58**, 49–57
- messenger RNA half-lives, **58**, 45–46
- superinduction with protein synthesis inhibitors, **58**, 46–47
- transcriptional regulation, **58**, 44–45
- Immune system, *sg/sg* mutation effects, **69**, 228
- Immunoassays, **68**, 140
- thymine glycols, **68**, 126
- Immunochemical analyses of nucleic acids, *see* Nucleic acids, immunochemical analyses of
- Immunoglobulin gene diversification by gene conversion, **45**, 27–29, 43
- enzymes, **45**, 38–43
- molecular mechanism, **45**, 32–38
- somatic genes, **45**, 29–32
- Immunoglobulin heavy-chain, pre-mRNA, poly A sites
- CstF64 levels, **71**, 343–347
- poly A site competition, **71**, 341–342
- poly A site complex stability, **71**, 342–343
- Immunoglobulin, *see* Antibody
- Immunoglobulin, splicing of polyadenylation sites in genes, **57**, 58–60
- Immunoglobulins
- isotype switch recombination, **50**, 83–94
- rearranged variable regions, **50**, 69–70
- Immunological characterization, ADP-ribosylation factors and, **45**, 52–53
- IMP cyclohydrolase, purine nucleotide biosynthesis and, **42**, 279–280
- IMP dehydrogenase, purine nucleotide biosynthesis and, **42**, 280–282
- IMPDH, *see* Inositol-5'-monophosphate dehydrogenase
- Imprinting process, theoretical model, **48**, 76–77
- Imprinting signal, methylation as, **48**, 73–75
- In situ* hybridization, FGF-1.B mRNA, **70**, 160–161
- IncP plasmid
- clustering of transfer functions, **54**, 200–201, 203
- entry exclusion function, **54**, 212–214
- physical properties of transfer-related products, **54**, 215–216
- regulation of transfer gene expression, **54**, 203–206
- relaxosome assembly at transfer origin, **54**, 217–218
- Independent phospholipase A₂ (iPLA₂)
- ankyrin, **67**, 13
- cloned Ca²⁺
- characteristics, **67**, 7
- Independent phospholipase A₂ α (iPLA₂ α)
- characteristics, **67**, 7
- Independent phospholipase A₂ β (iPLA₂ β)
- alternative splicing, **67**, 17–19
- ankyrin-repeat domain, **67**, 10–14
- alignment, **67**, 10
- apoptosis, **67**, 24–25
- ATP-binding domain, **67**, 8–10
- BEL suicide substrate, **67**, 6

- Independent phospholipase $A_2\beta$ (iPLA $_2\beta$)
 (cont.)
 bipartite nuclei localization signal,
 67, 14–15
 calmodulin, **67**, 16–17
 caspase-3 cleavage site, **67**, 15
 characteristics, **67**, 7
 chromosomal localization, **67**, 17–19
 cloning, **67**, 17
 enzymatic activities, **67**, 20
 future perspectives, **67**, 28–29
 gene structure, **67**, 17–19
 group VIA Ca $^{2+}$
 molecular biology, **67**, 1–29
 lipase consensus motif FXSXG, **67**, 5–8
 membrane homeostasis, **67**, 26–29
 membrane phospholipid remodeling, **67**,
 25–26
 mRNA encoding, **67**, 20
 phosphorylation, **67**, 17
 purified recombinant, **67**, 21
 rat brain, **67**, 21
 sequence, **67**, 4–17
 signaling function
 insulin-secreting cells, **67**, 22–23
 structural characteristics, **67**, 4–17
 tissue distribution, **67**, 20
 Independent phospholipase $A_2\gamma$ (iPLA $_2\gamma$)
 amino acid sequence, **67**, 6
 Indirect defense, plant–insect interactions, **72**,
 192–193
 Induced fit, role in domain–domain
 communication, **69**, 341–345
 Induced-systemic resistance, plant–pathogen
 interactions, **72**, 194
 Inducer of short transcripts, role in HIV gene
 expression, **49**, 170–171, 180
 Inducibility, ethanol utilization pathway,
 69, 151
 Inducible cyclic AMP early repressor (ICER)
 circadian rhythm role, **64**, 364–365
 DNA binding, **64**, 348
 inducibility and negative autoregulatory
 loop, **64**, 357–358
 promoter, **64**, 356–357
 Induction, superoxide dismutases and, **40**,
 242–245
 Infarction, FGF-1 role, **70**, 157–158
 Infection
 cytomegaloviruses, **71**, 450–451
 human cytomegalovirus, **71**, 450–451
 human herpesvirus, **71**, 448–449
 murine cytomegalovirus, **71**, 450–451
 viral mutation rates, **71**, 98–99
 Infection, HSV, productive and latent, **51**,
 129–137
 Infectious virions, pRNA assay, **72**, 420–421
 Infrared spectroscopy, *see* Fourier transform
 infrared spectroscopy
 Inhibitors
 5,6-dihydropyrimidine adducts
 and, **42**, 133
 bacterial adenyl cyclases and, **44**, 43–44
 enzymes in DNA precursor biosynthesis
 and, **44**, 194–195
 mammalian ribonuclease, *see* Mammalian
 ribonuclease inhibitor
 oligodeoxynucleotides as, *see*
 Oligodeoxynucleotides
 PDE4-selective, **69**, 261–262, 304–305
 PRPP synthetase reaction, **69**, 130–132
 Initiation
 at DNA replication origins, **51**, 93–96
 in yeast and mammals, **51**, 95–96
 Initiation complex, activation of origins, **72**, 71
 Initiation factor 4E, *see* Eukaryotic initiation
 factor 4E
 Initiation of transcription in RNA polymerase
 II, *see* RNA polymerase II transcription
 initiation
 Initiation pathway, 80S, eIF4A, **72**, 326–328
 Initiation, immunoglobulin gene diversification
 and, **45**, 39–41
 Inorganic phosphate, activator of PRPP
 synthetase, **69**, 132–133
 Inositol-1-phosphate synthase
 gene derepression in response to elevated
 phosphatidylcholine turnover, **61**,
 163–165, 170–171
 gene regulation with phosphatidylcholine
 synthesis, **61**, 160–163, 167, 169–170
 inositol-sensitive upstream activating
 sequence regulation model,
 61, 165, 167, 169–172
 mutants in *Saccharomyces cerevisiae*
 expression defects, **61**, 144–145
 inositol starvation studies, **61**, 153–154
 pleiotropic phenotypes of Ino $^-$ and Opi $^-$
 mutants, **61**, 146
 repression defects, **61**, 145–146

- role in phosphatidylinositol synthesis, **61**, 142–143
- structure, **61**, 143
- transcriptional regulation, **61**, 156–158
- yeast genes affecting expression, **61**, 143–144
- Inositol-5'-monophosphate dehydrogenase
 - cell proliferation role, **61**, 182–184, 191
 - down-regulation by p53, **61**, 200–201
 - expression in malignant transformation, **61**, 193–194
- inhibition
 - clinical applications, **61**, 202–203
 - effects
 - cell replication, **61**, 183, 201
 - immune system, **61**, 201–202
- isoforms
 - gene loci, **61**, 196
 - gene structures, **61**, 196–200
 - similarities, **61**, 190–191
 - tissue distribution, **61**, 191–192, 194–195
 - transcriptional regulation, **61**, 194–196
 - transcripts, **61**, 194, 199, 201
- kinetic mechanism and parameters, **61**, 190
- purification, **61**, 190–191
- purine biosynthesis, *de novo*, **61**, 184, 186–187
- purine salvage enzyme relationships, **61**, 187–189, 194
- substrate binding site, **61**, 191
- Inositol-sensitive upstream activating sequence
 - binding proteins, **61**, 158
 - gene distribution, **61**, 157–158
 - gene regulation in nutrient deprivation, **61**, 159–160, 169
 - modeling of gene regulation, **61**, 165, 167, 169–172
 - mutational analysis, **61**, 159
- Insecticide
 - Bacillus thuringiensis* insecticide proteins,
 - see* δ -Endotoxins
 - chemical versus biological approach, **60**, 1–2
- Insects, branched chain aminotransferases, **70**, 180–181
- Insertion, pRNA genetic analysis, **72**, 438–439
- Insertional mutagenesis, adenoviral DNA
 - integration and, **46**, 32–33
- In situ* hybridization, FGF-1.B mRNA, **70**, 160–161
- Insulin
 - adipocyte differentiation effects, **60**, 328–329
 - fatty acid synthase gene regulation
 - insulin response sequence
 - identification and characteristics, **60**, 322–325
 - USF binding, **60**, 326–328
 - quantitative response, **60**, 320
 - transgenic mouse model, **60**, 320–321
 - glycerol-3-phosphate acyltransferase gene regulation, **60**, 320, 326
 - IGFBP-1, effects on expression
 - hepatocyte cultures, **60**, 221, 224–225
 - in vivo*, **60**, 219–221
 - IGFBP-3
 - molecular mechanism of regulation, **60**, 246–250
 - regulation, **60**, 201–202, 239–241
 - insulin-like growth factor regulation, **60**, 196–197
 - insulin-like growth factor-I regulation, **60**
 - insulin-like growth factor-I regulation
 - circulating levels in deficiency, **60**, 200–201
 - concurrent regulation with binding proteins, **60**, 201–202
 - diabetes mellitus and insulin
 - downstream regions in exon 1,
 - mechanisms of response, **60**, 225–226, 230, 254
 - hepatocyte culture response, **60**, 221, 224–225
 - in vivo* effects, **60**, 219–221
 - homeostatic response to limitations, **60**, 199
 - phosphoenolpyruvate carboxykinase gene regulation, **60**, 325–326
- Insulin deficiency, effects on G protein expression, **47**, 102
- Insulin-like growth factor-1 (IGF-1)
 - inducible genes in mouse fibroblasts, **58**, 58–59
 - receptor and signal transduction, **58**, 58
- Insulin-like growth factor-binding proteins
 - hepatic contributions to circulating levels, **60**, 202
- IGFBP-1, insulin regulation

- Insulin-like growth factor-binding
 proteins (*cont.*)
in vivo, **60**, 219–221
 hepatocyte cultures, **60**, 221, 224–225
- IGFBP-3
 circulating ternary complex, functions, **60**,
 231–232
 gene
 locus, **60**, 234
 promoter, **60**, 235–236
 structure, **60**, 234–235
 transcripts, **60**, 236
 hepatic production, **60**, 238–239
 posttranslational regulation, **60**, 233–234
 potentiation of insulin-like growth
 factor-I, **60**, 232–233
 regulators
 developmental regulation, **60**, 238
 glucocorticoids, **60**, 244–245
 growth hormone, **60**, 245–246
 insulin effects and molecular mechanisms,
 60, 239–241, 246–250
 insulin-like growth factor-I, **60**, 241–244
 nutrition, **60**, 238
 tissue distribution, **60**, 236–238
 regulation by insulin and nutrition, **60**,
 201–202
 types, **60**, 201, 230–231
- Insulin-like growth factor-I
 binding proteins, *see* Insulin-like growth
 factor-binding proteins
 biological functions, **60**, 197–199,
 232–233, 251
 gene
 promoter regions in exon 1, identification
 and characterization
 DNA/protein interactions in
 downstream region, **60**,
 215, 226, 230
 DNA/protein interactions in upstream
 5' flanking region, **60**, 211, 214
 downstream sequence elements,
 60, 214
 template construction, **60**, 207
 transcription assay, *in vitro*, **60**, 208–209
 upstream sequence requirement, **60**,
 209–211
 structure, **60**, 203–204
 transcription initiation in exons 1 and 2
 developmental and metabolic
 responsiveness, **60**, 205–206
 sites, **60**, 204–205
 tissue specificity, **60**, 205
 in vivo versus *in vitro*, **60**, 206
 gene locus, **60**, 196
 growth hormone regulation, **60**, 198–199,
 217–218
 hepatic contributions to circulating levels,
 60, 202
 insulin and nutrition regulation
 circulating levels in deficiency, **60**,
 200–201
 concurrent regulation with binding
 proteins, **60**, 201–202
 diabetes mellitus and insulin
 downstream regions in exon 1,
 mechanisms of response, **60**,
 225–226, 230, 254
 hepatocyte culture response, **60**, 221,
 224–225
 in vivo effects, **60**, 219–221
 homeostatic response to limitations,
 60, 199
 mechanisms of nutritional regulation, **60**,
 218–219
 insulin comparison, **60**, 196–197
 receptor, **60**, 196
 regulation of IGFBP-3 expression, **60**,
 241–244
 structure, **60**, 203
 tissue distribution, **60**, 197, 251
- Insulin-like growth factor-II
 biological functions, **60**, 197–199
 gene locus, **60**, 196
 growth hormone mediation, **60**, 198–199
 insulin comparison, **60**, 196–197
 receptor, **60**, 196
 tissue distribution, **60**, 197
- Insulin, 6-phosphofructo-2-kinase/fructose-2,
 6-bisphosphatase and, **45**, 121–123
- Insulin, malic enzyme gene regulation, **52**,
 91–92
- Insulin, pyruvate dehydrogenase complex
 effect, **70**, 46–47
- Insulin, S6 kinase role in production, **65**, 119
- Insulin-secreting cells
 signaling function
 iPLA₂ β , **67**, 22–23
- Integral membrane proteins
 ankyrin-repeat domains, **67**, 12

- Integration host factor, lysogenic pathway in bacteriophage λ and, **46**, **45**
- β_1 -Integrin, identification as immediate-early response gene, **58**, **55**
- Intercalating agents, for triple helices, **69**, **22–23**
- Intercalators
- TFOs, **67**, **171**
- Intercellular bridges, protamines and, **40**, **61**
- Interferon
- short type I interferon expressed by pig trophoblast, **56**, **319–320**
- type I receptor, **56**, **290–291**
- types, **56**, **288–291**
- Interferon- γ , effect on prosome subunit structure, **49**, **32**
- Interferon- τ
- applications of recombinant protein, **56**, **303**
- discovery, **56**, **295**
- function, **56**, **303–304**
- gene
- evolution
- coding region, **56**, **309**, **311**, **313**, **315**
- promoter region, **56**, **315–317**
- linkage analysis, **56**, **317**, **319**
- locus, **56**, **317**
- glycosylation, **56**, **307**
- human genes, **56**, **320–321**
- purification, **56**, **302–303**
- receptor binding, **56**, **296–298**
- structure, **56**, **295–296**
- structure comparison with other type I interferons
- primary structure, **56**, **304–305**, **307**
- receptor-binding sites, **56**, **309**
- secondary structure, **56**, **305**, **307**
- three-dimensional structures, **56**, **307–309**
- transcriptional regulation, **56**, **301–302**
- trophoblast-specific expression, **56**, **298–301**
- Interferon- γ
- gene
- promoter, **56**, **111**, **119–120**
- regulation of transcription
- CD28, **56**, **111–112**
- cytokines, **56**, **112–114**
- DNA methylation, **56**, **114**, **116–119**
- enhancer elements, **56**, **120–123**
- estrogen, **56**, **123**
- promoter-binding proteins, **56**, **119–123**
- silencer, **56**, **124**
- structure, **56**, **109**, **119**, **288**
- transfection, **56**, **111**
- natural killer cell production, **56**, **110**
- regulation of genes, **56**, **289**
- T cell production, **56**, **110**, **116**
- Interferon-o
- discovery, **56**, **291–292**
- function, **56**, **294**
- gene
- evolution
- coding region, **56**, **309**, **311**, **313**, **315**
- promoter region, **56**, **315–317**
- linkage analysis, **56**, **317**, **319**
- locus, **56**, **317**
- variant of sheep, **56**, **319**
- genes, **56**, **292**, **294**
- glycosylation, **56**, **307**
- receptor, **56**, **294**
- structure, **56**, **292**
- structure comparison with other type I interferons
- primary structure, **56**, **304–305**, **307**
- receptor-binding sites, **56**, **309**
- secondary structure, **56**, **305**, **307**
- three-dimensional structures, **56**, **307–309**
- Interferon, inducibility of tryptophanyl-tRNA synthetase by, **48**, **110–113**
- Interferon, induction by double-stranded RNA, **57**, **126–128**
- Intergenic spacer, heterogeneity in, **50**, **30–33**
- Interleukin-1 (IL-1), squalene synthase regulation, **65**, **190–191**
- Interleukin-1 β messenger RNA, turnover role of AUF1, **62**, **284**
- Interleukin 4, production, sialidase role, **69**, **95**
- Interleukin-6, release stimulation by cellular binding of DNA, **57**, **129**
- Interleukin-8 receptor, ligand binding site, **49**, **129**
- Interleukin-1 β (IL-1 β), **67**, **24**
- Intermediate filaments
- effects of acrylamide monomer, **49**, **39**
- movement in cell cycle, **49**, **40**
- mRNA association, **49**, **10–11**, **40–41**, **44**
- networks, **49**, **36–37**
- prosome association, **49**, **39–43**
- Intermediate filaments, protein domains
- in, **43**, **67–68**
- assembly, **43**, **70–79**

- Intermediate filaments, protein domains
 in (*cont.*)
 functions, **43**, 79–81
 structure, **43**, 69–70
- Intermolecular crosslinking, pRNA dimers, **72**, 433
- Internal eliminated sequence (IES),
 see Ciliates
- Internal initiation model, for association of
 mRNA with ribosome, **48**, 191–194
- Internal ribosome entry site, **69**, 4
- Internal ribosome entry site
 alternative translation initiations, **72**,
 377–378
 cellular mRNAs, **72**, 374–376
 dependent translation, generalization, **72**,
 382–383
 discovery, **72**, 370–371
 FGF-2 mRNA, **72**, 387–390
 Mo-MuLV, PTB identification, **72**, 382
 MuLV genomic mRNA, **72**, 380–382
 P2 *c-myc* mRNA, **72**, 397
 RNA translation–packaging interplay, **72**, 10
 tissue specificity *in vivo*, **72**, 399–400
 transformed cells, **72**, 398–399
 VEGF mRNA, **72**, 393–394
 viral *vs.* cellular IRESs, **72**, 376
 viral mRNAs, **72**, 372–374
- Internal ribosome entry site *trans*-acting
 factors, FGF-2, **72**, 391
- Internal terminal repeat, in adeno-associated
 virus rescue and replication, **48**, 43–47
- Intestinal remodeling, *Xenopus* studies of
 thyroid hormone
 autonomous response to thyroid hormone
 cell culture studies, **65**, 76–77
 epithelial apoptosis, **65**, 75–76
 organ culture studies, **65**, 74–76
 connective tissue remodeling, **65**, 73–74
 epithelial transformation, **65**, 73
 larval intestine features, **65**, 70, 73
 matrix metalloproteinases
 cell fate determination mechanisms,
 65, 91
 collagenase, **65**, 87
 differential expression analysis, **65**, 87
 extracellular matrix remodeling, **65**, 85
 GelA, **65**, 87
 stromelysin-3
 apoptosis association, **65**, 86–87, 89
 developmental expression pattern,
 65, 86
 substrates, **65**, 89–90
 thyroid hormone regulation, **65**, 84–85
 muscle thickening, **65**, 74
 thyroid hormone receptor
 messenger RNA levels, **65**, 77
 TR β genes
 cell type-dependent temporal
 regulation, **65**, 79
 up-regulation by thyroid hormone, **65**,
 77–79, 82–83
 thyroid hormone response genes
 differential screening, **65**, 80
 early response genes, **65**, 80, 82–83
 gene regulation cascade model,
 65, 92–93
 late response genes, **65**, 83–84
 table, **65**, 81
- Intoxification, *alc* gene system by
 acetaldehyde, **69**, 172–173
- Intramolecular crosslinking, pRNA
 monomers, **72**, 433
- Intrastrand crosslink (Ixr1), **67**, 98
- Intron enhancer, poly A site choice, **71**,
 339–341
- Intron recognition
 cis requirements, **47**, 150–155
 intron splicing in heterologous systems, **47**,
 164–167
 model, **47**, 171–174
 snRNAs, **47**, 155–158
- Intron splicing
 (A + U)-rich sequences, **47**, 165–171
 alternative, **47**, 183–185
 enhancement of gene expression by, **47**,
 185–186
 in heterologous systems, **47**, 164–167
 site selection, **47**, 171–174
 stress effects, **47**, 186–188
- Intron splicing in monocots, **42**, 229, 253–255
 enhanced expression, **42**, 240
 5' exon length, **42**, 242–244
 maize protoplasts, **42**, 240–242
 mechanism, **42**, 250–251
 PCR analysis, **42**, 248–250
 required splicing, **42**, 244–248
 intron recognition, **42**, 232–240
 mechanisms, **42**, 230–232
 RNA transport, **42**, 251–253

- Introns, calcium-dependent animal lectins and, **45**, 216–218
- Introns, mitochondrial group-I, splicing, aminoacyl-tRNA synthetases in, **48**, 119–121
- Introns, splicing in plant mitochondrial transcripts, **70**, 137–138
- Invariant chain
- quality control, **67**, 251
- Invariant chain (Ii), major histocompatibility complex class II molecule processing role, **63**, 101
- Inverse immunoregulation, **69**, 87
- Ion channels
- ankyrin-repeat domains, **67**, 12
- Ionizing radiation
- DNA damage, **68**, 208
 - DNA lesions, **68**, 140
 - mutagenic effects, **68**, 139
 - pol beta-defective cells, **68**, 17, 48
- Ionomycin, effect on protein translation, **58**, 94–95, 98, 101
- IPLA₂
- ankyrin, **67**, 13
 - cloned Ca²⁺
 - characteristics, **67**, 7
- iPLA₂ α
- characteristics, **67**, 7
- iPLA₂ β . *See* Independent phospholipase A₂ β
- iPLA₂ γ
- amino acid sequence, **67**, 6
- IPTG, **68**, 136
- IQGAP, **67**, 199–200
- IQGAP1
- drug design, **67**, 221–222
 - E-cadherin, **67**, 199–200
- IRA1, in *Saccharomyces cerevisiae* growth control, **48**, 8–9
- IRA2, in *Saccharomyces cerevisiae* growth control, **48**, 8–9
- IRE, *see* Iron response element
- Ire1p, sensing of unfolded proteins, **58**, 88
- IRES, *see* Internal ribosome entry site
- Iridogoniodysgenesis
- FKHL7* mutation in type 1, **64**, 197
 - RIEGL*, mutation in type 2, **64**, 192–193
- Iron
- and heme synthesis, **51**, 31–33
 - cellular levels, regulation, **51**, 27–31
 - homeostasis, **58**, 189–190
 - iron-sulfur clusters, **58**, 190
- Iron-regulatory proteins, **69**, 3
- Iron response element (IRE), structure, **56**, 272–273
- Iron-response element, in mRNAs, **69**, 3
- Iron-responsive element
- augmentation by iron-responsive mRNA open reading frame sequences in ferritin, **55**, 127–129, 131
 - role in iron induction of ferritin, **55**, 122–124, 131
- Iron-responsive element-iron regulatory factor interaction, translation initiation and, **48**, 198–199
- Iron-responsive proteins
- hydrogen peroxide effects, **55**, 125–126
 - iron response, **55**, 124
 - nitric oxide effects, **55**, 125
 - phosphorylation of IRP-1, **55**, 126
 - role in iron induction of ferritin, **55**, 122–123
- Iron-sulfur proteins
- center, protein β , **72**, 116–119
 - nrdG* protein as prototype, **72**, 119
 - nrdG* protein definition, **72**, 114–115
- Iron(II)–EDTA, probing of RNA structure, **53**, 147, 153–154, 159
- Iron, superoxide dismutases and, **40**, 225–230, 233–234
- Ischemic heart disease, **68**, 274
- ISIS 5132, **67**, 219
- Islet β cells, **67**, 24
- Isocitrate dehydrogenase, yeast
- allosteric modulation, **57**, 326–327
 - cellular compartmentation, **57**, 330–331
 - genes, **57**, 327–329
 - mutant phenotypes, **57**, 327–329, 336
 - signal sequences, **57**, 330–331
 - subunit sequence homology
 - IDH, **57**, 327, 329
 - IDP, **57**, 330
- Isocoumarins, activation of multicatalytic proteinase, **49**, 29–30
- Isoguanine. *See* 2-OH-A
- Isoleucyl-tRNA synthetase
- aminoacylation and editing, **69**, 337–338
 - isoaccepting tRNAs, **69**, 327–328
 - split-protein constructs, **69**, 325
- Isoleucyl-tRNA synthetase, tRNA aptamer, **70**, 317

N⁶-Isopentenyl-2-thiomethyladenosine, and
ms²io⁶A37, presence in tRNA, **50**,
296–298

Isopropyl beta-D-thiogalactopyranoside
(IPTG), **68**, 136

Isotypes, immunoglobulins, switch
recombination, **50**, 83–94

Isozymes

alcohol dehydrogenase and, **40**, 256

aldehyde dehydrogenase and

biochemistry, **40**, 270–276

genetics of isozymes, **40**, 277–282

Isozymes, 6-phosphofructo-2-kinase/
fructose-2,6-bisphosphatase and, **45**,
101–104

mRNAs, **45**, 105–110

structure, **45**, 110–116

ISR, *see* Induced-systemic resistance

IST, *see* Inducer of short transcripts

ITAFs, *see* Internal ribosome entry site
trans-acting factors

Itron-containing replicons, **48**, 239–267

Itron, *see* Plasmid P1

Iterons, in replication control, **48**, 255

Ixr1, **67**, 98

J

JA, *see* Jasmonic acid

Jacobsen syndrome, trinucleotide repeat
expansion, **66**, 162–163

JAK 2, *see* Janus kinase 2

Jak, cytokine signaling, **56**, 113

Janus kinase 2 (JAK 2), growth hormone signal
transduction, **57**, 81, 85–86

Jasmonate-responsive promoters, **72**, 184–185

Jasmonates

external stimuli effects, **72**, 166–167

gene expression

down-regulation, **72**, 181

jasmonate-responsive promoters,
72, 184–185

up-regulation, **72**, 181–184

LOX pathway

AOC, **72**, 175–176

AOS, **72**, 173–175

biosynthesis regulation, **72**, 176–177

JA biosynthesis, transgenic
manipulation, **72**, 180

JA metabolism, **72**, 177–178

mutants, **72**, 178–180

OPR and β -oxidation, **72**, 176

overview, **72**, 171–173

mycorrhiza, **72**, 193–194

natural occurrence, **72**, 168–171

plant development

flowers, **72**, 198–200

germination and seedlings, **72**, 196–197

senescence, **72**, 202–205

tendrill coiling, **72**, 202

tuberization, **72**, 200–202

plant–insect interactions

direct defense, **72**, 190–192

indirect defense, **72**, 192–193

plant–pathogen interactions, **72**, 194–196

plant–plant interactions, **72**, 193

wound response pathway

ABA, **72**, 190

ethylene, **72**, 189

intracellular signal transduction,
72, 188

local generation, **72**, 187–188

overview, **72**, 185

SA, **72**, 190

systemic response, **72**, 189

Jasmonic acid

biosynthesis regulation, **72**, 176–177

biosynthesis, transgenic manipulation,
72, 180

identification, **72**, 166

metabolism, **72**, 177–178

natural occurrence, **72**, 168–171

signal transduction pathways, **72**, 167–168

Jasmonic acid- and elicitor-responsive
elements, **72**, 184

Jasmonic acid-induced protein

gene down-regulation, **72**, 181

gene up-regulation, **72**, 181–184

JEREs, *see* Jasmonic acid-and
elicitor-responsive elements

Jimpy mice, myelin basic protein, arginine
methylation, **61**, 119–120

JIP, *see* Jasmonic acid-induced protein

JM216, **67**, 117

chemical structure, **67**, 118

JM216, *see* bis-Acetatoamminedichloro
(cyclohexylamine) platinum(IV)

JM221, **67**, 117

chemical structure, **67**, 118

JM335, *see trans*-Amine(cyclohexylamine)
dichlorodihydroxoplatinum(IV)
JNK
PAK, **67**, 203
JNK, isoforms, **71**, 79
Jun, autoregulation of promoter, **60**, 152–153
Jun-B, identification as immediate-early
response gene, **58**, 51
Junction model, DNA bending, **47**, 199–200
Jun, *see c-Jun*; *Jun*-B
Jun transcription factor, structure and
recognition sequence, **47**, 236–237

K

K155A mutant fpg
oligonucleotides, **68**, 231
proteins
transient kinetics assay, **68**, 231
K155A protein, **68**, 228
K562.4CRF cells, **67**, 140–141
K57A mutant fpg
oligonucleotides, **68**, 231
Kaposi's sarcoma-associated herpesvirus,
microarray analysis, **71**, 452
Karyoskeleton
cisplatin cross-linking, **65**, 331
core filaments, **65**, 326
estrogen receptor association, **65**,
328–329
histone acetyltransferase and deacetylase
association, **65**, 329
isolation, **65**, 326–327
matrix attachment region, **65**, 326
mechanical signaling pathways and nuclear
DNA organization, **65**, 329–331
transcription role
transcriptionally active chromatin, **65**,
327–328
transcription factor association, **65**,
328–329
transcription factories, **65**, 327
Kearns-Sayre syndrome, **68**, 274
Keratan sulfate, in Morquio B disease, **69**,
101–102
Keratinocyte
fibroblast growth factor-inducible response
element activation in wound healing
delay in activation, **63**, 131
growth factor receptor inhibitor studies,
63, 126–127
signal transduction of growth factor
receptors, **63**, 127, 130–132
transgenic mouse models, **63**, 124–126
protein expression in wound healing, **63**, 132
Kethoxal, probing of RNA structure, **53**, 143
 α -Keto acid dehydrogenase complex, **70**, 41
Ketones, inducers of *alc* gene, **69**, 169–170
KH domains, vigilin interaction model, **72**,
151–153
KIAA0277, **71**, 416
KID, *see* Kinase-inducible domain
Kidney, pyruvate dehydrogenase kinase
distribution, **70**, 54
Kinase-inducible domain, CREB
definition, **72**, 274–279
KID phosphorylation, **72**, 293–296
polymerase complex assay, **72**, 290–291
transcription overview, **72**, 284–287
Kinase interaction motifs, **69**, 287
docking site, **69**, 291–292
Kinases, C-terminal domain, **48**, 165–172
associated with transcription factors, **48**,
166–168
binding DNA, **48**, 169
phosphorylating serine and threonine, **48**,
169–171
phosphorylating tyrosine, **48**, 171–172
Kinases, pyruvate dehydrogenase complex, **70**,
47–50
Kinetic specificity, tRNA structure and, **45**,
151–155
Kinetics
kissing complexes, **69**, 35–37
oligonucleotide invasion of RNA
structures, **69**, 12–13
Kinetics, RNA misfolding, **72**, 228
Kinking, DNA
neokinks, **47**, 204–205
stereochemical, **47**, 201–202
Kirromycin
EF-1 α , **71**, 537–538
EF-Tu binding sites, **71**, 535–537
EF-Tu resistance, **71**, 534–535
Kissing complexes
RNA–RNA, **69**, 31–32
structure, **69**, 32–35
thermodynamic and kinetic analyses, **69**,
35–37

Klenow fragment, **68**, 108–109
 KMSKS sequence
 AARS, **69**, 318
 ligand-free IleRS, **69**, 339
 Kniest syndrome, collagen type-II gene
 mutations, **47**, 53
 Knockout mice
 DNA glycosylase deficient, **68**, 381–382
 Knockout mouse models
 GS, **69**, 91–92
 PDE4, **69**, 304–305
 RORs, **69**, 226–236
KpnAI, gene structure, **64**, 10–11
 Krox20, transcriptional regulation in Schwann
 cells, **56**, 243–244
 KSI
 origin, **67**, 150
 KS32
 cDNA, **67**, 144
 origin, **67**, 150
 KS6
 cDNA, **67**, 144
 KSHV, *see* Kaposi's sarcoma-associated
 herpesvirus
 Ku, *see* Nonhistone protein, 1
 Ku, overexpression studies of metallothionein
 repression, **66**, 377–379
 Ku, ribosomal gene transcription
 regulation, **62**, 132–133

L

L1 elements, *see* LINE-1 elements
 L1, role in myelin, **56**, 242
 L10 operon, **47**, 358–359
 L11 operon, **47**, 356–358
 L20 operon, **47**, 361–362
 L32, identification as delayed-early response
 gene, **58**, 56
 L7/L12, frameshift suppression, **64**,
 147–148
 Labeling, transcripts, HSV-1 microarrays, **71**,
 455–456
lac operon, mRNA decay mechanisms, **52**,
 168–172
lac operator, repressor effects on DNA
 photodamage, **62**, 233
 LacI, *see* Lactose repressor protein
 Lacrimal gland, Muc4/SMC, **71**, 176

Lactate dehydrogenase, identification as
 delayed-early response gene, **58**, 56–57
 Lactobacilli, deoxynucleoside salvage
 deoxynucleoside kinases, **59**, 208–209
Lactobacillus acidophilus R-26
 deoxynucleoside kinases, *see* Deoxyadenosine
 kinase; Deoxycytidine kinase;
 Deoxyguanosine kinase
 deoxynucleoside metabolism, contrasts
 with other bacteria, **59**, 209–212
 growth requirements, **59**, 207
 mass determination, **59**, 240
 nucleoside, 2-deoxyribosyltransferases, **59**,
 208–209
 thymidylate synthase, **59**, 210–212
 Lactones, chromopeptides, **70**, 244–246
 Lactose repressor protein (LacI)
 amino acid modification studies,
 58, 147–148
 applications in recombinant gene
 expression, **58**, 155–156
 conformational change studies, **58**, 149,
 154–155
 DNA binding
 amino acid residues involved in
 binding, **58**, 139
 kinetics, **58**, 138
 loop formation, **58**, 137–138
 nonspecific binding, **58**, 134
 operator sequence identification, **58**,
 134–135
 searching for operator by repressor, **58**,
 136–137
 thermodynamics, **58**, 138–139
 domain structure, **58**, 130–131
 inducer binding
 amino acid residues involved in
 binding, **58**, 141–142
 kinetics, **58**, 140–141
 sugars, **58**, 140
 thermodynamics, **58**, 140–141
lac enzyme expression, overview, **58**,
 128–130, 166
 mutagenesis studies
 dimer assembly, **58**, 143
 DNA binding, **58**, 142–143, 146
 inducer binding, **58**, 142–143
 tetramer assembly, **58**, 133,
 143, 146
 tetrameric protein assembly

- shape of structure, **58**, 131, 133
 - subunit affinity, **58**, 133–134
 - three-dimensional structure
 - conformational change, **58**, 154–155
 - core domain, **58**, 150–151, 153–154
 - N-terminal domain, **58**, 149–151
 - nuclear magnetic resonance, **58**, 149–151
 - subunit interface, **58**, 154
 - X-ray crystallography, **58**, 149–151, 153–154
 - tryptophan fluorescence, **58**, 148
 - LacZ* α DNA reversion assay
 - uracil-initiated BER, **68**, 167–169
 - Lag1p
 - quality control, **67**, 250
 - λ repressor, autoregulation, **60**, 136–137
 - Laminin B1 gene, and ROR α 1, **69**, 240
 - LAT promoter, HSV, **51**, 141–144
 - Late promoters, HSV, **51**, 147–153
 - controlling $\beta\gamma$ transcripts, **51**, 150–153
 - U_L38 promoter, **51**, 147–150
 - Late response genes, *see also specific genes*
 - differential hybridization screening in
 - identification, **58**, 49–57
 - transcriptional regulation, **58**, 47–48
 - Latency, adeno-associated virus infection,
 - establishment, **48**, 33–35
 - Latent viruses and mutated oncogenes, **43**, 136
 - cancer
 - Burkitt's lymphoma, **43**, 167–170
 - constitutive oncogenes, **43**, 181–184
 - int* genes, **43**, 178–181
 - myelogenous leukemia, **43**, 170–173
 - point mutated proto-*ras* genes, **43**, 173–178
 - causes of clonal cancer
 - Burkitt's lymphoma, **43**, 166–167
 - cervical cancer, **43**, 160–164
 - Epstein–Barr virus, **43**, 166–167
 - hepatitis B virus, **43**, 164–165
 - herpes virus, **43**, 160–164
 - leukemia, **43**, 157–160
 - liver carcinoma, **43**, 164–165
 - papilloma viruses, **43**, 160–164
 - chromosomal abnormalities, **43**, 190–194
 - drugs, **43**, 187–188
 - harmless passenger hypothesis, **43**, 186–187
 - hepatitis, **43**, 153–154
 - human immunodeficiency virus, **43**, 154–155
 - human immunodeficiency virus and
 - AIDS, **43**, 140–141
 - drug-versus virus–AIDS hypothesis, **43**, 147–152
 - drug–AIDS hypothesis, **43**, 145–147
 - virus–AIDS hypothesis, **43**, 141–144
 - measles, **43**, 154–155
 - neurological disease, **43**, 155–157
 - pathogens, **43**, 184–185
 - hypothetical, **43**, 186
 - phantom viruses, **43**, 155–157
 - somatic mutations in cancer cells, **43**, 188–190
 - subacute scleroting panencephalitis, **43**, 154–155
 - theories, **43**, 140
 - hypothetical pathogens, **43**, 137–138
 - oncogene hypothesis, **43**, 138–139
- LBD, *see* Ligand-binding domain
- LDL
 - receptor family, **67**, 248
- LE-5132, **67**, 219
- Lead poisoning, effects on heme
 - production, **51**, 41
- Leaky scanning
 - eukaryote translation initiation, **72**, 5
 - polycistronic RNA translation, **72**, 22–23
- Leber's hereditary optic neuropathy, **68**, 274
- Lecithin:retinol acetyltransferase (LRAT)
 - cellular retinol-binding protein, activity
 - against bound ligands, **63**, 146–148
 - structure, **63**, 160
- Lectins, calcium-dependent, *see* Calcium-dependent animal lectins
- LEF-1, **67**, 98
- Leishmania amazonensis*, mini-exon
 - sequence, **69**, 8–9, 18, 25
- Lens DNA, **41**, 269
 - lenticular cDNAs, **41**, 269–272
 - lenticular genes, **41**, 272–276
- Lens proteins, **41**, 259–261, 277
 - α -crystallin, **41**, 261–263
 - enzymes, **41**, 263–265
 - evolution, **41**, 265–267
 - stress connection, **41**, 267–269
- Lenticular cDNAs, **41**, 269–272
- Lenticular genes, **41**, 272–276
- Lentivirus, types, **54**, 1

- Lentiviruses, IRES-dependent translation, **72**, 382–383
- leu363Pro mutation, sialidase, **69**, 105
- Leucine-accepting tRNAs, **70**, 319–321
- Leucine zipper, **67**, 51
- Leucine-zipper proteins
- plant, **47**, 249–250
 - structures and recognition sequences, **47**, 236–240
- Leucine/Lrp regulon
- direct regulation of genes, **55**, 65–66
 - footprinting assays for Lrp dissociation constants, **55**, 71
 - indirect regulation of glutamine synthetase, **55**, 66–67
 - Lrp affinity for leucine, physiological significance, **55**, 67–69
 - target gene
 - expression enhancement, **55**, 73
 - identification, **55**, 63–65
 - transcriptional activation by Lrp, **55**, 69, 71–73
- Leukemia
- acute lymphoblastic, **67**, 135
- Leukemia, latent viruses and mutated oncogenes and, **43**, 157–160, 170–173
- Leukotriene A₄ hydrolase, **45**, 81–83
- Lexitropsins, DNA sequence specificity of damage, **63**, 402
- LFB1, autoregulation of promoter, **60**, 161
- LH-iPLA₂ β
- alignment, **67**, 16
 - proline-rich region, **67**, 15–16
- Li-Fraumeni syndrome, *TP53* mutations, **63**, 213
- lic* operon, transcriptional attenuation, **62**, 363–364
- LIG1* gene, **68**, 126, 151–154
- LIG3* gene, **68**, 126, 151, 154–155
- LIG4* gene, **68**, 126, 151, 155, 159–160
- Ligand-activated trp repressor, *see* Trp repressor
- Ligand binding
- CooA, **67**, 54–56
- Ligand-binding domain
- nuclear hormone receptors, **69**, 207–208
 - ROR proteins, **69**, 212–215
- Ligase
- mitochondrial, **68**, 267–269
- Ligation-mediated polymerase chain reaction, determination of sequence specificity of DNA-damaging agents, **63**, 372–374, 376
- Ligation, *see* Strand ligation
- LIM, DNA-binding domain, **64**, 178
- LINE-1 (L1) elements
- 3'-untranslated region
 - function, **64**, 278–279
 - G-rich polypurine tract, **64**, 277–279
 - homology in mammals, **64**, 277–278
 - 5'-untranslated region
 - acquisition of novel sequences, **64**, 258–259
 - evolution, **64**, 258–261
 - homology in mammals, **64**, 258–259, 262
 - mice
 - developmental regulation, **64**, 264–266
 - structural properties, **64**, 266–268
 - primates
 - developmental regulation, **64**, 262–263
 - structural properties, **64**, 263–264
 - structure, **64**, 257
 - transcription regulation, **64**, 262
- abundance in genome, **64**, 257
- classification of retroelements, **64**, 256
- evolution mechanisms
- mutation, **64**, 281–282
 - replication, **64**, 282–284
 - strand switching, **64**, 284
- impact on mammals, **64**, 288–290
- natural history, **64**, 279–281
- open reading frame I
- evolution, **64**, 268–269, 271, 273
 - hypervariable domain, **64**, 268–269, 271, 273
 - protein function, **64**, 273–274
 - types in mice, **64**, 269
- open reading frame II protein domains and function, **64**, 275–277
- phylogenetic characters
- cladistic analysis, **64**, 284
 - hybridization probes, **64**, 285–286
 - murine analysis, **64**, 286, 288
 - SINE element comparison, **64**, 284–285
 - structure, overview, **64**, 256
- Linear amplification, determination of sequence specificity of DNA-damaging agents, **63**, 372, 374, 376
- Linear element, *Schizosaccharomyces pombe*, **61**, 353–354

- Link protein
 gene evolution, **62**, 210–211, 215
 transcriptional regulation, **62**, 208–209
- Linker histones
 chromatin fiber condensation, **52**, 218–220, 236–237, 243, 245, 254
 DNA interactions
 binding sequence, **52**, 231, 233–235
 cooperativity, **52**, 227
 crossover binding, **52**, 227–231
 linear DNA, **52**, 225–226
 high-mobility group protein interactions, **52**, 235–236
 location
 condensed chromatin fiber, **52**, 250–253
 nucleosome, **52**, 237–242, 254
 primary structure, **52**, 221–223
 synthesis, **52**, 225
 tertiary structure, **52**, 223–225
 types, **52**, 217–218
- Linker regions 1 and 2
 LR2 of PDE4A, **69**, 275–276
 PDE4 subfamily, **69**, 264–265
- Lipase consensus motif FXSXG
 iPLA₂ β , **67**, 5–8
- Lipopolysaccharide (LPS), squalene synthase
 regulation, **65**, 189–191
- Liposome, antisense oligonucleotide
 delivery, **57**, 110–113
- Liposomes, antisense oligonucleotides and, **44**, 158–160
- Lipoxygenase
 jasmonate and octadecanoids, **72**, 171–173
 jasmonates
 AOC, **72**, 175–176
 AOS, **72**, 173–175
 biosynthesis regulation, **72**, 176–177
 JA biosynthesis, transgenic manipulation, **72**, 180
 JA metabolism, **72**, 177–178
 mutants, **72**, 178–180
 OPR and β -oxidation, **72**, 176
- Lipoxygenases, **45**, 69
 5-lipoxygenase, **45**, 69–74
 12-lipoxygenase, **45**, 75–78
 15-lipoxygenase, **45**, 78–81
- Lithium, effects on G protein expression, **47**, 102
- Liver carcinoma, latent viruses and mutated
 oncogenes and, **43**, 164–165
- Liver rich activating protein mRNA,
 translation, **48**, 204–205
- Liver, 6-phosphofructo-2-kinase/fructose-2,
 6-bisphosphatase and, **45**, 100–101
- Liver, ALAS-1 mRNA, heme effects, **51**, 14–15
- Liver, gene expression, **71**, 71–73
- Liver, pyruvate dehydrogenase kinase
 distribution, **70**, 54
- LlaI*, classification of restriction–methylation
 system, **64**, 6
- LMC, *see* Lysosomal multienzyme complex
- LMP, *see* Low-molecular-weight protein
 complex
- LMX1B*, mutation in nail–patella syndrome, **64**,
 189–190
- Locked nucleic acid, efficiency *in vivo*, **69**, 14
- Lola, function, **66**, 139–140
- LolB, function, **66**, 139–140
- Lomustine (CCNU), DNA sequence
 specificity, **63**, 380, 390
- Lon protease, degradation of misfolded
 proteins, **58**, 330–331
- Long-oligonucleotides, herpesvirus DNA
 microarrays, **71**, 454
- Long-patch base excision repair, **68**, 6–9, 12,
 15, 23, 146, 160–161, 167, 291
 FEN-1, **68**, 338–342
 mtDNA, **68**, 287–289
 pol beta, **68**, 289–291
 uracil-DNA glycolyses, **68**, 289
vs. single-nucleotide BER, **68**, 58
- Long-terminal-repeat, *see* Human
 immunodeficiency virus
- Loop-closing pair, aptamer, **69**, 36–37
- Loop–loop complexes, *see* Kissing complexes
- Loop palindromes, **69**, 33–34
- LoVo cell extracts
 human colon adenocarcinoma
 uracil-initiated BER, **68**, 171–175
 patch size
 uracil-DNA BER, **68**, 175–181
 uracil-initiated BER
 mutation frequency, **68**, 182
- LoVo cells
 DNA mismatch repair
 uracil-initiated BER, **68**, 182–183
- Low-molecular-weight protein complex,
see also Prosomes
 discovery, **49**, 6
 role in antigen presentation, **49**, 3, 31

- Low-density lipoprotein (LDL)
 receptor family, **67**, 248
- LOX, *see* Lipoxygenase
- LOX, *see* Lysyl oxidase
- LOXL, *see* Lysyl oxidase-like protein
- LPA, **67**, 27
- LPS, *see* Lipopolysaccharide
- Lpz8, mediation of copper activation of
 genes, **58**, 177
- LRAT, *see* Lecithin:retinol acetyltransferase
- LST1
 quality control, **67**, 250
- LTQ, *see* Lysyl-tyrosylquinone cofactor
- LTR, *see* Long-terminal-repeat
- Luciferase assay, **69**, 11–12
- Lung, pyruvate dehydrogenase kinase
 distribution, **70**, 52
- LXXLL motif, CBP and SRC-1, **69**, 222
- LY231514 (MTA)
 structure, **67**, 136
- Lymph nodes, organogenesis, ROR γ role, **69**,
 230–231
- Lymphoblastoid cell lines
 mitochondrial extracts
 8-oxoG lesion, **68**, 294
 oxidative DNA damage repair
 mitochondria, **68**, 293
- Lymphoblasts, PRS isoform levels, **69**,
 142–143
- Lymphocyte adhesion antigen CD44
 ankyrin-repeat domains, **67**, 12
- Lymphocyte ankyrin, **67**, 12
- Lymphoid enhancer-binding factor 1
 (LEF-1), **67**, 98
- Lynch syndrome, genetic defects, **63**, 208
- D-Lysergic acid amides, 261–264
- D-Lysergyl peptide assembly, 262–264
- Lysine-65, HIV-1 RT, **71**, 120–121
- Lysine, **68**, 155, 226, 231
- Lysine, **68**, 57, 226
- Lysogenic pathway in bacteriophage λ ,
 posttranscriptional control, **46**, 37–38, 47
cII translation, **46**, 45
 λ genes, **46**, 38–39
 integration host factor, **46**, 45
 phage regulatory proteins, **46**, 46–47
 RNase II, **46**, 40–45
- Lysophosphatidic acid (LPA), **67**, 27
- Lysophospholipase
 group VIA PLA₂, **67**, 21–22
- Lysosomal carboxypeptidase A, *see*
 Cathepsin A
- Lysosomal multienzyme complex
 components, **69**, 84–97
 discovery, **69**, 82–84
 GALNS associated with, **69**, 96
 molecular pathology, **69**, 99–107
 stoichiometry and structure, **69**, 97–98
- Lysosomal targeting
 acid β -glucosidase, **66**, 207–209
 prosaposin, **66**, 218
- Lysyl oxidase
 amine oxidase activity, **70**, 16–18
 copper-binding site, **70**, 15
 cytokine receptor-like domain, **70**, 18–19
 developmental expression, **70**, 21–22,
 25–27
 encoding gene
 evolutionary relationships, **70**, 7–8
 expression regulation, **70**, 8–10
 posttranscriptional regulation, **70**, 11–12
 as transcriptional regulator, **70**, 12
 transcriptional regulation, **70**, 10–11
 functional domains, **70**, 2–3
 intracellular expression, **70**, 22
 intranuclear expression, **70**, 22
 LOX2 cDNA, **70**, 5
 LOX3 cDNA, **70**, 5
 LOXL expression overlap, **70**, 22–23
 lysyl-tyrosylquinone cofactor, **70**, 15–16
 mutations, chromosomal loci in tumors, **70**,
 6–7
 novel family members, **70**, 3–5
 synthesis, **70**, 13
- Lysyl oxidase-like protein
 amine oxidase activity, **70**, 16–18
 cDNA, **70**, 3–5
 cytokine receptor-like domain, **70**, 18–19
 developmental expression, **70**, 21–22, 25–27
 encoding gene
 at 15q24, **70**, 7
 expression regulation, **70**, 8–10
 transcriptional regulation, **70**, 11
- LOXL2
 basement membrane association, **70**,
 23–24
 mutations, **70**, 6–7
 processing, **70**, 14–15
 scavenger-receptor cysteine-rich
 domains, **70**, 20–21

- LOXL3
 brain expression, **70**, 24–25
 heart expression, **70**, 24–25
 scavenger-receptor cysteine-rich domains, **70**, 20–21
 uterus expression, **70**, 24–25
 lysyl oxidase expression overlap, **70**, 22–23
 processing, **70**, 14
 Lysyl–tyrosylquinone cofactor, **70**, 15–16
- M**
- M domains, *see* Methyltransferase domains
 m¹G, *see* 1-Methylguanosine
 m⁵U, *see* 5-Methyluridine
 M13 coat protein
 precursor structure, **66**, 132
 spontaneous insertion in plasma membrane
 avoidance of targeting machinery, **66**, 133
 driving forces, **66**, 133–134
 evidence, **66**, 133
 overview, **66**, 131
 steps, **66**, 132–133
 M13mp2lacZ *alpha*
 DNA-based reversion assay, **68**, 168,
 181–184
 M13mp2op14 DNA
 agarose gel electrophoresis, **68**, 173
 M26
ade6 transcription, requirement for hotspot
 recombination, **61**, 359
 chromatin structure in recombination, **61**,
 360–361
 genetic properties of mutation, **61**,
 355–356
 heptamer sequence
 associated binding proteins, **61**, 357–328
 chromosomal context, **61**, 359–360
 recombination hotspot, **61**, 347, 355
 Mac1, copper ion sensing, **58**, 171, 188–189
 Macromolecular ligands, EF-Tu interaction
 EF-Tu · EF-Ts, **71**, 521
 overview, **71**, 517
 ribosome, **71**, 521–524
 ternary complex, **71**, 520–521
 Macromolecular translocation, cell membranes
 and barrier walls, **72**, 461
 Macrophages, scavenger receptor, **50**,
 232–233, 257
- Mafosfamide
 pol beta-defective cells, **68**, 17
 MAG
 substrate bases, **68**, 190
 MAG, *see* Myelin-associated glycoprotein
 Magnesium
 complex with ATP, **69**, 128–129, 132
 DNA aptamer and, **69**, 29
 Mg²⁺
 bound and free states, **69**, 277–278
 effect on PRPP synthetase, **69**, 141
 TAR binding and, **69**, 37
 Magnesium-agarose gel system, TBP
 recruitment, **72**, 289–290
 Magnesium coordination network, EF-Tu, **71**,
 527–529
 Magnesium ion
 pRNA conformational change, **72**,
 443–444
 pRNA effect, **72**, 448–449
 Magnesium ion, in DNA polymerase α
 template/primer binding, **47**, 376–378
 Magnesium, transfer RNA modification effect
 on binding, **53**, 113–114, 119–120
 Maize genes, *dSpm* effects on
 RNA processing
 alterations after insertions, **47**, 178–183
Ds elements, **47**, 175–176
 RNA fates after *Ds* insertions, **47**,
 176–177
Spm properties, **47**, 177–178
 Maize, intron splicing in monocots and, **42**,
 240–242
 Major histocompatibility class I, **67**, 235–264
 assembly
 protein-specific factors, **67**, 260–263
 biogenesis
 ERAD, **67**, 258–259
 primary quality control, **67**, 254–260
 disulfide bonds, **67**, 256
 encoding, **67**, 251–252
 luminal domain
 structure, **67**, 253
 quality control, **67**, 251–263
 sequential folding and assembly, **67**, 254
 TAP, **67**, 260–263
 tapasin, **67**, 260–263
 Major histocompatibility complex
 antigen presentation, **49**, 3, 30–32
 gene locus, **49**, 30

- Malate dehydrogenase, yeast
 cellular localization and functions, **57**,
 325–326
 isozymes, **57**, 319
MDH genes, **57**, 319–320
 metabolic flux, **57**, 319
 mutant phenotypes, **57**, 319–320, 326, 336
 regulation of expression, **57**, 321
 sequence homology of subunits, **57**, 321
 signal sequences, **57**, 325
malEFG operon, messenger RNA decay, **62**,
 100–101
- Malic enzyme
 concentration regulation, **52**, 94
 gene
cis-acting elements, **52**, 112–119
 chromatin structure, **52**, 108–109,
 111–112
 DNase-I hypersensitivity, **52**,
 108–109, 111
 fatty acids and transcription, **52**, 92,
 104–108, 119–120
 hormonal control, **52**, 91–92, 102–104,
 112, 115–117, 119–122
 transcription and protein
 phosphorylation, **52**, 99, 101–102
 hepatocyte cell culture system, **52**, 92–93
 messenger RNA
 degradation, **52**, 97
 transcription, **52**, 97–99
 synthesis in hepatocytes, **52**, 94–95
- Mammalian *Ogg1/Mmh* gene
 8-OH-G, **68**, 107–121
- Mammalian cells
 8-OH-G, **68**, 109
 BER pathway, **68**, 5–7, 58
 DNA ligase genes, **68**, 126
 error-avoidance mechanisms, **68**, 77
 gene transcription, AMPK
 liver gene expression, **71**, 71–73
 muscle tissue gene expression, **71**, 77
 pancreatic β -cell, **71**, 74–77
 mtDNA, **68**, 291–294
 pol-beta null genotype, **68**, 59–62
 sphingosine kinase function, **71**, 497–498
- Mammalian cells, growth control of
 translation in, **51**, 339–363
- Mammalian DNA beta-polymerase
 BER, **68**, 57–72
 mutagenesis, **68**, 69–71
- Mammalian DNA ligases
 BER, **68**, 151–162
 encoding, **68**, 152
- Mammalian episomal chromatin,
 nucleosome positioning and, **40**, 174–175
- Mammalian MMH
 8-OH-G, **68**, 119–120
- Mammalian nervous system, genetic defects
 of, *see* Genetic defects of mammalian
 nervous system
- Mammalian P1 protamines, **40**, 37–38
- Mammalian P2 protamines, **40**, 38
- Mammalian pol beta
 POL3 mutants, **68**, 21
- Mammalian protamine genes, **40**, 45
- Mammalian ribonuclease inhibitor, **44**, 1–2,
 24–25
 biological role, **44**, 20–24
 inhibitory properties
 binding site, **44**, 12–20
 constants, **44**, 10–12
 experimental applications, **44**, 20
 mode, **44**, 12
 properties, **44**, 2–6
 structure, **44**, 6–10
- Mammalian sphingosine kinases, cloning, **71**,
 500–503
- Mammalian target of rapamycin (mTOR)
 essential amino acids in S6 kinase
 activation, **65**, 116–117
 mechanism of S6 kinase effector activity, **65**,
 115–116
 phosphorylation, **65**, 115
 sequence analysis, **65**, 115
- Mammals, CTD phosphatase, **72**, 337–341
- Mammary acinar cells, Muc4/SMC, **71**,
 170–175
- Manduca sexta*, ROR homologs, **69**, 211–212
- Manganese, pRNA effect, **72**, 449
- Manganese, superoxide dismutases and, **40**,
 225–230, 233–234
- Mannanase A, *Pseudomonas fluorescens*
 sub-sp. *cellulosa*
 overview, **61**, 221
 structure and catalytic mechanism, **61**,
 237–238
- MAO A, *see* Monoamine oxidase A
- MAO B, *see* Monoamine oxidase B
- MAP kinases, ERK, phosphorylation of PDE4
 enzymes, **69**, 290–297

- MAPK, *see* Mitogen-activated protein kinase
- Mapping, genetic defects of mammalian nervous system and, **41**, 253
- Mast cells, mouse, CPII, SPHK, **71**, 498
- MAT α 2 homeodomain, in yeast, cocrystal structure, **47**, 224–227
- mat2–mat3*, recombination coldspot, **61**, 347, 372–373
- Mathematical simulation, phi29 pRNA, **72**, 457–458
- Mating aggregate formation, *see* Conjugation, bacteria
- Matrigel, Muc4/SMC, **71**, 172–173
- Matrix attachment region, *see* Karyoskeleton
- Matrix metalloproteinases (MMPs) functions, **65**, 84
- intestinal development role in amphibians cell fate determination mechanisms, **65**, 91
- collagenase, **65**, 87
- differential expression analysis, **65**, 87
- extracellular matrix remodeling, **65**, 85
- GelA, **65**, 87
- stromelysin-3
- apoptosis association, **65**, 86–87, 89
- developmental expression pattern, **65**, 86
- substrates, **65**, 89–90
- thyroid hormone regulation, **65**, 84–85
- proteolytic processing, **65**, 84
- Maturity-onset diabetes of the young (MODY), *HNF4A* mutation, **64**, 199, 203
- Mbds, *see* Methylated DNA binding proteins
- MBF, *see* Mlul cell cycle box-binding factor
- MBP, *see* Myelin basic protein
- MBS, **67**, 196
- MCAD, *see* Medium-chain acyl-CoA dehydrogenase
- McCune–Albright syndrome, G protein mutations, **47**, 100–101
- Mcelp
- bifunctional activities, **66**, 3
- guanylyltransferase requirement for triphosphatase activity, **66**, 21–22
- triphosphatase catalysis, **66**, 21
- generation from alternative splicing, **66**, 26
- MCF-7 cells, Muc4/SMC, **71**, 174
- MCF-7 breast cancer
- cisplatin cytotoxicity assay plots, **67**, 124
- HMG1
- estrogen, **67**, 122–124
- MCM proteins, DNA replication role, **65**, 289–290
- Mcm2p, *see* Minichromosome maintenance protein 2
- Mcm7p, *see* Minichromosome maintenance protein 7
- Mcm10p, *see* Minichromosome maintenance protein 10
- MCMV, *see* Murine cytomegalovirus
- MCP-1, *see* Monocytic chemotactic and activating factor
- MCP, *see* Multicatalytic proteinase
- MCR, *see* Methyl-S-CoM reductase
- MDBP-2-H1, *see* Methylated DNA binding protein 2 H1
- MDH, *see* Malate dehydrogenase, yeast
- MDia 1/2
- biological functions, **67**, 197
- Me²⁺ binding sites, PDE4 isoenzymes, **69**, 267, 269–270, 278–279
- Measles, latent viruses and mutated oncogenes and, **43**, 154–155
- MeCp1, binding to methylated DNA, **57**, 235–236
- MeCp2
- binding to methylated DNA, **57**, 236–237
- embryogenesis role, **57**, 237
- MED1/MBD4, **68**, 134
- Mediator, Gal4p as component, **65**, 247
- Medium-chain acyl-CoA dehydrogenase (MCAD)
- deficiency disease
- clinical presentation, **58**, 311–312
- discovery, **58**, 311
- gene mutations, **58**, 312–313, 325–326
- incidence, **58**, 312
- expression system selection for mutant protein studies, **58**, 327–328
- flavin adenine dinucleotide effects on folding, **58**, 318–319
- G170R mutant, **58**, 326, 329
- gene family, **58**, 310–311
- K304E mutant
- aggregation, **58**, 313
- cell-free translation, **58**, 317–318

- Medium-chain acyl-CoA dehydrogenase (MCAD) (*cont.*)
 chaperonins
 complexes, **58**, 316–319
 overexpression effects on folding and aggregation, **58**, 314, 316–317
 charge replacement role in subunit interactions, site-directed
 mutagenesis studies, **58**, 321–324
 degradation, **58**, 313–314, 330
 expression in *Escherichia coli*, **58**, 313–314, 316, 319, 321
 temperature effects on folding, **58**, 319, 321, 324
 R28C mutant, **58**, 325–326
 S311R mutant, **58**, 326
 T168A mutant, **58**, 326
 three-dimensional structure, **58**, 311
- MEF2, *see* Myocyte enhancer factor 2
- Meiosis, *Schizosaccharomyces pombe*, *see also* M26; *rec* genes
 control of entry, **61**, 348–352
 nuclear cytology, **61**, 252–355
 overview, **61**, 346–348, 373–374
 recombination-deficient mutants and genes, **61**, 361–369
 recombination hotspots, **61**, 355–361
 region-specific control of recombination, **61**, 369–373
- Melatonin
 putative ligand for RORs, **69**, 218
 transcription, ROR β role, **69**, 229
- Melittanum*, **67**, 68
- Melphalan
 pol beta-defective cells, **68**, 17
- Melphalan, DNA sequence specificity, **63**, 379, 390
- Melphalan, immunochemical analyses of nucleic acids and, **42**, 69
- Membrane anchoring, nsP1, **71**, 201–203
- Membrane–chromosome replication, *see* *Bacillus subtilis*, membrane–chromosome replication
- Membrane homeostasis
 iPLA $_2\beta$, **67**, 26–29
- Membrane insertion of proteins, *see* M13 coat protein; Pf3 coat protein; SecYE translocon; Twin-arginine translocation
- Membrane insertion, PDE4A1, **69**, 280–281
- Membrane mucins
 characteristics, **71**, 150–151
 forms, **71**, 151–152
 members, **71**, 152–153
 transmembrane domain, **71**, 151
- Membrane phospholipid remodeling
 iPLA $_2\beta$, **67**, 25–26
- Membrane, cell
 composition, **65**, 362–363
 phosphatidylcholine biosynthesis
 inhibition and apoptosis induction, **65**, 382–386
 regulation, **65**, 364–374
 phosphatidylethanolamine biosynthesis
 regulation, **65**, 374–376
 phosphatidylinositol biosynthesis
 regulation, **65**, 376–379
 phosphatidylserine biosynthesis
 regulation, **65**, 379
 phospholipid biosynthesis
 homeostasis, **65**, 380–382
 overview, **65**, 362–363
- Membranes, associated collagenous proteins, **50**, 230–248
- Membranes, basement, LOXL2 association, **70**, 23–24
- Memory, cyclic AMP-responsive element
 binding protein role, **64**, 365–366
- Menadione, **68**, 31, 33–34, 280–281
- Menkes disease, gene, **58**, 169–170
- β -Mercaptoethanol, effect on branched chain aminotransferases, **70**, 183
- mer*-[Ru(II)(terpy)Cl $_3$]-DNA interactions, **71**, 53
- Mer $^-$ phenotype, alkyltransferase, **51**, 197–198
- Merbarone, inhibition of topoisomerase II, **64**, 242–243
- Messenger ribonucleoprotein, *see also* Prosomes
 classification, **49**, 53–54
 components, **49**, 7
 intermediate filament association, **49**, 40
 iron response element-binding protein, **49**, 10
 poly(A)-binding protein association, **49**, 9, 37
- RNA
 consensus sequence of binding site, **49**, 16
 incorporation, **49**, 3, 5, 7
 recognition, **49**, 56
 sucrose gradient profile, **49**, 7–9

- transfer from nucleus to cytoplasm, **49**, 9
- translation, **49**, 7
- Messenger RNA
 - 26S mRNA, synthesis, **71**, 196–197
 - 3' end-processing factor, yeast genes
 - CF1 complex, **71**, 354
 - CF11 complex, **71**, 355–356
 - conditional mutants, **71**, 358–359
 - genetic approaches, **71**, 359
 - mammalian homologs, **71**, 361–362
 - overview, **71**, 353–354
 - PF1 fraction, **71**, 356–357
 - synergistic lethality, **71**, 359
 - two-hybrid system, **71**, 360–361
- 5'-UTR, *cis*-acting elements, FGF-2, **72**, 387
- assay in bacteria, **52**, 165–166
- Bcl-X_L, **69**, 235–236
- binding proteins in bacteria, **52**, 205
- binding, eIF4A role, **72**, 314–315
- bulk decay rate, **52**, 164–165
- c-myc*
 - overview, **72**, 396–397
 - P0, IRES identification, **72**, 397–398
 - P2, IRES identification, **72**, 397
- cellular, shunting candidates, **72**, 21
- chemical decay, **52**, 154
 - assay, **52**, 161–163
 - mechanism, **52**, 163–164
- coordinate regulation, **72**, 138–139
- CTD phosphatase role, **72**, 353–354
- cytodistribution, **49**, 32–33
- deadenylation-dependent decay, **72**, 131–133
- decay mechanisms in bacteria, **52**, 167–176, 205–208
- determinants of decay in bacteria, **52**, 179–181
 - 3' determinants, **52**, 184–189
 - 5' determinants, **52**, 181–184, 194
 - internal determinants, **52**, 190–193
- discovery, **52**, 155
- endonucleases in bacteria, **52**, 196–205
- endonucleolytically cleaved
 - cell stress, **72**, 136–138
 - other systems, **72**, 139–142
 - site regulation, **72**, 138
- error-prone, removal, **72**, 135–136
- FGF-1.B, *in situ* hybridization, **70**, 160–161
- FGF-2
 - CUG start codons, **72**, 383–385
 - expression control, **72**, 392–393
 - IRES identification, **72**, 387–390
 - translational silencing by p53, **72**, 400–403
- functional decay, **52**, 154
 - assay, **52**, 157–159
 - factors affecting, **52**, 159–161
- genetic defects of mammalian nervous system and, **41**, 243–244
- half-life, range of values, **52**, 155, 164
- intermediate filament association, **49**, 10–11, 37, 40–41, 44
- iron-response element, **69**, 3
- iron response element-binding protein, **49**, 10
- life and half-life, **72**, 130–131
- MuLV, IRES, **72**, 380–382
- PDE1, 5' alternative splicing, **69**, 255
- plant, mitochondria
 - complex transcription patterns, **70**, 135–136
 - editing, **70**, 142
 - intron splicing, **70**, 137–138
 - processing and stability, **70**, 138–142
- poly A sequences, *Escherichia coli*
 - decay, **71**, 370
 - overview, **71**, 363–366
 - PAP1, **71**, 366–367
 - PAP1-stimulated mRNA decay, **71**, 370–372
 - RNases degrading, **71**, 370
 - target RNA decay, **71**, 367–369
- poly(A)-binding protein binding, **49**, 9, 11, 37
- polyadenylation
 - cleavage mechanism, **71**, 299–301
 - complexes, **71**, 302–304
 - 3' end formation, **71**, 298–299
 - 3' end processing, **71**, 347–349
 - poly A(+), polymerases, **71**, 288–290
- polyadenylation, pre-mRNA
 - calcitonin/CGRP, **71**, 337–341
 - immunoglobulin heavy-chain, **71**, 341–347
 - nuclei, **71**, 295–297
- polycistronic, translation
 - basic strategies, **72**, 21–22
- Icosahedral Caulimoviridae, **72**, 23–26
- leaky scanning, **72**, 22–23

Messenger RNA (*cont.*)

- TAV-activated reinitiation model, **72**, 27–28
 - proline-rich protein multigene families and, **41**, 6–9
 - prosome
 - binding, **49**, 11
 - function in translation, **49**, 22
 - recognition, **49**, 56
 - pulse-chase experiments, **52**, 156–157
 - regulation in bacteria, **52**, 166–167
 - antibiotic resistance genes, **52**, 177–178
 - cell growth rate, **52**, 178–179
 - ribonuclease genes, **52**, 179
 - ribosomal proteins, **52**, 176–177, 205–206
 - role in cell architecture, **49**, 12
 - ROR α , **69**, 209
 - ROR β , **69**, 209–210
 - ROR γ , **69**, 210–211
 - survival factor-like FGF-2 isoform, **72**, 386–387
 - translation role in decay, **52**, 193–196
 - transport, **49**, 9–12
 - unstable, decay regulation, **72**, 134–135
 - Vaccinia virus*, poly A signals
 - mechanism, **71**, 377–378
 - VP39, **71**, 379–380
 - VEGF, distinct IRES identification, **72**, 393–394
 - vitellogenin
 - 3'-UTR, vigilin binding, **72**, 148–151
 - vigilin functions, **72**, 153–154
 - vigilin identity, **72**, 147
 - vigilin interaction models, **72**, 151–153
 - vigilin localization and regulation, **72**, 147–148
 - vigilin overview, **72**, 145–147
 - vitellogenin and albumin, stability
 - regulation, **72**, 142–143
 - vitellogenin, stability
 - basic features, **72**, 144–145
 - precursor processing, **72**, 144
 - transcription, **72**, 143
 - vigilin role, **72**, 154–156
 - yeast poly A signals, **71**, 350–353
- Messenger RNA (mRNA)
- binding to methylated DNA, **57**, 235, 237–239
 - cis* elements
 - adenosine–uridine-rich elements, **56**, 267–269
 - amyloid precursor protein mRNA, **56**, 271–272
 - globin mRNA stabilization, **56**, 273
 - identification of new elements, **56**, 269–271
 - iron response element structure, **56**, 272–273
 - sequence homology, **56**, 267, 270
 - decay rate assays
 - pulse–chase, **56**, 258–259
 - serum-positive *fos* promoter assays, **56**, 259–260
 - transcriptional blockade, **56**, 259
 - transfection assays, **56**, 261
 - in vitro* systems, **56**, 260
 - 3'-end processing
 - coupling to transcription and splicing, **57**, 64–65
 - endonucleases, **57**, 48
 - nuclear processing, **57**, 48–54
 - polyadenylation, *see* Polyadenylation, RNA
 - principle, **57**, 41–42
 - protein complexes, **57**, 48–50, 53
 - sequences directing processing, **57**, 42–47
 - in vitro* systems, **57**, 48
 - yeast, **57**, 56–57
 - estradiol control, **57**, 237–240
 - gene silencing, **57**, 241, 243
 - half-life, **56**, 258
 - particle-mediated transfection and decay
 - actinomycin D effects, **56**, 265–266
 - cycloheximide effects, **56**, 265
 - granulocyte macrophage-colony stimulating factor mRNAs, **56**, 261, 263, 266–267
 - phorbol ester effects, **56**, 263, 265
 - uncapped mRNAs, **56**, 266
 - stability, *see also* Globins
 - half-lives, **57**, 251
 - ribonucleoprotein complex stabilization, **57**, 253, 269, 274, 283
 - structural determinants, **57**, 250–251
 - therapeutic applications, **57**, 283–284
 - trans-acting factors, **57**, 253
 - stabilization for gene therapy, **56**, 281–282
 - trans* factors
 - adenosine–uridine binding factor, **56**, 276–280

- hnRNP C, **56**, 280–281
 - identification, **56**, 274–276
 - nucleolin, **56**, 280–281
 - Messenger RNA decay, *see also*
 - Oligoribonuclease; Poly(A) polymerase;
 - Polynucleotide phosphorylase; RNA
 - helicase; RNase II; RNase III; RNase E;
 - RNase M
 - A + U rich elements in rapid turnover
 - destabilizing activity, **62**, 259, 261
 - AUF1 binding
 - β -adrenergic receptor messenger RNA
 - turnover role, **62**, 263–264, 282–283
 - affinity of binding, **62**, 280–281
 - cloning, **62**, 273
 - destabilizing mechanism, **62**, 277–278, 287
 - dimerization, **62**, 278–279
 - discovery, **62**, 269–271
 - α -globin messenger RNA stability
 - complex binding, **62**, 279–280
 - granulocyte-macrophage colony-stimulating factor messenger RNA turnover role, **62**, 283–284
 - Gro α messenger RNA turnover role, **62**, 284
 - hexamer binding to *c-fos* messenger RNA, **62**, 279
 - interleukin-1 β messenger RNA turnover role, **62**, 284
 - isoforms from alternative RNA splicing, **62**, 275–277
 - protein-protein interactions, **62**, 278
 - purification, **62**, 271, 273
 - RNA recognition motifs, **62**, 273–275
 - subcellular localization, **62**, 276
- AUH binding, **62**, 287
- coexistence with multiple turnover
 - determinants, **62**, 262
- consequences of instability, **62**, 57
- deadenylation of messenger RNA, **62**, 261–262, 277
- elav-like protein binding, **62**, 285
- Escherichia coli* enzymes, overview, **62**, 57–60
- c-fos* messenger RNA
 - half-life, **62**, 258, 268
 - mechanisms of ARE-mediated turnover, **62**, 261–262, 269–271, 279
- glyceraldehyde-3-phosphate binding, **62**, 285, 287
- half-lives, **62**, 56, 258
- his* operon messenger RNA processing, **62**, 101–102
- identification and characterization, **62**, 260
- inducible turnover with trans-acting factors, **62**, 263–264
- malEFG* operon, **62**, 100–101
- models
 - consensus model, **62**, 79–80
 - latent 3' decay model, **62**, 88, 90–91, 97–98
 - 3' tethering models, **62**, 91, 94–95
 - 5' tethering model, **62**, 80–81, 85–86, 95, 97–98
 - translation role, **62**, 95–96
- ompA*, **62**, 96–97
- RNA, **62**, 1, 97
- rpsO*, **62**, 98–100
- rpsT*, **62**, 97–98
- site-directed mutagenesis studies, **62**, 260
- trans-acting factor identification
 - affinity purification, **62**, 267
 - gel mobility-shift assay, **62**, 264–265, 280
 - Northwestern blot analysis, **62**, 263–264
 - reconstitution of decay reactions, **62**, 267–268
 - ultraviolet cross-linking, **62**, 265–266, 280
- translation coupling with turnover, **62**, 262–263
- trp* operon messenger RNA processing, **62**, 101
- Messenger RNA, *see also specific mRNAs*
 - association with ribosome, models, **48**, 188–194
 - internal initiation, **48**, 191–194
 - reinitiation, **48**, 190–191
 - scanning, **48**, 188–189
- complexes of aminoacyl-tRNA synthetases with, **48**, 121–122
- eukaryotic, translation initiation in, **48**, 181–228
- metabolism, interference, **48**, 224–225
- regions sensitive to translation arrest, **48**, 222–224
- transcript elongation catalyzed by RNA polymerase II, **48**, 152–154
- Messenger RNA, half-life in bacteria, **55**, 5–6

- Messenger RNA, nonsense-mediated decay
 cis-acting factors, **47**, 272–276
 codon location role, **47**, 272–275
 downstream element role, **47**, 277–280, 294–295
 functions, **47**, 290–293
 pathway modulation, **47**, 280–283
 position effects, **47**, 273–276
 requirements in *PGK1*, **47**, 277
 trans-acting factors, **47**, 283–290
 trans mutants for *cis* element
 identification, **47**, 288–290
 translation–turnover association, **47**, 293–294
 UPF gene product effects, **47**, 283–284
 Upflp-interacting proteins, gene
 identification, **47**, 286–288
 Upflp localization, **47**, 284–285
- Metabolic transformations, JA metabolism, **72**, 178
- Metal ions, RNA structures, **72**, 228–229
- Metal-responsive element (MRE)
 basal roles
 human MT-IG MREs, **59**, 263–266
 trout MT-B MREs, **59**, 266–268
 consensus sequence, **59**, 261
 distal and proximal element interactions, **59**, 268–270
 synergistic interactions in response to
 zinc, **59**, 263
 trans-acting factors
 assays, **59**, 274, 276
 MTF-1
 binding assays, **59**, 276
 cotransfection studies in human,
 mouse, and trout cell lines, **59**,
 280, 282–284
 gene cloning, **59**, 274–275
 metal specificity, **59**, 275, 279–280, 285
 nomenclature, **59**, 275
 zinc fingers, **59**, 276, 278–279
 table, **59**, 272–273
- Metallothionein
 acetylation of N-termini, **66**, 358–359
 cysteine content, **66**, 358
 expression regulation
 basal expression
 antioxidant response element, **66**,
 362–363
 metal regulatory elements, **66**, 362–363
 transcription factors, **66**, 364
 chromatin remodeling, **66**, 372–373
 cis-acting factors, **66**, 362
 CpG island methylation
 cancer role, **66**, 377
 definition of island, **66**, 374
 hypermethylation, **66**, 376–377
 Ku overexpression studies of
 repression, **66**, 377–379
 overview, **66**, 373–374
 repression mechanisms, **66**, 375–376
 tumor cell studies, **66**, 374–375, 377
 glucocorticoid induction, **66**, 368–369
 heavy metal induction
 general transcription factors, **66**, 365
 metal response elements, **66**, 365
 metal specificity, **66**, 365
 MTF-1 as transcription factor,
 66, 365–367
 lipopolysaccharide induction, **66**,
 369–370
 protein biosynthesis inhibitor effects,
 66, 371–372
 reactive oxygen species induction,
 66, 367–368
 repressors, **66**, 371
 trans-acting factors, **66**, 362
 functions
 epithelium differentiation by type IV,
 66, 361
 metal detoxification, **66**, 359
 metal homeostasis, **66**, 359–360
 reactive oxygen species scavenging,
 66, 360
 zinc storage by type III, **66**, 361
 gene structures, **66**, 361–362
 isoforms, **66**, 358, 378
 knockout mouse, **66**, 359, 367
 prospects for study, **66**, 378–379
 subcellular localization, **66**, 361
 tissue-specific expression, **66**, 370–371
- Metallothionein (MT)
 cis-acting elements, overview, **59**, 261
 functions, **59**, 258, 261
 gene structure conservation between
 humans and trout, **59**, 258–259
 induction
 metal specificity, **59**, 259–261,
 275, 279–280
 non-metals, **59**, 259

- metal-responsive element
 - basal roles
 - human MT-IG MREs, **59**, 263–266
 - trout MT-B MREs, **59**, 266–268
 - consensus sequence, **59**, 261
 - distal and proximal element interactions, **59**, 268–270
 - synergistic interactions in response to zinc, **59**, 263
- metal-responsive element trans-acting factors
 - assays, **59**, 274, 276
- MTF-1
 - binding assays, **59**, 276
 - transfection studies in human, mouse, and trout cell lines, **59**, 280, 282–284
 - gene cloning, **59**, 274–275
 - metal specificity, **59**, 275, 279–280, 285
 - nomenclature, **59**, 275
 - zinc fingers, **59**, 276, 278–279
 - table, **59**, 272–273
 - oxidative stress response of trout MT-B promoter, **59**, 270–271, 274
- Metastasis, Muc4/SMC, **71**, 160–161
- Methane
 - acetate conversion, **71**, 238
 - methylated C₁ compounds, **71**, 235–238
- Methanococcoides*, energy conservation, **71**, 273–274
- Methanococcus jannaschii*, **68**, 339
- Methanofuran, methanogenesis, **71**, 228–233
- Methanogenesis
 - acetate conversion, **71**, 238
 - cofactors, **71**, 228–232
 - ecological role, **71**, 225–227
 - formate, **71**, 234–235
 - H₂ + CO₂, **71**, 232–234
 - methylated C₁ compounds, **71**, 235–238
 - pathways, **71**, 238–240
- Methanogens
 - ATP synthesis, **71**, 240–242
 - cellular characteristics, **71**, 227–228
 - coenzyme F₄₂₀, **71**, 273
 - formate, **71**, 234–235
 - growth, proton translocation
 - acetate, **71**, 256–258
 - H₂ + CO₂, **71**, 256
 - methylated C₁ compounds, **71**, 256
 - membrane-bound methyltransferases, **71**, 259–261
 - proton-translocating pyrophosphatases, **71**, 258–259
 - taxonomy, **71**, 227–228
- Methanosarcina*
 - ATP synthases, **71**, 265–270
 - Ech hydrogenase, **71**, 248–249
 - F₄₂₀-nonreducing hydrogenase, **71**, 246–248
 - F₄₂₀-reducing hydrogenase, **71**, 245–246
 - formyl-methanofuran dehydrogenase system, **71**, 261–265
- Methanosarcina barkeri*, heterodisulfide reductase, **71**, 253–255
- Methanosarcina mazei*
 - F₄₂₀H₂ dehydrogenase, **71**, 249–253
 - membrane-bound electron transport systems, **71**, 255
 - proton-translocating pyrophosphatases, **71**, 258–259
 - redox-driven proton dislocation, **71**, 242–245
 - sodium ion pump, **71**, 260
- Methanosarcina thermophila*, heterodisulfide reductase, **71**, 253–255
- Methanosarcinaceae*
 - acetate conversion, **71**, 238
 - methane from methylated C₁ compounds, **71**, 235–238
- Methanothermobacter* strains
 - F₄₂₀-nonreducing hydrogenase, **71**, 271–273
 - heterodisulfide reductase, **71**, 271–273
- Methionine
 - residue 184, HIV-1 RT, **71**, 117–119, 123–124
 - residue 230, Mo-MLV RT, **71**, 125–126
- Methionine synthetase, recognition of tRNA and, **41**, 40–43
- Methionyl-tRNA formyltransferase, induced fit, **69**, 345
- Methotrexate (MTX), **67**, 133, 135
 - intracellular transfer, **67**, 138–139
 - polyglutamyl form, **67**, 135–138
 - structure, **67**, 136
- Methoxyamine-modified AP site, **68**, 11–12
 - repair, **68**, 13
 - structure, **68**, 8
- 2'-O-Methoxyethyl, RNA binding affinity enhanced by, **69**, 14

- Methyl groups, direct effect on binding factors, **48**, 61–62
- Methyl-N'-nitro/N-nitrosoguanidine (MNNG), **68**, 10
- O⁶-MeG, **68**, 44
- pol beta-defective cells, **68**, 17
- Methyl-S-CoM reductase, methanogenesis, **71**, 238–240
- 5—Methyl tetrahydrofolate structure, **67**, 136
- 3—Methyladenine DNA, **67**, 98
- 3—Methyladenine DNA glycosylase, **68**, 37
- 5—Methylcytosine, biological functions, **49**, 84, 86
- 5-Methylaminomethyl-2-thiouridine, stepwise synthesis in position, **51**, 34, 287–293
- Methylase, 5' cap, *Vaccinia virus* mRNA poly A signals, **71**, 379–380
- Methylated DNA binding protein 2 H1 (MDBP-2-H1)
- phosphorylation/dephosphorylation and binding, **57**, 240–241, 243
- regulation of expression, **57**, 238
- Methylated DNA binding proteins, corepressors recruited by, **69**, 51–53
- Methylating agents, in chemotherapy, **51**, 209–210
- Methylation
- as imprinting signal, **48**, 73–75
- DNA, **48**, 53–70
- parental imprinted genes, **48**, 71–77
- Methylation-dependent restriction system (MDRS)
- Mcr systems, **64**, 6–8
- Mrr systems, **64**, 7
- species distribution, **64**, 6
- Methylation, *see* DNA methylation
- Methylation, adenoviral DNA integration and, **46**, 23–26
- adjacent cellular DNA sequences, **46**, 30
- host defense mechanism, **46**, 26–27
- origin, **46**, 28–29
- viral replication cycles, **46**, 27–28
- Methylation, carcinogenic, prevention, **51**, 203–205
- Methylation, JA metabolism, **72**, 178
- Methylcytosine-binding protein, transcription mediated by, methylation and, **48**, 62–63
- methylcytosine-binding, transcription mediated by, methylation and, **48**, 62–63
- Methylene dimethanesulfonate, DNA sequence specificity, **63**, 378, 386–387
- O⁶-Methylguanine-DNA methyltransferases (MGMT), alkylation damage repair in genomes and
- activation, **44**, 128–129
- properties, **44**, 116–118
- regulation, **44**, 120–128
- sequences, **44**, 128–129
- 1-Methylguanosine, synthesis in position 37, 310–318
- Methylmethanesulfonate (MMS), **68**, 18, 42, 57
- comet assay, **68**, 62
- cytotoxicity, **68**, 58–59
- 5'-deoxyribose phosphate, **68**, 63–69
- DNA ligase, **68**, 160
- DNA single-strand breaks, **68**, 19
- fibroblast cell lines
- cytotoxic sensitivity, **68**, 64
- mutations, **68**, 69–70
- O⁶-MeG, **68**, 45–46
- pol beta, **68**, 58–59
- defective cells, **68**, 16–17, 48
- null cells, **68**, 61
- Methylnitrosourea (MNU), **68**, 10, 11, 275–276, 280
- pol beta-defective cells, **68**, 17
- Methylpurine-DNA glycosylase (MPG), **68**, 42, 134, 307–308
- BER, **68**, 46
- substrate bases, **68**, 190
- N-methylpurine-DNA glycosylase (MPG), alkylation damage repair in genomes and, **44**, 120–128
- 2-Methylthio-*cis*-ribosylzeatin
- lack of, **50**, 308–310
- stepwise synthesis in position, **50**, 37, 299–300
- Methyltransferase domains, **70**, 240
- Methyltransferase, *see* DNA (cytosine-5) methyltransferase
- Methyltransferase, domain of vaccinia capping enzyme, **50**, 106–108
- Methyltransferases
- membrane-bound, methanogenic archaea, **71**, 259–261
- nsP1 activity, **71**, 198–201
- Methyltransferases, 5,6-dihydropyrimidine adducts and, **42**, 145–149

- 5-Methyluridine, synthesis in position, **50**, 54, 279–286
- MetRS
- complex with tRNA^{Met}, **69**, 344
 - interface region, **69**, 324
 - microhelix
 - aminoacylation, **69**, 322
 - constructs, **69**, 335, 337
 - tRNA^{Met}, **69**, 327
- MetRS, homocysteine thiolactone formation catalyzed by, **48**, 128
- MFR, *see* Methanofuran
- MGMT, **68**, 41. *See* O⁶-alkylguanine-DNA alkyltransferase
- MHC, *see* Major histocompatibility complex
- Michael adducts, *see* 5, 6-Dihydropyrimidine adducts
- Michaelis constants, branched chain aminotransferases, **70**, 183–185
- Microbes
- anaerobic CO-oxidizing, **67**, 37
- Micrococcal nuclease, DNA sequence specificity, **63**, 383, 400
- Microhelix, MetRS
- aminoacylation, **69**, 322
 - constructs, **69**, 335, 337
- Microsatellite instability, types in cancer, **63**, 206–209
- Microsomal triglyceride transfer protein quality control, **67**, 251
- Mig1p
- changes in subcellular localization, **69**, 178
 - repression of transcription by, **69**, 179
 - sites, organized as repeats, **69**, 177
 - zinc fingers, **69**, 175
- Mikamycin B–streptogramin antibiotics group, **70**, 259–261
- Milk, Muc4/SMC, **71**, 170–175
- Mineralocorticoid receptor, *see* Steroid receptor
- Mini-exon sequence: *Leishmania*
- as target for antisense oligonucleotides, **69**, 8–9
 - folding into hairpin structure, **69**, 25
 - oligonucleotides complementary to, **69**, 18
- minibrain*
- comparison of N and C termini, **62**, 8
 - conserved residues and motifs with Dyrk-related kinases, **62**, 4–7
 - DH-box, **62**, 9–10
 - discovery and functions, **62**, 2
 - expression in development, **62**, 13
 - phylogenetic analysis with other kinases, **62**, 10–12
 - Y × Y motif in activation loop, **62**, 7–8
- Minichromosome maintenance protein 10, **72**, 56–57
- Minichromosome maintenance protein 2, **72**, 57–61
- Minichromosome maintenance protein 7, **72**, 57–61
- Minichromosomes, nucleosome positioning and, **40**, 168–174
- Minor-groove binders, **67**, 166
- Minus-strand RNA, nsP1 role, **71**, 203–204
- Minute virus of mice
- DNA replication
 - cis*-acting sequences required for replication
 - characterization of pPTLR minigenome, **55**, 258
 - internal replication sequence, **55**, 263–264
 - internal right-end sequences, **55**, 259, 263
 - left-hand hairpin deletion and replication prevention, **55**, 258–259
 - replication of minigenomes with multiple hairpin termini, **55**, 264–266
 - right-hand hairpin deletion and replication prevention, **55**, 254–255, 257–258
 - assay, **55**, 253–254
 - hairpin transfer mechanism, **55**, 250–251, 280
 - genome structure, **55**, 247, 267
- NS-1
- activities, **55**, 270–271
 - binding to origin region, **55**, 278–279
 - bridge dimers, *in vitro* resolution
 - 3′–3′ bridge dimer, **55**, 275–276
 - 5′–5′ bridge dimer, **55**, 274–275
 - domains, **55**, 269
 - essential amino acid residues for nicking activity, **55**, 279–280
 - half-life, **55**, 268
 - nickin B half of 3′–3′ bridge dimer, **55**, 276–278
 - nuclear targeting signal, **55**, 270
 - open reading frame, **55**, 268–269
 - phosphorylation, **55**, 282

- Minute virus of mice (*cont.*)
 role in replication, **55**, 250–251, 271,
 273–280, 282
 transcriptional activation, **55**, 269–270
- NS-2
 carboxy termini, **55**, 267
 functions, **55**, 268
 half-life, **55**, 268
 strains, **55**, 246
 structure, **55**, 247
- Misinsertion fidelity assay, retroviral RT, **71**,
 100–103
- Mismatch amplification mutation assay, **49**, 288
 annealing reaction
 duration, **49**, 293
 temperature, **49**, 293
 primer mismatches, **49**, 291–292
 reaction conditions, **49**, 292–293
 sensitivity maximization, **49**, 294–295
- Mismatch base pair, *see also*
 Guanosine–adenosine base pair;
 Guanosine–uridine base pair;
 Uridine–cytosine base pair;
 Uridine–uridine base pair
 adenosine–adenosine, **57**, 31
 adenosine–cytosine, **57**, 31–32
 biological roles, **57**, 33–35
 cytosine–cytosine, **57**, 32–33
 discovery, **57**, 1–2
 guanosine–guanosine, **57**, 30–31
- Mismatch repair (MMR), **68**, 41, 96
 genomic integrity maintenance, **66**, 189–190
 O⁶-MeG, **68**, 43–45
 regulation, **68**, 47–49
 triplet repeat sequence instability, **66**,
 179–180
- Mismatch repair (MMR), *see* DNA repair
- Mismatch repair, cisplatin-DNA adducts,
 71, 14
- Mismatch-specific uracil DNA glycosylase
 (Mug), **68**, 237
- Mismatched duplex, RNA–oligonucleotide, **69**,
 16–18
- Mismatched uracil
 TDG, **68**, 248–249
- Mispair extension fidelity assay, retroviral
 RT, **71**, 103–104
- Mitelfosine, **67**, 217
- MITF*, mutation in Waardenburg syndrome
 type 2, **64**, 196
- Mithramycin, DNA sequence specificity of
 damage, **63**, 383, 402
- Mitochondria
 BER enzymes, **68**, 292–293
 diversity, **70**, 124
 monophyletic origin, **70**, 121–122
 oxidative DNA damage repair
 human lymphoblastoid cell lines,
 68, 293
 oxidative phosphorylation, **68**, 76
 plant
 promoter primary structure, **70**, 127–129
 tissue-specific gene expression, **70**,
 134–135
 transcription initiation sites, **70**, 126–127
 transcription protein components, **70**,
 130–131
 transcription regulation, **70**, 131–134
 transcription units, **70**, 124–126
 tRNA maturation, **70**, 144–147
 tRNA population, **70**, 142–144
 plant, mRNAs
 complex transcription patterns, **70**,
 135–136
 editing, **70**, 142
 intron splicing, **70**, 137–138
 processing and stability, **70**, 138–142
 syntrophy-based symbiosis, **70**, 122–123
 Xenopus laevis, **68**, 292–293
 α -proteobacteria relatives, **70**, 123
- Mitochondria, *see* Uncoupling protein
- Mitochondria, ALAS transport, inhibition by
 heme, **51**, 16–17
- Mitochondrial biogenesis in *Saccharomyces*
 cerevisiae, **46**, 51–54, 82–85
 cell growth, **46**, 74–76
 ABF1, **46**, 76–80
 CPF1, **46**, 77–78
 multifunctional regulators, **46**, 80–81
 QCR8 gene, **46**, 77
 respiratory-chain component, **46**, 77–78
 evolution, **46**, 81–82
 gene pairs, **46**, 63–64
 path to nucleus, **46**, 71–73
 stress regulation, **46**, 70–71
 transcriptional regulation
 cis-acting elements, **46**, 54–55
 trans-acting factors, **46**, 55
 mechanistic models, **46**, 55–57
 signal transduction, **46**, 57–58

- transcriptional regulation by carbon source, **46**, 64, 68–70
- glucose repression, **46**, 65–67
- HAP2, **46**, 67–68
- HAP3, **46**, 67–68
- HAP4, **46**, 67–68
- transcriptional regulation by oxygen
- HAP1, **46**, 59–62
- HAP2, **46**, 62
- HAP3, **46**, 62
- HAP4, **46**, 62
- heme, **46**, 59–62
- ROX1, **46**, 62
- yeast cell cycle, **46**, 73–74
- Mitochondrial DNA (mtDNA)
- aging, **68**, 295–296
- apoptosis, **68**, 274
- BER, **68**, 255–256
 - AP endonuclease, **68**, 263–265
 - DNA glycosylases, **68**, 261–263
 - enzymology, **68**, 259–270
 - further study, **68**, 270
 - mammalian, **68**, 275–276
- damage, **68**, 258–259
 - incidence, **68**, 258–259
- lifetime, **68**, 258
- ligase
 - AP lyase, **68**, 268–269
- long-patch BER, **68**, 287–289
- mammalian cells, **68**, 291–294
- NO-induced damage, **68**, 276–279
- nucleotides, **68**, 277–279
- oxidative damage, **68**, 276
- point mutations, **68**, 258
- progressive cell death, **68**, 274
- repair
 - cell-specific differences, **68**, 279–282
 - enzymes, **68**, 261–270
 - mechanisms, **68**, 279
- Mitochondrial endonuclease G, **68**, 295–296
- Mitochondrial extracts
 - ethenoadenine, **68**, 293–294
 - hypoxanthine, **68**, 293–294
- Mitochondrial genome, overview, **60**, 269–270
- Mitochondrial group-I intron splicing, aminoacyl-tRNA synthetases in, **48**, 119–121
- Mitochondrial ligase, **68**, 267–269
 - identification, **68**, 267–268
- Mitochondrial localization signal (MLS), **68**, 257
- Mitochondrial short-patch base excision repair common pathway, **68**, 260
- Mitochondrial targeting signal (MTS), **68**, 80
 - hOGG1 polypeptides, **68**, 83
- Mitochondrial UNG1, **68**, 372–374
- Mitochondrial uracil DNA glycosylase (mtUDG), **68**, 295–296
- Mitogen-activated protein kinase (MAPK)
 - growth hormone signal transduction, **57**, 86–87
 - substrates, **57**, 86
 - types, **57**, 86
- Mitogen-activated protein kinase 2, **71**, 80
- Mitogen-activated protein kinase phosphatase (MKP)
 - cell cycle control in mice, **58**, 69
 - identification as immediate-early response gene, **58**, 51–52
- Mitogen-activated protein kinases
 - overview, **71**, 78–81
 - preproinsulin gene expression, **71**, 81–82
- Mitogenic activation, and protein synthesis, **51**, 340–343
- Mitogens, *Egr-1* induction in response to, **50**, 193–195
- Mitomycin C
 - pol beta-defective cells, **68**, 17
- Mitomycin C, DNA sequence specificity, **63**, 380, 390
- Mitosis, regulated proteolysis, **72**, 52
- Mitoxanthrone, DNA sequence specificity, **63**, 380, 392
- Mitoxanthrone, *see* Topoisomerase II poisons
- Mitoxanthrone, DNA sequence specificity, **63**, 382, 397
- MIuI cell cycle box-binding factor, yeast, **72**, 48–49
- Mizoribine, inositol-5'-monophosphate dehydrogenase inhibition and clinical applications, **61**, 202–203
- MKP, *see* Mitogen-activated protein kinase phosphatase
- ML162, **67**, 68
 - characteristics, **67**, 69
- MLS, **68**, 257
- MMF, *see* Mycophenolate mofetil

- MMH
 mammalian
 8-OH-G, **68**, 119–120
- Mmh* deficient mice
 8-OH-G, **68**, 118
- Mmh* homozygous mutations, **68**, 121
- Mmh* knockout mice
 8-OH-G, **68**, 113–119
 Mmh mutant, **68**, 113
 generation, **68**, 113
- Mmh* mutant
 8-OH-G, **68**, 115
 AP lyase
 liver extracts, **68**, 113
 mutation frequency, **68**, 115–119
 targeted disruption, **68**, 115
- MMFs, *see* Matrix metalloproteinases
- MMR, **68**, 41, 96
 O⁶-MeG, **68**, 43–45
 regulation, **68**, 47–49
- MMR, *see* Mismatch repair
- MMS. *See* Methylmethanesulfonate
- MNHT1
 Tg, **68**, 216–218
 urea, **68**, 216–218
- mmn⁵s²,
 see 5-Methylaminomethyl-2-thiouridine
- MNNG, **68**, 10
 O⁶-MeG, **68**, 44
 pol beta-defective cells, **68**, 17
- MNU, **68**, 10, 11, 275–276, 280
 pol beta-defective cells, **68**, 17
- Mobility shift, nuclear RNA-binding proteins
 and, **41**, 185
- Models
 antiviral strategy design, **72**, 458–459
 CREB activation domain, **72**, 272–273
 phi29 pRNA, **72**, 457
 phosphorylated CREB transcription, **72**,
 296–298
 pRNA 3D structure, **72**, 440–443
 pRNA dimers and trimers, **72**,
 457–458
 TAV-activated reinitiation, **72**, 27–28
 vigilin–single-stranded nucleic acid
 interaction, **72**, 151–153
 viral DNA packaging, **72**, 458–459
 vitellogenin mRNA stabilization, **72**, 156
- Models, cell culture, **50**, 163–172
- Models, HSV DNA replication, **70**, 107–111
- MODY, *see* Maturity-onset diabetes of
 the young
- MOGG1, **68**, 215–216
- Molecular biology
 human hereditary porphyrias, **51**, 34–41
 human hereditary sideroblastic anemia, **51**,
 41–46
- Molecular colony technique, **51**, 261–264
- Molecular pathology, LMC, **69**, 99–107
- Moloney murine leukemia virus
 cell surface antigen synthesis, **72**, 378–379
 PTB identification, **72**, 382
- Moloney murine leukemia virus, RT
 mutational analysis, Tyr-222, **71**, 124
 strand transfer fidelity, **71**, 109–110
- Mo-MLV, *see* Moloney murine leukemia virus
- Mo-MuLV, *see* Moloney murine
 leukemia virus
- Monoamine oxidase A (MAO A)
 deficiency in aggression, **65**, 130, 132
 functions
 catalytic reaction, **65**, 130
 central nervous system, **65**, 151
 gene
 cloning, **65**, 131
 locus, **65**, 132
 organization, **65**, 132, 135
 monoamine oxidase B chimera
 properties, **65**, 140, 148
 prospects for study, **65**, 152
 sequence homology with type B, **65**,
 131–132
 tissue and cell distribution, **65**, 149–150
- Monoamine oxidase B (MAO B)
 active site and catalytic residue
 mutagenesis, **65**, 148–149
 deprenyl inhibition, **65**, 151–152
 flavin adenine dinucleotide binding
 comparison with other flavin-binding
 enzymes, **65**, 141, 143, 146
 dot-blot assay of noncovalent binding,
 65, 140
 flavinylolation assay, **65**, 140, 142
 steps in flavinylolation, **65**, 146–147
 stoichiometry, **65**, 135
 functions
 catalytic reaction, **65**, 130
 central nervous system, **65**, 151
 gene
 cloning, **65**, 131

- locus, **65**, 132
- organization, **65**, 132, 135
- sequence homology between species, **65**, 131–134
- monoamine oxidase A chimera
 - properties, **65**, 140, 148
- Parkinson's disease role, **65**, 130–131, 151
- prospects for study, **65**, 152
- sequence homology with type A, **65**, 131–132
- site-directed mutagenesis of flavin-binding sites
 - covalent-binding site, **65**, 147–148
 - dinucleotide-binding site, **65**, 136–137, 140
 - fingerprint site, **65**, 144–147
 - overview, **65**, 135
 - second flavin adenine dinucleotide-binding site, **65**, 141–144
 - table of mutants, **65**, 139
 - target selection, **65**, 135–136, 141
 - transient transfection system, **65**, 136
- tissue and cell distribution, **65**, 149–150
- Monoclonal antibodies, protein tyrosine kinase substrates and, **44**, 216–222
- Monocot genes, rice, **45**, 22
- Monocots, intron splicing in, *see* Intron splicing in monocots
- Monocytic chemotactic and activating factor (MCP-1), identification as immediate-early response gene, **58**, 58
- Monodentate platinum(II) compounds–DNA interactions, **71**, 34–38
- Monofunctional DNA glycosylase
 - BER, **68**, 15
- Monomers, AlcR as, **69**, 159–160
- Mononuclear platinum complexes, **67**, 117–119
 - chemical structure, **67**, 118
- Monopolymerase system, for DNA synthesis, **51**, 98
- Monovalent cations, pRNA effect, **72**, 448–449
- Morpholino oligonucleotides, **67**, 172
- Morquio B disease, keratan sulfate in, **69**, 101
- Morquio disease, GALNS deficiency, **69**, 95–96
- Morula, genome-wide demethylation in, **48**, 66–67
- Mosaic analysis, Flp recombinase, **51**, 87
- Mosaicism, in osteogenesis imperfecta, **47**, 43
- Motion task, pRNA conformational change, **72**, 445
- Mouse
 - FGF-1 gene cloning, **70**, 159
 - FGF-1.B *in situ* hybridization, **70**, 160–161
- Mouse sphingosine kinases, cloning, **71**, 501–502
- Mouse, transgenic, expression and second intron enhancer, **50**, 175–179
- MP20, structure, **64**, 106
- Mpf, role in mating aggregate formation, **54**, 214, 217, 245–246
- MPG, **68**, 42, 134, 307–308
 - BER, **68**, 46
 - substrate bases, **68**, 190
- MR-guanine nucleotide exchange factor, **71**, 416
- MRE, *see* Metal-responsive element
- mRNA
 - ALAS-2, **51**, 33
 - α 1(XIII), tissue distribution, **50**, 246
 - binding proteins, regulation, **51**, 348–350
 - hepatic ALAS-1, **51**, 14–15
 - hMTH1*
 - SNP, **68**, 79–80
 - hMTH1* gene, **68**, 77–79
 - HSV, **51**, 153–154
 - identity, and capping enzyme, **50**, 122–124
 - nascent, cotranscriptional capping, **50**, 111–112
 - pre-mRNA
 - interaction with U1 snRNA, **50**, 139–141
 - interaction with U2 snRNP, **50**, 142–143
 - splicing, link with capping enzyme, **50**, 124–125
 - RQ RNA, **51**, 254–261
 - spliced, release, **50**, 156
 - synthesis, capping enzyme in, **50**, 101–129
- mRNA capping, *see* RNA (guanine-7) methyltransferase; RNA guanylyltransferase; RNA triphosphatase
- mRNA encoding
 - iPLA₂ β , **67**, 20
- mRNA, *see* Messenger RNA
- mRNA, *Trypanosoma brucei* and, **43**, 56–57
- mRNA, trp repressor and, **42**, 14–16
- ms²iA, *see* N⁶-Isopentenyl-2-thiomethyl-adenosine
- ms²io⁶A, *see* 2-Methylthio-*cis*-ribosylzeatin
- Msd*, **67**, 71, 74

- msd* locus, msDNA of bacteria and, **40**, 8–9
- msDNA of bacteria, **40**, 1–2, 22–23
- function, **40**, 21–22
- origin
- codon usage, **40**, 19–20
 - diversity, **40**, 17–19
 - evolution, **40**, 20–21
- structure, **40**, 2
- branch structure, **40**, 4–6
 - complex with protein, **40**, 6–7
 - covalent link to RNA, **40**, 2–4
 - hybrid structure, **40**, 6
- synthesis
- genetic locus, encoding by, **40**, 7–8
 - mechanism, **40**, 14–17
 - ORF encoding of RT, **40**, 9–12
 - retron unit, **40**, 9
 - RT purification, **40**, 13–14
 - transcription, **40**, 8–9
- MsDNAs, **67**, 65–89
- antisense DNA, **67**, 86–87
 - branch formation, **67**, 77
 - cDNA synthesis, **67**, 77
 - characteristics, **67**, 69
 - diversity, **67**, 82–84
 - host cell, **67**, 84–86
 - mutation frequencies, **67**, 84–85
 - new, **67**, 82–83
 - old, **67**, 84
 - origin, **67**, 82–84
 - potential applications, **67**, 88
 - potential uses, **67**, 86–87
 - prevalence, **67**, 82–84
 - primer-template RNA, **67**, 76
 - priming, **67**, 77
 - processing, **67**, 70–71
 - production, **67**, 71–75
 - protein, **67**, 70
 - repetitive sequences, **67**, 85–86
 - RT, **67**, 74–80
 - structure, **67**, 66–68
 - primary, **67**, 66–67
 - secondary conserved, **67**, 66–70
- Msr*, **67**, 71, 74
- msr* locus, msDNA of bacteria and, **40**, 8–9
- Mst87F* mRNA, translation, translational control element and, **48**, 204
- MSX2*, mutation in Boston-type craniosynostosis, **64**, 192
- MT, *see* Metallothionein
- MTA
- structure, **67**, 136
- MtDNA. *See* Mitochondrial DNA
- mtEXO, structure, **66**, 94
- MTF-1
- binding to metal-responsive element, assays, **59**, 276
 - cotransfection studies in human, mouse, and trout cell lines, **59**, 280, 282–284
 - gene cloning, **59**, 274–275
 - metal specificity, **59**, 275, 279–280, 285
 - nomenclature, **59**, 275
 - zinc fingers, **59**, 276, 278–279
- MTF-1, metallothionein transcription factor
- basal expression, **66**, 364
 - inhibitor, **66**, 367
 - knockout mouse, **66**, 366–367
 - reactive oxygen species induction, **66**, 367–368
 - structure, **66**, 365–366
- MTH, **68**, 134
- MTH1* gene
- SNP, **68**, 75
- MTH1a protein
- mitochondrial targeting sequences, **68**, 81
- MTH1d protein
- mitochondrial targeting sequences, **68**, 81
 - submitochondrial localization, **68**, 79
- mTOR, *see* Mammalian target of rapamycin
- MTS, **68**, 80
- hOGG1 polypeptides, **68**, 83
- MtUDG, **68**, 295–296
- MTX, **67**, 133, 135
- intracellular transfer, **67**, 138–139
 - polyglutamyl form, **67**, 135–138
 - structure, **67**, 136
- MUC1 forms, **71**, 151–152
- Muc4/SMC
- antiadhesion agent, **71**, 155
 - antirecognition agent, **71**, 155
 - breast cancer, **71**, 170–175
 - forms, **71**, 151–152
 - isolation, **71**, 153
 - ligand for ErbB2/HER2/Neu, **71**, 157–160
 - mammary acinar cells, **71**, 170–175
 - metastasis, **71**, 160–161
 - milk, **71**, 170–175
 - molecular cloning, **71**, 153–154
 - mucociliary transport, **71**, 163–164
 - ocular protection, **71**, 177

- oviduct, **71**, 167–170
- primary tumor growth, **71**, 161–163
- soluble form, **71**, 155–156
- soluble form production, **71**, 156–157
- uterus, **71**, 164–167
- vagina and cervix, **71**, 177
- Mucociliary transport, Muc4/SMC, **71**, 163–164
- Mug, **68**, 237, 249–250
 - base flipping, **68**, 240
 - crystal structure, **68**, 240
 - UDG, **68**, 240
- Muir-Torre syndrome, genetic defects, **63**, 208–209
- Multicatalytic proteinase, *see also* Prosomes; 26–S
- Multicistronic messenger, *c-myc*, *see c-myc*
- Multienzyme complex, aminoacyl-tRNA synthetases and, **40**, 118–121
 - assembly, **40**, 122–126
- Multigene families, proline-rich protein, *see* Proline-rich protein multigene families
- Multiple base excision repair pathways
 - switch mechanism, **68**, 3–25
 - control, **68**, 9–24
- Multiple DNA repair pathways
 - disruption
 - oxidizing agent sensitization, **68**, 33
- Multiple mRNA species
 - hOGG1, **68**, 196
- Multivalent/multispecific antibody generation
 - applications, **60**, 171, 190
 - bispecific molecule construction, **60**, 188–190
 - electrostatic complementarity, **60**, 183, 186, 188, 192
 - immunoglobulin class considerations, **60**, 186–188
 - tetraspecific molecule construction, **60**, 190
- MuLV, *see* Murine leukemia virus
- Murine *UNG* gene, **68**, 370–371
- Murine cytomegalovirus, infection and latency, **71**, 450–451
- Murine leukemia virus
 - dissemination and pathogenicity, **72**, 380
 - genomic mRNA, **72**, 380–382
- Murine UNG2
 - dUMP residues, **68**, 379–380
 - uracil, **68**, 380–381
- Muscarinic acetylcholine receptors
 - antagonist binding site, **49**, 124–125
 - coupling to effector enzymes, **49**, 133
 - desensitization, **49**, 142
 - down-regulation, **49**, 142–143
 - G protein binding site, **49**, 133–134
 - messenger RNA stability, **49**, 144
 - phosphorylation, **49**, 142
 - sequestration, **49**, 141
- Muscles
 - pyruvate dehydrogenase complex
 - activity, **70**, 43
 - pyruvate dehydrogenase kinase
 - distribution, **70**, 53
- MuT
 - amino acid residues, **68**, 80
 - Escherichia coli*
 - C-terminal region, **68**, 87
 - secondary structure, **68**, 82
- Mutagenesis
 - insertional
 - COLIA1* gene, **47**, 44–46
 - collagen type-I genes, **47**, 40–41
 - mammalian DNA beta-polymerase, **68**, 69–71
 - site-directed, *see* Site-directed mutagenesis
 - TFO, **67**, 180–181
- Mutagenesis, *see* Site-directed mutagenesis
- Mutagenesis, insertional, adenoviral DNA integration and, **46**, 32–33
- Mutagenesis, retroviral RT, **71**, 93–94
- Mutant carriers
 - RFC, **67**, 156–157
- Mutant HMG-domain protein
 - binding affinities, **67**, 110
 - studies, **67**, 110–112
- Mutant phenotype, superoxide dismutases and, **40**, 245–246
- Mutants
 - aro*, **50**, 322–324
 - genetic defects of mammalian nervous system and, **41**, 242–244, 253–254
 - hisT*, **50**, 269–279
 - miaA*, *miaB*, and *miaE*, **50**, 296–310
 - nuvA* and *nuvC*, **50**, 293–296
 - queA*, *queB*, and *tgt*, **50**, 318–322
 - structural elements in RNA
 - and, **41**, 166
 - trmA*, **50**, 279–286
 - trmC*, *trmE*, and *asuE*, **50**, 287–293
 - trmD*, **50**, 310–318

- Mutants, hypo- and hyper-recombination, isolation, **51**, 274–299
 Mutants, yeast mRNA 3' end-processing factor genes, **71**, 358–359
 Mutated oncogenes, latent viruses and, *see* Latent viruses and mutated oncogenes
 Mutation
 frequency
 Mmh mutant mice, **68**, 115–119
 Mmh homozygous, **68**, 121
 MMS, **68**, 69–70
 rates
 spontaneous recombination, **68**, 35
 uracil-initiated BER, **68**, 181–186
 Mutation frequencies
 msDNAs, **67**, 84–85
 Mutation rates, reverse transcriptase, **71**, 98–99, 130–131
 Mutation, DNA polymerase II and, **46**, 110–111
 Mutation, trp repressor and, **42**, 27–29
 Mutational analysis, HIV-1 RT fidelity
 amino acid role, **71**, 127–128
 Arg-72, **71**, 120–121
 Gln-151, **71**, 119–120
 Lys-65, **71**, 120–121
 Met-184, **71**, 117–119
 minor groove binding track residues, **71**, 126
 overview, **71**, 112–113
 primer grip residues, **71**, 124–126
 template strand residues, **71**, 121–123
 Tyr-115, **71**, 114–117
 Tyr-183, **71**, 123–124
 Mutational analysis, yeast
 guanylyltransferase, **50**, 114–115
 Mutational spectrometry
 appropriate data sets, **49**, 286
 bulk approach to mutant analysis, **49**, 286–287
 clone-by-clone spectra, **49**, 285
 human tissue
 requirements for measuring, **49**, 287
 screening approaches
 allele-specific polymerase chain reaction, **49**, 289–291
 constant denaturant gel electrophoresis, **49**, 302, 304–308
 constant denaturing capillary electrophoresis, **49**, 288, 304–310
 denaturing gradient gel electrophoresis, **49**, 286–289, 304–308
 high-efficiency restriction-enzyme digestion assay, **49**, 288, 295–302
 mismatch amplification mutation assay, **49**, 288, 291–295
 phenotypic selection, **49**, 287–288
 mitochondrial DNA, **49**, 300–302
 polymerase chain reaction, **49**, 288–289, 308–310
 sensitivity, **49**, 296, 310
 Mutations
 aldA loss-of-function, **69**, 170–172
 cathepsin A, **69**, 102–103
 CreA, derepressed, **69**, 177–178
 Flp protein, **51**, 66–68
 jasmonate biosynthesis, **72**, 178–180
 PDE4B, **69**, 278
 PEPCK, **72**, 272
 prevention, **51**, 203–207
 pRNA, **72**, 438–439, 455–456, 458–459
 PRS isoforms, **69**, 138
 sialidase, **69**, 104–105
 tumors, **70**, 6–7
 UL5 helicase motifs, **70**, 104–106
 W273L, **69**, 101
 Mutations, copy-up, **48**, 266–267
 Mutator mutants
 E. coli, **68**, 76
 Mutator phenotype, **68**, 36–37
 Mutator reverse transcriptase, error catastrophe, **71**, 129–130
 MutM, **68**, 194–197. *See also* OGG1
 Escherichia coli
 8-OH-G, **68**, 107
 Fapy-DNA glycosylase, **68**, 190
 substrate bases, **68**, 190
 substrate specificity, **68**, 196, 199
 yeast, **68**, 195
 MutT
 homolog proteins
 primary structure, **68**, 82
 MutY, **68**, 350–352
 8-oxoG, **68**, 350–352
 active site, **68**, 355
 catalytic domain
 structure, **68**, 353–354
 Escherichia coli
 double-flipping, **68**, 361–362
 glycosylase reaction mechanism, **68**, 356

- OGG, **68**, 200–201
 opportunistic lyase activity, **68**, 354–355
 p13, **68**, 360
 structural model, **68**, 361
 substrate bases, **68**, 190
 c-terminal domain
 solution structure, **68**, 357–360
 substrate specificity, **68**, 356–357
- MutY* gene, **68**, 109
- Mx162, **67**, 68
 characteristics, **67**, 69
- Mx65
 characteristics, **67**, 69
- Myc proteins, structures and recognition
 sequences, **47**, 237–239
- Myc, antisense oligonucleotide inhibition, **57**,
 117–118, 120–121
- Myc*, see *c-Myc*
- Mycobactin, **70**, 269–270
- Mycophenolate mofetil, inositol-5'-
 monophosphate dehydrogenase inhibition
 and clinical applications, **61**, 202
- Mycoplasma*, bacterial adenyl cyclases
 and, **44**, 44
- Mycorrhiza, jasmonates, **72**, 193–194
- Mycoviruses, yeast double-stranded RNAs
 and, **46**, 176–179
- Myelin
 axon–glial interactions, **56**, 235–243
 components in peripheral nervous system
 L1, **56**, 242
 lipids, **56**, 237
 myelin-associated glycoprotein,
 56, 240–241, 247
 myelin basic proteins, **56**, 238–239
 myelin protein zero, **56**, 237–238
 neural adhesion molecule, **56**, 242
 P2, **56**, 241
 periaxin, **56**, 242
 peripheral myelin protein, **56**,
 22, 239–240, 242–243
 structure, **56**, 236–237
- Myelin-associated glycoprotein (MAG), role in
 myelin, **56**, 240–241, 247
- Myelin basic protein, symmetric
 dimethylation, **61**, 67, 70, 73–74, 99–100
 consensus sequence for methylation, **61**,
 109–110
 functions
 defects in disease, **61**, 122–123
 development, **61**, 119
 jumpy mice, **61**, 119–120
 myelination role, **61**, 120–121
 ratio to monomethylation, **61**, 118–119
- Myelin basic proteins, role in myelin, **56**,
 238–239
- Myelin protein zero, role in myelin, **56**,
 237–238
- Myelination
 peripheral myelin protein 22 mutations in
 disease, **64**, 116–117
 progesterone regulation, **64**, 110
- Myelination, Tst-1 role, **63**, 238
- Myelogenous leukemia, latent viruses and
 mutated oncogenes and, **43**, 170–173
- Myf5, autoregulation of promoter, **60**, 161
- MYH, **68**, 134
 replication-coupled BER, **68**, 136
 UDG2
 PCNA, **68**, 135
- MYH protein, **68**, 129
 hypothetical representation, **68**, 90
 mitochondrial targeting sequences, **68**, 81
 submitochondrial localization, **68**, 79
- Myocyte enhancer factor 2 (MEF2), histone
 deacetylase recruitment, **65**, 317
- MyoD, autoregulation of promoter, **60**, 161
- Myogenesis, inhibition by dominant-negative
 ROR α , **69**, 239
- Myosin, arginine methylation, **61**, 98–99
- Myosin binding subunit (MBS), **67**, 196
- Myotonic dystrophy (DM), trinucleotide repeat
 expansion, **66**, 162–164, 167–168,
 187, 189
- Myxobacteria, msDNA of bacteria and, **40**,
 17–18
- Myxococcus xanthus*, **67**, 66
- Myxothiazole, **70**, 281–282
- N**
- N-CAM, see Neural adhesion molecule
- N-CoR, interaction with ROR γ , **69**,
 220–222
- N-CoR, thyroid hormone receptor
 corepressor, **65**, 62, 65
- N-tail translocation, see Pf3 coat protein
- N-terminal domain, steroid hormones and, **43**,
 14–15

- N*-Nitroso compounds
 content in tobacco, **49**, 99
 DNA damage, **49**, 99
- N*⁶-Isopentenyl-2-thiomethyladenosine, and
 ms²io⁶A37, presence in tRNA, **50**,
 296–298
- N3' → P5' phosphoramidate backbone,
69, 14
- N51, identification as immediate-early
 response gene, **53**, 57
- N65, identification as immediate-early
 response gene, **58**, **53**, 57
- Na[*trans*-Ru(III)((CH₃)₂SO)Cl₄Im]-DNA
 interactions, **71**, 52
- NABPs, *see* Nucleic acid-binding proteins
- NADH, pyruvate dehydrogenase kinase
 isoform, **70**, 55–58, 67–69
- Nail-patella syndrome, *LMX1B* mutation, **64**,
 189–190
- Nannocystis exedens*, **67**, 68
- Nascent peptide
 4.5S RNA in recognition, **66**, 122
 chaperonelike activity of ribosomes, **66**,
 56–57
 chaperones
 activation, **66**, 57–58
 rhodanese folding studies
 DnaJ, **66**, 58–59, 61
 DnaK, **66**, 58–59, 61
 GrpE, **66**, 58–59, 61
 stoichiometry with substrates, **66**, 58
 trigger factor, **66**, 59–60
 erythromycin binding and inhibition, peptide
 composition effects, **66**, 48–49
 folding
 C-terminal extension studies of protein
 activity, **66**, 54, 60
 conformational analysis, **66**, 54–55
 cotranslational versus posttranslational,
66, 54
 ribosomal sites, **66**, 54–55
 large ribosomal subunit tunnel interactions
 cross-linking, **66**, 52–53
 fluorescence anisotropy studies, **66**, 52
 pause-site peptide
 conformation in pausing, **66**, 55–56
 definition, **66**, 55
 pausing mechanisms, **66**, 55–56
 peptidyl transferase reaction
 stereochemistry, **66**, 47
 polyalanine synthesis studies, **66**, 49–51
 polylysine synthesis studies, **66**, 47–48
 polyphenylalanine synthesis studies, **66**,
 47–49
 polyserine synthesis studies, **66**, 49–51
 4.5S RNA in recognition, **66**, 122
- Nascent polypeptides
 glycoprotein folding
 ER, **67**, 239–241
- Natural folates
 metabolic roles, **67**, 133–135
- Natural product synthesis, thiazolidine ring
 formation, **70**, 274–277
- NBS, *see* Nijmegen breakage syndrome
- NBS1, *see* Nijmegen breakage syndrome 1
- 3' Noncoding exons, poly A site, **71**, 336–337
- Nef protein, effect on HIV gene expression,
49, 164
- Nei. *See* Endonuclease VIII
- Neocarzinostatin, DNA sequence
 specificity, **63**, 381, 395
- Neophrumycin, DNA sequence specificity,
63, 387
- Nephritis, hereditary, *COLA/A5* gene
 mutations, **47**, 64
- NER, **67**, 186–188
 pathway, **67**, 97
- NER, *see* Nucleotide excision repair, **65**, 66
- Nervous system
 axon–Schwann cell interactions
 bilateral communication, **56**, 235, 248
 myelination role, **56**, 235–243
 neural crest development, **56**, 227–229
 transcriptional regulation, **56**, 243–246
 degeneration and regeneration, **56**,
 246–248
 development, **56**, 226–227
 extracellular matrix, role in peripheral
 nervous system development, **56**,
 233–235
 membrane sorting in Schwann cells,
56, 249
 Schwann cell, proliferation and
 differentiation, **56**, 229–233
- Nervous system, mammalian, genetic defects
 of, *see* Genetic defects of mammalian
 nervous system
- NEST, **67**, 207
- Netropsin, DNA sequence specificity, **63**, 382,
 398–399

- Neural adhesion molecule (N-CAM), role in myelin, **56**, 242
- Neural crest, axon–glial interactions during development, **56**, 227–229
- Neuraminidase, *see* Sialidase
- Neuregulins, Schwann cell regulation, **56**, 230–232
- Neurocan
developmental expression, **62**, 185, 187 domains
C-terminal domain, **62**, 193–194
chondroitin sulfate-rich region, **62**, 195–197
keratin sulfate domain, **62**, 194–195
N-terminal hyaluronate-binding region, **62**, 191–193
sequence alignment, **62**, 188, 191
gene structure, **62**, 202, 204, 216–217
phylogenetic analysis, **62**, 211, 215–216
promoter analysis, **62**, 207–208
structure, **62**, 185
- Neurofilament
accumulation in disease, **61**, 2, 10–11
axon functions
caliber modulation, **61**, 7
regeneration role, **61**, 9
transport modulation by NF-H, **61**, 7–9, 14–16
BPAG1 cross-linking to actin, **61**, 9, 16, 20
codon deletion in amyotrophic lateral sclerosis, **61**, 13–14
intermediate filament proteins, **61**, 2–4
phosphorylation
alteration in disease, **61**, 5–6, 19–20
kinases, **61**, 4–7
phosphatases, **61**, 4, 6
physiological functions, **61**, 4–5
sites, **61**, 4–5, 19
structure, **61**, 2–4
superoxide dismutase mutation, role in accumulation, **61**, 18
transgenic mouse models of disease, **61**, 11–13
- Neurogenesis, abnormal, Purkinje cells, **69**, 227
- Neurokinins, *see* Tachykinin receptors
- Neurological disease, latent viruses and mutated oncogenes and, **43**, 155–157
- Neuronal interacting factor X1, ROR binding, **69**, 222
- Neurons, FGF-1 role, **70**, 158
- Neurons, signaling, *Egr-1* induction in, **50**, 197–199
- Neuropathogenicity, nsP2, **71**, 206–208
- Neurotrophins, Schwann cell regulation, **56**, 232
- Neutron scattering
ribosome shape determination
angular envelope function, **59**, 191–193, 198
coherent scattering, **59**, 190–191
comparison with electron microscopy, **59**, 197–199
contrast, **59**, 188
direct shape restoration, **59**, 192–193
hybrid ribosome studies, **59**, 193–194
model fitting and nonlinear refinement, **59**, 188–189, 195–197
parameter determination, **59**, 189
scattering length, **59**, 189–190
small-angle scattering intensities from four-phase systems, **59**, 194–195
transfer RNA localization on ribosomes with spin-dependent scattering, **59**, 199–201
- NF- κ B, autoregulation of promoter, **60**, 149
NF- κ B p50/p105, **60**, 150–151
NF- κ B2, **60**, 151
- NF- κ B, potential binding sites, **69**, 301
- NF-1, binding to phenobarbital-responsive unit, **61**, 49–51, 53–55, 59–61
- NF κ B, **67**, 13, 203
- NF κ B protein, binding to DNA, **47**, 243–245
- NF1, *see* Nuclear factor 1
- NFAT-1, *see* Nuclear factor of activated T cells
- NHP-1, *see* Nonhistone protein, 1
- Nibrin
gene
mutation in Nijmegen breakage syndrome, **63**, 200
structure, **63**, 200
structure and function, **63**, 200–201
- Nicking assay
TDG, **68**, 242
- Nijmegen breakage syndrome (NBS)
clinical features, **63**, 200
nibrin
gene structure and mutation, **63**, 200
structure and function, **63**, 200–201
- Nijmegen breakage syndrome 1, **72**, 79

- NinaA
quality control, **67**, 251
- Nip1p, protein-protein interactions, **70**, 228
- Nitrate reductase, flavin-binding site, **65**, 141
- Nitric oxide (NO)
induced damage
mtDNA, **68**, 276–279
- Nitric-oxide synthase, similarity with
prostaglandin synthase, **47**, 142–143
- Nitrocellulose-filter binding assay, steroid
hormones and, **43**, 8
- Nitrogen mustard, **68**, 275–276
- Nitrogen mustards, DNA sequence
specificity, **63**, 379, 388–390, 404
- Nitrogen regulon
glutamine synthetase
adenylation, **55**, 56–57
reaction catalyzed, **55**, 55
transcriptional regulation, **55**, 57
- NtrA
mapping of binding sites, **55**, 59
phosphorylation, **55**, 59–60
phosphorylated protein intermediates,
detection, **55**, 57–58
response rate, **55**, 61–62
signal transduction pathway, **55**, 54–55,
60–61, 74
two-component response regulator,
55, 54
- Nitrogen transfer, branched chain amino
acids, **70**, 199
- 4-Nitroquinoline 1-oxide, DNA sequence
specificity, **63**, 381, 394
- NLS, *see* Nuclear localization signal,
57, **58**, **59**,
- NO
induced damage
mtDNA, **68**, 276–279
- NodB domain
function in xylanases, **61**, 229, 231
sequence alignment, **61**, 231–232
xylanase E of *Pseudomonas fluorescens*
sub-sp. *cellulosa*, **61**, 219, 221, 229
- Nogalamycin, DNA sequence specificity, **63**,
380, 392
- Non-human reduced folate carrier
transport components, **67**, 146–147
- Nondissociating model, adenovirus shunt,
72, 19
- Nonesterified arachidonate, **67**, 22
- Nonhistone protein, 1 (NHP-1), DNA
demethylation role, **57**, 227
- Nonribosomal chromopeptides
arylpeptide-siderophores, **70**, 246–248
chromopolyketides, **70**, 249
lactones, Streptomyces and fungi, **70**,
244–246
oxazole-containing chromopeptides, **70**, 249
thiazole-containing chromopeptides, **70**, 249
- Nonribosomal peptides
bleomycin biosynthesis, **70**, 277–279
epothilone biosynthesis, **70**, 279–281
myxothiazole biosynthesis, **70**, 281–282
- Nonribosomal peptide synthetases
adenylation domains, **70**, 236–237
condensation domains, **70**, 239
cyclization domains, **70**, 241
epimerization domains, **70**, 240–241
methyltransferase domains, **70**, 240
overview, **70**, 235–236
peptidyl carrier protein domains, **70**, 238
thioesterase domains, **70**, 239–240
thiolation domains, **70**, 238
- Nonstructural proteins
- NsP1
guanylyltransferase activity, **71**, 198–201
membrane association, **71**, 201–203
methyltransferase activity, **71**, 198–201
minus-strand RNA synthesis, **71**, 203–204
- NsP2
neuropathogenicity, **71**, 206–208
NTPase activity, **71**, 204–205
nuclear transport, **71**, 206–208
protease activity, **71**, 206
RNA helicase activity, **71**, 204–205
RNA triphosphatase activity, **71**, 205–206
- NsP3
features, **71**, 210
phosphorylation, **71**, 209–210
sequence conservation, **71**, 208–209
- NsP4, **71**, 210–211
polyprotein P1234 processing, **71**, 197
- Northwestern blot analysis, A+U rich
elements, trans-acting factor
identification, **62**, 263–264
- Not1, ribosomal gene transcription
regulation, **62**, 316–317
- Novobiocin, inhibition of topoisomerase II, **64**,
242–243
- Npl3, arginine methylation, **61**, 97, 105, 124

- nrdD* protein, RNR component
3D structure, **72**, 103–106
allosteric regulation, **72**, 108–114
glycyl radical enzyme definition, **72**, 99–101
site-directed mutagenesis, **72**, 101–103
substrate reduction, **72**, 106–108
- nrdG* protein, RNR component
 $\alpha_2\beta_2$ complex, **72**, 115–116
activation reaction, **72**, 116–119
iron–sulfur protein definition, **72**, 114–115
iron–sulfur protein prototype, **72**, 119
- NRF, *see* Nuclear respiratory factor
- NRPS, *see* Nonribosomal peptide synthetases
- NS-1, *see* Minute virus of mice, NS-1
- NS-2, *see* Minute virus of mice, NS-2
- NsP, *see* Nonstructural proteins
- Ntg1, **68**, 293
- Ntg1p, **68**, 30, 31
- Ntg2, **68**, 293
- Ntg2p, **68**, 30, 31
- Nth, *see* Endonuclease III
- NTH1*, *see* Trehelase
- NTH2*, *see* Trehelase
- NTPase, *see* Nucleosidetriphosphatase
- NTR1
gene cloning, **58**, 247
sequence homology with other
transporters, **58**, 248, 250–256
structure, **58**, 248, 250
- NtrC, prokaryotic transcriptional enhancers
and, **43**, 111–116, 125–127
- Nuclear DNA
oxidative DNA damage, **68**, 286–291
- Nuclear envelope signal transduction
(NEST), **67**, 207
- Nuclear exchange reaction, GEFs, **71**, 396, 401
- Nuclear factor I (NF1), chromatin binding and
steroid receptor interaction, **66**, 282–285,
298, 300
- Nuclear factor of activated T cells
binding to HIV LTR, **49**, 165–166
immunosuppressant effects on levels, **49**, 166
- Nuclear gene expression, in *Trypanosoma*
brucei, *see* *Trypanosoma brucei*, nuclear
gene expression in
- Nuclear localization signal
nsP2, **71**, 207
poly A polymerase, **71**, 323
- Nuclear localization signal, Egr-1, mapping, **50**,
213–216
- Nuclear localization signals, AlcR, **69**, 165–166
- Nuclear localization, alkyltransferase, **51**,
195–196
- Nuclear magnetic resonance (NMR)
guanine quadruplex, **59**, 83–84, 86–88
pur*pur-pyr triplex, **59**, 77
pyr*pur-pyr triplex, **59**, 61, 63, 65, 76–77
- Nuclear magnetic resonance (NMR), lactose
repressor protein structural studies, **58**,
149–151
- Nuclear magnetic resonance (NMR),
structural studies of RNA mismatched
base pairs
guanosine–adenosine, **57**, 19–21
guanosine–uridine, **57**, 6–14
uridine–cytosine, **57**, 27–29
uridine–uridine, **57**, 27–29
- Nuclear magnetic resonance, Antp
homeodomain peptide, **47**, 222–223
- Nuclear magnetic resonance, structural
elements in RNA and, **41**, 162–164
- Nuclear magnetic spectroscopic analysis of
nucleic acids, **42**, 49–50, 52–54
- Nuclear receptor proteins, structures and
recognition sequences, **47**, 234–236
- Nuclear receptors, complexes with RXR, **69**,
214–215
- Nuclear respiratory factor, complex II gene
regulation, **60**, 291–292, 294
- Nuclear RNA-binding proteins, **41**, 179–181,
198–199
- RNA–protein interactions
in vitro detection, **41**, 181–186
sequences, **41**, 186–187
- RNA recognition motif family of proteins, **41**,
187–188
direct interaction, **41**, 188–192
domains, **41**, 194–195
origins, **41**, 188
RNA processing, **41**, 197–198
specificity, **41**, 192–194
structural features, **41**, 195–196
transcription, **41**, 196–197
- Nuclear short-patch base excision repair
common pathway, **68**, 260
- Nuclear transport, nsP2, **71**, 206–208
- Nuclear UNG1, **68**, 374
- Nuclease DI, properties, **52**, 38
- Nuclease DII, properties, **52**, 38–39
- Nuclease PCI, properties, **52**, 39

- Nuclease PCII, properties, **52**, 39
- Nucleases, homologous recombination in
Saccharomyces cerevisiae and, **46**,
 244–253
- Nucleic acid-binding proteins
 RNA contacts, **72**, 229–230
 vigilin identity, **72**, 147
- Nucleic acid chaperone proteins
 annealing assay, **72**, 235–237
 annealing *versus* unwinding, **72**, 245
 biochemical property experiments, **72**,
 234–235
 hammerhead ribozyme cleavage, **72**,
 239–241
 helix-destabilizing activity, **72**, 242–245
 self-primed cDNA synthesis, **72**, 241–242
 strand exchange assay, **72**, 237–239
- Nucleic acids
 eIF4A unwinding assay, **72**, 316–321
 vigilin interaction model, **72**, 151–153
- Nucleic acid sliding/riding processes, viral
 DNA, **72**, 459–461
- Nucleic acids, 5,6-dihydropyrimidine adducts
 and, **42**, 152–154
- Nucleic acids, immunochemical analyses of, **42**,
 39–40, 71
- antibodies, **42**, 40–44
 alkylated nucleic acids, **42**, 66, 68–70
 B-DNA, **42**, 44–48
 DNA, **42**, 62–63
 RNA, **42**, 62–63
 single-stranded DNA, **42**, 48–50
 Z-DNA, **42**, 50–60
- assays, **42**, 42–44
- branched-chain RNA, **42**, 63
- bromodeoxyuridine, **42**, 65–67
- cruciform DNA, **42**, 63–65
- double-stranded DNA, variants of, **42**, 60
- immunogenicity, **42**, 40–42
- triplex DNA, **42**, 60–62
- Nucleocytoplasmic transport, ribosome
 biogenesis in yeast, **41**, 118–123
- Nucleohistone, transition to nucleoprotamine
 chromatin structure, **40**, 68–70
 protein modifications, **40**, 71–83
- Nucleolin
 role in RNA processing, **49**, 220–221, 223
 solubility, **49**, 222–223
- Nucleolin, arginine methylation, **61**, 91,
 106–107
- Nucleolin, effect on mRNA stability, **56**,
 280–281
- Nucleoprotamine, nucleohistone transition to
 chromatin structure, **40**, 68–70
 protein modifications, **40**, 71–83
- Nucleoside
 fluorescein-modified
 chemical structure, **67**, 103
- Nucleoside diphosphate kinase, NM23,
 interaction with ROR/ β , **69**, 222–223
- Nucleoside, modified
 biological functions in transfer RNA, **53**,
 81–84
 discovery, **53**, 79–80
 drug therapy, **53**, 121
 modification effect on nucleoside
 conformation and dynamics, **53**,
 116–119
 modifying enzymes, **53**, 80
 physicochemical contributions
 base stacking, **53**, 109
 disruption of canonical base-pairing, **53**,
 114–116, 120
 magnesium binding, **53**, 113–114,
 119–120
 reordering of water, **53**, 112
 types, **53**, 81
 site-selective positioning of modifications, **53**,
 101–104
 structures and chemistry, **53**, 84–101
 symbols and common names, **53**, 122–123
- Nucleosides, antibodies to, **42**, 65–67
- Nucleosides, modified, in bacterial tRNA, **50**,
 263–338
- Nucleosidetriphosphatase, nsP2 activity, **71**,
 204–205
- Nucleosome
 activity of endonuclease complexes
 correction of XPA defects by normal
 endonuclease complexes, **63**, 291
 FA-A and FA-D cell endonuclease
 complex activity, **63**, 289
 normal endonuclease activity, **63**, 284–287
 reconstituted assay system and
 mutagenesis, **63**, 282–284
 XPA cell endonuclease complex
 activity, **63**, 287–289
 arginine methylation of histones, **61**,
 93–96, 101, 103
 core histones, **61**, 381, 383

- dinucleosomal templates in transcription
analysis, **61**, 406–409
- DNA interactions with histones
acetylation of histones and transcription
efficiency, **61**, 409–410
cross-linking studies, **61**, 383–384
DNA conformation, **61**, 389–390
DNA curvature in positioning histone
octamer, **61**, 386–388
hydroxyl radical cleavage studies, **61**, 384,
386, 388–389
linker histone structure, **61**, 390, 392–400
linking-number paradox, **61**, 388–389
surface twist calculations, **61**, 388–389
trinucleotide repeats and human
disease, **61**, 390
- functional studies using receptors
estrogen receptor, **61**, 409, 411–412
glucocorticoid receptor, **61**, 412, 414–415
thyroid hormone receptor, **61**, 415–417
micrococcal nuclease cleavage sites, **61**, 390,
392, 399
mutagens and DNA damage, **63**, 282
nucleosomal arrays and transcription
repression, **61**, 417–418
overview of transcriptional regulation, **61**,
379–380
structure, **63**, 281–282
transcription factor access to DNA
TATA-binding protein, **61**, 401–402
TFIIIA, **61**, 402–408
- Nucleosome disassembly, protamines
and, **40**, 85
- Nucleosome positioning, **40**, 143–144, 180–181
chromatin, **40**, 144–1447
function, **40**, 175–180
detection, **40**, 147–150
first investigations, **40**, 150–151
in vitro studies, **40**, 151–154
in vivo
centromeres, **40**, 167–168
mammalian episomal chromatin, **40**,
174–175
repetitive satellite sequences, **40**, 160–162
ribosomal RNA gene sequences,
40, 162–164
structural genes, **40**, 164–167
telomeres, **40**, 167–168
yeast minichromosomes, **40**, 168–174
mechanisms, **40**, 158–160
- DNA structure, **40**, 154–158
- Nucleosome, *see also* Chromatin
array
detection, **54**, 334–336
genomic signals influencing formation
 β -globin DNA, chicken, **54**, 363–366
growth hormone gene introns, rat, **54**,
366–367, 369–373
mechanisms, **54**, 358–359
ovalbumin gene introns, chicken, **54**,
359–363
plasmids in transfected cells, **54**,
374–375
linker length and DNA folding, **54**, 378
models for formation
DNA sequence-directed structures, **54**,
342–343
statistical positioning, **54**, 339, 341, 377
positioning with respect to gene,
measurement, **54**, 336–338
relationship to chromatin higher order
structure, **54**, 356–358
spacing periodicity, measurement, **54**,
335–336
- HMGs, **54**, 61–62, 77–81
structure, **54**, 333–335
- Nucleosome, *see* Chromatin, **61**, **62**,
Nucleosome, *see* Chromatin; GAL
- Nucleosome, structure, **64**, 173
- Nucleotide
flipping
DNA bases, **68**, 333–334
mtDNA, **68**, 277–279
- Nucleotide bases, RNA editing, **70**, 142
- Nucleotide-binding pocket, EF-Tu, **71**,
525–527
- Nucleotide excision repair
heterogeneity in nucleosomes, **62**, 238–240
histone modifications during repair, **62**,
248–250
nucleosome rearrangement following
repair, **62**, 250–251
nucleosome structure rearrangement during
repair, **62**, 244–248
pyrimidine dimer photoproducts in
nucleosomes, **62**, 238–241
transcribed chromatin, **62**, 241–244
- Nucleotide excision repair (NER), **67**,
186–188; **68**, 33, 96
domain-dependent repair, **68**, 216

- Nucleotide excision repair (NER) (*cont.*)
 mutant strains
 menadione, **68**, 34
 oxidative base lesions, **68**, 287–288
 pathway, **67**, 97
 sequence context-dependent repair, **68**, 216
- Nucleotide excision repair (NER)
 pathway, **68**, 30–31
 yeast, **68**, 33–36
- Nucleotide excision repair (NER), *see* DNA repair
- Nucleotide excision repair (NER), triplet repeat sequence transcription and instability, **66**, 180–181
- Nucleotide excision repair assay
 in vitro assays
 analytical chemical assays, **56**, 69
 biological activity–transformation assay, **56**, 72–73
 excision assay, **56**, 65–67, 69
 nicking/incision assay, **56**, 64–65
 repair synthesis assay, **56**, 71–72
 restriction enzyme sensitivity, **56**, 72
 in vivo assays
 host cell reactivation, **56**, 77–78
 immunological detection of photolesions, **56**, 75–76
 ligation-mediated polymerase chain reaction, **56**, 74–75
 nicking assay, **56**, 73
 postlabeling assay, **56**, 75
 T4 endonuclease V-sensitive site assay, **56**, 73–74
 unscheduled DNA synthesis and equilibrium sedimentation, **56**, 77
 overview, **56**, 63–64
- Nucleotide excision repair, *see also* Endonuclease; Fanconi anemia; Xeroderma pigmentosum
 damage-recognition proteins, **63**, 278–281
 overview, **63**, 258–259
- Nucleotide excision repair, cisplatin-DNA adducts, **71**, 13
- Nucleotide pools, purine, **69**, 123
- Nucleotide selectivity, pre–steady-state kinetic assays, **71**, 104–105
- Nucleotide sequence, yeast double-stranded RNA, **46**, 157–158
- Nucleotides
 antibodies to, **42**, 65–67
 biosynthesis, purine, *see* Purine nucleotide biosynthesis, *de novo*
 D-loop, **69**, 340–341
 modified, for triple helices, **69**, 22–23
 modified, in splicing, **50**, 154–156
 second-step function, **50**, 153
 trp repressor and, **42**, 6, 8
- Nucleotides, tRNA structure and, **45**, 169–180
- Nucleus, cytology during meiosis in yeast, **61**, 352–355
- Nucleus, pre-mRNA processing, **71**, 295–297
- Nucleus, pre-mRNA processing, *see* RNA processing, nuclear
- Nup475, identification as immediate-early response gene, **58**, 51
- Nur77
 identification as immediate-early response gene, **58**, 51
 knockout mice studies, **58**, 66
- Nutrient-signaling complex, in *Saccharomyces cerevisiae* growth control, **48**, 4–10
- Nutrient-signaling pathways, in *Saccharomyces cerevisiae*, **48**, 9–10
-
- O⁶-alkylguanine-DNA alkyltransferase (AGT), **68**, 316–319
 O⁶-MeG, **68**, 43–44
 pol beta-deficient cells, **68**, 52
 regulation, **68**, 47–49
- O⁶-MeG. *See* O⁶-methylguanine
- O⁶-methylguanine (O⁶-MeG), **68**, 43–44
 apoptosis, **68**, 43–44
 dimethyl methanesulfonate, **68**, 45–46
 genotoxicity, **68**, 45–46
 methyl methanesulfonate, **68**, 45–46
 MGMT, **68**, 43–44
 MMR, **68**, 43–45
 MNNG, **68**, 44
- O⁶-methylguanine-DNA methyl transferase (MGMT), **68**, 41
- O⁶-methylguanine-DNA methyltransferase. *See* O⁶-alkylguanine-DNA alkyltransferase
- Obligate hydrogenotrophic methanogens, **71**, 270–274
- OccR transcriptional activator, *Agrobacterium tumefaciens*, **47**, 245

- Octadecanoids
LOX pathway, **72**, 171–173
natural occurrence, **72**, 168–171
plant development
 flowers, **72**, 198–200
 germination and seedlings, **72**, 196–197
 senescence, **72**, 202–205
 tendrils coiling, **72**, 202
 tuberization, **72**, 200–202
- Octahedral platinum(IV) complexes–DNA interactions, **71**, 32–33
- Ocular protection, Muc4/SMC, **71**, 177–179
- Oculopharyngeal muscular dystrophy, trinucleotide repeat expansion, **66**, 164
- ODN2, chimeric antisense, **69**, 17
- ODNs, *see* DNA oligonucleotides
- Odp1, arginine methyltransferase, **61**, 84
- ODR-4
 quality control, **67**, 250
- ODR-8
 quality control, **67**, 250
- OGG, **68**, 193, 194
 mtDNA
 BER, **68**, 261
 MutY, **68**, 200–201
 substrate bases, **68**, 190
- OGG1, *See also* MutM, **68**, 14, 134, 193
 8-OH-G, **68**, 203–204
 AP lyase, **68**, 204
 apurinic sites
 assay, **68**, 98
 incised apurinic sites
 AAS CHO cells, **68**, 102–103
 Saccharomyces cerevisiae, **68**, 107
- OGG1-2a protein
 mitochondrial targeting sequences, **68**, 81
 submitochondrial localization, **68**, 79
- OGG1 gene
 Saccharomyces cerevisiae, **68**, 109
- OGG1 knockout mutant mice, **68**, 202
- OGG1 protein
 hypothetical representation, **68**, 90
- OGG1/Mmh* gene
 mammalian
 8-OH-G, **68**, 107–121
- OGG2, **68**, 193–194
 8-OH-G, **68**, 199–200
 E. coli, **68**, 198–199
 FPLC, **68**, 196
 substrate specificity, **68**, 196
 transcription-coupled repair, **68**, 202
 yeast, **68**, 196
- 8-OH-G. *See* 8-oxoguanine
- 8-OH-G:FPG
 repair, **68**, 109
- Okazaki fragment processing, **51**, 110–112
- 2',5'-Oligoadenylate synthetase, activation by double-stranded RNA, **57**, 126–127
- (2'–5')Oligo(A) synthetase
 activation by double-stranded RNA, 49
 activity in HIV-infected cells, 55
 biological role, 49–50
 isoforms in humans, 50
- Oligodendrocyte-specific protein (OSP), structure, **64**, 106–107
- Oligodeoxynucleotide
 antisense, **67**, 219
- Oligodeoxynucleotides, **42**, 119–120
 analogs, **42**, 111–112
 oligonucleotide conjugates, **42**, 116
 phosphodiester-modified, **42**, 115–116
 sugar-modified, **42**, 112–115
 as informational drugs, **42**, 79–83
 cellular uptake, **42**, 101–108
 inhibition
 of translation, **42**, 93–101
 oncogene, **42**, 108–111
 phosphorothioate, **42**, 83
 inhibition of HIV, **42**, 89–93
 physicochemical properties, **42**, 83–89
 ribozymes, **42**, 118
 triplex function, **42**, 116–118
- Oligomeric structures, aminoacyl-tRNA synthetases and, **40**, 99–101
- Oligomers, states of pyruvate dehydrogenase kinase, **70**, 59–64
- Oligonucleotide based-gene therapy
 problems, **67**, 164
- Oligonucleotide based triple helix interaction, **67**, 168–169
- Oligonucleotide, *see also* Antisense oligonucleotide
 analogs
 α -oligonucleotides, **57**, 97
 binding affinity enhancement, **57**, 97–98
 nonionic, **57**, 97, 108
 peptide nucleic acids, **57**, 98, 103–104, 112, 121
 phosphorothioate, **57**, 97, 109, 115
 positively charged for accelerated

- hybridization, **57**, 101–102
- reactive derivatives, **57**, 98–99
- cellular receptors, **57**, 109
- endocytosis, **57**, 105–109
- immune response, **57**, 128–131
- nuclear uptake, **57**, 107–108
- protein binding in drug therapy, **57**, 96, 104–105, 122–126
- ribozyme attachment, **57**, 99–100
- Oligonucleotides
 - antisense
 - future applications, **48**, 226–227
 - in isolation of regulatory proteins binding to 5'UTR, **48**, 227
 - in study of translation, **48**, 219–227
 - in translation initiation intermediate identification and purification, **48**, 226
 - inhibition of gene expression *in vivo*, **48**, 224–226
 - inhibition of translation *in vitro*, **48**, 219–224
 - antisense, *see* Antisense oligonucleotides
 - cellular uptake, **48**, 216–218
 - chemical stability, **48**, 213–215
 - chimeric, **69**, 17
 - clamp and circular, **69**, 23–24
 - enzymatic stability, **48**, 213–215
 - identified via combinatorial approaches, **69**, 25–37
 - K155A mutant fpg, **68**, 231
 - K57A mutant fpg, **68**, 231
 - morpholino, **69**, 15
 - phosphate-modified, **48**, 206–208
 - physicochemical properties, **48**, 209–216
 - platinated, **69**, 18–19
 - ribose-modified, **48**, 208–209
 - RNA ligands, **69**, 5
 - selective-binding complementary, **69**, 15
 - solubility, **48**, 209
 - target RNA binding, **48**, 209–213
 - types, **48**, 206–209
- Oligonucleotides, antisense, *see* Antisense oligonucleotides
- Oligonucleotides, HSV, DNA microarrays
 - basic approach, **71**, 453–454
 - chip data, **71**, 465–468
 - chip fabrication and scanning, **71**, 464–465
 - experimental data, **71**, 470–472
 - hybridization, **71**, 455
 - receiver operating characteristic, **71**, 465
 - scanning protocols, **71**, 456–459
 - specific oligonucleotides, **71**, 461–464
 - transcript labeling, **71**, 455–456
- Oligoribonuclease
 - eukaryotic homologs, **66**, 80
 - function, **66**, 80
 - gene and regulation, **66**, 79
 - structure, **66**, 79–80
 - substrate specificity, **66**, 79
- Oligoribonuclease, characterization and functions, **62**, 78
- Oligosaccharides, calcium-dependent animal lectins and, **45**, 227–229
- Oligosaccharides, sialylated, **69**, 91
- Oligotropha carboxidovorans*, **67**, 37
- Olivomycin, DNA sequence specificity of damage, **63**, 383, 402
- ompA*, messenger RNA decay, **62**, 96–97
- ompA*, mRNA decay mechanisms, **52**, 175, 178
- Oncogene inhibition, oligodeoxynucleotides and, **42**, 108–111
- Oncogenes
 - alkylation damage repair in genomes and, **44**, 127–128
 - protein tyrosine kinase substrates and, **44**, 211–215
- Oncogenes, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and, **45**, 123
- Oncogenes, mutated, latent viruses and, *see* Latent viruses and mutated oncogenes
- Oncogenesis, adeno-associated virus and, **48**, 41
- Oncogenesis, DNMT1 and, **69**, 64–71
- Oncoretroviruses, IRES-dependent translation, **72**, 382–383
- One-sided invasion model, *see* Double-strand break-induced recombination
- Oocyte, *Xenopus*
 - DNA injection, **54**, 102–103
 - homologous genetic recombination of exogenous DNA
 - developmental recombination activities, **54**, 116–119
 - exonuclease resection, **54**, 106–108, 123
 - gene-targeting implications, **54**, 121–123
 - GV extracts, recombination activity, **54**, 113–114, 118
 - kinetics of recombination, **54**, 112–113
 - marker recovery, **54**, 114–116

- mismatch repair, **54**, 114–116
- single-strand annealing mechanism, **54**, 101–102, 108–111, 119–121, 123
- substrate selection, **54**, 103–106
- intracellular volume, **54**, 102
- staging, **54**, 116–117
- OPDA, *see cis(+)-12-Oxo-phytodienoic acid*
- Open reading frames
 - eukaryotic translation initiation, **72**, 6
 - Gag–Pol translation, **72**, 11
 - papillomavirus shunt, **72**, 20–21
 - Sendai virus shunt, **72**, 19–20
- Open reading frames, msDNA of bacteria and, **40**, 9–12
- Open reading frames, regulation within 5' leader, **51**, 350–354
- Open reading frames, upstream, in 5' UTR of eukaryotic mRNA, **48**, 185
- Operon, *see* Regulon
- Operons, *hisT*, organization, **50**, 269–270
- OPR, *see cis(+)-12-Oxo-phytodienoic acid* reductase
- ORC, *see* Origin recognition complex
- ORF, *see* Open reading frames
- Organic molecules, tRNA mimics, **70**, 307–309
- Organogenesis, lymph nodes, ROR γ role, **69**, 230–231
- OriC*
 - DnaA binding, **57**, 157, 174
 - initiator titration, **57**, 164
 - replication role
 - Dam, **57**, 174–175
 - DnaA, **57**, 157, 172, 176–177, 179–180
 - SeqA, **57**, 174–175
 - strand opening, **57**, 158–159
- Origin recognition complex
 - DNA replication initiation, **72**, 54–55
 - prereplicative complex assembly, **72**, 70–71
- α -*ori*, in R6K regulation, **48**, 263–264
- β -*ori*, in R6K regulation, **48**, 263–264
- γ -*ori* replicon
 - antisense RNA, **48**, 262
 - comparison with roles of replication host proteins binding, **48**, 246–247
 - multipartite structure, **48**, 243–246
 - organization, **48**, 241–251
- Ornithine decarboxylase antienzyme,
 - programmed +1 frameshifting, **64**, 157–158
- Ornithine decarboxylase mRNA,
 - translation, **48**, 203
- Orotate phosphoribosyltransferase, *see also* UMP synthase
 - amino acid sequence homology between species, **53**, 20–26
 - developmental changes of enzyme activity, **53**, 9–10
 - dimerization, **53**, 34–35
 - stability, **53**, 35–36
 - structure and function, **53**, 26–29
- Orotic aciduria, etiology, **53**, 19–20
- Orotidylate decarboxylase, *see also* UMP synthase
 - abzyme model, **53**, 39–40
 - amino acid sequence homology between species, **53**, 20–26
 - developmental changes of enzyme activity, **53**, 9–10
 - dimerization, **53**, 34–35
 - stability, **53**, 35–36
 - structure and function, **53**, 29–32
- Orphan receptors
 - retinoid-related, *see* Retinoid-related orphan receptors
 - Rev-Erba and - β , **69**, 216
- Osmium tetroxide, DNA sequence specificity of damage, **63**, 383, 401
- Osmotic stress, jasmonate levels, **72**, 166–167
- OSP, *see* Oligodendrocyte-specific protein
- Osteodystrophy, Albright hereditary, *see* Albright hereditary osteodystrophy
- Osteogenesis imperfecta
 - lethal prenatal, **47**, 44–46
 - type 1A, **47**, 46
- Ovalbumin gene, introns and chromatin assembly, **54**, 359–363
- Overactivity, human PRPP synthetase, inherited, **69**, 136–140
- Overexpression
 - AlcR, **69**, 174
 - developmental regulatory genes, **69**, 193
 - DNMT1, in cancer cells, **69**, 65
 - RORs, **69**, 236–239
- Overlapping binding sites, steroid hormones and, **43**, 21–23
- Oviduct, Muc4/SMC, **71**, 167–170
- Oxaliplatin
 - chemical structure, **67**, 118
- Oxaliplatin–DNA interactions, **71**, 26–29

- Oxazole-containing chromopeptides, **70**, 249
- Oxfenicine, **70**, 198
- β -Oxidation, LOX pathway, **72**, 176
- Oxidative base lesions
- BER, **68**, 287–288
 - DNA substrates, **68**, 209
 - NER, **68**, 287–288
- Oxidative consumption, glucose, **70**, 42
- Oxidative DNA damage
- assays, **68**, 140–143
 - nuclear DNA, **68**, 286–291
- Oxidative DNA damage repair
- mitochondria
 - human lymphoblastoid cell lines, **68**, 293
- Oxidative purine lesions
- BER enzyme, **68**, 212
- Oxidative pyrimidine products
- fpg, **68**, 223
- Oxidative thymine lesions
- BER enzymes, **68**, 211–212
- Oxidized AP sites, **68**, 12–13
- structure, **68**, 14
- Oxidizing agents, **68**, 30
- wild-type sensitivity
 - yeast BER mutants, **68**, 31–32
- 8-oxo-G. *See* 8-oxoguanine
- 8-oxoguanine (8-OH-G), **68**, 14, 55, 88, 96, 107, 193, 287–288
- AA8 CHO cells, **68**, 98–103, 101
 - kinetics, **68**, 102
 - transcription-coupled repair, **68**, 100–102
- adenine
- hMYH, **68**, 85–88
- antimutagenic processing, **68**, 194–195
- BER, **68**, 98–100
 - BER pathway, **68**, 194
- bipartite antimutagenic processing, **68**, 197–198
- cell line and culture conditions, **68**, 97
 - CHO cell line, **68**, 85–103
 - closed circular plasmids, **68**, 97–98
 - Escherichia coli* MutM, **68**, 107
 - hMTH1, **68**, 91
 - dATP, **68**, 75
 - dGTP, **68**, 75
 - hMYH, **68**, 91
 - hOGG1, **68**, 91
 - cytosine, **68**, 83–85
 - HPLC, **68**, 108
 - human OGG1/MMH type 1a protein, **68**, 110–112
 - mammalian cells, **68**, 109
 - mammalian MMH, **68**, 119–120
 - Mmh* deficient mice, **68**, 118
 - Mmh* knockout, **68**, 113–119
 - Mmh* mutant mice, **68**, 115
 - mutagenesis, **68**, 96
 - MutY, **68**, 350–352
 - OGG1, **68**, 203–204
 - OGG2, **68**, 199–200
 - plasmid DNA
 - AA8 cells, **68**, 97–98
 - potassium bromate, **68**, 108
 - ROS, **68**, 194
 - short-patch BER, **68**, 99
- 8-Oxoguanine-DNA glycosylase (OGG), **68**, 193, 194
- mtDNA
 - BER, **68**, 261
 - MutY, **68**, 200–201
 - substrate bases, **68**, 190
- cis*(+)-12-Oxo-phytodienoic acid
- flower development, **72**, 198–199
 - natural occurrence, **72**, 168–171
- cis*(+)-12-Oxo-phytodienoic acid reductase, LOX pathway, **72**, 176
- Oxoplatin–DNA interactions, **71**, 33
- Oxygen, mitochondrial biogenesis and, **46**, 59–62
- Oxytocin, promoter region, RORE in, **69**, 239

P

- ³²P-postlabeling, **68**, 140
- P-element, transposition in *Drosophila*, **58**, 288
- P protein, *see* Ribosome stalk
- P0, association on membranes, **64**, 105–106
- P0, *c-myc* IRES, **72**, 397–398
- P1, *see* Plasmid P1
- p107, autoregulation of promoter, **60**, 147–148
- P13
- MutY, **68**, 360
- P13K, **67**, 212–214
- cancer, **67**, 213–214
- P16, identification as immediate-early response gene, **58**, 53–54
- P2, *c-myc* mRNA, IRES, **72**, 397

- P2, role in myelin, **56**, 241
- P21-activated kinase (PAK), **67**, 201–204
- biological functions, **67**, 197
 - drug design, **67**, 222
 - JNK, **67**, 203
 - membrane localization, **67**, 202
 - p38, **67**, 203
- P21 protein
- PCNA, **68**, 132–134
- p21, displacement from PCNA, **69**, 66
- P24 family
- quality control, **67**, 250
- P26MutY
- structure, **68**, 354
- p300, activation of cyclic AMP-responsive element binding protein, **64**, 352–354
- p37^{brn}, *cis*-acting sequence recognizing, **70**, 164–167
- P38
- PAK, **67**, 203
- p38/MAPK
- identification, **71**, 79–80
 - isoforms, **71**, 80–81
 - preproinsulin gene regulation, **71**, 81–82
- p4, *see* Phage ϕ 29 protein p4
- p53
- cell cycle control, **72**, 79
 - FGF-2 translational silencing, **72**, 400–403
 - functions, overview, **65**, 264
 - viral replication stimulation, **65**, 288
- p53 protein, DNA adduct recognition, **71**, 21
- p53, autoregulation of promoter, **60**, 148
- p53, cell cycle control in mice, **58**, 67
- p53, downregulation of inositol-5'-monophosphate dehydrogenase, **61**, 200–201
- p6 protein, structure and recognition
- sequence, **47**, 247
- p97, eIF4A effects, **72**, 313
- PABII, *see* Poly A-binding protein
- PacI ribonuclease, role in yeast, **52**, 36, 38
- Packaging
- DNA-packaging domain, pRNA, **72**, 449–450
 - DNA, *see* DNA packaging
 - viral RNA, translation interplay, **72**, 7–10
- PAF
- acetylhydrolase, **67**, 4
 - group VIA PLA₂, **67**, 21–22
 - group VIIIA, **67**, 7
- PAGE, *see* Polyacrylamide gel electrophoresis
- Pai protein, *Bacillus subtilis* gene expression and, **46**, 136–138
- Paip1, *see* Poly(A)-binding protein interacting protein 1
- Paired domain, DNA-binding domain, **64**, 178
- PAK, **67**, 201–204
- biological functions, **67**, 197
 - drug design, **67**, 222
 - JNK, **67**, 203
 - membrane localization, **67**, 202
 - p38, **67**, 203
- Pallister-Hall syndrome, *GLI* mutation, **64**, 187
- Palmitoylation, nsP1, **71**, 201–203
- Pancreatic islet β -cells, MIN6
- AMPK-activated gene expression, **71**, 74–77
 - preproinsulin gene expression, **71**, 81–82
- PAP, *see* Poly A polymerase
- PAPH-1, **67**, 23
- Papilloma viruses, latent viruses and mutated oncogenes and, **43**, 160–164
- Papillomaviruses, shunt, **72**, 20–21
- PAPs, complex with PRS isoforms, **69**, 134–136
- Par, plasmid replication role, **57**, 177–179
- Parallel synthesis
- platinum, **67**, 120–122
- Pararetroviruses
- retroelement Gag–Pol translation, **72**, 10–12
 - RNA translation–packaging interplay, **72**, 7–10
- Parkinson's disease, **68**, 274, 278
- Parkinson's disease, monoamine oxidase B
- role, **65**, 130–131, 151
- Parkinson's disease, neurofilament disorders, **61**, 2, 10
- Parotid acinal cells, **67**, 28
- PARP genes, *Trypanosoma brucei* and, **43**, 49–51, 58–59
- PARP nuclear protein
- BER, **68**, 161–162
- Particulate targeting, PDE4 isoforms, **69**, 284–285
- PAS domains, PDE8, **69**, 258
- Pat1 kinase, control of entry into meiosis, **61**, 348–351
- Patch size
- uracil-DNA BER
 - LoVo cell extracts, **68**, 175–181
- Pathogenicity, MuLV, GCSA role, **72**, 380

- Pathogens, latent viruses and mutated oncogenes and, **43**, 137–138, 140
 drugs as alternatives, **43**, 187–188
 hypotheses, **43**, 184–186
- Pax3, transcriptional regulation in Schwann cells, **56**, 244–246
- PAX3, mutation in human syndromes
 craniofacial–deafness–hand syndrome, **64**, 194
 Waardenburg syndrome types 1 and 3, **64**, 194
- PAX6, mutation in aniridia type II, **64**, 194, 196
- Pax8
 congenital hypothyroidism mutations, **66**, 340–341
 developmental expression, **66**, 326–327
 evolution, **66**, 327
 homology with other Pax members, **66**, 326
 identification and gene cloning, **66**, 311
 prospects for study, **66**, 342–343
 recycling during development, **66**, 334–335
 regulation
 cyclic AMP, **66**, 335–336
 redox conditions, **66**, 337–338
 thyroglobulin, **66**, 338–339
 structure
 isoforms and alternative splicing, **66**, 329–330
 nuclear localization sequence, **66**, 329
 PAI domain, **66**, 328–329
 Prd domain, **66**, 327–328
 RED domain, **66**, 328–329
 target genes
 cooperative interactions with other thyroid-specific transcription factors, **66**, 332–334
 identification
 criteria, **66**, 330
 examples, **66**, 330–331
 immunoprecipitation following cross-linking, **66**, 331–332
- PBCM, *see* Propylbenzylcholine mustard
- PC1, *see* Prohormone convertase 1
- PC2, *see* Prohormone convertase 2
- PCF11 gene, yeast mRNA 3' end-processing factor, **71**, 361
- Pcm1p, *see* RNA (guanine-7) methyltransferase
- PCNA, *see* Proliferating cell nuclear antigen
- PCNA. *See* Proliferating cell nuclear antigen
- PCR-based assays, **68**, 140
- PCR, *see* Polymerase chain reaction
- PDC, *see* Pyruvate dehydrogenase complex
- Pdcd4, eIF4A effects, **72**, 313
- pDd26* gene, mRNA induction kinetics, **47**, 6–7
- pDd56* gene, *see* *ecmB* gene
- pDd63* gene, *see* *ecmA* gene
- PDE
 families, **69**, 253–258
 intracellular targeting, **69**, 258–261
 isoenzymes
 regulation of cAMP levels, **69**, 251–252
 structural similarity, **69**, 254–255
- PDE, *see* Cyclic nucleotide phosphodiesterase
- PDE1
 calcium/calmodulin binding, **65**, 20–22
 inhibitors, **65**, 17
 phosphorylative regulation, **65**, 21
 proteolytic properties, **65**, 22
 subtypes and kinetic properties, **65**, 20–21
 tissue distribution, **65**, 22–23
- PDE1C2, colocalization with AC3, **69**, 258–259
- PDE2
 cyclic nucleotide stimulation and binding sites, **65**, 23–24
 functions, **65**, 24
 inhibitors, **65**, 17
 isoforms, **65**, 23
 kinetic parameters, **65**, 23
 tissue distribution, **65**, 24
- PDE2, isoforms with 5' domain swaps, **69**, 259
- PDE3
 functions, **65**, 26
 high affinity for cAMP hydrolysis, **69**, 255–256
 inhibitors, **65**, 17
 isoenzymes, intracellular localization, **69**, 259–260
 kinetic parameters, **65**, 24–25
 regulation, **65**, 25–26
 structures, **65**, 25–26
 tissue distribution, **65**, 25–26
- PDE3, *see also* Cyclic nucleotide phosphodiesterase
 chronic regulation in disease, **66**, 260–261
 cyclic AMP, chronic regulation of PDE3B, **66**, 262
 cytokines
 acute regulation of PDE3B, **66**, 260

- chronic regulation of PDE3B by tumor necrosis factor- α , **66**, 261–262
- discovery, **66**, 247
- gene organization in humans, **66**, 249–250
- inhibitors
 - pharmacology and therapeutic applications
 - anti-inflammatory actions, **66**, 266
 - antiplatelet actions, **66**, 264–265
 - antiproliferative actions, **66**, 265
 - antithrombotic actions, **66**, 264–265
 - asthma, **66**, 266
 - bronchodilatory actions, **66**, 265–266
 - cardiac side effects, **66**, 266, 268
 - chronic obstructive pulmonary disease, **66**, 266–268
 - diabetes, **66**, 262, 269
 - heart failure, **66**, 266–268
 - inotropic actions, **66**, 262–263, 267
 - peripheral vascular disease, **66**, 267
 - prospects, **66**, 268–269
 - safety profiles, **66**, 268
 - vasodilatory actions, **66**, 263–264
- specificity, **66**, 246–247, 268–269
- insulin regulation of PDE3B
 - adipose tissue, **66**, 254–256
 - liver, **66**, 259–260
 - pancreatic β -cells, **66**, 259
- PDE4 comparison, **66**, 248
- phosphorylation
 - dephosphorylation of PDE3B, **66**, 258–259
 - hormonal activation of PDE3B in adipose tissue
 - inhibitors, **66**, 254–256
 - insulin, **66**, 254–256
 - isoproterenol, **66**, 256
 - kinase cascade, **66**, 255–256
 - protein kinase B as PDE3B kinase in adipose tissue
 - insulin activation, **66**, 257–258
 - isoforms and homologs, **66**, 256–257
 - overexpression of mutant kinases, **66**, 258
 - sites, **66**, 248, 254
- platelets, acute regulation of PDE3A, **66**, 260
- structural organization, **66**, 248, 252
- structure/function studies of catalytic domain, **66**, 250–251
- subcellular localization
 - compartmentalization of signaling, **66**, 252
 - fragment studies, **66**, 252–254
 - overview, **66**, 251
 - substrate specificity, **66**, 247
 - tissue-specific expression, **66**, 250
- PDE4
 - amino-terminal domain, **65**, 27–28
 - functions, **65**, 29
 - genes, **65**, 26–27
 - metal studies of catalysis, **65**, 14, 16
 - regulatory domain functions, **65**, 28–29
 - rolipram inhibition, **65**, 17–18, 26, 29
 - tissue distribution, **65**, 26
- PDE4 cAMP-specific PDEs, and PDE4-selective inhibitors, **69**, 261–262
- PDE4 isoenzymes
 - catalytic unit, **69**, 266–271
 - conformational changes, **69**, 271–279
- PDE4 isoforms
 - activation via PI-3 kinase, **69**, 298–300
 - induction of, **69**, 301–304
 - intracellular targeting, **69**, 279–288
 - phosphorylation, activation by PKA, **69**, 288–290
- PDE4 knockouts, **69**, 304–305
- PDE4* genes, organization, **69**, 262–266
- PDE4B2, phosphorylation, TCR-induced, **69**, 297–298
- PDE4D3, long isoform, activation, **69**, 300–301
- PDE5
 - allosteric cGMP-binding sites, **65**, 31–33
 - genes, **65**, 29–30
 - inhibitors, **65**, 17–18, 31, 33
 - kinetic parameters, **65**, 30
 - metal studies of catalysis, **65**, 14, 16, 30–31
 - phosphorylative regulation, **65**, 31–32
 - site-directed mutagenesis of catalytic residues, **65**, 12–13, 30
 - tissue distribution, **65**, 33
- PDE5, GAF domains, **69**, 256
- PDE6
 - allosteric cGMP-binding sites, **65**, 34–35
 - association with GARP, **69**, 260–261
 - cGMP binding, **69**, 257–258
 - inhibitors, **65**, 17
 - metal studies of catalysis, **65**, 14, 16
 - structure, **65**, 34

- PDE6 (*cont.*)
 transducin–PDE- γ –PDE $\alpha\beta$ interactions in
 phototransduction, **65**, 36–37
 vision role, **65**, 33–35
- PDE7
 inhibitors, **65**, 17, 37–38
 tissue distribution, **65**, 38
 variants, **65**, 38
- PDE7, splice variants, **69**, 261
- PDE8
 inhibitors, **65**, 17, 39
 kinetic parameters, **65**, 38
 tissue distribution, **65**, 39
- PDE8, PAS domains, **69**, 258
- PDE9
 inhibitors, **65**, 17, 39
 kinetic parameters, **65**, 39
 subtypes, **65**, 39
- PDE10
 inhibitors, **65**, 17
 structure, **65**, 40
 tissue distribution, **65**, 40
- PDE11
 inhibitors, **65**, 17
 kinetic parameters, **65**, 40
 regulation, **65**, 40
 tissue distribution, **65**, 40–41
- PDGF, *see* Platelet-derived growth factor
- PDI, **67**, 237
- PDK1, S6 kinase as substrate, **65**,
 111–112, 122
- PDP, *see* Pyruvate dehydrogenase
 phosphatase
- PDR, *see* Phthalate dioxygenase reductase
- PDZ-guanine nucleotide exchange factors, **71**,
 416–418
- Pearson's syndrome, **68**, 274
- D-Penicillamine, HIV therapy, **49**, 184
- Penetrating loop mutants
 APE1, **68**, 332–333
- Penicillium citrinum*, **68**, 336
- PEPCK, *see* Phospho *enol* pyruvate
 carboxykinase
- PEPCK, *see* Phosphoenolpyruvate
 carboxykinase
- PEPT1
 gene cloning, **58**, 244–245
 hydrophobicity analysis, **58**, 257–258
 sequence homology with other
 transporters, **58**, 248, 250–256
 structure, **58**, 248–249
- PEPT2
 gene cloning, **58**, 244–245
 hydrophobicity analysis, **58**, 257–258
 sequence homology with other
 transporters, **58**, 248, 250–256
 structure, **58**, 248–249
- Peptide-based drugs
 combinatorial/parallel synthesis
 approaches, **67**, 120–122
- Peptide biosynthesis, *see* Nascent peptide;
 Ribosome
- Peptide-bond formation, ribosome-
 catalyzed, **50**, 1–23
- Peptide nucleic acids (PNAs), **67**, 166–167
- Peptide nucleic acids, cRNA binding, **69**, 15
- Peptidyl carrier proteins domains, **70**, 238
- Peptidyl prolyl *cis*–*trans* isomerase, *see also*
 Trigger factor
 general chaperone in *Escherichia coli*, **66**,
 139
 outer membrane protein chaperone, **66**,
 140–141
- Peptidyl–prolyl *cis*–*trans* isomerase, protein
 folding role, **58**, 309
- Peptidyl transferase reaction,
 stereochemistry, **66**, 47
- Peptidyltransferase, in peptide-bond
 formation, **50**, 1–23
- Periaxin, role in myelin, **56**, 242
- Peripheral myelin protein 22 (PMP22)
 association on membranes, **64**, 105–106
 disease and mutations
 Charcot–Marie–Tooth disease type 1A, **64**,
 114–116
 gene dosage in disease, **64**, 119–121
 hereditary neuropathy with liability to
 pressure palsies, **64**, 115–116
 mouse mutants
 knock-in mice, **64**, 119–120
 knock-out mice, **64**, 120–121
Tr, **64**, 117–118
Tr-J, **64**, 117–118
Tr-Ncnp, **64**, 118
 myelination disorders, **64**, 116–117
 overview, **64**, 99, 113–114
 promoter regulatory region mutations,
64, 110
 expression
 distribution and levels, **64**, 100, 114

- regulation, **64**, 109–110
- four transmembrane domain structure, **64**, 98
- functions
 - differentiation, **64**, 112
 - growth control, **64**, 111–112
- gene
 - cloning, **64**, 99–100
 - locus, **64**, 108
 - promoters, **64**, 109
 - structure, **64**, 107–108
- glycosylation, **64**, 105
- Schwann cell apoptosis regulation, **64**, 121–122
- sequence homology analysis, **64**, 103, 105
- trafficking, **64**, 103, 105
- Peripheral myelin protein 22 (PMP22), role in myelin, **56**, 239–240, 242–243
- Peripheral vascular disease, PDE3 inhibitor therapy, **66**, 267
- Perlecan
 - functions, **62**, 33
 - gene, **62**, 33
 - structure, **62**, 32–33
 - tissue distribution, **62**, 21, 33
 - transcriptional regulation, **62**, 33, 35
- Permeable mammalian cell systems
 - DNA repair
 - DNA polymerase inhibitors, **68**, 10
- Peroxisome proliferator activator receptor, *see* PPAR γ
- Pertussis toxin, **54**, 243–244
- Pf3 coat protein
 - spontaneous insertion of N-tail in plasma membrane
 - driving force, **66**, 134–135
 - N-tail translocation mechanism, **66**, 135
 - overview, **66**, 131
 - structure, **66**, 134
- pgs-1* gene
 - heterodimer formation with *tis10/pgs-2* proteins, **47**, 142
 - structure, **47**, 137–139
- Phage ϕ 29 protein p4
 - early A2b promoter repression, **60**, 36–37
 - early A2c promoter repression, **60**, 37, 39–42
 - late A3 promoter activation
 - binding site, **60**, 32–33
 - RNA polymerase binding with protein p4, **60**, 33–36
 - promoter repression and activation,
 - overview, **60**, 31
 - RNA polymerase α subunit binding site, **60**, 42–44
- Phage lambda, **70**, 91–92
- Phage regulatory proteins, lysogenic pathway in bacteriophage λ and, **46**, 46–47
- Phantom viruses, latent viruses and mutated oncogenes and, **43**, 155–157
- 1,10-Phenanthroline, DNA cleavage by copper complex, **49**, 313
- 1,10-Phenanthroline-copper, DNA scission
 - chemical mechanism, **52**, 125–126
 - clinical applications, **52**, 128–130
 - foot printing applications, **52**, 131–133
 - inhibition of *Escherichia coli* DNA polymerase, **52**, 124
 - inhibition of reaction, **52**, 127–128
 - nucleic acid-directed scission, **52**, 138–142
 - protein targeting, **52**, 142–145, 147–148
 - sensitivity to DNA conformation, **52**, 130–131, 148
 - site-specific targeting, **52**, 138
 - specificity for metal ion and phenanthroline structure, **52**, 126–128
 - transcription inhibition of analogs, **52**, 133–137
 - virus inactivation, **52**, 129–130
- Phenobarbital, induction of cytochromes P450
 - Bacillus megaterium*, *see* BM1; BM3
 - barbie box role, **61**, 32–35, 58
 - distal phenobarbital-responsive enhancer
 - CYP2B1/2*, DNase I hypersensitivity, **61**, 43–44, 58
 - CYP2B1*, **61**, 48, 57
 - Cyp2b10*, **61**, 51–56
 - CYP2B2*, **61**, 42–51, 55–57
 - Cyp2b9*, **61**, 51–57
 - CYP2C1*, **61**, 44, 47, 50–51
 - CYP2H1*, **61**, 41, 43
 - NF-1 binding to phenobarbital-responsive unit, **61**, 49–51, 53–55, 59–61
 - models, **61**, 60–61
 - overview, **61**, 27–30
 - proximal promoter elements and binding proteins
 - CYP1A1*, **61**, 40
 - CYP2B1/2*, **61**, 35–36, 38
 - Cyp2b10*, **61**, 40–41

- Phenobarbital, induction of cytochromes P450
(*cont.*)
CYP2B2, **61**, 38–41
- Phenotype, DNA polymerase II and, **46**,
110–111
- Phenotype, genetic defects of mammalian
nervous system and, **41**, 243–244,
253–254
- Phenotype, superoxide dismutases and, **40**,
245–246
- Phenoxazinone chromophore, **70**, 255–257
- Phenphi, pRNA cross-linking, **72**, 435
- Phenylalanine-160, HIV-1 RT, **71**, 114–117
- Phenylalanine-accepting tRNAs, **70**, 318–319
- Phenylalanine-tRNA synthetase, **70**, 316–317
- phi29
assembly, mutant pRNA, **72**, 458–459
cp-pRNA, **72**, 421–422
DNA packaging, **72**, 417–419, 452
DNA translocation, pRNA role, **72**, 453–457
pRNA antisense DNA targeting, **72**, 458
pRNA assay, **72**, 420–421
pRNA dimer images, **72**, 440
pRNA monomer images, **72**, 440
pRNA stoichiometry, **72**, 425
- Phleomycin
DNA cleavage site specificity, **49**, 333, 347
structure, **49**, 334
- Phorbol ester, effect on mRNA decay, **56**, 263,
265
- Phorbol esters, 6-phosphofructo-2-kinase/
fructose-2,6-bisphosphatase and, **45**, 123
- Phorbol-induced primary response genes
in 3T3 cells, induction by mitogens, **47**, 116
induction by ligands, **47**, 116–117
prostaglandin synthesis induction in Swiss
3T3 cells, **47**, 126–130
proteins encoded by, **47**, 118
subsets, in cell-type responses, **47**, 117–118
tis10 gene, **47**, 124–125
tis10/pgs-2
as second *pgs/cox* gene, **47**, 139
heterodimer formation with *pgs-1*
proteins, **47**, 142
induction
in macrophages, **47**, 139–142
in Swiss 3T3 cells, **47**, 130
inhibition, **47**, 130–134
regulation at transcriptional level, **47**,
134–137
structure, **47**, 137–139
tis11 gene, **47**, 121–124
tis21 gene, **47**, 119–121
transcription factors encoded by, **47**,
118–119
- Phosphatases, C-terminal domain, **48**,
172–173
- Phosphate-modified oligonucleotides, **48**,
206–208
- Phosphatidic acid
derepression of inositol-1-phosphate
synthase, **61**, 165, 167, 172
yeast mutants in metabolism, **61**, 152–153
- Phosphatidic acid, activation of long PDE4D3
isoform, **69**, 300–301
- Phosphatidylcholine
choline auxotrophs of *Schizosaccharomyces*
pombe, **61**, 149–151
choline-requiring mutants of *Saccharomyces*
cerevisiae, **61**, 146–147
synthesis in yeast, **61**, 137, 167
- Phosphatidylcholine, biosynthesis
enzymes, *see* CDP-choline:1,2-diacylglycerol
phosphotransferase; Choline kinase;
CTP:phosphocholine
cytidyltransferase
homeostasis, **65**, 380–381
inhibition and apoptosis induction, **65**,
382–386
overview, **65**, 362–364
regulation, **65**, 364–374
- Phosphatidylethanolamine, biosynthesis
ethanolamine cytidyltransferase, **65**,
375–376
ethanolamine kinase, **65**, 375
ethanolamine phosphotransferase, **65**, 376
overview, **65**, 362–363, 374–375
- Phosphatidylethanolamine, methylation
defective mutants in *Saccharomyces*
cerevisiae, **61**, 147–149, 155, 160
- Phosphatidylinositol 3-kinase (PI3K),
S6 kinase effector studies, **65**, 113
- Phosphatidylinositol 3-kinase, protein
tyrosine kinase substrates and, **44**,
211, 214
- Phosphatidylinositol-3-OH kinase (PI3K), **67**,
212–214
cancer, **67**, 213–214
- Phosphatidylinositol 4,5-bisphosphate
PDL, **67**, 206

- Phosphatidylinositol, *see also*
 Inositol-1-phosphate synthase
 kinases, **61**, 136–137, 139–140
 synthesis in yeast, **61**, 135–136
 turnover, **61**, 139–140
- Phosphatidylinositol, biosynthesis
 CDP-diacylglycerol synthase, **65**, 377–378
 diacylglycerol kinase, **65**, 377
 overview, **65**, 362–363, 376–377
 phosphatidylinositol synthase, **65**, 378–379
- Phosphatidylserine decarboxylase, mutants in
 yeast, **61**, 151–152, 155
- Phosphatidylserine, biosynthesis regulation, **65**, 379
- Phosphatidylserine, synthesis in yeast, **61**, 141
- Phospho *enol* pyruvate carboxykinase, **71**, 72–73
- Phosphocholine cytidyltransferase, **67**, 26–27
- Phosphodiester bond
 formation, **68**, 152
 hydrolysis, **68**, 337–338
- Phosphoenolpyruvate carboxykinase, **72**, 272
- Phosphoenolpyruvate carboxykinase, insulin
 response sequence and regulation, **60**, 325–326
- 6-Phosphofructo-2-kinase/fructose-2,
 6-bisphosphatase, **45**, 99–100, 124
 gene expression
 glucagon, **45**, 121–123
 glucocorticoids, **45**, 119–120
 growth factors, **45**, 123
 insulin, **45**, 121–123
 oncogenes, **45**, 123
 phorbol esters, **45**, 123
 thyroid hormones, **45**, 120–121
- genes
 characterization, **45**, 116–119
 chromosomal localization, **45**, 118–119
- isozymes, **45**, 101–104
 mRNAs, **45**, 105–110
 structure, **45**, 110–116
- liver, **45**, 100–101
 short-term control, **45**, 104–106
- Phosphoinositol-3-kinase-like complexes,
72, 77
- Phospholipase A₁ (PLA₁)
 activities, **67**, 20
- Phospholipase A₂ (PLA₂)
 activities, **67**, 20
 classification, **67**, 3–4
 molecular biology, **67**, 2–3
- Phospholipase A₂, snake venom
 catalytic mechanism, **59**, 313–315, 318
 chemical modification studies, **59**, 316–317
 classification, **59**, 311, 313
 complementary DNA structures, **59**, 324, 326
- Darwinian-type accelerated evolution
 intron analysis, **59**, 338–339
 numbers of nucleotide substitutions per
 nonsynonymous site, **59**, 330–331, 335–336, 338
 numbers of nucleotide substitutions per
 site, **59**, 327, 330–331, 335–336, 338
 numbers of nucleotide substitutions per
 synonymous site, **59**, 330–331, 335–336, 338
 phylogenetic relationships using
 untranslated regions of
 complementary DNA, **59**, 336–337
- gene structures, **59**, 326–327
 physiological effects, **59**, 321–322, 324
 primary structures, **59**, 311–312
 quaternary structures, **59**, 315–316
 refolding studies, **59**, 317
 substrate specificities, **59**, 317–321
 three-dimensional structures, **59**, 313–315
- Phospholipase C, **68**, 336
- Phospholipase C
 PLC_c, **71**, 418–420
 PLC_γ, SPHK activation, **71**, 499
- Phospholipase C, yeast gene, **61**, 139
- Phospholipase D
 cellular functions and yeast models,
61, 171
 phosphatidylcholine turnover, **61**, 170–171
 yeast gene, **61**, 137, 139
- Phospholipase D (PLD), **67**, 205–207
 cancer treatment, **67**, 216–217
- Phospholipases
 membrane phospholipid homeostasis
 maintenance, **65**, 380
- PLA₂
 functions, **65**, 381–382
 groups, **65**, 381
- Phospholipids
 group VIA PLA₂, **67**, 20–21
- Phospholipids, nsPI activity, **71**, 203
- Phosphoramidite method, **68**, 208
versus enzymatic method, **68**, 210

- 5-Phosphoribosyl α -1-pyrophosphate,
see PRPP
- Phosphoribosyltransferase, and PRPP
 utilization, **69**, 119–121
- Phosphorothioate oligodeoxynucleotides, **42**,
 83–93
- Phosphorothioates, oligonucleotide analogs,
69, 8
- Phosphorylation
 dephosphorylation, CTD, **72**, 354
 iPLA₂ β , **67**, 17
 KID, pol II, **72**, 293–296
 nsP3, **71**, 209–210
 PDE4 enzymes, by ERK MAP kinase, **69**,
 290–297
 PDE4 isoforms, activation by PKA, **69**,
 288–290
 poly A polymerase, **71**, 334–335
 RNA polymerase II, **72**, 334–335
- Phosphorylation, eukaryotic initiation factor 4E
 and, **46**, 197, 199, 201
- Phosphorylation, protamines and, **40**, 74–75
- Phosphorylation, protein tyrosine kinase
 substrates and, **44**, 208, 210–211, 216–224
- Phosphorylation, translational initiation
 factor, **51**, 343–346
- Phosphotyrosine, protein tyrosine kinase
 substrates and, **44**, 207–208
- Photoaffinity cross-linking, pRNA, **72**, 431–433
- Phthalate dioxygenase reductase (PDR),
 flavin-binding site, **65**, 141, 143
- Phylogenetic analysis, pRNA, **72**, 431
- Phylogenetic analysis, sphingosine kinases,
71, 508
- Phytochrome genes, rice, **45**, 5–7, 17–18
- PI-3 kinase, role in activation of PDE4
 isoforms, **69**, 298–300
- π protein
 domains, **48**, 248–250
 mutant, dominant-negative, properties,
48, 261
 replication inhibitor activity, IHF protein
 binding to site 1 modulating, **48**,
 261–262
 two forms, replication control by, **48**,
 256–260
- PI3K
 drug design, **67**, 222–223
- PI3K, *see* Phosphatidylinositol 3-kinase
- Pinch-push-pull model
 UDG, **68**, 325
- PINs
 plant-insect interactions, **72**, 190–192
 systemic wound response, **72**, 189
- PIP5 kinase
 biological functions, **67**, 197
- pir* gene
 autoregulation, in R6K copy-number
 control, **48**, 255–256
 regulation, **48**, 250–251
 structure, **48**, 247–248
- PIR1, *see* RNA triphosphatase
- Pit-1
 anterior pituitary, Pit-1 expression in
 development, **63**, 226, 248
 DNA binding and transcriptional
 regulation, **63**, 225–226
 human gene mutations, **63**, 227–228
 mutant mouse dwarf strains, **63**, 226–227,
 247–248
- Pit1, autoregulation of promoter, **60**,
 156–158, 162
- Pit1*, mutation in combined pituitary hormone
 deficiency, **64**, 199
- PKA, *see* Cyclic AMP-dependent protein
 kinase
- PKA, *see* Protein kinase A
- PKB, *see* Protein kinase B
- PKB, *see* Protein kinase B
- PKC, *see* Protein kinase C
- PKN, **67**, 196, 207–209
 biological functions, **67**, 197
- PKR, *see* Double-stranded RNA-activated
 protein kinase
- PKR, activation by double-stranded RNA,
57, 127
- PKS I, *see* Polyketide synthases
- PLA₁
 activities, **67**, 20
- PLA₂
 activities, **67**, 20
 classification, **67**, 3–4
 molecular biology, **67**, 2–3
- PLA₂, *see* Phospholipases
- Plant development, jasmonates and
 octadecanoids
 flowers, **72**, 198–200
 germination and seedlings, **72**, 196–197
 senescence, **72**, 202–205
 tendril coiling, **72**, 202

- tuberization, **72**, 200–202
- Plant–insect interactions
 - direct defense, **72**, 190–192
 - indirect defense, **72**, 192–193
- Plant–pathogen interactions, jasmonates, **72**, 194–196
- Plant–plant interactions, jasmonates, **72**, 193
- Plant viruses, replication of, *see* Replication of plant viruses
- Plants
 - branched chain aminotransferases, **70**, 180–181
 - mitochondria
 - complex transcription patterns, **70**, 135–136
 - editing, **70**, 142
 - intron splicing, **70**, 137–138
 - processing and stability, **70**, 138–142
 - promoter primary structure, **70**, 127–129
 - tissue-specific gene expression, **70**, 134–135
 - transcription initiation sites, **70**, 126–127
 - transcription protein components, **70**, 130–131
 - transcription regulation, **70**, 131–134
 - transcription units, **70**, 124–126
 - tRNA maturation, **70**, 144–147
 - tRNA population, **70**, 142–144
- Plants, SPHK and SIP, **71**, 497
- Plasma membrane complex, EBP, cathepsin A, and sialidase, **69**, 98–99
- Plasmid DNA
 - AA8 cells
 - 8-oxoG, **68**, 97–98
- Plasmid P1
 - basic replicon, **57**, 149–150
 - copy number limitation, **57**, 146–147, 159, 168
 - initiator proteins, functions, **57**, 155–158
 - iterons
 - cooperativity of initiator binding, **57**, 171–172
 - evolution, **57**, 150–153, 155
 - initiator titration, **57**, 161–165
 - inverted repeat sequences, **57**, 153, 155
 - pairing, **57**, 157, 165, 171
 - RepA binding, **57**, 150–152, 156
 - sequence conservation, **57**, 151, 155, 180
 - structure, **57**, 151–152
- Par locus, **57**, 177–179
- preparation, **57**, 149
- replication
 - cell cycle coordination, **57**, 168–179
 - mode, **57**, 158–159
 - negative control, **57**, 159, 161–165, 167–168
- Plasmid–plasmid pairing, in interon-mediated replication inhibition, **48**, 255
- Plasmid substrate
 - Ap site, **68**, 125
- Plasmid, copy-number control by
 - handcuffing, **48**, 260–261
- Plasmids, 2- μ m, structure and function, **51**, 53–57
- Plasmids, DNA replication, PAP1 regulation, **71**, 366–367
- Platelet-activating (PAF)
 - acetylhydrolase, **67**, 4
 - group VIA PLA₂, **67**, 21–22
 - group VIIIA, **67**, 7
- Platelet-derived growth factor
 - biological activity, **55**, 234, 241
- S1 nuclease analysis of A-chain gene
 - binding protein identification, **55**, 240
 - hypersensitivity mapping assay, **55**, 235
 - identification of hypersensitive sites, **55**, 235–236, 238–240
 - promoter, **55**, 234–235
 - rationale, **55**, 233–234
 - transcription suppression by
 - complementary oligonucleotide, **55**, 236–238, 241
 - structure, **55**, 234
- Platelet-derived growth factor (PDGF)
 - inducible genes in mouse fibroblasts, **58**, 57–58
 - receptor and signal transduction, **58**, 42
 - structure, **58**, 57
- Platelet-derived growth factor mRNA,
 - translation, **48**, 202
- Platelet-derived growth factor, SPHK
 - activation, **71**, 499
- Platinum
 - parallel synthesis, **67**, 120–122
- Platinum compounds–DNA interactions, **71**, 29–32
- Platinum derivatives, conjugated to oligonucleotides, **69**, 18–19

- Platinum drugs
 DNA cross-links, **67**, **96**
 new
 development, **67**, **117–125**
 Platinum drugs–DNA interactions, **71**, **31**
 PLC, *see* Phospholipase C
 PLD, **67**, **205–207**
 cancer treatment, **67**, **216–217**
 PLP, *see* Pyridoxal phosphate
 Pluramycins, DNA sequence specificity, **63**,
 378, **387**
 Plus-strand RNA, alphavirus, synthesis, **71**,
 194–196
 pME₁, identification as immediate-early
 response gene, **58**, **52**, **58**
 PMP, *see* Pyridoxamine
 PMP22, *see* Peripheral myelin protein 22
 PMR-1 nuclease system, vitellogenin
 mRNA, **72**, **155–156**
 PNAs, **67**, **166–167**
 PNPase, *see* Polynucleotide phosphorylase
 Point mutations
 mtDNA, **68**, **258**
 Pol α , *see* DNA polymerase α
 Pol β , *see* DNA polymerase β
 Pol δ , *see* DNA polymerase δ
 Pol ϵ , *see* DNA polymerase ϵ
 Pol beta. *See* DNA polymerase beta
 Pol delta, **68**, **129**, **165**
 Pol epsilon, **68**, **165**
 Pol gamma, **68**, **90**, **265–266**
 pol II, *see* RNA polymerase II
 POL3 mutants
 mammalian pol beta, **68**, **21**
 Pollen-tube–pathway method, rice genes
 and, **45**, **13–15**
 Polo-like kinase, cell cycle control in mice, **58**,
 68–69
 Poly A-binding protein
 CFI_m and CFII_m cleavage factors, **71**,
 331–333
 cleavage/polyadenylation, **71**, **317–318**
 clones, **71**, **330–331**
 mRNA 3' end processing, **71**, **347–349**
 sequence motifs and homologs, **71**, **331**
 Poly A polymerase
 cDNA clones, **71**, **320–322**
 characterization, **71**, **316–317**
 CPSF complex, **71**, **328**
 CstF complex 50-kDa subunit, **71**, **326–327**
 CstF complex 64-kDa subunit, **71**, **326**
 CstF complex 77-kDa subunit, **71**, **327–328**
 CstF complex cDNA clones, **71**, **325–326**
 genomic cloning, **71**, **322**
 phosphorylation, **71**, **334–335**
 plasmid DNA replication, **71**, **366–367**
 poly A-binding proteins, **71**, **330–333**
 poly A(+) mRNA, **71**, **288–290**
 second gene, **71**, **372–374**
 sequence motifs
 catalytic site, **71**, **323–324**
 characteristics, **71**, **322–323**
 NLS signal, **71**, **323**
 RNA-binding domain, **71**, **324**
 serine/threonine-rich domain,
 71, **324–325**
 sequence motifs and homologs, **71**, **328–330**
 stimulated mRNA decay, **71**, **370–372**
 Vaccinia virus, **71**, **375–377**
 yeast polyadenylation, **71**, **357–358**
 Poly A sequences
 Escherichia coli polyadenylation
 degradosome, **71**, **372**
 mRNA decay, **71**, **370**
 mRNA-degrading RNases, **71**, **370**
 overview, **71**, **363–366**
 PAP1, **71**, **366–367**
 PAP1-stimulated mRNA decay,
 71, **370–372**
 second gene search, **71**, **372–374**
 target RNA decay, **71**, **367–369**
 mRNA, polymerases, **71**, **288–290**
 Poly A sites
 choice regulation, **71**, **335–336**
 coding exons
 calcitonin/CGRP pre-mRNA, **71**,
 337–341
 immunoglobulin heavy-chain
 pre-mRNA, **71**, **341–347**
 cross-linking to proteins, **71**, **309**
 downstream sequences, **71**, **292–295**
 3' noncoding exons, **71**, **336–337**
 UV cross-linking of proteins, **71**, **308**
 Vaccinia virus mRNA, **71**, **377–380**
 yeast, **71**, **350–353**
 Poly(L-lysine), antisense oligonucleotides
 and, **44**, **155**, **157–158**
 Poly(A)-binding protein
 cytoskeleton association, **49**, **37**
 mRNA binding, **49**, **9**, **11**, **37**

- Poly(A)-binding protein interacting protein
1, **72**, 313
- Poly(A) polymerase
functions, **62**, 76
messenger RNA decay role, **62**, 90–91, 94
structure, **62**, 75
types, **62**, 75–76
- Poly(A) sites, FGF-2 mRNA expression
control, **72**, 392–393
- Poly(ADP-ribose) polymerase
antisense RNA
effects
apoptosis, **55**, 151–154
cell differentiation, **55**, 148
cell survival after DNA damage, **55**,
147–148
chromatin organization, **55**, 144–145
DNA repair, **55**, 147–148
DNA replication, **55**, 148, 150–151
DNA strand-break rejoining,
55, 146–147
endogenous mRNA transcripts, **55**, 142
genomic stability, **55**, 146
nuclear activity depletion, **55**, 138–139,
143–144
protein expression, **55**, 142–143
expression in transfected cells, **55**, 139,
141–142
vectors, **55**, 139
biological roles, **55**, 135–137, 151–154
domains, **55**, 136
inhibition of activity
competitive inhibitors, **55**, 136–137
deletion mutation, **55**, 137
knockout mice, **55**, 137–138
overexpression of DNA-binding domain
and *trans*-dominant inhibition,
55, 138
- Poly(ADP-ribosyl)ation, histone modification
effects on DNA repair, **62**, 249–250
- Polyacrylamide gel electrophoresis (PAGE),
pyr⁺pur•pyr triplex, **59**, 61–63, 66
- Polyadenylation
AAUAAA signal, **71**, 291–292
adenovirus primary transcripts, **71**, 290
cleavage, *see* Cleavage/polyadenylation
complexes, **71**, 302–304
core proteins, **71**, 319–320
Escherichia coli, overview, **71**, 362–363
Escherichia coli, poly A sequences
degradosome, **71**, 372
mRNA decay, **71**, 370
mRNA-degrading RNases, **71**, 370
overview, **71**, 363–366
PAP1, **71**, 366–367
PAP1-stimulated mRNA decay, **71**,
370–372
second gene search, **71**, 372–374
target RNA decay, **71**, 367–369
mRNA 3' end formation, **71**, 298–299
mRNA 3' end processing, **71**, 347–349
poly A polymerase phosphorylation, **71**,
334–335
poly A site choice, **71**, 335–336
poly A site downstream sequences, **71**,
292–295
poly A site processing
calcitonin/CGRP pre-mRNA, **71**,
337–341
immunoglobulin heavy-chain
pre-mRNA, **71**, 341–347
3' noncoding exons, **71**, 336–337
pre-mRNA processing, **71**, 295–297
snRNP role, **71**, 304
transcription
coupling to 3' end processing,
71, 297–298
initiation, **71**, 297
- Vaccinia virus
mRNA, poly A signals, **71**, 377–380
overview, **71**, 374–375
poly A polymerase, **71**, 375–377
- yeast
overview, **71**, 349–350
poly A polymerase, **71**, 357–358
poly A signals, **71**, 350–353
yeast, 3' end-processing factors
CF1 complex, **71**, 354
CF11 complex, **71**, 355–356
conditional mutants, **71**, 358–359
genetic approaches, **71**, 359
mammalian homologs, **71**, 361–362
overview, **71**, 353–354
PF1 fraction, **71**, 356–357
synergistic lethality, **71**, 359
two-hybrid system, **71**, 360–361
- Polyadenylation complexes, assembly from
nuclear fractions, **71**, 309–311
- Polyadenylation, RNA
cytoplasmic polyadenylation, **57**, 54–56

- Polyadenylation, RNA (*cont.*)
 deadenylation, **57**, 274
 functions, **57**, 42
in vitro systems, **57**, 48
 poly(A) binding protein II functions, **57**, 52–53
 poly(A) polymerase
 activation, **57**, 50
 cytoplasmic enzyme, **57**, 54
 mechanism, **57**, 50–52
 RNA affinity, **57**, 51–52
 yeast enzyme, **57**, 56–57
 protein complexes, **57**, 53
 regulation
 multiple polyadenylation sites, **57**, 58–60
 quantitative regulation, **57**, 62–64
 splicing of polyadenylation sites, **57**, 60–62
 sequences directing processing
 AAUAAA, **57**, 42–45, 47
 animals, **57**, 43–44, 47
 effects of mutations, **57**, 43–45
 plants, 46
 secondary structure, **57**, 44
 yeast, **57**, 44–47
 translational control in development, **57**, 54
 universal conservation, **57**, 42
 viruses, **57**, 42
- Polyanion binding properties, aminoacyl-tRNA synthetases and, **40**, 107–116
- Polyanions, antisense oligonucleotides and, **44**, 157–158
- Policitronic messenger RNA, translation
 basic strategies, **72**, 21–22
 leaky scanning, **72**, 22–23
 TAV-activated reinitiation model, **72**, 27–28
 TAV control, **72**, 23–24
 TAV–host interactions, **72**, 24–26
- Polyglutamate, mediation of chromatin assembly, **54**, 346–347, 350–351, 353–356
- Polyketide assembly systems, **70**, 274–277
- Polyketide synthases, **70**, 241–243
- Polymerase β , role in DNA repair, **51**, 113
- Polymerase δ , and PCNA, **51**, 98–99
- Polymerase ϵ , PCNA effects, **51**, 103–104
- Polymerase chain reaction
 DNA concentration limits, **49**, 287
 mutation generation, **49**, 299–300, 310
 mutational spectrometry, **49**, 288–289, 308–310
 allele-specific amplification, **49**, 289–290
 mismatch amplification mutation assay, **49**, 288, 291–295
 site-directed mutagenesis applications, **49**, 360–361
- Polymerase chain reaction (PCR)
 inducible gene identification by reverse transcription, **58**, 59–60
 internal eliminated sequence analysis, **56**, 27–28
 mapping of DNA photolesions, **56**, 74–75
 proton-coupled oligopeptide transporter gene identification by reverse transcription, **58**, 245
- Polymerase chain reaction, HSV DNA microarrays, **71**, 453
- Polymerase chain reaction, intron splicing in monocots and, **42**, 248–250
- Polymerase switching, on lagging strand, **51**, 109
- Polymerase, drug-resistant viruses, **71**, 129
- Polymerization
 cDNA synthesis, **67**, 77–80
- Polymorphism
 alcohol dehydrogenase and, **40**, 267–268
 aldehyde dehydrogenase and, **40**, 279–282
- Polynuclear platinum antitumor drugs–DNA interactions
 dinuclear compounds, **71**, 44–47
 overview, **71**, 42–44
 trinuclear compounds, **71**, 47–49
- Polynuclear platinum complexes, **67**, 119–120
 chemical structure, **67**, 119
- Polynucleotide ligases, sequence conservation, **50**, 119–122
- Polynucleotide phosphorylase
 catalytic mechanism, **62**, 70–71
 cloning, **62**, 72
 gene structure and regulation, **62**, 72–73
 messenger RNA decay role, **62**, 71, 73, 85–86, 88, 90, 94
 protein-protein interactions, **62**, 73
 purification, **62**, 70
 structure, **62**, 70
 substrate specificity, **62**, 71
- Polynucleotide phosphorylase (PNPase)
 chloroplast degradosome complex, **66**, 92

- chloroplast poly(A) polymerase complex, **66**, 93
- degradosome association and function, **66**, 91–92
- eukaryotic homolog, **66**, 74, 84
- function, **66**, 82–84
- gene and regulation, **66**, 83
- structure, **66**, 82
- substrate specificity, **66**, 82–83
- Polynucleotide phosphorylase, role in messenger RNA decay, **52**, 197–199, 208
- Polypeptide-chain release factor, as distinct protein, **48**, 113–114
- Polypeptides
- nascent
 - glycoprotein folding
 - ER, **67**, 239–241
- Polypeptides, EF-Tu, **71**, 514–515
- Polyprotein P123, alphavirus replication complex, **71**, 211–212
- Polyprotein P1234
- alphavirus replication complex, **71**, 211–212
 - processing, **71**, 197
- Polypyrimidine tract protein, intron enhancer, **71**, 339–340
- Polyscistronic transcription, *Trypanosoma brucei* and, **43**, 42–43
- POMC, *see* Proopiomelanocortin
- POR1
- biological functions, **67**, 197
- Porphyrias
- erythropoietic, **51**, 39–40
 - hepatic, **51**, 35–39
 - perspectives, **51**, 40–41
- POSH, **67**, 204
- biological functions, **67**, 197
- Position effect, AlcR targets in *alcA* promoter, **69**, 185
- Positive-strand RNA viruses, **71**, 190–191
- Post-transcriptional mechanisms, protamines and, **40**, 61–64
- Postaxial polydactyly, *GLI* mutation, **64**, 186–187
- Postmeiotic segregation, *see* Double-strand break-induced recombination
- Posttranscriptional control, lysogenic pathway in bacteriophage λ , *see* Lysogenic pathway in bacteriophage λ
- POT, *see* Proton-coupled oligopeptide transporter
- Potassium bromate
- 8-OH-G, **68**, 108
- Potassium permanganate, DNA sequence specificity of damage, **63**, 383, 401
- POU domain proteins
- class I proteins, *see* Pit-1
 - class III proteins, *see* Brn-2; Brn-4; Tst-1
 - class IV proteins, *see* Brn-3.0; Brn-3.1; Brn-3.2
 - classification, **63**, 225, 239
 - discovery, **63**, 224, 228
 - structure of domain, **63**, 224
- PP2A, *see* Protein phosphatase 2A
- PPAR γ , phosphorylation, **69**, 217
- PPAR γ , role in adipocyte differentiation, **60**, 328
- PPI, *see* Preproinsulin
- PpiD, outer membrane protein chaperone, **66**, 141
- pRb, *see* Retinoblastoma protein
- pRB, E2F cooperation, **72**, 46–48
- Pre-RNA, ribosome biogenesis in yeast and, **41**, 111–116
- Pre-steady-state kinetic assays, retroviral RT, **71**, 104–105
- Preadipocyte factor-1
- adipocyte differentiation role, **60**, 340–342
 - embryogenesis role, **60**, 342–343
 - epidermal growth factor repeat motif, **60**, 329–330
 - gene structure, **60**, 332–334
 - glycosylation, **60**, 335–336
 - levels during differentiation, **60**, 330–332, 342
 - phosphorylation, **60**, 338–339
 - proteolytic processing, **60**, 336–337
 - signal sequence, **60**, 339–340
 - soluble forms, **60**, 337–340
 - spliced products, **60**, 334–335, 341–342
- Pref-1, *see* Preadipocyte factor-1
- Pregastrula, *de novo* methylation in, **48**, 67–68
- Pregnancy, virgin rat, Muc4/SMC, **71**, 172
- Preproinsulin, pancreatic β -cell expression
- AMPK regulation, **71**, 74–75
 - glucose regulation, **71**, 81–82
- Prereplicative complex
- activation of origins, **72**, 71
 - assembly, **72**, 70–71

- Prestalk cells, *Dictyostelium discoideum*
 apical sorting response to
 cAMP-signaling, **47**, 15
 cell differentiation markers, **47**, 6–8
 heterogeneity, **47**, 10–13
 movement during culmination, **47**, 17–18
 mRNAs, functional analysis, **47**, 8–10
prfB, programmed +1 frameshifting, **64**,
 154–155
- PriA
 ATPase
 activity, **63**, 41–42
 knockout studies of primosome
 assembly, **63**, 50
 cloning, **63**, 48
 Cys metal-binding region, mutation and
 uncoupling of helicase and ATPase, **63**,
 50–51
 discovery, **63**, 39, 62
 DNA binding modes, **63**, 58–59
 DNA translocase activity, **63**, 45
 helicase activity, **63**, 44–45, 59
 null strains
 construction, **63**, 51
 modeling of PriA function in cell,
 63, 54–57
 phenotypes, **63**, 51–52
 temperature-sensitive *priA* alleles,
 63, 52–53
 priming of ϕ X174 ss(c)→RF DNA
 replication, **63**, 41–42
 primosome assembly
 D loop binding and primosome
 assembly, **63**, 59–61
 helicase activity, **63**, 46–47, 60, 64
 mutant phenotypes, **63**, 324
 replication fork progression,
 63, 47–48
 roles of other proteins
 DNaB, **63**, 45, 47–48, 60, 63
 DNaC, **63**, 48, 63
 DNaG, **63**, 45
 DNaT, **63**, 45
 PriB, **63**, 45–46, 57–58
 PriC, **63**, 45–46, 57–58
 sequential binding of proteins, **63**, 45
 site recognition, **63**, 42–44, 47, 63
 recombination protein interactions
 RecF, **63**, 53–54, 56–57, 64
 RecG, **63**, 54, 64
 recombinatorial DNA repair, mutant studies
 of frequency, **63**, 328–330
 replication fork assembly at D loops,
 63, 61, 63–64
 structure comparison to other
 helicases, **63**, 48–49
 PriA protein, **40**, 299–301, 305
 PriB, primosome assembly role, **63**, 45–46,
 57–58
 PriC, primosome assembly role, **63**, 45–46,
 57–58
 Primary response genes, *see* Immediate-early
 response genes
 Primer grip, HIV-1 RT, **71**, 124–126
 Primer strand, HIV-1 RT
 minor groove binding track residues, **71**, 126
 primer grip residues, **71**, 124–126
 Tyr-183, **71**, 123–124
 Primer-template RNA, **67**, 242
 msDNAs, **67**, 76
 Priming
 msDNAs, **67**, 77
 Priming reactions, initiation of DNA
 replication, **51**, 96–97
 Primosome assembly
 D loop binding by PriA, **63**, 59–61
 helicase activity of PriA, **63**, 46–47, 60, 64
 replication fork progression, **63**, 47–48
 replication restart following
 recombination, **63**, 322–325
 roles
 DNaB, **63**, 45, 47–48, 60, 63, 323–324
 DNaC, **63**, 48, 63, 324
 DNaG, **63**, 45, 324
 DNaT, **63**, 45
 PriB, **63**, 45–46, 57–58
 PriC, **63**, 45–46, 57–58
 sequential binding of proteins, **63**, 45
 site recognition by PriA, **63**, 42–44, 47, 63
 PRMT1, *see* Protein arginine methyltransferase
 type I
 pRNA
 assay with phi29, **72**, 420–421
 chemical modification, **72**, 435–436
 chemical modification interference, **72**, 436
 complementary modification, **72**, 430–431
 conformational change overview, **72**, 443
 cross linking by phenphi, **72**, 435
 cross linking by psoralen, **72**, 433–435
 cryo-AFM, dimer images, **72**, 440

- cryo-AFM, monomer images, **72**, 440
- dimer and trimer model, **72**, 457–458
- dimer as building block, **72**, 450–452
- dimer formation, RNA size, **72**, 453
- dimer–hexamer transition, **72**, 444–445
- DNA-filled capsid, **72**, 450
- DNA packaging, minimal sequence, **72**, 453
- domain separation, **72**, 449–450
- genetic analysis, **72**, 438–439
- inactive in DNA packaging, **72**, 430
- loops in dimer formation, **72**, 452–453
- macromolecular translocation, **72**, 461
- mono- and divalent cation effects, **72**, 448–449
- monomer–dimer transition, **72**, 443–444
- motion task, **72**, 445
- mutant, phi29 assembly, **72**, 458–459
- nucleic acid sliding/riding processes, **72**, 459–461
- phi29 assembly inhibition, **72**, 458
- phi29 DNA packaging, **72**, 417–419
- phi29 DNA translocation, **72**, 453–457
- photoaffinity cross linking, **72**, 431–433
- phylogenetic analysis, **72**, 431
- procapsid binding, minimal sequence, **72**, 453
- research study overview, **72**, 419–420
- ribonuclease probing, **72**, 438
- RNA–DNA hybridization analysis, **72**, 419
- SELEX, **72**, 439–440
- stoichiometry
 - binomial distribution, **72**, 423–424
 - common multiple technique, **72**, 426
 - concentration dependence slopes, **72**, 425
 - cryo-EM imaging, **72**, 428–429
 - six interlocking set, **72**, 428
 - three interlocking set, **72**, 428
 - two interlocking set, **72**, 427–428
- 3D structure modeling, **72**, 440–443
- viral DNA translocation, **72**, 459–461
- pRNA–protein interactions
 - connector and capsid proteins, **72**, 445–447
 - connector domain and sequence, **72**, 447–448
 - gp16, **72**, 448
 - procapsid-bound pRNA, **72**, 447
- PRO-2
 - CO
 - heme, **67**, 49–50
- Procapsids, pRNA binding
 - active pRNA, **72**, 430
 - binding domain, **72**, 449–450
 - footprinting and chemical probing, **72**, 447–448
 - minimal sequence, **72**, 453
 - mono- and divalent cation effects, **72**, 448–449
- Procarbazine, DNA sequence specificity, **63**, 381, 392
- Processosome
 - cross linking experiments, **49**, 230
 - role in rRNA processing, **49**, 229–230, 233–234
- Progesterone receptor
 - gene structure
 - DNA binding domain, **59**, 290–291
 - overview, **59**, 290
 - steroid binding domain, **59**, 291
 - transcription
 - autoregulation, **59**, 303–304
 - enhancers, **59**, 291
 - estrogen regulation, **59**, 301
 - promoter types, **59**, 301
 - suppressors/ repressors, **59**, 292–293
 - trans-acting factors, **59**, 291–292
- Progesterone receptor, *see* Steroid receptor
- Progesterone receptor, mutation in female infertility, **64**, 199, 201
- Progesterone, regulation of myelination, **64**, 110
- Programmed cell death
 - cisplatin, **67**, 116–117
 - iPLA₂ β , **67**, 24–25
- Progressive cell death
 - mtDNA, **68**, 274
- Prohormone convertase 1 (PC1)
 - antisense experiments, **63**, 79–80
 - carboxyl-terminal domain in subcellular routing, **63**, 78–79
 - domain structure, **63**, 71–72
 - expression and specificity, **63**, 72–73
 - posttranslational processing
 - cleavage
 - carboxyl-terminal truncation, **63**, 76–80
 - signal peptide removal, **63**, 73–75
 - endoplasmic reticulum, **63**, 73–74
 - glycosylation, **63**, 74, 76
 - Golgi apparatus, **63**, 74–76
 - overview, **63**, 80
 - stoichiometry with prohormones, **63**, 76

- Prohormone convertase 1 (PC1) (*cont.*)
 substrates, **63**, 73, 75–76, 79
 tissue distribution, **63**, 71
- Prohormone convertase 2 (PC2)
 activation pathway
 cleavage
 autoproccessing, **63**, 88–90
 inhibitors, **63**, 90
 intracellular site, **63**, 81, 88
 intramolecular site, **63**, 87–88
 7B2 requirement for productive
 cleavage, **63**, 90–92, 98, 100
 folding, **63**, 81–82
 glycosylation, **63**, 84–85, 98
 non-7B2 proteins in maturation,
63, 101–102
 overview, **63**, 98, 100
 retention in endoplasmic reticulum,
63, 81–82, 102
 sorting to secretory granules, **63**, 85–87
 sulfation, **63**, 85
- calnexin binding of proenzyme, **63**, 83
 domain structure, **63**, 71–72
 expression and specificity, **63**, 72–73
 knockout mouse studies, **63**, 97–98
 pH sensitivity, **63**, 76
 7B2
 cleavage
 overview, **63**, 82
 requirement for proPC2 maturation, **63**,
 91–92
 conservation between species, **63**, 82
 prohormone convertase 2 binding and
 functions
 carboxy-terminal peptide, regulation of
 PC2 activity in secretory
 granules, **63**, 96–97, 100
 coimmunoprecipitation
 experiments, **63**, 92
 inhibition of activity, **63**, 82
 recognition in endoplasmic
 reticulum, **63**, 82–84, 91
 requirement for productive
 cleavage, **63**, 90–92, 98, 100
 secretory pathway effects, **63**, 93–94
 specificity of binding, **63**, 100
 sorting to secretory granules, **63**, 85
 structure-function of 21-kDa domain, **63**,
 94, 96
 sulfation, **63**, 85
 tissue distribution, **63**, 71
- Prokaryotes, aminoacyl-tRNA synthetases
 and, **40**, 97–107
- Prokaryotes, purine nucleotide biosynthesis
 and, **42**, 262–269
- Prokaryotic transcriptional enhancers, **43**,
 109–110
 activation through DNA, **43**, 128–130
 gp33, **43**, 127–128
 NtrC, **43**, 111–116
 DNA polymerase accessory proteins, **43**,
 125–127
 T4 late genes, **43**, 124–125
 gp55 regulatory protein, **43**, 118–119
in vitro system for analysis,
43, 119–121
 promoters, **43**, 116–117
 properties, **43**, 121–124
 regulation, **43**, 117–118
- Prolactin gene
 cAMP control of expression, **54**, 137
 evolution, **54**, 128
 placental receptors, **54**, 130
- Proliferating cell nuclear antigen
 and polymerase δ , **51**, 98–99
 effect on polymerase ϵ , **51**, 103–104
 interaction with pol δ and synthetic
 oligonucleotide template–primers, **47**,
 393–394
 stimulation of DNA polymerase δ , **47**,
 391–392
- Proliferating cell nuclear antigen (PCNA), **68**,
 8, 25, 58, 125, 129, 147, 287, 339
- BER
 molecular mechanism, **68**, 129–137
 binding motif
 human proteins, **68**, 133
 dependent AP site repair, **68**, 130–132
 dependent BER, **68**, 8–9, 11, 129
 DNA glycosylases
 replication-coupled BER, **68**, 134–137
 DNA ligase I, **68**, 132, 156
 DNA polymerase holoenzyme assembly,
65, 272–274, 281
 FEN1, **68**, 132
 functions
 cell cycle regulation, **65**, 285–286
 chromatin assembly, **65**, 285
 DNA methylation, **65**, 284–285
 DNA repair, **65**, 282–284

- DNA replication, **65**, 263, 282–283
 overview, **65**, 263–264, 291–292
- MYH
 UDG2, **68**, 135
- p21 protein, **68**, 132–134
- protein interactions, **65**, 282–286
- proteins, **68**, 132–134
- replication factor C in clamp loading, **65**, 280–281
- structure, **65**, 281–282
- Proliferating cell nuclear antigen, complex with DNMT1, **69**, 61–62
- Proliferation, cellular, and gene regulation, **50**, 216–217
- Proliferin gene, *see*, 28H6
- Proline residue, PDE4C, **69**, 270–271
- Proline-rich protein multigene families, **41**, 1–5, 20
 amino-acid sequences, **41**, 9–11
 cDNAs, **41**, 9–11
 cell-free translation analysis, **41**, 6–9
 functional aspects of, **41**, 18–20
 mRNA, **41**, 6–9
 regulation of gene expression, **41**, 16–18
 sequences, **41**, 9–16
- Prolyl 4-hydroxylase
 quality control, **67**, 250
- Promoter elements, *cis*-acting, HSV, **51**, 137–140
- Promoter recognition factor TFIID, **72**, 280, 282–283
- Promoters
alcA and *aldA*, **69**, 151
alcA, AlcR targets in, **69**, 183–186
 AlcR-regulated, **69**, 161, 163
alcR, **69**, 180–181
aldA, **69**, 187, 191
 apo-B, localization, **50**, 163–166
 AT-rich binding sites in plants, **47**, 251–252
ecmA gene, **47**, 10–13
ecmB gene, **47**, 10–13, 18–19
Egr-1, analysis, **50**, 200–201
 FGF-1, **70**, 167–168
 FGF-1.B, **70**, 162, 170–171
 phytochrome *phA3*, **47**, 256–259
 plant mitochondria, **70**, 127–129
 proximal β^{maj} globin in mouse, **47**, 254–256
PRPS, **69**, 144–145
 ribosomal, activation at, **50**, 44–49
 RPOI, **50**, 33–36
- spacer
 and repetitive enhancers, **50**, 49–51
 role in transcription enhancement, **50**, 56–57
- Promoters, *Trypanosoma brucei* and, **43**, 51–55
- Promoters, RNA polymerase II transcription initiation and, **44**, 94–98
- Promotion, role of enhancosome, **50**, 48–49
- Proopiomelanocortin (POMC)
 ordered processing, **63**, 73
 prohormone convertase 1 processing in Golgi, **63**, 75–76
- PROPI*, mutation in combined pituitary hormone deficiency, **64**, 199
- 1*N*²-Propanodeoxyguanosine,
 template–primers, interaction with DNA polymerase α 388–389
- Propranolol, **67**, 23
- Propylbenzylcholine mustard, muscarinic acetylcholine receptor antagonist, **49**, 124
- ProRS, complex with tRNA^{Pro}, **69**, 341–342
- Prosaposin
 alternative splicing, **66**, 218, 220
 function, **66**, 211–212
 gene
 promoter studies in transgenic mice, **66**, 216–218
 structure, **66**, 211–212
 transcription factor-binding sites and regulation, **66**, 213, 215–217
 transcription start sites, **66**, 212–213
- posttranslational processing
 differential processing, **66**, 218
 lysosomal targeting, **66**, 218
 proteolysis, **66**, 221
 secretion, **66**, 220
- tissue distribution of expression, **66**, 212–213
- Prosomes, *see also* Low-molecular-weight protein complex; Multicatalytic proteinase
 antigens, **49**, 46
 autoimmune antibodies, **49**, 48
 content in oocyte, **49**, 46
 cytodistribution, **49**, 32–36
 cell surface, **49**, 43
 changes during cell cycle, **49**, 35–36
 extracellular space, **49**, 43

- Prosomes, *see also* Low-molecular-weight protein complex; Multicatalytic proteinase (*cont.*)
 intermediate filament association, **49**, 39–42, 55
 discovery, **49**, 3, 5–7
 genes
 classification, **49**, 16–17
 cloning, **49**, 16
 effect of deletion, **49**, 20, 51
 number per species, **49**, 19–20
 half-life, **49**, 34
 heat shock protein similarity, **49**, 2–3, 18
 immunophenotyping, **49**, 45
 indirect immunofluorescence, **49**, 33, 37–39
 junctions, **49**, 42–43
 nuclear localization signal, **49**, 16, 18, 34
 pathological response
 evaluation, **49**, 48–50
 tumor cells, **49**, 50
 phosphorylation sites, **49**, 18
 phylogenetic relationships, **49**, 18–20, 51
 polymerization, **49**, 14
 protein homeostasis role, **49**, 53–56
 RNA
 binding, **49**, 3, 5, 11–12, 16, 20, 32
 content, **49**, 21–22
 function in complex, **49**, 22
 prosome affinity for RNA types, **49**, 20–21, 53
 protection study, **49**, 20
 RNase resistance, **49**, 21
 sequence homology between species, **49**, 16–17, 51
 size, **49**, 2, 12
 species distribution, **49**, 3
 stability, **49**, 15
 structure, **49**, 2, 5, 12–15, 18
 subunits
 effect on composition
 interferon- γ , **49**, 32
 cell differentiation, **49**, 44–47
 embryogenesis, **49**, 46–47
 disease, **49**, 48
 types, **49**, 14–16
 translational repression, **49**, 22–23
 Prostaglandin-D synthase, **45**, 87–89
 Prostaglandin-F synthase, **45**, 89
 Prostaglandin G/H synthase, **45**, 83–86
 Prostaglandin synthase, similarity with nitric-oxide synthase, **47**, 142–143
 Prostaglandin synthesis, **69**, 294
 Prostaglandins, phorbol-induced synthesis in Swiss 3T3 cells, **47**, 126–130
 Prostate, fibroblast growth factor receptor complex
 proliferation role
 normal cells, **59**, 168–173
 PAP tumors, **59**, 170–171
 receptor isoforms in malignant tumors, **59**, 172–173
 tumor progression model, **59**, 173
 Protamines, **40**, 25–26
 amino acid sequences, **40**, 30–33
 avian, **40**, 37–38
 bony fish, **40**, 33–37
 dogfish, **40**, 38–39
 mammalian P1, **40**, 37–38
 mammalian P2, **40**, 38
 DNA–DNA hybridization, **40**, 51–53
 distinct bands, **40**, 53–58
 smeared signal, **40**, 53
 evolution of genes, **40**, 45–46
 detailed gene alignment, **40**, 46
 dot-matrix analysis of sequences, **40**, 46–50
 function, **40**, 83–84
 future research
 clinical applications, **40**, 86–87
 evolution, **40**, 85
 gene expression, **40**, 86
 nucleosome disassembly, **40**, 85
 genes
 copy number, **40**, 42–45
 sequences, **40**, 39–42
 history
 cysteine-containing protamines, **40**, 29–30
 stable protamines, **40**, 29–30
 true protamines, **40**, 26–29
 spermatogenesis, gene expression in, **40**, 58–60
 intercellular bridges, **40**, 61
 post-transcriptional mechanisms, **40**, 61–64
 timing, **40**, 60–61
 transcription, **40**, 64–68
 spermiogenesis
 chromatin structure, **40**, 68–70
 protein modifications, **40**, 71–83

- Protease, nsP2 activity, **71**, 206–208
- 26-S Proteasome
- ATPase, **49**, 26, 52
 - ATP dependence, **49**, 25, 30
 - inactivation by metals, **49**, 27
 - physiological role, **49**, 55
 - stability, **49**, 25
 - structure, **49**, 27, 52
 - substrates, **49**, 25–26
 - subunits, **49**, 24–26
- Proteasome
- activators, **49**, 29–30
 - cleavage site specificity, **49**, 27–29
 - discovery, **49**, 6
 - effects of SDS, **49**, 30
 - inactivation by metal ions, **49**, 15, 28
 - inhibitors, **49**, 29–30
 - modulation, **49**, 28–29
 - nomenclature, **49**, 6
 - protease class, **49**, 16, 20, 27–28
 - size, **49**, 2
 - structure, **49**, 2, 5, 52
 - substrates, **49**, 24–25, 51–52
 - subunits, **49**, 28, 44
- Protective protein
- quality control, **67**, 251
- Protective protein, 32-kDa, **69**, 84–85
- Protein
- 5,6-dihydropyrimidine adducts and, *see* 5,6-Dihydropyrimidine adducts
 - genetic defects of mammalian nervous system and, **41**, 243, 248–253
 - intermediate filaments and, *see* Intermediate filaments, protein domains in
 - lens, **41**, 259–269, 277
 - msDNA of bacteria and, **40**, 6–7
 - nuclear RNA-binding proteins, *see* Nuclear RNA-binding proteins
 - prokaryotic transcriptional enhancers and, **43**, 118–119, 125–128
 - proline-rich, *see* Proline-rich protein multigene families
 - ribosome biogenesis in yeast and, **41**, 103–111, 117–118
 - RNA phage coat, *see* RNA phage coat proteins
 - spermiogenesis and, **40**, 71
 - histone acetylation, **40**, 71–74
 - phosphorylation, **40**, 74–75
 - transition of nucleohistone, **40**, 76–83
 - ubiquitization of histones, **40**, 75–76
 - steroid hormones and, **43**, 24–26
 - structural elements in RNA and, **41**, 167–169
 - transcription factor IIIA and, **43**, 232–236
 - trp repressor and, **42**, 18–20, 29–32
 - Trypanosoma brucei* and, **43**, 59–60
- Protein α , glycyl radical, **72**, 116–119
- Protein β , iron-sulfur center, **72**, 116–119
- Protein arginine methylation
- analysis of modified arginines, **61**, 68–69
 - antibody probes, **61**, 69–70
 - discovery, **61**, 68
 - energetic cost, **61**, 67–68
 - enzymes, *see also* Protein arginine methyltransferase type I; Protein arginine methyltransferase type II
 - type III enzyme, **61**, 77, 110
 - type IV enzyme, **61**, 77, 110–111
 - functions
 - asymmetric methylation
 - development, **61**, 116
 - nuclear localization, **61**, 113–114
 - nucleic acid binding, **61**, 114–115
 - passive and active methylation modes in modeling, **61**, 116–118
 - signal transduction, **61**, 111–113
 - stabilization of proteins, **61**, 116
 - symmetric dimethylation of myelin basic protein
 - defects in disease, **61**, 122–123
 - development, **61**, 119
 - limpy mice, **61**, 119–120
 - myelination role, **61**, 120–121
 - ratio to monomethylation, **61**, 118–119
 - species distribution, **61**, 66, 77–78
- Protein arginine methyltransferase type I
- discovery, **61**, 73–74
 - human enzymes
 - expressed sequence tag searches, **61**, 81, 83
 - HCPI/IR1B4 identification, **61**, 80–81
 - substrates, **61**, 81
 - physiological functions
 - development, **61**, 116
 - nuclear localization, **61**, 113–114
 - nucleic acid binding, **61**, 114–115
 - passive and active methylation modes in modeling, **61**, 116–118

- Protein arginine methyltransferase
 type I (*cont.*)
 signal transduction, **61**, 111–113
 stabilization of proteins, **61**, 116
 purification, **61**, 70–75, 86–88
 rat enzymes
 PRMT3, **61**, 83
 3G identification, **61**, 78
 reaction specificity, **61**, 66, 70
 sequence homology between species, **61**, 79, 83–84
 size determination and protein
 complexes, **61**, 86–87
 substrates, **61**, 66–67, 76, 80, 90
 assays, **61**, 88–89
 basic fibroblast growth factor, **61**, 92–93
 consensus sequences, **61**, 100–101
 fibrillarin, **61**, 89, 91, 105–106
 heterogeneous nuclear ribonuclear
 protein A1, **61**, 76–77, 89, 91–92, 100, 106
 high-mobility-group proteins, **61**, 97–98, 103
 histones, **61**, 93–96, 101, 103
 HSP70, **61**, 97–98, 103, 123
 ICP27, **61**, 96–97
 myosin, **61**, 98–99
 Npl3, **61**, 97, 105, 124
 nucleolin, **61**, 91, 106–107
 potential substrates, **61**, 103–109
 subunit organization, **61**, 88
 yeast enzymes
 Odp1, **61**, 84
 potential substrates, **61**, 103–107
 Rmt1, **61**, 84–85, 104, 124
- Protein arginine methyltransferase type II
 discovery, **61**, 73–74
 purification, **61**, 70–75, 86–88
 reaction specificity, **61**, 66
 size determination and protein
 complexes, **61**, 86–87
 subunit organization, **61**, 88
 symmetric dimethylation of myelin basic
 protein, **61**, 67, 70, 73–74, 99–100
 consensus sequence for methylation, **61**, 109–110
 defects in disease, **61**, 122–123
 development role, **61**, 119
 jimpy mice, **61**, 119–120
 myelination role, **61**, 120–121
 ratio to monomethylation, **61**, 118–119
 tissue distribution, **61**, 100
- Protein disulfide isomerase (PDI), **67**, 237
 Protein disulfide isomerase, function, **58**, 85
 Protein–DNA recognition, sequence
 dependence
 binding specificity, **47**, 196–199
 DNA bending, **47**, 199–200
 DNA kinking, **47**, 200–202
- Protein elongation, *see* Elongation, protein
 Protein fold, *see* Three-fingered fold
 Protein folding
 chaperones
 Clp proteins, **58**, 307, 331
 complexes with proteins, **58**, 316–319
 families, **58**, 305
 GroEL, **58**, 306–308, 314, 316, 331
 GroES, **58**, 306–308, 314, 316
 Hsp60, **58**, 305–306, 308, 318–319, 331
 Hsp70, **58**, 305–308, 318, 327, 331
 mitochondria, **58**, 305–309
 overexpression effects on folding and
 aggregation, **58**, 314, 316–317
 cofactor effects, **58**, 318–319
 missense mutations
 diseases, **58**, 302–303, 310, 312–313, 325–326, 329
 expression system selection for protein
 studies, **58**, 327–328
 mutations affecting folding kinetics, **58**, 309–310
 prediction of effects, **58**, 328
 molten globule intermediates, **58**, 304
 pathways, **58**, 303–304, 307–308, 331–332
 peptidyl-prolyl *cis-trans* isomerase role, **58**, 309
 quality control systems and degradation, **58**, 330–332
 temperature effects, **58**, 319, 321, 324, 329
- Protein folding, EF-Tu, EF-Ts role, **71**, 529–531
 Protein genes, rice, **45**, 7–9
 Protein kinase A
 activation, **72**, 270–271
 activation of PDE4 phosphorylation, **69**, 258–290
 catalytic subunits, **72**, 271
 CREB activation domain, **72**, 273–274
 interaction with ERK2, **69**, 295–296
 isoenzymes, **69**, 253
 target serine in UCR1, **69**, 275

- Protein kinase A (PKA), steroid receptor modulation of chromatin remodeling, **66**, 288
- Protein kinase A, phosphorylation of G protein receptors, **49**, 138–139
- Protein kinase B, **67**, 213
- Protein kinase B (PKB), PDE3B kinase in adipose tissue
insulin activation, **66**, 257–258
isoforms and homologs, **66**, 256–257
overexpression of mutant kinases, **66**, 258
- Protein kinase B (PKB), S6 kinase effector studies, **65**, 113–114
- Protein kinase C (PKC), S6 kinase effector studies, **65**, 114
- Protein kinase C, antisense oligonucleotide inhibition, **57**, 117
- Protein kinase C, phosphorylation sites on ROR α 1, **69**, 217–218
- Protein kinase C, substrates
DNA (cytosine-5)methyltransferase, **49**, 92–93
G protein receptors, **49**, 142
- Protein kinase family
catalytic domains, **67**, 8
- Protein kinase N (PKN), **67**, 196, 207–209
biological functions, **67**, 197
- Protein kinase, cAMP-dependent
regulation of *Dictyostelium discoideum* stalk cell differentiation, **47**, 19–20
role in *Dictyostelium discoideum* morphogenesis, **47**, 19–20
- Protein kinase, double-stranded
RNA-dependent
interferon response role, **52**, 46
mechanism of activation, **52**, 48–49
phosphorylation, **52**, 47–48
signal transduction in mammalian cells, **52**, 51–53
substrates, **52**, 46–47, 52–53
- Protein kinases, in C-terminal domain
phosphorylation, **48**, 165–172
- Protein phosphatase 2A, **72**, 45–46
- Protein–protein interactions
DNMT1 and, **69**, 71
DNMT1 regulatory role and, **69**, 62–63, 66–67
- Protein–protein interactions, eIF5, eIF2 β , eIF2 ϵ , and Nip1p, **70**, 228
- Protein–RNA complex, **69**, 334
- Protein-specific
quality control, **67**, 250
- Protein synthesis
global control, **51**, 340–343
RQ mRNA-directed, **51**, 258–259
- Protein synthesis initiation factor 4E,
see Eukaryotic initiation factor 4E
- Protein tyrosine kinase substrates, **44**, 205–207
detection of proteins, **44**, 207–208
identification, **44**, 215–222
oncogenes, **44**, 211–215
phosphorylation, **44**, 222–224
receptors, **44**, 208–211
- Protein, ADP-ribosylation factors and, *see* ADP-ribosylation factors
- Protein, enzymes in DNA precursor biosynthesis and, **44**, 183–186
- Proteins
3'-UTR-binding protein, **72**, 145–154
50-kDa monomeric, eIF5, **70**, 210–212
- AAG
cisplatin, **67**, 114–115
alkylated, fate, **51**, 195
 α , HSV-1, *trans*-activation by, **51**, 134–137
ankyrin
ankyrin repeats, **67**, 11
ankyrin-repeat domain, **67**, 11
ARE-binding proteins, **72**, 134–135
binding
cisplatin-DNA adducts, **67**, 98–104
capsid proteins, **72**, 445–447, 450
catabolite responsive. *See* Catabolite responsive protein
Cdc25, **48**, 5–8
Cdc46 and Cdc6, in transcriptional control of G1/S genes in *Saccharomyces cerevisiae*, **48**, 16–19
cell division cycle proteins, **72**, 55–56, 61–63
Clb5 and Clb6, in transcriptional control of G1/S genes in *Saccharomyces cerevisiae*, **48**, 16
coiled-coil proteins, cell cycle, **72**, 77
collagenous, membrane-associated, **50**, 230–248
CREB, *see* Cyclic AMP response element-binding protein
cyclin, in transcriptional control of G1/S genes in *Saccharomyces cerevisiae*, **48**, 11, 13
growth control-related, **48**, 201–203

Proteins (*cont.*)

IHF, binding to site 1 modulating replication inhibitor activity of π protein, **48**, 261–262

methylcytosine-binding, transcription mediated by, methylation and, **48**, 62–63

DEAD box proteins, **72**, 308, 328–329

developmental

- ankyrin repeats, **67**, 11

DNA-binding proteins, replication protein A, **72**, 63–65

early growth response, Egr-1

- characterization, **50**, 201–205
- DNA binding activity, **50**, 205–210
- in vitro* role, **50**, 219
- structure-function analysis, **50**, 210–216
- targets of regulation, **50**, 216–219

folding, **67**, 236

- ER, **67**, 263–264

frizzled, **50**, 253–256, 258

hepatitis C virus NS3 proteins, **72**, 311–312

highly glycosylated hRFC

- transport-upregulated K562 human erythroleukemia cells, **67**, 139–141

histone linker, **67**, 98

HMG domain. *See* HMG-domain proteins

hRFC

- properties, **67**, 139–147

HSV replication, **70**, 97–98

human

- PCNA-binding motif, **68**, 133

in switch recombination, **50**, 86–88

integral membrane

- ankyrin-repeat domains, **67**, 12

iron–sulfur proteins, **72**, 114–119

jasmonic acid-induced protein, **72**, 181–184

Mcm10p, **72**, 56–57

Mcm2p, **72**, 57–61

Mcm7p, **72**, 57–61

mRNA binding, regulation, **51**, 348–350

msDNAs, **67**, 70

mutant HMG-domain

- binding affinities, **67**, 110
- studies, **67**, 110–112

nrdD protein, **72**, 99–114

nrdG protein, **72**, 114–119

nucleic acid-binding proteins, **72**, 147, 229–230

nucleic acid chaperone proteins, **72**, 234–245

π

- domains, **48**, 248–250
- mutant, dominant-negative, properties, **48**, 261
- replication inhibitor activity, IHF protein binding to site 1 modulating, **48**, 261–262
- two forms, replication control by, **48**, 256–260

plant mitochondria transcription, **70**, 130–131

poly(A)-binding protein interacting protein 1, **72**, 313

pRNA interactions, **72**, 445–448

protective

- quality control, **67**, 251

pyrimidine tract-binding protein, **72**, 382

Ras. *See* Ras proteins

receptor-associated, **67**, 248

regulatory

- binding sites for, in 5' UTR of eukaryotic mRNA, **48**, 185–186
- binding to 5' UTR, isolation, antisense oligonucleotide techniques in, **48**, 227

rep

- adeno-associated virus DNA replication and, **48**, 43, 48
- adeno-associated virus latency and, **48**, 34–35
- adeno-associated virus productive phase and, **48**, 42–43

Rep, in replication control, **48**, 253–255

replication host, binding to γ -*ori*, roles of, **48**, 246–247

replication protein A, **72**, 63–65

repressor, in replication control, **48**, 252, 253

Rho. *See* Rho proteins

ribosomal, in translational regulation, **48**, 199–201

RNA-binding proteins, **72**, 229–233

Saccharomyces cerevisiae, **48**, 19–20

secretory, encoded by Balbiani ring multigene family, **48**, 281–285

Sit4, in transcriptional control of G1/S genes in

- Srs2, **51**, 299–301

- synaptic
 - ankyrin repeats, **67**, 11
 - Swi4 and Swi6, in transcriptional control of
 - G1/S genes in *Saccharomyces cerevisiae*, **48**, 13–16
 - tail proteins, **72**, 448, 450
 - TATA-binding, **67**, 98
 - cisplatin, **67**, 114–115
 - TATA-binding protein, **72**, 280, 289–290
 - TGPase-activating, **67**, 194
 - transactivator/viropilin protein, **72**, 23–28
 - transcriptional factor
 - ankyrin repeats, **67**, 11
 - viral host range
 - ankyrin repeats, **67**, 11
 - WASP-family verprolin-homologous, **67**, 197–199
 - yeast eIF5 homolog, **70**, 217
 - Proteins, *see also specific proteins* homologous
 - recombination in *Saccharomyces cerevisiae* and, **46**, 232–244
 - Proteins, synthesis in *Escherichia coli*
 - ribosomes
 - alpha operon, **47**, 348–351
 - autogenous control, **47**, 336–338
 - gene organization, **47**, 332–336
 - L10 operon, **47**, 358–359
 - L11 operon, **47**, 356–358
 - L20 operon, **47**, 361–362
 - mRNA elongation, **47**, 340
 - mRNA stability, **47**, 340
 - regulatory r-protein–mRNA interaction, **47**, 338–339
 - rif* region, **47**, 355–357
 - S10 operon, L4-mediated regulation, **47**, 341–348
 - L4 binding to RNA, **47**, 343–345
 - transcription, **47**, 345–346
 - translation, **47**, 346–348
 - S15 operon, **47**, 351–353
 - spc* operon, **47**, 353–355
 - str* operon, **47**, 362–363
 - translation inhibition, **47**, 339–340
 - Proteoglycans, *see also* Aggrecan; Biglycan; Brevican; Decorin; Neurocan; Perlecan; Serglycin; Syndecan-1; Syndecan-4; Versican
 - classification, **62**, 20, 178
 - structure, **62**, 20, 178
 - Proteolysis
 - G1–S transition, **72**, 51–52
 - GO–G1 transition, **72**, 49–51
 - regulated, mitosis, **72**, 52
 - Proteolysis, limited, **50**, 115–116
 - Proteolysis, trp repressor and, **42**, 27–29
 - Proto-*abl* genes, latent viruses and mutated oncogenes and, **43**, 167–170
 - Proto-*myc* genes, latent viruses and mutated oncogenes and, **43**, 167–170
 - Proto-*ras* genes, latent viruses and mutated oncogenes and, **43**, 173–178
 - Proton-coupled oligopeptide transporter (POT)
 - cloning strategies
 - expression cloning, **58**, 244
 - functional complementation
 - CHL1 gene cloning, **58**, 246
 - DtpT gene cloning, **58**, 246–247
 - NTR1 gene cloning, **58**, 247
 - principle, **58**, 245–246
 - PTR2 gene cloning, **58**, 247–248
 - homologous hybridization, **58**, 244–245
 - reverse transcription–polymerase chain reaction, **58**, 245
 - energetics, **58**, 241, 243
 - hydrophobicity analysis, **58**, 257–258
 - physiological roles of peptide transport, **58**, 240, 259
 - sequence homology of transporters, **58**, 248, 250–256
 - structural properties, **58**, 248–250
 - subgroups, **58**, 253–254
 - substrate specificity, **58**, 241, 243, 257, 259
- Proton-coupled peptide transport, *see* ATP-binding cassette transporter; Proton-coupled oligopeptide transporter
- Proton dislocation, redox-driven, *Methanosarcina mazei*, **71**, 242–245
- Proton translocation, methanogens
 - Ech hydrogenase, **71**, 248–249
 - F₄₂₀-nonreducing hydrogenase, **71**, 246–248
 - F₄₂₀-reducing hydrogenase, **71**, 245–246
 - F₄₂₀H₂dehydrogenase, **71**, 249–253
- growth, **71**, 256–258
- heterodisulfide reductase, **71**, 253–255
- pyrophosphatases, **71**, 258–259
- Protoplasts, rice genes and, **45**, 10–11, 22
- PRPP
 - reaction, **69**, 117–119
 - regulatory role, **69**, 121–125

- PRPP (*cont.*)
 synthesis, regulation in human cells, **69**, 140–145
 utilization, **69**, 119–121
- PRPP synthetase
 allosteric control, disruption of, **69**, 137–138
 associated proteins, *see* PAPs
 bacterial, proposed mechanism of, **69**, 125–126
 human
 and isoform family, **69**, 126–127
 inherited overactivity, **69**, 136–140
 reaction effectors, **69**, 127–133
 structures, **69**, 133–134
 reaction, **69**, 117–119
- PRPS genes, **69**, 126–127
- PRPS promoters, **69**, 144–145
- PRPS1 transcription, **69**, 139–141
- PRS isoforms
 complex with PAPs, **69**, 134–136
 heteroaggregates, **69**, 141
 in fibroblasts and lymphoblasts, **69**, 142–143
 mutant, **69**, 138
- Pseudo-halfknots, RNA-binding, **69**, 10
- Pseudogene, accumulation, **53**, 303–304
- Pseudohypoparathyroidism, G protein mutations, **47**, 96–97
- Pseudoknot, prediction in RNA, **53**, 180–186
- Pseudoknots, RNA and, **41**, 150–152
- Pseudomonas fluorescens* sub-sp. *cellulosa*
 cell wall hydrolases, *see specific hydrolases*
 taxonomy, **61**, 217–218
- PsoAG10
 triple-helix, **67**, 174
- Psoralen
 adduct repair
 model, **67**, 188
 TFO, **67**, 173–174
 repair, **67**, 187
 TFO-induced recombination, **67**, 182
 TFO mutagenesis, **67**, 180–181
- Psoralen photoadducts, DNA sequence specificity, **63**, 381, 392
- Psoralen, cross-linking of RNA, **53**, 155–158
- Psoralen, pRNA cross linking, **72**, 433–435
- pstA cells, characterization, **47**, 10–13
- pstAB cells
 basipetal migration, **47**, 15
 characterization, **47**, 10–13
- pstO cells, characterization, **47**, 10–13
- PSupF2 vector
 schematic representation, **67**, 183
- PTB, *see* Polypyrimidine tract protein
- PTB, *see* Pyrimidine tract-binding protein
- [PtCl(dien)]Cl, *see*
 Chlorodiethylenetriamineplatinum(II) chloride
- cis*-[PtCl(NH₃)₂ (A)]⁺ compounds–DNA interactions, **71**, 34–37
- trans*-[PtCl₂(NH₃)(quinoline)], DNA modification, **71**, 38–40
- trans*-[PtCl₂(NH₃)(thiazole)], DNA modification, **71**, 38–40
- PTR2
 gene cloning, **58**, 247–248
 hydrophobicity analysis, **58**, 257–258
 sequence homology with other transporters, **58**, 248, 250–256
 structure, **58**, 248, 250
- Pulvomycin
 EF-Tu, **71**, 532–533
 EF-Tu binding sites, **71**, 535
 EF-Tu resistance, **71**, 535
- pur* operon, transcriptional attenuation, **62**, 363
- Purification, of msDNA of bacteria, **40**, 13–14
- Purified recombinant
 iPLA₂, **67**, 21
- Purine
 base salvage pathway, **69**, 124
 nucleotide synthesis, regulation by PRPP, **69**, 121–123
- Purine biosynthesis, *see* Inositol-5′monophosphate dehydrogenase
- Purine derivatives, O-alkylated, dealkylation, **51**, 178–181
- Purine motif triplexes, **69**, 20–21
- Purine nucleotide biosynthesis, *de novo*, **42**, 259–261, 282–283
- prokaryotes
Bacillus subtilis, **42**, 264–269
Escherichia coli, **42**, 262–264, 267–269
- vertebrates, **42**, 269–270, 274–282
 chromosomal localization, **42**, 270–271
 cloning, **42**, 271–272

- glutamine PRPP amidotransferase, **42**, 272–274
- Purine salvage
 - defects in disease, **61**, 189
 - inositol-5'-monophosphate dehydrogenase relationships to enzymes, **61**, 187–189, 194
- Purinenucleoside triphosphatase activity, **48**, 127–128
- Purkinje cells, abnormal neurogenesis, **69**, 227
- Puromycin, A-site substrate, **50**, 5–9
- Purple nonsulfur bacteria
 - CO metabolism, **67**, 37
- Pyochelin, **70**, 268–269
- Pyoverdines
 - bacterial production, **70**, 248
 - biosynthesis, **70**, 270–274
- Pyr, **68**, 307–308
- pyr* operon, *Bacillus subtilis*
 - antiterminator
 - antisense deoxyoligonucleotide analysis, **62**, 338–339
 - deletion analysis, **62**, 337–338
 - attenuation, evidence for three sites
 - Northern blot analysis, **62**, 337
 - pyr-lacZ* fusion studies, **62**, 337
 - pyrimidine repression, **62**, 331–332, 336
- PyrR
 - cessation of *pyr* expression at sporulation onset, **62**, 340–341
 - copy number effect on transcription, **62**, 339–340
 - crystal structure, **62**, 347–350, 356
 - deletion and constitutive
 - pyr* expression, **62**, 340
 - modeling attenuation of transcription, **62**, 333, 335–336
 - gel mobility-shift assay, **62**, 353, 355
 - mutation studies of RNA, **62**, 353
 - secondary structure of RNA
 - in binding, **62**, 355–357
 - sequence specificity, **62**, 351, 353, 355
 - UMP promotion, **62**, 346–347
 - pyr* messenger RNA binding
 - affinity, **62**, 346
 - footprinting analysis, **62**, 355
 - site-directed mutagenesis studies, **62**, 350–351
 - termination regulation, *in vitro*, **62**, 344–346
 - uracil phosphoribosyltransferase activity
 - comparison with other bifunctional proteins, **62**, 341, 343
 - discovery, **62**, 331, 341
 - function in repression, **62**, 357
 - sequence analysis, **62**, 343–344
 - regulation in other bacteria, **62**, 330–331, 358, 360–362
 - structural overview, **62**, 332–333
 - terminator
 - antisense deoxyoligonucleotide analysis, **62**, 338–339
 - deletion analysis, **62**, 337–338
- Pyridoxal phosphate, branched chain aminotransferase, **70**, 185–187, 193–194
- Pyridoxamine, branched chain aminotransferases, **70**, 186
- 2-Pyrimidinone 1- β -D-2'-deoxyribofuranoside, *see* DNA (cytosine-5)methyltransferase inhibition, **49**, 66–67
- Pyrimidine bases
 - TDG, **68**, 249–250
- Pyrimidine derivatives, O-alkylated, dealkylation, **51**, 178–181
- Pyrimidine metabolism
 - compartmentation of nucleotide pools, **53**, 12–13
 - liver function, **53**, 10–12
 - overview, **53**, 2–4
 - salvage versus *de novo* pathways
 - developmental changes of UMP synthesis
 - enzyme activities, **53**, 9–10
 - enzyme activity variation, **53**, 4–6
 - incorporation of exogenous orotate and uridine, **53**, 6–9
- Pyrimidine motif triplexes, **69**, 20, 24–25
- Pyrimidine tract-binding protein, **72**, 382
- Pyrimidine, nucleotide synthesis, PRPP role, **69**, 124–125
- Pyrimidines
 - UNG mutants, **68**, 377–378
- Pyrimidines, *see* 5,6-Dihydropyrimidine adducts
- Pyrococcus furiosus*, **68**, 339
- Pyrophosphatases, proton-translocating type, **71**, 258–259
- Pyrophosphate loop, **69**, 125
- PyrR, *pyr* operon regulation
 - Bacillus subtilis*

- PyrR, *pyr* operon regulation (*cont.*)
 cessation of *pyr* expression at sporulation onset, **62**, 340–341
 copy number effect on transcription, **62**, 339–340
 crystal structure, **62**, 347–350, 356
 deletion and constitutive *pyr* expression, **62**, 340
 modeling attenuation of transcription, **62**, 333, 335–336
pyr messenger RNA binding
 affinity, **62**, 346
 footprinting analysis, **62**, 355
 gel mobility-shift assay, **62**, 353, 355
 mutation studies of RNA, **62**, 353
 secondary structure of RNA in binding, **62**, 355–357
 sequence specificity, **62**, 351, 353, 355
 UMP promotion, **62**, 346–347
 site-directed mutagenesis studies, **62**, 350–351
 termination regulation, *in vitro*, **62**, 344–346
 uracil phosphoribosyltransferase activity
 comparison with other bifunctional proteins, **62**, 341, 343
 discovery, **62**, 331, 341
 function in repression, **62**, 357
 sequence analysis, **62**, 343–344
 distribution of homologs in bacteria, **62**, 361–362
 gram-positive bacteria, **62**, 358, 361
Mycobacterium tuberculosis, **62**, 360–361
Thermus strain ZO5, **62**, 358, 360
 Pyrrolidine abasic nucleotide (pyr), **68**, 307–308
 Pyruvate dehydrogenase complex
 α -keto acid dehydrogenase complex, **70**, 41
 active sites, **70**, 41–42
 associated reaction, **70**, 40–41
 Ca^{2+} signal effect, **70**, 46
 component subunits, **70**, 37–39
 conserved kinase isozymes, **70**, 47–50
 general function, **70**, 34–35
 glucose effects, **70**, 35
 hormonal control, **70**, 47
 insulin effect, **70**, 46–47
 kinase control, **70**, 44–45
 kinase isozymes, **70**, 35–36
 molecular weight, **70**, 40
 organization, **70**, 36–37
 regulation mechanisms, **70**, 35
 roles in mammalian tissues, **70**, 42–43
 specificity residues, **70**, 41
 Pyruvate dehydrogenase kinase
 ATP-binding protein relationships, **70**, 50–51
 control, **70**, 44–45
 E2 activation, **70**, 59–64
 isoform effector sensitivities, **70**, 55–58
 isoform regulation by E2, **70**, 65–69
 tissue distribution, **70**, 51–54
 Pyruvate dehydrogenase phosphatase
 isoform regulation, **70**, 45–46
 tissue distribution, **70**, 54–55
 Pyruvate dehydrogenase phosphatase 1, **70**, 64–65
- Q
- Q β phage, RQ RNAs as satellites, **51**, 238–240
 Q β replicase
 in RNA synthesis, **51**, 227–231
 separation from contaminating RQ RNAs, **51**, 233–235
 Q β RNA, replication, **51**, 229–230
 QCR8 gene, mitochondrial biogenesis in *Saccharomyces cerevisiae* and, **46**, 77
 Quadruplex, *see* Guanine quadruplex
 Quality control, **67**, 251
 Quaternary structure, PRPP synthetase, **69**, 133–134
 Queuosine, synthesis in position, **50**, 34, 318–322
 Quiescent cells
 pol beta, **68**, 23
 Quinacrine mustard, DNA sequence specificity, **63**, 379, 390
 Quinone antibiotics, DNA sequence specificity, **63**, 380, 390–391
 Quinoxaline antibiotics, **70**, 257–259
- R
- R–M, *see* Restriction and modification
 R-point protein, cell cycle regulation, **53**, 198–199, 202, 214
 R6K copy-number control, autoregulation of *pir* gene in, **48**, 255–256

- R6K replication control
 antisense RNA, **48**, 262
 autoregulation of *pir* gene, **48**, 255–256
 DNA looping, **48**, 263–264
 π protein, **48**, 256–260
 regulatory circuits, **48**, 255–262
- RA, *see* Retinoic acid
- Rac
 effectors, **67**, 199–200
- Rac1
 E-cadherin, **67**, 199–200
 effectors, **67**, 196–197
- RACK1, PDE4D5 binding, **69**, 285–286
- rad1, G₂-M checkpoint regulation,
 62, 376–377
- rad11, S-phase recovery role, **62**, 389–390
- rad17, G₂-M checkpoint regulation, **62**,
 378–379
- rad26
 G₂-M checkpoint regulation, **62**, 379
 intra-S-phase checkpoint role, **62**, 391–392,
 391–392
 S-M checkpoint regulation, **62**, 385
- rad3, G₂-M checkpoint regulation, **62**, 377–378
- RAD3 epistatic group, mutation effects on
 double-strand break-induced
 recombination, **58**, 292–295
- rad32, recombination-deficient mutants of
 Schizosaccharomyces pombe, **61**, 368
- rad4/cut5
 G₂-M checkpoint regulation, **62**, 375, 380
 intra-S-phase checkpoint role, **62**, 391–392,
 391–392
- RAD52 epistatic group, mutation effects on
 double-strand break-induced
 recombination, **58**, 291–293
- rad9, G₂-M checkpoint regulation, **62**, 378
- Radding's model, *see* Double-strand
 break-induced recombination
- Radiation-induced DNA damage
 measurement
 problems, **68**, 140–141
- Radiation, injury, and *Egr-1* induction, **50**, 197
- Raf-1 kinase
 drugs, **67**, 219
- Rainbow trout protamines, **40**, 33–35
 genes, **40**, 42–44
- Ral GDP dissociation stimulators
 (RalGDS), **67**, 214
- RalGDS, **67**, 214
- RalGDS, **71**, 420–421
- RalGDS family, **67**, 214
- RalGPS, **71**, 421–422
- Random selection, genetic defects of
 mammalian nervous system and, **41**,
 250–251
- RAP, **67**, 248
 quality control, **67**, 251
- Rap proteins, GRP/CalDAG-GEF family
 specificity, **71**, 411–412
- RAP, *see* Receptor-associated protein
- Rap1 guanine nucleotide factors, **71**, 420
- Ras
 farnesylation
 inhibition, **67**, 220–221
 PDL, **67**, 207
 proteins
 cycling, **67**, 194
 effectors, **67**, 209–214
 future perspectives, **67**, 223–224
 PI3K, **67**, 212–214
 RalGDS, **67**, 214
 signaling pathway
 anticancer drug development, **67**,
 215–216
 superfamily, **67**, 194
 Ras-activating domain, in Cdc25, **48**, 5–6
 Ras-c-Jun signaling pathway, **69**, 56
 Ras family-guanine nucleotide exchange factors
 BCAR3, **71**, 422–423
 C3G, **71**, 412–414
 disease relationship, **71**, 425–426
 dominant inhibitory Ras protein
 targeting, **71**, 402–404
 Epac/cyclic AMP-GEFs, **71**, 414–416
 GRASP-1, **71**, 412–414
 GRF1 and 2, **71**, 407–409
 GRP/CalDAG-GEF family, **71**, 409–412
 MR-GEF, **71**, 416
 nuclear exchange reaction, **71**, 396, 401
 PDZ-GEFs, **71**, 416–418
 phospholipase C $_{\alpha}$, **71**, 418–420
 RalGDS family, **71**, 420–421
 RalGPS, **71**, 421–422
 Rap1 GEFs, **71**, 420
 Ras-family, early identification, **71**, 393–396
 SmgGDS, **71**, 423–425
 Sos1 and 2, **71**, 405–407
 structure, **71**, 396, 401
 Ras-GTP, regulation *in vivo*, **71**, 393

- Ras proteins
 definition, **71**, 390–391
 dominant inhibitory, GEF targeting, **71**, 402–404
 subfamily activators, **71**, 391–393
- Ras-response adenylate cyclase complex, in *Saccharomyces cerevisiae* growth control, **48**, 4–5
- Ras, antisense oligonucleotide inhibition of mutated proteins, **57**, 117–118
- Ras*, see c-Ha-ras
- ras* oncogene, DNA structure, **49**, 97
- Rat brain
 iPLA₂ β , **67**, 21
- Rat, Muc4/SMC, Muc4/SMC, **71**, 170–175
- Ratl1p
 function, **66**, 88–89
 homologs, **66**, 89
 structure, **66**, 88
 substrate specificity, **66**, 88
- Rate-limiting step, in cap formation, **50**, 109–111
- Rationale-based design, tRNA mimics
 aminoacylation activity, **70**, 299–300
 aminoacyl-tRNA synthetase pair, **70**, 300–301
 conformational changes, **70**, 297–298
 duplex RNA pieces, **70**, 304–306
 framework engineering, **70**, 301–304
 functional and structural analysis, **70**, 298–299
 hairpins, **70**, 304–306
 natural occurrence, **70**, 306
 scaffold-directed design, **70**, 296–297
 small organic molecules, **70**, 307–309
 structural background, **70**, 297
 trinucleotides, **70**, 307–309
- Rb, see Retinoblastoma protein
- RB, see Retinoblastoma protein
- Rb, repression of *dnmt1*, **69**, 58
- RDH, see Retinol dehydrogenase
- rDNA, see Ribosomal gene
- rd*s gene, genetic defects of mammalian nervous system and, **41**, 243–250
- Re-replication, DNA sequence amplification in mammalian cells and, **41**, 220–224
- Reaction, unwinding, DNA helicases of *Escherichia coli* and, **40**, 292–296
- Reactivation, HSV infection, **51**, 133
- Reactive nitrogen species (RNS), **68**, 278
- Reactive oxygen species (ROS), **68**, 12–13, 30, 75, 76, 208
 8-OH-G, **68**, 194
 aging, **68**, 96
 carcinogenesis, **68**, 96
- Reading frame, maintenance, function of m¹G37, **50**, 314–318
- REB1, autoregulation of promoter, **60**, 141–142
- rec* genes
 activation of meiotic recombination
 Rec8, **61**, 369–371
 Rec10, **61**, 369–371
 Rec11, **61**, 369–371
 cloning, **61**, 363
 recombination-deficient mutants of
 Schizosaccharomyces pombe
 general features, **61**, 364–365
 isolation, **61**, 361–363
 rec7, **61**, 365–366
 rec8, **61**, 366
 rec10, **61**, 366
 rec11, **61**, 366
 rec12, **61**, 366
 rec14, **61**, 367
 rec16, **61**, 367–368
- rec* mutants, phenotype properties, **63**, 314–315
- RecA
 activities, overview, **63**, 331–332
- ATP
 binding site, **56**, 163–164
 hydrolysis
 conformational changes and cooperativity, **56**, 181–184
 DNA-dependent hydrolysis, **56**, 179–180
 DNA-independent hydrolysis, **56**, 179
- ATP hydrolysis
 assays, **63**, 335
 DNA dependence, **63**, 335–336
 inhibitors, **63**, 336
 substrate specificity, **63**, 336
- crystal structure, **56**, 150, 156, 169
- distribution in bacteria, **56**, 130
- DNA binding
 double-stranded DNA, **56**, 174–175
 gapped DNA, **56**, 175
 single-stranded DNA, **56**, 173–174
 site structure, **56**, 164–167

- DNA binding parameters, **63**, 340–341
 - DNA strand exchange
 - DNA pairing
 - energetics, **56**, 192–193, 195
 - intermediates, **56**, 188–192
 - kinetics, **56**, 187–188
 - mechanism, **56**, 186–187
 - overview, **56**, 184–186
 - DNA strand exchange
 - ATP hydrolysis and motor protein model, **63**, 343–345, 353
 - models of halting without ATP hydrolysis
 - facilitated DNA rotation model, **63**, 347–349, 351–353
 - RecA redistribution model, **63**, 345–347, 349–351
 - testable predictions of models, **63**, 349–353
 - pairing intermediates, **63**, 341–343, 354–357
 - domains, **56**, 138
 - exchange reactions with four DNA strands, **56**, 200
 - filament assembly and disassembly
 - ATP hydrolysis and disassembly, **63**, 337–338
 - cooperative binding, **63**, 336–337
 - disassembly rates, **63**, 338
 - mixed filament formation with mutant proteins, **63**, 338–340
 - nucleation and extension, **63**, 337
 - overview, **63**, 331–332, 336
 - polarity, **63**, 340
 - functions
 - chromosome partitioning, **56**, 210
 - coprotease, **56**, 208–209
 - DNA repair, **56**, 136–137, 210–212
 - induced stable DNA replication, **56**, 210
 - SOS mutagenesis, **56**, 209–210
 - hybrid DNA, unidirectional extension and ATP hydrolysis, **56**, 195–197, 199–200
 - loading onto DNA lesion, **63**, 321–322
 - MAW motif, **56**, 168–169
 - monomer–monomer interface, **56**, 167
 - mutation and structure/function studies, **63**, 334–335
 - physical properties, **63**, 332
 - polar filament, assembly and disassembly, **56**, 176–179, 184
 - protein interactions
 - exonuclease I, **56**, 208
 - RecF, **56**, 203, 205
 - RecJ, **56**, 208
 - RecO, **56**, 203–205
 - RecR, **56**, 204–205
 - RuvA, **56**, 206–207
 - RuvB, **56**, 206–207
 - single-strand DNA binding protein, **56**, 201–203
 - purification, **56**, 138
 - recombinatorial DNA repair, mutant studies of frequency, **63**, 327–330
 - role in bacteria, **56**, 130
 - sequence alignment
 - bacterial RecA proteins, **56**, 138, 140–141, 150, 154–156
 - bacteriophage homologs, **56**, 157, 162
 - eukaryotic homologs, **56**, 157, 162
 - Sms protein, **56**, 172
 - structure–function insights, **56**, 138, 140
 - sequence homology between species, **63**, 334
 - SOS response induction, **63**, 316–317, 331
 - species distribution, **63**, 331
 - structure, **63**, 333–334
 - tryptophan reporter group incorporation, **56**, 169, 171–172
 - viability of mutants, **63**, 315
- RecBCD enzyme, **40**, 310–312
 - RecBCD, recombinatorial DNA repair pathway, **63**, 317–318
 - Receiver operating characteristic, viral microarrays, **71**, 465
 - Receptor-associated protein (RAP), **67**, 248
 - quality control, **67**, 251
 - Receptor-associated protein (RAP), low-density lipoprotein receptor maturation role, **63**, 100–101
 - Receptor-interacting protein, **69**, 140, 219–222
 - RecF
 - contranscription with replication genes, **63**, 316
 - recombinatorial DNA repair pathway, **63**, 318
 - RecF, PriA interactions, **63**, 53–54, 56–57, 64
 - RecG, PriA interactions, **63**, 54, 64
 - Recombinant human thymine-DNA glycosylase
 - 5-FU, **68**, 245
 - Recombinant pol beta, **68**, 60

- Recombinants, RQ RNAs, **51**, 253–254, 257–258
- Recombinases, site-specific, **51**, 58–59
- Recombination
- adenoviral DNA integration and, **46**, 18–21
 - helicase role, **70**, 83–85, 89–91, 93
 - homologous, *see* Homologous recombination in *Saccharomyces cerevisiae*
 - phage lambda, **70**, 91–92
 - T4 gp41 role, **70**, 89
- Recombination, *see also* Hyper-recombination
- excisive, **51**, 87
 - Flp-mediated, **51**, 59–62
 - mitotic, and yeast hyper-rec mutants, **51**, 271–303
- Recombination, *see* Double-strand break-induced recombination
- Recombination, *see* Meiosis
- Recombination, immunoglobulin gene diversification and, **45**, 33–34, 41–43
- Recombination, switch, immunoglobulin isotypes, **50**, 83–94
- Recombinational repair (RR)
- disruption
 - oxidizing agent sensitization, **68**, 33
 - DNA, **68**, 31
 - mutant strains
 - menadione, **68**, 34
- Recombinational repair (RR) pathways
- yeast, **68**, 33–36
- Recombinatorial DNA repair, *see also* RecA
- bacteriophage T4, coupling of replication and recombination, **63**, 330–331
 - chromosome partitioning at cell division, effects of repair, **63**, 325
 - frequency of repair
 - estimation, **63**, 313, 327, 330
 - lesion types, **63**, 327
 - mutant studies
 - PriA, **63**, 328–330
 - RecA, **63**, 327–330
 - overview in bacteria, **63**, 312–313
 - oxidative DNA damage as trigger, **63**, 315–316
 - pathways, **63**, 317–318
 - replication fork
 - completion of replication following recombination, **63**, 322–325
 - fate following damage encounter, **63**, 318–321
 - lesion bypass mechanisms, **63**, 320–321
 - link between damage and recombination, **63**, 314
 - link between recombination and replication fork induction, **63**, 316–317
 - prevalence of DNA damage, **63**, 313–314
 - steps in recombination, **63**, 321–322
- Reconstituted viral envelope (RVE), antisense oligonucleotide delivery, **57**, 113–114
- Reconstitution
- joining of lagging-strand products, **51**, 105–107
 - two-polymerase, SV40 DNA replication, **51**, 100–101, 108–109
- Red cell anion exchanges
- ankyrin-repeat domains, **67**, 12
- Redox sensor
- CooA, **67**, 52–53
- Redox state
- CooA, **67**, 40–42
- Reduced AP site
- repair, **68**, 13
 - structure, **68**, 8
- Reduced folate carrier (RFC), **67**, 132–133
- functional properties, **67**, 138–139
 - MTX resistance
 - molecular mechanisms, **67**, 154–156
 - mutant carriers, **67**, 156–157
 - structural-functional determinants, **67**, 156–157
- Reducer effect, **50**, 170–172
- Ref-1. *See* APE
- Refetoff syndrome, thyroid hormone receptor mutation, **64**, 199, 203
- RegA, translational repression, **64**, 76
- Region specificity, isotype switch recombination, **50**, 85–86
- Regulator of G protein signaling (RGS)
- activity regulation and modulation, **65**, 348–349
 - domains, **65**, 344–345, 347–348
 - historical perspective of study, **65**, 342–344
 - membrane targeting, **65**, 348
 - prospects for study, **65**, 355
- RGS9
- cell type-specific expression
 - RNA processing, **65**, 351
 - subunit association and control through stability, **65**, 351–352

- transcriptional control, **65**, 350–351
- effector modulation, **65**, 353–354
- G α selectivity, **65**, 349–350
- knockout analysis, **65**, 354
- membrane targeting by domains outside catalytic domain, **65**, 352–353
- protein interactions, **65**, 354–355
- RNA processing and variants, **65**, 348
- specificity for G protein types, **65**, 344
- subfamilies, **65**, 342
- Regulatory circuits, cell cycle, disruption, **69**, 66–67
- cis*-Regulatory elements, human FGF-1.B promoter, **70**, 162
- Regulatory elements
 - apo-B gene
 - identification, **50**, 163–172
 - in vitro* function, **50**, 172–184
 - heavy-chain, in targeting hypermutation, **50**, 80–82
 - transcriptional, **50**, 90–92
- Regulatory protein binding sites, in 5' UTR of eukaryotic mRNA, **48**, 185–186
- Regulatory proteins, binding to 5' UTR, antisense oligonucleotide techniques in isolation, **48**, 227
- Regulatory role
 - antisense RNAs, **69**, 31–32
 - DNMT1 for growth suppressor genes, **69**, 62–63
 - PRPP, **69**, 121–125
 - ROR γ for TEA promoter, **69**, 232
- Regulon
 - alc* gene, in catabolic reactions, **69**, 168–169
 - ethanol, *A. nidulans*, **69**, 156–167
- Regulon, *see also* Heat-shock regulon; Leucine/Lrp regulon; Nitrogen regulon
 - continuum between regulatory proteins, **55**, 73
 - control of initiation in bacteria
 - DNA masking, **55**, 8–10
 - RNA polymerase
 - concentration, **55**, 7, 10–12
 - initiation complex formation and promoter clearance, **55**, 15–17
 - isomerization of closed-to-open RNA polymerase–promoter complex, **55**, 14–15
 - promoter binding, **55**, 12–14
- defined, **55**, 2–3
- global regulator
 - advantages for cell
 - coordinated response by large number of genes, **55**, 24
 - cross-regulation and regulatory integration, **55**, 25
 - economic model comparison, **55**, 27
 - improved genetic flexibility, **55**, 26
- comparison with local regulator
 - abundance, **55**, 17
 - DNA sequence specificity, **55**, 17–18
 - recruitment, **55**, 18
 - target operons, **55**, 3, 17
- design features and control, **55**, 22–23
- regulator protein control
 - coregulator binding, **55**, 20
 - covalent modification, **55**, 20
 - expression, **55**, 19
 - multimerization, **55**, 21
 - sequestration, **55**, 21
- identification of members
 - gene expression analysis by nucleic acid hybridization, **55**, 35–36
 - isolation of operon fusions to reporter genes, **55**, 28–32
 - polypeptide synthesis, differential rate detection by gel electrophoresis, **55**, 32–35
 - precautions, **55**, 36–37
- integration of responses, **55**, 74–75
- in vivo* studies
 - bacterial growth conditions, **55**, 41–42
 - DNA footprinting, **55**, 40
 - regulatory protein concentration determination, **55**, 37–40
- stimulus–response pathway, **55**, 3–5
- Regulons, superoxide dismutases and, **40**, 246–248
- REH, *see* Retinyl ester hydrolase
- Reinitiation
 - eukaryotic translation, **72**, 6
 - polycistronic translation
 - TAV control, **72**, 23–24
 - TAV–host interactions, **72**, 24–26
 - shunting definition, **72**, 16
 - TAV-activated model, **72**, 27–28
- Reinitiation model, for association of mRNA with ribosome, **48**, 190–191

- Rel protein, binding to HIV LTR, **49**, 167
- Rel, autoregulation of promoter, **60**, 149
- c-Rel, **60**, 151–152
- RelA/p65, **60**, 65, 152
- Relaxosome
- assembly at IncP transfer origin, **54**, 217–218, 245
- DNA relaxase assays, **54**, 229–231
- Reovirus
- assembly of segmented genome
- assortment mechanism, **53**, 250–251
- functions of reovirus proteins
- $\lambda 1$, **53**, 261–262
- $\lambda 2$, **53**, 262–263
- $\lambda 3$, **53**, 263–264
- $\mu 1$, **53**, 264–265
- $\mu 2$, **53**, 263–264
- μNS , **53**, 265–266
- $\sigma 1$, **53**, 266–267
- $\sigma 1S$, **53**, 267
- $\sigma 2$, **53**, 267
- $\sigma 3$, **53**, 268–269
- σNS , **53**, 267–268
- monoclonal antibodies against reovirus proteins, **53**, 269–270
- nature of genome segments, **53**, 255, 257–259
- reassortments, **53**, 260–261
- signal interplay requirements for genetic information insertion, **53**, 274–277
- defective interfering particles, **53**, 259–260
- infectious RNA system, **53**, 270–273
- multiplication cycle, **53**, 252–253
- taxonomy, **53**, 249–250
- Rep protein, **40**, 296–299
- Rep protein-intron complexes, in replication control, **48**, 253–255
- Rep proteins
- adeno-associated virus DNA replication and, **48**, 43, 48
- adeno-associated virus latency and, **48**, 34–35
- adeno-associated virus productive phase and, **48**, 42–43
- RepA
- cooperativity of iteron binding, **57**, 171–172
- initiator titration, **57**, 163–165
- iteron binding, **57**, 150–152, 156
- promoter autoregulation, **57**, 169
- Repac, **71**, 416
- Repair helicases, *Escherichia coli* and
- helicase II, **40**, 305–309
- UvrAB complex, **40**, 309–310
- Repair mechanisms
- causing site-specific demethylation, **69**, 54
- demethylase, **69**, 69
- Repair patch size, **68**, 132
- Repair shielding
- cisplatin, **67**, 97
- Repair systems
- DNA alterations
- TFO, **67**, 186–189
- Repair, *see* DNA repair
- Repeat arrays, in Balbiani ring multigene family genes, **48**, 301–307
- efficiently homogenized, **48**, 303–304
- loss/gain of, from unequal crossover/slipped-strand mispairing during DNA replication/repair, **48**, 301–303
- remodeling, **48**, 304–307
- Repeat sequences, LOXL gene at 15q24, **70**, 7
- Repeats
- DNA sites, in AlcR-responsive promoters, **69**, 196–197
- Mig1p sites organized as, **69**, 177
- organized, AlcR targets in *alcA* promoter, **69**, 183–184
- Repetitive satellite sequences, nucleosome positioning and, **40**, 160–162
- Repetitive sequences
- msDNAs, **67**, 85–86
- Repetitive sequences, *see also* Alu evolution, **53**, 296, 298–301, 313
- families, **53**, 284
- genetic effects, **53**, 284, 301–302
- identification, **53**, 294–295
- LINEs, **53**, 292
- MaLR, **53**, 293
- microsatellites, **53**, 294
- MIRs, **53**, 293–294
- prevalence in human genome, **53**, 283–284, 288, 313
- retroposition, **53**, 290–294
- sequence analysis by DNA renaturation studies, **53**, 285, 287–288
- tandem clusters, **53**, 288, 290
- Replication
- alphavirus RNA
- genome complement, **71**, 192–194
- 26S mRNA, **71**, 196–197

- plus-strand RNA synthesis, **71**, 194–196
- DNA polymerase II and, **46**, 114–115
- DNA, cisplatin adduct effects, **71**, 10
- helicase role
 - bacterial DNA, **70**, 84
 - eukaryotic origins, **70**, 85
 - generalizations, **70**, 93
 - higher organisms, **70**, 85
 - overview, **70**, 83–84
 - restart, **70**, 84–85
- HSV-1 DNA
 - circular DNA intermediates, **70**, 95
 - greater-than-unit-length, **70**, 95–97
 - overview, **70**, 93–94
- HSV DNA, model, **70**, 107–111
- HSV proteins, **70**, 97–98
- T4 gp41 role, **70**, 87–89
- in T7 phage, helicase role, **70**, 89–91
- yeast double-stranded RNAs, **46**, 173–174
- Replication complex, alphavirus, **71**, 211–214
- Replication-coupled base excision repair
 - DNA glycosylases
 - PCNA, **68**, 134–137
 - MYH, **68**, 136
 - UDG2, **68**, 136
- Replication cycle, alphaviruses, **71**, 188–190
- Replication cycles, adenoviral DNA integration and, **46**, 27–28
- Replication factor C (RF-C)
 - DNA polymerase holoenzyme assembly, **65**, 272–273
 - functions
 - DNA polymerase switching, **65**, 281
 - overview, **65**, 262–264
 - proliferating cell nuclear antigen loading, **65**, 280–281
 - subunits, **65**, 279
- Replication factor C (RF-C), **68**, 8, 125, 129, 131
- Replication factor C, elongation reaction, **72**, 72
- Replication factors, G1–S phase transition, **72**, 61–63
- Replication fork
 - D loop, replication fork assembly, **63**, 61, 63–64
 - demethylases in, **69**, 59–61
 - DNMT1 targeted to, **69**, 61–62
 - primosome assembly, replication fork progression, **63**, 47–48
 - recombinatorial DNA repair
 - completion of replication following recombination, **63**, 322–325
 - fate following damage encounter, **63**, 318–321
 - lesion bypass mechanisms, **63**, 320–321
 - link between damage and recombination, **63**, 314
 - link between recombination and replication fork induction, **63**, 316–317
 - prevalence of DNA damage, **63**, 313–314
- Replication fork barrier, TTF-I function, **62**, 146–148
- Replication host proteins, binding to γ -ori, roles, **48**, 246–247
- Replication-initiation factors, chromatin
 - activation of origins, **72**, 71
 - elongation reaction, **72**, 72–73
 - leading and lagging strands, **72**, 72
 - overview, **72**, 69–70
 - prereplicative complex assembly, **72**, 70–71
- Replication of plant viruses, **42**, 157–163, 214–218
 - alfalfa mosaic virus RNA, **42**, 186–193
 - brome mosaic virus RNA, **42**, 163–175
 - cowpea chlorotic mottle virus RNA, **42**, 175–178
 - cowpea mosaic virus RNA, **42**, 207–212
 - cucumber mosaic virus RNA, **42**, 178–186
 - tobacco mosaic virus RNA, **42**, 197–207
 - turnip yellow mosaic virus RNA, **42**, 193–196
 - velvet tobacco mottle virus RNA, **42**, 212–214
- Replication protein A, **72**, 63–65
- Replication protein A (RPA), **68**, 58, 125, 370
- Replication–translation system, coupled, **51**, 258–259
- Replication, *see* Deoxyribonucleic acid, replication
- Replication, enzymes in DNA precursor biosynthesis and, **44**, 181–186, 189–191, 198–200
- Replicative helicases, *Escherichia coli* and DnaB protein, **40**, 301–305
- PriA protein, **40**, 299–301, 305
- rep protein, **40**, 296–299

- Replicons, iteron-containing, **48**, 239–267
 γ -ori, *see* γ -ori replicon
 localization and activation, components
 required for, **48**, 241
- Replisome
 bacteriophage T4, *see* Bacteriophage T4
 Escherichia coli, components and
 functions, **64**, 78–80
- Repression
 aldA, **69**, 187–188
 carbon catabolite, **69**, 181–183, 190–191
 mechanisms, in *alc* genes, **69**, 197–198
 transcriptional, *alcA*, **69**, 186
- Repression domain, Egr-1, localization, **50**,
 211–213
- Repressor protein in replication control, **48**,
 252, 253
- repressor, in replication control, **48**, 252, 253
- Repressors, ribosomal genes, **50**, 55–56
- Research, *alc* system in, **69**, 192–195
- Resistance, antibiotic, EF-Tu, **71**, 534–535
- Resnick's model, *see* Double-strand
 break-induced recombination
- Resolution reaction, role of core homology,
51, 83
- Resolution, synthetic χ -structures by Flp, **51**,
 81–83
- Respiratory-chain component, mitochondrial
 biogenesis in *Saccharomyces cerevisiae*
 and, **46**, 77–78
- Restriction and modification (R–M)
 classification overview
 methylation-dependent restriction
 systems, **64**, 6–8
 type I systems, **64**, 3
 type II systems, **64**, 5
 type III systems, **64**, 5
 type IV systems, **64**, 5–6
 cleavage sites, **64**, 2
 discovery, **64**, 1–2
 distribution in nature, **64**, 8, 51–52
 evolution, **64**, 50, 53
 functions, **64**, 2–3, 53–54
 methylation sites, **64**, 2
 recombination role, **64**, 51
 selfish gene hypothesis, **64**, 50–51
 type I enzymes, *see* Type I
 restriction–modification enzymes
 type III enzymes, *see* Type III
 restriction–modification enzymes
- Restriction fragment-length polymorphism,
 methylation patterns, **49**, 89–91
- Restriction fragment length polymorphisms,
 alcohol dehydrogenase and, **40**, 265–267
- Ret*, **67**, 74
- Retina, in ROR $\beta^{-/-}$ mice, **69**, 229–230
- Retinal
 binding protein, *see* Cellular
 retinol-binding protein
 metabolic enzyme identification, **63**,
 140–141
- Retinal dehydrogenase
 cellular retinol-binding protein, activity
 against bound ligand, **63**, 147–149,
 171–173
- RALDH
 isozymes, **63**, 154, 170–171
 RALDH2 crystal structure, **63**, 174
 substrate specificity, **63**, 173–174
 types, **63**, 170
- Retinitis pigmentosa, rhodopsin mutations,
49, 134
- Retinoblastoma protein, autoregulation of
 promoter, **60**, 144, 146–147, 162
- Retinoblastoma protein, cell cycle
 regulation, **53**, 201, 210
- Retinoblastoma protein, ribosomal gene
 transcription regulation, **62**, 135–136,
 315–316
- Retinoic acid (RA)
 alcohol dehydrogenase metabolism
 biosynthesis role, **63**, 179–180
 responsive elements in dehydrogenase
 genes, **63**, 179
 androgen activity effects, **63**, 169
 binding protein, *see* Cellular retinoic
 acid-binding protein
 degradation
 cytochromes P450, **63**, 175–176
 glucuronidation, **63**, 174–175
 hydroxylation, **63**, 175
 half-life, **63**, 174
 metabolism
 enzyme identification, **63**, 140–141
 homeostasis modeling, **63**, 152–159
 inhibition effects on biopotency, **63**,
 156–157
 responses of various cells, **63**, 158–159
 steady-state concentration, **63**, 140, 154,
 174–175

- Retinoic acid receptor, binding to HIV LTR, **49**, **165**
- Retinoid-related orphan receptors
- dn-ROR α , **69**, **239**
 - interaction with coactivators and corepressors, **69**, **218–223**
 - overexpression, **69**, **236–239**
 - protein structure, **69**, **212–214**
 - response elements, *see* ROREs
 - ROR α , **69**, **208–209**
 - ROR $\alpha^{-/-}$ mice, **69**, **226–228**
 - ROR β , **69**, **209–210**
 - ROR $\beta^{-/-}$ mice, **69**, **229–230**
 - ROR γ , **69**, **210–211**
 - genomic structure, **69**, **224–226**
 - ROR $\gamma^{-/-}$ mice, **69**, **230–236**
 - transactivation, CaMKIV role, **69**, **223–224**
 - transcriptional control by, **69**, **217–224**
- Retinoid X receptors, complexes with nuclear receptors, **69**, **214–215**
- Retinol
- alcohol dehydrogenase metabolism
 - classes in retinol dehydration, **63**, **178–180**
 - deermouse, **63**, **178**
 - fetal alcohol syndrome, retinol dehydrogenation inhibition in pathogenesis, **63**, **180–182**
 - binding proteins, *see* Cellular retinol-binding protein; Retinol-binding protein
 - esterification, **63**, **154**
 - metabolic enzyme identification, **63**, **140–141**
 - metabolic homeostasis modeling, **63**, **152–159**
 - retinyl ester formation during uptake, **63**, **153**
 - steady-state concentration, **63**, **140**
- Retinol-binding protein, receptor and uptake, **63**, **152**
- Retinol dehydrogenase (RDH)
- cellular retinol-binding protein, activity against bound ligands, **63**, **149–151**, **154**, **160–161**
 - classification, **63**, **161**, **163–164**
 - cross-linking with other proteins, **63**, **161**
 - CYP2D copurification, **63**, **167**
 - membrane forms, **63**, **166–167**
 - sequence homology between types, **63**, **161**, **163–164**
 - steroids as substrates, **63**, **167–169**
 - substrate specificity, **63**, **165–166**
 - tissue distribution and intensity of expression, **63**, **164–165**
- Retinyl ester hydrolase (REH)
- bile salt stimulation, **63**, **159–160**
 - regulation of activity, **63**, **153**, **159–160**
 - types, **63**, **160**
- Retron, **67**, **71–75**
- insertion site, **67**, **72–74**
 - E. coli*, **67**, **72–74**
- Retron element
- transcription, **67**, **74–75**
- Retron reverse transcriptase
- structural domains, **67**, **81**
- Retron, msDNA of bacteria and, **40**, **9**
- Retroviral mutagenesis, RT, **71**, **93–94**
- Retroviral reverse transcriptase, HIV-1
- amino acid role, **71**, **127–128**
 - Arg-72, **71**, **120–121**
 - enhanced fidelity, **71**, **129**
 - fidelity *in vitro* assays, **71**, **99–100**
 - fidelity at initiation, **71**, **108–109**
 - fidelity, accessory proteins, **71**, **110–112**
 - genetic assays, **71**, **105–108**
 - Gln-151, **71**, **119–120**
 - Lys-65, **71**, **120–121**
 - Met-184, **71**, **117–119**
 - minor groove binding track residues, **71**, **126**
 - misinsertion fidelity assay, **71**, **100–103**
 - mispair extension fidelity assay, **71**, **103–104**
 - mutagenesis, **71**, **93–94**
 - mutation rate variations, **71**, **130–131**
 - mutation rates, **71**, **98–99**
 - mutational analysis overview, **71**, **112–113**
 - mutator RT, error catastrophe, **71**, **129–130**
 - pre-steady-state kinetic assays, **71**, **104–105**
 - primer grip residues, **71**, **124–126**
 - proviral DNA, **71**, **97**
 - strand transfer fidelity, **71**, **109–110**
 - structure, **71**, **94–97**
 - template strand residues, **71**, **121–123**
 - Tyr-115, **71**, **114–117**
 - Tyr-183, **71**, **123–124**
- Retrovirus
- antisense oligonucleotide therapy, **57**, **120**, **122**
 - polyadenylation sites in messenger RNA, **57**, **59–60**

- Retroviruses
 retroelement Gag–Pol translation,
 72, 10–12
 RNA translation–packaging interplay, **72**,
 7–10
 Rev-Erb α , association with RORs, **69**, 216
 Rev response element (RRE)
 mismatched base pair functions, **57**, 35
 nuclear magnetic resonance of human
 immunodeficiency virus structure, **57**,
 21–22, 30
 Rev response element, HIV-1, **69**, 26
 Reverse-transcribing elements, gene
 economy, **72**, 2–4
 Reverse transcriptase
 interspersed nuclear elements, **49**, 21
 tRNA primer, **49**, 21, 52
 Reverse transcriptase (RTO), **67**, 66
 Reverse transcriptase, *see* Human
 immunodeficiency virus
 reverse transcriptase
 Reverse transcriptase, *see* Retroviral
 reverse transcriptase
 Reverse transcriptase, inhibition by
 oligonucleotide binding, **57**,
 122–123, 125
 Reversibility, epigenome, **69**, 49
 Reversible resolution, superoxide dismutases
 and, **40**, 234, 236
 RF-C, **68**, 8, 125, 129, 131
 RFC, *see* Replication factor C
 RF-C, for complete SV40 DNA replication, **51**,
 99–101
 RFAI, mutation effects on double-strand
 break-induced recombination, **58**,
 293–294
 RFC, **67**, 132–133
 functional properties, **67**, 138–139
 MTX resistance
 molecular mechanisms, **67**, 154–156
 mutant carriers, **67**, 156–157
 structural-functional determinants, **67**,
 156–157
 RFC, *see* Replication factor C
 RFLP, *see* Restriction fragment-length
 polymorphism
 RFX5, mutation in bare lymphocyte
 syndrome, **64**, 198
 RFXANK, mutation in bare lymphocyte
 syndrome, **64**, 198
 RFXAP, mutation in bare lymphocyte
 syndrome, **64**, 198
 RGS, *see* Regulator of G protein signaling
 Rhizobium, bacterial adenyl cyclases and, **44**,
 49–53
 Rho
 farnesylation
 inhibition, **67**, 220–221
 proteins
 cell transformation, **67**, 195
 effectors, **67**, 196–209
 future perspectives, **67**, 223–224
 PDL, **67**, 207
 signaling pathway
 anticancer drug development, **67**, 215–216
 Rho protein, **40**, 318–320
 Rho, *see* RNA helicase
 RhoA, **67**, 204–205
 E-cadherin, **67**, 199–200
 effectors, **67**, 196–197
 PDL, **67**, 205–206
 PKN, **67**, 207–209
 Rhodamine acceptor
 structure, **67**, 102
 Rhodobacter sphaeroides, **67**, 56
 Rhodopsin
 absorption spectroscopy
 intermediates, **59**, 2, 19–20
 mutants, **59**, 10–11
 active conformation, molecular switches and
 determinants, **59**, 20–22
 chromophores
 binding site, **59**, 7–9
 isomerization, **59**, 3–4, 13–14, 20–22
 types, **59**, 2
 cytoplasmic domain
 rhodopsin kinase interactions, **59**, 9
 transducin interactions, **59**, 9–10, 22
 extracellular domain
 cysteine roles, **59**, 6
 glycosylation, **59**, 7
 mutation analysis, **59**, 6–7
 light-induced conformational change
 coupling to transducin activation, **59**,
 22–25
 cytoplasmic surface changes, **59**, 18–20
 electron paramagnetic resonance
 analysis, **59**, 19
 fluorescence studies of tryptophan,
 59, 15–16

- Fourier transform infrared spectroscopy analysis, **59**, 14–15, 19, 23–24, 29
- functional interactions between
 - transmembrane helices 3 and 6, **59**, 15–18
- metal ion binding site introduction in analysis, **59**, 18
- photolysis pathways, **59**, 13
- membrane-embedded domain and chromophore-binding site, **59**, 7–9
- mutations in disease
 - autosomal dominant retinitis pigmentosa, **59**, 28–29
 - congenital night blindness, **59**, 29
- phosphorylation, **59**, 5–6, 9
- purification from cattle, **59**, 5
- structure
 - peptide characterization, **59**, 28
 - projection mapping of structure, **59**, 25–28
 - secondary structure, **59**, 2–3, 5
- Rhodospirillum rubrum*, **67**, 35–36
- CO oxidation, **67**, 36–38
- coo* regulon, **67**, 53
- transcriptional organization, **67**, 38
- Rhopilin, **67**, 196
- biological functions, **67**, 197
- Rhotekin, **67**, 196
- biological functions, **67**, 197
- rhp9/crb2
 - G₂-M checkpoint regulation, **62**, 376, 380
- S-M checkpoint regulation, **62**, 387
- Ribonuclease
 - exonucleases, **49**, 217
 - magnesium dependence, **49**, 216
 - RNase MRP, **49**, 216
 - RNase PRI, **49**, 216
- Ribonuclease A, double-stranded RNA as substrate, **52**, 25
- Ribonuclease BS-1, double-stranded RNA as substrate, **52**, 25
- Ribonuclease D, properties
 - HIV-1, **52**, 41–42
 - Krebs II ascites cells, **52**, 38
- Ribonuclease DS, properties, **52**, 40
- Ribonuclease E
 - cleavage sites, **52**, 201–202
 - gene identification, **52**, 199–200
 - purification, **52**, 200–201
 - role in mRNA decay, **52**, 196–197, 201–203, 206, 208
- Ribonuclease H
 - antisense effects mediated by, **69**, 6–7
 - RNA–oligonucleotide duplex and, **69**, 16–17
- Ribonuclease II, role in mRNA decay, **52**, 197–199, 208
- Ribonuclease III
 - catalytic mechanism, **52**, 19
 - catalytic sites, **52**, 22–23
 - gene, **52**, 19, 26–28
 - phosphorylation, **52**, 28
 - role in mRNA decay, **52**, 203–204
 - substrate recognition, **52**, 19–22, 24
- Ribonuclease inhibitor, mammalian, *see* Mammalian ribonuclease inhibitor
- Ribonuclease K, role in mRNA decay, **52**, 203
- Ribonuclease P
 - catalytic mechanism, **55**, 93–95
 - structures in various species, **55**, 88–91
 - substrate recognition, **55**, 91–93
 - tRNA precursor processing, **55**, 87–88, 91
 - yeast nuclear enzyme
 - RPRI* gene
 - expression, **55**, 97
 - mature domain replacements, **55**, 108
 - randomization mutagenesis, **55**, 108–109
 - structure, **55**, 95, 97
 - catalytic subdomain identification, **55**, 109, 111, 113
 - mutation affecting rRNA processing, **55**, 113–115
 - phylogenetic analysis, **55**, 98–99
 - structure analysis by footprinting, **55**, 99, 101, 105
- Ribonuclease probing, pRNA, **72**, 438
- Ribonuclease V₁/inf, substrate specificity, **52**, 24
- Ribonuclease, *see* Exoribonuclease; *specific RNases*
- Ribonucleic acid, *see also* Messenger RNA
 - antisense
 - in R6K regulation, **48**, 262
 - in replication control, **48**, 251–253
 - target, binding by oligonucleotides, **48**, 209–213
- Ribonucleoparticles
 - abundance, **72**, 257
 - complexes, **72**, 246

Ribonucleoparticles (*cont.*)FMRP association, **72**, 257functions, **72**, 259–261

Ribonucleoprotein particles, small nuclear

hybrid, **50**, 136spliceosome built of, **50**, 134–135U2, interaction with pre-mRNA, **50**,
142–143

Ribonucleoside triphosphate, RT fidelity,

Tyr-115, **71**, 114–117

Ribonucleotide reductase

activity in eukaryotic cell cycle, **53**, 361

bacteriophage T4 enzyme

deoxyribonucleotide synthetase extended
complex, **53**, 387–390events leading to expression, **53**, 351–353

synthesis of deoxyribonucleotides and

ratio of bases, **53**, 384–386template damage and deoxyribonucleotide
synthesis, **53**, 386translational delay, **53**, 353–356cancer role, **53**, 374

clam oogenesis, regulation of expression

large subunit, **53**, 378mRNA masking and polyadenylation, **53**,
376–377small subunit translation, **53**, 377–378early history, **53**, 345–346*Escherichia coli* enzyme subunitsexpression control, **53**, 356–359induction by DNA damage, **53**, 374types, **53**, 346–347herpes virus, transcriptional control, **53**,
380–382initiation of replication, role, **53**, 348–349

mouse enzyme subunits

coordinated synthesis, **53**, 367–368factors controlling mRNA stability, **53**,
364–366, 370ferritin relationship in expression, **53**, 369gene structure, **53**, 362–363induction by DNA damage, **53**, 373iron requirement in R2 synthesis, **53**,
368–369mRNA truncation during G1, **53**, 364–365phosphorylation of R2, **53**, 368relationship to synthesis of other
proteins, **53**, 366–367vaccinia virus enzyme regulation, **53**,
382–383

yeast enzyme subunits

ferric reductase relation to RAP1 gene,
53, 370induction by DNA damage, **53**, 371–373Ribonucleotide reductases, *see* Anaerobic

ribonucleotide reductases

Ribonucleoprotein complex (RNP), messenger

RNA stabilization, **57**, 253, 269,
274, 283

Ribose-5-phosphate, substrate in PRPP

synthetase reaction, **69**, 128–130Ribose-modified oligonucleotides, **48**, 208–209

Ribosomal gene

active gene measurements, **62**, 297amplification, **62**, 296chromatin remodeling at promoter by
TTF-I, **62**, 144–146, 307–308copy number, **62**, 296

enhancer elements

organization in vertebrates, **62**, 302polymerase preinitiation complex
stabilization, **62**, 302–304upstream binding factor binding, **62**, 303

yeast enhancer

binding proteins, **62**, 304

control of intergenic spacer

elements, **62**, 304–305structure, **62**, 303–304

promoter elements

cell-free assays, **62**, 111core promoter element, **62**, 112–113, 298,
300–301divergence of control sequences, **62**, 111upstream control element, **62**, 112–113,
298, 300rate-limiting step in ribosome synthesis, **62**,
110, 297, 311–312replication fork arrest, TTF-I role, **62**,
146–148silencing proteins and aging, **62**, 319–322species specificity of promoter recognition
and transcription, **62**, 128–129

termination of transcription

mechanism, **62**, 142–144Sal box terminator element, **62**, 140species differences in termination
sequences, **62**, 139–140T₀ terminator, **62**, 144, 307TTF-I termination factor, **62**, 141–143,
307–308

- topology of transcription, **62**, 138–139
- transcription-coupled repair, **62**, 242–243
- transcriptional regulation
 - core promoter binding factor, **62**, 122, 126
 - DNA-PK, **62**, 133
 - enhancement, **62**, 129–131
 - growth-dependent regulation, **62**, 133–135
 - Ku, **62**, 132–133
 - Not1, **62**, 316–317
 - repression, **62**, 131–133
 - retinoblastoma protein, **62**, 135–136, 315–316
 - RNA polymerase I, **62**, 118–119, 126
 - SV40 large T antigen, **62**, 136–137
 - TIF-1A, **62**, 122–124, 126, 133
 - TIF-IB/SL1, **62**, 118–119, 126, 131–132, 137–138
 - TIF-IC, **62**, 124–125, 126
 - upstream binding factor, **62**, 121–122, 126, 130–135
- Ribosomal initiation complex, **70**, 212–215
- Ribosomal protein, amino acid control of gene expression, **53**, 238–239, 241–245
- Ribosomal proteins, in translational regulation, **48**, 199–201
- Ribosomal RNA
 - cleavage sites
 - 3'-end of 28S rRNA, **49**, 202, 206, 208–209
 - 3'-ETS, **49**, 209
 - 5'-end of 18S rRNA, **49**, 203, 205–206, 228–229
 - 5'-end of 5.8S rRNA, **49**, 207–208
 - 5'-ETS, **49**, 202, 205, 224–227
 - ITS1, **49**, 203, 207, 227
 - ITS2, **49**, 203, 208, 227–228
 - recognition signals, **49**, 223–229
 - processing
 - methylation
 - base, **49**, 233
 - catalysis, **49**, 232–233
 - inhibitors, **49**, 232
 - patterns, **49**, 231
 - ribose, **49**, 231–233
 - pathways, **49**, 199–204
 - pseudouridylation, **49**, 233
 - role in processing
 - B23 protein, **49**, 221
 - fibrillarin, **49**, 218–219
 - helicases, **49**, 217
 - magnesium, **49**, 215–216
 - noncatalytic nucleolar proteins, **49**, 213, 215, 218–223
 - NSR1 protein, **49**, 220
 - nucleolin, **49**, 220–221
 - processosome, **49**, 229–230, 233–234
 - ribonucleases, **49**, 213, 215–217
 - RNA secondary structure, **49**, 223–225
 - snoRNA, **49**, 210–213
 - SOF1 protein, **49**, 221
 - sequence of events, **49**, 199
 - tagging, **49**, 225–226
 - transcription units, **49**, 197, 199
 - Ribosomal RNA (rRNA)
 - amino acid residue associations on nascent peptide, **66**, 46
 - cross-linking of aminoacyl-tRNA puromycin analog, **66**, 44–45, 47
 - mismatched base pair functions, **57**, 34–35
 - nuclear magnetic resonance, structural studies of mismatched base pairs, **57**, 7–8, 21–22, 28–29, 31
 - peptide synthesis in evolution, **66**, 45–46
 - Ribosomal RNA, *see* Ribosome biogenesis in yeast
 - Ribosomal RNA, nucleosome positioning and, **40**, 162–164
 - Ribosomal RNA, translational stop signal decoding, **52**, 303–308
 - Ribosome
 - association with mRNA, models, **48**, 188–194
 - chaperonelike activity, **66**, 56–57
 - conservation between species, **49**, 234
 - cross-linking of aminoacyl-tRNA puromycin analogs to rRNA, **66**, 44–45, 47
 - crystallography, **66**, 62
 - folding of nascent peptides, **66**, 54–55
 - nascent peptides, *see* Nascent peptide
 - peptidyl transferase reaction
 - stereochemistry, **66**, 47
 - production, **49**, 198
 - prospects for study, **66**, 42, 60–62
 - RNA-binding site models
 - three-site models
 - displacement model, **66**, 43–44
 - hybrid-state model, **66**, 44
 - two-site model, **66**, 43
 - RNA content, **49**, 198

- Ribosome (*cont.*)
- subunits, in eukaryotic translation
 - initiation, **48**, 186–188
 - trigger factor association, **66**, 60–61
 - tunnel in large ribosomal subunit
 - crystal structures, **66**, 51–52
 - nascent peptide interactions
 - cross-linking, **66**, 52–53
 - fluorescence anisotropy studies, **66**, 52
- Ribosome biogenesis in yeast, **41**, 89–91
- expression of ribosomal-protein genes
 - post-transcriptional regulation, **41**, 109–111
 - structure, **41**, 103–104
 - transcriptional regulation, **41**, 104–109
- modification of ribosomal proteins, **41**, 117–118
- nucleocytoplasmic transport and assembly, **41**, 118–123
- pre-RNA
 - modification of, **41**, 116
 - processing of, **41**, 111–116
- transcription of ribosomal-RNA genes
 - 5-S rRNA and yeast RNA Pol III, **41**, 103
 - initiation by yeast RNA Pol I, **41**, 92–99
 - regulation and yeast RNA Pol I, **41**, 101–102
 - structure, **41**, 91–92
 - termination by yeast RNA Pol I, **41**, 99–101
- Ribosome stalk
 - bacterial components, **55**, 157–158
 - cytoplasmic pool
 - L11-like protein, **55**, 167
 - P0, **55**, 166
 - P1, **55**, 165–166
 - P2, **55**, 165–166
 - essentiality of acidic P proteins in yeast, **55**, 177, 179
 - eukaryotic components and structure
 - L11-like protein, **55**, 165
 - P0, **55**, 164–165
 - P1, **55**, 159–160, 163
 - P2, **55**, 159–160, 163
 - expression of acidic P proteins,
 - regulation, **55**, 187–189
 - functional exchange of heterologous acidic P proteins between species, **55**, 183–184
 - P protein exchange in ribosome
 - P0, **55**, 170–171
 - P1, **55**, 169–170
 - P2, **55**, 169–170
- P1/P2–P0 protein complex
 - ribosomal binding, **55**, 177, 179
 - stability, **55**, 168–169
 - stoichiometry, **55**, 168
 - structure, **55**, 167–168, 182–183
- phosphorylation of proteins
 - effect on P protein function, **55**, 175–176
- kinases, **55**, 173–175, 190
- P0, **55**, 172–173
- P1, **55**, 171–173
- P2, **55**, 171–173
- PO function
 - carboxyl-terminal domain, **55**, 181–183
 - essentiality for cell viability, **55**, 181
 - protein expression pattern, role of acidic P proteins, **55**, 180–181
 - ribosome activity regulation, **55**, 184, 186–187, 189
- Ribosome, *see also* S6
 - cell cycle progression changes, **65**, 102
 - energy investment in biogenesis, **65**, 102
- Ribosome, *see* Elongation, protein
- Ribosome, *see* Elongation, translation
- Ribosomes
 - catalyzed peptide-bond formation, **50**, 1–23
 - gene transcription, in eukaryotes, **50**, 25–66
- Ribosomes–EF-Tu interactions, **71**, 521–524
- Ribosomes, *Escherichia coli*, protein synthesis
 - alpha operon, **47**, 348–351
 - autogenous control, **47**, 336–338
 - gene organization, **47**, 332–336
 - L10 operon, **47**, 358–359
 - L11 operon, **47**, 356–358
 - L20 operon, **47**, 361–362
 - mRNA elongation, **47**, 340
 - mRNA stability, **47**, 340
 - regulatory r-protein–mRNA interaction, **47**, 338–339
- rif* region, **47**, 355–357
- S10 operon, L4-mediated regulation, **47**, 341–348
 - L4 binding to RNA, **47**, 343–345
 - transcription, **47**, 345–346
 - translation, **47**, 346–348
- S15 operon, **47**, 351–353
- spc* operon, **47**, 353–355
- str* operon, **47**, 362–363
- translation inhibition, **47**, 339–340

- Ribosomes, 40S, in GTP hydrolysis, **70**, 225–227
- Ribosomes, eukaryotic initiation factor 4E and, **46**, 186–187, 193–198, 200
- Ribosomes, shunting, **72**, 6, 15–16
- Ribozyme
- manganese binding, **57**, 14
 - nuclear magnetic resonance of P1 helix, **57**, 10
 - oligonucleotide therapy application, **57**, 99–100
 - X-ray structure of hammerhead ribozyme, **57**, 17
- Ribozyme, *see also* Hairpin ribozyme
- discovery, **58**, 2, 5
 - types, **58**, 2
- Ribozyme, *see* Ribonuclease P
- Ribozyme, efficiency in prokaryotes, **52**, 33–34
- Ribozymes, catalyzed tRNA aminoacylation, **70**, 326–327
- Ribozymes, HIV therapy, **49**, 183
- Ribozymes, synthetic, antisense
- oligonucleotides and, **44**, 147–148
- Rice genes, **45**, 1–2, 22–23
- actin, **45**, 3–5
 - gene transfer, DNA, **45**, 9
 - Agrobacterium*, **45**, 16
 - biolistic method, **45**, 11–13
 - pollen-tube-pathway method, **45**, 13–15
 - protoplasts, **45**, 10–11
 - phytochrome, **45**, 5–7
 - storage protein, **45**, 7–9
 - transgenic plants, **45**, 16, 22
 - actin-1 gene, **45**, 16–17
 - agronomic uses, **45**, 22–23
 - glutelin gene, **45**, 18–19
 - phytochrome genes, **45**, 17–18
 - protease inhibitor genes, **45**, 19–22
- Rice tungro bacilliform virus
- polycistronic RNA translation, **72**, 22–23
 - RNA translation–packaging interplay, **72**, 9
 - shunting ribosomes, **72**, 15–16
- Rickets, vitamin D receptor mutation, **64**, 199, 201, 203
- RIEG1*, mutation in human syndromes
- iridogoniodysgenesis type 2, **64**, 192–193
 - Rieger syndrome, **64**, 192–193
- Rieger syndrome, *RIEG1* mutation, **64**, 192–193
- rif* region, **47**, 355–357
- Rik1, repression of meiotic recombination, **61**, 372–373
- Rmt1, arginine methyltransferase, **61**, 84–85, 104, 124
- RNA
- RNA interactions
 - in spliceosome assembly, **50**, 139–146
 - in splicing, **50**, 137–138
 - alphavirus, replication
 - genome complement, **71**, 192–194
 - 26S mRNA, **71**, 196–197
 - plus-strand RNA synthesis, **71**, 194–196
 - anaerobic ribonucleotide reductases, **72**, 120–124
 - cellular, classification, **72**, 225
 - composition in virus, **72**, 416–417
 - CPSF binding, **71**, 315–316
 - defective-interfering, alphavirus, **71**, 192–194
 - duplex pieces, **70**, 304–306
 - dynamic, **50**, 136–137
 - functional role, **72**, 224
 - hybridization, chaperones, **72**, 259–260
 - immunochemical analyses of, **42**, 54–55, 62–63
 - in cytoplasmic male sterility, **70**, 147–149
 - in spliceosome, **50**, 138–139
 - intron splicing in monocots and, **42**, 251–253
 - messenger, *see* Messenger RNA
 - messenger, eukaryotic initiation factor 4E and, **46**, 186–187
 - metal ion role, **72**, 228–229
 - minus-strand, nsP1 role, **71**, 203–204
 - misfolding, **72**, 228
 - msDNA of bacteria and, **40**, 2–4
 - occupancy of RNA chaperones, **72**, 246
 - plus-strand, alphavirus, **71**, 194–196
 - primer-template, **67**, 242
 - msDNAs, **67**, 76
 - replication of plant viruses and, *see* Replication of plant viruses
 - ribosomal, **50**, 23-S, 10–17
 - RNA phage coat proteins and, *see* RNA phage coat proteins
 - secondary and tertiary structures, **72**, 226
 - Semliki Forest virus*, **71**, 188–190
 - size for pRNA dimer formation, **72**, 453
 - small nuclear, *see* snRNA
 - TFOs, **67**, 178
 - transcription factor IIIA and, **43**, 225–229

RNA (*cont.*)

- transfer, *see* Transfer RNA
- transfer, *see* tRNA
- Trypanosoma brucei* and, **43**, 42
- viral translation–packaging interplay, **72**, 7–10
- yeast double-stranded, *see* Yeast double-stranded RNAs
- RNA (guanine-7) methyltransferase
 - active site modeling, **66**, 28–30
 - genetic and physical organization of RNA capping apparatus, **66**, 3–4, 35
- human Hcm1p
 - features, **66**, 32–33
 - quaternary structure, **66**, 4
 - site-directed mutagenesis, **66**, 33
- mRNA capping role, **66**, 2, 28
- yeast enzymes
 - Abd1p
 - discovery, **66**, 2
 - essential residues, **66**, 33–34
 - mutant analysis, **66**, 2–3, 30–31
 - quaternary structure, **66**, 4
 - site-directed mutagenesis, **66**, 32–34
 - Ccm1p, **66**, 31–32
 - Pcm1p, **66**, 31
- RNA 1, decay, **62**, 97
- RNA annealing protein, mechanism of action, **52**, 45–46
- RNA-binding domain, poly A polymerase, **71**, 324
- RNA binding motifs, RNA chaperones, **72**, 233–234
- RNA-binding proteins
 - amino acid–RNA contacts, **72**, 229–230
 - cooperativity, **72**, 230
 - other platforms, **72**, 231
 - reciprocal induced fit, **72**, 230
 - RNA folding problem, **72**, 231–233
- RNA-binding proteins, *see* Nuclear RNA-binding proteins
- RNA-capping pathway, nsP1, **71**, 198–201
- RNA chaperones
 - biotechnological applications, **72**, 262
 - classes, **72**, 225–226
 - functionality, **72**, 246–250
 - molecular level, **72**, 258–259
 - RNA binding motifs, **72**, 233–234
 - RNA helicase interactions, **72**, 261–262
 - RNA hybridization, **72**, 259–260
 - RNA occupancy, **72**, 246
 - structural and functional diversity, **72**, 250, 257–258
- RNA–DNA hybridization analysis, pRNA, **72**, 419
- RNA folding
 - large RNAs, **72**, 225
 - RNA-binding proteins role, **72**, 231–233
- RNA guanylyltransferase
 - bifunctional enzyme with triphosphatase, *see* Hce1p; Mce1p
 - conservation between species, **66**, 4–5
 - crystal structure of *Chlorella virus* enzyme, **66**, 7–8
 - evolution, **66**, 10–12
 - genetic and physical organization of RNA capping apparatus, **66**, 3–4, 35
 - kinetic mechanism, **66**, 4–5
 - mRNA capping role, **66**, 2
 - protein engineering, **66**, 10–11
- yeast Ceg1p
 - assembly of complex with Cet1p, **66**, 22–24
 - catalytic residues and mechanism, **66**, 8–10
 - mutant analysis, **66**, 2
 - site-directed mutagenesis, **66**, 5–7
- RNA helicase, **52**, 44–45
- RNA helicase
 - DEAD-box helicases, **62**, 76–77, 86, 90
 - messenger RNA decay role, **62**, 76–77, 86, 90
 - Rho, **62**, 77
- RNA helicase, nsP2 activity, **71**, 204–205
- RNA helicase, RNA chaperone interactions, **72**, 261–262
- RNA ligands
 - aminoglycoside antibiotics, **69**, 4
 - oligonucleotides, **69**, 5
- RNA phage coat proteins, RNA and, **40**, 185
- components
 - coat proteins, **40**, 189–192
 - RNA binding sites, **40**, 192–196
 - cooperative binding, **40**, 212
 - encapsidation, **40**, 210–211
 - Escherichia coli* RNA bacteriophages, **40**, 185–189
 - hairpin binding proteins, **40**, 212–215
 - interaction
 - solution properties, **40**, 199–200
 - study, **40**, 196–199

- phage assembly, **40**, 210–212
- recognition, **40**, 200–201, 209–210
 - bulged adenosine, **40**, 204–206
 - consensus structure, **40**, 201–204
 - covalent bond, **40**, 206–209
- RNA polymerase
 - α subunit
 - early A2c promoter repression by protein p4, **60**, 39
 - late A3 promoter binding with protein p4, **60**, 33–36
 - promoter context and outcome of regulator interactions, **60**, 40–44
 - protein p4 binding site, **60**, 42–44
 - roles, **60**, 31–32
 - alternate sigma factors, **55**, 43–44
 - autoregulation of promoters in yeast, **60**, 140–141, 162
 - control of initiation in bacteria
 - concentration, **55**, 7, 10–12
 - initiation complex formation and promoter clearance, **55**, 15–17
 - isomerization of closed-to-open RNA polymerase–promoter complex, **55**, 14–15
 - promoter binding, **55**, 12–14
 - early A2b promoter binding, **60**, 36–37
 - subunit functions, **60**, 31
 - transcription initiation, **60**, 30–31
- RNA polymerase (RNAP)
 - binding, **67**, 56, 57
- RNA polymerase I
 - accessory proteins, *see also* Core promoter binding factor; TIF-1A; TIF-1B/SL1; TIF-1C; Upstream binding factor TFIIS, **62**, 306–307
 - topoisomerases, **62**, 307
 - assembly of holoenzyme complex, **62**, 126–128
 - complexity, **50**, 43–44
 - essential products, **62**, 294
 - forms, **62**, 117
 - in growth-regulated activation, **50**, 54–55
 - in ribosomal transcription, **50**, 25–66
 - initiation complex components, **62**, 113
 - mechanisms of transcriptional regulation
 - Acanthamoeba* down-regulation, **62**, 311
 - enhancement, **62**, 129–131
 - growth-dependent regulation, **62**, 133–135, 297, 309–311, 317–318
 - hormones, **62**, 317–318
 - mitotic shutdown, **62**, 318–319
 - repression, **62**, 131–133
 - silencing proteins and aging, **62**, 319–322
 - yeast down-regulation in stationary phase, **62**, 310–311
- messenger RNA transcription, **62**, 294–295
- nucleolus
 - nucleolar dominance as consequence of competition for preinitiation complex formation, **62**, 313–315
 - structure in active transcription, **62**, 295–296
- preinitiation complex formation as rate-limiting step, **62**, 311–313
- promoter, *see* Ribosomal gene
- promoters, **50**, 33–36
- ribosomal gene transcription, **62**, 118–119, 126, 129–130
- subunits
 - antibodies, **62**, 115, 117
 - comparison between species, **62**, 114
 - mouse, **62**, 306
 - RPA194 and RPA116, homology, **62**, 114–115
 - RPA53 versus polymerase-associated factor, **62**, 53, 117
 - yeast, **62**, 305–306
- TAF mediation of promoter recognition, **62**, 118–119, 128–129
- termination of transcription
 - mechanism, **62**, 142–144
 - Sal box terminator element, **62**, 140
 - species differences in termination sequences, **62**, 139–140
 - T₀ terminator, **62**, 144
 - TTF-I termination factor, **62**, 141–143
- topology of ribosomal gene transcription, **62**, 138–139
- RNA polymerase II
 - accessory factors, **65**, 286
 - activity, multisite phosphorylation in regulation, **48**, 143–176
 - basal transcription initiation, **72**, 284–285
 - C-terminal domain in, discovery, **48**, 145–147, 148
 - CAD role
 - assay, **72**, 289–291

- RNA polymerase II (*cont.*)
- CAD:TAF interaction, **72**, 291–292
 - KID phosphorylation, **72**, 293–296
 - CTD phosphatase
 - dephosphorylation and transcript termination, **72**, 354
 - discovery, **72**, 335–337
 - early elongation complexes, **72**, 349–350
 - elongation complex RNAP II, **72**, 355–357
 - mobilization role, **72**, 347–348
 - mRNA processing regulation, **72**, 353–354
 - purification and characterization, **72**, 337–341
 - recombinant, cloning and expression, **72**, 342–346
 - TFIIF and TFIIB regulation, **72**, 341–342
 - transcript elongation link, **72**, 350–351
 - transcription cycle, **72**, 346–347
 - turnover, **72**, 351–352
- IIA and IIO
- in vivo* ratio, **48**, 151–152
 - discrimination between, in complex assembly, **48**, 156–158
- IIA, subunit IIA, phosphorylation, **48**, 147–151
- IIO, transcript elongation catalyzed by, **48**, 152–154
- phosphorylation
- and progression through transcription cycle, temporation relationship, **48**, 158–160
 - cycle of, model, **48**, 154–156
 - early research, **48**, 145
- phosphorylation dynamics, **72**, 334–335
- progression through transcription cycle, RNA polymerase II phosphorylation and, temporal relationship, **48**, 158–160
- recruitment, **65**, 247, 289
- recruitment to preinitiation complex, C-terminal domain in, **48**, 160–162
- release from preinitiation complexes, C-terminal domain and, **48**, 163–165
- RNA polymerase II transcription initiation, **44**, 67–68
- domains, **44**, 69–75
 - motifs, **44**, 98–100
 - promoters, **44**, 94–98
 - repression, **44**, 102–105
 - structure, **44**, 68–69
 - transcription factors, **44**, 75–76, 93–94
 - activation, **44**, 100–102
 - TFIIA, **44**, 89–93
 - TFIIB, **44**, 81–83
 - TFIID, **44**, 75–81
 - TFIIE, **44**, 86–89
 - TFIIF, **44**, 83–86
 - TFIIH, **44**, 89
- RNA polymerase II, *see also specific transcription factors*
- elongation factors, **56**, 335–338, 340–341
 - preinitiation complex formation and activation, **56**, 328–335
- RNA polymerase II, holoenzyme complex, **62**, 125, 127
- RNA polymerase II, retroviral mutagenesis, **71**, 93–94
- RNA polymerase, triplet repeat sequence transcription and instability, **66**, 182–183
- RNA polymerases, yeast double-stranded RNAs and, **46**, 158–165, 175–176
- RNA processing, nuclear
- assays for plant splicing, **47**, 158–159
 - cis* requirements, **47**, 150–155
 - intron splicing in heterologous systems, **47**, 164–167
- maize genes, *dSpm* effects
- alterations after insertions, **47**, 178–183
 - Ds* elements, **47**, 175–176
 - fates after *Ds* insertions, **47**, 176–177
 - Spm* properties, **47**, 177–178
- plant intron structure
- base content, **47**, 162–164
 - consensus splice junction sequences, **47**, 154
 - conserved motifs, **47**, 160–162
 - intron length, **47**, 162–164
- snRNAs, **47**, 155–158
- RNA recognition motif family of proteins, **41**, 187–196
- RNA processing, **41**, 197–198
 - transcription, **41**, 196–197
- RNA structures
- functional, **69**, 3–4
 - invaded by oligonucleotide, **69**, 9–13
- RNA synthesis
- by airborne RQ RNA molecules, **51**, 240–241
 - by Q β replicase, **51**, 227–231

- RNA templates, misinsertion fidelity assay, **71**, 103
- RNA triphosphatase
- baculovirus phosphatase features, **66**, 26–27
 - bifunctional enzyme with
guanylyltransferase, *see* Hce1p; Mce1p
 - classes, **66**, 12
 - genetic and physical organization of RNA
capping apparatus, **66**, 3–4, 35
 - metazoan enzyme
 - metal inhibition, **66**, 19, 21
 - sequence homology between species, **66**, 19–20
 - site-directed mutagenesis, **66**, 21
 - substrate-binding site, **66**, 22 - mRNA capping role, **66**, 2
 - PIR1 from humans, **66**, 27–28
 - structural conservation in fungi, **66**, 12–13
 - yeast Cei1p
 - assembly of complex with Ceg1p, **66**, 22–24
 - catalytic mechanism, **66**, 18–19
 - crystal structure, **66**, 13–15
 - dimerization, **66**, 19
 - domains, **66**, 12–13
 - metal-binding site, **66**, 15, 17
 - metal requirement, **66**, 12
 - mutant analysis, **66**, 2–3 - yeast Cth1p
 - function, **66**, 25
 - sequence homology with Cei1p, **66**, 24–25
 - subcellular localization, **66**, 25
 - substrate specificity, **66**, 25
- RNA triphosphatase, nsP2 activity, **71**, 205–206
- RNA viruses, positive-strand, members, **71**, 190–191
- RNA, *see also* mRNA; Q β RNA; RQ RNAs
- generation *de novo*, **51**, 235–236
 - heterologous templates, copying, **51**, 230–231
- RNA, *see also* Transfer RNA
- biophysical investigation, **53**, 108–109
 - computer analysis of secondary structure
algorithms, **53**, 164, 168–170
 - comparative approach, **53**, 174–180
 - prediction of pseudoknots, **53**, 180–186
 - simulation of folding, **53**, 172–174
 - statistical analysis, **53**, 186–190
 - thermodynamic approach, **53**, 166–170
 - gel sequencing, **53**, 137–138
 - modification, *see* Nucleoside, modified;
transfer RNA
 - radiolabeling, **53**, 137–138
 - structure determination
 - chemical probing of modified RNA, **53**, 133–140, 142–143, 146–147, 149, 153–159
 - cross-linking and intramolecular
modifications, **53**, 155–161, 191
 - enzymatic probing, **53**, 133–142, 150–151, 159–161
 - nucleotide interactions and folding, **53**, 148–152
 - physical methods, **53**, 132, 191
 - scission by complexed metals, **53**, 161–164
 - tertiary structure, **53**, 152–155
 - thermodynamic parameters of secondary
structure, **53**, 165–166
- RNA, *see* Antisense RNA; BC1 RNA;
Double-stranded RNA; Heterogeneous
nuclear RNA; Messenger RNA;
Ribosomal RNA
- RNA, *see* Messenger RNA; Ribonucleic acid
- RNA, *see* Messenger RNA; Ribosomal RNA;
Small nucleolar RNA; transfer RNA
- RNA, *see* Messenger RNA; Ribosomal RNA;
Transfer RNA
- RNA, messenger, *see* Messenger RNA
- RNA, ribosomal, *see* Ribosome biogenesis in
yeast
- RNA, structural elements in, **41**, 131–132
- determination of RNA structure, **41**, 161–162
 - chemical modification, **41**, 165–166
 - cross linking, **41**, 165
 - fluorescence energy transfer, **41**, 165
 - mutation, **41**, 166
 - nuclear magnetic resonance, **41**, 162–164
- protein–RNA interactions
- protein–duplex interactions, **41**, 167
 - protein–loop binding, **41**, 167–168
 - recognition of three-dimensional
structure, **41**, 168–169
- RNA–DNA interactions, **41**, 170–171
- RNA–RNA interactions, **41**, 169–170

- RNA, structural elements in (*cont.*)
 secondary structure, **41**, 132–134
 bulge loops, **41**, 140–141
 duplexes, **41**, 134–136
 hairpins, **41**, 136–140
 internal loops, **41**, 142–145
 junctions, **41**, 145–147
 phylogenetic comparison, **41**, 148
 prediction of, **41**, 147–149
 single-stranded regions, **41**, 136
 thermodynamic stability, **41**, 148–159
 tertiary interactions, **41**, 150
 helix–helix, **41**, 156–157
 loop–loop interactions, **41**, 152
 phylogenetic comparison, **41**, 158
 predictions of, **41**, 157–160
 pseudoknots, **41**, 150–152
 single strand–helix, **41**, 153–156
 thermodynamic stabilities, **41**, 158–160
 three-dimensional structure, **41**, 160–161
 RNA1, poly A sequences, **71**, 367–369
 RNAP
 binding, **67**, 56, 57
 RNAP II, *see* RNA polymerase II
 RNase BN
 discovery, **66**, 80–81
 function, **66**, 81–82
 gene and regulation, **66**, 81
 structure, **66**, 81
 substrate specificity, **66**, 81
 RNase D
 eukaryotic homologs, **66**, 74, 76–77
 function, **66**, 75–76
 gene and regulation, **66**, 76
 structure, **66**, 75
 substrate specificity, **66**, 75
 RNase E
 activity in deficient strains of *Escherichia coli*, **62**, 79
 catalytic mechanism, **62**, 70
 cloning, **62**, 61–62
 degradosome complex, **62**, 66–67
 functional domains, **62**, 63–66
 gene structure, **62**, 62
 homologs, **62**, 62–63
 messenger RNA decay role, **62**, 60–61, 63, 69, 80–81, 85–86, 88, 91, 96–99, 101–103
 purification, **62**, 61, 69
 structure, **62**, 60
 substrate specificity, **62**, 60, 67–69
 RNase E, degradosome association and function, **66**, 91–92
 RNase H, **67**, 80
 RNase H, in mRNA translation study, **48**, 215–216
 RNase H1, in Okazaki fragment processing, **51**, 110–112
 RNase II
 function, **66**, 72
 gene and regulation, **66**, 72
 gene structure and expression, **62**, 74–75
 messenger RNA decay role, **62**, 74, 85–86, 90–91, 98, 100
 purification, **62**, 73–74
 structure, **62**, 75; **66**, 71
 substrate specificity, **66**, 71–72
 RNase III, messenger RNA decay role, **62**, 60, 81
 RNase M, characterization and functions, **62**, 78
 RNase PH
 discovery, **66**, 84–85
 eukaryotic homologs, **66**, 74, 86–87
 function, **66**, 86
 gene and regulation, **66**, 85–86
 structure, **66**, 85
 substrate specificity, **66**, 85
 RNase protection analysis,
 FGF-1 expression, **70**, 161–162
 RNase R
 eukaryotic homologs, **66**, 73–74
 function, **66**, 73
 RNase II comparison, **66**, 72–73
 structure, **66**, 73
 substrate specificity, **66**, 72
 RNase T
 DNA exonuclease activity, **66**, 78
 eukaryotic homolog, **66**, 74, 79
 function, **66**, 78–79
 gene and regulation, **66**, 79
 structure, **66**, 77
 substrate specificity, **66**, 77–78
 RNase, *see* Ribonuclease
 RNases, mRNA-degrading, *Escherichia coli*, **71**, 370
 RNP, *see* Ribonucleoprotein complex
 RNPDE4A1, membrane-bound, **69**, 280–281
 RNPs, *see* Ribonucleoparticles
 RNRs, *see* Anaerobic ribonucleotide reductases
 RNS, **68**, 278

- ROC, *see* Receiver operating characteristic
- ROCK, **67**, 196, 204–205
 biological functions, **67**, 197
 inhibitors
 antitumor activity, **67**, 216
 Y-27632, **67**, 216
- Rod cell
 opsin, *see* Rhodopsin
 photosensitivity, **59**, 3–4
- Rolipram, cyclic nucleotide phosphodiesterase inhibition, **65**, 17–18, 26, 29
- Rolipram, PDE4 isoform sensitivity to, **69**, 265, 271, 274–279
- Rop protein, loop–loop complex binding, **69**, 33–35
- ROREs
 characterization, **69**, 214–216
 in 5-lipoxygenase, **69**, 239–240
 in transcriptional activation, **69**, 218
- ROS, **68**, 12–13, 30, 75, 76, 208
 8-OH-G, **68**, 194
 aging, **68**, 96
 carcinogenesis, **68**, 96
- ROX1, mitochondrial biogenesis in
 Saccharomyces cerevisiae and, **46**, 62
- RP-A, role in SV40 replication,
 51, 99–101
- RPA, **68**, 58, 125, 370
- RPA, *see* Replication protein A
- RPOI, *see* RNA polymerase I
- rpsO*, messenger RNA decay, **62**, 98–100
- rpsT*, messenger RNA decay, **62**, 97–98
- RQ RNAs
 cloning, **51**, 261–263
 origin, **51**, 236–247
 replication and structure, **51**, 247–252
 separation of Q β replicase from, **51**, 233–235
 variant hypothesis, **51**, 231–233
 vectors, **51**, 252–261
- rqh1, S-phase recovery role, **62**, 388–389
- RR
 disruption
 oxidizing agent sensitization, **68**, 33
 DNA, **68**, 31
 mutant strains
 menadione, **68**, 34
- RRE, *see* Rev response element
- rRNA, *see* Ribosomal RNA
- Rrp4p, exoribonuclease family features, **66**, 89
- RT (Retroviral-encoded polymerase genes),
 msDNA of bacteria and
 ORFs, **40**, 9–12
 purification, **40**, 13–14
- RT, *see* Retroviral reverse transcriptase
- RTBV, *see* Rice tungro bacilliform virus
- RTO, **67**, 66
- cis*-[Ru(II)(bpy)₂Cl₂]-DNA interactions,
 71, 53
- cis*-[Ru(II)((CH₃)₂SO)₄Cl₂]-DNA
 interactions, **71**, 49–52
- trans*-[Ru(II)((CH₃)₂SO)₄Cl₂]-DNA
 interactions, **71**, 49–52
- {*cis*-Ru(II)((CH₃)₂SO)₃Cl₂}NH₂(CH₂)₄NH₂
 {*cis*-PtCl₂(NH₃)}-DNA interactions, **71**,
 53–54
- [Ru(II)Cl(bpy)(terpy)]Cl-DNA
 interactions, **71**, 53
- mer-[Ru(II)(terpy)Cl₃]-DNA interactions,
 71, 53
- RU-486, steroid hormones and, **43**, 28–29
- Rubiflavin, DNA sequence specificity, **63**,
 378, 387
- Rubinstein-Taybi syndrome, CREB-binding
 protein mutation, **64**, 185–186
- Runt, DNA-binding domain, **64**, 176–177
- Ruthenium(III) heterocyclic complexes-DNA
 interactions, **71**, 52
- Ruv proteins, *see* RecA
- RVE, *see* Reconstituted viral envelope

S

7B2

- cleavage
 overview, **63**, 82
 requirement for proPC2 maturation, **63**,
 91–92
- conservation between species, **63**, 82
- prohormone convertase 2 binding and
 functions
 carboxy-terminal peptide, regulation of
 PC2 activity in secretory
 granules, **63**, 96–97, 100
- coimmunoprecipitation experiments,
 63, 92
- inhibition of activity, **63**, 82
- recognition in endoplasmic reticulum, **63**,
 82–84, 91

7B2 (*cont.*)

- requirement for productive cleavage, **63**, 90–92, 98, 100
- secretory pathway effects, **63**, 93–94
- specificity of binding, **63**, 100
- sorting to secretory granules, **63**, 85
- structure–function of 21-kDa domain, **63**, 94, 96
- sulfation, **63**, 85
- s^4U , *see* 4-Thiouridine
- S1 nuclease
 - analysis of platelet-derived growth factor A-chain gene
 - binding protein identification, **55**, 240
 - hypersensitivity mapping assay, **55**, 235
 - identification of hypersensitive sites, **55**, 235–236, 238–240
 - promoter, **55**, 234–235
 - rationale, **55**, 233–234
 - transcription suppression by
 - complementary oligonucleotide, **55**, 236–238, 241
 - conformational heterogeneity of substrate DNA, **55**, 229–233, 241
 - hypersensitivity of actively transcribed genes, **55**, 228, 231
- S10 operon, L4-mediated regulation, **47**, 343–345
 - transcription, **47**, 345–346
 - translation, **47**, 346–348
- S12, frameshift suppression, **64**, 147
- S15 operon, **47**, 351–353
- S6
 - Drosophila* S6
 - extraribosomal function, **65**, 107–108
 - gene and transcripts, **65**, 107
 - homology between species, **65**, 104–105
 - location in ribosomes, **65**, 105
 - phosphorylation
 - 5'TOP messenger RNA regulation, **65**, 106–107, 117–118
 - inducers, **65**, 103
 - kinase, *see* S6 kinase
 - regulatory functions, **65**, 105–107
 - sites, **65**, 103–104
 - S6 kinase (S6K1)
 - 5'TOP messenger RNA translation
 - regulation, **65**, 106–107, 117–118
 - cell cycle progression role, **65**, 118–119
 - domains, **65**, 108, 110–111

Drosophila mutants

- Minutes* mutant comparison, **65**, 122
- advantages of study, **65**, 120–121
- deficiency phenotype, **65**, 121
- overexpression effects, **65**, 121–122
- insulin production role, **65**, 119
- isoforms, **65**, 108
- knockout mouse phenotype, **65**, 119–120
- phosphorylative activation
 - PDK1 as kinase, **65**, 111–112, 122
 - signaling pathways, **65**, 113–114
 - sites, **65**, 111–113
- prospects for study, **65**, 122–123
- S6K2 comparison to S6K1, **65**, 108, 119–120
- upstream effectors
 - mammalian target of rapamycin
 - essential amino acids in activation, **65**, 116–117
 - mechanism of effector activity, **65**, 115–116
 - phosphorylation, **65**, 115
 - sequence analysis, **65**, 115
 - phosphatidylinositol 3-kinase, **65**, 113
 - protein kinase B, **65**, 113–114
 - protein kinase C, **65**, 114
- S6K1, *see* S6 kinase
- SA, wound response, **72**, 190
- Sal163, **67**, 68
 - characteristics, **67**, 69
- sacB* operon, transcriptional attenuation, **62**, 363–364
- Saccharide-binding specificity, calcium-dependent animal lectins and, **45**, 220–230
- Saccharomyces cerevisiae*, **68**, 30, 214
 - cAMP in, periodic fluctuation, **48**, 20–21
 - CDC9* gene, **68**, 151–152
 - cell cycle
 - G1 phase, morphological events, **48**, 2–3
 - growth control
 - Cdc25 and, **48**, 5–8
 - IRA1* and, **48**, 8–9
 - IRA2* and, **48**, 8–9
 - by nutrient-signaling complex, **48**, 4–10
 - Ras-response adenylate cyclase complex and, **48**, 4–5
 - START control, **48**, 1–25
 - START cycle
 - regulatory network operating at, **48**, 21–24

- START phase, **48**, 3
- DNA damage
 - processing, **68**, 37
- DNA ligase, **68**, 153
- DNA ligase IV, **68**, 150
- DNA polymerase II and, *see* DNA polymerase II
- DNA replication initiation, **51**, 95–96
- DNL4* gene, **68**, 151–152
- double-stranded RNAs from, *see* Yeast double-stranded RNAs
- G1/S genes in, transcriptional control, **48**, 11–20
 - Cdc46 and Cdc6 in, **48**, 16–19
 - Clb5 and Clb6 in, **48**, 16
 - cyclin proteins in, **48**, 11, 13
 - mRNA fluctuations in, **48**, 11
 - Sit4 protein phosphatase in, **48**, 19–20
 - Swi4/Swi6 in, **48**, 13–16
- nutrient signaling pathways, **48**, 9–10
- general advantages as model system, **61**, 134–135, 171
- homologous recombination in, *see* Homologous recombination in *Saccharomyces cerevisiae*
- homologs, **68**, 30
- hydrogen peroxide, **68**, 32
- hyper-recombination mutants, **51**, 278–299
- menadione, **68**, 32
- mitochondrial biogenesis in, *see* Mitochondrial biogenesis in *Saccharomyces cerevisiae*
- OGG1, **68**, 107
- OGG1 gene, **68**, 96, 109
- phospholipid synthesis, overview, **61**, 135–137
- phospholipid turnover, **61**, 137, 139–140
- Saccharomyces cerevisiae*, SPHK and SIP, **71**, 496–497
- Saethre–Chotzen syndrome, *TWIST* mutation, **64**, 191–192
- SAICAR synthetase, purine nucleotide biosynthesis and, **42**, 276–278
- Salivary gland proline-rich protein, *see* Proline-rich protein multigene families
- Salivary glands, Muc4/SMC, **71**, 175
- Salivary glands, of Balbiani ring multigene family, **48**, 278–281
- silk formation, **48**, 281–285
- Salmonella typhimurium*, mutants, isolation, **50**, 296–298
- Salmonid protamines, **40**, 35–36
- SAPKs, *see* Stress-activated protein kinases
- Saposin A
 - function, **66**, 211–212
 - gene, **66**, 211
 - liposome interactions, **66**, 225
 - proteolysis, **66**, 221
 - structure, **66**, 221
- Saposin B
 - function, **66**, 211–212, 221–222
 - gene, **66**, 211
 - membrane interactions, **66**, 232
 - proteolysis, **66**, 221
 - structure, **66**, 221
- Saposin B, activation of hydrolysis, **69**, 88
- Saposin C
 - activation of acid β -glucosidase
 - acid phospholipid interaction, **66**, 225–226
 - mechanism, **66**, 228–229
 - structural analysis of activating segments, **66**, 223–225
 - function, **66**, 211–212, 223
 - fusogenic activity
 - depth of liposome insertion, **66**, 231–232
 - fluorescence analysis, **66**, 230–232
 - function, **66**, 229–230
 - intersaposin interactions, **66**, 232–233
 - gene, **66**, 211
 - neurotogenic activity, **66**, 223–224
 - proteolysis, **66**, 221
 - structure, **66**, 221
- Saposin D
 - function, **66**, 211–212
 - gene, **66**, 211
 - proteolysis, **66**, 221
 - structure, **66**, 221
- Sarcoplasmic reticulum calcium channels, inotropic effects of PDE3 inhibitors, **66**, 262–263
- Satellite sequences, nucleosome positioning and, **40**, 160–162
- SBF, *see* Swi cell cycle box-binding factor
- SBMA, *see* Spinobulbar muscular atrophy
- SC, *see* Synaptonemal complex
- SCA, *see* Spinocerebellar ataxia
- Scaffold attachment region, *see* Karyoskeleton

- Scaffold complexes, RACK1 binding, **69**, 285–286
- Scaffold-directed design, tRNA mimic, **70**, 296–297
- Scanning, HSV-1 microarrays
chips, **71**, 464–465
protocols, **71**, 456–459
- Scanning model, for association of mRNA with ribosome, **48**, 188–189
- Scanning model, translation initiation, **72**, 371–372
- ScAPN2, **68**, 264
- Scavenger-receptor cysteine-rich domains, **70**, 20–21
- Scavenger receptor, macrophage, **50**, 232–233, 257
- SCGE, **68**, 18
- Schizencephaly type II, *EMX2* mutation, **64**, 192
- Schizosaccharomyces pombe*, **68**, 214
DNA ligase, **68**, 153
general advantages as model system, **61**, 134–135, 171–172
meiosis, *see also M26; rec* genes
control of entry, **61**, 348–352
nuclear cytology, **61**, 252–355
overview, **61**, 346–348, 373–374
recombination hotspots, **61**, 355–361
recombination-deficient mutants and genes, **61**, 361–369
region-specific control of recombination, **61**, 369–373
phospholipid synthesis, overview, **61**, 135–137
TDG homologs, **68**, 237
- Schwann cell
axon–glial interactions
bilateral communication, **56**, 235, 248
myelination role, **56**, 235–243
neural crest development, **56**, 227–229
transcriptional regulation
c-Jun, **56**, 246
Krox20, **56**, 243–244
Pax3, **56**, 244–246
SCIP, **56**, 243–244
extracellular matrix, role in peripheral nervous system development, **56**, 233–235
membrane sorting in myelinating cells, **56**, 249
premyelination marker proteins, **56**, 229
regulation
cyclic AMP, **56**, 229–230
Eph, **56**, 233
fibroblast growth factor, **56**, 229
GAS6, **56**, 232
neuregulins, **56**, 230–232
neurotrophins, **56**, 232
transforming growth factor, **56**, 229–230
- Schwann cell, apoptosis regulation by peripheral myelin protein 22, **64**, 121–122
- SCIP, transcriptional regulation in Schwann cells, **56**, 243–244
- SCLC, **67**, 201
- SDS, *see* Sodium dodecylsulfate
- SecA
ATPase activity and function, **66**, 114, 127–128
chaperone substrates, **66**, 111
GroEL binding, **66**, 111
membrane association, **66**, 110
SecG interactions, **66**, 129
SecY interactions, **66**, 127–128
structure, **66**, 114
targeting function
discrimination from signal recognition particle-dependent proteins at ribosome, **66**, 120–121
SecB interactions, **66**, 113–115
signal sequence binding, **66**, 114–115
- SecB
abundance, **66**, 111
chaperone substrates, **66**, 111–113
chaperonin level effect on expression, **66**, 111–112
structure, **66**, 111
targeting function
concerted targeting with signal recognition particle, **66**, 123–124
discrimination from signal recognition particle-dependent proteins at ribosome, **66**, 120–121
SecA interactions, **66**, 113–115
signal sequence binding, **66**, 112–113
- SecD, protein translocation role, **66**, 129–130
- SecE, *see* SecYE translocon
- SecF, protein translocation role, **66**, 129–130
- SecG
integrase function, **66**, 131
SecYE translocon association and translocation role, **66**, 128–129

- Second messenger, degradation, **69**, 250
- Second messengers, in regulation of *Egr-1*, **50**, 199–200
- Secondary response genes, *see* Delayed-early response genes
- Secretogranin III, genetic defects of
mammalian nervous system and, **41**, 250–254
- Secretory phospholipase A2 (sPLA₂)
classification, **67**, 3–4
- Secretory proteins, encoded by Balbiani ring
multigene family, **48**, 281–285
- SecY, *see* SecYE translocon
- SecYE translocon
components and conservation between
species, **66**, 124–125
genetic screens, **66**, 125
integrase function, **66**, 130–131
interactions between SecE and SecY,
66, 126
membrane association, **66**, 110
protein targeting, *see* SecA; SecB; Signal
recognition particle
SecA ATPase energetics, **66**, 127–128
SecE topology, **66**, 126
SecG association and translocation role, **66**, 128–129
- SecY
SecA interactions, **66**, 127–128
signal sequence interactions, **66**, 126–127
topology, **66**, 125
SecYEGDFYajC holocomplex, **66**, 129–130
- Seedling development, jasmonates and
octadecanoids, **72**, 196–197
- Selection, genetic defects of mammalian
nervous system and, **41**, 250–251
- Selective-binding complementary bases, **69**, 38
- Selective-binding complementary
oligonucleotides, **69**, 15
- Selenazofurin, inositol-5'-monophosphate
dehydrogenase inhibition and clinical
applications, **61**, 203
- SELEX, aptamers identified by, **69**, 26
- SELEX, pRNA, **72**, 439–440
- SELEX, *see* Systematic Evolution of Ligands
by Exponential enrichment
- Semliki Forest virus*
26S mRNA synthesis, **71**, 196
nsP1, minus-strand RNA synthesis, **71**, 203
nsP2, neuropathogenicity, **71**, 207–208
nsP2, RNA helicase, **71**, 204–205
nsP3, **71**, 209–210
replication cycle, **71**, 188–190
RNA complementary to genome, **71**, 192–194
- Sendai virus, shunt, **72**, 19–20
- Senescence, jasmonates and octadecanoids, **72**, 202–205
- SenS protein, *Bacillus subtilis* gene expression
and, **46**, 141–142
- Sensitivity
PAP39, to digestion, **69**, 135
rolipram, **69**, 265, 271, 274–279
- SeqA
DNA replication role, **57**, 174–175
synchrony regulation, **57**, 176
- Sequence context-dependent repair
nucleotide excision repair, **68**, 216
- Sequence motif, conservation, **50**, 119–122
- Sequences
alkylation damage repair in genomes and, **44**, 128–129
amino acid, *see* Amino acid sequences
bacterial adenyl cyclases and, **44**, 53–56
calcium-dependent animal lectins and, **45**, 222–225
DNA, amplification in mammalian cells and,
see DNA sequence amplification in
mammalian cells
nuclear RNA-binding proteins and, **41**, 186–187
nucleosome positioning and
ribosomal RNA, **40**, 162–164
satellite, **40**, 160–162
proline-rich protein multigene families
and, **41**, 9–16
tRNA structure and, **45**, 156–159
- Sequences, trp repressor and, **42**, 6, 8, 16–18
- Serglycin
genes, **62**, 30
structure, **62**, 29–30
transcriptional regulation, **62**, 31–32
- Serine
C-terminal domain kinases
phosphorylating, **48**, 169–171
RNA polymerase subunit IIa
phosphorylation, **48**, 147, 149–150
- Serine-accepting tRNAs, **70**, 319–321
- Serine protease, **70**, 7

- Serine protease inhibitor 2.1 (SPI 2.1), growth hormone and promoter responsive elements, **57**, 83, 85, 87
 signal transduction, **57**, 87–89
- Serine/threonine-rich domain, poly A polymerase, **71**, 324–325
- Serine, nsP3 phosphorylation, **71**, 209–210
- Serotonin receptors
 agonist binding site, **49**, 126
 types, **49**, 125–126
- SerRS, tRNA^{Ser} binding, **69**, 332–333
- Serum response element (SRE), **67**, 208
- Serum response elements, in human FGF-1 promoter 1.D, **70**, 167–168
- Serum response factor, autoregulation of promoter, **60**, 153–154
- Serum response factor (SRF), **67**, 208
- Sex-determining factor Y (SRY), **67**, 98
- SFV, *see Semliki Forest virus*
- SGLT1, **67**, 147
- sg/sg* mice, ROR α gene disruption in, **69**, 226–228
- SH3 domains
 interactions among PDE4 isoforms, **69**, 281–284
 PDE4 isoform binding, **69**, 265, 274
- SHEP1, **71**, 422–423
- SH-iPLA₂ β , **67**, 19
- Short open reading frame-dependent shunt
 other initiation events, **72**, 17
 overview, **72**, 12–14
 shunting as reinitiation, **72**, 16
 shunting ribosome initiation, **72**, 15–16
 take-off and landing sites, **72**, 14–15
- Short open reading frames, viral RNA, **72**, 9–10
- Short-patch base excision repair, **68**, 5, 15, 147, 160–161, 167
 8-oxoG, **68**, 99
 nuclear
 common pathway, **68**, 260
 pol beta, **68**, 265, 289–291
 uracil, **68**, 294
- Short-patch mismatch
 thymine DNA glycosylase, **68**, 236–237
- Shr3p
 quality control, **67**, 250
- Shunting
 adenovirus, **72**, 17–19
 animal virus internal initiation combinations, **72**, 21
 cellular mRNAs, candidates, **72**, 21
 eukaryote translation initiation, **72**, 6
 papillomaviruses, **72**, 20–21
 ribosome, translation initiation, **72**, 376–377
 Sendai virus, **72**, 19–20
 sORF-dependent, Caulimoviridae, **72**, 12–17
- Sialidase
 catalytically active conformation, **69**, 103–104
 complex with EBP and cathepsin A, **69**, 98–99
 features and specificity, **69**, 91–92
 mutants, **69**, 104–105
 structure, **69**, 92–93
 synthesis and function, **69**, 93–95
- Sialidosis, dysmorphic and nondysmorphic, **69**, 104–105
- Sickle cell anemia, **67**, 179, 186
- Signal
 bipartite nuclei localization iPLA₂ β , **67**, 14–15
- Signal recognition particle (SRP)
 noncanonical functions in bacteria, **66**, 122–123
 protein targeting to SecYE
 cell-free assay, **66**, 119
 concerted targeting with SecA/SecB, **66**, 123–124
 cotranslational targeting, **66**, 121–123
 discrimination from SecA/SecB-dependent proteins at ribosome, **66**, 120–121
 evidence, **66**, 117–118
 multispinning inner membrane proteins, **66**, 118–120
 signal sequence binding, **66**, 121
 receptor subunits, **66**, 116–117
 ribosome association, **66**, 116–117
 species distribution, **66**, 115–116
 subunits, **66**, 116–117
- Signal transducer and activator of transcription (STAT)
 dimerization, **57**, 81–82
 growth hormone signal transduction by STAT, **57**, 5, 85–86, 89–90
 phosphorylation, **57**, 80–81
 types, **57**, 82

- Signal transduction
Bacillus subtilis gene expression and, **46**, 143–145
 jasmonic acid, **72**, 167–168
 mitochondrial biogenesis in *Saccharomyces cerevisiae* and, **46**, 57–58
 nuclear envelope, **67**, 207
 systemin via jasmonate, **72**, 188
- Signaling function
 iPLA₂ β
 insulin-secreting cells, **67**, 22–23
- Signaling molecules
 cell adhesion
 ankyrin-repeat domains, **67**, 12
- Signaling, neuronal, *Egr-1* induction in, **50**, 197–199
- Signaling pathway
 Ras
 anticancer drug development, **67**, 215–216
 Rho
 anticancer drug development, **67**, 215–216
- Signaling pathways, nodal mitogenic and oncogenic, **69**, 56
- SII, nascent transcript cleavage, **56**, 336–337
- SIHI, *see* Elongin
- Sildenafil, cyclic nucleotide phosphodiesterase inhibition, **65**, 17–18
- Silk formation, salivary gland, Balbiani ring multigene family and, **48**, 281–285
- Simian immunodeficiency virus (SIV)
 base composition of leader RNA, **54**, 25–29
 phylogenetic analysis, **54**, 1–2
- Simian virus 40, DNA replication, **51**, 98–101, 108–109
 origins, initiation at, **51**, 93–95
- Sin protein, *Bacillus subtilis* gene expression and, **46**, 134–136
- SIN, *see* *Sindbis virus*
- Sin3
 histone deacetylase recruitment, **65**, 316
 thyroid hormone receptor corepressor, **65**, 62, 66
- Sindbis virus*
 26S mRNA synthesis, **71**, 196
 nsP3, **71**, 209–210
 nsP4, **71**, 211
 RNA complementary to genome, **71**, 192–194
- Single-nucleotide base excision repair
 vs. long-patch BER, **68**, 58
- Single-nucleotide gap, **68**, 58
- Single-nucleotide patch repair, **68**, 291
- Single-nucleotide polymorphism (SNP)
hMTH1 mRNA, **68**, 79–80
MTH1 gene, **68**, 75
- Single pathway defect mutants
 spontaneous mutator phenotypes, **68**, 33–36
- Single-strand annealing, *see* DNA recombination, *recA*-independent; Homologous genetic recombination
- Single-strand annealing model, *see* Double-strand break-induced recombination
- Single-strand breaks (ssb)
 factories, **68**, 25
 genomic
 comet assay, **68**, 62
 induction, **68**, 18
- Single-stranded DNA-binding proteins, homologous recombination in *Saccharomyces cerevisiae* and, **46**, 254–256
- Single-strand ligation polymerase chain reaction, determination of sequence specificity of DNA-damaging agents, **63**, 373–374, 376
- Single-stranded tethered donor TFOs
 schematic diagram, **67**, 184
- SIP, *see* Sphingosine-1-phosphate
- SIPR, *see* Sphingosine-1-phosphate receptor
- Sister chromatid exchange, formation, resistance to, **51**, 202–203
- Sit4 protein phosphatase, in transcriptional control of G1/S genes in *Saccharomyces cerevisiae*, **48**, 19–20
- Site-directed mutagenesis
COL1A1 gene, **47**, 44–46
 collagen type-II gene, **47**, 55–57
 collagen type-IX genes, **47**, 68
 collagen type-X gene, **47**, 69–70
 monoamine oxidase B
 active site and catalytic residue mutagenesis, **65**, 148–149
 flavin-binding sites
 covalent-binding site, **65**, 147–148
 dinucleotide-binding site, **65**, 136–137, 140

- Site-directed mutagenesis (*cont.*)
 fingerprint site, **65**, 144–147
 overview, **65**, 135
 second flavin adenine dinucleotide-binding site, **65**, 141–144
 table of mutants, **65**, 139
 target selection, **65**, 135–136, 141
 transient transfection system, **65**, 136
- PDE5 catalytic residues, **65**, 12–13, 30
 squalene synthase catalytic residues
 acidic residues in section B, **65**, 173–174
 aromatic residues in sections A and C, **65**, 169–170, 172–173
 Asp-219, **65**, 174
 Asp-223, **65**, 174
 Phe-286, **65**, 172–173
 Phe-288, **65**, 172–173
 thioredoxin fusion proteins, **65**, 169
 Tyr-171, **65**, 170, 172
 Tyr-174, **65**, 170
- Site-directed mutagenesis, *nrdD* protein, **72**, 101–103
- Skeletal muscle, AMPK-activated gene expression, **71**, 77
- Skp, outer membrane protein chaperone, **66**, 140
- SL1, *see* TIF-IB/SL1
- Slug formation, *Dictyostelium discoideum*, **47**, 13–15
- Small cell lung cancer (SCLC), **67**, 201
- Small-molecular-weight G protein guanine nucleotide-dissociation stimulator, **71**, 423–425
- Small nucleolar RNA
 characteristics, **49**, 209–210
 role in rRNA processing, **49**, 210, 212–213
 size, **49**, 210–210
- Smeared signal, protamines and, **40**, 53
- SmgGDS, *see* Small-molecular-weight G protein guanine nucleotide-dissociation stimulator
- SMRT, thyroid hormone receptor
 corepressor, **65**, 62, 65
- Sms protein, homology with RecA, **56**, 172
- SNAIGE concept
 antisense oligonucleotides and, **44**, 145–146
 limitations, **44**, 148–153
 synthetic ribozymes, **44**, 147–148
 triple helix, **44**, 145, 147
 sense oligonucleotides and, **44**, 148
- Snake toxin, *see also* Phospholipase A₂, snake venom; Three-fingered fold
 classification, **59**, 310
 protein folds, **59**, 310–311
 species producing toxins, **59**, 309
 structural overview, **59**, 308, 310
- SNF1, *see* Sucrose nonfermenting-1 complex
- SNP
hMTH1 mRNA, **68**, 79–80
MTH1 gene, **68**, 75
- snRNA
 –exon hybrid snRNP, **50**, 136
 regeneration, **50**, 156
 U1 and U2, **50**, 139–143
 U1 departure, **50**, 146
 U2, U4, U5, and U6, **50**, 146–150
 U2.U6 helix Ia, **50**, 153–154
 U4 and U6, extensive interaction, **50**, 143–145
 U5, interaction with second exon, **50**, 151–153
- SnRNP
 3' end-processing complexes, **71**, 304
 CPSF, **71**, 314–315
- snRNP, *see* Ribonucleoprotein particles, small nuclear
- SOD1, *see* Superoxide dismutase
- SOD1, induction by copper, **58**, 171, 174, 186
- Sodium channel
 amiloride-sensitive
 ankyrin-repeat domains, **67**, 12
- Sodium-dependent D-glucose cotransporter (SGLT1), **67**, 147
- Sodium dodecylsulfate, effects on
 multicatalytic proteinase, **49**, 30
- Sodium ion pump, methanogenic archaea, **71**, 259–261
- SOF1 protein, role in RNA processing, **49**, 221
- Somatic mosaicism, in osteogenesis
 imperfecta, **47**, 43
- sORF, *see* Short open reading frames
- Sos1, **71**, 405–407
- Sos2, **71**, 405–407
- SOX9, mutation in campomelic dysplasia, **64**, 186
- SP1 transcription factor, binding to HIV LTR, **49**, 167–168
- Spacer length, AlcR-regulated promoter targets, **69**, 161
- SPB, *see* Spindle pole body

- spc* operon, **47**, 353–355
- Specificity
- AlcR DNA binding, **69**, 160–164
 - GALNS, **69**, 95–96
 - sialidase, **69**, 91–92
 - versus* affinity, antisense oligomer, **69**, 16–18
- Spermatogenesis, cyclic AMP-responsive element modulator regulation
- ACT protein, role in CREM activation, **64**, 361–363
 - germ cell expression levels, **64**, 358–360
 - haploid gene expression regulation, **64**, 360–361
- Spermatogenesis, protamines and, **40**, 58–60, 86
- intercellular bridges, **40**, 61
 - post-transcriptional mechanisms, **40**, 61–64
 - timing, **40**, 60–61
 - transcription, **40**, 64–68
- Spermiogenesis, protamines and
- chromatin structure, **40**, 68–70
 - protein modifications, **40**, 71–83
- Sphingosine-1-phosphate
- function in mammalian cells, **71**, 497–498
 - plants, **71**, 497
 - pleiotropic functions, **71**, 494–495
 - yeast, **71**, 495–497
- Sphingosine-1-phosphate receptor, **71**, 494–495
- Sphingosine kinase
- activation, **71**, 498–499
 - cloning, **71**, 500–503
 - mammalian cells, **71**, 497–498
 - phylogenetic analysis, **71**, 508
 - plants, **71**, 497
 - SPHK family, **71**, 503–504
 - SPHK superfamily domains, **71**, 504–508
 - yeast, **71**, 495–497
- SPHK, *see* Sphingosine kinase
- SPI 2.1, *see* Serine protease inhibitor 2.1
- Spindle pole body, reorganization in
- meiosis, **61**, 352
- Spindle pole body, satellite, formation in G1
- phase of yeast cell cycle, **48**, 3
- Spinobulbar muscular atrophy (SBMA), trinucleotide repeat expansion, **66**, 163, 166, 187
- Spinocerebellar ataxia (SCA), trinucleotide repeat expansion, **66**, 161–163, 166, 168–169
- SPLA₂
- classification, **67**, 3–4
- Spliceosome
- and RNA–RNA interactions, **50**, 143–146
 - assembled, **50**, 150–151
 - built of snRNPs, **50**, 134–136
 - RNA, in cross-linking, **50**, 138–139
- Splicing
- alternative, **50**, 239–246
 - catalytic steps, **50**, 146–150
 - complexes, early, **50**, 141–142
 - general features, **50**, 132–136
 - modified nucleotides in, **50**, 154–156
 - RNA–RNA interactions in, **50**, 137–138
- trans*-splicing, **50**, 136
- Splicing, intron, in monocots, *see* Intron splicing in monocots
- Spondyloepiphyseal dysplasia congenita, collagen type-II gene mutations, **47**, 51–53
- Spontaneous mutator phenotypes
- single and double pathway defect mutants, **68**, 33–36
- Spontaneous recombination
- mutation rates, **68**, 35
- spoO* genes, *Bacillus subtilis* gene expression and, **46**, 143–145
- Sporadic endocrine neoplasia, G protein mutations, **47**, 100
- Sporulation, *Bacillus subtilis* gene expression and, **46**, 143–146
- SpRad3p, cell cycle control, **72**, 77
- SQS, *see* Squalene synthase
- Squalene synthase (SQS)
- assay, **65**, 169
 - deletion studies of catalytic domain, **65**, 168
 - dietary effects on levels, **65**, 161–162, 177–179
 - domains, **65**, 166–168
 - functional overview, **65**, 158–159
 - genes
 - cloning, **65**, 164
 - loci, **65**, 174
 - structure, **65**, 164, 174, 176, 180–181 - historical perspective of research, **65**, 159, 161
 - hydropathy analysis, **65**, 167–168
 - interleukin-1 regulation, **65**, 190–191
 - lipopolysaccharide regulation, **65**, 189–191
 - messenger RNA

- Squalene synthase (SQS) (*cont.*)
 organ distribution, **65**, 176–177
 sizes, **65**, 176
 sterol effects on levels, **65**, 179
 physiological significance of regulation, **65**, 178
 purification of rat liver enzyme
 column chromatography, **65**, 162
 dietary induction, **65**, 161–162
 microsome preparation, **65**, 162
 size, **65**, 162–163
 reaction mechanism, **65**, 158, 166
 sequence alignment of mammalian enzymes, **65**, 164–167
 site-directed mutagenesis of
 catalytic residues
 acidic residues in section B, **65**, 173–174
 aromatic residues in sections A and C, **65**, 169–170, 172–173
 Asp-219, **65**, 174
 Asp-223, **65**, 174
 Phe-286, **65**, 172–173
 Phe-288, **65**, 172–173
 thioredoxin fusion proteins, **65**, 169
 Tyr-171, **65**, 170, 172
 Tyr-174, **65**, 170
 species-specific functional domains, **65**, 168–169
 sterol regulatory element binding protein
 regulation
 accessory transcription factor binding sites, **65**, 181, 185
 reporter assays of binding specificity, **65**, 185–187
 scanning mutagenesis of promoter, **65**, 183, 185
 SREBP-1a
 accessory transcription factor requirements, **65**, 188–189
 binding element specificity, **65**, 185–187
 nonhuman promoter specificity studies, **65**, 189
 promoter mutation studies of binding, **65**, 187–189
 sterol depletion studies, **65**, 189
 SREBP-2
 accessory transcription factor requirements, **65**, 188–189
 binding element specificity, **65**, 185–187
 nonhuman promoter specificity studies, **65**, 189
 promoter mutation studies of binding, **65**, 187–189
 sterol regulatory elements, **65**, 181
 truncation analysis of promoter, **65**, 181–183
 subcellular localization, **65**, 163–164
 therapeutic targeting, **65**, 159
 tumor necrosis factor- α regulation, **65**, 190–191
 SRC-1, *see* Steroid receptor coactivator-1
 SRC-1, thyroid hormone receptor coactivator, **65**, 62–63
 SRCR domains, *see* Scavenger-receptor cysteine-rich domains
 SRE, **67**, 208
 SREBP, *see* Sterol regulatory element binding protein
 SRF, **67**, 208
 SRF, cell cycle control in mice, **58**, 66–67
 SRF, *see* Serum response factor
 SRP, *see* Signal recognition particle
 SRY, **67**, 98
 Ssb
 factories, **68**, 25
 genomic comet assay, **68**, 62
 induction, **68**, 18
 SSRP1, **67**, 97, 98
 ST2/T1, identification as immediate-early response gene, **58**, 55, 57
 Stalk cells, *Dictyostelium discoideum*, differentiation ammonia effects, **47**, 21
 cAMP-dependent protein kinase role, **47**, 19–20
 extracellular cAMP effects, **47**, 21–22
 START phase, in yeast cell cycle, **48**, 3
 regulatory network operating at, **48**, 21–24
 Starvation, pyruvate dehydrogenase kinase effects, **70**, 53–54
 STAT, cytokine signaling, **56**, 113, 291
 Staurosporine, inhibition of topoisomerase II, **64**, 242–243
 Ste11, control of entry into meiosis, **61**, 349–350
 Stem cells, adult neural, genesis, **70**, 171
 Stem-loop structures, **69**, 31–33, 39
 anticodon, **69**, 344

- Sterility, protamines and, **40**, 86
- Steroid hormones, gene expression and, **43**,
1–3, 30–31
- antagonists, **43**, 27–30
- DNA sequences, **43**, 3–6
- induction, **43**, 15–17
- negative action, **43**, 20–26
- receptor–DNA interaction, **43**, 6–10
- receptor structure, **43**, 10–15
- repression of action, **43**, 26–27
- transcription factors, **43**, 17–20
- Steroid receptor
- chromatin involvement in gene regulation by
receptors
- bimodal model for receptor function, **66**,
284–286
- differential expression from transient and
replicated templates, **66**, 286–288
- dynamics of glucocorticoid receptor
interactions, **66**, 296
- glucocorticoid receptor-dependent
transition, molecular characterization
- higher-order structure transitions, **66**,
295–296
- model systems, **66**, 288–290
- multiple nucleosome frames,
66, 292–294
- nucleosome mapping, **66**, 290–292
- transition regions defined by hormone
response elements, **66**, 294–295
- histone acetyl transferases and
- deacetylases as receptor coactivators
and repressors, **66**, 285–286
- kinase cascades, **66**, 288
- nuclear factor 1 binding, **66**, 282–285,
298, 300
- protein–protein interaction model,
66, 281–282
- template-dependent signaling
- cross-talk, **66**, 288
- mouse mammary tumor virus
- differential access of transcription
factors to long terminal repeat, **66**,
282–285
- glucocorticoid receptor model system, **66**,
284–285, 288–290
- progesterone receptor model system,
66, 287
- protein expression regulation by
receptors, **66**, 280–281
- regulatory element identification, **66**,
280–281
- trafficking
- gene targeting
- accessory factors, **66**, 299–300
- dynamic imaging, **66**, 299
- footprinting studies, **66**, 298
- model, **66**, 301
- site occupancy measurements,
66, 298–299
- green fluorescent protein tagging, **66**,
297, 299
- subcellular trafficking, **66**, 297–298
- thyroid hormone receptor, **66**,
297–298, 301
- Steroid receptor coactivator-1, ROR
cofactor, **69**, 217–222
- Steroid receptor, *see also* Androgen receptor;
Estrogen receptor; Glucocorticoid
receptor; Progesterone receptor
- gene structure
- DNA binding domain, **59**, 290–291
- overview, **59**, 290
- steroid binding domain, **59**, 291
- transcription
- autoregulation, **59**, 303–304
- enhancers, **59**, 291
- suppressors/repressors, **59**, 292–293
- trans-acting factors, **59**, 291–292
- Sterol regulatory element binding protein
(SREBP)
- accessory factors, **65**, 180
- biosynthesis, **65**, 180
- squalene synthase gene regulation
- accessory transcription factor binding
sites, **65**, 181, 185
- reporter assays of binding specificity, **65**,
185–187
- scanning mutagenesis of promoter, **65**,
183, 185
- SREBP-1a
- accessory transcription factor
requirements, **65**, 188–189
- binding element specificity, **65**,
185–187
- nonhuman promoter specificity
studies, **65**, 189
- promoter mutation studies of
binding, **65**, 187–189
- sterol depletion studies, **65**, 189

- Sterol regulatory element binding protein (SREBP) (*cont.*)
- SREBP-2
 - accessory transcription factor requirements, **65**, 188–189
 - binding element specificity, **65**, 185–187
 - nonhuman promoter specificity studies, **65**, 189
 - promoter mutation studies of binding, **65**, 187–189
 - sterol regulatory elements, **65**, 181
 - truncation analysis of promoter, **65**, 181–183
 - sterol regulatory element features, **65**, 179–180
 - target genes, **65**, 179
 - types, **65**, 180
- Stickler syndrome, collagen type-II gene mutations, **47**, 53–54
- Stigmatella*, **67**, 68
- Stimulon, defined, **55**, 3
- Stoichiometry, LMC, **69**, 97–98
- Stop codon, *see* Translational stop signal
- Stop–start sequence, insertion, **69**, 324
- Storage products
 - G_{M1}-gangliosidosis, **69**, 100
 - galactosialidosis, **69**, 102
- Storage protein genes, rice, **45**, 7–9
- str* operon, **47**, 362–363
- Strand break-based assays, **68**, 140
- Strand cleavage, *see also trans* cleavage
 - by Flp, **51**, 69
 - chemistry, **51**, 74–75
- Strand exchange
 - Holliday intermediate, **51**, 75–76
 - topological studies, **51**, 76–77
- Strand exchange assay, nucleic acid chaperone proteins, **72**, 237–239
- Strand ligation
 - and polymerase switching, **51**, 109
 - assay and chemistry, **51**, 77–81
- Strand transfer, RT fidelity, **71**, 109–110
- Streptolysin O, antisense oligonucleotide delivery, **57**, 110
- Streptomycetes, chromopeptide lactones, **70**, 244–246
- Stress-activated protein kinases
 - overview, **71**, 78–81
 - preproinsulin gene expression, **71**, 81–82
- Stress regulation, mitochondrial biogenesis in *Saccharomyces cerevisiae* and, **46**, 70–71
- Stress response, *see* Endoplasmic reticulum stress response; Heat shock response
- Stress, effects on intron splicing, **47**, 186–188
- Stress, lens protein and, **41**, 267–269
- Stressed cells, FGF-2 isoforms, **72**, 390–391
- Stromelysin-3, intestinal development role in amphibians
 - apoptosis association, **65**, 86–87, 89
 - developmental expression pattern, **65**, 86
 - substrates, **65**, 89–90
- Structural domains
 - retron reverse transcriptase, **67**, 81
- Structural genes, nucleosome positioning and, **40**, 164–167
- Structural proteins, 26S mRNA, **71**, 196–197
- Structure–function analysis, Egr-1, **50**, 210–216
- Structure–function relationship, CreA, **69**, 177–178
- Structure–function relationships, EF-Tu catalytic domain 1, **71**, 524
- magnesium coordination network, **71**, 527–529
 - nucleotide-binding pocket, **71**, 525–527
 - regulatory domains 2 and 3, **71**, 525
- Structure-specific recognition protein 1 (SSRP1), **67**, 97, 98
- Sty*LT1
 - discovery, **64**, 48
 - gene cloning, **64**, 48
 - subunits, **64**, 48–49
- Subacute scleroting panencephalitis, latent viruses and mutated oncogenes and, **43**, 154–155
- Subcellular localization
 - AlcR, **69**, 165–166
 - Mig1p, **69**, 178
- Substance P, *see* Tachykinin receptors
- Substrate channeling, UMP synthase, **53**, 69–71
- Substrate specificity
 - 5'-to-3' exonuclease, **51**, 107–108
 - alkyltransferase, **51**, 191–194
 - UGT1-encoded isoforms, **51**, 327–328
- Substrate specificity, branched chain aminotransferases enzymes, **70**, 181–183

Substrates

ALDH, physiological inducers of *alc* gene system, **69**, 173–174

for PRPP synthetase reaction, **69**, 128–130

Substrates, protein tyrosine kinase, *see* Protein tyrosine kinase substrates

Subtilisin

structure homology with prohormone

convertases, **63**, 103

unproductive cleavage of

cysteine-substituted proenzyme, **63**, 91

Succinate:quinone oxidoreductase

anchor protein sequence conservation, **60**, 301, 303

assembly

cofactor requirements, **60**, 308–309

mutant analysis, **60**, 304–307

order of component assembly, **60**, 304

substitution of sequences between species, **60**, 306–308

cofactors, **60**, 271

eukaryotic genes

cloning and characteristics

flavoprotein subunit gene, **60**, 278–279

iron–protein subunit gene, **60**, 279–282

membrane anchor protein genes, **60**, 282–283

regulation in *Saccharomyces cerevisiae*

overview, **60**, 285

posttranscriptional control, **60**, 287–288

signal transduction pathway in

messenger RNA turnover, **60**, 288–291

transcriptional control, **60**, 285–287

regulation in animal cells

fibroblasts and myoblasts, **60**, 293–295

iron-responsive element in *Drosophila melanogaster*, **60**, 295–297

mitochondrial protein involvement, **60**, 295

nuclear respiratory factors for

transcriptional activation, **60**, 291–292, 294

translocation of nuclear genes, **60**, 292–293

types and organelle location, **60**, 275–276, 291

flavoprotein sequence conservation, **60**, 301–302

histochemical assay, **60**, 309

iron–sulfur cluster

localization, **60**, 273

sequence comparison between species, **60**, 297–301

mutations causing activity alterations

cultured cells, **60**, 276–277

human patients, **60**, 277–278

Ustilago maydis, **60**, 278

peptide components, **60**, 267, 270–271

prokaryotic genes and expression, **60**, 273–274

sequence analysis, **60**, 297, 301

structure, **60**, 271–273

Sucrose nonfermenting-1 complex, glucose repression in yeast, **71**, 71

SUF5, frameshift suppressor transfer RNA, **64**, 165

sufA6, frameshift suppressor transfer RNA, **64**, 137, 140

sufB2, frameshift suppressor transfer RNA mutants, **64**, 144–146, 163

sufD42, frameshift suppressor transfer RNA, **64**, 136–137

suff128, frameshift suppressor transfer RNA, **64**, 140

sufT621, frameshift suppressor transfer RNA, **64**, 14

Sugar, calcium-dependent animal lectins and, **45**, 220–222

Sugar transport, bacterial adenyl cyclases and, **44**, 36–41

Suicide substrate

BEL

iPLA₂ β , **67**, 22

SUN2, multicopy suppression of casein kinase yeast mutants, **59**, 107–109

Superoxide, **68**, 76Superoxide dismutase, **68**, 76

Superoxide dismutase

incidence in amyotrophic lateral sclerosis, **61**, 16–17

role in neurofilament accumulation, **61**, 18

toxicity of mutations, **61**, 17–18

Superoxide dismutases, **40**, 248

cellular regulation

inductions, **40**, 242–245

mutant phenotype, **40**, 245–246

regulons, **40**, 246–248

dangers of substrate superoxide, **40**, 222–224

- Superoxide dismutases (*cont.*)
 DNA damage, **40**, 238–239
 enzymatic repair, **40**, 240–242
 prevalence, **40**, 242
 products, **40**, 239–240
 history, **40**, 221–222
 varieties, **40**, 224–225
 catalytic mechanism, **40**, 236–237
 copper, **40**, 225
 evolution, **40**, 230–235
 iron, **40**, 225–230
 manganese, **40**, 225–230
 reactions with H_2O_2 , **40**, 237–238
 reversible resolution, **40**, 234, 236
 X-ray crystallography, **40**, 226–230
 zinc, **40**, 225
- Suppression of proliferation, protamines
 and, **40**, 87
- SurA, outer membrane protein chaperone, **66**,
 140–141
- Survival factors, related FGF-2 isoform, **72**,
 386–387
- SV40
 DNA
 transfection, **68**, 236
 SV40 large T antigen, ribosomal gene
 transcription regulation, **62**, 136–137
 SV40, *see* Simian virus 40
 SV40, UL9 comparison, **70**, 100
 Swi cell cycle box-binding factor, yeast, **72**,
 48–49
 Swi4 protein, in transcriptional control of G1/S
 genes in *Saccharomyces cerevisiae*, **48**,
 13–16
swi5, recombination-deficient mutants of
Schizosaccharomyces pombe, **61**,
 368–369
 Swi6 protein, in transcriptional control of G1/S
 genes in *Saccharomyces cerevisiae*, **48**,
 13–16
 Swi6, repression of meiotic recombination, **61**,
 372–373
 Switch mechanism
 multiple BER pathways, **68**, 3–25
 Symbiosis, syntrophy-based, mitochondria, **70**,
 122–123
 Synapsis, FRT sites, for recombination, **51**,
 68–69
 Synaptic proteins
 ankyrin repeats, **67**, 11
- Synaptonemal complex
 linear elements in *Schizosaccharomyces*
pombe, **61**, 353–354
 meiosis role, **61**, 353–355
 structure, **61**, 353
- Syndactyly type II, *HOXD13* mutation, **64**,
 188–189
- Syndecan-1
 constitutive expression, **63**, 113–114
 functions, **62**, 21–22
 epithelial morphology maintenance, **63**,
 111–112
 fibroblast growth factor action
 modification, **63**, 112–113, 133–134
 gene structure in mouse, **63**, 118
 genes, **62**, 22
 growth factor regulation of expression
 fibroblast growth factor-inducible
 response element
 autoregulatory loop between fibroblast
 growth factors and syndecan-1, **63**,
 133–134
 cell specificity of regulation,
 63, 123–124
 cross-linking with binding proteins,
 63, 121
 developmental regulation, **63**, 130–131
 discovery, **63**, 118–120
 DNase I footprinting studies,
 63, 120–121
 keratinocyte activation in wound
 healing, **63**, 124–127, 130–132
 mutagenesis of protein-binding
 sites, **63**, 124
 specificity for fibroblast growth factors
 and mechanisms, **63**, 121–122,
 128–130
 transcription factor antibodies in
 gel retardation assays, **63**, 121
 inducers and cell types, **63**, 115–116
 levels of regulation, **63**, 116, 118
 inducible expression, overview, **63**, 114–115
 structure, **63**, 110–111
 transcriptional regulation
 fibroblast growth factor-2, **62**, 26–27
 posttranscriptional control, **62**, 23, 25
 promoter elements, **62**, 23
 transcription factors, **62**, 22–23
 transforming growth factor β , **62**, 25–26
 wound healing, **62**, 25

WT1 activation, **62**, 27
 WT1 binding to promoter, **63**, 118
 Syndecan-4
 functions, **62**, 21
 genes, **62**, 22, 29
 structure, **62**, 28
 tissue distribution, **62**, 28
 transcriptional regulation, **62**, 29
 Synergism, between AlcR targets, **69**, 185
 Synergistic lethality, yeast mRNA 3'
 end-processing factor genes, **71**, 359
 Synpolydactyly, *HOXA13* mutation, **64**, 189
 Synthesis-dependent strand-annealing model,
 see Double-strand break-induced
 recombination
 Synthetases, recognition of tRNA by, *see* tRNA,
 recognition of
 System A
 amino acid regulation, **53**, 230–232
 amino acid transport, **53**, 227–228
 repressor protein, **53**, 228–230
 Systematic Evolution of Ligands by
 Exponential enrichment (SELEX)
 antisense oligonucleotide sequence
 optimization, **57**, 101
 oligonucleotide ligand for protein,
 identification, **57**, 104–105,
 125–126
 Systematic evolution of ligands by exponential
 enrichment, *see* SELEX
 Systemic wound response, jasmonates, **72**, 189
 Systemin, jasmonates, **72**, 187–188

T

tis genes, *see* Phorbol-induced primary
 response genes
 T antigen, transgenic mouse tumors, **70**,
 170–171
 T cell receptors
 gene rearrangements, **69**, 231–232
 PDE4B2 phosphorylation induced by, **69**,
 297–298
 T cell, cytokine production, **56**, 110
 T cells
 from ROR γ 2 mice, **69**, 237–238
 sialidase in, **69**, 94–95
 T04c10
 comparison of N and C termini, **62**, 8

 conserved residues and motifs with
 Dyrkrelated kinases, **62**, 4–7
 DH-box, **62**, 9–10
 phylogenetic analysis with other kinases, **62**,
 10–12
 YxY motif in activation loop, **62**, 7–8
 T3R, *see* Thyroid hormone receptor
 T4 dNTP synthetase, DNA precursor
 biosynthesis and, **44**, 177–181
 T4 endonuclease VII, DNA adduct
 recognition, **71**, 21
 T4 late genes, prokaryotic transcriptional
 enhancers and, **43**, 116–125
 T4, *see* Bacteriophage T4
 T4, *see* Bacteriophage T4; DNA
 polymerase, T4
 Tachykinin receptors
 antagonists, **49**, 127, 129
 binding site, **49**, 127, 129
 types, **49**, 127
 TAFs, *see* TATA-binding protein-associated
 factors
 Tag
 Escherichia coli, **68**, 191
 Tail proteins
 gp16, pRNA interaction, **72**, 448
 gp9, pRNA DNA-filled capsid departure,
 72, 450
 Tallimustine, DNA sequence specificity, **63**,
 382, 398–399
 Tallysomyicin
 DNA cleavage site specificity, **49**, 333
 structure, **49**, 334
 TANDEM, DNA sequence specificity of
 damage, **63**, 383, 402
 TAP
 MHC1, **67**, 260–263
 Tapasin
 MHC1, **67**, 260–263
 quality control, **67**, 251
 TAR, *see* Transactivation response element
 Targeted knockouts, RORs, **69**, 226–236
 Targeting
 intracellular
 PDE4 isoforms, **69**, 279–288
 PDEs, **69**, 258–261
 particulate, PDE4 isoforms, **69**,
 284–285
 recombination, **50**, 93–94
 switch recombination, **50**, 86

- Tat protein
 association
 cellular factors, **49**, 181–182
 oligonucleotide binding proteins, **49**, 181
 binding of long-terminal-repeat element, **49**, 158, 168, 171–172, 178–180
 cellular localization, **49**, 177
 conformational changes on binding, **49**, 178
 effect of interferon-, **49**, 176
 inhibitors in HIV therapy, **49**, 184
 mechanism of action, **49**, 171–172, 180
 site-directed mutagenesis, **49**, 177–178
 structure, **49**, 177–178
- Tat, *see* Twin-arginine translocation
- TATA-binding protein
 autoregulation of promoter in yeast, **60**, 140–142
 CREB CAD interactions, **72**, 280
 functions, **60**, 137
 Mg²⁺ agarose gel system, **72**, 289–290
 NotI competition for promoters, **62**, 316–317
 TAF complexes in RNA polymerase I
 promoter recognition, **62**, 118–119, 128–129, 136
 TBPf regulation of promoter
 Acanthamoeba, **60**, 137–138, 141
 mechanism, **60**, 138–139
 promoter strength, **60**, 139–140
- TATA-binding protein (TBP), **67**, 98, 194
 cisplatin, **67**, 114–115
- TATA-binding protein-associated factors
 CAD:TAF in transcription activation, **72**, 291–292
 CREB CAD interactions, **72**, 280–281
- TATA-binding protein, access to nucleosomal DNA, **61**, 401–402
- TATA binding protein, C-terminal domain
 interaction, **48**, 161–162
- TATA-binding protein, DNA adduct
 recognition, **71**, 18
- TATA box
 modulatory factors, **49**, 169
 role in HIV gene expression, **49**, 168–170
- TATA box binding protein,
 in RPOI, **50**, 35–42
- TATA promoter element, flexibility, **47**, 242–243
- TAV, *see* Transactivator/viroplasma protein
- Tay–Sachs disease, **69**, 92
- TBE, *see* Telomere-bearing element
- TBP, **67**, 98, 194
 cisplatin, **67**, 114–115
- TBP, *see* TATA-binding protein
- TBX3, mutation in ulnar–mammary syndrome, **64**, 189
- TBX5, mutation in Holt–Oram syndrome, **64**, 188
- TCA cycle, *see* Tricarboxylic acid cycle
- TCP80, translational regulation of acid β -glucosidase, **66**, 209–210
- TCR, **68**, 95
 8-oxoG
 AAS CHO cells, **68**, 100–102
 OGG2, **68**, 202
- TDG. *See* Thymine–DNA glycosylase
- TE domains, *see* Thioesterase domains
- TEA promoter, regulatory role of ROR γ , **69**, 232
- Tec, *see* Transposon
- Telomerase, DNA adduct effects, **71**, 23
- Telomere-bearing element (TBE), *see* Transposon
- Telomere, chromosome pairing in meiosis, **61**, 353
- Telomere shortening
 cisplatin, **67**, 112–114
- Telomeres, nucleosome positioning and, **40**, 167–168
- Template strand, HIV-1 RT, **71**, 121–123
- TenA protein, *Bacillus subtilis* gene expression and, **46**, 142
- Tendril coiling, jasmonates and octadecanoids, **72**, 202
- TenI protein, *Bacillus subtilis* gene expression and, **46**, 142
- Teniposide, DNA sequence specificity, **63**, 382, 397
- Termination
 cDNA synthesis, **67**, 77–80
- Terminators, of transcription, **50**, 52–54
- Tetracycline, **67**, 152–153
- Tetradecanoyl phorbol acetate-induced
 sequence genes, *see* Phorbol-induced
 primary response genes
- Tetrahydrofolate cofactors, **67**, 133–134
- Tetrahydrofuran, **68**, 11
 structure, **68**, 8
- Tetrahyromethanopterin, methanogenesis, **71**, 228–232, 234–235

- Tetraplatin, DNA sequence specificity, **63**, 378, 385
- TFC, *see* Thyroid follicular cell
- TFIIB, binding of RNA polymerase II to
TFIID–core promoter complex, **56**, 330
- TFIIB, *see* Transcription factor IIB
- TFIID
DNA binding, **56**, 329–330
preinitiation complex assembly, **56**, 328–330
- TFIID transcription factor complex, **47**, 240–243
- TFIIE, preinitiation complex formation and activation, **56**, 332–333
- TFIIF
assembly of active preinitiation complex, **56**, 330–332
elongation activity, **56**, 337–338
structure, **56**, 331
- TFIIF, *see* Transcription factor IIF
- TFIIH
ATPase, **56**, 334
helicase activity, **56**, 333–334
kinase activity, **56**, 334–335
preinitiation complex formation and activation, **56**, 332–335
- TFIIIA, access to nucleosomal DNA, **61**, 402–406
- TFIIIA, autoregulation of promoter, **60**, 142
- TFIIIA, 5s rRNA gene binding effects on DNA photodamage, **62**, 233, 235, 237
- TFIIIA transcription factor, structure, **47**, 227–233
- TFOs. *See* Triplex forming oligonucleotides
- TGF α , *see* Transforming growth factor α
- TGF β , *see* Transforming growth factor β
- 3' end processing
mRNA, polyadenylation, **71**, 298–299, 347–349
polyadenylation, coupled transcription, **71**, 297–298
snRNP role, **71**, 304
yeast mRNA
CFI complex, **71**, 354
CFII complex, **71**, 355–356
conditional mutants, **71**, 358–359
genetic approaches, **71**, 359
mammalian homologs, **71**, 361–362
overview, **71**, 353–354
PF1 fraction, **71**, 356–357
synergistic lethality, **71**, 359
two-hybrid system, **71**, 360–361
- TGF, *see* Transforming growth factor
- TGN, *see* Trans-Golgi network
- TGPase-activating proteins (GAPs), **67**, 194
- TH, *see* Thyroid hormone
- Thalassemia
globin gene mutations, **57**, 262, 261–263
therapy, **57**, 283–284
- Thalassemia, **67**, 179
- Thapsigargin, effect on protein translation, **58**, 94–95, 98–99, 101
- Thermodynamic stability, triple-stranded complexes, **69**, 20
- Thermodynamics
kissing complexes, **69**, 35–37
oligonucleotide invasion of RNA structures, **69**, 10–12
- Thermodynamics, RNA misfolding, **72**, 228
- Thermus aquaticus*, **68**, 339
- Thiazole-containing chromopeptides, **70**, 249
- Thiazole-containing peptide assembly systems, **70**, 274–277
- Thiazole, ring biosynthesis
bleomycin, **70**, 277–279
epothilone, **70**, 279–281
myxothiazole, **70**, 281–282
- Thiazolidine, ring formation mechanisms, **70**, 274–277
- Thioesterase domains, nonribosomal peptide synthetases, **70**, 239–240
- Thiolation domains, nonribosomal peptide synthetases, **70**, 238
- Thiostrepton, rRNA-binding, **69**, 4
- ThioTEPA, DNA sequence specificity, **63**, 379, 388
- 4-Thiouridine
as sensor for near-UV light, **50**, 294–296
synthesis in position, **50**, 8, 293–294
- 2-Thiouridine, modification effect on conformation and dynamics, **53**, 117–119
- Three-dimensional structure
nrdD protein, **72**, 103–106
pRNA, **72**, 440–443
- Three-fingered fold
functional diversity engineering, **59**, 353
functional site identification
chemical modification studies, **59**, 348–350
comparison of curare-mimetic toxin and fasciculin sites, **59**, 351, 353

- Three-fingered fold (*cont.*)
 dendroaspin, **59**, 353
 erabutoxin a, **59**, 350–351
 fasciculin, **59**, 351
 mutagenesis studies, **59**, 350–351
 toxin α , **59**, 348–350
 toxin γ , **59**, 348–350
 X-ray crystallography, **59**, 351
 nontoxic protein examples, **59**, 354–355
 receptor specificity, **59**, 343–344
 snake toxins
 complementary DNA
 evolutionary analysis, **59**, 345,
 348, 356–357
 sequence homology, **59**, 344–345
 structures, **59**, 339–341
3G, arginine methyltransferase, **61**, 78
Threonine
 C-terminal domain kinases
 phosphorylating, **48**, 169–171
 RNA polymerase subunit IIa
 phosphorylation, **48**, 149–150
L-Threonine, degradation, **69**, 168
Threonine, nsP3 phosphorylation, **71**,
 209–210
Thromboxane-A synthase, **45**, 86–87
Thymidine kinase
 cloning of MT3-binding proteins, **53**,
 210–212
 promoter, MT2 region
 binding
 E2F complexes, **53**, 204–208
 Yi complexes, **53**, 208–210, 213–214
 DNase I footprinting, **53**, 203
 transcriptional regulation and late G1
 events, **53**, 202–204
Thymidylate synthase, **67**, 134–135
Thymidylate synthase, 5,6-dihydropyrimidine
 adducts and, **42**, 134–144
Thymidylate synthase mRNA, translation, **48**,
 203–204
Thymine, **68**, 209
Thymine-DNA glycosylase (TDG), **68**, 134,
 191, 235–251, 377–378
 biochemistry, **68**, 241–246
 biology, **68**, 246–251
 damaged pyrimidine bases, **68**, 249–250
 EMSA, **68**, 242
 enzymatic activities, **68**, 241–243
 evolutionary conservation, **68**, 238–239
 G-T mismatch correction, **68**, 247–248
 HNPPC, **68**, 251
 human cancer, **68**, 250–251
 minimal catalytic domain, **68**, 245
 mismatched uracil, **68**, 248–249
 nicking assay, **68**, 242
 physiological role, **68**, 251
 protein
 structure, **68**, 237–238
 recombinant human
 5-FU, **68**, 245
 short-patch mismatch, **68**, 236–237
 substrate specificity, **68**, 243–246
 three-dimensional structure, **68**, 239–247
 transcription-associated DNA repair,
 68, 250
Thymine glycol (Tg), **68**, 214, 287–288
 A549 cells
 kinetics, **68**, 146
 BER, **68**, 4
 CE-LIF, **68**, 143–145
 DNA
 human cells, **68**, 147
 endo III, **68**, 216–218
 gamma-irradiated human cells, **68**, 139–148
 immunoassay, **68**, 126
 measurement, **68**, 141, 144
 mNHT1, **68**, 216–218
 proliferative status, **68**, 148
 repair activity, **68**, 215
 structure, **68**, 140
Thymocytes, double-positive, **69**, 231–233
Thymopoiesis
 ROR γ effect on, **69**, 236–238
 ROR γ role in, **69**, 231–236
Thyroid follicular cell (TFC)
 disease, *see* Congenital hypothyroidism
 functions, **66**, 308–309
 prospects for study, **66**, 341–343
 transcriptional regulation
 identification and cloning of specific
 transcription factors, **66**, 311–312
 overview, **66**, 308
 transcription factors, *see* Pax8; Thyroid
 transcription factor 1; Thyroid
 transcription factor 2
Thyroid hormone (TH)
 amphibian metamorphosis role, *see*
 Amphibian metamorphosis, thyroid
 hormone regulation

- chromatin remodeling in gene regulation
 - chromatin disruption assays, **65**, **66**, **68**
 - histone acetylation regulation, **65**, **65–66**
 - Xenopus* oocyte system advantages, **65**, **63**, **65**, **93**
- deficiency in cretinism, **65**, **55–56**
- interconversion of forms, **65**, **58–59**
- intestine development, *see* Intestinal
 - remodeling, *Xenopus* studies of thyroid hormone
- mammalian development role, **65**, **55–56**
- receptors
 - DNA binding, **65**, **60–61**
 - domains, **65**, **59–60**
 - hormone binding, **65**, **60**
 - transcriptional regulation of genes
 - activation versus repression, **65**, **61–62**
 - coactivators, **65**, **62–63**
 - corepressors, **65**, **62**
 - model of action, **65**, **68**, **70**
- Thyroid hormone receptor
 - ROR α and, **69**, **227**
 - ROR α 1 and, **69**, **215–216**
 - T3R-interacting proteins, *see* TRIP-1
- Thyroid hormone receptor, bending of binding genes, **54**, **139–140**, **142–143**
- Thyroid hormone receptor, mutation in Refetoff syndrome, **64**, **199**, **203**
- Thyroid hormone receptor, nucleosomal DNA transcription analysis, **61**, **415–417**
- Thyroid hormone, malic enzyme gene regulation, **52**, **92**, **102–104**, **112**, **115–117**, **119–120**
- Thyroid hormones, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and, **45**, **120–121**
- Thyroid stimulating hormone, induction of PDE4 isoforms, **69**, **302**
- Thyroid transcription factor 1 (TTF-1)
 - calreticulin binding, **66**, **337**
 - congenital hypothyroidism mutations, **66**, **340–341**
 - developmental expression
 - amphioxus ortholog, **66**, **319**
 - brain, **66**, **315–316**
 - lung, **66**, **314–315**
 - thyroid, **66**, **312–313**
 - tunicate ortholog, **66**, **318–319**
 - GATA cofactor with Nkx proteins, **66**, **312**, **317**
 - identification and gene cloning, **66**, **311**
 - nomenclature, **66**, **312**
 - phosphorylation, **66**, **336**
 - prospects for study, **66**, **342–343**
 - recycling during development, **66**, **334–335**
 - redox regulation, **66**, **337–338**
 - species distribution, **66**, **316**
 - structure
 - homeodomain, **66**, **319–320**
 - nuclear localization signal, **66**, **320**
 - promoter-binding regions, **66**, **320**
 - transcriptional activation domains, **66**, **321**
- target genes
 - cooperative interactions with other thyroid-specific transcription factors, **66**, **332–334**
 - identification
 - criteria, **66**, **330**
 - examples, **66**, **330–331**
 - immunoprecipitation following cross-linking, **66**, **331–332**
- thyroglobulin effects, **66**, **338–339**
- thyroid tumor expression, **66**, **318**
- titf1* gene
 - Hox activation, **66**, **317–318**, **342**
 - knockout mouse, **66**, **314–316**
 - locus, **66**, **312**
 - transcription and promoter characterization, **66**, **312**, **316–318**
- Thyroid transcription factor 2 (TTF-2)
 - congenital hypothyroidism mutations, **66**, **340–341**
 - developmental expression, **66**, **322–324**
 - fkf-containing proteins in development, **66**, **324–325**
 - identification and gene cloning, **66**, **311**
 - nomenclature, **66**, **322**
 - promoter binding specificity, **66**, **324**
 - prospects for study, **66**, **342–343**
 - recycling during development, **66**, **334–335**
 - regulation
 - cyclic AMP, **66**, **335–336**
 - insulin, **66**, **338**
 - thyroglobulin, **66**, **338–339**
 - structure, **66**, **325**
 - target genes
 - cooperative interactions with other thyroid-specific transcription factors, **66**, **332–334**
 - identification

- Thyroid transcription factor 2 (TTF-2) (*cont.*)
 criteria, **66**, 330
 examples, **66**, 330–331
 immunoprecipitation following
 cross-linking, **66**, 331–332
tif2 gene
 knockout mouse, **66**, 322–323
 locus, **66**, 322
- Thyrotropin-releasing hormone receptor
 binding site, **49**, 129
 messenger RNA stability, **49**, 144
- Tiazofurin, inositol-5'-monophosphate
 dehydrogenase inhibition and clinical
 applications, **61**, 203
- TIF-1A
 activities, **62**, 122–123, 306
 cell growth effects, **62**, 309–310
 purification, **62**, 123
 RNA polymerase I initiation role, **62**, 123,
 126, 133
 TFIC activity homology, **62**, 124, 310
- TIF-1B/SL1
 mitotic repression of activity, **62**,
 137–138
 Not1 competition for TATA-binding protein
 promoters, **62**, 316–317
 purification, **62**, 118
 recruitment of RNA polymerase I, **62**, 118
 ribosomal gene transcription regulation, **62**,
 118–119, 126, 131–132, 300–301
 TATA-binding protein-TAF complexes in
 RNA polymerase I promoter
 recognition, **62**, 118–119, 128–129,
 136, 300
- TIF-1C
 activity homology with TFIIF, **62**, 125
 RNA polymerase I initiation role, **62**,
 124–126, 306
- TIM, **68**, 335
- TIS/PGS-2 protein, induction in Swiss 3T3
 cells, **47**, 126–130
- Tissue distribution
 cathepsin A, **69**, 86
 GAL, **69**, 90
 PAPs, **69**, 135
 ROR α mRNA, **69**, 209
 ROR β mRNA, **69**, 210
 ROR γ , **69**, 211
- Tissue specificity, IRES *in vivo*, **72**,
 399–400
- Tissues
 basal expression of ALAS-1, **51**, 11
 branched chain aminotransferase
 distribution, **70**, 178–179
 distribution of collagen mRNAs, **50**,
 246, 253
 FGF-1 expression, **70**, 158–159
 injury, and *Egr-1* induction, **50**, 197
 mitochondrial gene expression, **70**, 134–135
 pyruvate dehydrogenase complex roles, **70**,
 42–43
 pyruvate dehydrogenase kinase
 distribution, **70**, 51–54
 pyruvate dehydrogenase phosphatase
 distribution, **70**, 54–55
 specific levels of alkyltransferase, **51**,
 198–200
 specificity of transgene expression, **50**, 179
tif1, *see* Thyroid transcription factor 1
tif2, *see* Thyroid transcription factor 2
- TLS mutant strains
 menadione, **68**, 34
- TLS pathways
 yeast, **68**, 33–36
- TNF- α , *see* Tumor necrosis factor- α
- Tobacco mosaic virus RNA, replication of, **42**,
 197–207
- Tobacco, rice genes and, **45**, 18–19
- Tobacco ringspot virus hairpin ribozyme, *see*
 Hairpin ribozyme
- Tolerance, alkylation damage repair in genomes
 and, **44**, 134–135
- Tomudex, **67**, 135
 structure, **67**, 136
- 5' TOP messenger RNA, translation regulation
 by S6 kinase, **65**, 106–107, 117–118
- Topoisomerase
 inhibitors, DNA sequence specificity, **63**,
 382, 396–398
 type II specificity for DNA sequences, **63**,
 383, 400
- Topoisomerase I, human
 camptothecin inhibition
 linker region role, **60**, 125–126
 mechanism, **60**, 113
 resistant mutants, **60**, 127
 catalytic mechanism, **60**, 112–113
 classification, **60**, 111–112
 crystal structure, **60**, 128–129
 domains

- boundaries, **60**, 113–116, 127–128
 - C-terminal domain functions, **60**, 122–123
 - core domain
 - catalytic role, **60**, 121–122
 - substrate specificity, **60**, 119–121
 - linker region
 - attachment sites, **60**, 126
 - camptothecin inhibition role, **60**, 125–126
 - DNA binding and nicking-closing reaction, **60**, 123–125
 - N-terminal domain
 - mutation analysis, **60**, 117–118
 - nucleolin binding, **60**, 118–119
 - signal sequence, **60**, 118
 - physical properties, **60**, 116–117
 - proteolysis, **60**, 114–116
 - sequence alignment with other eukaryotes, **60**, 113–114, 127
- Topoisomerase II
- cancer chemotherapy targeting, **64**, 245
 - catalytic inhibitor
 - definition, **64**, 242–243
 - types and mechanisms, **64**, 243–244
 - catalytic mechanism
 - ATP hydrolysis, **64**, 227
 - DNA binding, **64**, 225
 - enzyme recycling, **64**, 227
 - overview, **64**, 223
 - poststrand passage DNA cleavage/religation, **64**, 227
 - prestrand passage DNA cleavage/religation, **64**, 225–226
 - strand passage, **64**, 226
 - cleavage site specificity, **64**, 227–228
 - cytotoxic actions, **64**, 228
 - domain structure, **64**, 223–224
 - functions, **64**, 222–223
 - isoforms, **64**, 224, 231
 - poisons, *see* Topoisomerase II poisons
- Topoisomerase II poisons
- amsacrine, **64**, 230, 232
 - ciprofloxacin, **64**, 230, 232
 - CP-115, **64**, 953, 230, 232
 - cytotoxic mechanisms, **64**, 229–230
 - DNA lesions as endogenous poisons, **64**, 235
 - doxorubicin, **64**, 230, 232
 - drug-topoisomerase interactions
 - domains, **64**, 238–239
 - ternary complex formation with DNA, **64**, 236–237
 - effects on enzyme
 - DNA cleavage/religation equilibrium, **64**, 231–232
 - DNA cleavage specificity, **64**, 233–235
 - ellipticine, **64**, 230, 232
 - etoposide, **64**, 230, 232
 - genistein, **64**, 230, 232
 - mitoxantrone, **64**, 230, 232
 - positional poison model, **64**, 239–241
 - sensitivity of enzyme, factors affecting
 - alterations in drug binding, **64**, 241–242
 - ATP affinity, **64**, 242
 - enzyme exclusion from nucleus, **64**, 241
 - enzyme expression level, **64**, 230–231
 - specificity for prokaryotes or eukaryotes, **64**, 232–233
 - structure, **64**, 229–230
- Topoisomerase, DNA adduct effects, **71**, 23–24
- Toxicity, preventive role of alkyltransferase, **51**, 201
- Toxin, *see* Snake toxin
- Toxins
- ankyrin repeats, **67**, 11
 - TP53, mutations in cancer, **63**, 213
- TPA-induced sequence genes, *see* Phorbol-induced primary response genes
- Tra, *see* Conjugation, bacteria
- trans*-acting element, **48**, 247–251
- Trans*-acting factor, PTB identification, **72**, 382
- trans*-acting factors, mitochondrial biogenesis and, **46**, 55
- trans*-activation domains, Egr-1, definition, **50**, 210–211
- trans*-activating responsive element
- HIV-1, **69**, 4–5, 39
 - aptamers to, **69**, 28–31
 - RNA, complex with aptamer, **69**, 36–37
- Trans*-DDP
- structure, **67**, 94
- Trans-Golgi network (TGN)
- prohormone convertase 1 processing of
 - prohormones, **63**, 75–76
 - prohormone processing, **63**, 70
- Transactivation response element (TAR),
- nuclear magnetic resonance of equine infectious anemia virus structure, **57**, 9–10

- Transactivator/viropilin protein
 activated reinitiation model, **72**, 27–28
 TAV control, **72**, 23–24
 TAV–host interactions, **72**, 24–26
- Transacylase
 group VIA PLA₂, **67**, 21–22
- Transamination
 branched chain aminotransferase
 hypoglycemic agent effects, **70**, 197–198
 inhibitor structures, **70**, 195–197
 discovery, **70**, 176–177
- trans* cleavage, *see also* Strand cleavage
 FRT site, **51**, 72–73
- Transcription
 alcohol dehydrogenase regulation, *see*
 Alcohol dehydrogenase
 conformational heterogeneity of DNA, **55**,
 229–233, 241–242
 control of initiation in bacteria
 DNA masking, **55**, 8–10
 RNA polymerase
 concentration, **55**, 7, 10–12
 initiation complex formation and
 promoter clearance, **55**, 15–17
 isomerization of closed-to-open RNA
 polymerase–promoter complex, **55**,
 14–15
 promoter binding, **55**, 12–14
 control of initiation in eukaryotes, **55**,
 228–229
 CREB CAD and P-KID roles, **72**, 284–287,
 289–290
 CTD dephosphorylation, **72**, 354
 CTD phosphatase role, **72**, 346–347
 cyclic AMP-responsive factors, *see* Activating
 transcription factor 1; Cyclic AMP-
 responsive element binding protein;
 Cyclic AMP-responsive element
 modulator; Inducible cyclic AMP early
 repressor
 DNA, adduct effects, **71**, 10–11
 DNA-binding domains of factors, *see*
 DNA-binding domains
 DNA compaction, **64**, 173
 early, shut-off, **51**, 145–146
 genes, *see* Gene transcription
 genetic defects of mammalian nervous
 system and, **41**, 255–256
 herpesvirus, microarray analysis, **71**, 452
 higher plant mitochondria
 initiation sites, **70**, 126–127
 monocistronic units, **70**, 124–126
 polycistronic units, **70**, 124–126
 promoter primary structure, **70**, 127–129
 protein components, **70**, 130–131
 regulation, **70**, 131–134
 HSV-mediated, **51**, 134
 in somatic hypermutation, **50**, 79–80
 initiation, **64**, 173
 late, cellular factors, **51**, 156
 LINE-1, *see* LINE-1 elements
 LOX gene, **70**, 10–12
 LOXL gene, **70**, 11
 msDNA of bacteria and, **40**, 8–9
 nuclear RNA-binding proteins and, **41**,
 196–197
 nuclease hypersensitivity of actively
 transcribed genes, **55**, 227–228,
 230–233
 phosphorylated CREB, model, **72**, 296–298
 plant mitochondrial mRNAs, **70**, 135–136
 polyadenylation
 coupling to 3' end processing, **71**,
 297–298
 initiation, **71**, 297
 pre-mRNAs in nuclei, **71**, 295–297
 protamines and, **40**, 64–68
 purine nucleotide biosynthesis and, **42**,
 266–267
 ribosomal, in eukaryotes, **50**, 25–66
 ribosome biogenesis in yeast and, **41**,
 104–111
 RNA, in cytoplasmic male sterility, **70**,
 147–149
 RT fidelity at initiation, **71**, 108–109
 RT fidelity, accessory proteins, **71**, 110–112
 syndromes associated with transcriptional
 regulators, *see also specific regulators*
 and syndromes
 mutation frequency and types,
 64, 209–210
 overview and table, **64**, 178–185
 trp repressor and, **42**, 8–11
 units, looped-domain organization, **50**, 185
 vaccinia virus, **50**, 112–114
 vitellogenin mRNA, **72**, 143
- Transcription-associated DNA repair
 TDG, **68**, 250
- Transcription-coupled repair (TCR), **68**, 95
 8-oxoG

- AAS CHO cells, **68**, 100–102
OGG2, **68**, 202
Transcription factor E2F, pRM cooperation, **72**, 46–48
Transcription factor IIB, CTD phosphatase regulation, **72**, 341–342
Transcription factor IIF, CTD phosphatase regulation, **72**, 341–342
Transcription factor IIIA
background, **43**, 206–211
evolution, **43**, 232–236
function in 5-S RNA synthesis, **43**, 225–229
history, **43**, 205–206
nucleic-acid-binding properties, **43**, 218–225
proteins, **43**, 232–236
regulation of gene expression, **43**, 229–232
structure, **43**, 211–218
Transcription factors
activation of recombination, **50**, 92–93
basal, **50**, 36–44
zinc-finger family, Egr-1 as prototype, **50**, 191–224
Transcription factors, *see also specific factors*
autoregulation
assays, **60**, 135
eukaryotes, *see specific factors*
prokaryotes, **60**, 136–137
rationale, **60**, 163
basal factors, **60**, 134
regulatory factors, **60**, 134–135
Transcription factors, binding, DNA
methylation interference, **69**, 51
Transcription factors, C-terminal domain
kinases associated with, **48**, 166–168
Transcription factors, steroid hormones
and, **43**, 17–20, 26–27
Transcription factors, yeast SBF and MBF, **72**, 48–49
Transcription in *Trypanosoma brucei*, **43**, 46–57
Transcription initiation, *see also* Phage ϕ 29
protein p4; RNA polymerase
regulation, **60**, 30–31
steps, **60**, 30
Transcription initiation, of RNA polymerase II,
see RNA polymerase II transcription
initiation
Transcription of ribosomal-RNA genes,
ribosome biogenesis in yeast and
5-S rRNA and yeast RNA Pol III, **41**, 103
initiation by yeast RNA Pol I, **41**, 92–99
regulation and yeast RNA Pol I, **41**, 101–102
structure, **41**, 91–92
termination by yeast RNA Pol I, **41**, 99–101
Transcription, bacterial adenylyl cyclases
and, **44**, 32–34
Transcription, immunoglobulin gene
diversification and, **45**, 38–39
Transcription, methylcytosine-binding protein
mediated, methylation and, **48**, 62–63
Transcription, mitochondrial biogenesis in
Saccharomyces cerevisiae and, **46**, 64–70
Transcriptional activator
CooA, **67**, 40–42
Transcriptional enhancers, prokaryotic, *see*
Prokaryotic transcriptional enhancers
Transcriptional factor proteins
ankyrin repeats, **67**, 11
Transcriptional switches, during HSV
infection, **51**, 133–140
Transcripts, and variant transcripts, type XIII
collagen, **50**, 239–246
Transcripts, HSV-1, **51**, 127–129
Transducin
light-induced conformational change
coupling to transducin activation with
rhodopsin, **59**, 22–25
rhodopsin interactions, **59**, 9–10, 22
Transducin, phototransduction, **65**, 343
Transesterifications, in splicing, **50**,
132–134
Transfer RNA
aminoacylation, **69**, 322–324
as molecular scaffold, **70**, 295
biological functions of modified
nucleosides, **53**, 81–84
cleavage by bleomycin, **49**, 339–341
conformational changes in, communication
by, **69**, 334–335
conservation, **70**, 294–295
covalent continuity, communication and, **69**,
335–337
discovery, **70**, 292
factors affecting chemical reactivity of
groups, **53**, 135–136
functional properties, **70**, 295–296
higher plant mitochondria
maturation, **70**, 144–147
population, **70**, 142–144

- Transfer RNA (*cont.*)
- identity elements, recognized by AARS, **69**, 345
 - macromolecular partners, **70**, 293–294
 - mimics, combinatorial selection
 - amino acid affinities, **70**, 327–328
 - aminoacyl-tRNA synthetases, **70**, 314
 - aminoacylated tRNAs, **70**, 315
 - arginine-accepting tRNAs, **70**, 319–321
 - aspartate-accepting tRNAs, **70**, 319–321
 - elongation factor-recognizing variants, **70**, 323–324
 - elongation factors, **70**, 314
 - glutamyl-tRNA synthetase affinity, **70**, 315–316
 - in vitro* selection, **70**, 309–311
 - isoleucyl-tRNA synthetase aptamer, **70**, 317
 - leucine-accepting tRNAs, **70**, 319–321
 - library choice, **70**, 311–313
 - phenylalanine-accepting tRNAs, **70**, 318–319
 - phenylalanine-tRNA synthetase aptamer, **70**, 316–317
 - ribozyme-catalyzed tRNA aminoacylation, **70**, 326–327
 - self-aminoacylatable RNA, **70**, 324–325
 - serine-accepting tRNAs, **70**, 319–321
 - valine-accepting tRNA-like molecules, **70**, 321–323
 - mimics, rationale design
 - aminoacyl-tRNA synthetase pair, **70**, 300–301
 - aminoacylation activity, **70**, 299–300
 - conformational changes, **70**, 297–298
 - duplex RNA pieces, **70**, 304–306
 - framework engineering, **70**, 301–304
 - functional and structural analysis, **70**, 298–299
 - hairpins, **70**, 304–306
 - natural occurrence, **70**, 306
 - scaffold-directed design, **70**, 296–297
 - small organic molecules, **70**, 307–309
 - structural background, **70**, 297
 - trinucleotides, **70**, 307–309
 - physicochemical contributions of nucleoside modification
 - base stacking, **53**, 109
 - disruption of canonical base-pairing, **53**, 114–116, 120
 - magnesium binding, **53**, 113–114, 119–120
 - reordering of water, **53**, 112
 - types, **53**, 81
 - qualities, **70**, 292–293
 - reverse transcription and analysis of modified RNA, **53**, 138–140
 - site-selective positioning of modifications
 - biophysical investigation, **53**, 108–109
 - synthesis, **53**, 105–110
 - transfer RNA, **53**, 101–104
 - structure determination
 - chemical probing of modified RNA, **53**, 133–140, 142–143, 146–147, 149, 153–159
 - cross-linking and intramolecular modifications, **53**, 155–161, 191
 - enzymatic probing, **53**, 133–142, 150–151, 159–161
 - nucleotide interactions and folding, **53**, 148–152
 - physical methods, **53**, 132, 191
 - scission by complexed metals, **53**, 161–164
 - tertiary structure, **53**, 152–155
 - tertiary structure, **53**, 133–134
 - tRNA₂^{Ile} isoacceptor, **69**, 327–328
 - tRNA^{Ala} variants, **69**, 326–327
 - tRNA^{Gln}:GlnRS complex, **69**, 330
 - tRNA^{Ile} D loop substitutions, **69**, 338
 - tRNA^{Lys}, ³
 - binding to HIV LTR, **49**, 173
 - prosome binding, **49**, 20–21, 52
 - retroviral primer, **49**, 21, 52
 - tRNA^{Pro}:ProRS complex, **69**, 341–342
 - tRNA^{Ser} binding to SerRS, **69**, 332–333
 - Transfer RNA (tRNA)
 - mismatched base pair functions, **57**, 34
 - nuclear magnetic resonance, structural studies, **57**, 7–9, 14
 - X-ray structure, **57**, 5
 - Transfer RNA (tRNA), *see* Elongation, protein
 - Transfer RNA, *see* Aminoacyl-tRNA synthetases
 - Transfer RNA, *see* Frameshifting
 - Transferase repression, alkylation damage repair in genomes and, **44**, 127–128
 - Transferases, structural diversity, determination by exons 1, **51**, 319–324

- Transferrin
 receptor
 messenger RNA stability, **57**, 252–253
 uptake of oligonucleotides, **57**, 112
 regulation of messenger RNA
 polyadenylation, **57**, 63
- Transformation, oncogenic, and translation, **51**, 355–357
- Transformations
 cell, FGF-2 isoforms, **72**, 390–391
 cell, IRES activity, **72**, 398–399
 JA metabolism, **72**, 178
- Transforming growth factor α
 expression in *E. coli*, **49**, 361
 site-directed mutagenesis, **49**, 365
- Transforming growth factor (TGF), Schwann
 cell regulation, **56**, 229–230
- Transforming growth factor β , FGF-1 promoter
 response, **70**, 167
- Transforming growth factor β , Muc4/SMC, **71**, 172–173
- Transgenes
 expression, **50**, 179–180
 immunoglobulin, analyses, **50**, 83
 integrated, DNase-I hypersensitivity, **50**, 180–184, 187–188
 κ , *cis*-acting elements, **50**, 74–79
- Transgenic constructs, expression in cell
 culture, **50**, 173–175
- Transgenic manipulation, JA biosynthesis,
 72, 180
- Transgenic mouse, tumors, T antigen, **70**, 170–171
- Transgenic plants, *alc* system in, **69**, 194–195
- Transgenic plants, rice genes and, **45**, 16–23
- Transglutaminase
 activation, **60**, 106
 expression in cartilage hypertrophy, **60**, 106
- Translation
 accuracy of elongation, **64**, 132, 134
 allosteric three-site model, **64**, 134–135
 and oncogenic transformation, **51**, 355–357
 elongation phase, **50**, 3–4, 9–10, 16
 elongation, *see* Elongation, translation
 error frequencies, **64**, 132
 FGF-2, **72**, 387
 frameshifting, *see* Frameshifting
 function of
 cmo⁵U34 in, **50**, 323–324
 hisT mutants in, **50**, 270–276
 m¹G37 in, **50**, 313–318
 m⁵U54 in, **50**, 282–285
 mmn⁵s²34 in, **50**, 289–292
 ms²t⁶A37 and ms²io⁶A37 in, **50**, 300–308
 Q34 in, **50**, 320–321
 s⁴8 in, **50**, 294–296
 Gag–Pol, retroelement, **72**, 10–12
 hopping, **64**, 160–162
 in mammalian cells, growth control, **51**, 339–363
 initiation complex, **54**, 166
 initiation factors, *see* eIF-2B
 internal initiation, shunting
 combinations, **72**, 21
 IRES-dependent translation, **72**, 382–383, 398–399
 kinetic proofreading model, **64**, 134–135
 missense errors, **64**, 133
 phases, **54**, 166
 polycistronic mRNA
 basic strategies, **72**, 21–22
 leaky scanning, **72**, 22–23
 TAV control, **72**, 23–24
 TAV–host interactions, **72**, 24–26
 processivity errors, **64**, 133–134
 programmed alternative decoding,
 overview, **64**, 149
 viral RNA, packaging interplay, **72**, 7–10
- Translation enhancer, FGF-2 mRNA
 expression control, **72**, 392–393
- Translation initiation
 calcium role, **58**, 92–95
 eIF-2 role, **58**, 91–92, 95–97, 101–102
 eIF-4 complex role, **58**, 91–92
 eIF4A, *see* eIF4A
 eukaryotic, *see* Eukaryotic translation
 initiation
 FGF-2 mRNA, **72**, 383–385
 GRP78 role, **58**, 117–119
 herpes simplex virus 1 infection and
 translational tolerance to stress,
 58, 115
 inhibition by stressors
 arsenite ion, **58**, 97–98, 100–102
 cadmium, **58**, 98
 ionomycin, **58**, 94–95, 98, 101
 mechanism, **58**, 97
 thapsigargin, **58**, 98–99, 101
 messenger RNA selection frequency,
 58, 91

- Translation initiation (*cont.*)
 phosphorylation of initiation factors, **58**,
 91–92, 95–97, 101–108
 reticulocyte lysates, **58**, 108–110
 ribosome loading, **58**, 90–92, 119
Translation initiation, **70**, 208–210
Translation initiation factor, eIF2 α , poly A
 site, **71**, 336–337
Translation initiation factor, eIF5 as, **70**,
 216–217
Translation system, coupled, **51**, 254–257
Translation, *see* Elongation, protein
Translation, in eukaryotes, **48**, 181–228
 helicases in, **48**, 218–219
 in vitro inhibition
 antisense oligonucleotides in, **48**,
 219–224
 mRNA regions sensitive to, **48**, 222–224
 RNase-H-independent, **48**, 220–222
 in vivo arrest, **48**, 225–226
 initiation
 antisense technologies and, **48**,
 205–219, 226
 association of mRNA with 43–S
 preinitiation complexes in, **48**,
 186–187
 association of mRNA with ribosome in,
 models for, **48**, 188–194
 dissociation of ribosomal subunits in,
 48, 186
 joining of ribosomal subunits in, **48**,
 187–188
 Met-tRNA^{infi}/inf binding to 40–S
 ribosomal subunit in, **48**, 186
 pathway, **48**, 186–188
Translation, proline-rich protein multigene
 families and, **41**, 6–9
Translational control element, in *Mst87F*
 mRNA translation, **48**, 204
Translational control, physiological roles, **51**,
 357–359
Translational initiation factors, regulation, **51**,
 343–348
Translational silencing, FGF-2, p53, **72**,
 400–403
Translational stop signal
 amino acid-coding exceptions, **52**,
 294–296, 316
 decoding
 context effects in mRNA, **52**, 297–299
 coupling to polypeptide release, **52**, 310
 models, **52**, 303
 primary structure of stop signal, **52**,
 301–303
 protein factors, **52**, 300–301
 release factor role, **52**, 308,
 310–311, 324, 326
 ribosomal RNA role, **52**, 303–308
 ribosome decoding, **52**, 299
 template for the decoding event,
 52, 309
 discovery, **52**, 293–294
 evolution, **52**, 296–297
 four-base signals, **52**, 319–324
 natural stop codons, **52**, 294–296, 318–319
 physiological advantages, **52**, 326–330
 recoding at stop codon, **52**, 311–318
Translocation
 adenovirus shunt model, **72**, 19
 cell membranes and barrier walls, **72**, 461
 DNA, phi29, pRNA role, **72**, 453–457
 viral DNA, nucleic acid sliding/riding
 processes, **72**, 459–461
Transplatin–DNA
 adducts, **71**, 4, 11
 cross links, **71**, 8–9
 imino ether groups, **71**, 40–41
 planar amine ligand, **71**, 38–40
Transplatin, DNA sequence specificity, **63**,
 378, 385–386
Transport-impaired hamster cells
 hRFC cDNA cloning, **67**, 140–146
Transport-impaired human cells
 hRFC cDNA cloning, **67**, 140–146
Transport-impaired K562
 hRFC, **67**, 146–147
Transport-mediated-methotrexate resistance
 molecular mechanisms, **67**, 153–157
Transport-up-regulated K562 human
 erythroleukemia cells
 highly glycosylated hRFC protein, **67**,
 139–141
Transporter-associated protein, gene
 interspersions with major
 histocompatibility complex, **49**, 31
Transporter associated with antigen processing
 (TAP)
 MHC1, **67**, 260–263
Transposable element-induced mutants
 Ds elements, **47**, 175–176

- dSpm* elements, **47**, 177–178
- RNA processing fate
 - after *Ds* insertion in exons, **47**, 176–177
 - after *dSpm* insertion, **47**, 178–183
- Transposition, DNA sequence amplification in mammalian cells and, **41**, 226–228
- Transposon
 - internal eliminated sequences in ciliates
 - evolution
 - abdication and fading, **56**, 52–54
 - bloom, **56**, 48–52
 - germ-line soma system, role in ciliates, **56**, 49–51
 - overview, **56**, 46, 58
 - Tetrahymena*, **56**, 54–56
 - transposon function maintenance, **56**, 51–52
 - transposon invasion, **56**, 47–48
 - transposon multiplication limits, **56**, 48–49
 - Tec elements, **56**, 14–15, 21–23, 32–34
 - Tel-1, **56**, 17
 - telomere-bearing elements, **56**, 9, 11–14, 24–25, 51–52
 - Tlr1, **56**, 17–18, 35–36
 - retrovirus, **56**, 2
- Trehalase
 - discovery, **58**, 199
 - inhibitors as insecticides, **58**, 232
 - renal disease marker, **58**, 232
 - sequence homology between species, **58**, 213, 218–221
 - yeast
 - acid trehalase
 - ATH1* gene, **58**, 201, 209
 - cloning of gene, **58**, 212–213
 - glycosylation, **58**, 208–209, 214
 - inhibitors, **58**, 208
 - mutation studies, **58**, 214, 225
 - pH optimum, **58**, 200–201, 207–208
 - size, **58**, 207–208
 - substrate specificity, **58**, 208
 - transport, **58**, 214–215
 - assay, **58**, 211, 213
 - biological functions
 - overview, **58**, 201
 - spore germination, **58**, 229
 - stress response, **58**, 219, 222–223, 226–228
 - trehalose hydrolysis, **58**, 226
 - trehalose transport, **58**, 228–229
 - elimination in baker's yeast, **58**, 231–232
 - localization, **58**, 207, 214
 - neutral trehalase
 - gene cloning, **58**, 216
 - inhibitors, **58**, 210
 - mutation studies, **58**, 217–218, 225, 228
 - NTH1* gene, **58**, 201, 211, 216–217
 - NTH2* gene, **58**, 217
 - pH optimum, **58**, 200–201, 207, 210
 - phosphorylation, **58**, 210–211, 217–218, 222–223, 225–226
 - purification, **58**, 209
 - size, **58**, 210, 216
 - substrate specificity, **58**, 210
 - regulation of expression
 - catabolite repression, **58**, 224–226
 - heat stress, **58**, 219, 222–223, 229–231
 - mutagen stress, **58**, 223
- Trehalose
 - accumulation in yeast
 - heat stress, **58**, 204–205
 - levels during life cycle, **58**, 202–203
 - mutagen stress, **58**, 205
 - nutrient stress, **58**, 203–204, 224–226
 - assays, **58**, 201–202
 - biosynthesis, **58**, 199–200, 212
 - discovery, **58**, 198
 - species distribution, **58**, 199
 - stress protection
 - baker's yeast, **58**, 231–232
 - mechanisms, **58**, 205, 207
- Tricarboxylic acid (TCA) cycle, *see also specific enzymes*
 - compartmental localization of enzymes in yeast, **57**, 317–318
 - metabolic flux, **57**, 317
- Tricho-dento-osseous syndrome, *DLX3*
 - mutation, **64**, 193–194
- Trichostatin A (TSA), histone deacetylase
 - inhibition studies of thyroid hormone action, **65**, 66
- Trichothiodystrophy (TTD), genetic
 - defects, **63**, 210–211
- Triethylenemelamine, DNA sequence
 - specificity, **63**, 379, 388
- Trigger factor
 - cross-linking to nascent peptides, **66**, 120

- Trigger factor (*cont.*)
- DnaK complementarity, **66**, 60–61
 - peptidyl prolyl *cis-trans* isomerase activity, **66**, 59–60, 112
 - protein targeting
 - pathway discrimination, **66**, 120–121
 - role, **66**, 112
 - ribosome association, **66**, 60–61
- Triiodothyronine receptor, *see* Thyroid hormone receptor
- Triiodothyronine, control of gene expression
- chorionic somatomammotropin, **54**, 138–140, 142
 - growth hormone, **54**, 138–140, 142–145
- Trinucleotides, tRNA mimics, **70**, 307–309
- Triose phosphate isomerase (TIM), **68**, 335
- Triostin A, DNA sequence specificity of damage, **63**, 383, 402
- Triostin assembly enzymes, **70**, 257–259
- TRIP-1
- interaction with ROR β , **69**, 222
 - ROR coactivator, **69**, 219
- Triphosphatase, domain of vaccinia capping enzyme, **50**, 108–109
- Triple helix
- oligonucleotide based, **67**, 168–169
 - psoAG10, **67**, 174
- Triple helix, *see* DNA triplex
- Triple helix, antisense oligonucleotides and, **44**, 145, 147
- Triple-stranded complexes
- chemistry, **69**, 19–21
 - clamp and circular oligonucleotides, **69**, 23–24
 - double hairpin, **69**, 24–25
 - modified nucleotides and intercalating agents for, **69**, 22–23
- Triplet repeat sequence (TRS)
- DNA repair and instability
 - mismatch repair, **66**, 179–180
 - nucleotide excision repair, **66**, 177–179
 - recombination pathways, **66**, 181
 - strand break repair, **66**, 181
 - dynamic mutation, **66**, 160
 - genetic instability *in vivo*
 - Escherichia coli*, **66**, 186–187
 - length effects, **66**, 187
 - mammalian cell culture, **66**, 188–189
 - transgenic mice, **66**, 187–188
 - yeast, **66**, 186–187
- human diseases of expansion
- anticipation, **66**, 161, 191
 - candidate disorders, **66**, 164–165
 - classification of diseases, **66**, 161–164
 - length of repeat and phenotype, **66**, 161
 - nonclinical expansions, **66**, 165
 - pathology
 - expansions in noncoding regions, **66**, 167–169
 - expansions within proteins, **66**, 165–167
 - well-established disorders, **66**, 161–164
- methylation in chromatin, **66**, 185–186
- microsatellites versus minisatellites, **66**, 160
- recombination and instability
- contraction of repeats, **66**, 175
 - gene conversion pathway, **66**, 175, 177
 - homologous recombination and expansion, **66**, 174–175
- replication and instability
- length effects, **66**, 174
- Okazaki fragments in expansion, **66**, 173
- orientation dependence with respect to replication direction, **66**, 171–173
- in vitro* studies, **66**, 169–171
- in vivo* studies, **66**, 171–174
- structure of DNA and instability, **66**, 183, 185–186, 191
- transcription and instability
- in vitro* studies, **66**, 182–183
 - in vivo* studies, **66**, 183
 - overview, **66**, 181
- Triplex forming oligonucleotides (TFOs), **67**, 163–164
- antigene agents, **67**, 177–178
 - chemical substitutions, **67**, 172
 - chemistry, **67**, 167–171
 - improvements, **67**, 171–172
 - chromatin barrier, **67**, 174–177
 - chromosomal mutations, **67**, 176
 - cleaving tool, **67**, 173
 - delivery, **67**, 164–165
 - DNA
 - sequence change, **67**, 185–186
 - DNA alterations
 - repair systems, **67**, 186–189
 - EDTA-Fe, **67**, 173
 - half-life, **67**, 165

- intercalators, **67**, 171
 - molecular tools, **67**, 172–174
 - motifs
 - limitations, **67**, 169–170
 - mutagenesis, **67**, 180–181
 - recombination, **67**, 181–185
 - psoralen, **67**, 182
 - RNA, **67**, 178
 - strand crossing, **67**, 171
 - up-regulation
 - gene expression, **67**, 178–180
 - Triplex, DNA formation in Friedreich's ataxia, **66**, 185
 - tRNA
 - bacterial, modified nucleosides in, **50**, 263–338
 - codon-context sensitivity, **50**, 300–306
 - lack of
 - m¹G37, **50**, 318
 - Q34, **50**, 322
 - (m¹G37)methyltransferase, synthesis, **50**, 310–313
 - modification, **50**, 322–323
 - (m⁵U54)methyltransferase, synthesis, **50**, 279–282
 - presence of ms²i⁶A and ms²io⁶37, **50**, 296–298
 - tRNA-pseudouridine synthase, 5,
 - 6-dihydropyrimidine adducts and, **42**, 150–151
 - tRNA structure, aminoacylation and, **45**, 130–141, 192–194
 - aminoacyl-tRNA synthetases, **45**, 147–149
 - complexes
 - crystallization, **45**, 163–164
 - in solution, **45**, 159–163
 - three-dimensional structures, **45**, 164–166
 - functional observations, **45**, 149–151
 - identity, **45**, 166–169
 - antideterminants, **45**, 189–190
 - conformational features, **45**, 186–188
 - evolution, **45**, 190–192
 - nucleotides, **45**, 169–180
 - RNA substrates, **45**, 180–186
 - kinetic specificity, **45**, 151–155
 - mechanisms, **45**, 155–156
 - noncanonical tRNAs, **45**, 142–147
 - sequences, **45**, 156–159
 - tRNA-uracil methyltransferase, 5,
 - 6-dihydropyrimidine adducts and, **42**, 148–149
 - tRNA, *see* Elongation, translation
 - tRNA, *see* Transfer RNA
 - tRNA, recognition of, **41**, 23–24, 81–82
 - acceptor stem and discriminator base, **41**, 44, 57–58
 - alanine synthetases, **41**, 44–51
 - E. coli* glutamine synthetase, **41**, 53–55
 - E. coli* serine synthetase, **41**, 51–53
 - E. coli* synthetase, **41**, 55–57
 - anticodon, role of, **41**, 29–30, 44
 - E. coli* tRNAs, **41**, 30–43
 - yeast tRNAs, **41**, 43–44
 - assays of amino-acid-receptor specificity, **41**, 25–29
 - binding domains of synthetases, **41**, 72–81
 - complex of *E. coli* glutamine tRNA and glutamine synthetase, **41**, 66–71
 - modified bases, **41**, 65–66
 - E. coli* isoleucine synthetase, **41**, 64–65
 - yeast arginine synthetase, **41**, 65
 - profiles, **41**, 63–64
 - E. coli* arginine synthetase, **41**, 58–60
 - E. coli* phenylalanine synthetase, **41**, 62–63
 - yeast phenylalanine synthetase, **41**, 60–62
 - recognition versus identity, **41**, 24
- tRNA^{Lys,3}, *see* Human immunodeficiency virus reverse transcriptase
- Tropoelastin, EBP binding, **69**, 99
- Trp 45, at protein/DNA interface, **69**, 164
- Trp repressor, **42**, 1–2
 - amino acid sequence, **42**, 16–18
 - DNA-binding proteins, **42**, 29–32
 - early research, **42**, 2–5
 - future of research, **42**, 32–34
 - holorepressor, **42**, 22–27
 - mRNA translation, **42**, 14–16
 - nucleotide sequence of DNA, **42**, 6, 8
 - protein purification, **42**, 18–20
 - signal strength of promoter, **42**, 11–14
 - structural alterations, **42**, 27–29
 - structure–function analysis, **42**, 5–7
 - transcriptional regulation, **42**, 8–11
 - tryptophan, **42**, 20–22
- trp* operon
 - messenger RNA processing, **62**, 101
 - transcriptional attenuation, **62**, 362–363

- trp* operon, mRNA decay mechanisms, **52**, 172–174
- TRS, *see* Triplet repeat sequence
- Truncation, C-terminal of AlaRS, **69**, 321–322
- Truncation, pRNA genetic analysis, **72**, 438–439
- Trypanosoma brucei*, nuclear gene expression in, **43**, 37–38
- development biology, **43**, 38–41
- differentiation, **43**, 57–61
- future prospects, **43**, 61–62
- housekeeping genes, **43**, 41–46
- mRNA, **43**, 56–57
- PARP genes, **43**, 49–51
- promoters, **43**, 51–55
- transcription initiation, **43**, 55
- transcription of surface protein genes, **43**, 46
- VSG gene transcription unit, **43**, 47–49
- VSG polymerase, **43**, 46–47
- Tryptophan operon, attenuation, **53**, 220
- Tryptophan, *trp* repressor and, **42**, 20–22
- Tryptophanyl-tRNA synthetase, **48**, 107–114
- interferon inducibility, **48**, 110–113
- mammalian, as distinct protein, **48**, 113–114
- structural features, **48**, 107–110
- TSA, *see* Trichostatin A
- Tst-1
- developmental expression, **63**, 236–237
- homology with other class III POU domain proteins, **63**, 229
- knockout mouse studies of developmental role, **63**, 237–238
- TTD, *see* Trichothiodystrophy
- TTF-1, *see* Thyroid transcription factor 1
- TTF-2, *see* Thyroid transcription factor 2
- TTF-1
- chromatin remodeling at ribosomal gene promoter, **62**, 144–146, 307–308
- domains, **62**, 141
- homologs, **62**, 141
- replication fork arrest role, **62**, 146–148
- termination factor activity, **62**, 141–143, 307–308
- TTP, allosteric regulation of RNRs, **72**, 108–114
- Tuberization, jasmonates and octadecanoids, **72**, 200–202
- Tumor necrosis factor
- apoptosis, **68**, 274
- Tumor necrosis factor- α (TNF- α), squalene synthase regulation, **65**, 190–191
- Tumor necrosis factor receptor, pharmacological intervention in HIV infection, **49**, 182
- Tumor suppressor genes
- CpG islands in, **69**, 52
- hypermethylation, **69**, 65
- histone deacetylases and, **69**, 70–71
- in cancer cells, **69**, 67
- selective advantage conferred by methylation, **69**, 67–68
- Tumor suppressor, FGF-2 translational silencing, **72**, 400–403
- Tumorigenesis, *see* DNA methylation; E-cadherin
- Tumors
- LOX and LOXL2 chromosomal loci mutations, **70**, 6–7
- transgenic mouse, T antigen, **70**, 170–171
- Tumors, immunoglobulin gene diversification and, **45**, 31–32
- Tumors, Muc4/SMC metastasis, **71**, 160–161
- primary growth, **71**, 161–163
- Tumors, occurrence of alkyltransferase, **51**, 168–170
- Turnip yellow mosaic virus, RNA aminoacylation, **69**, 328–329
- Turnip yellow mosaic virus RNA, replication of, **42**, 193–196
- Twin-arginine translocation (Tat)
- cofactor binding before translocation, **66**, 137–138
- discovery, **66**, 136
- genes in *Escherichia coli*, **66**, 136–137
- mechanism, **66**, 138
- TWIST, mutation in human syndromes acrocephalo-syndactyl type III, **64**, 191–192
- Saethre-Chotzen syndrome, **64**, 191–192
- Two-hybrid system, yeast mRNA 3' end-processing factor genes, **71**, 360–361
- Ty1, programmed +1 frameshifting, **64**, 155–156, 163
- Ty3, programmed +1 frameshifting, **64**, 156–157
- Type I restriction–modification enzymes
- ATP hydrolysis, **64**, 25
- classification, **64**, 3

- cleavage of DNA
 - AdoMet requirement and role, **64**, 22, 25–27
 - ATP requirement and role, **64**, 22, 27–28
 - DNA structure requirements, **64**, 22–23
 - EcoR124I* mechanism, **64**, 23–24
 - EcoR124II* mechanism, **64**, 24
 - kinetics, **64**, 22
 - reaction mechanism, **64**, 28–29
- evolutionary origin, **64**, 53
- families of type I enzymes, **64**, 11–13
- gene structure
 - KpnAI*, **64**, 10–11
 - order of *hsd* genes, **64**, 9
 - promoters, **64**, 9–10
- methylation of DNA, **64**, 21–22
- proteases in regulation, **64**, 29–30
- recognition sequence, **64**, 11
- regulation of restriction activity, **64**, 29–31
- sequence homology, **64**, 8–9
- sequence specificity, mechanisms for changing, **64**, 52–53
- species distribution, **64**, 8, 51–52
- structure
 - adenine methyltransferase, **64**, 19–20
 - conformational changes on DNA binding, **64**, 20–21
 - DEAD-box motifs, **64**, 13
- subunits
 - HsdM, **64**, 18, 21
 - HsdR functions, **64**, 21
 - interactions, **64**, 14–15, 17, 19
 - mutation studies, **64**, 15, 18
 - purification, **64**, 17–18
 - repeat sequences in specificity subunits, **64**, 16–17
 - sequence homology and analysis of HsdS polypeptides, **64**, 15–16, 19
 - target recognition domains, **64**, 16
 - types, **64**, 13–14
- Type III restriction–modification enzymes
 - classification, **64**, 5
 - EcoP151*
 - ATP hydrolysis, **64**, 40–41
 - discovery, **64**, 40
 - methylation of DNA, **64**, 43–46
 - mutant analysis, **64**, 45–46
 - recognition sequence, **64**, 40
 - tracking–collision model of cleavage, **64**, 41, 43
- EcoPI*
 - AdoMet requirement and functions, **64**, 32–33
 - ATP hydrolysis, **64**, 37–39
 - helicase requirement, **64**, 38–39
 - host specificity role, **64**, 32
 - methylation of DNA, **64**, 35–37
 - mutant analysis, **64**, 36–37, 39
 - recognition sequence, **64**, 35
 - subunits, **64**, 35
 - transcription of gene, **64**, 33–35
 - translation, **64**, 33–34
- HinIII*
 - AdoMet requirement and functions, **64**, 47–48
 - discovery, **64**, 46
 - purification, **64**, 46
 - recognition sites, **64**, 46–47
- putative systems, **64**, 49–50
- recognition sequences, **64**, 31
- StyLT1*
 - discovery, **64**, 48
 - gene cloning, **64**, 48
 - subunits, **64**, 48–49
- subunits, **64**, 31
- Type X collagen
 - developmental acquisition and subsequent degradation, **60**, 87–89
 - expression in cartilage hypertrophy, **60**, 80, 105–106
- matrix diffusion
 - assay, **60**, 98–99
 - motive force, **60**, 99–100
 - role in hypertrophic cartilage modification, **60**, 100–102
 - size restriction, **60**, 98
- mutation in disease, **60**, 82
- stability in tissues, **60**, 89–92
- structure
 - covalent cross-linking, **60**, 86–87
 - domains, **60**, 82–84
 - size, **60**, 82
 - supramolecular forms, **60**, 84–86
- tissue distribution, **60**, 81–82
- transcriptional regulation analysis
 - in situ* hybridization, **60**, 92–95
 - in vivo* footprinting, **60**, 95–96
 - transient transfection, **60**, 95–97

- Type X collagen (*cont.*)
 type IX collagen, **60**, 93, 95
- Tyrosine
 C-terminal domain kinase
 phosphorylating, **48**, 171–172
 residue 115, HIV-1 RT, **71**, 114–117
 residue 183, HIV-1 RT, **71**, 123–124
 residue 222, Mo-MLV RT, **71**, 124
 RNA polymerase subunit IIa
 phosphorylation on, **48**, 147–151
- Tyrosine kinase substrates, protein, *see*
 Protein tyrosine kinase substrates
- Tyrosine kinase, *see* Fibroblast growth factor
 receptor tyrosine kinase
- Tyrosine receptor kinase, ErbB2/HER2/Neu,
 Muc4/SMC ligand, **71**, 157–160
- Tyrosyl-tRNA synthetase, RNA folding, **72**,
 232–233
- TyrRS
 absence of anticodon-binding domain,
 69, 328
 crystal structures, **69**, 343–344
- U**
- U-A basepairs, in uracil-DNA, **48**, 330–333
- U-C, *see* Uridine-cytosine base pair
- U-G mispairs, in uracil-DNA, **48**, 333–336
- U-U, *see* Uridine-uridine base pair
- U251
 human
 uracil-initiated BER, **68**, 174, 182
- UAS_{INO}, *see* Inositol-sensitive upstream
 activating sequence
- UBF, *see* Upstream binding factor
- Ubiquitination
 cisplatin, **67**, 116–117
- Ubiquitination, histones, **65**, 306–307
- Ubiquitization of histones, protamines and,
40, 75–76
- UCP, *see* Uncoupling protein
- UCR1
 interaction with UCR2, **69**, 289–290
 PDE4, **69**, 262
 PKA-mediated phosphorylation, **69**, 269,
 275, 277
- UCR2
 connected to catalytic unit, **69**, 264
 in ERK phosphorylation, **69**, 296–297
- UDG. *See* Uracil DNA glycosylase
- UDG2, **68**, 23, 129, 134
- MYH
 PCNA, **68**, 135
 replication-coupled BER, **68**, 136
- UDP-glucuronosyltransferase system, **51**,
 306–307
- UGGT, **67**, 239–241
 glycoprotein folding
 ER, **67**, 239–241
- Ugi
 uracil-DNA BER, **68**, 179–181
- Ugi-resistant uracil-DNA
 glycosylase-initiated DNA repair, **68**,
 185–186
 human colon adenocarcinoma LoVo cell
 extracts, **68**, 172–175
- UL5
 gene structure, **70**, 102–103
 helicase motif mutations, **70**,
 104–106
- UL52
 gene structure, **70**, 102–103
 in helicase activity, **70**, 106–107
- UL8, gene structure, **70**, 102–103
- UL9
 biochemical properties, **70**, 98–100
 domain structure, **70**, 98–100
 in cell culture, **70**, 98
 SV40 comparison, **70**, 100
 unwinding activity, **70**, 101–102
- Ulnar-mammary syndrome, *TBX3*
 mutation, **64**, 189
- Ultraviolet cross-linking, nuclear RNA-binding
 proteins and, **41**, 184–185
- Ultraviolet irradiation, *Trypanosoma brucei*
 and, **43**, 56–57
- Ultraviolet irradiation, protein cross-linking to
 poly A sites, **71**, 308
- Ultraviolet light, DNA sequence specificity of
 damage, **63**, 383, 400–401
- Ultraviolet light, induced deamination of
 cytosine, **48**, 325–330
- Ultraviolet radiation, **68**, 275–276
 pol beta-defective cells, **68**, 17
- Ultraviolet spectroscopy, melting curves and
 analysis of DNA
 guanine quadruplex, **59**, 86
 triple helices, **59**, 63–64, 67, 69–71
- UMP synthase, *see also* Orotate phosphoribo-
 syltransferase; Orotidylate decarboxylase

- allosteric regulation by oligomer dissociation, **53**, 13–15
- amino acid sequence homology between species, **53**, 20–26
- defects in orotic aciduria, **53**, 18–20
- dimerization, **53**, 34–35
- gene fusion, **53**, 67–70
- human mutants, **53**, 38–39
- kinetics of orotidylate decarboxylase, **53**, 37–38
- proteolysis, **53**, 36–37
- stability, **53**, 35–36
- substrate channeling, **53**, 69–71
- Unc-86, developmental role, **63**, 247–249
- Uncoupling protein (UCP)
 - discovery, **56**, 86–87
 - expression
 - mammalian cells, **56**, 92
 - yeasts, **56**, 92–94, 96
 - fatty acid sensitivity of mutants, **56**, 96
 - flow cytometry of yeast mutants, **56**, 93, 105
 - gene
 - comparison between species, **56**, 97
 - comparison with genes of other carriers, **56**, 97–98
 - organization in rat, **56**, 96–97
 - polymorphism in humans, **56**, 104–105
 - regulation of transcription
 - cis*-acting elements, **56**, 98–99
 - enhancer, **56**, 99–103
 - inhibitory regions, **56**, 103
 - norepinephrine, **56**, 98
 - retinoic acid, **56**, 98, 100–103
 - thyroid hormones, **56**, 98
 - trans*-factors, **56**, 100–101, 103
 - nucleotide
 - mutants, **56**, 94
 - regulation, **56**, 85–86
 - sequence homology, **56**, 87–89
 - topology, **56**, 89–92
 - uncoupling pathway of brown adipose tissue mitochondria, **56**, 85–86
- Unequal sister-chromatid exchange, DNA sequence amplification in mammalian cells and, **41**, 219–220
- UNG
 - CDG
 - active-site mutants, **68**, 377–378
 - gene
 - chromosomal localization, **68**, 371–372
 - expression, **68**, 376–377
 - human uracil-DNA glycosylase, **68**, 365–384
 - promoters, **68**, 376–377
 - UNG mutants
 - pyrimidines, **68**, 377–378
 - UNG1
 - nuclear, **68**, 374
 - UNG2
 - human
 - dUMP residues, **68**, 379–380
 - phosphorylation, **68**, 375
- Unified matrix hypothesis, **49**, 11
- 5' untranslated region, of eukaryotic messenger RNAs
 - binding sites for regulatory proteins, 185–186
 - cap structure, 183–184
 - features affecting translation initiation, 183–186
 - length, 184–185
 - nucleotide contest of initiation codon, 185
 - in proteins related to growth control, 201–203
 - regulatory proteins binding to, antisense oligonucleotide techniques in isolation, 227
 - secondary structure, 184
 - selective translational regulation via, 194–205
 - upstream AUGs, 185
 - upstream open reading frames, 185
- Unwinding
 - eIF4A-dependent unwinding assay, **72**, 316–321
 - nucleic acid chaperone proteins, **72**, 245
- Unwinding reaction, DNA helicases of *Escherichia coli* and
 - helicase assay, **40**, 292–294
 - mechanism, **40**, 294–296
- UPF gene
 - effects on nonsense-mediated mRNA decay, **47**, 283–285
 - mutants, **47**, 288–290
- UPflp
 - genes encoding interacting proteins, **47**, 286–288
 - subcellular localization, **47**, 284–285
- Upstream binding factor
 - enhancer element binding, **62**, 303

- Upstream binding factor (*cont.*)
 in ribosomal activation, **50**, 55
 in ribosomal transcription, **50**, 36–50
 retinoblastoma protein binding, **62**, 315
 ribosomal gene transcription regulation, **62**,
 121–122, 126, 130–135
 sequence homology between species, **62**,
 119, 301
 structure, **62**, 120–121, 301
 substrate specificity, **62**, 121
 types, **62**, 120–121
Upstream binding factor (hUBF), **67**, 98
Upstream control element, *see* Upstream
 promoter element
Upstream promoter element, in RPOI, **50**,
 33–38
ura4-aim, recombination hotspot, **61**, 361
Uracil, **68**, 126, 135
 BER
 dUTPase, **68**, 320
 DNA, **68**, 290
 mismatched
 TDG, **68**, 248–249
 murine UNG2, **68**, 380–381
 short-patch BER, **68**, 294
Uracil-DNA
 biological consequences, **48**, 330–336
 U-A basepairs in, **48**, 330–333
 U-G mispairs in, **48**, 333–336
Uracil-DNA glycosylase, **48**, 336–353
 bacterial, **48**, 340
 cell-cycle regulation, **48**, 351–352
 in *Escherichia coli*, **48**, 336–339, 340
 inhibitor
 bacteriophage PB32, **48**, 353–356
 mechanism of action, **48**, 355
 phenotype, **48**, 356
 properties, **48**, 354–355
 bacteriophage T5, **48**, 356
 mammalian, **48**, 342–352
 biochemical properties, **48**, 343–347
 human genes for, **48**, 347–351
 mitochondrial, **48**, 342–343
 nuclear, **48**, 342–343
 mycoplasma, **48**, 341
 plant, **48**, 341
 viral, **48**, 352–353
 yeast, **48**, 339, 342
Uracil DNA glycosylase (UDG), **68**, 136, 189,
 323–324, 324–328
 conserved gene family, **68**, 368–369
 discovery, **68**, 366–367
 DNA repair
 human colon adenocarcinoma LoVo cell
 extracts, **68**, 171–172
 enzyme-induced distortions, **68**, 326
 functions, **68**, 367–368
 human, **68**, 4
 UNG gene, **68**, 365–384
 long-patch BER, **68**, 289
 mammalian activities, **68**, 368
 mtDNA
 BER, **68**, 261
 Mug, **68**, 240
 pinch-push-pull model, **68**, 325
 substrate bases, **68**, 190
 UNG gene, **68**, 365–384
Uracil-excision DNA repair, **48**, 315–363
 pathway, **48**, 356–363
 DNA synthesis and ligase, **48**, 362–363
 incision and AP-site removal,
 48, 360–362
 one-nucleotide DNA repair patches, **48**,
 356–359
 uracil removal, **48**, 359–360
Uracil glycol, **68**, 210
Uracil glycosylase, repairing of DNA
 mismatch, **49**, 105
Uracil-initiated base excision repair, **68**,
 166–187
 aphidicolin, **68**, 177–180
 DNA mismatch repair
 LoVo cells, **68**, 182–183
 E. coli BH156, **68**, 183
 error frequency, **68**, 186
 Escherichia coli cell free extracts
 mutation frequency, **68**, 183
 human colon adenocarcinoma LoVo cell
 extracts, **68**, 171–175
 human U251, **68**, 174
 lacZalpha DNA reversion assay, **68**, 167–169
 measurement, **68**, 170
 mutation frequency
 human U251 cell extracts, **68**, 182
 LoVo cell extracts, **68**, 182
 mutational spectrum, **68**, 184–186
 mutations, **68**, 181–186
 nucleotide incorporation, **68**, 168, 169–171
 patch size
 LoVo cell extracts, **68**, 175–181

Ugi, **68**, 179–181
 Uracil mustard, DNA sequence specificity, **63**, 379, 390
 Uracil, introduced into DNA by cytosine deamination, **48**, 322–330
 Urea
 endo III, **68**, 216–218
 mNHT1, **68**, 216–218
 Uridine-5-oxyacetic acid, synthesis in position, **50**, 34, 322–324
 Uridine–cytosine base pair (U·C)
 nuclear magnetic resonance, structural studies of RNA, **57**, 27–29
 pairing arrangements, **57**, 23–24, 29
 pH dependence of structure, **57**, 28–29
 water stabilization, **57**, 25, 27
 Uridine diphosphate glucose:glycoprotein glucosyltransferase (UGGT), **67**, 239–241
 glycoprotein folding
 ER, **67**, 239–241
 Uridine kinase
 allosteric regulation by oligomer dissociation, **53**, 13–15
 complementary DNA from mouse brain, **53**, 46–48
 gene copy number, **53**, 48–49, 71
 gene expression, **53**, 40–42
 importance, **53**, 40
 isozymes, **53**, 42–44
 pseudogene, **53**, 48
 regulation, **53**, 45–46
 structure, **53**, 44–45
 Uridine–uridine base pair (U·U)
 glycosyl bond angles, **57**, 26
 nuclear magnetic resonance, structural studies of RNA, **57**, 27–29
 pairing arrangements, **57**, 23–26
 water stabilization, **57**, 25–26
 US2/US11, **67**, 259–260
 USF, insulin response sequence binding, **60**, 326–328
 Uterus, LOXL3 expression, **70**, 24–25
 Uterus, Muc4/SMC, **71**, 164–167
 3'-UTR
 translation enhancer, FGF-2 mRNA, **72**, 392–393
 vitellogenin mRNA, **72**, 148–151, 156
 3'-UTR-binding protein, vitellogenin mRNA, **72**, 145–154

5'-UTR, mRNA, *cis*-acting elements, FGF-2, **72**, 387
 UvrAB complex, **40**, 309–310

V

V(D)J recombination, *see* Double-strand break-induced recombination
Vaccinia virus
 capping enzyme, **50**, 103–109
 transcription, **50**, 112–114
Vaccinia virus, enzymes in DNA precursor biosynthesis and, **44**, 199–200
Vaccinia virus, polyadenylation
 mRNA, poly A signals, **71**, 377–380
 overview, **71**, 374–375
 poly A polymerase, **71**, 375–377
 Vacuoles, cytoplasmic
 alphavirus plus-strand RNA, **71**, 195–196
 alphavirus replication complex, **71**, 212, 214
 Vagina, Muc4/SMC, **71**, 177
 Val-tRNA^{Ile}, **69**, 338
 Valine-accepting tRNAs, **70**, 321–323
 ValRS-eEF1H complex, **48**, 92
 ValRS, variant RNA-bound, **69**, 328–329
 Valyl-tRNA synthetase, **40**, 122
 Vascular endothelial cell growth factor
 mRNA, distinct IRES identification, **72**, 393–394
 new isoform identification, **72**, 394–396
 Vascular smooth muscle cell (VSMC), antisense oligonucleotide inhibition of proliferation, **57**, 118–119
 Vasopressin, regulation of messenger RNA polyadenylation, **57**, 64
 Vc95, **67**, 68
 characteristics, **67**, 69
 VEGF, *see* Vascular endothelial cell growth factor
 Velvet tobacco mottle virus RNA, replication of, **42**, 212–214
 Venom, *see* Snake toxin
 Versican
 alternative splicing of messenger RNA, **62**, 185
 cloning, **62**, 187–188
 domains
 C-terminal domain, **62**, 193–194

- Versican (*cont.*)
 chondroitin sulfate-rich region, **62**, 195–197
 keratin sulfate domain, **62**, 194–195
 N-terminal hyaluronate-binding region, **62**, 191–193
 sequence alignment, **62**, 188, 191
 gene
 mapping, **62**, 217, 220
 promoter, **62**, 40–41
 structure, **62**, 216–217
 phylogenetic analysis, **62**, 211, 215–216
 structure, **62**, 35–36, 40, 185
 transcriptional regulation
 growth factors, **62**, 41–42
 interleukin-1 inhibition, **62**, 42
 promoter, **62**, 41, 207
- Vertebrate protamines, *see* Protamines
- Vertebrates, higher, heme biosynthesis, **51**, 3–6
- Vesicles, yeast double-stranded RNAs and, **46**, 178–179
- Vigilin
 binding to vitellogenin mRNA 3'-UTR, **72**, 148–151
 interaction with single-stranded nucleic acids, **72**, 151–153
 localization and regulation, **72**, 147–148
 nucleic acid-binding protein identity, **72**, 147
 overview, **72**, 145–147
 proposed functions, **72**, 153–154
 vitellogenin mRNA stabilization role, **72**, 154–156
- Villin, thyroid hormone regulation in intestinal development, **65**, 83–84
- Viomycin, recognizing RNA pseudoknots, **69**, 4
- Viral assembly, mono and divalent cation effects, **72**, 448–449
- Viral host range proteins
 ankyrin repeats, **67**, 11
- Viral protein, mRNA 3' end processing, **71**, 347–349
- Viral replication cycles, adenoviral DNA integration and, **46**, 27–28
- Viral replication, transcription factors, **65**, 286–287
- Viral RNA
 composition in virus, **72**, 416–417
 IRESs, **72**, 372–374
 translation–packaging interplay, **72**, 7–10
- Viral transcripts
 HSV-1, abundance changes, **71**, 474, 478–479, 483, 486
 microarray analysis, **71**, 455–456, 461–464
Virbio cholerae, **67**, 68
- Virus, *see also* Adeno-associated virus
 uracil-DNA glycosylase in, **48**, 352–353
- Viruses
 DNA and RNA composition, **72**, 416–417
 DNA packaging, model, **72**, 458–459
- Viruses, drug-resistant, enhanced polymerase fidelity, **71**, 129
- Viruses, latent, and mutated oncogenes, *see* Latent viruses and mutated oncogenes
- Viruses, plant, replication of, *see* Replication of plant viruses
- Vitamin D
 forms, **53**, 321
 genes, transcriptional regulation, **53**, 329, 331–333
 hydroxylases, molecular biology, **53**, 333, 335–338
 synthesis, **53**, 321, 333, 335–338
- Vitamin D receptor
 cloning, **53**, 322–323, 338
 genes, transcriptional regulation, **53**, 329, 331–333
 immunoradioassay, **53**, 322
 phosphorylation, **53**, 325, 338
 responsive elements, **53**, 325–328
 structure determination, **53**, 323–324
 tissue expression, **53**, 322–324
- Vitamin D receptor, mutation in rickets, **64**, 199, 201, 203
- Vitellogenin, mRNA
 stability regulation
 basic features, **72**, 144–145
 early work, **72**, 142–143
 precursor processing, **72**, 144
 transcription, **72**, 143
- vigilin
 3'-UTR binding, **72**, 148–151
 interaction model, **72**, 151–153
 localization and regulation, **72**, 147–148
 nucleic acid-binding protein identity, **72**, 147
 overview, **72**, 145–147
 proposed functions, **72**, 153–154
 stabilization role, **72**, 154–156
- Vma12p-Vma22p complex
 quality control, **67**, 250

von Hippel–Landau tumor suppressor,
regulation of elongin, **56**, 338, 340
 VP39, *Vaccinia virus*
 mRNA poly A signals, **71**, 379–380
 poly A polymerase, **71**, 376
 VP55, *Vaccinia virus* mRNA poly A signals, **71**,
 377–378
 VSG gene transcription unit, **43**, 47–49
 VSG gene transcription unit, *Trypanosoma*
 brucei and, **43**, 47–49
 VSG polymerase, **43**, 46–47
 VSG polymerase, *Trypanosoma brucei* and, **43**,
 46–47
 VSG, *Trypanosoma brucei* and, **43**, 58–59
 VSMC, *see* Vascular smooth muscle cell

W

Waardenburg syndrome
 MITF mutation in type 2, **64**, 196
 PAX3 mutation in types 1 and 3, **64**, 194
 WASP, **67**, 198–199
 biological functions, **67**, 197
 drug design, **67**, 221
 WASP-family verprolin-homologous protein
 (WAVE), **67**, 197–199
 WAVE, **67**, 197–199
 Wedge model, DNA bending, **47**, 199
 West-Northern blotting, nuclear RNA-binding
 proteins and, **41**, 186
 White blood cells, GAL function in, **69**, 90
 Wild-type p53
 hRFC, **67**, 152–153
 Wild-type sensitivity
 yeast BER mutants
 oxidizing agents, **68**, 31–32
 Wilson disease, gene, **58**, 169–170
 Wiskott-Aldrich syndrome protein (WASP),
 67, 198–199
 biological functions, **67**, 197
 drug design, **67**, 221
 Wound response pathway, jasmonates
 ABA, **72**, 190
 ethylene, **72**, 189
 intracellular signal transduction, **72**, 188
 local generation, **72**, 187–188
 overview, **72**, 185
 SA, **72**, 190
 systemic response, **72**, 189

X

X chromosome, modification and inactivation,
 methylation and, **48**, 69
 X-inactive specific transcript (XIST)
 DNA methylation role, **57**, 228
 models for formation of specific patterns, **57**,
 229, 231–233
 X-ray crystallography
 human immunodeficiency virus reverse
 transcriptase, **58**, 344, 346
 lactose repressor protein structural
 studies, **58**, 149–151, 153–154
 medium-chain acyl-CoA dehydrogenase,
 58, 311
 X-ray crystallography, superoxide dismutases
 and, **40**, 226–230
 X-ray, DNA sequence specificity of damage, **63**,
 383, 400
 X-rays
 endonucleases, **68**, 214
Xenopus laevis, **68**, 11, 130
 mitochondria, **68**, 292–293
Xenopus
 APE, **68**, 264
 mitochondrial enzyme, **68**, 263
 XerCD system, recombinatorial DNA repair
 effects at cell division, **63**, 325
 frequency estimation, **63**, 329
 Xeroderma pigmentosum (XP)
 clinical features, **63**, 209, 259
 damage-recognition protein in XPA cells, **63**,
 278–280
 DNA repair defects compared to Fanconi
 anemia, **63**, 259–260
 repair defect modeling in XPA cells, **63**,
 299–300
 types and gene defects, **63**, 209–210, 259
 XPA
 electroporation of normal endonuclease
 complexes into XPA cells, **63**,
 290–291, 301
 endonucleolytic incision activity, **63**,
 272–273, 302
 nucleosomal DNA activity, **63**,
 287–289
 protein–protein interactions, **63**, 278
 target site localization for repair
 naked DNA, **63**, 293–294, 296
 nucleosomal DNA, **63**, 296

- Xeroderma pigmentosum (XP) (*cont.*)
 processive mechanism restoration to
 XPA endonucleases, **63**, 298–299
- Xeroderma pigmentosum (XP), **68**, 236, 279
- Xeroderma pigmentosum (XPA), **67**, 98
- XIST, *see* X-inactive specific transcript
- XP complementation group A (XP-A), **68**, 279
- XP complementation group D (XP-D), **68**, 279
- XP, *see* Xeroderma pigmentosum
- XPA, **67**, 98
- XPG protein, **68**, 147
- XRCC1* gene, **68**, 157–158
- XRCC4* gene, **68**, 159
- Xrn1p
 abundance, **66**, 88
 discovery, **66**, 87
 function, **66**, 88–89
 gene and regulation, **66**, 88
 structure, **66**, 87
 substrate specificity, **66**, 87
- Xylanase, *Pseudomonas fluorescens* subsp.
 cellulosa
 cellulose-binding domain, **61**, 227–229
 genes, **61**, 219, 221
 NodB domain of xylanase E, **61**, 219, 221,
 229, 231
 xylanase A
 calcium-binding site, **61**, 236–237
 catalytic domain, structure, **61**,
 233–234, 236
 catalytic mechanism, **61**, 233–234, 236

Y

- Y-27632, **67**, 205
 ROCK, **67**, 216
- Y-box binding protein 1, **71**, 18
- Y-box binding protein 1 (YB-1), **67**, 98
- Yak1
 activation by tyrosine phosphorylation,
 62, 14
 comparison of N and C termini, **62**, 8
 conserved residues and motifs with
 Dyrk-related kinases, **62**, 4–7
 DH-box, **62**, 9–10
 discovery, **62**, 3
 dual-specificity protein kinase activity, **62**,
 3, 14
 functions, **62**, 15
 phylogenetic analysis with other kinases,
 62, 10–12
 YxY motif in activation loop, **62**, 7–8
- YB-1, **67**, 98
- Yeast
 Cdc6/Cdc18 protein, **72**, 55–56
 CTD phosphatase, **72**, 337–341
 cyclin-dependent kinases, **72**, 43–44
 DNA polymerase II and, *see* DNA
 polymerase II
 eIF5 as translation initiation factor, **70**,
 216–217
 eIF5 cDNA cloning, **70**, 215–216
 eIF5 substitution, **70**, 217
 GCN4 transcriptional factor, **47**, 239–240
 genomic stability, RecQ helicase role, **70**, 86
 glucose repression, SNF1, **71**, 71
 homologous recombination in, *see*
 Homologous recombination in
 Saccharomyces cerevisiae
 hydrogen peroxide, **68**, 31
 mitochondrial biogenesis in, *see*
 Mitochondrial biogenesis in
 Saccharomyces cerevisiae
 MutM, **68**, 195
 nonsense-mediated mRNA decay
 cis-acting factors, **47**, 272–276
 codon location role, **47**, 272–275
 downstream element role, **47**, 277–280,
 294–295
 trans-acting factors, **47**, 283–290
 trans mutants for *cis* element
 identification, **47**, 288–290
 functions, **47**, 290–293
 pathway modulation, **47**, 280–283
 position effects, **47**, 273–276
 requirements in *PGK1*, **47**, 277
 UPF gene product effects, **47**, 283–284
 translation-turnover association, **47**,
 293–294
 Upflp-interacting proteins, gene
 identification, **47**, 286–288
 Upflp localization, **47**, 284–285
- OGG2, **68**, 196
- pol beta, **68**, 21
- polyadenylation
 overview, **71**, 349–350
 poly A polymerase, **71**, 357–358
 poly A signals, **71**, 350–353
 polyadenylation, 3' end-processing

- CF1 complex, **71**, 354
CF11 complex, **71**, 355–356
conditional mutants, **71**, 358–359
genetic approaches, **71**, 359
mammalian homologs, **71**, 361–362
overview, **71**, 353–354
PF1 fraction, **71**, 356–357
synergistic lethality, **71**, 359
two-hybrid system, **71**, 360–361
proteolysis at G1–S transition, **72**, 51–52
recombination, **68**, 30–31
SBF and MBF, **72**, 48–49
SPHK and SIP, **71**, 495–497
- Yeast, **50**, 114–118, *pombe*
Yeast arginine synthetase, recognition of tRNA and, **41**, 65
Yeast base excision repair, **68**, 29–38
characteristics, **68**, 36
network, **68**, 36–38
oxidizing agents, **68**, 31–32
sensitize, **68**, 33
phenotypes, **68**, 33–36
wild-type sensitivity
oxidizing agents, **68**, 31–32
Yeast double-stranded RNAs, **46**, 155–156, 179–180
configuration, **46**, 169–173
evolution, **46**, 179
mycoviruses, **46**, 176–177
coat proteins, **46**, 177–178
vesicles, **46**, 178–179
replication cycles, **46**, 173–174
RNA polymerases, **46**, 175–176
sedimentation, **46**, 174–175
single-stranded RNA counterparts, **46**, 165–169
T, genomic organization
nucleotide sequences, **46**, 157–158
RNA polymerases, **46**, 158–165
W, genomic organization
nucleotide sequences, **46**, 157–158
RNA polymerases, **46**, 158–165
Yeast minichromosomes, nucleosome positioning and, **40**, 168–174
Yeast phenylalanine synthetases, recognition of tRNA and, **41**, 60–62
Yeast, ribosome biogenesis in, *see* Ribosome biogenesis in yeast
- Yeast tRNA, recognition of tRNA and, **41**, 43–44
Yeast, *see* *Saccharomyces cerevisiae*
Yeast, *see also* *Saccharomyces cerevisiae*
uracil-DNA glycosylase in, **48**, 339, 342
Yersiniabactin, biosynthesis, **70**, 265–268
Yi complex, cell cycle regulation, **53**, 208–210, 213–214
YOGG1, **68**, 215–216
- Z**
- Zaprinast, cyclic nucleotide phosphodiesterase inhibition, **65**, 17–18
ZD1694, **67**, 135
structure, **67**, 136
ZDS1, multicopy suppression of casein kinase yeast mutants, **59**, 106–107, 116
ZDS2, multicopy suppression of casein kinase yeast mutants, **59**, 106–107, 116
Zidovudine, RT mutation rates, **71**, 130–1311
Zif268, identification as immediate-early response gene, **58**, 51
Zif268 protein, structure and recognition sequence, **47**, 232–233
- Zinc
Ace1 binding, **58**, 180–181
Amt1 binding, **58**, 180–181
homeostasis, **58**, 167
Zinc-binding proteins, C_n class, **47**, 233–236
Zinc binuclear cluster protein
AlcR, **69**, 156–159
dimer *versus* monomer, **69**, 159–160
target discrimination by, **69**, 163–164
Zinc-finger proteins
plant, **47**, 250–251
structure and recognition sequence, **47**, 227–233
Zinc finger, DNA-binding domain, **64**, 177
Zinc-finger, family of transcription factors, **50**, 191–224
Zinc, cyclic nucleotide phosphodiesterase binding and catalysis, **65**, 14–16, 30–31
Zinc, superoxide dismutases and, **40**, 225

This Page Intentionally Left Blank

Contributor Index

Numbers in bold indicate volume numbers.

A

Aas, Per Arne, **68**:365
Abell, Creed W., **65**:129
Ackowski, Suzanne, **65**:361
Agris, Paul F., **53**:79
Aguilar, S. A., **71**:445
Ahola, Tero, **71**:187
Akbari, Mansour, **68**:365
Alexander, Rebecca W., **69**:317
Alexenko, Andrei, **56**:287
Altuvia, Shoshy, **46**:37
Amin, Niranjana, **44**:31
Andersen, Sonja, **68**:365
André, P., **49**:285
Andresen, Brage S., **58**:301
Ankowski, Janusz A. J., **57**:187
Arango, Maria, **71**:149
Ares, Manuel, **50**:131
Arnold, Andrew M., **54**:127
Arts, Eric J., **58**:339
Ashmarina, Mila, **69**:81
Astell, Caroline R., **55**:245
Avadhani, Narayan G., **61**:309
Aznar, Salvador, **67**:193

B

Baillie, Rebecca A., **52**:89
Baker, Jason C., **70**:33
Ballesta, Juan P. G., **55**:157
Bambara, Robert A., **51**:93
Baran, Chris, **70**:155
Bârzu, Octavian, **49**:241
Bash, R., **65**:197
Bateman, Erik, **60**:113
Bauerschmidt, Christina, **72**:41

Beck, Konstanze, **66**:107
Becker, Michael A., **69**:115
Becker, Walter, **62**:1
Bedford, Fiona K., **57**:187
Bennett, Samuel E., **48**:315; **68**:165
Bentele, Marc, **68**:235
Berkhout, Benjamin, **54**:1
Berns, Kenneth I., **48**:29
Bey, Fayçal, **49**:1
Beyer, Wayne, **40**:185
Bhasker, C. Ramana, **51**:1
Bi, Xin, **54**:253
Bina, Minou, **64**:171
Binder, Stefan, **70**:119
Björk, Glenn R., **50**:263
Blackburn, Michael R., **55**:195
Bloemendal, H., **43**:67
Bloemendal, Hans, **41**:259
Blumenthal, Robert M., **55**:1
Bogenhagen, Daniel F., **68**:257
Bohr, Vilhelm A., **68**:255, 285
Boiteux, Serge, **68**:95
Borst, Deborah W., **55**:1
Bottomley, Sylvia S., **51**:1
Bouillaud, Frédéric, **56**:83
Boulain, J.-C., **59**:307
Bouton, Amy H., **44**:207
Bowater, Richard P., **66**:159
Brabec, Viktor, **71**:1
Brosius, Jürgen, **52**:67
Bross, Peter, **58**:301
Brostrom, Charles O., **58**:79
Brostrom, Margaret A., **58**:79
Bruhat, Alain, **57**:217
Brunstein, John, **55**:245
Buehler, L., **71**:445
Bulleid, Neil J., **67**:235
Bustin, Michael, **54**:35

C

Campion, Stephen R., **49**:353
 Carlson, Don M., **41**:1
 Carothers Carraway, Coralie A., **71**:149
 Carraway, Kermit L., **71**:149
 Carroll, Dana, **54**:101
 Casey, Brian P., **67**:163
 Castro, Ariel F., **71**:391
 Cato, Andrew C. B., **43**:3
 Cha, R., **49**:285
 Chakravarty, Debyani, **71**:493
 Chamberlain, Joel R., **55**:87
 Champoux, James J., **60**:111
 Chastain, Michael, **41**:131
 Chatteraj, Dhruba K., **57**:145
 Chen, Li, **60**:317
 Chen, Ling, **68**:151
 Chen, Qian, **60**:79
 Chen, Weizu, **52**:89
 Chiu, Ing-Ming, **70**:155
 Christmann, Markus, **68**:41
 Clarenc, Jean Pierre, **44**:143
 Clarke, Steven, **61**:65
 Clayton, Christine, **43**:27
 Coburn, Glen A., **62**:55
 Cohen, Jack S., **42**:79
 Cohen, Seth M., **67**:93
 Cole, William G., **47**:29
 Conaway, Joan Weliky, **56**:327
 Conaway, Ronald C., **56**:327
 Conconi, Antonio, **62**:227
 Conti, Marco, **63**:1
 Cooper, Priscilla K., **68**:139
 Corbin, Jackie D., **65**:1
 Court, Donald L., **46**:37
 Cowan, Christopher W., **65**:349
 Cox, Michael M., **56**:129; **63**:311
 Cox, Timothy C., **51**:1
 Craig, Nessly, **49**:197
 Cristofari, Gaël, **72**:223
 Csiszar, Katalin, **70**:1
 Czworkowski, John, **54**:293

D

Dahlberg, Albert E., **50**:1
 Dahmus, Michael E., **48**:145; **72**:333
 Damante, Giuseppe, **66**:307
 Danchin, Antoine, **49**:241

Daniels, Douglas S., **68**:315
 Danielson, Keith G., **62**:19
 Danse, J. M., **59**:307
 Darlix, Jean-Luc, **72**:223
 Darwish, Hisham M., **53**:321
 Das, Supratik, **70**:207
 Däschner, Klaus, **70**:119
 David, Chantal, **42**:157
 Davie, James R., **65**:299
 De Cesare, Dario, **64**:343
 de Jong, Wilfried W., **41**:259
 de Winde, J. H., **46**:53
 Dean, Donald H., **60**:1
 Degerman, Eva, **66**:241
 Degols, Geneviève, **44**:143
 Deininger, Prescott L., **52**:67
 Dellis, Stephanie, **48**:241
 DeLuca, Hector F., **53**:321
 Demmon, Sarah, **64**:171
 Deppenmeier, Uwe, **71**:223
 Detich, Nancy, **69**:47
 Deuel, Thomas F., **55**:227
 Deutscher, Murray P., **66**:67
 Devi-Rao, G. B., **71**:445
 Di Lauro, Roberto, **66**:307
 Di Primo, C., **69**:1
 Dianov, Grigory L., **68**:285
 Dijkwel, Pieter A., **41**:203
 Ding, Ruchuang, **55**:135
 Dixon, Gordon H., **40**:25
 Dixon, Jack E., **42**:261
 Dodson, Robin E., **72**:129
 Doerfler, Walter, **46**:1
 Doetsch, Paul W., **68**:29
 Dogliotti, Eugenia, **68**:1, 3
 Dogra, Satish C., **51**:1
 Dolan, M. Eileen, **51**:167
 Domowicz, Miriam S., **62**:177
 Dong, Jianchun, **70**:33
 Dong, Zhiwan, **68**:151
 Dou, Qing-Ping, **53**:197
 Drickamer, Kurt, **45**:207
 Duan, Xiaolan, **45**:1
 Ducancel, F., **59**:307
 Duesberg, Peter H., **43**:137
 Dunkern, Torsten, **68**:41

E

Eberhardt, Norman L., **54**:127

Edenberg, Howard J., **64**:295
 Edmonds, Mary, **71**:285
 Eichler, Duane C., **49**:197
 El'skaya, A. V., **60**:47
 Ellenberger, Tom, **68**:305
 Emala, C. W., **47**:81
 Engelke, David R., **55**:87
 Escalante-Semerena, Jorge C., **56**:347
 Esteban, Luis M., **46**:155
 Esteban, Rosa, **46**:155

F

Fantozzi, Dominic A., **52**:89
 Farabaugh, Philip J., **64**:131
 Farmery, Mark R., **67**:235
 Fei, You-Jun, **58**:239
 Felenbok, Béatrice, **69**:149
 Filutowicz, Marcin, **48**:241
 Fisher, Paul A., **47**:371
 Fletcher, Bradley S., **47**:115
 Flipphi, Michel, **69**:149
 Florentz, Catherine, **45**:131
 Flowers, Kevin M., **54**:165
 Flynn, Daniel C., **44**:207
 Fontecave, Marc, **72**:95
 Fortini, Paola, **68**:3
 Fortune, John M., **64**:221
 Fox, Mary E., **61**:345
 Francis, Sharron H., **65**:1
 Fraser, Claire M., **49**:113
 Fridovich, Irwin, **40**:185
 Fritz, Gerhard, **68**:41
 Fromen, C., **59**:307
 Funk, Colin D., **45**:69
 Furano, Anthony V., **64**:255

G

Ganapathy, Vadivel, **58**:239
 Garcia, Joseph A., **49**:157
 Gargouri-Bouazid, Radhia, **42**:157
 Gary, Jonathan D., **61**:65
 Gashler, Andrea, **50**:191
 Gaskins, Chris J., **43**:205
 Gaynor, Richard B., **49**:157
 Gedamu, Lashitew, **59**:259
 Geiduschek, E. Peter, **43**:111

Ghazal, Peter, **71**:445
 Ghosh, Mridul K., **42**:79
 Ghosh, Paritosh, **56**:109
 Ghoshal, Kalpana, **66**:357
 Giegé, Richard, **45**:131; **70**:291
 Gilbert, Harry J., **61**:211
 Gilbert, Rebecca S., **47**:115
 Glazer, Peter M., **67**:163
 Glover III, Claiborne V. C., **59**:95
 Goessling, Lisa S., **55**:121
 Gong, Xiaoming, **70**:33
 Goodridge, Alan G., **52**:89
 Gorenstein, David G., **68**:349
 Gott, Jonatha M., **40**:143
 Grösch, Sabine, **68**:41
 Grabowski, Gregory A., **66**:203
 Greenberg, G. Robert, **53**:345
 Gregersen, Niels, **58**:301
 Grivell, L. A., **46**:53
 Grosse, Frank, **72**:41
 Grummt, Ingrid, **62**:109
 Gruss, Claudia, **52**:337
 Gu, Jing-Jin, **61**:181
 Guo, Peixuan, **72**:415
 Guzowski, John F., **51**:93

H

Haenni, Anne-Lise, **42**:157
 Hager, Gordon L., **66**:279
 Hakvoort, Theodorus B. M., **61**:243
 Haldosén, Lars-Arne, **57**:73
 Hamlin, Joyce L., **41**:203
 Hampel, Arnold, **58**:1
 Hanas, Jay S., **43**:205
 Haq, Bushra, **71**:149
 Hardeland, Ulrike, **68**:235
 Hardesty, Boyd, **66**:41
 Harrington, Rodney E., **47**:195
 Harris, Colin E., **55**:245
 Hause, Bettina, **72**:165
 Hazlewood, Geoffrey P., **61**:211
 Hazra, Tapas K., **68**:193
 He, Feng, **47**:271
 He, Wei, **65**:349
 Hecht, Sidney M., **49**:313
 Hengstschläger, Markus, **50**:67
 Henry, Susan A., **61**:133
 Hentze, Matthias W., **48**:181

Herrick, Glenn, **56:1**
 Herrlich, Peter, **43:3**
 Herschman, Harvey R., **47:115**
 Heyer, W.-D., **46:221**
 Hickson, Ian D., **63:189**
 Hilfinger, John M., **53:345**
 Hill, Jeff W., **68:193**
 Hiromasa, Yasuaki, **70:33**
 Hodnett, Dean W., **52:89**
 Hoffmann, Michaela, **70:119**
 Hohn, Thomas, **72:1**
 Hollis, Thomas, **68:305**
 Holst, Lena Stenson, **66:241**
 Holzer, Helmut, **58:197**
 Hosfield, David J., **68:315**
 House, Paul G., **68:349**
 Houslay, Miles D., **69:249**
 Hsu, Lily C., **40:255**
 Hu, G., **49:285**
 Huang, Lin, **51:93**
 Huberman, Joel A., **62:369**
 Hübscher, Ulrich, **65:261**
 Hue, Louis, **45:99**
 Hutson, Richard G., **53:219**
 Hutson, Susan, **70:175**

I

Ide, Hiroshi, **68:207**
 Idris, Nebila, **71:149**
 Ikeda, Seiichiro, **59:205**
 Imlay, James, **40:185**
 Inouye, Masayori, **40:1; 67:65**
 Inouye, Sumiko, **40:1; 67:65**
 Iozzo, Renato V., **62:19**
 Ishizuya-Oka, Atsuko, **65:53**
 Ivanetich, Kathryn M., **42:129**
 Ives, David H., **59:205**
 Izumi, Tadahide, **68:193**

J

Jaakkola, Panu, **63:109**
 Jackman, Joany, **55:135**
 Jacob, Samson T., **66:357**
 Jacobson, Allan, **47:271**
 Jalkanen, Markku, **63:109**
 Jefferson, Leonard S., **54:165**

Jepson, Scott, **71:149**
 Jetten, Anton M.,
 64:97; 69:205
 Jiang, Shi-Wen, **54:127**
 Jin, S.-L. Catherine, **63:1**
 Jindal, Hitesh K., **55:245**
 Jinks-Robertson, Sue, **68:29**
 Jiricny, Josef, **68:235**
 Johansson, Hans E., **48:181**
 Joklik, Wolfgang K., **53:249**
 Jones, Mary Ellen, **53:1**
 Jónsson, Zophonias O., **65:261**
 Joost, Hans-Georg, **62:1**
 Joshi-Barve, Swati, **46:183**
 Jost, Jean-Pierre, **57:217**
 Julien, Jean-Pierre, **61:1**

K

Kääriäinen, Leevi, **71:187**
 Kafri, Tal, **48:55**
 Kaina, Bernd, **68:41**
 Kan, Mikio, **59:135**
 Kane, Stefanie A., **49:313**
 Karam, Jim D., **64:65**
 Kasten, Shane A., **70:33**
 Kavli, Bodil, **68:365**
 Keene, Jack D., **41:179**
 Kellems, Rodney E., **55:195**
 Keller, Ullrich, **70:233**
 Kemper, Byron, **61:25**
 Kerby, Robert L., **67:35**
 Kerlavage, Anthony R., **49:113**
 Khrapko, K., **49:285**
 Kilberg, Michael S., **53:219**
 Kim, Joomyeong, **52:67**
 Kim, Young S., **57:187**
 Kimball, Scot R., **54:165**
 Kisselev, Lev L., **48:85**
 Klautky, Stephen A., **52:89**
 Klein, Hannah L., **51:271**
 Klobutcher, Lawrence A., **56:1**
 Knippers, Rolf, **52:337**
 Koch, Hans-Georg, **66:107**
 Kolchanov, N. A., **53:131**
 Kolodner, R. D., **46:221**
 Komar, Anton A., **72:307**
 Komatsu, Masanobu, **71:149**
 Konigsberg, William H., **64:65**

Kornitzer, Daniel, **46:37**
 Kow, Yoke W., **68:223**
 Krab, Ivo M., **71:513**
 Kramer, Gisela, **66:41**
 Krishnamurthy, Vinita, **64:1**
 Krokan, Hans E., **68:365**
 Kuhn, Josef, **70:119**
 Kühn, Uwe, **57:41**
 Kujubu, Dean A., **47:115**
 Kumar, M. Vijay, **59:289**
 Küntzel, Hans, **48:1**
 Kurebayashi, Shogo, **69:205**
 Kurumizaka, Hitoshi, **61:379**
 Kwan, Sau-Wah, **65:129**

L

Lacal, Juan Carlos, **67:193**
 Laine, Roney O., **53:219**
 Laliberté, Josée, **61:181**
 Lambert, Muriel W., **63:257**
 Lambert, W. Clark, **63:257**
 Lamers, Wouter H., **61:243**
 Lampson, Bert, **67:65**
 Lampson, Bert C., **40:1**
 Landstrom, Tova Rahn, **66:241**
 Lanka, Erich, **54:197**
 Lanzilotta, William N., **67:35**
 Lau, Albert, **68:305**
 Le Du, M. H., **59:307**
 Le Grice, Stuart F. J., **58:339**
 Le Page, Florence, **68:95**
 Le, X. Chris, **68:139**
 Leadon, Steven A., **68:139**
 Lebleu, Bernard, **44:143**
 Leclerc, Isabelle, **71:69**
 LeDoux, S. P., **68:273**
 Lee, Frank S., **44:1**
 Lee, Jane, **68:139**
 Lee, Mi Kyong, **60:1**
 Lee, Norman H., **49:113**
 Leibach, Frederick H., **58:239**
 Lenka, Nibedita, **61:309**
 Leonard, C. J., **48:29**
 Leonetti, Jean Paul, **44:143**
 Leppard, John B., **68:151**
 Lettieri, Teresa, **68:235**
 Leu, Tzeng-Horng, **41:203**

Leung, Helios, **50:67**
 Levchenko, Igor, **48:241**
 Levin, David S., **68:151**
 Levine, M. A., **47:81**
 Levy-Wilson, Beatriz, **50:161**
 Li, Zhongwei, **66:67**
 Lie-Venema, Heleen, **61:243**
 Lieberman, Kathy R., **50:1**
 Liebhaber, Stephen A., **57:249**
 Limmer, Stefan, **57:1**
 Lin, Patrick S., **72:333**
 Lindahl, Lasse, **47:331**
 Lindahl, Thomas, **68:xvii**
 Lindberg, I., **63:69**
 Linsenmayer, Thomas F., **60:79**
 Lippard, Stephen J., **67:93**
 Lips, Jochen, **68:41**
 Liu, Hong, **71:493**
 Liu, Leroy F., **54:253**
 Liu, Limin, **56:287**
 Liu, Qingquan, **55:245**
 Lloyd, R. Stephen, **62:155; 68:349**
 Logan, Derek T., **72:95**
 Lohr, D., **65:197**
 Long, Fanxin, **60:79**
 Lu, Yang, **62:329**
 Luehrsen, Kenneth R., **47:149**
 Luxon, Bruce A., **68:349**
 Lykidis, Athanasios, **65:361**

M

Ma, Chi, **41:203**
 Ma, Qiufu, **47:115**
 Ma, Zhongmin, **67:1**
 Maceyka, Michael, **71:493**
 Mackey, Zachary B., **68:151**
 Mackie, George A., **62:55**
 Maitra, Umadas, **70:207**
 Maizels, Nancy, **50:67**
 Malter, James S., **56:257**
 Manganiello, Vincent, **66:241**
 Mannering, Sally A., **52:261**
 Manuel, Raymond C., **68:349**
 Marians, Kenneth J., **63:39**
 Marintcheva, Boriana, **70:77**
 Marshall, Nicholas F., **72:333**
 Mascotti, David P., **55:121**

Matherly, Larry H., **67**:13
 Mathews, Christopher K., **44**:167
 Matson, Steven W., **40**:291
 Matsumoto, Yoshihiro, **68**:129
 Matthews, Kathleen Shive, **58**:127
 Matthews, Rowena G., **55**:1
 May, Brian K., **51**:1
 Mazumder, Abhijit, **52**:123
 McAlister-Henn, Lee, **57**:317
 McCormack, Wayne T., **45**:29
 McEvilly, Robert J., **63**:223
 McKeehan, Wallace L., **59**:135
 Mechti, Nadir, **44**:143
 Mellor, Harry, **54**:165
 Ménez, A., **59**:307
 Ménez, R., **59**:307
 Menéndez-Arias, Luis, **71**:91
 Mencía, Mario, **60**:29
 Mensch, James R., **62**:177
 Merrick, William C., **72**:307
 Mettler, Irvin J., **42**:229
 Miller, Paul S., **52**:217
 Milstien, Sheldon, **71**:493
 Mirande, Marc, **40**:97
 Mitchell, Beverly S., **61**:181
 Mitra, Sankar, **68**:193, 1890
 Mol, Clifford D., **68**:315
 Monsalve, María, **60**:29
 Moore, Peter B., **54**:293
 Moorman, Antoon F. M., **61**:243
 Morales, Julia, **57**:249
 Moreau, S., **69**:1
 Morey, Natalie J., **68**:29
 Morris, David R., **51**:339
 Morrison, Alan, **46**:93
 Morrison, Alastair, **47**:3
 Mosbaugh, Dale W., **48**:315; **68**:165
 Moschel, Robert C., **51**:167
 Moss, Joel, **45**:49
 Moss, Tom, **50**:25
 Motycka, Teresa A., **68**:151
 Movsesian, Matthew, **66**:241
 Mu, David, **56**:63
 Muller, L., **63**:69
 Müller, Matthias, **66**:107
 Mullick, Jayati, **61**:309
 Mulliez, Etienne, **72**:95
 Murakawa, George J., **52**:153
 Murray, Vincent, **63**:367
 Mushynski, Walter E., **61**:1

N

Nakabeppu, Yusaku, **68**:75
 Napoli, Joseph L., **63**:139
 Nasheuer, Heinz-Peter, **72**:41
 Negrutskii, B. S., **60**:47
 Nichols, Jeffry C., **58**:127
 Nicholson, Allen W., **52**:1
 Nierhaus, Knud H., **59**:177
 Nierlich, Donald P., **52**:153
 Nikolaev, Igor, **69**:149
 Nilsen, Hilde, **68**:365
 Nishimura, Susumu, **68**:107
 Niyogi, Salil K., **49**:353
 Norbury, Christopher J., **63**:189
 Norstedt, Gunnar, **57**:73
 Nurminskaya, Maria, **60**:79
 Nwaka, Solomon, **58**:197
 Nyaga, Simon G., **68**:285

O

Ochs, Kirsten, **68**:41
 Ogawa, T., **59**:307
 Ogilvie, Martha K., **43**:205
 Ohno, M., **59**:307
 Oliva, Rafael, **40**:25
 Oppenheim, Amos B., **46**:37
 Osheroff, Neil, **64**:221
 Osman, Fekret, **58**:263
 Otterlei, Marit, **68**:365
 Owens, Ida S., **51**:305

P

Padlan, Eduardo A., **60**:169
 Pagán-Ramos, Eileen, **55**:87
 Pansegrau, Werner, **54**:197
 Pantopoulos, Kostas, **48**:181
 Pao, Ching-I, **60**:195
 Pardee, Arthur B., **53**:197
 Pares-Matos, Elsie I., **64**:171
 Parikh, Sudip S., **68**:315
 Parlanti, Eleonora, **68**:3
 Parmeggiani, Andrea, **71**:513
 Parsons, J. Thomas, **44**:207
 Pascucci, Barbara, **68**:3
 Patton-Vogt, Jana L., **61**:133

Pautova, L. V., **57**:95
 Pegg, Anthony E., **51**:167
 Pellegrino, Susan M., **49**:113
 Peltz, Stuart W., **47**:271
 Peng, Tao, **70**:33
 Perez, Aymee, **71**:149
 Perez-Jannotti, Romina M., **68**:257
 Perrin, David M., **52**:123
 Phillips, Lawrence S., **60**:195
 Pinz, Kevin G., **68**:257
 Pirok III, Edward W., **62**:177
 Planta, R. J., **41**:89
 Ponta, Helmut, **43**:3
 Pooggin, Mikhail, **72**:1
 Poole, Elizabeth S., **52**:261
 Poulos, Thomas, **67**:35
 Prats, Anne-Catherine, **72**:367
 Prats, Hervé, **72**:367
 Preiss, Jack, **47**:301
 Price-Schiavi, Shari A., **71**:149
 Pshezhetsky, Alexey V., **69**:81
 Puglisi, Joseph D., **45**:131
 Putnam, Christopher D., **68**:315
 Pütz, Joern, **70**:291

Q

Qi, Xiaoyang, **66**:203
 Query, Charles C., **41**:179
 Quilliam, Lawrence A., **71**:391
 Quinn, Patrick G., **72**:269

R

Raats, J. M. H., **43**:67
 Rabow, Lois, **68**:223
 Rajagopalan, Lakshman E., **56**:257
 Rajamohan, Francis, **60**:1
 Ramirez, J. J. Garcia, **71**:445
 Rao, Desirazu N., **64**:1
 Raué, H. A., **41**:89
 Razin, Aharon, **48**:55
 Rebhun, John F., **71**:391
 Reddy, Srinivasa T., **47**:115
 Reeder, Ronald H., **62**:293
 Reeves, Raymond, **54**:35
 Reinberg, Danny, **44**:67
 Remacha, Miguel, **55**:157

Rhoads, Robert E., **46**:183
 Ricquier, Daniel, **56**:83
 Rinker-Schaeffer, Carrie, **46**:183
 Ritter, Joseph K., **51**:305
 Roach, Peter J., **57**:289
 Roberts, Gary P., **67**:35
 Roberts, R. Michael, **56**:287
 Roca, Alberto I., **56**:129
 Roche, Thomas E., **70**:33
 Rodriguez-Cousiño, Nieves, **46**:155
 Rogers Jr., George W., **72**:307
 Rojo, Fernando, **60**:29
 Romeo, Tony, **47**:301
 Roncero, Cesar, **52**:89
 Rondon, Michelle R., **56**:347
 Roner, Michael R., **53**:249
 Rosenfeld, Michael G., **63**:223
 Rosenthal, Dean S., **55**:135
 Rottjakob, Hans-Werner, **48**:1
 Rousseau, Guy G., **45**:99
 Rup, Diane, **55**:121
 Russell, J. Eric, **57**:249
 Rutter, Guy A., **71**:69
 Ryabova, Lyubov A., **72**:1

S

Sadlon, Tim J., **51**:1
 Sadowski, Paul D., **51**:53
 Saha, Swati, **64**:1
 Sakmar, Thomas P., **59**:1
 Salas, Margarita, **60**:29
 Samson, Susan L.-A., **59**:259
 Sancar, Aziz, **56**:63
 Sanderson, Russell J., **68**:165
 Santi, Daniel V., **42**:129
 Santos, Ameurfina D., **60**:169
 Sassone-Corsi, Paolo, **64**:343
 Schäfer, Ute, **66**:107
 Schaller, Michael D., **44**:207
 Schär, Primo, **68**:235
 Schauwecker, Florian, **70**:233
 Scheffler, Immo E., **60**:267
 Scherrer, Klaus, **49**:1
 Schimmel, Paul, **69**:317
 Schmid, Carl W., **53**:283
 Schmid, Thomas M., **60**:79
 Schneider, Thomas D., **57**:145
 Schulman, LaDonne H., **41**:23

Schwartz, Jody R., **43**:137
 Schwartz, Nancy B., **62**:177
 Schwed, Angelika, **48**:1
 Schwindinger, W. F., **47**:81
 Shafer, Richard H., **59**:55
 Shakur, Yasmin, **66**:241
 Shapiro, David J., **72**:129
 Shechter, Ishaiahu, **65**:157
 Shepard, Allan R., **54**:127
 Shi, Yun-Bo, **65**:53
 Shimohigashi, Y., **59**:307
 Shuman, Stewart, **50**:101; **66**:1
 Sigman, David S., **52**:123
 Simbulan-Rosenthal, Cynthia M. G., **55**:135
 Simpson, Robert T., **40**:131
 Singh, Jasbir, **51**:93
 Sinibaldi, Ralph M., **42**:229
 Skjelbred, Camilla, **68**:365
 Skorpen, Frank, **68**:365
 Skurat, Alexander V., **57**:289
 Sliva, Daniel, **57**:73
 Slupphaug, Geir, **68**:365
 Small, W. Curtis, **57**:317
 Smas, Cynthia M., **60**:317
 Smerdon, Michael J., **62**:227
 Smith, Gerald R., **61**:345
 Smith, James F., **43**:205
 Smith, Richard, **72**:41
 Smith, Steven S., **49**:65
 Smulson, Mark E., **55**:135
 Sobol, Robert W., **68**:57
 Somerville, Ronald, **42**:1
 Souza-Pinto, Nadja, **68**:285
 Spencer, Virginia A., **65**:299
 Spiegel, Sarah, **71**:493
 Staglar, Igor, **65**:261
 Stefanovsky, Victor Y., **50**:25
 Stein, Arnold, **54**:333
 Steinacher, Roland, **68**:235
 Stevensner, Tinna, **68**:285
 Stingley, S. W., **71**:445
 Stollar, B. David, **42**:39
 Stucki, Manuel, **65**:261
 Stuhrmann, Heinrich B., **59**:177
 Subramani, Suresh, **58**:263
 Sueoka, Noboru, **59**:35
 Sugino, Akio, **46**:93
 Sukhatme, Vikas P., **50**:191
 Sul, Hei Sook, **60**:317
 Sundström, Michael, **57**:73

Sung, Jung-Suk, **68**:165
 Sutcliffe, J. Gregor, **41**:241
 Suter, Ueli, **56**:225; **64**:97
 Svergun, Dmitri, **59**:177
 Swanson, Rebecca L., **68**:29
 Switzer, Robert L., **62**:329
 Szyf, Moshe, **69**:47

T

Taha, Sharif, **47**:149
 Tainer, John A., **68**:299, 315
 Tam, Pat, **55**:245
 Tamiya, T., **59**:307
 Tansey, Terese R., **65**:157
 Tate, Warren P., **52**:261
 Taylor, Verdon, **56**:225
 Tell, Gianluca, **66**:307
 Thach, Robert E., **55**:121
 Thilly, W. G., **49**:285
 Thiviyanathan, Varatharasa, **68**:349
 Thomas, George, **65**:101
 Thompson, Craig B., **45**:29
 Thorsteinsson, Marc V., **67**:35
 Thurmond, Debbie C., **52**:89
 Thybo, Tanja, **68**:285
 Tiedge, Henri, **52**:67
 Tindall, Donald J., **59**:289
 Tinoco, Jr., Ignacio, **41**:131
 Titov, I. I., **53**:131
 Tjoelker, Larry W., **45**:29
 Tomicic, Maja, **68**:41
 Tomkinson, Alan E., **68**:151
 Touhalisky, Kathy, **70**:155
 Toulmé, J. J., **69**:1
 Tranguch, Anthony J., **55**:87
 Traut, Thomas W., **53**:1
 Travis, Gabriel H., **41**:241
 Trujillo, Miguel A., **54**:127
 Trzebiatowski, Jodi R., **56**:347
 Turk, John, **67**:1
 Turkan, Ali, **70**:33
 Turko, Ilarion V., **65**:1
 Turner, Robert J., **62**:329

U

Ueda, Eiichiro, **69**:205
 Uhlenbeck, Olke C., **40**:143
 Urh, Marjeta, **48**:241

V

Vörtler, Stefan, **70**:291
 Vallee, Bert L., **44**:1
 van Hemert, Formijn J., **61**:243
 van Holde, Kensal, **52**:161
 Varnum, Brian C., **47**:115
 Vaughan, Martha, **45**:49
 Vaughn, James P., **41**:203
 Venkataraman, Radhika, **68**:223
 Vessey, Carina J., **63**:189
 Vijayasathy, C., **61**:309
 Villafuerte, Betty C., **60**:195
 Vlassov, V. V., **53**:131; **57**:95
 Vlassova, I. E., **53**:131; **57**:95
 Volarević, Siniša, **65**:101
 Volk, David E., **68**:349
 von Kitzing, Eberhard, **43**:89

W

Wagner, Edward K., **51**:93; **71**:445
 Wahle, Elmar, **57**:41
 Walbot, Virginia, **47**:149
 Wand, G. S., **47**:81
 Wang, Dong, **60**:317
 Wang, Fen, **59**:135
 Wang, Zhao-Yi, **55**:227
 Wasternack, Claus, **72**:165
 Weinfeld, Michael, **68**:125, 139
 Weiser, Bryn, **50**:131
 Weisshart, Klaus, **72**:41
 Welch, Ellen, **47**:271
 Weller, Sandra K., **70**:77
 Wells, Robert D., **66**:159
 Wensel, Theodore G., **65**:349
 Wieslander, Lars, **48**:277
 Williams, Jeffrey, **47**:3
 Wilson, G. L., **68**:273
 Wilson, Samuel H., **68**:55; **68**:57
 Winge, Dennis R., **58**:165

Winicov, Ilga, **47**:195
 Winkles, Jeffrey A., **58**:41
 Witherell, Gary W., **40**:143
 Wolffe, Alan P., **61**:379
 Wolfson, Alexey D., **48**:85
 Wood, Timothy J. J., **57**:73
 Wright, Paul S., **41**:1
 Wu, Frank, **48**:241
 Wu, Ray, **45**:1

X

Xavier, Gabriela da Silva, **71**:69
 Xing, James Z., **68**:139
 Xu, Deping, **45**:1
 Xu, Gang, **52**:89

Y

Yan, Xiaohua, **70**:33
 Yasunami, Michio, **40**:255
 York, Dona, **48**:241
 Yoshida, Akira, **40**:255
 Young, Howard A., **56**:109

Z

Zalkin, Howard, **42**:261
 Zavel, Leigh, **44**:67
 Zengel, Janice M., **47**:331
 Zhang, Jin, **71**:149
 Zhou, Jie, **41**:1
 Zhu, Peng-Peng, **44**:31
 Zimmermann, Albert G., **61**:181
 Zinn-Justin, S., **59**:307
 Zlatanova, Jordanka, **52**:161
 Zwerschke, Werner, **48**:1

This Page Intentionally Left Blank